fludarabine and vidarabine

fludarabine has been researched along with vidarabine in 3305 studies

Research

Studies (3,305)

TimeframeStudies, this research(%)All Research%
pre-199024 (0.73)18.7374
1990's433 (13.10)18.2507
2000's1331 (40.27)29.6817
2010's1283 (38.82)24.3611
2020's234 (7.08)2.80

Authors

AuthorsStudies
Cristalli, G; Esker, JL; Jacobson, KA; Ji, XD; Melman, N; Olah, ME; Schneller, SW; Secrist, JA; Siddiqi, SM; Tiwari, KN1
Cheson, BD10
Anaissie, E; Elting, L; Kantarjian, H; Keating, M; Kontoyiannis, DP; Robertson, LE1
Elmhorn-Rosenborg, A; Juliusson, G; Liliemark, J1
Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Robertson, L1
Robak, T3
Butler, JJ; Hirsch-Ginsberg, C; Huh, YO; Kantarjian, H; Keating, MJ; Pugh, WC; Robertson, LE; Stass, S1
Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN1
Phyliky, RL; Tefferi, A1
Crowley, S; Dahut, WL; Frame, JN1
Ali Ege, M; Amadori, S; Caruso, R; D'Adamo, F; Girelli, G; Maurillo, L; Mauro, FR; Picardi, A; Tosti, S1
Gandhi, V; Plunkett, W6
Adjei, AA; Dagnino, L; Paterson, AR; Wong, MM1
Gandhi, V; Keating, M; Kemena, A; Plunkett, W; Shewach, DS1
Huang, P; Plunkett, W4
Lawrence, HJ; Perez, EA; Sanders, C1
Marlton, P; McCarthy, C; Taylor, K1
Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W2
Bastion, Y; Bryon, PA; Coiffier, B; Dumontet, C; Espinouse, D1
Oken, MM1
Crowley, J; Eyre, HJ; Hynes, HE; Jaeckle, C; Pollock, TW; Stephens, RL; Taylor, SA1
Schilling, PJ1
Gribbin, TE1
Chubb, S; Huang, P; Plunkett, W1
Grever, MR; Malspeis, L; Staubus, AE; Young, D1
Catovsky, D; Davis, CL; Lister, TA; Mehta, AB; Ranson, M; Rohatiner, AZ; Rule, S; Smith, OP; Whelan, JS1
Cassileth, PA; Green, MD; Hochster, HS; Kim, KM; Mann, RB; Neiman, RS; O'Connell, MJ; Oken, MM; Ritch, P; Stott, P1
Gandhi, V; Keating, MJ; Kemena, A; Plunkett, W2
Parks, NP; Santiago, NM; Trissel, LA1
Sporn, JR1
Kantarjian, HM; Keating, MJ; Schachner, J1
Beran, M; Childs, C; Huh, Y; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Schachner, J1
Finley, RS; Hood, MA1
Bladé, J; Cervantes, F; Marín, P; Montserrat, E; Rozman, C; Rozman, M1
Hutton, JJ; Von Hoff, DD1
Huang, P; Plunkett, W; Siciliano, MJ1
Barrueco, JR; Sirotnak, FM1
Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W1
Danhauser, L; Gandhi, V; Plunkett, W1
Barrueco, JR; Brockman, RW; Chang, CH; Jacobsen, DM; Sirotnak, FM1
Bacon, PE; Brown, NC; Carter, GL; Cory, JG; Montgomery, JA; Sato, A1
Kufe, D; Mitchell, T; Robbins, G; Spriggs, D1
Clark, G; Hersh, M; Hutton, JJ; Kuhn, J; Phillips, J; Von Hoff, DD1
Bell, DE; Dow, LW; Fridland, A; Poulakos, L1
Brockman, RW; Cheng, YC; Montgomery, JA; Schabel, FM1
Cory, JG; Montgomery, JA; Sato, A1
Chello, PL; Dorick, DM; Montgomery, JA; Sirotnak, FM1
Chello, PL; Dorick, DM; Montgomery, JA; Sirotnak, FM; Yang, CH1
Avramis, VI; Plunkett, W2
Alexander, L; Chubb, S; Montgomery, JA; Plunkett, W1
Bennett, LL; Brockman, RW; Shaddix, SC; White, EL1
Bennett, LL; Brockman, RW; Cheng, YC; Derse, D; Tseng, WC1
Brockman, RW; El Dareer, SM; Hill, DL; Kirk, MC; Montgomery, JA; Shortnacy, AT; Struck, RF; Thorpe, MC1
Ashique, A; Begleiter, A; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L1
del Villar, V; López, L; Pascual, T1
Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L1
Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Robertson, LE; Thall, P1
Escudier, SM; Seymour, JF1
Bourquard, P; Emberger, JM; Exbrayat, C; Fégueux, N; Lavabre-Bertrand, C; Lavabre-Bertrand, T; Navarro, M; Poncelet, P; Rousset, T; Taïb, J1
Juliusson, G2
Estey, E; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE1
Hiddemann, W; Pott-Hoeck, C2
Dighiero, G2
Carrara, P; Cenacchi, A; Clavio, M; Gamberi, B; Manfroi, S; Ottaviani, E; Testoni, N; Tosi, P; Visani, G; Zinzani, PL1
Manfori, S; Ottaviani, E; Tosi, P; Tura, S; Visani, G; Zinzani, PL1
Cabanillas, F; Dimopoulos, M; Gandhi, V; Gregoire, V; Kantarjian, H; Keating, MJ; Li, YY; McLaughlin, P; O'Brien, S; Robertson, LE1
Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL1
Bosanquet, AG; Catovsky, D; Crotty, GM; McCann, SR; Mills, MJ1
Gollard, R; Lee, TC; Piro, LD; Saven, A1
Estey, E; Gandhi, V; Plunkett, W1
Cacciola, E; Di Raimondo, F; Giustolisi, R; Impera, S; Milone, G; Palumbo, GA; Romeo, MA1
Paolini, R; Petracca, GE; Ramazzina, E; Rimondi, AP; Zamboni, S; Zennaro, R1
Bromidge, TJ; Howe, DJ; Johnson, SA; Phillips, MJ1
Bendandi, M; Tura, S; Zinzani, PL1
Andreeff, M; Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE1
Byrd, JC; Diehl, LF; Freiman, J; Hertler, AA; Kweder, SL; Weiss, RB1
Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE1
Andreeff, M; Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, LE1
Brugiatelli, M; Callea, I; Callea, V; Iacopino, P; Messina, G; Morabito, F; Nobile, F; Rodinò, A1
Leoni, P; Montillo, M; Tedeschi, A2
Hakimian, D; Tallman, MS2
Estey, EH; Jaiyesimi, IA; Kantarjian, HM1
Faulds, D; McTavish, D; Ross, SR1
Aitini, E; Bendandi, M; Gherlinzoni, F; Salvucci, M; Tura, S; Zaccaria, A; Zinzani, PL1
Gouldesbrough, DR; Macheta, MP; Parapia, LA1
Keating, MJ; Li, L; Plunkett, W; Yang, LY2
Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P1
O'Brien, RK; Sparling, TG1
Byrd, JC; Diehl, LF; Hargis, JB; Hospenthal, DR; Kester, KE; Knutson, SW1
Allegra, CJ; Chabner, BA; Chu, E; Grem, JL; Johnston, PG; Takimoto, CH; Van Groeningen, C1
Björkholm, M; Osby, E1
Briz, M; Cabrera, JR; Díez, JL; Fernández, MN; Forés, R; Herrero, M; Regidor, C; Sanjuán, I1
del Giglio, A; Keating, M; O'Brien, S1
Appleton, AL; Hamilton, PJ; Jackson, GH; Maung, ZT; Turner, GE; Wood, AC1
Abboudi, Z; Agrawal, S; Catovsky, D; Matutes, E1
Keating, MJ; O'Brien, S; Plunkett, W; Robertson, LE; Wright, SJ1
Simon, R; Thall, PF1
Cass, Y; Dann, EJ; Gillis, S; Polliack, A; Rochlemer, RR1
Catovsky, D; Cunningham, D; Ellis, PA; Emmett, E; Hickish, T; Hill, M; Matutes, E; Mercieca, J; Milan, S; O'Brien, ME1
Gandhi, V; Huang, P; Plunkett, W1
Calvert, L; Deisseroth, AB; Feldman, E; Hester, J; Kantarjian, HM; Korbling, M; Liang, J; Rios, MB; Smith, TL; Talpaz, M1
Benner, A; Bentz, M; Cabot, G; Coy, J; Diehl, D; Döhner, H; Fischer, K; Galle, PR; Hansen, K; Hunstein, W; Lichter, P; Poustka, A; Schlenk, R; Stilgenbauer, S; Volkmann, M1
Alfarano, A; Bergui, L; Caligaris-Cappio, F; De Leo, AM; Gottardi, D; Stacchini, A1
Piro, LD; Saven, A2
Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Pierce, S; Robertson, B1
Alexanian, R; Dimopoulos, MA; Estey, EE; Kantarjian, H; Keating, MJ; O'Brien, S1
Saven, A3
Juliusson, G; Liliemark, J3
Piro, L; Saven, A1
Lundberg, JH; Tefferi, A; Weitz, JJ; Witzig, TE1
Brock, WA; Grégoire, V; Hittelman, WN; Hunter, N; Milas, L; Plunkett, W2
Bastian, A; Cotelingam, JD; Fischmann, AB; Foss, FM; Ghosh, BC; Ihde, DC; Linnoila, IR; Schechter, GP; Steinberg, SM; Stocker, JL1
Cheson, BD; Foss, FM; Sorensen, JM; Vena, DA1
Hopkins, JA; Howe, D; Johnson, SA; Phillips, MJ; Richardson, DS1
Domizio, P; Fearnley, J; Gawler, J; Goldin, J; Johnson, PW; Lister, TA; Nagendran, K; Rohatiner, AZ1
Girmenia, C; Mauro, FR; Rahimi, S1
Canellakis, ZN; Costin, D; Degar, B; Drygas, JC; Mani, M; Morse, L; Newcomb, EW; Potmesil, M; Rosenberg, CR; Silber, R1
Brock, WA; Grégoire, V; Hittelman, WN; Milas, L; Plunkett, W; Stephens, LC; Van, NT1
Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D1
Aguilera, A; Liaño, F; Montalban, C1
Bendandi, M; Buzzi, M; Farabegoli, P; Martinelli, G; Ottaviani, E; Salvucci, M; Tosi, P; Visani, G; Zaccaria, A; Zinzani, PL1
Dean, MG; Mulligan, SP1
Buzzi, M; Farabegoli, P; Fortuna, A; Martinelli, G; Tosi, P; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL1
Bruijn, JA; van Groningen, K; van Royen, EA; Wijermans, PW1
Berman, E; Kempin, S; Spiess, T; Weiss, M1
Doorduijn, JK; Michiels, JJ1
Bendandi, M; Tabanelli, M; Tura, S; Zinzani, PL1
Chubb, S; Ford, R; Hittelman, WN; Meyn, RE; Plunkett, W; Robertson, LE; Story, M1
Delannoy, A; Ferrant, A; Hanique, G1
Lemon, RH; Piro, LD; Saven, A1
Larson, RA; Spielberger, RT; Stock, W1
Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Robertson, LB1
Leporrier, M; Reman, O; Troussard, X1
Woodcock, BE1
Clauvel, JP; Jaccard, A; Oksenhendler, E1
Chamone, DF; Deisseroth, AB; Del Giglio, A; Ford, RJ; Johnston, D; Keating, M; Manning, J; O'Brien, S; Saya, H1
Huh, Y; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, W; Robertson, L1
Gandhi, V1
Buckley, C; Hoffbrand, AV; Smith, OP1
Collins, KA; Davda, RK; Kitchens, CS1
Gandhi, V; Keating, MJ; Plunkett, W; Robertson, LE1
Cabanillas, F; Gandhi, V; Gregoire, V; Keating, MJ; McLaughlin, P; O'Brien, S; Plunkett, W; Robertson, LE; Yang, L1
Hałaburda, K; Hellmann, A1
Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Kemena, A; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, L1
Cacciola, E; Di Raimondo, F; Giustolisi, R; Kantarjian, H; Keating, MJ; O'Brien, S; Robertson, LB1
Estey, E; Gandhi, V; Gregoire, V; Huang, P; Keating, MJ; Plunkett, W; Robertson, LE; Yang, LY1
Amess, J; Ganjoo, RK; Johnson, PW; Lim, J; Lister, TA; Norton, AJ; Pigaditou, A; Rohatiner, AZ; Rossi, A; Whelan, JS1
Engert, A; Freund, M; Gassmann, W; Hiddemann, W; Holtkamp, W; Pott, C; Sandford, D; Seufert, J; Unterhalt, M; Wörmann, B1
Bapat, A; Goldberg, J; Goldman, N; Gordon, R; Gryn, J1
Cleveland, KO; Gelfand, MS1
Cannon, LM; Garfinkel, H; Pezzimenti, J; Rhodes, R; Spilove, L1
Rai, KR3
McCulloch, EA; Rayappa, C1
Alexanian, R; Barlogie, B; Delasalle, K; Dimopoulos, MA; Kantarjian, H; Keating, MJ; O'Brien, S; Pierce, S1
Bergmann, L; Fenchel, K; Hoelzer, D; Jahn, B; Mitrou, PS1
Bendandi, M; Benfenati, D; Bocchia, M; Fanin, R; Gozzetti, A; Lauria, F; Raspadori, D; Rondelli, D; Zaja, F; Zinzani, PL1
Benfenati, D; Bocchia, M; Cavo, M; Cirio, TM; Gozzetti, A; Lauria, F; Raspadori, D; Rondelli, D; Zaja, F; Zinzani, PL1
Beran, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, M; O'Brien, S; Plunkett, W; Rios, MB; Suki, S1
Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB1
Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Robertson, LE; Smith, T1
Abdallah, JM; Cohen, RB; Foss, F; Gray, JR1
Estey, E; Gandhi, V; Keating, MJ; Plunkett, W2
Hopkins, J; Howe, D; Johnson, SA; Phillips, MJ; Richardson, D1
Cortes-Franco, J; Estey, E; Kornblau, SM1
Ganjoo, R; Johnson, PW; Lister, TA; Rohatiner, AZ; Whelan, JS1
Feldman, EJ; Keating, MJ1
Binet, JL2
Ang, KK; Brock, WA; Grégoire, V; Hittelman, WN; Plunkett, WK; Price, RE; Ruifrok, AC1
Pawelski, S1
Bergmann, L; Diehl, V; Engert, A; Fenchel, K; Hoelzer, D; Mitrou, PS; Pralle, H; Wijermans, P1
Keating, MJ; Lerner, S; O'Brien, S; Robertson, LE; Seymour, JF1
Archimbaud, E; Thomas, X1
de Marie, S; Leenders, A; Sonneveld, P1
Copplestone, JA; Craig, V; Curtis, D; Hamblin, TJ; Hamon, MD; Myint, H; Orchard, J; Oscier, DG; Prentice, AG1
Algora, M; Briz, M; Cabrera, R; Díez, JL; Fernández, MN; Forés, R; Herrero, M; Regidor, C; Sanjuán, I1
Calleja, E; Gabrilove, J; Menzel, T; Rahman, Z; White, K; Wieder, R; Wilson, EL1
Björkholm, M; Celsing, F; Runarsson, G; Waldenström, J1
Denny, AW; Huh, YO; Keating, MJ; Nelson, JA; Plunkett, W; Robertson, LE1
Maclean, R; Meiklejohn, D; Soutar, R1
Kelleher, DK; Thews, O; Vaupel, P1
Anderlini, P; Estey, EH; Kantarjian, HM; Keating, MJ; Luna, M; O'Brien, S; Pierce, S1
Estey, EH; Kantarjian, HM; Keating, MA1
Hapke, DM; Mitchell, BS; Stegmann, AP1
Bernabei, PA; D'Ippolito, G; Ermini, A; Rossi-Ferrini, P; Santini, V; Zoccolante, A1
Falkson, CI1
Brown, RD; Gibson, J; Joshua, DE; Luo, XF; Petersen, AJ; Pope, B; Schutz, L; Wiley, JS1
Gandhi, V; Loughlin, S; Plunkett, W; Zwelling, LA1
Catovsky, D; Murphy, RL1
Alcorta, I; Briones, J; Pereira, A1
Bachelez, H; Bazarbachi, A; Dehen, L; Delmer, A; Dubertret, L; Zittoun, R1
Emmerich, B; Hiddemann, W; Johnson, S; Juliusson, G; Löffler, H; Osby, E; Smith, AG; Wyld, PJ1
Geisen, F; Konwalinka, G; Michlmayr, G; Schirmer, M1
Estey, EH; Gandhi, V; Keating, MJ; Plunkett, W1
Huang, P; Kamiya, K; Plunkett, W1
Williamson, LM; Wimperis, JZ; Wood, ME; Woodcock, B1
Falkson, CI; Falkson, G; Hocepied, AM1
Gjedde, SB; Hansen, MM1
Enzenauer, RJ; Judson, PH2
Catovsky, D; Glynne, P; Hamblin, M; Matthey, F; Mehta, J; Middleton, G; Powles, R; Prendiville, J; Singhal, S; Treleaven, J; Zomas, A1
Faure, P; Madelaine-Chambrin, I; Piquet-Sevrin, V1
Keating, MJ; Wright, SJ1
Estey, E; Kuschel, B1
Bosch, F; Briones, J; Colomer, D; Esteve, J; Hadjieu, E; López-Guillermo, A; Montserrat, E; Rozman, C; Urbano-Ispizua, A1
Lawrence, TS; McGinn, CJ; Shewach, DS1
Chandra, J; Keating, M; McConkey, DJ; McDonnell, TJ; Plunkett, W; Reed, JC; Wright, S1
Koeppen, H; Larson, RA; Olopade, OI; Ong, ST1
Lärfars, G; Samuelsson, J; Udén-Blohmé, AM1
Ueda, T1
Crozat-Grosleron, S; Dubois, A; Reynaud, D; Rossi, JF; Yeche, S1
Błasinka-Morawiec, M; Ceglarek, B; Dmoszynska, A; Durzynski, T; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Kasznicki, M; Komarnicki, M; Konopka, L; Kopec, I; Kotlarek-Haus, S; Krykowski, E; Lewandowski, K; Maj, S; Mazur, G; Potemski, P; Płuzanska, A; Robak, T; Sikorska, A; Skotnicki, AB; Urasinski, I; Zaucha, JM; Zdziarska, B1
Bayle, C; Cartron, J; Lambert, T; Rudent, A; Tchernia, G; Tertian, G1
Brock, WA; Grégoire, V; Hittelman, WN; Hunter, NR; Milas, L; Plunkett, W1
Fraternale, A; Magnani, M; Rossi, L1
Zaja, F1
Johnson, SA3
Lipton, JH; Pierratos, A; Tisler, A1
Jacobs, A1
Aristei, C; Aversa, F; Chionne, F; Latini, P; Martelli, MF; Perruccio, K; Raymondi, C; Terenzi, A1
Adam, Z; Hejlová, N; Vorlícek, J1
De Marco, C; Gornati, D; Orlandi, L; Silvestrini, R; Vaglini, M; Zaffaroni, N1
Wiley, JS1
Baldwin, SA; Beaumont, N; Boumah, CE; Cass, CE; Coe, I; Davies, A; Griffiths, M; Kwong, FY; Sundaram, M; Yao, SY; Young, JD1
Al-Katib, A; Gabrilove, JL; König, A; Lynen, S; Menzel, T; Raveche, E; Rosén, A; Wrazel, L1
Kantarjian, H; Keating, MJ; O'Brien, S1
Byrnes, JJ; Frankfurt, OS; Villa, L1
Bowen, AL; Catovsky, D; Dyer, MJ; Emmett, E; Matutes, E; Zomas, A1
Bourantas, KL; Briasoulis, E; Christou, L; Konstantinidou, P; Panteli, A; Tsiara, S1
Glassman, AB; Keating, MJ; Li, L; Liu, X; Plunkett, W; Stros, M; Yang, LY1
Dimopoulos, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Lerner, S; McLaughlin, P; O'Brien, S; Plunkett, W1
Gati, WP; Kieller, DM; Rahn, JJ; Tyrrell, DL1
Behrens, J; Killick, S; Mercieca, J; Nandi, A1
Aziz, M; Levin, M; Opitz, L1
Boscagli, A; Dujardin, P; Gary-Toussain, M; Peyrade, F; Roa, M; Taillan, B1
Andersson, BS; Champlin, RE; Giralt, S; Keating, MJ; Khouri, IF; Körbling, M; Lerner, S; Mehra, RC; O'Brien, S; Palmer, JL; Przepiorka, D; van Besien, K; Vriesendorp, HM1
Brisou, P; de Jaureguiberry, JP; Gisserot, O; Hequet, O; Jaubert, D; Muzellec, Y1
Hayag, MV; Nouri, K; Taylor, JR; Tie, C1
Alcala, A; Arias-Sampedro, J; Bosch, F; Fernandez, MN; Garcia-Conde, J; Guardia, R; Lopez-Lorenzo, JL; Manso, F; Martin, A; Montserrat, E; Odriozola, J; Oyarzabal, FJ; Prieto, E1
Beran, M; Cortes, J; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Talpaz, M1
Hiddemann, W; Pott, C1
Bergmann, L1
Hilgenfeld, E; Jäger, U; Knauf, WU; Mitterbauer, M; Wilfing, A1
Arning, M; Schneider, W; Südhoff, T1
Adkins, JC; Markham, A; Peters, DH1
Petryshyn, RA; Slomiany, DJ; Woldehawariat, G1
Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K1
Catovsky, D; Dyer, MJ; Emmett, E; Hale, G; Kelsey, SM; Mackay, HJ; Newland, AC; Thornton, P; Waldmann, H1
Huang, P; Iwasaki, H; Keating, MJ; Plunkett, W1
Or, R; Polliack, A; Teiman, S; Weiss, L1
Bendandi, M; Gherlinzoni, F; Magagnoli, M; Merla, E; Tura, S; Zinzani, PL1
Ballin, A; Davidovitz, Y; Meytes, D1
Cohen, JD; Katz, TB; Marcel, PD; Strock, DJ; Teik, JE1
Frewin, RJ; Provan, D; Smith, AG1
Hájek, R; Krahulcová, E; Mayer, J; Penka, M; Vásová, I1
Blanche, P; Colbert, N; Galezowski, N; Golstein, FW; Lasoudris, J; Mainardi, JL; Maulin, L; Nguyen, TB1
Hoskin, PJ; Kanegaonkar, R; Mahadevan, A1
Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; North, L; Pate, O; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, AH; Younes, A1
Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S1
Egle, A; Geley, S; Greil, R; Hartmann, BL; Kofler, R; Kos, M; Villunger, A1
Ballal, K; Huang, P; Plunkett, W1
Heitjan, DF1
Cusack, JC; Keating, MJ; Lerner, S; Pollock, RE; Seymour, JF1
Bendandi, M; Benni, M; Cavo, M; de Vivo, A; Magagnoli, M; Rondelli, D; Tura, S; Zamagni, E; Zinzani, PL1
Emilia, G; Ferrara, L; Gandini, G; Longo, G; Torelli, U1
Magagnoli, M; Ottaviani, E; Pellacani, A; Tosi, P; Tura, S; Zinzani, PL1
Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Talpaz, M1
Alfarano, A; Aragno, M; Bergui, L; Caligaris-Cappio, F; Circosta, P; De Leo, AM; Gottardi, D; Gregoretti, MG; Stacchini, A1
Bolam, S; Orchard, J; Oscier, D1
Cummins, M; Deane, M; Emery, V; Gor, D; Griffith, PD; Macmahon, ME; Prentice, HG1
Soda, R; Tada, A; Takahashi, K; Takeuchi, M1
Antich Rojas, J; Balaguer, H; Cladera, A1
Andreeff, M; Beran, M; Estey, EH; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, S; Pierce, S1
Abbondanzo, SL; Aguilera, NI; Byrd, JC; Diehl, LF; Lichy, JH; Shields, DJ1
Begleiter, A; Daeninck, P; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L; Williams, G1
Berrebi, A; Klepfish, A; Shtarlid, M; Shvidel, L; Sigler, E1
Baccarani, M; Marin, L; Rogato, A; Russo, D; Silvestri, F; Zaja, F1
Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR1
Andreeff, M; Armitage, RJ; Clodi, K; Consoli, U; Palmer, JL; Snell, V; Thomas, EK; Younes, A; Zhao, S1
Kapelushnik, J; Nagler, A; Or, R; Slavin, S1
Beal, CL; Byrd, JC; Chaffin, DJ; Vick, DJ1
Avramis, VI; Kowck, R; Krailo, MD; Liu-Mares, W; Ramilo-Torno, LV; Reaman, GH; Sato, JK; Sharpe, A; Wiersma, S1
Bolam, S; Orchard, JA; Oscier, DG1
Chapman, R; Grigg, A; Szer, J1
Losonczy, H1
Bertone, A; Candoni, A; Grattoni, R; Russo, D; Zaja, F1
Nagler, A; Slavin, S1
Byrd, JC; Diehl, LF; Freiman, J; Kweder, SL; Weiss, RB1
Duley, JA; Fabianowska-Majewska, K; Ruckemann, K; Simmonds, HA1
Fabianowska-Majewska, K; Wyczechowska, D2
Amoroso, V; Baccarani, M; Beltrami, CA; Damiani, D; Di Loreto, C; Fanin, R; Infanti, L; Mariuzzi, L; Russo, D; Salmaso, F; Silvestri, F; Zaja, F1
Arizpe-Bravo, D; Garcés-Eisele, J; Ponce-de-León, S; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ; Sánchez-Sosa, S1
Aitini, E; Costa, P; Forghieri, ME; Lazzarini, L; Luzzati, R; Nicolato, A; Perboni, G; Scalzini, A; Zinzani, PL1
Ferrara, F; Latagliata, R; Magrin, S; Mele, G; Mirto, S; Montillo, M; Petti, MC; Pinto, A; Tedeschi, A; Zagonel, V1
Ben-Othman, T; Caspard, H; Clauvel, JP; Deconinck, E; Delgado, MA; Delmer, A; Duboisset, P; Entezam, S; Fort, N; Guibon, O; Harousseau, JL; Hermine, O; Leblond, V; Maloisel, F; Mariette, X; Merlet, M; Morel, P; Taksin, AL; Yakoub-Agha, I1
Baudet, S; Binet, JL; Blanc, C; Issaly, F; Mentz, F; Merle-Beral, H1
Beauduin, M; Bruniaux, M; De Coster, B; Grégoire, V; Octave Prignot, M; Scalliet, P1
Cheson, BD; Frame, JN; Quashu, N; Sorensen, JM; Vena, D1
Clauvel, JP; Eftekhari, P; Lassoued, K; Oksenhendler, E; Scieux, C1
Alfinito, F; Bonelli, P; Chiurazzi, F; Costantini, S; Defrance, T; Lamberti, A; Romano, MF; Tassone, P; Tuccillo, F; Turco, MC; Venuta, S1
Leach, M; Parsons, RM; Reilly, JT; Winfield, DA2
O'Brien, S1
Keating, MJ1
Bellucci, R; Cordone, I; de Fabritiis, P; De Propris, MS; Foà, R; Lisci, A; Mauro, FR; Sala, R1
Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE1
Brugiatelli, M; Callea, I; Callea, V; Console, G; Dattola, A; di Raimondo, F; Iacopino, P; Morabito, F; Pucci, G; Stelitano, C1
Catovsky, D; Killick, S; Matutes, E; Sternberg, AJ; Wotherspoon, AC1
Bromidge, TJ; Howe, DJ; Johnson, SA; Rule, SA; Turner, DL1
Azar, N; Binet, JL; Dighiero, G; Gabarre, J; Gonzalez, H; Leblond, V; Sutton, L; Vernant, JP1
Anderlini, P; Andersson, B; Champlin, R; Claxton, D; Donato, M; Gajewski, J; Gee, A; Giralt, S; Ippoliti, C; Keating, M; Khouri, IF; Körbling, M; O'Brien, S; Przepiorka, D; Ueno, N; von Wolff, B1
Miller, M1
Bai, L; Bräutigam, M; Kon, K; Tatsumi, M; Yamaguchi, M1
Bode, U; Fleischhack, G; Graf, N; Hasan, C; Mann, G1
Christopherson, RI; Mulligan, SP; Szabados, E; Wilson, PK1
Boumpas, DT; Davis, JC; Fessler, BJ; Fleisher, TA; Klippel, JH; McInnes, IB; Pillemer, S; Tassiulas, IO; Wilder, R; Yarboro, CH1
Bolam, S; Hamblin, TJ; Myint, H; Orchard, J; Oscier, DG1
Kim, HS; Niihara, Y; Yospur, L1
Hamblin, TJ; Myint, H; Orchard, JA; Oscier, DG1
Ballerini, F; Beltrami, G; Bruni, R; Canepa, L; Cavaliere, M; Celesti, L; Clavio, M; Congiu, M; Damasio, E; Gobbi, M; Miglino, M; Nati, S; Pierri, I; Pietrasanta, D; Rossi, E; Santini, G; Spriano, M; Vallebella, E; Vimercati, R1
Anaissie, EJ; Kantarjian, H; Keating, MJ; Kontoyiannis, DP; Lerner, S; O'Brien, S; Robertson, L1
Flandrin, G; Maloisel, F; Troussard, X1
Callea, I; Console, G; Filangeri, M; Messina, G; Morabito, F; Sculli, G1
Byrd, JC; Diehl, LF; Flinn, IW; Fuchs, EJ; Grever, MR; Lehman, TA; Nguyen, PL; Sausville, E; Shinn, C; Waselenko, JK1
Du, M; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W1
Du, M; Estey, E; Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W1
Huang, P; Plunkett, W; Robertson, LE; Wright, S1
Consoli, U; Plunkett, W; Sandoval, A1
Gandhi, V; Huang, P; Plunkett, W; Seymour, JF1
Cawley, M; Kaplan, B; Narasihman, P; Taha, HM; Venkatesh, L1
Azgui, Z; Baudet, S; Brefort, K; Chretien, MC; Dujarric, C; Maloum, K; Mentz, F; Merle-Béral, H; Sevin, O; Vinsobre, MF1
Crollo, R; D'Oronzio, L; Dambra, P; Dell'Osso, A; Grande, M; Lasaracina, E; Loria, MP; Lucivero, G1
Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ1
Filangeri, M; Morabito, F; Oliva, B; Sculli, G1
Andrieu, V; Carbon, C; Couvelard, A; Encaoua, R; Grange, MJ1
Adams, EM; Bartlett, ML; Fleisher, T; Hicks, JE; McGarvey, C; Plotz, PH; Pucino, F; Sonies, BC; Thornton, B; Villalba, ML; Yarboro, C1
Machaczka, M; Rucińska, M; Skotnicki, AB; Załuska, A1
Estey, EH2
Bosanquet, AG1
Berrebi, A; Klepfish, A; Shimoni, A; Shtalrid, M; Shvidel, L; Sigler, E1
Koski, T; Vilpo, J; Vilpo, L2
Asfoura, J; Butty, H; Cortese, F; Doyle, M; Rutecki, G1
Astori, C; Bernasconi, C; Brusamolino, E; Corso, A; Lazzarino, M; Montillo, M; Morra, E; Orlandi, E; Pagnucco, G; Simoncini, L; Tedeschi, A1
Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G1
Davies, S; Frewin, R; Johnson, S; Rule, S; Tighe, M; Turner, D1
Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P1
Karadogan, I; Timuragaoglu, A; Undar, L1
Bamborschke, S; Diehl, V; Fätkenheuer, G; Lehrke, R; Re, D; Reiser, M; Salzberger, B; Schröder, R; Tesch, H1
Bergmann, L; Hoelzer, D; Jäger, E; Käfer, G; Mitrou, PS; Pfreundschuh, M; Reinhardt, U; Rummel, MJ1
Brugiatelli, M; Callea, V; Iuliano, F; Kropp, MG; Levato, D; Molica, S; Morabito, F; Nobile, F; Oriana, V; Stelitano, C1
Elliott, MA; Hammack, JE; Hoyer, JD; Letendre, L; Li, CY1
Albertini, P; Magagnoli, M; Ottaviani, E; Pellacani, A; Tosi, P; Tura, S; Zinzani, PL1
Lossos, IS; Paltiel, O; Polliack, A1
Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF1
Bardy, P; Byron, K; Grigg, A; Seymour, JF; Szer, J1
Al-Katib, AM; Beck, FW; Dutcher, BS; Hamdy, N; Limvarapuss, C; Mohammad, RM; Wall, NR1
Frank, DA; Mahajan, S; Ritz, J1
Camerone, G; Epis, R; Marruchella, A; Tondini, M1
Hughes, RA; Lunn, MP; Schey, S; Wilson, HC1
Zingman, BS1
Bravery, CA; Hoffbrand, AV; Lewin, J; Mehta, AB; Mengubas, K; Owens, DL; Riordan, FA; Wickremasinghe, RG1
Alvegård, TA; Békássy, AN; Chan, KW; Ha, CS; Nunez, C; Sallerfors, B1
Byrd, JC; Diehl, LF; Dow, NA; Hospenthal, DR; Howard, RS; McGrail, LH1
Emmanouilides, C; Kunkel, L; Rasti, S; Rosen, P; Territo, M1
Friedenberg, WR; Hogan, TF; Marx, JJ; Mazza, JJ; Musser, C; Rodvold, KA; Rushing, DA; Spencer, SK; Tewksbury, DA1
Dizdari, A; Lemoli, RM; Leopardi, G; Martinelli, G; Motta, MR; Pastano, R; Piccaluga, PP; Ricci, P; Rizzi, S; Testoni, N; Tosi, P; Tura, S; Visani, G1
Bouabdallah, R; Cohen-Valensi, R; Coso, D; Costello, R; Gastaut, JA; Nezri, M; Sainty, D1
Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C1
Kalaycio, M; Sen, K1
Chen, JH; Grant, S; Kramer, LB; Rao, AS; Tang, L; Vrana, JA; Wang, Z1
Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Ketterer, N; Moullet, I; Salles, G; Sonet, A; Thieblemont, C1
Dreger, P; Emmerich, B; Hallek, M; Montserrat, E; Schmitt, B; Wendtner, CM; Wilhelm, M1
del Potro Gómez, E; Morales Sanz, D1
Hieke, K; Howard, P; Kerrigan, M; McIntyre, AM; Smartt, PF; Sweetenham, J; Townshend, S1
Bosanquet, AG; Johnson, SA; Richards, SM1
Callet Bauchu, E; Dumontet, C; Fabianowska-Majewska, K; Fang, X; Gandhi, V; Gazzo, S; Lepoivre, M; MacKey, J; Mantincic, D; Peters, GJ; Rolland, MO; Tigaud, I; Vanier-Viornery, A; Voorn, DA; Wyczechowska, D1
Blanche, P; Bouscary, D; Dreyfus, F; Gombert, B; Sicard, D; Stieltjes, N1
Fiser, J; Jindra, P; Koza, V; Svojgrová, M; Vozobulová, V1
Ahmed, N; Baumforth, KR; Hassan, HT; Laverick, L; Sammons, J1
Algeri, R; Bigazzi, C; Bocchia, M; Forconi, F; Lauria, F; Marconcini, S; Marotta, G1
Demeter, J; Lehoczky, D; Varga, F1
Costello, C; Shah, S; Stern, SC1
Magagnoli, M; Pellacani, A; Tosi, P; Tura, S; Visani, G; Zinzani, PL1
Austin, HA; Balow, JE; Boumpas, DT; Fleisher, TA; Kim, Y; Piscitelli, S; Pucino, F; Tassiulas, IO; Vaughan, E1
Hast, R; Hjalmar, V; Jacobsson, B; Petrescu, A1
Akça, S; Karadoğan, I; Undar, L1
Allen, PD; Kelsey, SM; Newland, AC; Richardson, DS2
Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N1
Cawley, JC; Pettitt, AR; Sherrington, PD2
Baccarani, M; Marin, L; Ramello, M; Russo, D; Silvestri, F; Zaja, F1
Bolgert, F; Camporo, P; Gonzalez, H; Leblond, V1
Beinert, T; Hallek, M; Langelotz, C; Mergenthaler, HG; Possinger, K; Schmid, P; Schweigert, M; Sezer, O1
Aitini, E; Battista, R; Bendandi, M; Bocchia, M; Cellini, C; De Renzo, A; Fattori, PP; Gentilini, P; Gherlinzoni, F; Guardigni, L; Magagnoli, M; Moretti, L; Ronconi, F; Tura, S; Zaccaria, A; Zinzani, PL1
Cawley, JC; Clarke, AR; Griffiths, SD; Pettitt, AR1
Ahsan, G; Jones, R; Schey, S1
Catovsky, D; Ribeiro, I; Tsatalas, C1
Peterson, BA1
Barrett, J; Childs, RW; Clave, E; Hensel, N; Plante, M; Tisdale, J1
Barrett, J; Cheson, BD; Freidlin, B; Vena, DA1
Li, MJ; Yang, LY1
Ciolli, S; Ferrara, F; Leoni, F; Magrin, S; Mele, G; Mirto, S; Montillo, M; Morra, E; Pinto, A; Zagonel, V1
Bentley, P; Davies, S; Hidalgo de Quintana, J; Hoy, T; Pepper, C; Thomas, A1
Blaschke, V; Braess, J; Brinck, U; Dames, K; Letschert, M; Neumann, C; Reich, K; Rünger, TM; Wörmann, B1
Bahceci, E; Barrett, J; Childs, R; Clave, E; Epperson, D1
Grau, E; Pastor, E; Real, E; Sandra, S1
Belanger, C; Bouabdallah, R; Brice, P; Brousse, N; Coiffier, B; Haioun, C; Janvier, M; Neidhardt-Bérard, EM; Péaud, PY; Pico, JL; Solal-Celigny, P; Tilly, H1
Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB1
Faure, I; Leng, B; Mercié, P; Pellegrin, JL; Viallard, JF1
Albertioni, F; Eriksson, S; Månsson, E; Sällström, J; Spasokoukotskaja, T1
Arcaini, L; Astori, C; Baldanti, F; Bernasconi, C; Furione, M; Gerna, G; Lazzarino, M; Orlandi, E; Pagnucco, G; Paulli, M; Viglio, A1
Gandhi, V; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Robertson, LE; Santini, V; Seymour, JF1
Albertioni, F; Larsson, BS; Liliemark, J; Lindemalm, S1
Calvo Villas, J; Ramírez Sánchez, M; Sicilia Guillén, F1
Honma, Y; Niitsu, N; Umeda, M1
Bauer, O; Golfier, S; Klein, A; Miera, O; Schriever, F1
Campos, F; Dufour, P; Giron, C; Maloisel, F1
Arnaud, MC; Otto, J; Pivot, X; Schneider, M; Tchiknavorian, X; Thyss, A1
Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL1
Cantú, OE; Gómez-Almaguer, D; González-Llano, O; Hernández, NE; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ1
Lamberti, A; Romano, MF; Turco, MC; Venuta, S1
Amurri, B; Mazza, P; Palazzo, G; Pricolo, G; Prudenzano, A; Stani, L1
Bowyer, JD; Gregson, RM; Horn, EH; Johnson, EM1
Bennett, JM; Cassileth, PA; Gordon, LI; Hochster, HS; Oken, MM; Raphael, BG; Winter, JN1
Carella, AM; Giralt, S; Slavin, S1
Calabrò, ML; Coppolino, S; Ficarra, P; Ficarra, R; Melardi, S; Semreen, M; Tommasini, S; Villari, A1
Blum, HE; Geissler, M; Krohne, TU; Mohr, L; Roberts, B; Shankara, S; Wands, JR; Yoon, SK1
Horning, SJ1
Ahmad, I; Al-Katib, AM; Beck, FW; Liu, KZ; Mantsch, HH; Mohammad, RM; Wall, NR1
Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S1
Freireich, EJ; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S; Robertson, LE; Smith, TL1
Bigazzi, C; Bocchia, M; Bucalossi, A; Galieni, P; Laszlo, D; Lauria, F; Marotta, G; Raspadori, D; Scalia, G; Tozzi, M1
Chastang, C; Chevret, S; Leporrier, M1
Casabianca, A; Celeste, AG; Chiarantini, L; Fraternale, A; Magnani, M; Schiavano, GF; Tonelli, A1
Chatterjee, R; Goldstone, A; Haines, GA; Morris, ID; Perera, DM1
Andreeff, M; Clodi, K; Consoli, U; Jiang, S; Kliche, KO; Schenk, T; Snell, V; Weidner, D; Zhao, S1
Apperley, JF; Belhabri, A; Björkstrand, B; Dreger, P; Hamon, M; Kimby, E; Michallet, M; Milpied, N; Remes, K; Santini, G; Tanguy, ML; Thiébaut, A1
Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P1
Bernard, N; Beylot, J; Delevaux, I; Lacoste, D; Morlat, P; Nouts, C1
Belanger, C; François, S; Hermine, O; Lebas de La Cour, JC; Lefrère, F; Tilly, H; Troussard, X; Valensi, F; Varet, B1
Bosanquet, AG; Bosanquet, MI1
Barth, S; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Schinköthe, T; Schulz, H; Wittor, H1
Cerretti, R; Coluzzi, S; Foa, R; Giannarelli, D; Girelli, G; Mandelli, F; Mauro, FR1
Eberhardt, W; Heim, MM; Müller, MR; Seeber, S1
Champlin, R; Giralt, S; Khouri, I1
Bendandi, M; Cellini, C; Gherlinzoni, F; Magagnoli, M; Orcioni, GF; Pileri, SA; Stefoni, V; Tura, S; Zinzani, PL1
Achanta, G; Feng, L; Huang, P; Pelicano, H; Plunkett, W; Zhang, W1
Eckhaus, MA; Fowler, DH; Gress, RE; Petrus, MJ; Williams, JF1
Nagler, A; Naparstek, E; Or, R; Samuel, S; Slavin, S; Varadi, G1
Braess, J; Hiddemann, W; Jahns-Streubel, G; Kern, W; Keye, S; Schleyer, E; Unterhalt, M; Wegendt, C1
Haznedar, R; Sucak, GT; Yağci, M2
Chim, CS; Liang, R; Wong, SS; Yuen, KY1
Grigg, A; Roberts, A; Seymour, JF; Szer, J1
Januszewicz, EH; Juneja, S; Prince, HM; Seymour, C; Strickland, AH; Wolf, M1
Catovsky, D; Dearden, CE; Matutes, E1
Beer, M; Byrd, JC; Grever, MR; Lucas, MA; Waselenko, JK1
Kipps, TJ1
Foss, FM1
Ambinder, RF; Byrd, JC; Diehl, LF; Flinn, IW; Grever, MR; Jamison, J; Morrison, C; Murphy, T; Piantadosi, S; Seifter, E; Vogelsang, G1
Auxenfants, E; Bourgeois, E; Dubest, C; Jouffrey, C; Mahieu, M; Rose, C1
Molinari, A; Poletti, G; Poletti, V; Salvucci, M; Zaccaria, A; Zanchini, R; Zuffa, E1
Nagler, A; Or, R; Slavin, S; Varadi, G1
Campbell, S; Ghosh, S; Parker, A; Thomas, R1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Kroschinsky, F; Naumann, R; Neubauer, A; Platzbecker, U; Plettig, R; Röllig, C; Schuler, U; Thiede, C1
Vastag, B1
Cawley, JC; Pettitt, AR1
Galloway, MJ; Hamilton, PJ; Tiplady, CW1
Huang, P; Keating, MJ; Plunkett, W; Sandoval, A; Van Den Neste, E1
Byrd, JC; Rai, KR1
Au, WY; Choy, C; Kwong, YL; Ng, WM1
Cervantes, F; Cervera, A; Cid, J; Ferrer, I; Montserrat, E; Muñoz, E; Revilla, M1
Akhter, S; Ambrus, JL; Donahue, T; Islam, A; Sands, AM; Vladutiu, AO1
Amaranto, P; Capria, S; Cimino, G; Cordone, I; de Fabritiis, P; Foa, R; Mandelli, F; Mauro, F; Meloni, G; Proia, A; Rapanotti, C; Reato, G; Vignetti, M1
Baccarani, M; Capello, D; Fanin, R; Gaidano, G; Patriarca, F; Zaja, F1
Bartholomew, A; Chen, YH; Devine, S; Hoffman, R; Koshy, M; Peace, D; Sher, D; Sosman, J; Stock, W; van Besien, K1
Glenn, M; Golde, DW; Maslak, P; Noy, A; Rahman, Z; Scheinberg, DA; Weiss, MA; Zelenetz, A1
Casado, FJ; Inzillo, SM; Larrayoz, IM; Lostao, MP; Mata, JF; Pastor-Anglada, M1
Crawley, CR; Foran, JM; Gupta, RK; Johnson, PW; Johnson, SA; Lister, TA; Matthews, J; Micallef, IN; Radford, JA; Rohatiner, AZ; Summers, K; Sweetenham, JW1
Chakrabarti, S; Chakraverty, RK; Chopra, R; de Elvira, MC; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD1
Gabeeva, NG; Kaplanskaia, IB; Kremenetskaia, AM; Moiseeva, TN; Pivnik, AV; Samoĭlova, RS; Varlamova, EIu; Zybunova, EE1
Astori, C; Bernasconi, C; Bernasconi, P; Boni, M; Calatroni, S; Caresana, M; Cavigliano, P; Giglio, S; Lazzarino, M; Orlandi, E; Pagnucco, G1
Boguszewski, CL; Collaço, LM; Graf, H; Neto, JZ; Nomura, LM; Pereira, FO1
Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT1
Du, M; Gandhi, V; Keating, MJ; Nowak, B; Paff, MT; Plunkett, W; Ramakrishna, P; Rodriguez, CO1
Chee, YL; Culligan, DJ; Kurtz, JB; Molyneaux, P; Olson, JA; Watson, HG1
Albertini, P; Bendandi, M; Magagnoli, M; Rondelli, D; Stefoni, V; Tani, M; Tura, S; Zinzani, PL1
Abdel-Raheem, MM; Gross, GG; Jamil, MG; Potti, A1
Adachi, S; Carrera, CJ; Carson, DA; Chao, Q; Cottam, HB; Genini, D; Leoni, LM; Rose, DW1
Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M1
Chott, A; Geissler, K; Gisslinger, H; Jäger, U; Knöbl, P; Lechner, K; Schwarzinger, I; Thalhammer-Scherrer, R1
Plunkett, W; Sampath, D1
Harousseau, JL; Mahé, B; Milpied, N; Morin, O; Rapp, MJ; Vigouroux, S1
Bishop, MR; McCarthy, NJ1
Bigazzi, C; Bocchia, M; Lauria, F; Lenoci, M; Marotta, G; Tozzi, M1
Appelbaum, FR; Cheson, BD; Elias, L; Hines, J; Kolitz, J; Larson, RA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L; Threatte, GA1
Binet, JL; Dighiero, G1
Acquaah-Mensah, GK; Biswal, SS; Datta, K; Kehrer, JP1
Higashi, Y; Pallis, M; Russell, NH; Turzanski, J1
Oddis, CV1
Johnson, SA; Thomas, W1
Back, DJ; Hoggard, PG; Johnson, MA; Kewn, S; Sales, SD1
Aul, C; Gattermann, N; Germing, U; Misgeld, E1
del Mar Castellanos, M; Gardella, S; Mata, MI; Ortiz, MR1
Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G1
Ciolli, S; Fanci, R; Leoni, F; Nozzoli, C; Rossi Ferrini , P; Santini, V1
Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A1
Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X1
Auerbach, AD; Boulad, F; Collins, N; George, D; Gillio, A; Kernan, NA; O'Reilly, RJ; Prasad, V; Regan, AD; Small, TN; Torok-Castanza, J1
Baccarani, M; Fanin, R; Patriarca, F; Silvestri, F; Sperotto, A; Zaja, F1
Almeida, A; Daly, P; Dokal, I; McCloy, M; Roberts, IA; Vulliamy, T1
Ahn, J; Chi, H; Kim, W; Lee, J; Lee, K; Park, C1
Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA1
Claviez, A; Dreger, P; Glass, B; Humpe, A; Schmitz, N; Schoch, R; Seyfarth, B; Suttorp, M; von Neuhoff, N1
Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A1
Beran, M; Cortes, J; Giles, FJ; Kantarjian, HM; Keating, M; Koller, CA; Lerner, S; O'Brien, SM1
Bruzzone, BM; Cataldi, A; Franceschini, R; Icardi, G; Tenconi, GL1
Dai, Y; Decker, R; Dent, P; Grant, S; Harvey, S; Kramer, L; Schaefer, G; Tang, L1
Ahlmann, M; Baumann, M; Boos, J; Freund, A; Lanvers, C; Lümkemann, K; Rössig, C1
Chisesi, T; Congiu, AM; Gallamini, A; Gobbi, M; Marino, G; Mattei, D; Nati, S; Pierluigi, D; Rossi, E; Rubagotti, A; Santini, G; Sertoli, MR; Spriano, M; Truini, M; Vimercati, R1
Bone, N; Han, L; Kay, NE; Williams, G1
Filippa, D; Glenn, M; Keenan, JR; Maslak, P; Noy, A; Rahman, ZU; Verma, R; Weiss, M; Zelenetz, AD1
Brandi, G; Casabianca, A; Chiarantini, L; Fraternale, A; Magnani, M; Tonelli, A1
Andolina, M; Jankovic, G; Lepore, L; Maximova, N; Parco, S; Rabusin, M; Tuveri, G1
Aker, M; Brautbar, C; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G1
Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ1
Greene, V; Kanold, J; Schneider, P; Vannier, JP1
Chan, KW; Chik, KW; Jeha, S; Li, CK; Shing, MK; Worth, LL; Yuen, PM1
Weiss, MA1
Barosi, G; Liberato, LN; Marchetti, M1
Copur, MS; Ledakis, P; Muhvic, J1
Celik, I; Erman, M; Tekuzman, G1
Mounter, P; Proctor, SJ; Summerfield, GP1
Ayres, M; Du, M; Gandhi, V; Hodge, JP; Keating, MJ; O'Brien, S; Plunkett, W; Ramakrishna, P; Rodriguez, CO; Rosner, GL; Weller, S1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Helwig, A; Mohr, B; Platzbecker, U; Röllig, C; Schaich, M; Schäkel, U; Thiede, C1
Nagler, A; Or, R; Panigrahi, S; Shapira, MY; Slavin, S; Wolf, DG1
Hendrick, A1
Balázs, M; Kappelmayer, J; Karászi, E; Kiss, A; Mezei, G; Rák, K; Rejtó, L; Telek, B; Udvardy, M; Ujj, G1
Joshi, SS; Pavletic, ZS; Vu, UE; Wang, X1
Imrie, KR; Tinmouth, A; Zanke, B1
Chatterjee, R; Goldstone, AH; Kottaridis, PD; McGarrigle, H1
Boumpas, DT; Burstein, AH; Illei, GG; Kuo, GM; Pucino, F; Yarboro, C1
Antin, JH; Duffy, KM; Kathakali, A; Laport, G; Leonard, DG; Luger, SM; McDaid, K; Orloff, G; Porter, DL; Schuster, SJ; Stadtmauer, EA; Tsai, D1
Child, FJ; Clift, A; Russell-Jones, R; Sabroe, R; Scarisbrick, JJ; Spittle, M; Whittaker, SJ1
Akiyama, H; Hiruma, K; Kaku, H; Karasawa, K; Kono, N; Maeda, Y; Mizuchi, D; Mori, S; Ohashi, K; Okamoto, R; Okoshi, Y; Okuyama, Y; Sakamaki, H; Sasaki, E; Sasaki, T1
Carbone, GM; Catapano, CV; Fernandes, DJ1
Byrd, JC; Flinn, IW; Grever, MR; Lehman, T; Lucas, D; Sausville, E; Shinn, C; Willis, CR1
Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD1
Ogura, M1
Bourikas, G; Kaloutsi, V; Kotsianidis, I; Margaritis, D; Martinis, G; Tsatalas, C1
Dumontet, C; Galmarini, CM; Mackey, JR1
Barlogie, B; Crowley, JJ; Dhodapkar, MV; Gertz, MA; Jacobson, JL; Kyle, RA; Rivkin, SE; Roodman, GD; Shurafa, M; Tuscano, JM1
Allen, J; Amagai, M; Carmichael, AJ; Dean, D; Frith, P; Gooptu, C; Hashimoto, T; Littlewood, TJ; Lyon, CC; MacWhannell, A; Oliwiecki, S; Wojnarowska, F1
Delannoy, A; Feremans, W; Ferrant, A; Michaux, L; Van Den Neste, E1
Ariola, C; Cordone, I; Fazi, F; Fenu, S; Mandelli, F; Montefusco, E; Nanni, M; Petti, MC; Spadea, A; Spiriti, MA1
Carella, AM; Carotenuto, M; Cascavilla, N; D'Arena, G; Greco, MM; Ladogana, S; Melillo, L; Perla, G; Sajeva, MR1
Balleari, E; Beltrami, G; Canepa, L; Carrara, P; Cerri, R; Clavio, M; Damasio, E; Gatto, S; Ghio, R; Gobbi, M; Masoudi, B; Miglino, M; Pierri, I; Sessarego, M1
Ghalie, R; Gregory, SA; Kraemer, K; Menduni, T; Modiano, M; Rifkin, R; Rubin, A; Vose, J1
Baccarani, M; Bertone, A; Bucalossi, A; De Vivo, A; Gobbi, M; Lauria, F; Marin, L; Mazza, P; Michelutti, A; Michieli, M; Pierri, I; Pricolo, G; Raspadori, D; Russo, D; Zaccaria, A; Zuffa, E1
Cacciola, E; Di Raimondo, F; Giustolisi, R; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S1
Cazin, B; Chevret, S; Delabarre, F; Leporrier, M; Levy, V; Porcher, R1
Boehrer, S; Chow, KU; Engels, K; Hansmann, ML; Harder, L; Hinz, T; Hoelzer, D; Janssen, O; Kabelitz, D; Kriener, S; Mitrou, PS; Rummel, MJ; Siebert, R; Weidmann, E1
Emmerich, B; Hallek, M; Schmitt, B; Stein, H1
Brandt, L; Glimelius, B; Kimby, E; Nygren, P1
Blume, KG; Chauncey, T; Feinstein, L; Flowers, C; Georges, G; Kiem, HP; Little, MT; Maloney, D; Maris, M; McSweeney, PA; Nash, RA; Niederwieser, D; Radich, J; Sandmaier, B; Shizuru, J; Storb, R; Woolfrey, A; Zaucha, JM1
Hallek, M; Schmitt, B1
Bentley, P; Fegan, C; Hoy, T; Pepper, C; Thomas, A1
Braess, J; Büchner, T; Hiddemann, W; Kern, W; Ohnesorge, J; Schleyer, E; Unterhalt, M; Wittmer, E; Wörmann, B1
Bryon, RJ; Chakrabarti, S; Griffiths, MJ; Handa, SK; Milligan, DW1
Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Jenke, A; Lutterbeck, K; Oelschlagel, U; Platzbecker, U; Plettig, R; Röllig, C; Thiede, C1
Classen, CF; Debatin, KM; Fairbanks, L; Friedrich, W; Hoffmann, GF; Schulz, AS; Sigl-Kraetzig, M; Simmonds, HA1
Grigg, AP; Ritchie, DS; Roberts, AW; Seymour, JF; Szer, J1
de Medeiros, CR; Pasquini, R; Silva, LM1
Blume, KG; Chauncey, T; Forman, S; Maloney, DG; Maris, M; McSweeney, PA; Niederwieser, D; Sandmaier, BM; Shizuru, J; Storb, R; Woolfrey, A1
Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Martell, RE; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L1
Czuczman, MS2
Derigs, HG; Fischer, T; Huber, C; Kolbe, K; Kreiter, S; Schneider, PM; Schuler, M; Ullmann, AJ; Winkelmann, N1
Cazin, B; Chevret, S; Fermand, JP; Guibon, O; Harousseau, JL; Leblond, V; Lévy, V; Maloisel, F; Porcher, R; Remenieras, L1
Brittinger, G; Busch, R; Döhner, H; Emmerich, B; Fostitsch, HP; Franke, A; Freund, M; Hallek, M; Herold, M; Hiddemann, W; Knauf, W; Kröber, A; Kuse, R; Nerl, C; Schmitt, B; Schriever, F; Sezer, O; Thiel, E; Wendtner, CM; Wilhelm, M1
Fujioka, T; Hirabayashi, N; Ikegame, K; Kawakami, M; Murakami, M; Ogawa, H; Soma, T; Sugiyama, H; Takahashi, R; Takimoto, T; Tamaki, H1
Chi, HS; Kim, WK; Lee, JH; Lee, JS; Lee, KH1
Akerstein, A; Engelhard, D; Gelfand, Y; Morecki, S; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G1
Churn, M; Clough, V1
de Andrés, I; Gallardo, E; Illa, I1
Bassan, R; Di Gaetano, N; Erba, E; Golay, J; Introna, M; Rambaldi, A; Xiao, Y1
Ehninger, G; Fiedler, F; Friedrichsen, K; Hänel, A; Hänel, M; Herbst, R; Morgner, A; Neser, S; Nicklisch, M; Teich, M1
Owen, RG1
Eigler, A; Emmerich, B; Endres, S; Loher, F; Meinhardt, G; Siegmund, B; Welsch, J1
Beran, M; Cortes, J; Despa, S; Estey, EH; Faderl, S; Giles, FJ; Kantarjian, H; Koller, CA; O'Brien, S; Shen, Y; Thomas, DA1
Cortes, J; Giles, F; Kantarjian, H; Keating, M; Koller, C; Loscertales, J; O'Brien, S; Thomas, D1
Chizuka, A; Iijima, K; Iizuka, A; Kamijo, K; Kanai, S; Kanda, Y; Kawano, Y; Makimoto, A; Mineishi, S; Nakai, K; Niiya, H; Ohnishi, M; Ohnishi, T; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Ueda, K; Wakasugi, H; Yakushijin, K1
Amin, K; Chen, YH; Devine, H; Devine, SM; Huml, M; Jessop, E; Maningo, M; Peace, D; Sanborn, R; Stock, W; Thomason, D; van Besien, K; Wickrema, A; Yassine, M1
Rouger, P; Wautier, JL1
Kashyap, A; Snowden, J1
Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Pagnucco, G; Varettoni, M1
Lim, LC; Ng, HJ1
Cazin, B; Deconinck, E; Desablens, B; Fermand, JP; Gardembas, M; Guibon, O; Guilhot, F; Harousseau, JL; Leblond, V; Lévy, V; Maloisel, F; Marit, G; Philippe, G; Porcher, R; Remenieras, L; Stamatoullas, A1
Sallah, S; Wan, JY1
Beltrami, G; Carella, AM; Carella, M; Corsetti, MT; Greco, M; Scalzulli, RP1
Battista, C; Broccia, G; Capalbo, S; Castoldi, G; Cuneo, A; Leoni, P; Liso, V; Molica, S; Montillo, M; Pogliani, E; Specchia, G1
Abreu-Díaz, G; Bravo, G; Gómez-Almaguer, D; Jaime-Pérez, JC; López-Martínez, B; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ1
Egerer, G; Ho, AD; Sauerland, K1
Gabrilove, JL1
Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR1
Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A1
Keating, MJ; Nowak, BJ; Plunkett, W; Yamauchi, T1
Engstrom, LW; Fuchs, EJ; Iannone, R; Jalla, S; Luznik, L1
Bornhäuser, M; Ehninger, G; Hertenstein, B; Kiehl, M; Kröger, N; Martin, H; Runde, V; Sayer, HG; Schetelig, J; Schwerdtfeger, R; Siegert, W; Theuser, C1
Bargay, J; Caballero, MD; Canals, C; Conde, JG; Léon, A; Martino, R; Odriozola, J; Rayón, C; San Miguel, J; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A1
Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; O'Brien, S; Pierce, SA; Thall, PF; Wang, X1
Bensinger, WI; Gooley, T; Maloney, DG; Sandmaier, BM; Storb, R; Weissinger, F1
Anderlini, P; Cabanillas, FF; Champlin, RE; Donato, ML; Gajewski, JL; Giralt, SA; Hagemeister, FB; Ippoliti, C; Khouri, IF; Korbling, M; Lee, MS; McLaughlin, P; Okoroji, GJ; Saliba, RM; Younes, A1
Adams, DJ; Colvin, OM; Flowers, JL; Levesque, MC; Moore, J; Silber, R; Smith, KL; Weinberg, JB1
Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F1
Fox, RM; Grigg, AP; Seymour, JF; Szer, J2
Barrett, AJ; Carter, C; Childs, R; de Witte, M; Kang, EM; Leitman, SF; Little, R; Malech, H; Morgan, RA; Phang, S; Tisdale, JF1
Brune, M; Ekman, T; Johansson, JE1
Bacigalupo, A; Endo, T; Fujimoto, K; Koike, T; Nakao, S; Nishio, M; Sakai, T; Sawada, K; Takashima, H1
Chevret, S; Mahé, C1
Czyz, M; Fabianowska-Majewska, K; Wyczechowska, D1
Branson, K; Chakrabarti, S; Chakraverty, R; Chopra, R; Craddock, C; Geary, J; Goldstone, AH; Hale, G; Hunter, A; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, DW; Parker, A; Peggs, K; Thuraisundaram, D; Verfuerth, S; Waldmann, H; Williams, CD; Yong, K1
Imamura, N1
Kolb, HJ; Ledderose, G; Schlemmer, M; Schleuning, M; Stoetzer, O; Waterhouse, C1
Cuello, MT; Fundia, AF; González-Cid, M; Larripa, I1
Champain, K; Csermak, K; Ganeshaguru, K; Gordon, M; Hart, SM; Hoffbrand, AV; Jones, DT; Man, A; Mehta, AB; Prentice, HG; Virchis, AE; Wickremasinghe, RG1
Appelbaum, FR1
Cavenagh, J; Edgar, JD; Haque, T; Helbert, MR; Longhurst, HJ; Syndercombe-Court, D; Taussig, D1
Benyunes, M; Bernstein, SH; Bernstein, ZP; Brown, K; Czuczman, MS; Fallon, A; Grillo-López, AJ; Klippenstein, D; Loud, P; McCarthy, P; Miller, K; Mohr, A; Rock, MK; Skipper, M; Stewart, C; Wentling, D1
Cabanillas, F; Ford, RJ; Jiang, Y; McLaughlin, P; Medeiros, LJ; Rassidakis, GZ; Sarris, AH; Thomaides, A; Tsimberidou, AM1
Albitar, M; Keating, MJ; O'Brien, S1
Fezoui, H; Genet, P; Lionnet, F; Louvel, D; Pulik, M; Touahri, T1
Aschan, J; Barkholt, L; Brune, M; Hentschke, P; Mattsson, J; Ringdén, O; Stierner, U; Uzunel, M1
Bertz, H; Finke, J; Illerhaus, G; Veelken, H1
Casanova, B; de la Fuente, MT; Garcia-Gila, M; Garcia-Marco, J; Garcia-Pardo, A; Moyano, JV; Sanz, L; Silva, A1
Carter, C; Hillmen, P; Kennedy, B; Lucas, G; Rawstron, A; Ryan, M; Speed, K1
Bradlow, BA; Chen, YH; Devine, SM; Hoffman, R; Huml, M; Jessop, E; Maynard, V; Peace, D; Shah, R; Stock, W; Thomason, D; van Besien, K; Verma, A1
de Frutos, MA1
Mounter, PJ; Proctor, SJ; Summerfield, GP; Taylor, PR1
Beltrami, G; Carella, AM; Cavaliere, M; Corsetti, MT; Lerma, E1
Bashey, A1
Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kiamouris, C; Mantzios, G; Nicolaides, C; Papageorgiou, E1
Hulkkonen, J; Hurme, M; Kivekäs, I; Vilpo, J; Vilpo, L1
Apostolidis, J; Bradburn, M; Cavenagh, JD; Crawley, CR; Foran, JM; Gupta, RK; Leonhardt, M; Lister, TA; Matthews, J; Micallef, IN; Okukenu, E; Rohatiner, AZ; Salam, A; Wiggins, C1
Byrd, JC; Flynn, JM; Howard, RS; Perkins, JG1
Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC1
Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R1
Jain, VK; Ogden, JL; Wilder, DD1
Abruzzo, LV; Jones, D; Keating, MJ; Luthra, R; Manning, JT; Medeiros, LJ; Rosales, CM; Vega, F1
Goldschmidt, H; Görner, M; Ho, AD; Kordelas, L; Luft, T; Moos, M; Pfeiffer, S; Punzel, M; Thalheimer, M; Ustaoglu, F; Weber-Nordt, R1
Albitar, M; Binet, JL; Brettman, L; Byrd, J; Flinn, I; Hillmen, P; Jain, V; Keating, MJ; Rai, KR; Santabarbara, P; Wacker, B1
Clausen, NT; Hansen, PB; Larsen, CR1
Isaksson, HJ; Mosher, DF; Onundarson, PT; Salamat, MS; Vidarsson, B1
Halaburda, K; Hellmann, A; Lewandowski, K1
Castells, G; Escoda, L; Marés, R; Richart, C; Saumoy, M; Ugarriza, A1
Dwyer, KM; Firkin, F; Hill, PA; Lee, P; Murphy, BF1
Da Prada, GA; Della Cuna, GR; Giorgiani, G; Giraldi, E; Landonio, G; Locatelli, F; Pedrazzoli, P; Schiavo, R; Siena, S; Zambelli, A1
Barton, P; Bryan, S; Davenport, C; Fry-Smith, A; Hyde, C; Song, F; Wake, B1
Barth, S; Borchmann, P; Diehl, V; Engert, A; Oberhäuser, F; Pfitzner, T; Reiser, M; Schinköthe, T; Schulz, H; Tur, M; Wessels, J1
Voutsadakis, IA1
Cerretti, R; De Propriis, MS; Foa, R; Gentile, M; Giannarelli, D; Guarini, A; Mancini, F; Mauro, FR1
Kawai, Y; Ueda, T; Yamauchi, T1
Amir, G; Berrebi, A; Cohen, Y; Da'as, N; Libster, D; Polliack, A1
Kasznicki, M; Robak, T1
Bosanquet, AG; Bosanquet, MI; Daniel, PT; Dörken, B; Essmann, F; Head, DJ; Sturm, I; Wieder, T1
Hallek, M3
Barlogie, B; Desikan, KR; Dhodapkar, MV1
Amir, G; Cohen, Y; Polliack, A1
Ang, KK; Beauduin, M; Garden, AS; Grégoire, V; Hamoir, M; Hittelman, WN; Humblet, Y; Khuri, FR; Milas, L; Mitine, C; Rosier, JF; Scalliet, P1
Andreesen, R; Bauer, S; Eissner, G; Gerbitz, A; Haffner, S; Holler, E; Kirchner, S; Multhoff, G; Sondermann, D1
Diehl, V; Voliotis, D1
Bissières, P; Devillers, C; Dusanter-Fourt, I; Fagard, R; Feuillard, J; Lenoir, G; Martin, A; Mouas, H; Raphaël, M; VanTan, H1
Brando, B; Cafro, AM; Cairoli, R; Montillo, M; Morra, E; Oreste, P; Pungolino, E; Rossi, V; Tedeschi, A; Veronese, S1
Batlle, M; Feliu, E; Mate, JL; Millá, F; Ribera, JM; Rodríguez, L; Xicoy, B1
Itälä, M; Remes, K1
Brugger, S; Gisslinger, H; Greinix, HT; Kalhs, P; Keil, F; Lechner, K; Mannhalter, C; Mitterbauer, G; Mitterbauer, M; Moser, K; Prinz, E1
Cohen, HJ; Elias, L; Hines, J; Hurwitz, HI; Larson, RA; Martell, RE; Morrison, VA; Peterson, BL; Petros, WP; Rai, KR; Schiffer, CA; Shepherd, L1
Bard, V; Foon, KA; LaRocca, RV; Rohatgi, N; Sethuraman, G1
Basmaji, N; Garg, MS; Garg, S1
Herrera, GA; Isaac, J1
Guo, K; Song, Z; Wu, B; Xiao, L; Yan, D; Yang, Y1
Batár, P; Kiss, A; Rák, K; Rejtó, L; Reményi, G; Telek, B; Udvardy, M1
Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM1
Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C1
Andreeff, M; Cortes, JE; Faderl, S; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Tsimberidou, AM1
Bos, GM; Huugen, D; Jansen, M; Jansen, R; Lalisang, R; Schouten, HC; Wagstaff, J1
Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K1
Chakrabarti, S; Chakraverty, RK; Chopra, R; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; MacKinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Ruiz de Elvira, MC; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD1
Bellosillo, B; Bosch, F; Campo, E; Colomer, D; López-Guillermo, A; Marcé, S; Montserrat, E; Villamor, N1
Montserrat, E2
Plunkett, W; Sampath, D; Shi, Z1
Champlin, RE; Keating, MJ; Khouri, IF; Saliba, RM1
Bargay, J; Brunet, S; Caballero, MD; Canals, C; Léon, A; Martino, R; Moraleda, JM; Pérez-Simón, JA; San Miguel, J; Sanz, GF; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A1
Cheson, BD; Hegde, UP; White, T; Wilson, WH1
Belch, AR; Cass, CE; Coupland, R; Graham, KA; Mackey, JR; Reiman, T; Wong, J; Young, J1
Appel, GB; Radhakrishnan, J; Rosenstock, JL; Sherman, WH; Stern, L1
Chao, NJ; Clay, TM; Hobeika, AC; Lyerly, HK; Morse, MA; Mosca, PJ; Rizzieri, D; Stenzel, TT; Vredenburgh, JJ1
Balzarotti, M; Bertuzzi, A; Castagna, L; Farè, M; Grimoldi, MG; Magagnoli, M; Nozza, A; Santoro, A; Sarina, B; Sinnone, M; Siracusano, L; Timofeeva, I1
de Fabritiis, P; De Propris, MS; Foa, R; Gentile, M; Giammartini, E; Giannarelli, D; Mandelli, F; Mauro, FR; Meloni, G; Rapanotti, MC1
Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D1
Ales, NC; Byrd, JC; Helman, DL; Shorr, AF1
Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L1
Brettman, L; Cooper, MR; Freter, CE; Mercier, RJ; Mitchell, BS; Rai, KR; Santábarbara, P; Stadtmauer, EA; Wacker, B1
Darbyshire, PJ; Kinning, E; Ortín, M; Raj, R; Williams, M1
Aleman, A; Alexanian, R; Anagnostopoulos, A; Anderlini, P; Champlin, R; Donato, M; Gajewski, J; Giralt, S; Khouri, I; Korbling, M; Molldrem, J; Ueno, NT; Weber, D1
Field, K; Seymour, JF; Slavin, MA1
Andreeff, M; Bennett, F; Charboneau, L; Kim, Y; Kipps, TJ; Kitada, S; Liotta, LD; Pedersen, IM; Rassenti, L; Reed, JC; Schimmer, A; Sporn, MB; Zapata, JM1
Bolaños-Meade, J; Khanwani, SL; Sarkodee-Adoo, C1
Fukiya, E; Kimura, S; Kobayashi, Y; Kuroda, J; Murotani, Y; Ozawa, M; Terao, K; Yoshikawa, T1
Afanasyev, BV; Anagnostopoulos, A; Andreeff, M; Champlin, RE; Mikhailova, N; O'Brien, S; Pankratova, OS; Rondón, G; Semenova, EV; Ueno, NT; Zaritskey, AY; Zoubarovskaya, LS1
Azuma, T; Fujita, S; Ishimura, M; Takada, K; Yamauchi, H; Yasukawa, M1
Licht, A; Meier, R; Taverna, C; Trojan, A1
Andersson, BS; Brown, C; Chaudhry, A; Duggan, P; Glick, S; Gyonyor, E; Morris, D; Quinlan, D; Ruether, JD; Russell, JA; Stewart, D; Tran, HT1
Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J1
Aulitzky, WE; Diehl, V; Engert, A; Hallek, M; Hensel, M; Herold, M; Hinke, A; Huhn, D; Klein, SK; Knauf, WU; Rehwald, U; Reiser, M; Schulz, H1
Caballero, D; Chopra, R; Craddock, C; García-Conde, J; Goldstone, AH; Hunter, A; Kottaridis, PD; Leon, A; Linch, DC; Mackinnon, S; Martino, R; Milligan, DW; Parker, A; Pérez-Simón, JA; San Miguel, JF; Schey, S; Sierra, J; Sureda, A; Urbano-Ispizua, A; Yong, K1
Byrd, JC; Hoke, E; Jacobson, R; Larson, RA; Morrison, VA; Park, K; Peterson, BL; Rai, K; Schiffer, CA; Vardiman, JW1
Ayuk, F; Fehse, B; Kiehl, M; Kröger, N; Nagler, A; Renges, H; Sayer, HG; Schmitz, N; Schwerdtfeger, R; Wittkowsky, G; Zabelina, T; Zander, AR1
Anasetti, C; Blume, KG; Chauncey, T; Deininger, M; Hegenbart, U; Lange, T; Little, MT; Maloney, DG; Maris, M; McSweeney, PA; Niederwieser, D; Petersdorf, E; Pönisch, W; Sandmaier, BM; Shizuru, JA; Storb, RF; Storer, B; Woolfrey, A1
Belohradsky, BH; Blanche, S; Bordigoni, P; Cant, A; Di Bartolomeo, P; Fischer, A; Flood, T; Gungor, T; Landais, P; Müller, S; Nagler, A; Ozsahin, H; Passwell, JH; Porta, F; Seger, RA; Slavin, S; Wulffraat, N; Zintl, F1
Ackerstein, A; Aker, M; Amar, A; Nagler, A; Naparstek, E; Or, R; Resnick, I; Samuel, S; Shapira, MY; Slavin, S1
Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A1
Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G1
Eucker, J; Huhn, D; Jakob, C; Kingreen, D; Mergenthaler, HG; Possinger, K; Schetelig, J; Schille, C; Schmid, P; Sezer, O1
Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H1
Gertz, MA2
Antoun, S; Carpiuc, I; Delabarthe, A; Driss, B; Fenaux, R; Griscelli, F; Ribrag, V; Vantelon, JM1
Canazzio, A; De Stefano, P; Giorgiani, G; Locatelli, F; Nobili, B; Perrotta, S; Rossi, G; Zecca, M1
Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M1
Hansz, J1
Garzia, M; Laurenti, L; Leone, G; Piccioni, P; Sabatelli, M; Sora', F1
Basara, N; Fauser, AA; Guenzelmann, S; Kiehl, MG; Kraut, L; Roemer, E; Schmetzer, B1
Aversa, F; Carotti, A; Falcinelli, F; Felicini, R; Martelli, MF; Tabilio, A; Terenzi, A; Velardi, A1
Agura, E; Blume, KG; Bruno, B; Chauncey, TR; Feinstein, L; Forman, S; Georges, GE; Hegenbart, U; Little, MT; Malone, DG; Maris, M; McSweeney, PA; Niederweiser, D; Pulsipher, MA; Radich, JP; Sahebi, F; Sandmaier, BM; Shizuru, JA; Storb, R; Woolfrey, AE1
Ayuk, FA; Erttmann, R; Hansen, A; Hessling, J; Kordes, U; Kröger, N; Panse, J; Renges, H; Werner, M; Zabelina, T; Zander, AR1
Basok, A; Mostoslavsky, M; Rogachev, B; Shnaider, A; Tovbin, D1
Brandi, G; Casabianca, A; Chiarantini, L; Fraternale, A; Magnani, M; Orlandi, C; Silvestri, G1
Chamorey, AL; Milano, G; Thyss, A1
Anxionnat, R; Grignon, Y; Hulin, C; Léonard, S; Taillandier, L; Vespignani, H1
Altés, A; Bellosillo, B; Besalduch, J; Bosch, F; Cobo, F; Colomer, D; Esteve, J; Ferrer, A; Giné, E; López-Guillermo, A; Montserrat, E; Perales, M; Ribera, JM; Villamor, N1
Giralt, S; Goldman, JM; Hale, G; Mackinnon, S; Slavin, S; Waldmann, H1
Abonour, R; Logan, TF; Nelson, RP1
Gajewski, JL; Hicks, K; Peng, D1
Baldwin, SA; Cass, CE; Clarke, ML; Mackey, JR; Young, JD1
Grenier, JF; Guévin, R; Klasa, RJ; Laplante, S; Maksymiuk, A; Meyer, RM; Rubinger, M; Samosh, M; Sawka, CA; Shustik, C; Smith, A1
Albertioni, F; Elford, H; Eriksson, S; Flordal, E; Lagercrantz, S; Liliemark, J; Månsson, E; Spasokoukotskaja, T1
Horie, T; Horikoshi, A; Hosokawa, Y; Sawada, S; Takei, K1
Cavalli-Björkman, N; Gruber, A; Kalin, M; Lundin, J; Osby, E; Osterborg, A1
Cragg, L; Feldman, EJ; Grant, S; Roberts, JD; Smith, MR1
Appelbaum, FR; Bruno, B; Chauncey, TR; Feinstein, LC; Gooley, TA; Hegenbart, U; Maloney, DG; Maris, MB; McSweeney, PA; Niederwieser, DW; Sandmaier, BM; Storb, RF1
Baron, F; Beguin, Y; Fillet, G; Frère, P; Herens, C1
Caenazzo, L; Calore, E; Cesaro, S; De Silvestro, G; Destro, R; Gazzola, MV; Marson, P; Messina, C; Pillon, M; Varotto, S; Zanesco, L1
Glasmacher, A; Gorschlüter, M; Mey, U; Pralle, H; Schmidt-Wolf, I; Strehl, J; Ziske, C1
Adams, DJ; Chao, NJ; DeCastro, CM; Foster, T; Gasparetto, C; Gockerman, JP; Ibom, VK; Long, GD; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL; Thompson, M; Vredenburgh, JJ1
Chakrabarti, S1
Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK1
Eagleton, H; Hatton, C; Leyden, K; Littlewood, T; Pearson, D; Pillai, N; Sternberg, A; Turner, S1
Chakrabarti, S; Mackinnon, S1
Byrd, JC; Larson, RA; Peterson, B; Piro, L; Saven, A; Schiffer, C; Vardiman, JW1
Jeleń, M; Kuliczkowski, K; Kuliszkiewicz-Janus, M; Małecki, R1
Balleari, E; Capaia, M; Clavio, M; de Totero, D; Foa, R; Gobbi, M; Montera, MP; Tazzari, PL1
Fernandez, MJ; Grau, E; Llopis, I; Pastor, E; Real, E1
Clouse, LH; Hussain, K; Mazza, JJ1
Beyer, J; Bornhäuser, M; Ehninger, G; Fauser, AA; Hensel, M; Ho, AD; Kiehl, M; Kienast, J; Kröger, N; Neubauer, A; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR1
Beyan, C; Cetin, T; Kaptan, K; Nevruz, O; Satar, B1
Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL1
Albiin, N; Barkholt, L; Hentschke, P; Martola, J; Mattsson, J; Pisa, P; Remberger, M; Ringdén, O; Söderberg, M; Thörne, A; Uzunel, M; Wernerson, A; Wersäll, P1
Abdul-Hai, A; Amir, G; Or, R; Polliack, A; Weiss, L1
Bourikas, G; Kaloutsi, V; Margaritis, D; Pantelidou, D; Spanudakis, E; Tsatalas, C1
Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Thomas, D; Tsimberidou, A; Verstovsek, S1
Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C1
Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P1
Bocchia, M; Forconi, F; Gentili, S; Lauria, F; le Noci, M; Tozzi, M1
Dreyling, M; Hiddemann, W; Unterhalt, M1
Ayash, L; Braun, T; Ferrara, JL; Hutchinson, R; Levine, JE; Ratanatharathorn, V; Reynolds, C; Silver, SM; Uberti, JP; Yanik, G1
Albitar, M; Alvarado, Y; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Thomas, DA; Tsimberidou, AM; Verstovsek, S; Wierda, W1
Flowers, ME; Leisenring, W; Maloney, DG; Maris, MB; Martin, PJ; Mielcarek, M; Sandmaier, BM; Storb, R1
Aliff, TB; Frankel, SR; Horgan, D; Jurcic, JG; Kossman, SE; Lamanna, N; Maslak, PG; Scheinberg, DA; Weiss, MA1
Abbasi, MR; Sarta, C; Sparano, JA; Wiernik, PH1
Comoli, P; De Stefano, P; Giorgiani, G; Locatelli, F; Maccario, R; Nobili, B; Rossi, G; Salvaneschi, L1
Abebe, L; Adiga, GU; Wiernik, PH1
Anasetti, C; Appelbaum, FR; Bornhauser, M; Deeg, HJ; Ehninger, G; Hansen, J; Jenke, A; Martin, PJ; McDonald, GB; Nichols, WG; Radich, J; Schleyer, E; Slattery, JT; Storer, B; Thiede, C; Woolfrey, A1
Baron, F; Baudoux, E; Beguin, Y; Fillet, G; Frère, P; Sautois, B1
Canelhas, A; Coelho, H; Guerra, M; Lima, M; Pinto Ribeiro, AC; Teixeira, Mdos A1
Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Kontoyiannis, D; Lerner, S; O'Brien, S; Plunkett, W1
Joshi, SS; Pavletic, ZS; Wang, P1
Bar, M; Cohen, NS; del Prete, S; Flamm, M; Garrett, TJ; Heitjan, D; Hesdorffer, CS; Lonberg, M; March, R; Mears, JG; Nichols, G; Oster, MW; Savage, DG; Talbot, S; Taub, RN1
Lucas, T; Samorapoompichit, P; Schedled, A; Sperr, WR; Steiner, M; Valent, P; Wachtler, F1
De Braekeleer, M; Herry, A; Le Bris, MJ; Morel, F; Morice, P1
Aquino, VM; Berryman, B; Collins, RH; Douek, DC; Jain, VK; Johnson, M1
Korycka, A; Robak, T2
Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H1
Bertz, H; Finke, J; Potthoff, K1
Gazelka, H; Go, RS; Hogan, JD; Wester, SM1
Kovacs, MJ; Wells, T1
Bosanquet, AG; Daniel, PT; Dörken, B; Güner, D; Hermann, S; Sturm, I1
Barlogie, B; Crowley, JJ; Dhodapkar, MV; Gertz, MA; Jacobson, JL1
Choquet, S; Leblond, V1
Agura, EA; Blume, KG; Chauncey, TR; Feinstein, LC; Forman, SJ; Gooley, TA; Hegenbart, U; Maloney, DG; Maris, MB; McSweeney, PA; Niederwieser, DW; Pulsipher, MA; Sandmaier, BM; Storb, RF; Stuart, MJ1
Beyer, J; Biersack, H; Bornhäuser, M; Ehninger, G; Kiehl, M; Kröger, N; Sayer, HG; Schäfer-Eckardt, K; Schwerdtfeger, R; Wandt, H; Zander, AR1
Barker, JN; Blazar, BR; DeFor, TE; Miller, JS; Wagner, JE; Weisdorf, DJ1
Balcerzak, SP; Chapman, RA; Dakhil, SR; Fisher, RI; Grogan, TM; Lanier, KS; Lew, D; Miller, TP; Spiridonidis, CH; Velasquez, WS1
Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ1
Hiruma, K; Maeda, Y; Matsumoto, G; Omuro, Y; Sakamaki, H; Sasaki, T; Takahashi, T; Tanaka, Y; Tsuruta, K1
Boudová, L; Cerná, K; Jindra, P; Karas, M; Koza, V; Lysák, D; Svojgrová, M; Vozobulová, V1
Brand, R; Corradini, P; Deliliers, GL; Dreger, P; Finke, J; Hansz, J; Martino, R; Michallet, M; Milligan, D; Niederwieser, D; Russell, N; Van Biezen, A1
Davis, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Shen, Y; Thomas, MB; Yang, Y1
Amir, G; Cohen, Y; Da'as, N; Libster, D; Polliack, A1
Björkstrand, B; Gruber, A; Johnsen, HE; Pelliniemi, TT; Rasmussen, T; Remes, K1
Ajchenbaum-Cymbalista, F; DeCaprio, JA; Delmer, A; Sanhes, L; Tang, R1
Arase, Y; Hamaki, T; Hayashi, M; Igarashi, M; Ishibashi, T; Kami, M; Kusumi, E; Miyakoshi, S; Morinaga, S; Mutou, Y; Shimamura, K; Takaue, Y1
Paschal, BR1
Bearman, SI; Cagnoni, PJ; Jones, RB; Kolhouse, JF; McSweeney, PA; Medeiros, BC; Nieto, Y; Rabinovitch, R; Ryder, J; Shpall, EJ1
Pettitt, AR1
Baker, RJ; Foroni, L; Ganeshaguru, K; Jones, DT; Mehta, AB; Mitchell, WA; Prentice, HG; Wickremasinghe, RG1
Cortes, JE; Giles, FJ; Kantarjian, HM; Keating, AR; Keating, MJ; O'Brien, SM; Shi, GG; Thomas, D1
Agura, E; Anasetti, C; Blume, K; Chauncey, T; Hegenbart, U; Heimfeld, S; Maloney, D; Maris, MB; McSweeney, P; Niederwieser, D; Petersdorf, E; Pulsipher, M; Sandmaier, BM; Slattery, J; Storb, R; Storer, B; Stuart, M; Woolfrey, A1
Annunziata, M; Copia, C; D'Amico, MR; De Simone, M; Ferrara, F; Palmieri, S; Pocali, B; Schiavone, EM; Vecchio, LD1
Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M1
Alliot, C1
Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Matsouka, C; Mitsibounas, D; Papadimitriou, C; Siapkaras, I1
Carta, F; Dore, F; Dore, S; Pinna, A; Salis, A1
Albitar, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A; Verstovsek, S1
Beyer, J; Bornhauser, M; Ehninger, G; Fauser, AA; Held, TK; Hensel, M; Ho, AD; Hoffken, K; Kiehl, M; Kienast, J; Kroger, N; Neubauer, A; Sayer, HG; Scheffold, C; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zander, AR1
Okamoto, S1
Durrant, S; Grigg, AP; Morton, J; Ritchie, DS; Roberts, AW; Shuttleworth, P; Szer, J1
Fruchtman, S; Grosskreutz, C; Isola, L; Ross, V; Scigliano, E1
Anderlini, P; Booser, DJ; Champlin, RE; Cheng, YC; Couriel, DR; de Lima, MJ; Gajewski, JL; Giralt, SA; Hortobagyi, GN; Hosing, C; Jonasch, E; Khouri, IF; Pagliaro, LC; Rondón, G; Tannir, NM; Ueno, NT1
Chi, HS; Choi, SJ; Kim, S; Kim, WK; Lee, JH; Lee, JL; Lee, JS; Lee, KH; Lee, YS; Park, CJ; Seol, M1
Cotter, M; Enright, H1
Bunjes, D; Döhner, H; Zenz, T1
Burrows, A; Edenfield, WJ; Ekstrand, J; Lucas, M; Myhand, RC; Nelson, DA; Waselenko, JK1
Plunkett, W; Rao, VA1
Disel, U; Paydas, S; Sahin, B; Yavuz, S1
Amylon, M; Casella, JF; Chen, AR; Fuchs, EJ; Iannone, R; Jones, RJ; Storb, RF; Sullivan, KM; Walters, MC; Woolfrey, A1
Callea, V; Cutrona, G; Ferrarini, M; Ferraris, AM; Mangiola, M; Morabito, F; Oliva, BM; Rapezzi, D; Rossi, E; Spriano, M; Stelitano, C; Zupo, S1
Amin, K; Chen, YH; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sossman, J; Stock, W; Van Besien, K; Wickrema, A; Yassine, M1
Bardou, VJ; Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Braud, AC; Cahn, JY; Chabannon, C; Choufi, B; Faucher, C; Fleury, J; François, S; Gratecos, N; Gravis, G; Maraninchi, D; Michallet, M; Mohty, M; Sotto, JJ; Viens, P; Viret, F1
Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D1
Ackerstein, A; Bitan, M; Elad, S; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Zilberman, I2
Castagna, L; Santoro, A; Sarina, B1
Aquaro, S; Balestra, E; Casabianca, A; Cervasi, B; Fraternale, A; Garaci, E; Magnani, M; Paiardini, M; Perno, CF1
Caracciolo, F; Fazzi, R; Galimberti, S; Petrini, M1
Azar, N; Bastit, D; Belhadj, K; Cazin, B; Delmer, A; Diviné, M; Feugier, P; Grosbois, B; Leprètre, S; Maloisel, F; Maloum, K; Manhès, G; Michallet, M; Tournilhac, O; Travade, P; Villard, F; Villemagne, B1
de la Fuente, J; Dokal, I; McCloy, M; Rahemtulla, A; Reiss, S; Roberts, IA; Vulliamy, T1
Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, S; Thomas, DA; Tsimberidou, AM; Verstovsek, S1
Black, JH; Fleming, DR; Frankel, AE; Gartenhaus, R; Hall, PD; Leftwich, C; Powell, BL1
Bentley, P; Fegan, C; Hooper, L; Hoy, T; Milligan, D; Pepper, C; Pratt, G; Starczynski, J; Thomas, A1
Astrow, AB1
Fujioka, T; Ikegame, K; Kawakami, M; Kawase, I; Ogawa, H; Oji, Y; Oka, Y; Sugiyama, H; Tamaki, H; Tsuboi, A1
Hino, M; Yamane, T1
Ogawa, H1
Miyakoshi, S1
Kusumi, E; Taniguchi, S1
Nakao, S1
Omuro, Y; Sasaki, T1
Koshida, K; Nakao, S; Namiki, M; Takami, A1
Figgitt, DP; Plosker, GL1
Huhn, D1
Oscier, D1
Chan, KW; Gomez Almaguer, D; Gordon, N; Mullen, CA; Tran, H; Worth, L1
Fil'chenkov, AA; Nesina, IP; Smirnova, IA; Zavelevich, MP1
Aymerich, M; Carreras, E; Fernández-Avilés, F; Jiménez, M; Martínez, C; Montserrat, E; Rovira, M; Talarn, C; Urbano-Ispizua, A1
Andreeff, M; Calvert, LR; Faderl, S; Keating, M; McConkey, DJ; Niemer, I; Pahler, JC; Ruiz, S1
Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhang, Y; Zheng, WY1
Barrett, AJ; Childs, RW; Greene, A; Sloand, E; Solomon, S; Young, NS1
Boyer, MW; Giver, CR; Jaye, DL; Li, JM; Lonial, S; Mittelstaedt, S; Montes, RO; Waller, EK1
Brito, C; Cayota, A; Dighiero, G; Gabús, R; Landoni, AI; Oppezzo, P; Pritsch, O; Robello, C; Tiscornia, AC; Vuillier, F1
Addison, E; Folarin, NI; Ganeshaguru, K; Hoffbrand, AV; Jones, DT; Lowdell, MW; Mehta, AB; North, JM; Wickremasinghe, RG1
Boumpas, DT; Danning, CL; Davis, JC; Fleisher, TA; Illei, GG; Kuroiwa, T; Schlimgen, R; Takada, K; Tassiulas, IO; Yarboro, CH1
Brando, B; Cafro, AM; Cairoli, R; D'Avanzo, G; Farioli, R; Intropido, L; Montillo, M; Morra, E; Pungolino, E; Rossi, V; Scarpati, B; Tedeschi, A; Veronese, S1
Bergmann, M; Emmerich, B; Fingerle-Rowson, G; Goede, V; Hallek, M; Schmitt, B; Schweighofer, C; Wendtner, CM1
Ciancia, R; De Divitiis, B; De Renzo, A; Del Giudice, A; Pane, F; Persico, M; Picardi, M; Quintarelli, C; Rotoli, B; Salvatore, F1
Dumontet, C; Fernández-Calotti, P; Galmarini, CM; Gamberale, R; Geffner, J; Giordano, M; Jordheim, L; Sánchez-Avalos, J1
Begleiter, A; Gibson, SB; Hu, X; Johnston, JB; Kabore, AF; Kropp, DM; Kuschak, B; Paul, JT; Strutinsky, J1
Boeckh, M; Carter, RA; Corey, L; Junghanss, C; Maloney, DG; Maris, MB; McSweeney, PA; Sandmaier, BM; Storb, R1
Ambulkar, I; Parikh, PM; Saikia, T1
Cantero, E; Casanova, B; de la Fuente, MT; Garcia-Marco, J; Garcia-Pardo, A; Hernández del Cerro, M; Silva, A1
Beyer, J; Claviez, A; Dörffel, W; Dreger, P; Ehninger, G; Klingebiel, T; Nürnberger, W; Schmitz, N; Suttorp, M1
Fujisawa, S; Hatsumi, N; Kishi, K; Miyakoshi, S; Miyawaki, S; Mori, S; Nakajima, H; Oki, M; Sakamaki, H; Sakura, T; Tanaka, Y; Ueyama, J; Yokota, A1
Balow, JE; Bolan, CD; Boumpas, DT; Illei, GG; Klippel, JH; Leitman, SF; Popovsky, MA; Tisdale, JF1
Fu, ZZ; Li, CX; Lin, BJ; Liu, YJ; Ma, X; Miao, M; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xia, XM1
Ai, HS; Guo, M; Qiao, JH; Shi, BF; Sun, QY; Sun, WJ; Wang, DH; Yao, B; Yu, CL; Zhang, S1
Stiefelhagen, P1
Battle, TE; Dong, DA; Fisher, DC; Frank, DA; Freedman, AS; Friedberg, JW; Gribben, JG; Jurgens, R; Kim, H; Li, S; Neuberg, D; Noonan, K; Stephans, K; Takvorian, T1
Ueda, T; Yamauchi, T1
Hirayama, Y; Kawano, Y; Kogawa, K; Kuribayashi, K; Matsunaga, T; Murase, K; Niitsu, Y; Okamoto, T; Sato, T; Takayama, T; Watanabe, H1
Lokhorst, HL; Petersen, EJ; Verdonck, LF1
Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A1
Ferry-Dumazet, H; Mamani-Matsuda, M; Marit, G; Molimard, M; Mossalayi, MD; Moynet, D; Reiffers, J1
Baccarani, M; Fanin, R; Gentile, M; Mandelli, F; Marin, L; Mauro, FR; Stefoni, V; Tura, S; Vegna, ML; Zaja, F; Zinzani, P1
Fricová, M; Guman, T; Kafková, A; Stecová, N; Tóthová, E1
Kiewe, P; Knauf, W; Körper, S; Rieger, K; Seyfert, S; Thiel, E1
Braester, A; Elmalah, Y; Quitt, M1
Huang, F; Liu, QF; Liu, XL; Meng, FY; Sun, J; Xu, B; Yang, LJ; Zhang, Y; Zheng, WY1
Erba, HP1
Adil, SN; Khurshid, M; Sajid, R; Usman, M1
Dlubek, D; Dybko, J; Klimczak, A; Lange, A1
Fan, H; Sun, YF; Yao, SQ; Zhu, HL1
Beelen, D; Bornhäuser, M; Ehninger, G; Fauser, AA; Held, TK; Kiehl, M; Kröger, N; Runde, V; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zabelina, T; Zander, A1
Byrd, JC; Flinn, IW; Grever, MR; Hackbarth, ML; Harbison, J; Heerema, NA; Lin, T; Lozanski, G; Lucas, D; Lucas, M; Moran, M; Proffitt, JH; Smith, L; Webb, J1
Abecasis, M; da Costa, FL; Miranda, N; Nave, M; Nunes, R; Passos-Coelho, JL1
Bairey, O; Berrebi, A; Lugassy, G; Polliack, A; Rahimi-Levene, N; Shpilberg, O; Shtalrid, M; Shvidel, L1
Amadori, S; Ballatore, G; Caravita, T; Catalano, G; Cristina Cox, M; Cudillo, L; Cupelli, L; Dentamaro, T; Fabritiis Pd, Pd; Picardi, A; Venditti, A1
Paydas, S1
Champlin, RE; Donato, ML; Gershenson, DM; Levenback, C; McMeekin, S1
Chizuka, A; Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Tajima, K; Takaue, Y; Taniguchi, S; Usubuchi, N1
Hamaki, T; Heike, Y; Hori, A; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Tanosaki, R; Ueyama, J; Yuji, K1
Barry, T; Ben Alon, D; Ben Dor, D; Blumental, R; Ducach, A; Lugassy, G; Nemets, A1
Champlin, RE; Khouri, IF1
Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y1
Enosawa, S; Haga, S; Ohnuma, N; Ozaki, M; Terui, K1
Grigg, A; Januszewicz, EH; Matthews, JP; Morgan, SJ; Prince, HM; Seymour, JF; Wolf, MM1
Imagawa, J; Imamura, N; Katayama, Y; Kimura, A; Nimi, H; Simomura, T1
Hillmen, P3
Bongarzoni, V; Buffolino, S; Cimino, G; Montanaro, M; Niscola, P; Scaramucci, L1
Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K1
Devereux, S; Ho, AY; Kenyon, M; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE1
Bordonaro, R; Cordio, S; Giannitto-Giorgio, C; Giuffrida, D; Manusia, M; Marletta, F; Novello, G; Petralia, G; Restuccia, N; Salice, P; Serraino, D; Todaro, AM; Ursino, M1
Bucher, C; Buser, AS; Gratwohl, A; Heim, D; Passweg, JR; Tichelli, A1
Al-Kadhimi, Z; Angelopoulou, M; Cohen, S; Falk, PM; Forman, SJ; Fung, HC; Kogut, N; Krishnan, AY; Nademanee, A; O'Donnell, MR; Parker, P; Popplewell, L; Rodriguez, R; Sahebi, F; Schriber, J; Senitzer, D; Slovak, M; Smith, D; Snyder, DS; Somlo, G; Spielberger, R; Stein, A1
Gartenhaus, RB; Nabhan, C; Tallman, MS1
Chen, JB; Kaushal, GP; Kurten, RC; Lacy, HM; Schichman, SA; Zent, CS1
Biesma, DH; Daenen, SM; Delforge, M; Graveland, WJ; Löwenberg, B; Muus, P; Noordhuis, P; Ossenkoppele, GJ; Peters, GJ; Schaafsma, MR; Selleslag, D; Sonneveld, P; van der Holt, B; Verdonck, LF; Verhoef, GE; Westveer, PH1
Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X1
Gadea, I; Llamas, P; Prieto, E; Román, A; Santos, AB; Subirá, D; Tomás, JF1
Leporrier, M1
Eichhorst, BF; Hallek, M1
Boogaerts, MA1
Zinzani, PL2
Jackson, GH1
Carella, AM1
Guan, ZZ; Huang, HQ; Jiang, WQ; Li, XB; Li, YH; Lin, TY; Peng, YL; Sun, XF; Xia, ZJ1
Albert, S; Bhogal, B; Black, MM; Oyama, N; Powell, AM; Sakuma-Oyama, Y1
Coyle, L; Hsiao, E; Huynh, T; Mansberg, R; Roach, P1
Nicolle, A; Proctor, SJ; Summerfield, GP1
Bolognesi, A; Farini, V; Lubelli, C; Polito, L; Ricci, F; Stirpe, F; Tazzari, PL; Zinzani, PL1
Grdisa, M1
Fujioka, T; Ishida, Y; Numaoka, H; Omori, S; Ono, Y1
Boniver, J; de Leval, L; De Prijck, B; Du, MQ; Harris, NL; Isaacson, P; Vivario, M; Zhou, Y1
Beran, M; Cortes, JE; Estey, E; Giles, FJ; Kantarjian, HM; O'Brien, SM1
Ferrajoli, A; O'Brien, SM1
Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A1
Käser, L; Kolyvanos Naumann, U; Vetter, W1
Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Coso, D; Damaj, G; Faucher, C; Gastaut, JA; Maraninchi, D; Michallet, AS; Michallet, M; Mohty, M; Perreau, V; Stoppa, AM; Tabrizi, R1
Alizadeh, AA; Arthur, DC; Chuang, EY; Davis, RE; Fowler, DH; Marti, GE; Mitchell, JB; Rosenwald, A; Staudt, LM; Wiestner, A; Wilson, WH1
Appelbaum, FR; Byrd, JC; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, K; Schiffer, CA; Shepherd, L1
Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM2
Alinari, L; Baccarani, M; Gabriele, A; Marchi, E; Musuraca, G; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL1
Galieni, P; Laszlo, D; Lauria, F; Martinelli, G; Raspadori, D; Tozzi, M1
Anastasi, J; Larson, R; Odenike, T; Smith, S; Stock, W; Thirman, M; Van Besien, K1
Christopherson, RI; Mulligan, SP; Wilson, PK1
Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E1
Disel, U; Ergin, M; Paydas, S; Yavuz, S1
Fujiwara, T; Harigae, H; Ishizawa, K; Kameoka, J; Minegishi, M; Miyamura, K; Sasaki, T; Tomiya, Y; Tsuchiya, S; Yamada, M1
Hamaki, T; Hayashi, T; Kami, M; Kanemaru, M; Kim, SW; Kishi, Y; Kobayashi, K; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Ueyama, J; Yuji, K1
Giver, CR; Hossain, MS; Li, JM; Lonial, S; Waller, EK1
Improta, S; Mastrullo, L; Nitrato Izzo, G; Polistina, MT; Quirino, AA; Rocco, S; Russolillo, S; Sagristani, M1
Balashov, DN; Dyshlevaja, ZM; Maschan, AA; Rumiantsev, AG; Samochatova, EV; Shipicina, IP; Skorobogatova, EV; Skvortsova, YV; Trakhtman, PE1
Andreeff, M; Beran, M; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Tsimberidou, AM; Wierda, WG1
Blume, KG; Edelstein, CL; Maloney, DG; Maris, MB; McSweeney, P; Nieto, Y; Parikh, CR; Sahebi, F; Sandmaier, BM; Schrier, RW; Storb, RF1
Cao, Z; Chen, YC; Fang, J; Jiang, BH; Reed, E1
Baran-Marszak, F; Béchet, JM; Bornkamm, GW; Dusanter-Fourt, I; Fagard, R; Feuillard, J; Le Clorennec, C; Najjar, I; Raphaël, M1
Alinari, L; Baccarani, M; Bonifazi, F; Gentilini, P; Guardigni, L; Martelli, M; Molinari, AL; Perrotti, A; Pileri, S; Pulsoni, A; Stefoni, V; Tani, M; Tura, S; Villivà, N; Visani, G; Zinzani, PL1
Assmann, M; Bartsch, R; Eschenburg, H; Franke, A; Herold, M; Jentsch-Ullrich, K; Kahl, C; Knauf, W; Koenigsmann, M; Lakner, V; Mohren, M; Müller, G; Pasold, R1
Baker, JE; Baron, F; Blume, KG; Chauncey, TR; Gooley, TA; Grumet, FC; Heimfeld, S; Little, MT; Maloney, DG; Maris, MB; Oparin, D; Radich, JP; Sandmaier, BM; Storb, R; Zellmer, E1
Avivi, I; Chakrabarti, S; Dogan, A; Goldstone, AH; Kottaridis, P; Kyriaku, C; Linch, D; Mackinnon, S; Milligan, DW1
Al-Ali, H; Brand, R; Deininger, M; Gentilini, C; Hegenbart, U; Krahl, R; Lange, T; Leiblein, S; Niederwieser, D; Petersdorf, E; Poenisch, W; Storb, RF; Uharek, L1
Barnardo, M; Campbell, AJ; Collins, GP; Eagleton, H; Jones, J; Keen-Mcguire, A; Littlewood, TJ; Malladi, RK; Miller, E; Morgenstern, G; Norton, AE; Peniket, AJ; Samol, J1
Acharya, MR; Figg, WD1
Holyoake, TL; McQuaker, IG; Osborne, WL; Parker, AN1
Böck, HP; Dreyling, M; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rohrberg, R; Rothmann, F; Unterhalt, M; Wandt, H1
Asch, J; Ford, CD; Petersen, FB; Pulsipher, M1
Bowen, A; Catovsky, D; Hendry, L; Matutes, E; Swansbury, J1
Agura, E; Chauncey, T; Langston, AA; Maloney, DG; Maris, MB; Maziarz, RT; Pulsipher, M; Sandmaier, BM; Storb, R; Storer, BE; Stuart, MJ1
Au, WY; Ho, SL; Kwong, YL; Leung, SY; Mak, W1
Buser, A; Gratwohl, A; Heim, D; Kostova, G; Passweg, J; Tichelli, A1
Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C1
Dreyling, M; Hiddemann, W; Lenz, G1
Barr, WG; Brush, M; Burt, RK; Oyama, Y; Quigley, K; Statkute, L; Traynor, A; Verda, L; Yaung, K1
Baumbach, T; Benner, A; Ho, AD; Kerowgan, M; Kraemer, A; Leo, A; Leo, E; Mey, U; Parwaresch, R; Scheuer, L; Schmidt-Wolf, IG; Schmitt, C1
D'Arena, G; Di Renzo, N; Iodice, G; Pizza, V; Tartarone, A; Vigliotti, ML; Volpe, G1
Aversa, S; Candela, M; Chisesi, T; Congiu, AM; Marino, G; Nati, S; Patti, C; Polacco, A; Porcellini, A; Ravetti, JL; Rizzoli, V; Rubagotti, A; Santini, G; Spriano, M; Vimercati, R; Zoli, V; Zupo, S1
Dmoszyńska, A; Hellmann, A; Komarnicki, M; Kowal, M; Kuliczkowski, K; Kłoczko, J; Lewandowski, K; Piszcz, J; Roznowski, K; Skotnicki, AB; Wegrzyn, J; Wołowiec, D1
Byun, JH; Hong, YS; Kim, CC; Lee, JW; Lee, MA; Min, WS; Park, JN; Roh, SY; Shim, BY; Song, CW1
Cheang, M; Gibson, SB; Haney, N; Hu, X; Johnston, JB; Kropp, DM; Neufeld, NJ; Paul, JT1
Argyrakos, T; Galani, V; Grigoriou, E; Harhalakis, N; Kanavaros, P; Kapsimali, V; Karmiris, T; Naum, C; Nikiforakis, E; Pantelidaki, C; Rontogianni, D; Tsantekidou, M1
Grigg, AP; Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM1
Delavault, P; Fegan, CD; Hambly, RM; Pepper, CJ; Thurston, DE1
Delarue, R; François, S; Hermine, O; Ifrah, N; Lefrère, F; Lévy, V; Tilly, H; Troussard, X; Valensi, F; Varet, B1
Bone, ND; Geyer, SM; Kaufmann, SH; Kay, NE; Lee, YK; Narayanan, VL; Sausville, EA; Shanafelt, TD; Strege, AK1
Alegre, A; Ayuk, F; Beyer, J; Brand, R; Fauser, A; Kiehl, M; Klingemann, H; Kröger, N; Leon, A; Martino, R; Myint, H; Nagler, A; Perez-Simon, JA; San Miguel, JF; Sayer, HG; Schwerdtfeger, R; Shimoni, A; Tomas, JF; Zabelina, T; Zander, AR1
Arnold, R; Dörken, B; Heine, F; Le Coutre, P; Massenkeil, G; Nagy, M; Rosen, O1
Kawai, Y; Takagi, K; Ueda, T; Yamauchi, T1
Binet, JL; Cass, CE; Dabbagh, L; Delmer, A; Dumontet, C; Galmarini, CM; Glubrecht, D; Graham, KA; Hanson, J; Jewell, LD; Joy, AA; Lai, R; Lang, T; Mackey, JR; Merle-Béral, H; Young, JD1
Lamanna, N; Weiss, M1
Bitan, M; Mador, N; Or, R; Resnick, IB; Saleh, N; Samuel, S; Schechter, E; Shapira, MY; Slavin, S; Weinberger, KM; Wolf, DG1
Bellosillo, B; Bosch, F; Campo, E; Colomer, D; Espinet, B; Ferrer, A; López-Guillermo, A; Marcé, S; Montserrat, E; Solé, F; Villamor, N1
Carew, JS; Dunner, K; Huang, P; Keating, MJ; McConkey, DJ; Nawrocki, ST; Wierda, WG; Xu, RH1
Ahn, HS; Choi, HS; Kang, HJ; Shin, HY1
Kolb, HJ; Ledderose, G; Rolf, B; Schleuning, M; Schnittger, S; Schoch, C; Schwerdtfeger, R; Weisser, M1
Bengtzen, S; Lehmann, S; Merup, M; Mollgard, L; Nahi, H; Paul, C; Selivanova, G; Wiman, KG1
Batár, P; Kiss, A; Méhes, L; Rejto, L; Telek, B; Udvardy, M1
Ai, HS; Hou, CM; Li, JJ; Mao, N; Wu, Y; Zhang, MW; Zhang, Y1
Celsing, F; Jondal, M; Morales, AA; Olsson, A; Osorio, LM; Osterborg, A1
Cooper, BW; Creger, RJ; Gerson, SL; Gosky, D; Hoppel, CL; Ingalls, ST; Koc, ON; Lazarus, HM; Meyerson, HJ; Nowell, GM; Pearson, G; Radivoyevitch, T; Tilby, MJ; Veal, GJ1
Brecher, BA; Butrin, L; Goldberg, SL; Hsu, JS; Kobbe, K; McKiernan, P; Pecora, AL; Preti, R; Rowley, SD1
Bellosillo, B; Casado, FJ; Colomer, D; Gil, J; Huber-Ruano, I; Marcé, S; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M; Villamor, N1
Chan, ES; Linn, YC; Samuel, M; Tan, DC; Zhu, Q1
Briones, J; Forné, I; Juarez, C; Martinez-Gallo, M; Martinez-Lostao, L; Rodriguez-Sanchez, JL; Sierra, J1
Alessandrino, EP; Bernasconi, P; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Montanari, F; Troletti, D; Vanelli, L; Varettoni, M1
Belka, C; Daniel, PT; Dörken, B; Hasenjäger, A; Klöpfer, A; Schulze-Osthoff, K1
Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G1
Korycka, A; Robak, T; Smolewski, P1
Blumberg, N; Fenton, P; Horan, JT; Liesveld, JL; Walters, MC1
Broekhuizen, R; Cloos, J; Creutzig, U; Fleischhack, G; Haarman, EG; Hubeek, I; Huismans, DR; Kaspers, GJ; Litvinova, E; Peters, GJ; Zwaan, CM1
Fabbri, A; Forconi, F; Gozzetti, A; Lauria, F; Lenoci, M; Marotta, G; Raspadori, D1
Majumdar, G; Ramachandran, A1
Broekhuizen, AJ; Hubeek, I; Kaspers, GJ; Peters, GJ1
Cao, TM; Grumet, FC; Johnston, LJ; Laport, GG; Lowsky, R; Negrin, RS; Sheehan, K; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ; Wong, RM1
Beilken, A; Das, A; Gal, A; Grigull, L; Luecke, T; Lukacs, Z; Rehe, K; Sander, A; Sauer, M; Schmid, H; Schrappe, M; Stanulla, M; Sykora, KW; Welte, K1
Childs, RW; Leppert, MF; Otterud, BE; Riddell, SR; Sandmaier, BM; Storb, R; Thompson, JA; Tykodi, SS; Warren, EH1
Amadori, S; Bruno, A; Buccisano, F; Cox, MC; Degan, M; Del Poeta, G; Del Principe, MI; Gattei, V; Marini, R; Maurillo, L; Panetta, P; Suppo, G; Venditti, A1
Boyd, RL; Clyde, J; Halbherr, T; Millenson, MM; Morris, GJ; Padavic-Shaller, K; Rogatko, A; Schilder, RJ; Smith, MR; Wang, H; Yeslow, G1
Beltrami, G; Carella, AM; Corsetti, MT; Musto, P; Scalzulli, P1
Asaka, M; Ehira, N; Fukushima, A; Imamura, M; Kanamori, H; Masauzi, N; Minami, H; Musashi, M; Obara, S; Ogura, N; Tanaka, J; Tsutsumi, Y; Yamato, H1
Canpinar, H; Demirpençe, E; Doğan, A; Doğan, AL; Duzgunçinar, O1
Kato, Y; Kohno, A; Morishita, Y; Narimatsu, H; Ozeki, K; Saito, S; Shimada, K1
Chang, V; Donepudi, S; Kotenko, S; Lee, J; Mansour, A; McCarthy, B; Raveche, E; Schwander, SK1
Gibson, SB; Haney, N; Hu, X; Johnston, JB; Kabore, AF; Kropp, D1
Abdall, N; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gatto, S; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R; Venturino, C1
Briones, J; Ferrer, B; Forné, I; Juarez, C; Martinez-Gallo, M; Martinez-Lostao, L; Rodriguez-Sanchez, JL; Sierra, J1
Alexander, PJ; Feliz, A; Gok, F; Good, RA; Jones, JM; Jones, OY; Lacson, A; Madivi, C; Marikar, Y1
Lennard, AL; Osborne, WL1
Creamer, D; Devereux, S; Mufti, G; Perera, GK; Salisbury, J1
Ball, SE; Freires, M; Gordon-Smith, EC; Gupta, V; Marsh, JC; Ortin, M; Sage, D1
Benesch, M; Lackner, H; Schwinger, W; Sykora, KW; Urban, C1
Hamasaki, Y; Hara, T; Ihara, K; Imayoshi, M; Ishii, E; Miyazaki, S; Muraoka, K1
Borelli, S; Herr, D; Kempf, W; Trojan, A1
Alam, A; Benyunes, M; Bernstein, SH; Bernstein, ZP; Blumenson, L; Brown, K; Chanan-Khan, A; Czuczman, MS; Donohue, K; Grillo-Lopez, A; Hernandez-Ilizaliturri, F; Klippenstein, D; Koryzna, A; Loud, P; McCarthy, P; Mohr, A; Rock, MK; Skipper, M; Stewart, C1
Berthou, C; Casassus, P; Colombat, P; Deconinck, E; Delwail, V; Desablens, B; Foussard, C; Ghandour, C; Gressin, R; Lamy, T; Mahé, B; Maisonneuve, H; Pignon, B; Rachieru, P; Rousselet, MC1
Cabanillas, F; Coleman, M; Gregory, SA; Hagemeister, F; Zinzani, PL1
Catovsky, D; Del Giudice, I; Matutes, E; Osuji, N; Parry-Jones, N; Swansbury, J1
Chevret, S; Leblond, V; Lévy, V; Morel, P; Porcher, R; Wattel, E1
Ayyildiz, O; Bolaman, Z; Isikdogan, A; Muftuoglu, E1
Dziecioł, J; Kłoczko, J; Lemancewicz, D; Piszcz, J1
Gershanovich, ML; Tikhonova, VV1
Abe, Y; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Tachikawa, Y1
Ayuk, F; Fehse, B; Fehse, N; Kröger, N; Kvasnicka, HM; Panse, J; Schieder, H; Stute, N; Thiele, J; Waschke, O; Zabelina, T; Zander, A1
Bellas, C; Catovsky, D; Matutes, E; Pocock, C; Santon, A; Shah, G; Thornton, PD; Wotherspoon, AC1
Nichols, GL; Skerrett, DL1
Hartwig, UF; Herr, W; Huber, C; Kolbe, K; Kreiter, S; Meyer, RG; Schneider, PM; Ullmann, AJ; Wehler, T; Winkelmann, N1
Ahlberg, L; Apperley, JF; Björkstrand, B; Boiron, JM; Carella, A; Cavenagh, J; Chopra, R; Crawley, C; Einsele, H; Gahrton, G; Garban, F; Gilleece, M; Gratwohl, A; Juliusson, G; Lalancette, M; Mackinnon, S; Nagler, A; Niederwieser, D; Peggs, K; Shimoni, A; Sureda, A; Szydlo, R; Zander, A1
Choi, SJ; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, YS; Ryu, SG; Seol, M1
Badagnani, I; Brett, CM; Burchard, EG; Carlson, EJ; Castro, RA; Chan, W; Ferrin, TE; Giacomini, KM; Huang, CC; Johns, SJ; Kawamoto, M; Stryke, D1
Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M1
Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F1
Diaconescu, R; Maloney, DG; Maris, MB; McSweeney, P; Parikh, CR; Sandmaier, BM; Schrier, RW; Sorror, ML; Storb, R; Storer, B1
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Jenke, A; Johne, C; Knoth, H; Schleyer, E1
Mikhailenko, VM; Philchenkov, AA; Zavelevich, MP1
Emerson, SG; Goldstein, SC; Green, J; Loren, AW; Luger, SM; Nasta, SD; Oliver, JC; Orloff, G; Perl, A; Porter, DL; Schuster, S; Stadtmauer, EA; Tsai, DE1
Byrd, JC; Grever, MR; Lin, TS1
Albitar, M; Beran, M; Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Thomas, D; Wen, S; Wierda, W1
Albitar, M; Andreeff, M; Cortes, J; Detry, MA; Faderl, S; Giles, F; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; Lynn, A; O'Brien, S; Plunkett, W; Thomas, D; Wierda, W1
Jindra, P; Koza, V; Lysak, D; Schutzova, M; Steinerova, K; Vozobulova, V1
Baron, F; Chauncey, TR; Diaconescu, R; Flowers, ME; Maloney, DG; Maris, MB; Mielcarek, M; Sandmaier, BM; Sorror, M; Storb, R; Storer, BE; Woolfrey, AE1
Barulli, S; D'Adamo, F; Guiducci, B; Isidori, A; Leopardi, G; Malagola, M; Malerba, L; Mele, A; Nicolini, G; Piccaluga, P; Politi, P; Sparaventi, G; Stramigioli, S; Talevi, N; Visani, G1
Andreesen, R; Blüml, S; Burger, V; Eissner, G; Haffner, S; Holler, E; Iacobelli, M1
Jindra, P; Koza, V; Lysák, D; Steinerová, K; Vozobulová, V1
Naito, K; Ohnishi, K1
Jaeger, U; Johnson, SA; Leblond, V; Levy, V; Oscier, DG; Owen, RG; Seymour, JF1
Abati, A; Berman, DM; Dudley, ME; Filie, AC; Gea-Banacloche, J; Gracia, GJ; Jones, SA; Kammula, U; Mangiameli, DP; Mavroukakis, SA; Pelletier, MM; Restifo, NP; Robinson, MR; Rogers, LJ; Rosenberg, SA; Royal, RE; Sherry, RM; Topalian, SL; White, DE; Wunderlich, JR; Yang, JC1
Agura, E; Al-Ali, HK; Blume, KG; Bruno, B; Chauncey, TR; Epner, EM; Gooley, T; Hegenbart, U; Kerbauy, FR; Maloney, DG; Niederwieser, D; Radich, JP; Sandmaier, BM; Shizuru, J; Storb, R1
Agirre, X; Calasanz, MJ; Giraldo, P; Larráyoz, MJ; Odero, MD; Rubio-Felix, D; Rubio-Martinez, A; Valgañón, M1
Arbiser, J; Battle, TE; Frank, DA1
Agura, E; Al-Ali, H; Blume, KG; Bredeson, C; Bruno, B; Chauncey, TR; Hegenbart, U; Langston, A; Leis, J; Loken, MR; Maloney, DG; Maris, MB; McSweeney, P; Pulsipher, M; Radich, JP; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Stuart, MJ1
Fong, D; Gastl, G; Kaiser, A; Spizzo, G; Tzankov, A1
Dumontet, C; Galmarini, CM; Jordheim, LP1
Coiffier, B; Michallet, AS; Michallet, M; Salles, G1
Brenner, MK; Carrum, G; Heslop, HE; Krance, RA; Lamba, R; May, R; Popat, U1
Benesch, M; Dornbusch, HJ; Lackner, H; Schwinger, W; Sovinz, P; Urban, C1
Li, WX; Mao, X; Yu, C1
Langiewicz, P; Rzepecki, P; Sarosiek, T; Szczylik, C; Zolnierek, J1
Czock, D; Hertenstein, B; Keller, F; Kielstein, JT; Radermacher, J; Stadler, M1
Richards, S1
Kalhorn, TF; McCune, JS; Ren, AG; Slattery, JT; Wang, J1
Burger, JA; Burger, M; Fujii, N; Hartmann, T; Kipps, TJ; Krome, M; Rawluk, J; Tamamura, H1
Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M1
Dührsen, U; Frey, UH; Nückel, H; Röth, A; Siffert, W1
Beyer, M; Darabi, K; Debey, S; Endl, E; Hallek, M; Jensen, M; Knolle, PA; Kochanek, M; Popov, A; Schultze, JL; Thomas, RK; von Bergwelt-Baildon, M1
Ayuk, F; Beyer, J; Binder, T; Bornhäuser, M; Eiermann, T; Iacobelli, S; Kiehl, M; Kröger, N; Madrigal, A; Marks, DI; Nagler, A; Peggs, K; Sayer, HG; Schwerdtfeger, R; Shaw, B; Shimoni, A; Zabelina, T; Zander, AR1
Molica, S; Ribatti, D; Tucc, L; Vacca, A1
Bond, R; Brown, M; Campbell, P; Grigg, AP; Ritchie, D; Scarlett, J; Seymour, JF; Tam, C; Underhill, C1
Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH1
Briones, J; Brunet, S; Caballero, D; Cañizo, C; Clopés, A; Martino, R; Mateos, M; Moreno, E; Pérez-Simón, JA; Queraltó, JM; San Miguel, JF; Sierra, J; Sureda, A; Vazquez, L1
Attarbaschi, A; Gadner, H; Grois, N; Holter, W; Matthes-Martin, S; Minkov, M; Ouachee, M; Steiner, M; Unger, E; Vormoor, J; Wawer, A; Woessmann, W1
Amin, CJ; Rabinowitz, I1
Boudreaux, CW; Michael, CW; Richardson, PH1
Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A1
Califano, C; D'Arco, AM; Danise, P; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B1
Goor, KM; Huijgens, PC; Schaafsma, MR; van Agthoven, M1
Hara, S; Hayashi, S; Kamimura, T; Ogata, K; Suzumiya, J; Takamatsu, Y; Tamura, K; Yamauchi, K1
Chim, CS; Leung, WH; Tsang, SF1
Barrett, AJ; Childs, R; Donohue, T; Espinoza-Delgado, I; Geller, N; Gorak, E; Srinivasan, R; Suffredini, A1
Adler, SS; Enschede, SH; Gregory, SA; Porter, C; Rao, R; Shammo, JM; Venugopal, P1
Artz, A; Bennett, D; Cao, D; Casey, B; Daugherty, C; Del Cerro, P; Godley, L; Jones, D; Larson, RA; Odenike, O; Rich, S; Smith, S; Stock, W; Thirman, M; van Besien, K; Wickrema, A; Zimmerman, T1
Hillmen, P; Johnson, SA; Owen, RG; Rule, SA; Seymour, JF; Thomas, DW; Wolf, MM1
Hirschman, R; Mastan, A; Ng, R; Rashid, K; Sager, D1
Baba, Y; Fujimaki, K; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Takabayashi, M; Takasaki, H; Yamaji, S1
Berdel, WE; Berning, B; Beyer, J; Bornhauser, M; Buchner, T; Ehninger, G; Fauser, AA; Heinecke, A; Kienast, J; Kroger, M; Neubauer, A; Sauerland, MC; Scheffold, C; Silling, G; Stelljes, M1
Claxton, DF; Ehmann, C; Rybka, W1
Kwong, YL; Lam, CC; Ma, ES1
Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S1
Carluccio, P; Ciuffreda, L; Liso, A; Liso, V; Mestice, A; Pastore, D; Pietrantuono, G; Rizzi, R; Specchia, G1
Berger, C; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Donohue, K; Klippenstein, D; Koryzna, A; Miller, KC; Mohr, A; Takeshita, K; Wallace, P; Zeldis, JB1
Auerbach, AD; Defor, TE; Macmillan, ML; Slungaard, A; Tan, PL; Wagner, JE1
Bao, L; Huang, XJ; Jiang, B; Lu, DP; Lu, J; Lu, XJ; Qiu, JY; Shi, HX; Wang, DB; Wang, FR1
Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T1
Mielcarek, M; Storb, R1
Kolb, HJ; Ledderose, G; Schleuning, M; Schmid, C; Tischer, J1
Cesarman, E; Chadburn, A; Coleman, M; Fiore, J; Furman, RR; Goldsmith, SJ; Kostakoglu, L; Kroll, S; Leonard, JP; Muss, D; Niesvizky, R; Schuster, MW; Tidmarsh, G; Vallabhajosula, S1
Jacobs, MI; Mantha, S; Savage, DG1
Hamblin, TJ1
Au, WY; Chim, CS; Kwong, YL; Lam, CC; Pang, AW1
Bornkessel, A; Hahnfeld, S; Weyers, W; Ziemer, M1
Barrett, AJ; Childs, R; Kurlander, R; Leitman, SF; Montero, A; Read, EJ; Savani, BN; Solomon, SR1
Chaleteix, C; Choquet, S; Christian, B; Delmer, A; Dreyfus, F; Fermand, JP; Grange, MJ; Leblond, V; Lévy, V; Morel, P; Stalniewicz, L; Tamburini, J1
Bontemps, F; Cardoen, S; Offner, F; Van den Neste, E1
Carew, JS; Dunner, K; Huang, P; Keating, MJ; Krupnik, YV; McConkey, DJ; Nawrocki, ST1
Aulitzky, W; Borchmann, P; Elter, T; Engert, A; Gramatzki, M; Hallek, M; Hasan, I; Jensen, M; Josting, A; Rech, J; Reiser, M; Schinköthe, T; Schnell, R; Schulz, H; Staib, P; Stützer, H; Trelle, S1
Bakkun, A; Medved, I; Sergienko, T; Slobozhanina, E; Svirnovski, A; Tamashevski, A; Taras, I1
Hori, H; Kawai, Y; Ueda, T; Yoshio, N1
Abbott, BL1
Cho, HS; Chun, SH; Hyun, MS; Kim, KO; Kim, MK; Lee, KH; Shin, SJ1
Baumgart, J; Casper, J; Freund, M; Grobe, N; Hähling, D; Hartung, G; Hilgendorf, I; Junghanss, C; Kahl, C; Lück, A; Pichlmeier, U; Steiner, B; Wilhelm, S; Wolff, D1
Austin, H; Balow, JE; Barrett, J; Childs, R; Geller, N; Igarashi, T; Lundqvist, A; Sabnis, S; Srinivasan, R; Takahashi, Y; Tisdale, J1
Albertioni, F; Löfgren, C; Paul, C1
Chun, K; Daly, A; Gupta, V; Hasegawa, W; Kamel-Reid, S; Kiss, T; Lipton, JH; Messner, H; Minden, M; Tsang, R; Yi, QL1
Benner, A; Gerull, S; Goerner, M; Goldschmidt, H; Hegenbart, U; Ho, AD; Klein, U; Schaefer, H1
Batár, P; Telek, B; Uvardy, M1
Appelbaum, FR; Boldt, DH; Budd, GT; Dakhil, SR; Dobin, SM; Elias, L; Foon, KA; Gundacker, H; Head, DR; Hussein, MA1
Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E1
Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K1
Bacigalupo, A; Cesaro, S; Lanino, E; Locasciulli, A; Locatelli, F; Marsh, J; Maury, S; Passweg, J; Prete, A; Socié, G1
De La Cruz, M; Ferrin, TE; Giacomini, KM; Huang, CC; Johns, SJ; Kawamoto, M; Lagpacan, LL; Owen, RP; Stryke, D; Taylor, TR1
Bergmann, M; Brittinger, G; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Hallek, M; Hensel, M; Hopfinger, G; Jäger, U; Pasold, R; Schweighofer, C; Siehl, S; Steinbrecher, C; Stilgenbauer, S; Wendtner, CM1
Cass, CE; Damaraju, VL; King, KM; Lang, T; Mowles, DA; Ng, AM; Tackaberry, TE; Vickers, MF; Yao, SY; Young, JD1
Ernemann, U; Hebart, H; Herrlinger, U; Kanz, L; Knop, S1
Alinari, L; Baccarani, M; Fina, M; Gabriele, A; Marchi, E; Musuraca, G; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL1
Barbarotto, E; Corallini, F; di Iasio, MG; Melloni, E; Secchiero, P; Tiribelli, M; Zauli, G1
Amadori, S; Bruno, A; Buccisano, F; Cantonetti, M; Capelli, G; Consalvo, MA; Del Poeta, G; Del Principe, MI; Gattei, V; Gianní, L; Lo Coco, F; Maurillo, L; Mazzone, C; Venditti, A1
Beijnen, JH; Hillebrand, MJ; Rosing, H; Silvertand, LH; van Maanen, MJ; Vazvaei, F; Weigl, P1
Ball, ED; Bashey, A; Carrier, E; Castro, JE; Corringham, S; Hassidim, K; Holman, P; Ihasz, A; Keese, K; Lane, TA; Liu, L; Medina, B1
Adam, K; Bergmann, J; Buchheidt, D; Hehlmann, R; Hummel, M; Reiter, S1
Abdul Hai, A; Ben-Harush, M; Bitan, M; Hershkovitz, E; Kapelushnik, J; Or, R; Resnick, IB; Schwartz, A; Shapira, MY; Slavin, S1
Begum, G; Chopra, R; Cook, G; Cook, M; Craddock, C; Goldstone, A; Hale, G; Hunter, A; Jackson, G; Khwaja, A; Littlewood, T; Mackinnon, S; Mahendra, P; Marsh, J; Milligan, D; Parker, A; Peggs, K; Peniket, A; Russell, N; Tauro, S1
Asaka, M; Ikarashi, Y; Kuwatani, M; Mineishi, S; Wakasugi, H1
Blau, IW; Fietz, T; Gentilini, C; Glass, B; Marinets, O; Muessig, A; Munz, DL; Rieger, K; Sandrock, D; Thiel, E; Uharek, L1
Byrd, JC; Diehl, LF; Flinn, IW; Garrett-Mayer, E; Goodman, SN; Grever, MR; Kasamon, YL; Lucas, MS1
Baxter-Lowe, LA; Cowan, M; Desantes, K; Englert, L; Horn, B; McMillan, A; Quinn, M1
Chen, L; Ng, AP; Prince, HM; Seymour, JF; Slavin, M; Thursky, K; Worth, L1
Carney, DA; Estrov, Z; Garcia-Prieto, C; Harris, DM; Huang, P; Jin, Z; Kang, Y; Keating, MJ; Kondo, S; Liu, J; Lou, C; Pelicano, H; Xu, RH; Yu, W; Zhou, Y1
Andreani, M; Gaziev, J; Lucarelli, G; Polchi, P; Sodani, P1
Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR1
Byrd, JC; Caligiuri, MA; Grever, MR; Gribben, JG; Heerema, NA; Lampson, B; Larson, RA; Lozanski, G; Lucas, DM; Peterson, BL1
Hong, WD; Li, J; Luo, SK; Tong, XZ; Zhao, Y1
Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Lerner, S; O'brien, S; Ravandi-Kashani, F; Thomas, D; Wang, X; Wierda, W1
Avery, RK; Mawhorter, SD; Prayson, RA; Procop, GW; Sierk, A; Sobecks, R; Staugaitis, SM; Yen-Lieberman, B1
Bukin, M; Jabłońska, E; Kiersnowska-Rogowska, B; Parfieńczyk, A; Puzewska, W; Rogowski, F1
Ito, M; Johnson-Pais, TL; Kajiya, H; Key, LL; Reddy, SV; Srinivasan, S1
Cassoni, A; Cooper, N; Delgado, J; Duarte, R; Jarmulowicz, M; Kottaridis, P; Mackinnon, S; Peggs, K; Thomson, K1
Bernardi, M; Bregni, M; Corradini, P; Deola, S; Fleischhauer, K; Guggiari, E; Lunghi, F; Mazzi, B; Monari, M; Peccatori, J; Pescarollo, A; Re, F; Scaramuzza, S; Servida, P; Setola, E1
Abramenko, I; Bazyka, D; Bebeshko, V; Bilous, N; Chumak, A; Kryachok, I1
Cho, HS; Kim, CC; Kim, SY; Kim, Y; Lee, JW; Lee, S; Lee, SM; Min, CK; Min, WS; Woo, HY1
Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A1
Rzepecki, P; Sarosiek, T; Szczylik, C1
Gale, R; Gray, A; Hancock, B; Hutchinson, J; Lloyd, A1
Fay, M; Murphy, PT; Nolan, A; O'Donnell, R; Quinn, J; Swords, R1
Champlin, RC; Chan, KW; Choroszy, M; Ha, CS; Madden, R; Mahajan, A; Mullen, CA; Petropoulos, D; Worth, LL1
Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Plunkett, W; Shan, J1
Barón, A; Bearman, SI; Hawkins, T; Jones, RB; McSweeney, PA; Nieto, Y; Patton, N; Rabinovitch, R; Shpall, EJ; Spearing, R; Zeng, C1
Fujimori, Y; Hara, H; Itoi, H; Itsukuma, T; Kai, S; Misawa, M; Nakajima, T; Nishioka, K; Nomura, K; Ogawa, H; Okada, M; Takatsuka, H; Toda, A; Wakae, T1
Kneba, M; Moosig, F; Schoch, R1
Khurshid, M; Syed, NN1
Inamoto, Y; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Oba, T; Tokunaga, M; Tsujimura, A1
Bernardi, P; Cabrelle, A; Cesura, AM; Colonna, R; Costantini, P; Gambalunga, A; Milanesi, E; Petronilli, V; Pinard, E; Semenzato, G1
Sikorski, AF; Stebelska, K; Wyrozumska, P1
Benson, GM; Clarke, J; Kettle, PJ; Murtagh, E; Wilson, L1
Birchall, J; Johnson, SA; Luckie, C; Oscier, DG; Owen, RG1
Kami, M; Kusumi, E; Masuoka, K; Miura, Y; Murashige, N; Tachibana, S; Taniguchi, S; Yoshimura, M1
Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-Rangel, JD; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Rivas-Vera, S; Ruiz-Argüelles, GJ; Sobrevilla-Calvo, P; Vela-Ojeda, J1
Faria, JR; Faria, RM; Kerbauy, J; Oliveira, JS; Yamamoto, M1
Castro, ED; Coelho, AM; Linden, R; Maia, RC; Silva, KL; Vasconcellos, DV1
Abe, Y; Choi, I; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Shibata, K; Tachikawa, Y1
Choudhry, VP; Chowdhary, DR; Kumar, R; Mahapatra, M; Mehra, NK; Mishra, P; Narendra, AM; Pillai, L; Prem, S; Saxena, R; Seth, T1
Higashihara, M; Horie, R; Motoji, T; Okamura, T; Shoda, M; Taira, M; Umezawa, K; Utsunomiya, A; Watanabe, M; Watanabe, T1
Alberto, MF; Fernández-Calotti, P; Gamberale, R; Geffner, J; Giordano, M; Sánchez-Avalos, J1
Aguado, JM; Díaz-Pedroche, C; Folgueira, D; Giménez-Mesa, E; Lizasoain, M1
Robak, E; Sysa-Jedrzejowska, A; Wozniacka, A1
Ikeda, Y; Murase, T; Nishida, H; Park, JW; Ueno, H; Yano, T1
Andreeff, M; Kojima, K; Konopleva, M; McQueen, T; O'Brien, S; Plunkett, W1
Agura, E; Blume, KG; Bruno, B; Chauncey, TR; Kliem, C; Langston, AA; Maloney, DG; Maris, MB; Maziarz, RT; McSweeney, PA; Pulsipher, M; Sandmaier, BM; Shizuru, JA; Storb, R; Storer, BE; Wade, J1
Costas, M; Fernández-Calotti, P; Gamberale, R; Geffner, J; Giordano, M; Sánchez Avalos, J1
Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S1
Kay, NE1
Imamura, T; Kadota, J; Kikuchi, H; Kohno, K; Ogata, M; Ohtsuka, E; Tomo, T1
Seymour, JF; Tam, CS1
Asano, S; Iseki, T; Konuma, T; Nakaoka, T; Ooi, J; Takahashi, S; Takasugi, K; Tojo, A; Tomonari, A; Tsukada, N; Uchiyama, M1
Cai, Z; Wu, WJ1
Cairoli, R; Colosimo, A; Intropido, L; Miqueleiz, S; Montagna, M; Montillo, M; Morra, E; Nichelatti, M; Regazzi, M; Ricci, F; Scarpati, B; Tedeschi, A; Veronese, S1
Benetatos, L; Bourantas, KL; Hatzimichael, E; Vassou, A1
Bretonnet, AS; Cros, E; Dumontet, C; Gagnieu, MC; Galmarini, CM; Jordheim, LP; Krimm, I; Lancelin, JM1
Liu, H; Sheng, ZY; Yao, YM; Yu, Y1
Barrett, AJ; Childs, RW; Dorrance, C; Espinoza-Delgado, I; Geller, N; Igarashi, T; Lundqvist, A; McCoy, JP; Srinivasan, R; Takahashi, Y; Young, NS1
Carney, D; Januszewicz, EH; Lin, KI; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M1
Byrd, JC; Croce, CM; De Lay, MD; Edwards, RB; Grever, MR; Johnson, AJ; Lucas, DM; Muthusamy, N; Smith, LL1
Au, WY; Chan, LC; Kwong, YL; Liang, R1
Mitra, S; Murphy, PT; O'Donghaile, D1
Califano, C; Celentano, M; D'Amico, MR; D'Arco, AM; Ferrara, F; Mele, G; Palmieri, S; Pollio, F1
Abdul-Hai, A; Ackerstein, A; Aker, M; Bitan, M; Gesundheit, B; Lvovich, A; Miron, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, PD; Yoffe, L; Zilberman, I1
Hanamura, A; Hayakawa, M; Naito, K1
Ohnishi, K1
Smolej, L2
Inamoto, Y; Kasai, M; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Murata, M; Naoe, T; Oba, T; Terakura, S; Tokunaga, M; Tsujimura, A1
Goh, YT; Hwang, WY; Koh, BC; Koh, LP; Linn, YC; Loh, SM; Ratnagopal, P; Tan, HC1
Aly, F; Diehl, V; Rehwald, U; Schmitz, S; Steinmetz, T1
Abinun, M; Ferreira, RA; Foster, HE; Kuis, W; Modesto, C; Olivé, T; Vastert, SJ; Wulffraat, NM1
Ackerstein, A; Aker, M; Bitan, M; Elad, S; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S1
Kotani, T; Nakamura, Y; Ueda, M; Yamaguchi, M1
Alexopoulou, A; Archimandritis, AJ; Dourakis, SP; Karayiannis, P; Pandelidaki, H1
de la Fuente Bobillo, MA; Mendo González, M; Peñarrubia Ponce, MJ; Rodríguez Toves, A; Torres Nieto, A; Vara Castrodeza, A1
Bohlius, J; Greil, R; Pall, G; Richards, S; Schwarzer, G; Steurer, M2
Giver, CR; Li, JM; Waller, EK1
Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Laurenti, L; Leone, G; Piccioni, P; Piccirillo, N; Sica, S; Tarnani, M1
Cutting, R; Edbrooke, D; El-Ghariani, K; Ezaydi, Y; Snowden, JA; Stamps, R1
Byrd, JC; Esseltine, DL; Faderl, S; Flinn, IW; Gribben, J; Keating, MJ; O'Brien, S; Rai, K; Sheng, S1
Adachi, S; Hamanoue, S; Inoue, H; Ishiguro, H; Kato, S; Koike, H; Koike, K; Koike, T; Kojima, S; Matsumoto, M; Mori, T; Morimoto, A; Sako, M; Suzuki, K; Tsuchida, M; Tsuji, K; Yabe, H; Yabe, M1
Bowcock, SJ; Lim, Z; Mufti, GJ; Rassam, SM; Ryali, MM; Ward, SM1
Januszewicz, EH; Milner, A; Polizzotto, MN; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM1
Alexaki, P; Christakis, GB; Megalakaki, A; Perlorentzou, S; Zarkadis, IK1
Cantu-Rodríguez, O; Gomez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, H; Herrera-Garza, J; Jaime-Pérez, J; Mancias-Guerra, C1
Coleman, M; Feldman, EJ; Harpel, J; Leonard, JP; Roboz, GJ; Schuster, MW; Shore, T; Silver, RT1
Chuah, CT; Goh, YT; Hwang, WY; Koh, LP; Koh, MB; Linn, YC; Loh, YS; Ng, HJ; Ng, HY; Tan, DC; Tan, KW; Tan, PH1
Elter, T; Engert, A; Hallek, M1
Audouin, J; Compérat, E; Delmer, A; Diebold, J; Le Tourneau, A; Molina, TJ1
Brugiatelli, M; Callea, V; Console, G; Iacopino, P; Irrera, G; Martino, M; Morabito, F; Musolino, C; Piro, E; Praticò, G; Quartarone, E; Stelitano, C1
Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Khouri, IF; Korbling, M; Lekakis, L; Martin, T; Shpall, EJ1
Bauta, WE; Cantrell, WR; Schulmeier, BE1
Taniguchi, S1
Fujii, H; Goto, H; Ikuta, K; Isaki, S; Kajiwara, R; Kuroki, F; Takahashi, H; Yanagimachi, M; Yokota, S1
Choudhury, A; Kiaii, S; Lundin, J; Mellstedt, H; Mozaffari, F; Osterborg, A; Rezvany, R1
Czepulkowski, B; Devereux, S; Duarte, RF; Ho, AY; Ingram, W; Kenyon, M; Lim, ZY; Mufti, GJ; Pagliuca, A; Pearce, L1
Bulanov, AIu; Chernova, NG; Gretsov, EM; Kalinin, NN; Kravchenko, SK; Kremenetskaia, AM; Mar'in, DS; Petrova, VI; Semenova, EA; Valiev, TT; Vinogradova, IuE; Volkova, IaK; Vorob'ev, AI1
Böck, HP; Dreyling, M; Einsele, H; Forstpointner, R; Hänel, A; Hartmann, F; Hiddemann, W; Lehmann, T; Metzner, B; Pott, C; Repp, R; Seymour, JF; Unterhalt, M; Wandt, H1
Everett, PC; Lerner, A; Makkinje, A; Meyers, JA; Rabbi, M1
Keating, MJ; Moufarij, MA; Plunkett, W; Sampath, D1
Cabanillas, F; Liboy, I; Pavia, O; Rivera, E1
Andreasson, B; Birgegård, G; Brune, M; Kutti, J; Lazarevic, V; LeBlanc, K; Malm, C; Merup, M; Nahi, H; Nilsson, L1
Dmoszyńska, A; Giannopoulos, K; Roliński, J1
Beri, R; Chen, HY; Chunduri, S; Dobogai, LC; Hoffman, R; Jessop, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y1
Brychtova, Y; Dolezal, T; Doubek, M; Dvorakova, D; Horky, O; Koristek, Z; Krejci, M; Lengerova, M; Mayer, J; Pospisil, Z; Racil, Z; Vorlicek, J1
Dalal, J; Davies, SM; Filipovich, A; Kamani, N; Lee, SM; Rao, A; Shenoy, S1
Nelson, JA; Pan, BF1
Denning, MF; Nickoloff, BJ; Qin, JZ; Sitailo, LA; Xin, H1
Benedetti, F; Boccadoro, M; Chisesi, T; De Blasio, A; Drandi, D; Gallamini, A; Ladetto, M; Locasciulli, A; Majolino, I; Tarella, C1
Montillo, M; Ricci, F; Tedeschi, A1
Carter, WH; Cragg, L; Feldman, EJ; Grant, S; Honeycutt, C; Millenson, MM; Murgo, AJ; Padavic-Shaller, K; Ramakrishnan, V; Roberts, JD; Roboz, GJ; Smith, MR; Thune, R1
Ijichi, O; Ikarimoto, N; Ishikawa, S; Kawano, Y; Kodama, Y; Manago, K; Nishikawa, T; Okamoto, Y; Shinkoda, Y; Tanabe, T1
Hori, A; Kami, M; Kobayashi, K; Komatsu, T; Kurita, N; Kusakabe, M; Matsumura, T; Murashige, N; Narimatsu, H; Tanaka, Y; Yoshimi, A; Yuji, K1
Barkholt, L; Hassan, Z; Mattsson, J; Omazic, B; Remberger, M; Ringdén, O; Sairafi, D; Uzunel, M1
Cervasi, B; Engram, J; Fraternale, A; Lawson, B; Magnani, M; Menotta, M; Paiardini, M; Perno, CF; Piedimonte, G; Serafini, S; Silvestri, G; Staprans, SI1
Campo, E; Gaya, A; Martinez, A; Mercadal, S; Nomdedeu, B; Rozman, M; Salamero, O1
Aribi, A; Faderl, S; Ferrajoli, A; Huh, Y; Kantarjian, H; Keating, M; O'brien, S; Ravandi, F; Wierda, W1
Chang, VT; Harrison, J; Mansour, A; Raveche, E; Srinivas, S1
Aghaiipour, M; Bernard, D; David, G; Hadjati, E; Iravani, M; Shaiegan, M1
Cabanillas, F; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Tiongson, LP; Younes, A1
Bianchi, M; Castiglioni, MG; Mechelli, S; Pandolfo, C; Scatena, P1
Fabianowska-Majewska, K; Krawczyk, B1
Alyea, EP; Antin, JH; Cutler, C; DeAngelo, DJ; Ho, V; Kim, HT; Ritz, J; Soiffer, RJ; Stone, R1
Dhar, S; Fryknäs, M; Göransson, H; Gustafsson, M; Isaksson, A; Larsson, R; Nygren, P; Oberg, F; Pettersson, U; Rickardson, L; Rydåker, M1
Januszewicz, EH; Kenealy, M; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M1
Busch, R; Eichhorst, BF; Emmerich, B; Hallek, M; Schweighofer, C; Wendtner, CM1
Alyea, EP; Antin, JH; Brown, JR; Cutler, C; Fisher, DC; Gribben, JG; Ho, V; Kim, HT; Lee, SJ; Li, S; Milford, EL; Ritz, J; Soiffer, RJ; Stephans, K1
Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S1
Anhalt, GJ; Cummins, DL; Meyerle, JH; Mimouni, D; Owens, N; Tzu, J1
Flinn, IW; Kasamon, YL1
Croce, C1
Lazarevic, V; Wahlin, A1
Kay, NE; O'Brien, S; Rai, KR1
Eurelings, M; Fijnheer, R; Franssen, H; Lokhorst, H; Niermeijer, JM; Notermans, NC; Wokke, JH1
Fujiwara, M; Hori, A; Kami, M; Kanda, Y; Komatsu, T; Koyama, R; Kusumi, E; Masuoka, K; Matsumura, T; Miyakoshi, S; Murashige, N; Seki, K; Tanaka, Y; Taniguchi, S; Wake, A; Yuji, K1
Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J1
Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P1
Brunstein, C; DeFor, T; Ebeling, B; Green, K; Jacobson, P; McGlave, P; Rogosheske, J; Weisdorf, D1
Hartmann, JT; Kanz, L; Klingel, K; Kröber, SM; Meisinger, I; Weisel, K1
Bergeman, T; Bonin, M; Bornhauser, M; Ehninger, G; Illmer, T; Leopold, T; Pursche, S; Schleyer, E1
Hanke, A; Lohse, P; Meissner, B; Rehe, K; Sauer, M; Sykora, KW; Welte, K; Zeidler, C1
Emmons, RV; Jillella, AP; Klumpp, TR; Mangan, KF; Shafer, D1
Celsing, F; Hansson, L; Karlsson, C; Lundin, J1
Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S1
Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ1
Baccarani, M; Bergonzi, C; Bocchia, M; Bonini, A; Candoni, A; Cesana, B; Damiani, D; Fanin, R; Filí, C; Geromin, A; Gobbi, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michelutti, A; Ottaviani, E; Piccaluga, PP; Pierri, I; Priccolo, G; Roccaro, AM; Russo, D; Skert, C; Testoni, N; Tiribelli, M; Visani, G; Vivo, AD; Zaccaria, A; Zuffa, E1
Alyea, E; Antin, JH; Attar, E; Ballen, KK; Cutler, C; Dey, BR; Haspel, R; Ho, V; Kao, G; Lee, S; Liney, D; McAfee, S; Soiffer, R; Spitzer, TR; Yeap, BY1
Bakke, AC; Braziel, RM; Fan, G; Gatter, KM; Huang, JZ; Leis, JF; Maziarz, RT; Zhong, Y1
Avcu, F; Cetin, T; Kubar, A; Nevruz, O; Safali, M; Tastan, HB; Ural, AU1
King, I; Li, Z; Liu, L; Song, BL; Zheng, LM1
Bertz, H; Bley, TA; Feuerhake, F; Finke, J; Mielke, S; Potthoff, K; Windfuhr, M1
Abrahamsson, J; Clausen, N; Forestier, E; Gustafsson, G; Hasle, H; Heldrup, J; Hovi, L; Jonmundsson, G; Zeller, B1
Appelbaum, FR; Bennett, JM; Dewald, GW; Flinn, IW; Grever, MR; Hussein, MA; Larson, RA; Moore, DF; Neuberg, DS; Paietta, EM; Tallman, MS1
Cavaliere, AL; Coppola, C; Curcio, A; De Serio, D; Ellison, GM; Galuppo, V; Gasparri, C; Indolfi, C; Leone, A; Surace, FC; Torella, D1
Bociek, RG; Boyd, TE; Chanan-Khan, AA; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Pavletic, S; Rai, KR; Seymour, JF; Skotnicki, A1
Andreesen, R; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Fauser, AA; Fietz, T; Freund, M; Hopfenmüller, W; Kanz, L; Keilholz, U; Knauf, W; Marinets, O; Ruutu, T; Schmidt-Hieber, M; Stuhler, G; Thiel, E; Trenschel, R; Uharek, L; Volin, L1
Aschan, J; Barkholt, L; Dahllöf, G; Gustafsson, B; Hassan, Z; Ljungman, P; Mattsson, J; Omazic, B; Remberger, M; Ringdén, O; Svahn, BM; Svenberg, P; Uzunel, M; Winiarski, J1
Abidi, MH; Alangaden, G; Chandrasekar, PH; Heilbrun, LK; Klein, JL; Mellon-Reppen, S; Narreddy, S; Peres, E; Smith, D1
Gadre, SA; Ge, Y; Lockhart, LH; Northup, JK; Velagaleti, GV1
Chuhjo, T; Kondo, Y; Kotani, T; Nakao, S; Ohtake, S; Okumura, H; Ozaki, J; Sugimori, C; Sugimori, N; Takami, A; Ueda, M; Yamaguchi, M; Yamazaki, H1
Brown, C; Chaudhry, A; Larratt, L; Morris, D; Quinlan, D; Russell, JA; Stewart, D; Turner, AR1
Calixto, R; Domingues, MC; Florêncio, R; Ostronoff, F; Ostronoff, M; Souto Maior, AP; Sucupira, A; Tagliari, C1
Austin, HA; Balow, JE; Boumpas, DT; Chitkara, P; Fleisher, T; Illei, GG; Klippel, JH; Kuroiwa, T; Schlimgen, R; Tisdale, JF; Yarboro, CH1
Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM1
Iwasaki, H; Kawai, Y; Kishi, S; Takemura, H; Ueda, T; Urasaki, Y; Yamamoto, S; Yamauchi, T; Yoshida, A1
Algüneş, C; Demir, M; Ongören, S; Pala, FS; Pamuk, GE; Soysal, T; Tabakcioğlu, K; Turgut, B; Vural, O1
Bauters, F; Berthon, C; Boulanger, F; Cracco, P; Darré, S; Jouet, JP; Micol, JB; Terriou, L; Tricot, S; Yakoub-Agha, I1
Bertetto, O; Busca, A; de Fabritiis, P; Falda, M; Locatelli, F; Novarino, A; Picardi, A; Zeuli, M1
Ashida, T; Higashishiba, M; Kanamaru, A; Kawanishi, K; Mayama, T; Miyatake, J; Tatsumi, Y1
Bruno, C; Cappelli, B; Castagnola, E; Cuzzubbo, D; Dallorso, S; Dini, G; Faraci, M; Lanino, E; Micalizzi, C; Morreale, G; Rossi, A; Schiaffino, MC1
Bay, JO; Bertuzzi, A; Carrabba, MG; Castagna, L; Corradini, P; Demirer, T; Grosso, F; Niederwieser, D; Pedrazzoli, P; Secondino, S; Siena, S; Spina, F1
O' Brien, S1
Borthakur, G; Cortes, JE; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Thomas, DA; Wierda, WG1
Ikezoe, T; Koeffler, HP; Nishioka, C; Taguchi, H; Yang, J1
Bonnefoy-Bérard, N; Brien, G; Trescol-Biemont, MC1
Algarotti, A; Bernasconi, P; Boni, M; Brusamolino, E; De Amici, M; Giardini, I; Lazzarino, M; Orlandi, E; Paulli, M; Perfetti, V; Tenore, AM; Vanelli, L; Zibellini, S1
Antolak, J; Chan, KW; Ha, CS; Kornguth, DG; Mahajan, A; Woo, S1
Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; de Meis, E; Donato, M; Ghosh, S; Giralt, S; Hosing, C; Kebriaei, P; Khouri, I; Oran, B; Popat, U; Qazilbash, M; Saliba, R1
Busch, R; Eichhorst, BF; Hallek, M; Herschbach, P; Kuhn-Hallek, I; Obwandner, T1
Bocchia, M; Bucalossi, A; Defina, M; Forconi, F; Gozzetti, A; Lauria, F; Pirrotta, MT1
Robak, P; Robak, T1
Attarbaschi, A; Fritsch, G; Gadner, H; Lawitschka, A; Lion, T; Matthes-Martin, S; Minkov, M; Mittheisz, E; Steiner, M; Zoubek, A1
Bunker, CB; Chapman, A; Dearden, CE; Dungarwalla, M; Field-Smith, A; Jameson, C; Matutes, E; Riley, U1
Buzyn, A; Candon, S; Casadevall, N; Hummel, A; Ittah, M; Lavie, F; Louache, F; Mariette, X; Soumelis, V; Terrier, B; Tourneur, L1
Chao, NJ; Chute, JP; Dressman, HK; Ginsburg, GS; Marshall, D; Meadows, S; Muramoto, GG; Nevins, JR1
Hashimoto, T; Hull, CM; Ishii, N; Leiferman, KM; Taintor, AR; Zone, JJ1
Mikkelsen, NE; Piskur, J; Sandrini, MP; Söderbom, F1
Bardy, PG; Bradstock, KF; Gibson, J; Grigg, AP; Kennedy, G; Koelmeyer, RL; Reynolds, J; Roberts, AW; Shuttleworth, P; Szer, J; To, LB1
Amadori, S; de Fabritiis, P; Del Poeta, G; Fratoni, S; Maurillo, L; Niscola, P; Palombi, M; Piccioni, D; Principe, MI1
Choi, Y; Keam, B; Kim, BK; Kim, I; Koo, NH; Lee, KH; Park, S; Yoo, KY; Yoon, SS1
Kiyoi, H; Mizutani, E; Murata, M; Naoe, T; Narimatsu, H; Tomita, A1
Chandy, M; George, B; Kavitha, ML; Mathews, V; Srivastava, A; Viswabandya, A2
Chen, J; Li, JP; Zhang, T; Zhong, J; Zhu, KE1
Arkenau, HT; Chau, I; Cunningham, D; Gordon, C; Norman, A; Wotherspoon, A1
Arbelaez, JE; Bacigalupo, A; Bregni, M; Carnevalli, E; Corradini, P; Davoli, M; De Fabritiis, P; Di Bartolomeo, P; Locasciulli, A; Majolino, I; Musso, M; Narni, F; Olivieri, A; Pogliani, L; Ruscio, C; Scimè, R; Selleri, C1
Admirand, J; Bueso-Ramos, C; Champlin, RE; Giralt, S; Keating, MJ; Khouri, IF; Korbling, M; Lee, MS; Lima, de M; O'Brien, S; Saliba, RM; Samuels, BI1
Allwinn, R; Beske, F; Klingebiel, T; Kriener, S; Lehrnbecher, T; Modrow, S; Schmidt, H; Schwabe, D; Sörensen, J1
Alimoghaddam, K; Ashouri, A; Chahardovali, B; Evazi, MR; Ghaffari, SH; Ghavamzadeh, A; Iravani, M; Mousavi, SA; Samiee, S; Shamshiri, AR; Tavakoli, M1
Blau, IW; Blau, O; Göldner, H; Hopfenmüller, W; Knauf, W; Leschinger, N; Schmidt-Hieber, M; Thiel, E1
Akahane, D; Fukuda, T; Heike, Y; Kim, SW; Kusumoto, S; Mori, S; Morita-Hoshi, Y; Onishi, Y; Sugimoto, K; Takaue, Y; Tanosaki, R; Tobinai, K1
Arakawa, S; Hamanoue, S; Inoue, H; Ishiguro, H; Katob, S; Koike, T; Masukawa, A; Matsumoto, M; Miyachi, H; Morimoto, T; Ohshima, T; Yabe, H; Yabe, M; Yamashita, T1
Aprahamian, M; Deharvengt, S; Hajri, A; Rejiba, S; Wack, S1
Bilgrami, S; Mahipal, A1
Blaise, D; Faucher, C; Mohty, M; Vey, N1
Balère-Appert, ML; Boiron, JM; Bordigoni, P; Chir, Z; Galambrun, C; Kanold, J; Maillard, N; Marie-Cardine, A; Maury, S; Milpied, N; Socié, G; Yakouben, K1
Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S1
Appelbaum, FR; Bedalov, A; Bryant, EM; Chang, C; Clurman, BE; Deeg, HJ; Flowers, ME; Hansen, JA; Nash, RA; Sanders, JE; Sandmaier, BM; Scott, BL; Shulman, HM; Storb, R; Storer, BE; Witherspoon, RP1
Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D1
León-Mateos, A; Sánchez-Aguilar, D; Toribio, J1
Au, WY; Chan, JC; Kwong, YL; Lam, CC; Leung, AY; Pang, A; Tse, E1
Alinari, L; Andritsos, L; Baiocchi, RA; Byrd, JC; Lapalombella, R; Lin, TS1
Byrd, JC; Grever, M; Jacob, ST; Kutay, H; Lucas, DM; Majumder, S; Motiwala, T; Neuberg, DS; Smith, DS1
Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, CH; Jaime-Pérez, JC; Martinez-González, O; Morales-Toquero, A; Ruiz-Argüelles, GJ; Salazar-Riojas, R; Tarín-Arzaga, LC1
Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, SY; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS1
Barker, JN; Blazar, BR; Brunstein, CG; DeFor, TE; McGlave, PB; Miller, JS; Wagner, JE; Weisdorf, DJ1
Chiang, KY; Doering, CB; Gangadharan, B; Ide, LM; Spencer, HT1
Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T1
Cascavilla, N; D'Arena, G1
Delavault, P; Fegan, C; Hartley, JA; Lowe, H; Pepper, C; Thurieau, C; Thurston, DE1
Chen, CS; Goh, YT; Hwang, WY; Koh, LP; Koh, MB; Lee, YM; Lim, S; Linn, YC; Liu, TC; Loh, YS; Mow, BM; Ng, HJ; Ng, HY; Tai, BC; Tan, B; Tan, DC; Tan, KW; Tan, LK; Tan, PH1
Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR1
Gojkovic, Z; Hasholt, L; Joergensen, T; Knecht, W; Le Breton, C; Munch-Petersen, B; Piskur, J; Rozpedowska, E; Sandrini, MP; Willer, M1
Alexander, S; Ballen, KK; Dey, BR; Dombkowski, D; McAfee, S; Means, TK; Preffer, FI; Sachs, DH; Saidman, S; Shaffer, J; Spitzer, TR; Sykes, M; Villard, J1
Albarello, A; Bacigalupo, A; Balleari, E; Balocco, M; Carella, AM; Catania, G; Clavio, M; Gobbi, M; Manna, A; Michelis, G; Miglino, M; Pierri, I; Sessarego, M; Van Lint, MT; Varaldo, R; Vignolo, L1
Anderlini, P; Champlin, RE; Couriel, DR; Giralt, SA; Jabbour, E; Khouri, IF; Rondon, G1
Barge, RM; Beaumont, F; Falkenburg, JH; Hoogendoorn, M; Jedema, I; Marijt, EW; van Luxemburg-Heijs, SA; Willemze, R1
Allione, B; Bacigalupo, A; Baldi, I; Bruno, B; Busca, A; Falda, M; Locatelli, F; Mordini, N; Morello, E; Narni, F; Rambaldi, A; Santarone, S1
Balashov, D; Filimonov, A; Maschan, A; Maschan, M; Novichkova, G; Shelikhova, L; Shipicina, I; Skorobogatova, E; Skvortsova, Y; Trakhtman, P1
Goto, H; Ito, S; Kajiwara, R; Kuroki, F; Yanagimachi, M; Yokosuka, T; Yokota, S1
Chae, YS; Cho, GJ; Cho, YY; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Moon, JH; Shin, HJ; Sohn, SK; Yang, DH1
Giles, FJ; Gojo, I; Greer, J; Johnson, B; Karp, JE; Low, J; Morris, L; Sznol, M; Thein, M1
Alousi, A; Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; Detry, MA; Giralt, S; Hosing, C; Kebriaei, P; Khouri, IF1
Kay, NE; Shanafelt, TD1
Bezares, RF; Bosanquet, AG; Brito-Babapulle, V; Catovsky, D; Child, JA; Davis, Z; Dearden, CE; Dyer, M; Else, M; Hamblin, T; Hamilton, MS; Hillmen, P; Matutes, E; Milligan, DW; Oscier, D; Pettitt, AR; Richards, S; Smith, AG; Wade, R1
Anderson, VR; Perry, CM1
Gesundheit, B; Resnick, IB1
Antonov, M; Buyukunal, E; Demirkesen, C; Kursunoglu, SG; Ozguroglu, M; Serdaroglu, S; Turna, H; Yanmaz, MT; Yildiz, O1
Hardan, I; Herscovici, C; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R1
Bierings, M; Bittencourt, M; Bonfim, C; Champagne, MA; Darbyshire, P; Fernandez, MN; Gluckman, E; Harris, RE; Ionescu, I; Kurtzberg, J; Locatelli, F; Pasquini, R; Rocha, V; Wagner, J1
Cassells, R; Cheow, HK; Giles, A; Lim, Z; Mir, N1
Keating, MJ; Tam, CS2
Hillmen, P; Rawstron, AC; Sayala, HA1
Bureo, E; Diaz de Heredia, C; Gonzalez-Vicent, M; Maldonado, MS; Martinez, A; Muñoz, A; Olivé, T; Sastre, A1
Cordonnier, M1
Cervasi, B; Fraternale, A; Magnani, M; Paiardini, M; Serafini, S; Silvestri, G1
Byrd, JC; Lee, RJ; Muthusamy, N; Wu, J; Zhao, X1
Amarasinghe, K; Dalley, C; Dokal, I; Gupta, V; Laurie, A; Marsh, J1
Bhatia, R; Chang, K; Forman, SJ; Kirschbaum, M; Kogut, N; Naing, A; Nakamura, R; O'Donnell, MR; Palmer, J; Pullarkat, V; Rodriguez, R; Slovak, ML; Spielberger, R; Stein, A; Tsai, N1
Anevlavis, E; Christopoulos, C; Fortis, A; Tassidou, A1
Celsing, F; Choudhury, A; Derkow, K; Jondal, M; Norberg, M; Okvist, A; Olsson, A; Osorio, LM; Osterborg, A; Rosenquist, R; Tobin, G1
Christopherson, RI; Henrich, S1
Baou, M; Naresh, K; Wagner, SD; Willimott, S1
Mirabelli, R; Molica, S; Montillo, M; Morra, E; Ribatti, D; Ricci, F; Tedeschi, A; Vacca, A; Veronese, S1
Decker, T; Fend, F; Götze, KS; Hoffmann, D; Peschel, C; Schätzl, HM1
Bacchu, S; Fegan, C; Neal, J1
Demidova, IA; Kut'ina, RM; Misiurin, AV; Ol'shanskaia, IuV; Parovichnikova, EN; Poreshina, LP; Savchenko, VG; Shpakova, AP1
Biderman, BV; Kolosheĭnova, TI; Kolosova, LIu; Kovaleva, LG; Lorie, IuIu; Nikitin, EA; Risinskaia, NA; Salogub, GN; Stadnik, EA; Sudarikov, AB; Tsyba, NN; Zaritskiĭ, IuA1
Artz, AS; Daugherty, C; Godley, L; Huo, D; Larson, R; Odenike, OM; Pollyea, DA; Rich, E; Smith, SM; Stock, W; van Besien, K; Zhang, Y; Zimmerman, T1
Abdul-Hai, A; Ackerstein, A; Aker, M; Amar, A; Bitan, M; Gesundheit, B; Or, R; Resnick, IB; Samuel, S; Shapira, MY; Slavin, S; Tsirigotis, P1
Alvarez, I; Arranz, R; Caballero, D; Canales, M; Cavet, J; Garcia-Conde, J; Goldstone, AH; Hunter, A; Linch, DC; Mackinnon, S; Mahendra, P; Milligan, D; Parker, A; Peggs, KS; Qian, W; Ribera, JM; Sanz, G; Sierra, J; Sureda, A; Thomson, K; Urbano-Ispizua, A1
Chitarrelli, I; Fabbri, A; Gobbi, M; Gozzetti, A; Lauria, F; Lenoci, M; Olcese, F; Raspadori, D1
Bifulco, C; Parnes, A; Vanasse, GJ1
Baer, MR; Barcos, M; Claydon, MA; Conroy, JM; Nowak, NJ; Sait, SN1
Bamberg, M; Belka, C; Bethge, W; Faul, C; Handgretinger, R; Heinzelmann, F; Lang, PJ; Ottinger, H1
Canales, MA; de Paz, R; Hernandez-Navarro, F; Martin-Salces, M1
Grosskreutz, C; Isola, L; Osman, K; Scigliano, E1
Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C1
Bowen, DA; Call, TG; Habermann, TM; Hoyer, JD; Jelinek, DF; Kay, NE; Maddocks-Christianson, K; Reinalda, M; Schwager, S; Shanafelt, TD; Slager, SL; Zent, CS1
Mulligan, SP1
Browning, M; Faderl, S; Ferrajoli, A; Kantarjian, H; Khouri, I; Lerner, S; O'Brien, S; Tam, CS; Tsimberidou, AM; Wierda, WG1
Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W1
Boulad, F; Castro-Malaspina, H; Chewning, JH; Collins, NH; Heller, G; Hsu, KC; Jakubowski, A; Kernan, NA; O'Reilly, RJ; Papadopoulos, EB; Perales, MA; Prockop, SE; Small, TN; van den Brink, MR; Young, JW1
Huisman, CA; Laros-van Gorkom, BA; Schipperus, MR; Wijermans, PW1
Li, SX; Liu, Y; Lu, XC; Zhu, HL1
An, XM; Cao, S; Qi, J; Ren, XB; Xin, N; Yu, JP1
Dyer, MJ; Gesk, S; Kennedy, DB; Majid, A; Siebert, R; Tsoulakis, O; Walewska, R1
Bi, X; Fang, J; Meng, D; Wu, G; Xue, J1
Austen, B; Baker, C; Dyer, M; Gardiner, A; Majid, A; Moss, PA; Oscier, D; Powell, JE; Siebert, R; Skowronska, A; Stankovic, T; Taylor, AM1
Heiskanen, J; Itälä, M; Jantunen, E; Juvonen, E; Koistinen, P; Koivunen, E; Kuittinen, T; Nousiainen, T; Remes, K; Siitonen, T; Silvennoinen, R; Volin, L1
Ding, W; Meng, H; Ni, W; Qian, W; Yang, C; Yang, X1
Bethge, W; Bornhäuser, M; de Witte, T; Kobbe, G; Kröger, N; Kvasnicka, HM; Schubert, J; Schwerdtfeger, R; Thiele, J; Zander, A1
Garratty, G; Petz, LD1
Byrd, JC; Flynn, JM1
Chen, MH; Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hsu, HC; Lin, PC; Liu, JH1
Anderlini, P; Andersson, BS; Caldera, Z; Champlin, RE; Chan, KW; Cook, JD; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Jabbour, E; Kebriaei, P; Khouri, I; Martin, TG; McCormick, G; Patah, PA; Qazilbash, M; Shpall, EJ; Thall, PF; Wang, X1
Baran-Marszak, F; Bornkamm, GW; Fagard, R; Feuillard, J; Gachard, N; Le Clorennec, C; May, E; Najjar, I; Reminieras, L; Youlyouz-Marfak, I1
Ikezoe, T; Nishioka, C; Togitani, K; Yokoyama, A1
Alonzo, TA; Arceci, RJ; Arndt, C; Barnard, DR; Dinndorf, P; Dusenbery, K; Feig, S; Feusner, J; Gerbing, RB; Heerema, NA; Lange, BJ; Luna-Fineman, S; Seibel, N; Shannon, K; Smith, FO; Weiman, M1
Akdemir, Y; Arpaci, F; Balci, YI; Cetin, M; Gumruk, F; Uckan, D1
Dabrowska, M; Dzieciol, J; Kloczko, J; Lemancewicz, D; Piszcz, JA; Rusak, M1
Heimfeld, S; McCune, JS; Ren, AG; Wang, J; Woodahl, EL1
Cattaneo, R; Frenzke, ME; Johnston, PB; Lampe, J; Parker, WB; Sorscher, EJ; Springfeld, C; Ungerechts, G1
Chao, N; Chute, J; Essell, J; Gasparetto, C; Horwitz, ME; Long, G; Morris, A; Rizzieri, D; Spasojevic, I; Sullivan, K; Telen, M1
Bernardo, ME; Di Bartolomeo, P; Fagioli, F; Locatelli, F; Longoni, D; Messina, C; Morreale, G; Nobili, B; Pession, A; Porta, F; Zecca, M1
Barnes, Y; Bleesing, J; Davies, SM; Filipovich, AH; Hansen, MD; Hayashi, R; Jodele, S; Mehta, P; Shenoy, S1
Byrd, J; Cheney, C; Chu, P; Hariharan, K; Molina, A; Pathan, NI1
Bettembourg, O; Cochard, C; Cochener, B; Roussel, B1
Díaz, MA; González-Vicent, M; Madero, L; Pérez, A; Ramirez, M; Sevilla, J1
Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N1
Catovsky, D; Dearden, C; Else, M; Hamblin, T; Milligan, D; Richards, S; Wade, R1
Fabianowska-Majewska, K; Krawczyk, B; Rudnicka, K1
Hardan, I; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R1
Grosicki, S; Hołowiecki, J; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Seferynska, I; Skotnicki, AB; Warzocha, K; Zdziarska, B1
Avalos, JS; Cañones, C; Chianelli, M; Fernández Calotti, P; Galmarini, CM; Gamberale, R; Giordano, M; Rosenstein, R; Saénz, D1
Debey, S; Hallek, M; Kofler, D; Königs, S; Pallasch, CP; Schultze, JL; Schulz, A; Schwamb, J; Ultsch, A; Wendtner, CM1
Bernal, MT; Besalduch, J; Brunet, MS; Caballero, D; Carrera, D; Ferra, C; Martin, J; Martino, R; Moraleda, JM; Nieto, JB; Perez-Simón, JA; Piñana, JL; Ribera, JM; Sampol, A; Sierra, J; Valcárcel, D; Vazquez, L1
Barbarotto, E; Celeghini, C; Corallini, F; Fadda, R; Grill, V; Mischiati, C; Rimondi, E; Vaccarezza, M1
Besser, M; Cargill, JS; Craig, JI; Crawley, C; Enoch, DA; Follows, G; Gudgin, E; Ludlam, HA; Marcus, RE; Min, SY; Sartori, P; Todd, T1
Cho, HS; Hyun, MS; Kim, HD; Kim, MK; Lee, KH; Shin, KC1
Abella, E; Altés, A; Asensi, A; Aymerich, M; Bertazzoni, P; Bosch, F; Briones, J; Escoda, L; Ferrer, A; Font, L; Gardella, S; Giné, E; González, M; González-Barca, E; Montserrat, E; Muntañola, A; Pérez-Ceballos, E; Rozman, M; Sayas, MJ; Villamor, N1
Alexandrescu, DT; Wiernik, PH1
Browning, ML; Faderl, S; Ferrajoli, A; Keating, MJ; LaPushin, R; O'Brien, SM; Wierda, WG1
Byrd, JC; Caligiuri, MA; Carson, WE; Cheney, C; Gowda, A; Hussain, SR; Jarjoura, D; Joshi, T; Kindsvogel, W; Lehman, A; Muthusamy, N; Ramanunni, A; Roda, J; Schmidt, S; Tridandapani, S; Zhang, X1
Brown, JR; Estrov, Z; Ferrajoli, A; Fiorentino, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Kipps, TJ; Kurzrock, R; Lerner, S; O'Brien, S; Plunkett, W; Ravandi-Kashani, F; Tsimberidou, AM; Wen, S; Wierda, WG1
Baccarani, M; Derenzini, E; Fanti, S; Fina, M; Musuraca, G; Perrotti, A; Stefoni, V; Tani, M; Vitolo, U; Zinzani, PL1
Bearden, JD; Greco, FA; Hainsworth, JD; Raefsky, E; Saez, RA; Spigel, DR; Vazquez, ER1
Fujiwara, M; Hashimoto, S; Koike, T; Satoh, N; Takenouchi, S1
Azuma, T; Kami, M; Komatsu, T; Kusumi, E; Matsumura, T; Miura, Y1
An, J; Ando, Y; Cui, W; Cui, Y; Feng, W; Guo, K; Ikehara, S; Inaba, M; Li, M; Li, Q; Omae, M; Sakaguchi, Y; Song, C; Tsuda, M; Wang, J; Wang, X1
Fukuda, T; Heike, Y; Kato, R; Kim, S; Koido, K; Maruyama, D; Mori, S; Takaue, Y; Tanosaki, R; Teshima, T; Tobinai, K; Usui, E; Yamasaki, S1
Kohno, A; Kuwatsuka, Y; Miyamura, K; Morishita, Y; Murata, M; Narimatsu, H; Sugimoto, K; Uchida, T; Watanabe, M1
Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Papageorgiou, S; Psyrri, A; Tsatalas, C; Xiros, N1
Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A1
Huisman, C; Lokhorst, HM; Meijer, E; Petersen, EJ; Verdonck, LF1
Andersson, BS; Bahlis, NJ; Brown, C; Chaudhry, MA; Geddes, M; Kangarloo, SB; Naveed, F; Quinlan, D; Russell, JA; Savoie, ML; Stewart, D; Storek, J1
Agura, ED; Bethge, WA; Blume, KG; Bruno, B; Chauncey, TR; Curtin, PT; Epner, E; Forman, SJ; Lange, T; Laport, GG; Maloney, DG; Maris, MB; Petersen, FB; Sandmaier, BM; Scott, BL; Storb, RF; Storer, BE; Stuart, MJ; Wade, JC; Wong, RM1
Acholonu, S; Anderlini, P; Andersson, B; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, SA; Hagemeister, F; Hosing, C; Khouri, IF; Munsell, MF; Pro, B; Qazilbash, MH; Romaguera, J; Saliba, R; Ueno, NT; Younes, A1
Baron, F; Beguin, Y; Castermans, E; Cheynier, R; Geenen, V; Gothot, A; Herens, C; Meuris, N; Schaaf-Lafontaine, N; Seidel, L; Vanbellighen, JF; Willems, E1
Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; de Sevilla, AF; Domingo-Doménech, E; Escoda, L; Estany, C; Galán, P; Gardella, S; López-Guillermo, A; Montoto, S; Montserrat, E; Moreno, C; Oriol, A; Pedro, C; Ribera, JM; Vivancos, P1
Fukushima, M; Hasegawa, D; Hosokawa, Y; Kawasaki, K; Kosaka, Y; Mizukami, T; Morio, T; Nunoi, H; Ochiai, H; Takeda, H1
Dickmeiss, E; Heilmann, C; Jakobsen, B; Kornblit, B; Madsen, HO; Masmas, T; Olesen, G; Petersen, SL; Ryder, LP; Sengeløv, H; Svejgaard, A; Vindeløv, L1
Esser, R; Kalaäoui, RE; Klingebiel, T; Kloess, S; Koehl, U; Kreuter, J; Lehrnbecher, T; Munkelt, D; Schubert, R; Schwabe, D; Wehner, S; Zimmermann, SY1
Chen, L; Lü, SQ; Ni, X; Song, XM; Wang, JM; Xu, XQ; Yang, JM; Zhang, WP1
Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Hurter, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y1
Bari, A; Brugiatelli, M; Buda, G; Gobbi, PG; Lazzaro, A; Lombardo, M; Luminari, S; Marcheselli, L; Marcheselli, R; Morabito, F; Pozzi, S; Quarta, G; Sacchi, S; Stelitano, C1
Andrýs, C; Belada, DZ; Krejsek, J; Malý, J; Siroký, O; Smolej, L; Zák, P1
Asslaber, D; Greil, R; Hamacher, F; Heyder, C; Holler, C; Merkel, O; Papak, C; Prokesch, A; Scheideler, M; Stöcher, M; Tinhofer, I; Trajanoski, Z1
Auerbach, AD; Boulad, F; Chaudhury, S; Heller, G; Kernan, NA; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Small, TN; Wolden, S1
Gandhi, V; Jewell, RC; Keating, MJ; Lerner, S; O'Brien, S; Plunkett, W; Rodriguez, CO; Tam, C1
Friedberg, JW1
Catovsky, D; Dearden, CE; Dungarwalla, M; Evans, SO; Matutes, E; Riley, U1
Bierings, MB; Heitink-Pollé, KM; Lilien, MR1
Bernardeschi, P; Del Conte, A; Dentico, P; Fiorentini, G; Giannessi, PG; Giustarini, G; Montenora, I; Rossi, S; Turrisi, G1
Bengtzen, S; Concha, H; Lehmann, S; Merup, M; Möllgård, L; Nahi, H; Paul, C; Selivanova, G; Svensson, A; Wiman, KG1
Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL1
Murata, M; Naoe, T; Narimatsu, H; Sugimoto, K; Terakura, S1
Attal, M; Blaise, D; Boiron, JM; Bordigoni, P; Bourhis, JH; Chir, Z; Deconinck, E; Esperou, H; Le, QH; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Nicolini, F; Prébet, T; Renaud, M; Rio, B; Yakoub-Agha, I1
Anderson, KC; Ciccarelli, B; Dammacco, F; Ghobrial, IM; Hatjiharissi, E; Jia, X; Leleu, X; Moreau, AS; Ngo, HT; Patterson, CJ; Roccaro, AM; Russo, D; Sacco, A; Treon, SP; Vacca, A; Xu, L1
Bonavita, S; Conforti, R; Della Corte, M; Gallo, A; Monsurrò, MR; Russo, A; Sacco, R; Tedeschi, G; Tessitore, A1
Christian, BA; Lin, TS1
Koike, N; Mulé, JJ; Pilon-Thomas, S1
Hamdi, S; Huguet, F; Laporte, F; Oksman, F1
Banerji, V; Gibson, SB; Hu, X; Johnston, JB; Mendoza, FJ; Sun, J1
Adachi, S; Kobayashi, C; Kojima, S; Kurosawa, H; Manabe, A; Nakahata, T; Nakazawa, Y; Nara, T; Ogawa, C; Ohtsuka, Y; Osugi, Y; Sako, M; Tokuyama, M; Yabe, H; Yabe, M; Yanagimachi, M1
Blough, DK; Heimfeld, S; McCune, JS; O'Donnell, PV; Phillips, B; Risler, L; Sandmaier, BM; Wang, J; Woodahl, EL1
Cutler, FJ; Murphy, JA; Niciu, C; Soutar, RL1
Chao, N; Chute, J; Gasparetto, C; Horwitz, ME; Long, G; McPherson, J; Morris, A; Rizzieri, D; Sullivan, K1
Cortes, J; Do, KA; Kantarjian, H; Keating, MJ; Lerner, S; O'Brien, S; Tam, CS; Thomas, DA; Wen, S; Wierda, W1
Alousi, A; Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, S; Hagemeister, F; Hosing, C; Khouri, IF; Korbling, M; Kwak, LW; Lee, MS; McLaughlin, P; Medeiros, LJ; Neelapu, SS; Saliba, RM; Samaniego, F; Samuels, BI; Ueno, NT1
Coiffier, B; Rioufol, C1
Calvo-Villas, JM; Sicilia, F; Umpierrez, AM; Urcuyo, BM1
Atanackovic, D; Ayuk, F; Bacher, U; Bethge, W; Bokemeyer, C; Bornhäuser, M; Dierlamm, J; Gutierrez, NC; Hansen, T; Kröger, N; Liebisch, P; Miguel, JS; Nagler, A; Otterstetter, S; Penas, EM; Pérez-Simón, JA; San Miguel, J; Schilling, G; Schwerdtfeger, R; Shimoni, A; Simon-Perez, JA; Zabelina, T; Zander, A1
Auberger, J; Clausen, J; Erdel, M; Gastl, G; Gunsilius, E; Nachbaur, D; Petzer, A; Willenbacher, W1
Barge, RM; Falkenburg, JH; Marijt, EW; Starrenburg, CW; von dem Borne, PA; Willemze, R1
He, GS; Jin, ZM; Miao, M; Sun, AN; Wang, XL; Wu, DP; Zhang, X1
Anolik, J; Conners, C; Fisher, RI; Friedberg, JW; Kleiner, A; Rich, L; Walker, AR1
Bertz, H; Finke, JM; Hahn, J; Holler, E; Ihorst, G; Marks, R; Potthoff, K; Spyridonidis, A1
Forsberg, K; Lazarevic, VLj; Liljeholm, M; Söderberg, S; Wahlin, A1
Atra, AA; Baothman, A; Elimam, NA; Kassar, A; Khattab, TM; Zayed, A1
Hamaki, T; Hori, A; Kami, M; Kanda, Y; Katayama, Y; Kishi, Y; Kobayashi, K; Mori, S; Murashige, N; Onishi, Y; Tajima, K; Takaue, Y; Tanosaki, R1
Gill, S; Grigg, A; Ritchie, D; Szer, J1
Curbo, S; Karlsson, A1
Shen, JP; Ye, BD; Zhou, YH1
Ambinder, RF; Bolaños-Meade, J; Borrello, I; Brodsky, RA; Chen, AR; Flowers, M; Fuchs, EJ; Gooley, TA; Harrington, E; Huff, CA; Jones, RJ; Kaup, M; Leffell, MS; Luznik, L; Matsui, W; O'Donnell, PV; Piantadosi, S; Powell, JD; Sandmaier, BM; Storb, RF; Symons, HJ; Warnock, S; Zahurak, M1
Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D1
Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, RB; Korbling, M; Pierre, B; Roberson, S; Russell, JA; Shpall, EJ; Thall, PF; Wang, X1
Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J1
Bhatla, D; Bleesing, J; Crockett, M; Davies, SM; Filipovich, AH; Hansen, M; Harris, RE; Jodele, S; Jordan, M; Mehta, PA; Shenoy, S; Shoultz, L; Smolarek, T1
Baldwin, SA; Cass, CE; Damaraju, VL; Elwi, AN; Kuzma, ML; Sawyer, MB; Young, JD1
Brandi, G; Dominici, S; Magnani, M; Schiavano, GF1
Thieblemont, C1
Hagist, S; Hallek, M; Krause, G; Pallasch, CP; Patz, M; Veldurthy, A; Wendtner, CM1
Chakraborty, NG; Chattopadhyay, S; Chhabra, A; Das, R; Hegde, U; Ray, S1
Azlin, I; Fadilah, SA; Muhaya, M1
Gorman, C; Hudson, E; Lester, JF; Maughan, TS; Poynton, CH; Westmoreland, D1
Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A1
Chen, Z; Du, M; Feng, L; Huang, P; Keating, MJ; Pelicano, H; Plunkett, W; Trachootham, D; Wierda, WG; Zhang, H; Zhang, W; Zhou, Y1
Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Innocenti, I; Laurenti, L; Leone, G; Piccirillo, N; Sica, S; Sorà, F; Tarnani, M; Zini, G1
van der Griend, R; van der Spek, E1
Nabhan, C1
Berger, J; Berger, MG; Jeanpierre, S; Maguer-Satta, V; Michallet, M; Nicolini, FE; Richard, C; Satta, VM; Tournilhac, O1
Austen, B; Brennan, P; Fegan, C; Hewamana, S; Hiller, L; Hills, R; Hooper, L; Lin, TT; Pepper, C; Pratt, G; Stankovic, T; Starczynski, J; Ward, R1
Christopherson, RI; Crossett, B; Gez, S; Henrich, S; Mulligan, SP1
Cass, CE; Dabbagh, L; Ghosh, S; King, K; Lai, R; Mackey, JR; Santos, C; Tsang, RY; Young, J1
Candoni, A; Chiarvesio, A; Damiani, D; Fanin, R; Malagola, M; Martinelli, G; Michelutti, A; Piccaluga, PP; Russo, D; Simeone, E; Tiribelli, M; Toffoletti, E1
Angelucci, E; Baronciani, D; Depau, C; Di Bartolomeo, P; Iori, AP; Mico, C; Pettinau, M; Pilo, F; Rambaldi, A; Santarone, S1
Baccarani, M; Bergonzi, C; Bocchia, M; Bonini, A; Candoni, A; Damiani, D; De Rosa, F; Fanin, R; Filì, C; Gobbi, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Paolini, S; Peli, A; Piccaluga, PP; Pierri, I; Priccolo, G; Roccaro, AM; Russo, D; Skert, C; Tiribelli, M; Visani, G; Zaccaria, A; Zuffa, E1
Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duan, Q; Duggan, P; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N1
Fujimori, Y; Hara, H; Ikegame, K; Itoi, H; Itsukuma, T; Kai, S; Misawa, M; Nakajima, T; Nishioka, K; Ogawa, H; Okada, M; Okikawa, Y; Satake, A; Takatsuka, H; Tamaki, H1
Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ1
Andersen, MK; Christiansen, CB; Geisler, C; Hastrup, N; Jurlander, J; Madsen, HO; Pedersen, LB; Rath, J1
Fabbri, A; Forconi, F; Gozzetti, A; Lauria, F; Lenoci, M; Raspadori, D; Sozzi, E; Tassi, M1
Berthou, C; Dalbies, F; De Braekeleer, M; Feuerbach, J; Ianotto, JC; Le Bris, MJ; Marion, V; Tempescul, A1
Alessandro, A; Allegra, A; Alonci, A; Bellomo, G; Caterina, M; D'Angelo, A; Granata, A; Quartarone, E; Rizzotti, P1
Bednarek, JD; Blonski, JZ; Goralski, P; Hanausek, M; Kilianska, ZM; Piekarski, H; Robak, T; Rogalinska, M; Walaszek, Z; Wozniak, K1
Cwynarski, K; Duke, VM; Hart, SM; Hoffbrand, AV; Howard-Reeves, JD; Kottaridis, PD; Nacheva, EP; Prentice, AG; Steele, AJ; Vassilev, LT; Wickremasinghe, RG; Yogashangary, BC1
Becker, ST; Klapper, W; Repp, R; Sinis, N; Warnke, PH; Wiltfang, J1
Cupelli, L; de Fabritiis, P; Dentamaro, T; Giovannini, M; Niscola, P; Palumbo, R; Perrotti, AP; Piccioni, D; Scaramucci, L; Tendas, A1
Mattsson, J; Remberger, M; Ringdén, O; Svahn, BM1
Bhandari, S; Cranfield, T; Simon, G; Walker, M1
Lamanna, N; Weiss, MA1
Camera, A; Cantore, N; Ferrara, F; Grimaldi, F; Guerriero, A; Luciano, L; Mastrullo, L; Mele, G; Mettivier, V; Miraglia, E; Palmieri, S; Rinaldi, CR; Rotoli, B1
Andresen, S; Bolwell, BJ; Chan, J; Cherni, K; Copelan, E; Dean, R; Ferraro, C; Kalaycio, M; Macklis, R; Pohlman, B; Rybicki, LA; Sobecks, RM; Sweetenham, J; Theil, KS1
Chen, LJ; Gu, WJ; Hong, M; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Wu, YJ; Xu, W1
Blau, IW; Busse, A; Knauf, W; Reufi, B; Schmidt-Hieber, M; Thiel, E1
Lamanna, N; Sauter, C; Weiss, MA1
Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ1
Bole, J; Castro, JE; Kipps, TJ; Rassenti, L; Sandoval-Sus, JD1
Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR1
Cheon, HG; Jung, WH; Rhee, SD; Sung, YY1
Baldanti, F; Citro, A; Gatti, M; Lazzarino, M; Orlandi, EM; Pochintesta, L1
Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J1
Hara, J; Hashii, Y; Kusuki, S; Ohta, H; Ozono, K; Sakai, N; Takizawa, S; Taniike, M; Tokimasa, S1
Baron, F; Baudoux, E; Beguin, Y; Bonnet, C; Fillet, G; Frère, P; Gothot, A; Hafraoui, K; Herens, C; Seidel, L; Vanbellinghen, JF; Vanstraelen, G; Wanten, N; Willems, E1
Citrin, DE; Downey, SG; Dudley, ME; Huang, J; Hughes, MS; Kammula, U; Klapper, J; Laurencot, C; Leitman, SF; Morton, K; Restifo, NP; Robbins, PF; Rosenberg, SA; Royal, R; Sherry, R; Smith, FO; Thomasian, A; White, DE; Wunderlich, J; Yang, JC1
de Campos-Nebel, M; González-Cid, M; Larripa, I1
Karasawa, M1
Balakrishnan, K; Burger, JA; Gandhi, V; Wierda, WG1
Benninghoff, U; Debatin, KM; Friedrich, W; Gatz, S; Hoenig, M; Schuetz, C; Schulz, A; Speth, F1
Almenara, JA; Atadja, P; Coe, S; Dent, P; Grant, S; Maggio, SC; Rosato, RR1
Atkinson, K; Burns, AM; Hart, DN; Kambouris, ME; Lange, J; Lourie, R; Munster, DJ; Rice, AM; Sinfield, L; Turner, BE1
Ahmed, N; Bollard, CM; Brenner, MK; Carrum, G; Gottschalk, S; Heslop, HE; Krance, RA; Leung, KS; Myers, GD; Rosenblatt, H1
Kersting, S; Verdonck, LF1
Campo, E; Casado, FJ; Colomer, D; López-Guerra, M; Molina-Arcas, M; Montserrat, E; Pastor-Anglada, M; Trigueros-Motos, L; Villamor, N1
Chim, CS; Kwong, YL; Loong, F; Ng, WK1
Dmoszynska, A; Halicka, HD; Klimek, P; Kowal, M; Podhorecka, M1
Führer, M1
Ambinder, RF; Bolaños-Meade, J; Brodsky, RA; Fuchs, EJ; Huff, CA; Jones, RJ; Kasamon, YL; Levy, MY; Luznik, L; Matsui, WH; Muth, M; Powell, JD; Smith, BD; Swinnen, LJ1
Blum, KA; Brooker-McEldowney, M; Byrd, JC; Dalton, JT; Farley, KL; Fischer, B; Grever, MR; Heerema, NA; Hurh, E; Jarjoura, D; Johnson, AJ; Lin, TS; Mitchell, SM; Moran, ME; Phelps, MA; Rozewski, DM; Schaaf, LJ; Wu, D1
Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M1
Carney, DA; di Iulio, J; Herbert, KE; Morgan, S; Prince, HM; Seymour, JF; Westerman, DA; Wolf, MM; Yuen, K1
Asano, S; Iseki, T; Kasahara, S; Kato, S; Konuma, T; Monma, F; Ooi, J; Sato, A; Takahashi, S; Tojo, A; Tomonari, A; Tsukada, N; Uchimaru, K1
Borchmann, P; Elter, T; Engert, A; Hallek, M; Kilp, J; Schulz, H1
Bauduer, F1
Berchem, G; Bouzar, AB; Boxus, M; Bron, D; Burny, A; Chatelain, B; Chatelain, C; Defoiche, J; Lagneaux, L; Macallan, D; Pettengell, R; Willems, L; Willis, F1
Dumoulin, FL; Fischer, HP; Sauerbruch, T; Wasmuth, JC1
Champlin, RE; Couriel, D; de Lima, M; de Souza, J; Giralt, S; Komanduri, KV; Oran, B; Patah, P; Rondon, G; Saliba, RM1
Branagan, AR; Emmanouilides, C; Frankel, SR; Gregory, SA; Ioakimidis, L; Kimby, E; Lister, A; Matous, J; Morel, P; Patterson, CJ; Soumerai, JD; Treon, SP; Turnbull, B; Wasi, P1
Abenhardt, W; Busch, R; Eichhorst, BF; Hallek, M; Kneba, M; Ritgen, M; Schweighofer, CD; Wendtner, CM1
Borsky, M; Brychtova, Y; Cejkova, S; Chumchalova, J; Doubek, M; Klabusay, M; Mayer, J; Novakova, V; Pospisilova, S; Potesil, D; Rocnova, L; Smardova, J; Trbusek, M; Zezulkova, D1
Abruzzo, LV; Barron, LL; Coombes, KR; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Kipps, TJ; Lerner, S; Lin, KI; O'Brien, S; Rassenti, L; Schlette, E; Tam, CS; Wierda, WG1
Aloyz, R; Amrein, L; Ferrario, C; Gibson, SB; Hernandez, TA; Johnston, J; Panasci, L1
Bloor, A; Chakraverty, R; Clark, F; Cook, G; Linch, DC; Mackinnon, S; Milligan, D; Morris, EC; Parker, A; Peggs, KS; Thomson, KJ; Yung, L1
Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP1
Bierman, P; Bociek, RG; Dickinson, JD; Emanuel, K; Hegde, GV; Joshi, AD; Joshi, SS; Kollessery, GJ; Mittal, AK; Peterson, KJ; Vose, JM; Weisenburger, DD1
Ahmadi, T; Schuster, SJ1
Boyiadzis, M; Butchko, A; Foon, KA; Laman, A; Land, SR; Lenzer, D; Marks, S; Meisner, D; Pietragallo, L; Raptis, A; Schaefer, P; Sulecki, M; Tarhini, A1
Brentjens, RJ; Gencarelli, AN; Golde, DW; Heaney, ML; Jurcic, JG; Lamanna, N; Maslak, P; Noy, A; Panageas, KS; Scheinberg, DA; Weiss, MA; Zelenetz, AD1
Ativitavas, T; Jootar, S; Niparuck, P; Ungkanont, A1
du Toit, C; McDonald, A; Novitzky, N; Thomas, V1
Chen, ZC; Li, QB; Li, WM; Xia, LH; You, Y; Zhou, H; Zou, P1
Brennan, P; Burnett, AK; Fegan, C; Hewamana, S; Jenkins, C; Jordan, CT; Lin, TT; Pepper, C; Rowntree, C1
Amato, R; Butler, EB; Furge, K; Gao, Y; Hui, Z; Li, Y; Mai, W; Qian, CN; Teh, BS; Teh, BT; Tretiakova, M; Wang, X; Zhang, Z; Zhu, JX1
Akhter, S; Chaudhuri, A; Kanmogne, GD; Yang, B1
Benvegnú, DM; Bonfanti, G; Frediani, AV; Gonçalves, TL; Pereira, DV; Rocha, JB1
Altavilla, G; Arrigo, C; Pitini, V1
Barba, P; Briones, J; Brunet, S; Delgado, J; Martino, R; Moreno, E; Piñana, JL; Sierra, J; Sureda, A; Valcárcel, D; Vega, M1
Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Ryu, SG; Seol, M; Shin, HJ1
Flomenberg, N; Greipp, PR; Huff, CA; Lazarus, HM; Vesole, DH; Zhang, L1
Briones, J; Brunet, S; Delgado, J; Marco, A; Martino, R; Moreno, E; Piñana, J; Sierra, J; Sureda, A; Valcarcel, D1
Baker, JM; Crooks, BN; Doyle, JJ; Dror, Y; Duval, M; Fernandez, CV; Freedman, MH; Lewis, VA; Yuille, K1
Tan, J; Wu, T; Yang, K1
Blazar, BR; Brunstein, CG; Burns, LJ; Cantero, S; Cao, Q; Majhail, N; McClune, B; McGlave, PB; Miller, JS; Tomblyn, M; Wagner, JE; Weisdorf, DJ1
Cafro, AM; Marbello, L; Montillo, M; Morra, E; Nichelatti, M; Nosari, AM; Ricci, F; Tedeschi, A1
Bae, SH; Joo, YD; Kim, H; Lee, JH; Lee, KH; Lee, WS; Mo Ryoo, H; Park, JH1
Higuchi, T; Kako, S; Kanda, Y; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sato, M; Tanaka, Y; Tanihara, A; Terasako, K; Yamazaki, R1
Eve, HE; Linch, D; Qian, W; Ross, M; Rule, SA; Seymour, JF; Smith, P; Stevens, L1
Eve, HE; Rule, SA; Seymour, JF1
Kamijo, T; Koike, K; Nakazawa, Y; Sakashita, K; Shikama, N; Shiohara, M; Tanaka, M; Yanagisawa, R1
Byrd, JC; Caligiuri, MA; Cheney, C; Heerema, N; Lin, TS; Lucas, DM; Lucas, MS; Moran, ME; Wei, L; Woyach, JA1
Angrilli, F; Baldini, L; Bari, A; Ilariucci, F; Lazzaro, A; Luminari, S; Marcheselli, L; Pozzi, S; Sacchi, S; Stelitano, C1
Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O1
Aksoy, S; Dizdar, O; Harputluoğlu, H; Hayran, M1
Cao, J; Reilly, JZ; Rodmyre, RM; Thompson, JA; Wallen, H; Yee, C1
Boyer, SH; Erion, MD; Linemeyer, DL; MacKenna, DA; Montag, A1
Butters, TD; Ganeshaguru, K; Gerrard, G; Mehta, AB1
Carney, DA; Mulligan, SP1
Boelens, J; Bracke, M; Derycke, L; Janssens, A; Lust, S; Offner, F; Philippé, J; Van Bockstaele, F; Van Gele, M; Vanhoecke, B1
Antic, D; Gotic, M; Jakovic, L; Jankovic, S; Mihaljevic, B; Perunicic-Jovanovic, M; Sretenovic, A1
Cazin, B; Chapiro, E; Davi, F; Delmer, A; Dreyfus, B; Leporrier, M; Leprêtre, S; Lesty, C; Mahe, B; Maloum, K; Merle-Béral, H; Nguyen-Khac, F; Settegrana, C; Tournilhac, O1
Apter, S; Besser, MJ; Catane, R; Hardan, I; Itzhaki, O; Kubi, A; Kuchuk, I; Markel, G; Nagler, A; Nun, AB; Schachter, J; Schallmach, E; Segal, E; Shalmon, B; Shapira-Frommer, R; Shimoni, A; Treves, AJ; Zippel, D1
Brown, JR; Dal Cin, P; Feng, Y; Fisher, DC; Fisher, RI; Freedman, AS; Friedberg, JW; Joyce, R; Liesveld, J; Marquis, D; Neuberg, D; Phillips, K; Scofield, S; Takvorian, RW1
Ferrajoli, A1
Karas, M; Koza, V; Steinerova, K; Vokurka, S1
Ashcroft, AJ; Moreton, P; Owen, RG; Rawstron, AC; Varghese, AM1
Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kastritis, E; Migkou, M; Roussou, M; Tassidou, A; Terpos, E1
Alamos, SM; Greco, A; Morra, E; Ricci, F; Tedeschi, A1
Castejón, R; Citores, MJ; García-Marco, JA; Vargas, JA; Villarreal, M; Yebra, M1
Hong, M; Li, JY; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, R1
Brass, D; Cunningham, J; Gelly, K; Groves, M; MacCallum, S; Sales, M; Tauro, S1
Keating, MJ; Tsimberidou, AM2
Elliott, P; Haines, I; Stanley, R1
Bruns, I; Czibere, A; Fenk, R; Gräf, T; Haas, R; Kobbe, G; Schroeder, T; Zohren, F1
Bojarska-Junak, A; Bullinger, L; Dmoszynska, A; Döhner, H; Giannopoulos, K; Kowal, M; Rolinski, J; Stilgenbauer, S; Wasik-Szczepanek, E1
Cho, BS; Cho, SG; Chung, NG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS1
Asaka, M; Endo, T; Hashino, S; Imamura, M; Kahata, K; Koike, T; Kondo, T; Nishio, M; Okada, K; Onozawa, M; Ota, S; Sato, N; Shigematsu, A; Sugita, J; Takahata, M; Tanaka, J; Yamamoto, S; Yasumoto, A1
Abidi, MH; Braun, TM; Ibrahim, RB; Khaled, YA; Krijanovski, OI; Levine, JE; Mineishi, S; Peres, E1
Dishaw, LJ; Dorsey, MJ; Morrow, MR; Petrovic, A; Sleasman, JW1
Bordigoni, P; Cachin, F; Curtillet, C; David, A; Demeocq, F; Dore, E; Halle, P; Isfan, F; Kanold, J; Merlin, E; Michel, G; Paillard, C; Rochette, E; Rousseau, R; Salmon, A1
Brown, PV; Conneally, E; Delaney, E; Hayat, A; Lawler, M; Liptrot, S; McCann, SR; McGuckin, S; O'Brien, D; O'Rourke, P; Quinn, F; Vandenberghe, E1
Eyzaguirre-Zapata, R; Gómez-Almaguer, D; González-Carrillo, ML; Gutiérrez-Aguirre, CH; Gutiérrez-Riveroll, KI; Priesca-Marin, M; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ1
Ferrajoli, A; Motta, M; Wierda, WG1
Alonso, R; Bantia, S; Bontemps, F; Campo, E; Colomer, D; López-Guerra, M; Manz, C; Mehrling, T; Montserrat, E; Smal, C; Upshaw, R; Villamor, N1
Amdur, RJ; Buzzeo, MP; Cable, C; Jamieson, K; Khan, S; Leather, H; Moreb, J; Reddy, V; Schold, JD; Scornik, J; Wingard, JR1
Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Mactal-Haaf, C; Mahmud, N; Peace, DJ; Quigley, JG; Rondelli, D; Shord, S; Sweiss, K1
Ahn, JS; Chae, YS; Cho, YY; Choi, YJ; Chung, JS; Kim, HJ; Kim, JG; Kim, YK; Lee, JJ; Lee, SR; Shin, HJ; Sohn, SK; Yang, DH1
Chen, YM; Dou, HJ; Hu, JP; Tang, Y; Yao, YY; Zhu, Q; Zou, LF1
Bartholomé, K; Buchner, M; Burger, M; Chevalier, N; Dierks, C; Fuchs, S; Gribben, JG; Jumaa, H; Pfeifer, D; Prinz, G; Timmer, J; Vallat, L; Veelken, H; Zirlik, K1
Burgaleta, C; Cabrera, C; Canales, M; De la Serna, J; Fernández de Sevilla, A; Gonzalez, M; Martínez, R; Martínez-López, J; Montalbán, C; Monteagudo, MD; Paz-Carreira, J; Peñalver, FJ; Peñarrubia, MJ; Prieto, E; Queizán, JA; Rapado, I; Rivero, A; Salar, A; Sánchez-Godoy, P; Tomás, JF1
Andersson, BS; Champlin, RE; de Lima, M; Madden, T; Russell, JA; Thall, PF1
Hazar, V; Karasu, GT; Kupesiz, A; Uygun, V; Yesilipek, MA1
Brent, S; Dyker, A; Erhorn, S; Ferrie, L; Horsley, W; Macfarlane, K; Palmer, S; Thomas, S; Walker, S; White, S1
Bleakley, M; Hudecek, M; Kostic, A; Maloney, D; Nishida, T; Riddell, SR; Storb, R; Warren, EH1
Sosnowski, M; Trusz-Gluza, M; Wita, K; Wróbel, W1
Imataki, O; Ishida, T; Kitanaka, A; Kubota, Y; Ohbayashi, Y; Ohnishi, H; Tanaka, T1
Ando, K; Hayashi, M; Hotta, T; Ishizawa, K; Itoh, K; Matsusako, M; Morishima, Y; Nakata, M; Nawano, S; Ogura, M; Taniwaki, M; Terauchi, T; Tobinai, K; Uchida, T; Watanabe, T; Yamamoto, J1
Bühler, A; Busch, R; Döhner, H; Dreger, P; Dührsen, U; Finke, J; Groner, S; Hallek, M; Hensel, M; Hohloch, K; Jäger, U; Kneba, M; Lengfelder, E; Schlag, R; Schlenk, RF; Söling, U; Stilgenbauer, S; Winkler, D; Zenz, T1
Al-Mojalli, H; Ashour, M; Ayas, M; Turkistani, W1
Bergmann, MA; Brittinger, G; Burkhard, O; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Fink, AM; Fischer, K; Goede, V; Hallek, M; Kranzhöfer, N; Ritgen, M; Rohrberg, R; Schweighofer, CD; Söling, U; Stauch, M; Stilgenbauer, S; Wendtner, CM; Westermann, A1
Kay, NE; Lamanna, N1
Lin, TS; Maddocks, KJ1
Carney, D; Gill, S; Januszewicz, H; Prince, HM; Ritchie, D; Seymour, JF; Westerman, D; Wolf, M1
Bos, GM; Fleskens, AJ; Jansen, RL; Lalisang, RI; Schouten, HC; van Gelder, M1
Carney, D; Januszewicz, EH; Peinert, S; Prince, HM; Seymour, JF1
Chew, E; Fairlie, WD; Grigg, AP; Huang, DC; Khaw, SL; Lee, EF; Mason, KD; Rayeroux, KC; Roberts, AW; Seymour, JF; Szer, J1
Bühler, A; Busch, R; Denzel, T; Döhner, H; Groner, S; Häbe, S; Hallek, M; Mertens, D; Mohr, J; Sarno, A; Stilgenbauer, S; Winkler, D; Zenz, T1
Faderl, S; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Wierda, W1
Beijnen, JH; Rosing, H; Schellens, JH; Vainchtein, LD1
Janikova, A; Koristek, Z; Kral, Z; Mayer, J; Navratil, M; Pavlik, T; Sticha, M; Vasova, I; Vinklarkova, J1
Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR1
Champlin, RE; de Lima, M; de Padua Silva, L; de Souza, JA; Efebera, Y; Hosing, C; Patah, P; Popat, U; Qazilbash, MH; Ribeiro, R; Rondon, G; Saliba, RM1
Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL1
Canales, MA; Domingo-Domenech, E; Estany, C; Fraile, G; Gallardo, F; Montalbán, C; Salar, A; Servitje, O1
Eurelings, M; Franssen, H; Lokhorst, HL; Niermeijer, JM; Notermans, NC; van der Pol, WL; Wokke, JH1
Abe, Y; Arita, Y; Baba, E; Choi, I; Harada, M; Ito, T; Kawabe, K; Miyamoto, T; Nagafuji, K; Nakano, S; Teshima, T1
Stilgenbauer, S; Zenz, T1
Assanasen, T; Polprasert, C; Prayongratana, K; Wongchitrat, C1
Błoński, JZ; Kiliańska, ZM; Robak, T; Wesierska-Gadek, J; Zolnierczyk, JD1
Adams, S; Amrolia, PJ; Berrie, E; Bird, P; Brenner, MK; Brown, L; Davies, EG; Eyrich, M; Gaspar, HB; Gennery, AR; Goulden, N; Hale, G; Landais, P; Rao, K; Schlegel, PG; Straathof, KC; Veys, PA1
Candoni, A; Fanin, R; Malagola, M; Russo, D; Simeone, E; Tiribelli, M1
Aljurf, M; Anderlini, P; Bacigalupo, A; Marsh, J; Maury, S; Oneto, R; Passweg, JR; Socié, G1
Jeong, KH; Lew, BL; Sim, WY1
Boyd, TE; Chanan-Khan, AA; Gribben, J; Itri, LM; Koziner, B; Larratt, LM; Moore, JO; O'Brien, S; Rai, KR; Seymour, JF; Skotnicki, AB1
Cao, TM; Franke, GN; Gyurkocza, B; Hoppe, R; Lange, T; Leisenring, W; Maloney, DG; Negrin, RS; Sandmaier, BM; Shizuru, JA; Sorror, M; Storb, RF1
Tam, CS2
Eve, HE; Gambell, J; Qian, W; Rule, SA; Smith, P1
Brum, S; Carvalho, D; Carvalho, F; Ferreira, AC; Pataca, I; Santos, JR; Santos, MC1
Beert, E; Bontemps, F; Connerotte, T; de Viron, E; Hermans, C; Knoops, L; Michaux, L; Saussoy, P; Smal, C; Van Den Neste, E; Vannuffel, P; Vekemans, MC1
Brion, JP; Epaulard, O; Garin-Bastuji, B; Gressin, R; Maurin, M; Meneses, A; Pavese, P; Stahl, JP1
Appelbaum, FR; Deeg, HJ; Fisher, DR; Gooley, TA; Gopal, AK; Martin, PJ; Matthews, DC; Pagel, JM; Press, OW; Rajendran, J; Sandmaier, BM; Storb, RF; Wilson, WA1
Abboud, CN; Augustin, KM; Cashen, AF; Dipersio, JF; Goyal, S; Hladnik, L; Martin, MG; Monahan, RS; Reichley, RM; Stockerl-Goldstein, K; Tiwari, D; Uy, GL; Vij, R; Welch, JS; Westervelt, P1
Baurmann, H; Bethge, W; Bornhäuser, M; Brand, R; Burchert, A; Corradini, P; de Witte, TM; Dreger, P; Einsele, H; Holler, E; Kaufmann, M; Kobbe, G; Kröger, N; Kvasnicka, HM; Nagler, A; Niederwieser, D; Schubert, J; Schwerdtfeger, R; Stelljes, M; Thiele, J; Uharek, L; Wandt, H; Wulf, GG; Zabelina, T; Zander, AR1
Desjardins, P; Duncan, AM; Fernandez, L; Kipps, T; Larratt, L; Li, D; Rassenti, L; Rizi, D; Rubin, S; Sadura, A; Shepherd, L; Shustik, C; Turner, AR1
Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC1
Andritsos, L; Bechtel, T; Benson, DM; Blum, W; Byrd, JC; Devine, SM; Elder, P; Garzon, R; Hamadani, M; Hofmeister, C; Klisovic, R; Krugh, D; Lin, T; Marcucci, G; O'Donnell, L; Penza, S; Phillips, G1
Browne, PV; Butini, S; Campiani, G; Catherwood, MA; Greene, LM; Hayat, A; Lawler, M; Maginn, EN; McElligott, AM; McGuckin, S; Vandenberghe, E; Williams, DC; Zisterer, DM1
Horiike, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M1
Buti, M; Esteban, R; Homs, M; Palacios, A; Rodriguez-Frias, F; Sanchez, MJ1
Hong, M; Li, JY; Li, Q; Lu, H; Qian, SX; Qiu, HX; Sheng, WY; Wu, HX; Xu, W; Zhang, R1
Chen, X; Tian, LP; Wang, JS; Wang, Z; Wu, L1
Byrd, JC; Castro, J; Flinn, IW; Harris, S; Heerema, N; Hughes, S; Kipps, TJ; Leigh, B; Lin, TS; Molina, A; O'Brien, S; Tangri, S; Wierda, W; Woodworth, J; Wynne, D1
Brejcha, M; Brychtova, Y; Cejkova, S; Doubek, M; Klabusay, M; Kuglik, P; Malcikova, J; Mayer, J; Pospisilova, S; Rocnova, L; Skuhrova Francova, H; Smardova, J; Svitakova, M; Tichy, B; Trbusek, M; Vranova, V1
Brown, M; Gibson, SB; Hernandez, TA; Hu, X; Johnston, JB; Kumar, SA; Kuschak, B1
Greenblatt, DJ; Karyagina, EV; Lister-James, J; Lundberg, AS; Yin, W1
Byrd, JC; Gockerman, J; Hohl, R; Hurd, D; Larson, RA; Nattam, S; Perry, MC; Peterson, BL; Rai, KR1
Abruzzo, L; Admirand, J; Keating, MJ; Lerner, S; Lin, KI; O'Brien, S; Schlette, EJ; Tam, C; Wierda, W1
Harnalikar, M; Kharkar, V; Khopkar, U; Pande, S1
Alatrash, G; Albitar, M; Burger, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Lerner, S; Manshouri, T; O'Brien, S; Wang, X; Wierda, WG1
Kosseifi, SG; Krishnaswamy, G; Smith, S; Vyas, B; Vyas, H1
Bruno, B; Chauncey, TR; Maloney, DG; Maris, MB; Nakamae, H; Panse, J; Petersdorf, E; Petersen, FB; Pulsipher, MA; Sandmaier, BM; Storb, R; Storek, J; Storer, BE; Wade, JC; Woolfrey, A1
Błoński, JZ; Góralski, P; Kiliańska, ZM; Komina, O; Piekarski, H; Robak, T; Rogalińska, M; Wesierska-Gadek, J; Zołnierczyk, JD1
Bornhäuser, M; Brand, R; de Witte, T; Gahrton, G; Heinzelmann, M; Kröger, N; Morris, C; Nagler, A; Niederwieser, D; Schilling, G; Schwerdtfeger, R; Shimoni, A; Zander, AR1
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L1
Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T1
Bradstock, K; George, B; Gilroy, N; Gottlieb, D; Hertzberg, M; Huang, G; Kerridge, I1
Buda, G; Orciuolo, E; Pelosini, M; Petrini, M1
Bahlis, NJ; Balogh, A; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Irish, W; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Zacarias, N1
Chen, HR; DU, ZL; He, XP; Hu, B; Si, YJ; Yang, K; Zhang, CC; Zhang, XM1
Eldering, E; Kater, AP; Tonino, SH; van Gelder, M; van Oers, MH1
Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D1
Celadin, M; Furlan, A; Pietrogrande, F; Sanzari, M; Vianello, F; Villanova, F1
Bazargan, A; Tam, CS1
Hoffman, PC1
Baiocchi, RA; Blum, KA; Byrd, JC; Fischer, DB; Grever, MR; Johnson, AJ; Kraut, EH; Lin, TS; Mitchell, SM; Moran, ME; Porcu, P; Ruppert, AS; Schaaf, LJ1
HANDA, H; KARASAWA, M; MATSUSHIMA, T; MAWATARI, M; MURAKAMI, H; NOJIMA, Y; OSAKI, Y; SAITOH, T; SEKIGAMI, T; TAHARA, K; TOYAMA, K; TSUKAMOTO, N; UCHIUMI, H; YOKOHAMA, A1
Castejon, R; Citores, MJ; Garcia-Marco, JA; Rosado, S; Vargas, JA; Villarreal, M1
Desmond, R; Farrell, M; Gleeson, M; Lynch, K; Murphy, P1
Hong, M; Li, JY; Lu, H; Qian, SX; Wu, HX; Xu, W1
Kiss, E; Szodoray, P1
Aleksandrowicz, P; Dolińska-Krajewska, B; Draga, A; Dubielecka, PM; Grzybek, M; Jaźwiec, B; Kolondra, A; Kołodziejczyk, M; Kuliczkowski, K; Serwotka, A; Sikorski, AF; Warchoł, J1
Abonour, R; Baute, JA; Cornetta, K; Cox, EA; Cripe, LD; Dlouhy, SR; Farag, SS; Fausel, CA; Haut, PR; Hromas, R; Nelson, RP; Robertson, KA; Robertson, MJ; Schwartz, JE; Srivastava, S; Vance, GH; Wood, LL; Yu, M1
Chiba, K; Horiuchi, K; Ikegami, H; Kimura, T; Kosaki, N; Matsumoto, M; Nakamura, T; Okada, Y; Ota, N; Tajima, K; Takaishi, H; Takito, J; Tohmonda, T; Toyama, Y; Yoda, M1
Biagi, E; Brenner, MK; Carrum, G; Dotti, G; Foster, AE; Goodell, MA; Heslop, HE; Lu, A; Okur, FV; Savoldo, B; Yvon, E1
Aldridge, J; Alyea, EP; Antin, JH; Armand, P; Cutler, C; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ1
Bell, T; Inaba, H; Leung, W; Pounds, S; Pui, CH; Ribeiro, RC; Rooney, B; Rubnitz, JE1
Cavallin, M; Damante, G; Damiani, D; Fabbro, D; Fanin, R; Geromin, A; Malagola, M; Michelutti, A; Pianta, A; Russo, D; Tiribelli, M1
Akiba, T; Hyodo, H; Ishiguro, H; Kato, S; Koike, T; Morimoto, T; Shimizu, T; Yabe, H; Yabe, M1
Fan, L; Li, JY; Liu, P; Miao, KR; Qiao, C; Wu, YJ; Xu, W; Yao, L; Zhu, DX; Zhu, HY1
Chow, KU; Dreyling, M; Hess, G; Jäger, E; Kim, SZ; Krause, SW; Kruse, J; Mitrou, PS; Napieralski, S; Rech, J; Soekler, M; Subklewe, M; Weidmann, E; Weisel, KC1
Aractingi, S; Auffret, N; Bodemer, C; Brousse, N; Duong, T; Fraitag, S; Grange, F; Hermine, O1
Asaka, M; Endo, T; Hashino, S; Imamura, M; Ito, YM; Kahata, K; Koike, T; Kondo, T; Nishio, M; Okada, K; Onozawa, M; Shigematsu, A; Sugita, J; Takahata, M; Tanaka, J; Yamamoto, S1
Elliott, B; Grosskreutz, C; Isola, L; Malone, A; Mandeli, J; Osman, K; Scigliano, E1
Fernández-Calotti, P; Pastor-Anglada, M1
Brace, JR; Lee, MS; McKinney, AM; Santacruz, K1
Afanasiev, BV; Catalano, J; Dartigeas, C; Dmoszynska, A; Ganly, PS; Geisler, CH; Larratt, L; Loscertales, J; Maurer, J; Mendila, M; Moiseev, SI; Montillo, M; Robak, T; Rosta, A; Saville, MW; Solal-Céligny, P; Valente, N; Warzocha, K; Wenger, MK; Zyuzgin, I1
Chan, G; Davis, R; Dyer, MJ; Furman, RR; Hellmann, A; Hillmen, P; Kipps, TJ; Kozak, T; Losic, N; Mayer, J; Osterborg, A; Padmanabhan, S; Piotrowska, M; Robak, T; Russell, CA; Stilgenbauer, S; Trneny, M; Wierda, WG; Williams, CD; Wilms, J1
Andreadis, C; Kanetsky, PA; Nasta, SD; Olin, RL; Schuster, SJ; Ten Have, TR1
Ansell, SM; Elliott, MA; Gastineau, DA; Hogan, WJ; Holtan, SG; Inwards, DJ; Johnston, PB; Lacy, MQ; Litzow, MR; Micallef, IN; Porrata, LF1
Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszyñska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Hellmann, A; Jamroziak, K; Konopka, L; Kostyra, A; Lewandowski, K; Piotrowska, M; Piszcz, J; Potoczek, S; Robak, T; Seferynska, I; Stella-Holowiecka, B; Warzocha, K; Zawilska, K; Zdunczyk, A1
Abad, L; Diaz, MA; Gonzalez-Vicent, M; Perez, A; Ramirez, M; Sevilla, J1
Bojarska-Junak, A; Chocholska, S; Dmoszynska, A; Klimek, P; Kowal, M; Podhorecka, M1
Bishop, RJ; Caruso, R; Chan, CC; Cunningham, D; Ding, X; Heller, CK; Illei, G; Pavletic, S1
Andresen, S; Bolwell, B; Copelan, EA; Dean, R; Kalaycio, M; Mickelson, DM; Pohlman, B; Rybicki, L; Sobecks, R; Sproat, L; Sweetenham, J1
Ali, MA; Balbaa, OA; Farahat, NM; Hussein, Ael-S; Shamaa, LA1
Baran, Y; Bassoy, EY; Oztekin, C1
Bot, FJ; Chaker, L; Maartense, E; Segeren, CM1
Acholonu, S; Champlin, R; Dabaja, B; Donato, M; Duvic, M; Hosing, C; Khouri, I; Richmond, H; Singh, L; Wei, W1
Buus, S; Garred, P; Kornblit, B; Larsen, ME; Larsen, MV; Lund, O; Masmas, TN; Nielsen, M; Stryhn, A; Thiim, M; Vindelov, L1
Disel, U; Karakoc, E; Paydas, S; Yavuz, S1
Auewarakul, CU; Karoopongse, E; Khuhapinant, A1
Golubeva, ME; Isaeva, NV; Kudriavtseva, AV; Malykh, OV; Tkachenko, SB; Zagoskina, TP1
Albert, MH; Belohradsky, BH; Ehl, S; Freudenberg, F; Güngör, T; Koletzko, S; Prell, C; Roesen-Wolff, A; Roesler, J; Roos, D; Seger, R; Strahm, B; Tommasini, A; Ventura, A; Wintergerst, U1
Chakraverty, R; Denovan, S; Fielding, AK; Hough, R; Kottaridis, PD; Linch, DC; Mackinnon, S; Mead, AJ; Mohamedbhai, S; Morris, EC; Orti, G; Peggs, KS; Thomson, KJ1
de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV1
Brunstein, CG; Cao, Q; Green, KG; Jacobson, PA; Long-Boyle, JR; McGlave, PB; Miller, JS; Rogosheske, J; Wagner, JE; Weisdorf, DJ1
Alter, BP; Baker, KS; Dietz, AC; Giller, RH; Orchard, PJ; Savage, SA; Tolar, J1
Garratty, G1
Beitinjaneh, A; Cao, Q; McKinney, AM; Weisdorf, DJ1
Lamanna, N1
Khouri, I; Tam, CS1
Balakrishnan, K; Bantia, S; Bickel, S; Chen, Y; Gandhi, V; Kantarjian, H; Keating, MJ; Kilpatrick, JM; O'Brien, S; Ravandi, F; Tyler, BF; Verma, D1
Asano-Mori, Y; Ishiwata, K; Masuoka, K; Matsuno, N; Miyakoshi, S; Ohashi, K; Ota, Y; Takagi, S; Takahashi, K; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, H1
Bednarek, A; Fabianowska-Majewska, K; Rudnicka, K; Stefanska, B1
Brewer, SC; Cleveland, KO; Gelfand, MS1
Blanc, A; Corre, J; Fournié, JJ; Gross, E; Kühlein, E; Laurent, G; Quillet-Mary, A; Ysebaert, L1
Aoyama, M; Hashimoto, S; Itagaki, N; Iwanaga, T; Kawamura, M; Kazuta, T; Matsuda, M; Rai, S; Yamairi, N1
Aouali, N; Berchem, G; Bernardin, F; Cornillet-Lefebvre, P; Delmer, A; Duhem, C; El Khoury, V; Leners, B; Moussay, E; Muller, A; Palissot, V; Poirel, HA; Ries, F; Vallar, L; van Dyck, E; Van Moer, K; Wenner, T1
Bacigalupo, A; Brune, M; Cesaro, S; Lanino, E; Locasciulli, A; Locatelli, F; Marsh, J; Oneto, R; Passweg, J; Prete, A; Shimoni, A; Socie', G; Van Lint, MT1
Aschan, J; Baumgart, J; Blau, IW; Casper, J; Freund, M; Giebel, S; Hilgendorf, I; Holowiecki, J; Knauf, W; Kröger, N; Mylius, HA; Pichlmeier, U; Ruutu, T; Schäfer-Eckart, K; Volin, L; Wandt, H; Wolff, D; Zander, AR1
Chocholska, S; Dmoszynska, A; Halicka, D; Klimek, P; Kowal, M; Podhorecka, M2
Cavazzini, F; Ciccone, M; Cuneo, A; De Angeli, C; Ferracin, M; Grilli, A; Lupini, L; Negrini, M; Rizzotto, L; Saccenti, E; Veronese, A; Zagatti, B1
Balasubramanian, A; Bambach, BJ; Bennett, RR; Darras, BT; Estrella, E; Gussoni, E; Kang, PB; Kunkel, LM; Kurtzberg, J; Lidov, HG; Mitchell, M; Shapiro, FD; White, AJ1
Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H1
Aarden, L; Baars, JW; Beijnen, JH; Huitema, AD; Tran, L1
Li, JY; Xu, W; Yao, L1
Andersson, BS; Valdez, BC2
Flowers, ME; Frangoul, H; Kiem, HP; Kletzel, M; Kurre, P; Leisenring, W; Pulsipher, MA; Sandmaier, BM; Storb, R; Thakar, MS; Woolfrey, A1
Appelbaum, FR; Douglas, JG; Mayadev, JS; Storb, R; Storer, BE1
Berman, DM; Buchwald, P; Han, D; Kenyon, NM; Kenyon, NS; Rothen, D; Willman, M1
Bloor, A; Chakraverty, R; Clark, A; Clark, R; Collin, M; Crawley, C; Fielding, A; Hale, G; Johnson, P; Kottaridis, P; Mackinnon, S; Milligan, D; Morris, E; Orti, G; Parker, A; Peggs, K; Pettengell, R; Pettitt, A; Roughton, M; Shen, J; Snowden, J; Thomson, K1
Almog, S; Gopher, A; Halkin, H; Hassoun, E; Kurnik, D; Loebstein, R; Nagler, A; Shimoni, A1
Chiang, R; Earp, J; Gootenberg, JE; Keegan, P; Lemery, SJ; McDougal, A; Pazdur, R; Pilaro, A; Rothmann, MD; Yang, J; Zhang, J; Zhao, H1
Bond, KM; Cianciolo, GJ; Diehl, LF; Friedman, DR; Gockerman, JP; Kennedy, MN; Lanasa, MC; Moore, JO; Mowery, YM; Pizzo, SV; Weinberg, JB1
Chiusolo, P; D'Arena, G; De Padua, L; Efremov, DG; Falcucci, P; Innocenti, I; Laurenti, L; Leone, G; Marietti, S; Piccirillo, N; Sica, S; Sora', F; Tarnani, M; Zini, G1
Cao, X; Dong, HJ; Fang, C; Hong, M; Li, JY; Miao, KR; Wang, DM; Xu, W; Zhu, DX1
Beiske, K; Berentsen, S; Dalgaard, J; Hjorth-Hansen, H; Jacobsen, EM; Randen, U; Thoresen, AS; Tjønnfjord, GE; Vågan, AM; Vik, A1
Dong, HJ; Fang, C; Li, JY; Miao, KR; Qiao, C; Wang, DM; Wu, YJ; Xu, W; Zhu, DX; Zhu, HY1
Gocke, CD; Hristov, AC; Nava, VE; Saladino, A1
Allain, JP; Candotti, D; El Chaar, M; Power, JP; Spillane, D; Temple, J; Thomas, M1
Burroughs, LM; Carpenter, PA; Englund, J; Ochs, HD; Rawlings, DJ; Sanders, J; Scharenberg, AM; Skoda-Smith, S; Storb, R; Torgerson, TR; Woolfrey, AE1
Mupo, A; Russo, GL; Russo, M; Spagnuolo, C; Tedesco, I; Volpe, S1
Celentano, M; Criscuolo, C; Ferrara, F; Izzo, T; Mele, G; Riccardi, C1
Batár, P; Rejto, L; Telek, B; Udvardy, M1
Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Zohren, F1
Bishop, MR; Bryant, K; Dean, RM; Fowler, DH; Hakim, F; Jamshed, S; Neelapu, SS; Odom, J; Steinberg, SM1
Appay, V; Canellini, G; Laurent, J; Leyvraz, S; Papaioannou, A; Rimoldi, D; Romero, P; Rufer, N; Speiser, DE; Touvrey, C; Vicari, M; Voelter, V1
Aytac, S; Balci, YI; Cetin, M; Gumruk, F; Gurgey, A; Kuskonmaz, B; Tavil, B; Tuncer, M; Uckan, D; Unal, S; Yetgin, S1
Tsimberidou, AM1
Ahn, HS; Cho, B; Chung, NG; Im, HJ; Kang, HJ; Kim, HK; Kim, SY; Koo, HH; Lee, YH; Lim, YT; Park, JE; Park, SK; Seo, JJ; Shin, HY; Sung, KW; Yoo, KH1
Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE1
Cattaneo, R; Frenzke, ME; Johnston, PB; Miest, T; Ungerechts, G; Yaiw, KC1
Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW1
Atkins, JN; Bengtson, EM; Byrd, JC; Donohue, KA; Hoke, EE; Larson, RA; Lin, TS; Link, BK; Lucas, MS; Rai, KR1
Bergmann, M; Bühler, A; Busch, R; Denzel, T; Döhner, H; Edelmann, J; Eichhorst, B; Häbe, S; Hallek, M; Hensel, M; Hopfinger, G; Stilgenbauer, S; Winkler, D; Zenz, T1
Alyea, E; Antin, JH; Armand, P; Attar, E; Ballen, K; Boussiotis, VA; Brown, J; Cutler, C; Dey, BR; Herrera, M; Ho, V; Kao, G; Kim, HT; Koreth, J; Liney, D; McDonough, S; Reynolds, C; Ritz, J; Soiffer, R; Spitzer, T; Stevenson, K1
Arber, C; Bucher, C; Buser, A; Gerull, S; Gratwohl, A; Halter, J; Heim, D; Stern, M; Tichelli, A1
Afanasiev, BV; Bence-Bruckler, I; Catalano, J; Dmoszynska, A; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Geisler, CH; Larratt, L; Loscertales, J; Moiseev, SI; Montillo, M; Robak, T; Rossiev, VA; Solal-Celigny, P; Spleiss, O; Warzocha, K; Weisser, M; Wenger, MK; Yeh, RF; Zhi, J1
Brychtová, Y; Doubek, M; Mayer, J; Panovská, A1
Anasetti, C; Ayala, E; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kim, J; Perez, L; Perkins, J; Pidala, J1
Au, MA; Boeckh, MJ; Chien, JW; Deeg, HJ; Milano, F1
Ahmed, S; Al-Anazi, K; Al-Mohareb, F; Al-Sharif, F; Al-Zahrani, H; Aljurf, M; Bakr, M; Chaudhri, N; Elhassan, T; Elkum, N; Hussain, F; Ibrahim, K; Mohamed, S; Nassar, A; Nurgat, Z; Patel, M; Rasheed, W; Saleh, AJ1
Bär, C; Brantner, P; Buchner, M; Burger, M; Dierks, C; Gribben, JG; Mertelsmann, R; Ott, A; Pfeifer, D; Prinz, G; Stickel, N; Veelken, H; Zirlik, K1
Anderson, KC; Ghobrial, IM; Rourke, M1
Dan, K; Yamaguchi, H1
Bulgar, AD; Donze, JR; Gerson, SL; Kirkland, EB; Li, L; Liu, L; Snell, M; Xu, Y; Yang, S1
Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Garvin, JH; George, D; Harrison, L; Milone, MC; Morris, E; Satwani, P; Schwartz, J; Shaw, LM; Styczynski, J; Tallamy, B; van de Ven, C; Waxman, I1
Giné, E; Gutiérrez-García, G; López-Guillermo, A1
Brassac, M; Fournié, JJ; Gross, E; Kheirallah, S; L'Faqihi-Olive, FE; Laurent, G; Quillet-Mary, A; Struski, S; Ysebaert, L1
Abramson, J; Brown, JR; Dalton, V; Freedman, AS; Hochberg, E; Kuang, Y; McDonough, SM; Mikler, E; Neuberg, D; Reynolds, H; Ritz, J; Thompson, C; Werner, L1
Angchaisuksiri, P; Apilugsanachit, A; Atichartakarn, V; Boonsakan, P; Chuncharunee, S; Jootar, S; Kanoksil, W; Karntisaviwat, K; Niparuck, P; Nitiyanant, P; Rerkamnuatchoke, B; Ungkanont, A1
Baldini, L; Federico, M; Ferrario, A; Goldaniga, MC; Luminari, S; Mannina, D; Marcheselli, L; Mazza, P; Merli, F; Russo, M; Stelitano, C1
Eto, T; Fukuda, T; Hagihara, M; Hatanaka, K; Iida, H; Kanda, Y; Kasai, M; Kawano, F; Maeda, Y; Masuoka, K; Mori, T; Murata, M; Nagafuji, K; Nakagawa, H; Nakamae, M; Nishiwaki, K; Shirafuji, N; Takahashi, S; Takaue, Y; Taniguchi, S; Taniwaki, M; Togami, K; Uchida, T; Ueda, Y; Utsunomiya, A; Wake, A; Waki, F; Yakushiji, K; Yakushijin, K; Yamashita, T1
Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; El Cheikh, J; Esterni, B; Farnault, L; Faucher, C; Fürst, S; Ladaique, P; Lemarie, C; Marchetti, N; Mohty, M; Prebet, T; Stoppa, AM; Vey, N1
De Brasi, C; Narbaitz, M; Noriega, MF; Rodríguez, A; Slavutsky, I1
Egle, A; Gassner, FJ; Geisberger, R; Greil, R; Hartmann, TN; Hofbauer, JP; Tinhofer, I; Weiss, L1
Carney, DA; Seymour, JF1
Chao, NJ; Chute, JP; Gasparetto, C; Hogge, DE; Horwitz, ME; Kanda, J; Long, GD; Morris, A; Niedzwiecki, D; Nitta, J; Rizzieri, DA; Smith, CA; Song, K; Sullivan, KM1
Burchette, J; Foo, WC; Huang, Q; Hutchinson, CB; Sebastian, S; Wang, E1
Dagis, A; Forman, S; Hitt, D; Naeem, H; Qian, D; Rosenthal, J; Stein, A; Thomas, SH; Wong, J1
Bergmann, M; Berrebi, A; Böttcher, S; Bühler, A; Busch, R; Caligaris-Cappio, F; Catalano, J; Cazin, B; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hess, G; Hopfinger, G; Jäger, U; Kneba, M; Mayer, J; Mendila, M; Ritgen, M; Seymour, JF; Staib, P; Stilgenbauer, S; Trneny, M; von Grünhagen, U; Wendtner, CM; Westermann, A; Winkler, D; Zenz, T; Zinzani, PL1
Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Komrokji, RS; Nishihori, T; Perkins, J; Pidala, J; Roman-Diaz, J1
Artz, AS; Del Cerro, P; Godley, LA; Hart, J; Horowitz, S; Innocenti, F; Larson, RA; O'Donnell, PH; Odenike, OM; Pai, RK; Stock, W; Undevia, SD; Van Besien, K1
Peinert, S; Seymour, JF1
Anasetti, C; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Perez, L; Perkins, J; Pidala, J1
Bouscary, D; Dreyfus, F; Park, S; Pilorge, S; Tamburini, J1
Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B1
Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC1
Baron, F; Beguin, Y; Castermans, E; Cheynier, R; Dutrieux, J; Geenen, V; Gothot, A; Hannon, M; Humblet-Baron, S; Sandmaier, BM; Seidel, L; Storb, R; Vanbellinghen, JF; Willems, E1
Eldering, E; Kater, AP; Tonino, SH; van Laar, J; van Oers, MH; Wang, JY1
Januszewicz, EH; Peinert, S; Prince, HM; Scarlett, J; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM1
Acholonu, SA; Anderlini, P; Bassett, RE; Champlin, RE; Giralt, SA; Okoroji, GJ; Popat, UR; Qazilbash, MH; Shpall, EJ; Worth, LL1
Lech-Maranda, E; Robak, P; Robak, T1
Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL1
Holmes, NE; Kelman, A; Korman, TM; Opat, S1
Came, N; Carney, DA; Januszewicz, EH; Kenealy, M; Milner, A; Prince, HM; Ritchie, D; Seymour, JF; Tam, CS; Westerman, DA; Wolf, M1
Béliveau, C; Cohen, S; Kent, D; Kiss, T; Labbé, AC; Lachance, S; Laverdière, M; Logvinenko, T; Martel-Laferrière, V; Roy, J; Snydman, DR; Su, SH1
Canales, M; de la Serna, J; de Oña, R; de Sevilla, AF; Martínez, R; Martínez-López, J; Montalbán, C; Paz-Carreira, J; Rapado, I; Rivero, A; Sánchez-Godoy, P; Tomás, JF1
Arnold, R; Dokal, I; Dörken, B; Hemmati, PG; le Coutre, P; Neuburger, S; Terwey, TH; Vulliamy, T; Vuong, LG1
Main, C; Moxham, T; Pitt, M; Stein, K1
Aurora, M; Bachanova, V; Blazar, BR; Brunstein, C; Burns, L; Cao, Q; Cooley, S; Defor, T; Dusenbery, K; Kaufman, D; Macmillan, M; Majhail, NS; McClune, B; McGlave, P; Miller, J; Oran, B; Slungaard, A; Tomblyn, M; Vercellotti, G; Verneris, M; Wagner, J; Warlick, ED; Weisdorf, DJ1
Jordheim, LP1
Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; El Kourashy, S; Geddes, M; Larratt, L; Quinlan, D; Russell, JA; Savoie, ML; Stewart, DA; Storek, J; Turner, AR; Williamson, T; Yang, M; Zacarias, N1
Dan, K; Mizuki, T; Nakamura, H; Nakayama, K; Tajika, K; Yamaguchi, H1
An, X; Cao, S; Chen, Y; Hao, X; Li, H; Ren, X; Sun, H; Yan, F; Yu, J; Zhang, N1
Bredeson, C; Ewell, M; Goodman, SA; Horowitz, MM; Kahl, BS; Laport, GG; Negrin, RS; Tomblyn, MR; Vose, JM1
Anderlini, P; Andersson, BS; Bashir, Q; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Fernandez-Vina, M; Giralt, S; Popat, U; Rodrigues, M; Sharma, M; Shpall, EJ; Wei, W1
Best, G; Buggins, AG; Devereux, S; Dyer, MJ; Fegan, C; Fishlock, K; Hewamana, S; Hills, R; Kennedy, BJ; Lin, TT; Majid, A; Miall, F; Oscier, DG; Pepper, C; Pratt, G; Wagner, S; Yallop, D1
Choi, MK; Chung, CW; Hong, JY; Jang, JH; Kim, DH; Kim, HO; Kim, K; Kim, SJ; Kim, WS; Min, YH1
Ascaso, FJ; Fuertes, MA; Jimenez, B; Keane, PA; Sadda, S1
Ali, D; Bengtzén, S; Deneberg, S; Jönsson-Videsäter, K; Lehmann, S; Nahi, H; Paul, C1
Aloyz, R; Amrein, L; Assouline, S; Caplan, S; Desjardins, P; Egorin, MJ; Hebb, J; Panasci, L; Rousseau, C1
Amarnath, S; Buxhoeveden, N; Felizardo, TC; Foley, J; Fowler, DH; Mariotti, J; Massey, PR; Mossoba, ME; Ryan, K; Taylor, J1
Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R1
Anasetti, C; Ayala, E; Fancher, K; Fernandez, H; Field, T; Gardiner, JA; Kharfan-Dabaja, MA; Kim, J; Miller, S; Milone, MC; Perez, L; Perkins, J; Shaw, LM; Tate, C1
Gao, W; Nimmagadda, S; Patel, P; Rondelli, D; Sweiss, K1
Nagler, A; Shimoni, A1
Doorduijn, JK; Lam, KH; van de Langerijt, B; van den Bent, MJ1
Criscuolo, C; Ferrara, F; Izzo, T; Palmieri, S; Riccardi, C1
Abadie, E; Ersbøll, J; Gravanis, I; Marty, M; Pignatti, F; Skovlund, E1
Amsailale, R; Arts, A; Bastin-Coyette, L; Bontemps, F; Cardoen, S; de Viron, E; Smal, C; Van Den Neste, E1
Che, Y; Christopherson, RI; Henrich, S; Kohnke, PL; Mactier, S1
Angulo-Pachón, CA; Carda, M; Díaz-Oltra, S; Falomir, E; Marco, JA; Murga, J1
Chen, R; Delioukina, M; Forman, S; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Rosenthal, J; Shen, J; Smith, E1
Casak, SJ; Davis, G; Jarral, V; Keegan, P; Khandelwal, A; Lemery, SJ; Pazdur, R; Rothmann, MD; Shen, YL; Zhao, H1
Bae, KS; Choi, Y; Han, SB; Hur, EH; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lim, HS; Lim, SN; Noh, GJ; Yun, SC1
Huisman, C; Paquay, MM; Tilanus, MG; van der Straaten, HM; van Geloven, N; Verdonck, LF1
Balashov, D; Brooks, R; Maschan, A; Or, R; Resnick, IB; Revel-Vilk, S; Rheingold, L; Shapira, MY; Skorobogatova, E; Stein, J; Stepensky, P; Trakhtman, P; Weintraub, M1
Booth, GA; Brown, J; Cocks, K; Cohen, DR; Dearden, C; Ezekwisili, R; Fegan, C; Hillmen, P; Kennedy, DB; Mercieca, J; Milligan, DW; Pettitt, A; Pocock, C; Radford, J; Rawstron, AC; Sayala, HA; Smith, AF; Varghese, AM1
Brunstein, CG; DeFor, TE; Oran, B; Wagner, JE; Weisdorf, DJ1
Evangelista, M; Lucotti, S; Patella, F; Rainaldi, G; Rizzo, M1
Badoux, XC; Burger, J; Faderl, S; Ferrajoli, A; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, SM; Wang, X; Wierda, WG2
Anasetti, C; Ayala, E; Fernandez, HF; Field, T; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Perkins, J; Pidala, J; Roman-Diaz, J; Tate, C; Tomblyn, M1
Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N1
Ariga, T; Cho, Y; Ichikawa, M; Iguchi, A; Inamoto, J; Kaneda, M; Kawamura, N; Kobayashi, I; Kobayashi, R; Ohkura, Y; Ohshima, J; Sato, T; Takezaki, SI; Yamada, M1
Bakun, AV; Fedosenko, VV; Khlebko, PV; Kustanovich, AM; Serhiyenka, TF; Svirnovski, AI; Taras, IB1
Bossuyt, X; Mariën, G; Uyttebroeck, A1
Bajo, R; Burgaleta, C; Caballero, MD; Canales, M; De La Serna, J; De Oña, R; De Sevilla, AF; Díaz, N; Martínez, R; Martínez-López, J; Montalbán, C; Peñalver, J; Prieto, E; Queizán, JA; Salar, A; Sánchez-Godoy, P; Tomás, JF1
Delioukina, ML; Forman, SJ; Krishnan, A; Palmer, JM; Stiller, T; Thomas, SH1
de Lima, M; de Souza Santos, FP; Hamerschlak, N; Kerbauy, FR; Kutner, JM; Ribeiro, AA; Rodrigues, M; Sobrinho, JN; Torres, MA1
Bansal, D; Gautam, V; Marwaha, N; Marwaha, RK; Oberoi, S; Sharma, RR1
Atsuta, Y; Imahashi, N; Ito, T; Kato, T; Miyamura, K; Morishita, Y; Murata, M; Naoe, T; Nishiwaki, S; Ohashi, H; Sawa, M; Suzuki, R; Terakura, S; Yasuda, T1
Colledan, M; Conter, V; Cornelli, P; Fiocchi, R; Giraldi, E; Provenzi, M; Rambaldi, A; Torre, G1
Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J1
Assisi, D; D'Andrea, M; Dessanti, L; Maini, CL; Petti, MC; Pisani, F; Sciuto, R1
Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ1
Schnaiter, A; Stilgenbauer, S1
Byrd, JC; Gribben, JG; Heerema, NA; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Ruppert, AS; Woyach, JA1
Abrisqueta, P; Bosch, F; Crespo, M1
Freedman, AS; Sweetenham, JW1
Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W1
Castillo, JJ; Reagan, JL1
Baumann, M; Bluyssen, HA; Chmielewski, S; Heemann, U; Przybyl, L; Sikorski, K; Wesoly, J1
Cervigón, I; Palomo, A; Solano, F; Torres-Iglesias, LM; Zapata, AM1
Delioukina, M; Forman, S; Palmer, JM; Thomas, S; Tsai, N; Zain, J1
Baurmann, H; Braess, J; Buechner, T; Haferlach, C; Hahn, J; Haude, KH; Hiddemann, W; Holler, E; Kolb, HJ; Oruzio, D; Schleuning, M; Schlimok, G; Schmid, C; Schwerdtfeger, R; Spiekermann, K; Tischer, J1
Abraham, J; Andritsos, L; Benson, DM; Blum, W; Bunner, P; Craig, M; Cumpston, A; Devine, SM; Efebera, Y; Elder, P; Garzon, R; Gibson, L; Hamadani, M; Hofmeister, C; Leadmon, S; Penza, S; Phillips, GS; Remick, SC; Tse, W1
Cai, YX; Lu, QY; Niu, XQ; Wang, Z; Zaho, JN1
Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M1
Bautista, G; Cabrera, JR; Gonzalo-Daganzo, R; Regidor, C1
Berentsen, S1
Alsina, M; Anasetti, C; Ayala, E; Di Nicola, M; Fernandez, H; Field, T; Janssen, W; Kharfan-Dabaja, MA; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Raychaudhuri, J; Santarone, S1
Hivert, B; Leblond, V; Morel, P; Tamburini, J; Tournilhac, O; Vekhoff, A1
Aimoto, M; Aimoto, R; Hayashi, Y; Hino, M; Inoue, A; Inoue, E; Koh, H; Koh, KR; Nakamae, H; Nakamae, M; Nakane, T; Nishimoto, M; Terada, Y; Yamane, T; Yoshimura, T1
Alousi, AM; Anderlini, P; Andersson, BS; Champlin, RE; de Lima, MJ; Giralt, SA; Hosing, C; Kebriaei, P; Khouri, IF; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Saliba, RM1
Fan, L; Fang, C; Hong, M; Li, JY; Liu, P; Miao, KR; Qiao, C; Wu, YJ; Xu, M; Xu, W; Zhu, DX; Zhu, HY; Zhuang, Y1
Tadmor, T1
Ba, LA; Doering, M; Hallek, M; Herling, M; Jacob, C; Lilienthal, N; Peer-Zada, AA; Prinz, C1
Allen, JC; Chowbay, B; Diong, CP; Goh, YT; Hwang, WY; Linn, YC; Loh, SM; Wong, AM1
Fujioka, T; Ikegame, K; Inoue, T; Kaida, K; Kato, R; Kim, EH; Nakata, J; Ogawa, H; Okada, M; Soma, T; Tamaki, H; Taniguchi, K; Yoshihara, S1
Catovsky, D; Dearden, CE; Gonzalez, D; Hockley, S; Martinez, P; Matutes, E; Morgan, GJ; Oscier, D; Richards, SM; Wade, R1
Ansaldi, F; Balleari, E; Bedognetti, D; Boccardo, F; Bruzzone, A; Caltabiano, G; De Maria, A; Durando, P; Ferrarini, M; Icardi, G; Marincola, FM; Massucco, C; Messina, M; Racchi, O; Sertoli, MR; Zanardi, E; Zoppoli, G; Zupo, S1
Chan, G; Chang, CN; Dürig, J; Gorczyca, M; Griniute, R; Griskevicius, L; Gupta, I; Hernandez-Ilizaliturri, FJ; Hess, G; Kipps, TJ; Mayer, J; Nielsen, TG; Padmanabhan, S; Russell, CA; Smolej, L; Stilgenbauer, S; Wierda, WG1
Costello, R; Csako, G; Langan, RC; Prieto, PA; Rosenberg, SA; Sherry, RM; White, DE; Wunderlich, J; Yang, JC; Zlott, D1
Gopal, AK; Guthrie, KA; Maloney, DG; Matesan, MC; Oliveira, G; Pagel, JM; Press, OW; Rajendran, J; Storb, RF1
Cassuto, JP; Cluzeau, T; De Matteis, M; Gratecos, N; Mannone, L; Mounier, N; Raynaud, S; Sirvent, A; Thyss, A; Ticchioni, M1
Chen, S; Du, X; Li, Y; Liu, Q; Wu, J; Wu, X; Yang, L; Zhu, K1
Gupta, V; Hayden, J; Ho, AY; Ireland, RM; Islam, MS; Koh, MB; Lim, Z; Marks, DI; Marsh, JC; Mufti, GJ; Pagliuca, A; Potter, V; Russell, N1
Cencini, E; Fabbri, A; Forconi, F; Lauria, F; Raspadori, D; Sicuranza, A; Sozzi, E1
Cavallin, M; Damante, G; Damiani, D; Fabbro, D; Fanin, R; Geromin, A; Michelutti, A; Pianta, A; Russo, D; Tiribelli, M1
Bae, SH; Choi, SJ; Hyun, MS; Jeon, M; Joo, YD; Kang, MJ; Kang, YA; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Lee, YS; Park, JH; Ryoo, HM; Seol, M; Yun, SC1
Argnani, L; Baccarani, M; Broccoli, A; Cavalieri, E; De Renzo, A; Derenzini, E; Fanti, S; Fina, M; Gandolfi, L; Montini, GC; Pellegrini, C; Pileri, S; Pulsoni, A; Quirini, F; Rossi, M; Scopinaro, F; Stefoni, V; Tani, M; Torelli, F; Zinzani, PL1
Ai, WZ; Czerwinski, DD; Hsu, FJ; Hwang, J; Kohrt, HE; Levy, R; Taidi, B; Timmerman, J1
Calixto, R; Chandrasekaran, V; Domingues, MC; Florêncio, R; Maior, AP; Ostronoff, F; Ostronoff, M; Sucupira, A1
Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J1
Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R1
Ayari, S; Blin, N; Brissot, E; Cahu, X; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Harousseau, JL; Le Gouill, S; Mahe, B; Malard, F; Miplied, N; Mohty, M; Moreau, P1
Crathorne, L; Garside, R; Hoyle, M; Hyde, C1
Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M1
Haller, NA; Lee, B; Novak, R; Robertson, S; Smith, RS; Tanphaichitr, N1
Einberger, C; Fleiss, K; Fonatsch, C; Gaiger, A; Gruber, M; Hauswirth, AW; Heintel, D; Jäger, U; Porpaczy, E; Shehata, M; Skrabs, C; Thalhammer, R; Vanura, K1
Chen, R; Ewald, B; Plunkett, W; Sampath, D; Wierda, W; Zecevic, A1
Barbour, SJ; Beaulieu, MC; Magil, AB; Zalunardo, NY1
Khouri, IF1
Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR1
Cohen, GI; Fayad, LE; Kuepfer, C; Liebmann, JE; Modiano, MR; Pro, B; Romaguera, JE; Singer, JW; Srokowski, TP1
Alimoghaddam, K; Ghavamzadeh, A; Hadjibabaie, M; Hayatshahi, A; Iravani, M; Javadi, MR; Khoee, SH; Mansouri, A; Shamshiri, AR1
Bayer, R; Fung, HC; Gregory, SA; Karmali, R; Kassar, M; O'Brien, T; Shammo, JM; Venugopal, P1
Bossow, S; Cattaneo, R; Grossardt, C; Leber, MF; Rieber, EP; Sawall, S; Temme, A; Ungerechts, G; von Kalle, C1
Burchert, A; Neubauer, A; Wilhelm, C1
Abdullah, A; Ho, AY; Kenyon, M; Krishnamurthy, P; Lea, N; Lim, ZY; Marsh, J; Mufti, GJ; Nagi, W; Pagliuca, A; Potter, V; Reiff-Zall, L; Tindell, V1
Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC1
Argentieri, D; Bartomioli, M; Bezares, RF; Diaz, A; Garay, G; Milone, G; Ryser, R; Stemelin, G; Zubiaur, EL1
James, DF; Kipps, TJ1
Arampatzis, S; Eleftheriadis, T; Giannakoulas, N; Karasavvidou, F; Kourti, P; Liakopoulos, V; Matsouka, P; Stefanidis, I1
Beksac, M; Björkstrand, B; Bosi, A; Corradini, P; de Witte, T; Gahrton, G; Goldschmidt, H; Greinix, H; Gruber, A; Hegenbart, U; Iacobelli, S; Milone, G; Morris, C; Musto, P; Narni, F; Niederwieser, D; Volin, L1
Battista, ML; Benevolo, G; Lazzarino, M; Meneghini, V; Morra, E; Nichelatti, M; Pioltelli, P; Ricci, F; Sacchi, S; Tedeschi, A; Varettoni, M; Visco, C; Vitolo, U; Zaja, F; Zinzani, PL1
Blough, DK; Deeg, HJ; McCune, JS; McDonald, GB; O'Donnell, PV; Pawlikowski, MA; Rezvani, A; Yeh, RF1
Brychtova, Y; Doubek, M; Dvorakova, D; Horky, O; Krejci, M; Lengerova, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M1
Andersohn, F; Bronder, E; Garbe, E; Grüneisen, A; Hildebrandt, M; Klimpel, A; Kurtal, H; Mayer, B; Salama, A; Schrezenmeier, H; Späth-Schwalbe, E; Thomae, M1
Bergmann, L; Chow, KU; Cordes, HJ; Kim, SZ; Schlegelberger, B; Stilgenbauer, S; von Neuhoff, N; Wunderle, L1
Badoux, X; Burger, J; Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Parikh, SA; Wang, X; Wierda, WG1
Solis, EC1
Boiron, JM; Bouabdallah, K; Coiffard, J; Dilhuydy, MS; Lafarge, X; Leguay, T; Marit, G; Melot, C; Milpied, N; Pigneux, A; Schmitt, A; Tabrizi, R; Vigouroux, S1
Connors, JM; Gerrie, AS; Li, CH; Ramadan, KM; Sutherland, J; Toze, CL; Yee, A1
Attolico, I; Crugnola, M; De Blasio, A; Ilariucci, F; Montillo, M; Morra, E; Petrizzi, VB; Ricci, F; Spedini, P; Spriano, M; Tedeschi, A; Uziel, L; Vismara, E; Zaccaria, A1
Colović, M; Colović, N; Fekete, MD; Janković, G; Palibrk, V; Suvajdžić, N; Tomin, D1
Jungova, A; Karas, M; Koza, V; Svoboda, T; Vokurka, S1
Cao, JN; Fan, Y; Gu, KS; Guo, Y; Hong, XN; Li, XQ; Liu, XJ; Wang, CF; Wu, XH; Zhang, J1
Baccarani, M; Bandini, G; Bontadini, A; Curti, A; D'Addio, A; Dan, E; Fruet, F; Giudice, V; Isidori, A; Lemoli, RM; Martinelli, G; Motta, MR; Paolini, S; Parisi, S; Ruggeri, L; Trabanelli, S; Urbani, E; Velardi, A1
Chang, T; Dang, E; Feng, Z; Jin, L; Liu, Y; Shi, X; Wang, G1
Appelbaum, FR; Bennett, JM; Byrd, JC; Dewald, G; Flinn, IW; Grever, MR; Hussein, MA; Larson, RA; Lazarus, HM; Litzow, MR; Neuberg, D; Paietta, EM; Rowe, JM; Smith, MR; Tallman, MS1
Chao, NJ; Chute, JP; Gasparetto, C; Hennig, T; Horwitz, ME; Kanda, J; Li, Z; Long, GD; Morris, A; Rizzieri, DA; Sullivan, KM1
Bergmann, M; Buske, C; Dreyling, M; Egensperger, R; Franke, D; Herold, T; Mumm, FF; Schinwald, N; Seiler, T; Trumm, C1
Friedmann, M; Gutierrez, H; Han, L; Hornberger, J; Keating, MJ; Lerner, S; Reyes, C; Satram-Hoang, S; Shewade, A1
Huynh, M; Neubauer, A1
Cook, H; Datto, M; Daugherty, FJ; Davis, PH; DeCastro, CM; Diehl, LF; Friedman, DR; Gockerman, JP; Lanasa, MC; Li, Z; Matta, KM; Moore, JO; Rehder, C; Rizzieri, D; Weinberg, JB1
Bahlis, NJ; Carlson, L; Duan, Q; Duggan, P; Hasegawa, W; Russell, JA; Stewart, DA; Voralia, M1
Horino, S; Matsuhashi, T; Minegishi, M; Niizuma, H; Onuma, M; Rikiishi, T; Sakamoto, O; Sasahara, Y; Tsuchiya, S; Uchiyama, T; Uematsu, M1
Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D1
Aleman, BM; Boot, H; de Boer, JP; de Jong, D; Raderer, M; van Tinteren, H1
Baxter-Lowe, LA; Bhatia, M; Bradley, MB; Cairo, MS; Della-Latta, P; Freedman, J; Garvin, JH; George, D; Geyer, MB; Harrison, L; Jacobson, JS; Moore, V; Morris, E; Satwani, P; Schwartz, J; van de Ven, C1
Aurran-Schleinitz, T; Dartigeas, C; Feugier, P; Leprêtre, S; Letestu, R; Van Den Neste, E; Ysebaert, L1
Chan, GW; Gupta, IV; Lisby, S; Osterborg, A; Padmanabhan, S; Wierda, WG1
Acholonu, S; Alousi, AM; Anderlini, P; Champlin, RE; Chancoco, C; Ciurea, S; Fanale, MA; Hosing, CM; Khouri, IF; Ledesma, C; Nieto, Y; Popat, UR; Saliba, RM; Shpall, EJ; Valverde, R; Younes, A1
Abraham, A; Kasow, KA; Morales-Tirado, VM; Persons, DA; Riberdy, JM; Shurtleff, SA; Wichlan, D1
Al-Ahmari, A; Al-Jefri, A; Al-Seraihi, A; Aldali, A; Ayas, M; El-Solh, H; Khairy, A; Markiz, S; Siddiqui, K1
Boudova, L; Jindra, P; Karas, M; Kazakov, D; Koza, V; Svoboda, T; Vokurka, S1
Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J1
Fan, L; Li, JY; Liu, P; Miao, KR; Xu, M; Xu, W1
Bezares, RF; Bitsmans, A; Borge, M; Galmarini, CM; Gamberale, R; Giordano, M; González, M; Jancic, C; Morande, PE; Nannini, P; Rodríguez, AL; Zanetti, SR1
Bhattacharyya, J; Kimura, A; Mihara, K; Takihara, Y1
Sinsabaugh, C1
Acar, H; Aydemir, E; Bayrak, OF; Gulluoglu, S; Ozen, M; Sahin, F; Sevli, S; Yalvac, ME1
Capoluongo, N; Coppola, N; Fiore, M; Guastafierro, S; Iodice, V; Messina, V; Pasquale, G; Pisaturo, M; Sagnelli, C; Sagnelli, E; Stanzione, M; Tonziello, G1
Baldini, L; Cortelezzi, A; Gritti, G; Maura, F; Molica, S; Neri, A; Piciocchi, A; Reda, G1
Asmar, L; Boehm, KA; Di Bella, N; Hyman, W; Lyons, RM; Reynolds, C; Richards, DA; Robbins, GJ; Vellek, M; Zhan, F1
Molica, S2
Iwasaki, H; Kawai, Y; Takagi, K; Ueda, T; Yamauchi, T1
Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F1
Arnoulet, C; Béné, MC; Brumpt, C; Capiod, JC; de Carvalho Bittencourt, M; Degenne, M; Durrieu, F; Eghbali, H; Feugier, P; Feuillard, J; Garand, R; Geneviève, F; Kara-Terki, A; Kulhein, E; Maynadié, M; Ochoa-Noguera, ME; Plesa, A; Roussel, M; Truchan-Graczyk, M1
Eshkar-Sebban, L; Gellman, YN; Lytton, SD; Nagler, A; Naor, D; Or, R; Refaeli, E; Rosenblum, N; Shimoni, A; Shimony, O; Stanevsky, A; Yerushalmi, R1
Alimoghaddam, K; Bahar, B; Behfar, M; Ghavamzadeh, A; Hamidieh, AA; Iravani, M; Jahani, M; Jalali, A; Jalili, M; Mousavi, SA1
Kalk, E; Karanth, M; Khan, N; McLarnon, A; Moss, PA; Murray, J; Piper, KP; Pratt, G1
Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Neumann, T; Wilfert, H1
Bassett, R; Champlin, RE; Chan, KW; Ciurea, SO; Couriel, DR; de Lima, M; Fernandez-Vina, M; Hamerschlak, N; Hosing, CM; Jones, RB; Karduss Aurueta, AJ; Kebriaei, P; McMannis, J; Nieto, Y; Petropoulos, D; Qazilbash, M; Rondon, G; Saliba, RM; Sharma, M; Shpall, EJ; Worth, LL1
Jäger, U; Janssens, A; Leblond, V; Lepretre, S; Nikitin, E; Robak, T; Wendtner, CM1
Elter, T; Engert, A; Gercheva-Kyuchukova, L; Hallek, M; Jaksic, B; Kyrcz-Krzemień, S; Pylylpenko, H; Rekhtman, G; Robak, T; Sirard, C; Vatutin, M; Wu, J1
Amadori, S; Biagi, A; Bomben, R; Bruno, A; Buccisano, F; Bulian, P; Coletta, AM; Dal Bo, M; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Gattei, V; Luciano, F; Maurillo, L; Neri, B; Rossi, FM; Simotti, C; Venditti, A; Zucchetto, A1
Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S1
Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N1
Cornblath, DR; Huff, CA; Hughes, RA; Merkies, IS1
Beaumont, M; Garidi, R; Ghomari, K; Gruson, B; Just, A; Marolleau, JP; Merle, P; Merlusca, L; Royer, B1
Baro, J; Bermúdez, A; Colorado, M; Conde, E; Díez-Gallarreta, Z; Gutiérrez, ML; Insunza, A; Iriondo, A; López-Duarte, M; Olalla, I; Pérez-Vázquez, G; Richard, C; Sanroma, P; Yañez, L1
Cesano, A; Evensen, E; Fantl, WJ; Huang, YW; Nolan, GP; Palazzo, AL1
Fournié, JJ; Laurent, G; Liffraud, C; Quillet-Mary, A; Ysebaert, L1
Hollweg, A; Rai, KR1
Bertoni, F; Bruscaggin, A; Cerri, M; Chiaretti, S; Cresta, S; Dalla-Favera, R; Deaglio, S; Deambrogi, C; Del Giudice, I; Fangazio, M; Foà, R; Forconi, F; Gaidano, G; Gargiulo, E; Gattei, V; Guarini, A; Khiabanian, H; Messina, M; Monti, S; Pasqualucci, L; Rabadan, R; Rasi, S; Rossi, D; Spina, V; Vaisitti, T1
Bergier, G; Glass, F; McCardle, T; Moscinski, L; Naghashpour, M; Setoodeh, R; Sokol, L1
Agura, E; Bethge, W; Blume, KG; Bruno, B; Chauncey, TR; Franke, GN; Georges, GE; Hari, P; Hübel, K; Langston, A; Laport, GG; Maloney, DG; Maris, MB; Maziarz, RT; McSweeney, PA; Mielcarek, M; Niederwieser, D; Petersen, FB; Pulsipher, MA; Sahebi, F; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Vindeløv, L; Yeager, A1
Mineishi, S1
Choi, ES; Im, HJ; Jang, S; Kim, BE; Koh, KN; Kwon, SW; Park, CJ; Seo, JJ1
Spaner, DE1
Dietrich, S; Dreger, P; Giese, T; Hahn, E; Hess, M; Ho, AD; Hüllein, J; Krämer, OH; Luft, T; Rieger, M; Schäfer, C; Tretter, T; Zenz, T1
Dai, Y; Dent, P; Grant, S; Hock, S; Rosato, R1
Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H1
Schuh, A1
Keating, MJ; McDonnell, TJ; Medeiros, LJ; Tang, G; Wang, SA; Wierda, WG; Zhou, Y1
Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Komina, O; Robak, P; Smolewski, P; Węsierska-Gądek, J; Żołnierczyk, JD1
Anne, N; Eeva, J; Heli, U; Liisa, V; Tapani, R1
Beaumont, T; Breij, EC; Eldering, E; Elias, JA; Geest, CR; Kater, AP; Luijks, DM; Tromp, JM; van Laar, J; van Oers, MH1
Best, G; Christopherson, RI; Crossett, B; Henrich, S; Mactier, S; Mulligan, SP1
Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A1
Byrd, JC; Woyach, JA1
Best, OG; Che, Y; Christopherson, RI; Forsyth, C; Mulligan, SP; Singh, N1
Ahn, HS; Han, EJ; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Lee, JW; Lee, SH; Park, KD; Shin, HY; Song, SH; Yu, KS; Yuk, YJ1
Anasetti, C; Cooley, S; Curtsinger, J; Defor, T; Devine, S; DiPersio, J; Drobyski, W; Farag, S; Fehniger, TA; Haagenson, M; Miller, J; Porter, D; Waller, EK; Weisdorf, D1
Chatterjee, A; Mahata, SK; Mir, SA; Mitra, A; Pathak, K; Sarkar, S1
Baumgart, J; Beelen, DW; Blau, I; Bornhaeuser, M; Casper, J; Einsele, H; Freund, M; Giebel, S; Holowiecki, J; Kruzel, T; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Ruutu, T; Schaefer-Eckart, K; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Wandt, H; Zander, AR1
Brown, JR2
Catovsky, D; Cocks, K; Crofts, S; Else, M; Richards, SM; Smith, AG; Wade, R1
Baldini, L; Ferrario, A; Gamba, E; Goldaniga, M; Mannina, D; Merli, F; Musto, P; Olivero, B; Pulsoni, A; Rigacci, L; Rossi, F; Rossi, G; Stelitano, C; Tedeschi, A; Vitolo, U1
Colomer, D; Fernández-Calotti, PX; Lopez-Guerra, M; Pastor-Anglada, M1
Anasetti, C; Ayala, E; Fernandez, HF; Field, TL; Kharfan-Dabaja, MA; Kim, J; Perez, LE; Perkins, JB; Pidala, JA; Sullivan, DM; Tomblyn, MR1
Bonacorsi, G; Bulgarelli, J; Castelli, I; Coluccio, V; Deaglio, S; Debbia, G; Fiorcari, S; Fontana, M; Luppi, M; Maffei, R; Marasca, R; Martinelli, S; Narni, F; Torelli, G; Zucchini, P1
Breikša, B; Chapenko, S; Feldmane, L; Garcia-Cabeza, M; Gomez-Roman, J; Jaunmuktane, Z; Lejniece, S; Lejnieks, A; Murovska, M; Ziediņa, I1
Connors, JM; Gerrie, AS; Zypchen, LN1
Borthakur, G; Cortes, J; Eghtedar, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Pierce, S; Ravandi, F1
Dmoszynska, A; Joshi, A; Li, J; Mangat, R; Robak, T; Valente, N; Visich, J; Wenger, M; Zhi, J1
Ichikawa, M; Iwata, A; Koya, J; Kurokawa, M; Nagashima, Y; Nakamura, F; Tsuji, S1
Ding, KY; Geng, LQ; Liu, HL; Sun, ZM; Tang, BI; Tong, J; Wang, XB; Wang, ZY1
Bacigalupo, A; Bazarbachi, A; Geara, F; Kharfan-Dabaja, MA; Mahfouz, RA; Otrock, ZK1
Jacobson, PA; Jensen, K; Johnson, LA; Kachler, S; Kirstein, MN; Klotz, KN; Lamba, J1
Fan, H; Guo, B; Li, SX; Lin, J; Lu, XC; Ran, HH; Yang, Y; Zhai, B; Zhu, HL1
Chen, CH; Kuo, CY; Ma, MC; Pei, SN; Rau, KM; Su, CY; Wang, MC1
Artz, AS; Hart, J; O'Donnell, PH; Pai, RK; van Besien, K1
Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A1
Argnani, L; Cabras, MG; Casadei, B; De Renzo, A; Derenzini, E; Fabbri, A; Gandolfi, L; Gobbi, M; Pellegrini, C; Perotti, A; Pulsoni, A; Rigacci, L; Voso, MT; Zaccaria, A; Zinzani, PL1
Elashoff, D; Giannoni, F; Kahl, CA; Kohn, DB; Lee, CC; Louie, SG; Martinez, M; Sumiyoshi, T; Tarantal, AF; Wherley, J1
Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El Cheikh, J; Esterni, B; Etienne, A; Faucher, C; Fürst, S; Prebet, T; Vey, N1
Bertoni, F; Bruscaggin, A; Chiaretti, S; Cresta, S; Dalla-Favera, R; Daniele, G; Deaglio, S; Deambrogi, C; Del Giudice, I; Fabbri, G; Famà, R; Fangazio, M; Foà, R; Forconi, F; Gaidano, G; Gattei, V; Greco, M; Guarini, A; Marinelli, M; Monti, S; Pasqualucci, L; Rasi, S; Rossi, D; Spina, V; Vaisitti, T1
Bishop, MR; Bryant, K; Dean, RM; Dunleavy, K; Fowler, DH; Fry, TJ; Gress, RE; Hakim, F; Hughes, TE; Odom, J; Pavletic, SZ; Salit, RB; Steinberg, SM; Wilson, WH1
Barrenetxea, C; Boluda, JC; de Heredia, CD; Ferrá, C; González, M; Martín, C; Martinez, AM; Sanz, GF; Sanz, J; Sanz, MA; Serrano, D; Solano, C1
Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R1
Berentsen, S; Tjønnfjord, GE1
Böttcher, S; Bühler, A; Busch, RM; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, MJ; Kneba, M; Mendila, M; Ritgen, M; Stilgenbauer, S; Wendtner, CM; Wenger, MK; Zenz, T1
Chen, DB; Shen, DH1
Faber, E; Hubacek, J; Indrak, K; Jarosova, M; Katrincsakova, B; Kurfurst, P; Pikalova, Z; Raida, L; Rusinakova, Z; Skoumalova, I; Tucek, P; Vondrakova, J1
Bauer, K; Elter, T; Engert, A; Hallek, M; Monsef, I; Roloff, V; Skoetz, N1
Aurran, T; Béné, MC; Casasnovas, O; Cazin, B; Chevret, S; Corront, B; Cymbalista, F; Delépine, R; Delmer, A; Feugier, P; Leblond, V; Lepretre, S; Letestu, R; Mahé, B; Maisonneuve, H; Royer, B; Tournilhac, O; Van Den Neste, E; Vaudaux, S1
Li, QS; Mao, P; Zhuang, XY1
Burger, JA; Chen, G; Croce, CM; Garcia-Prieto, C; Huang, P; Keating, MJ; Liu, J; Lu, W; Pelicano, H; Plunkett, W; Trachootham, D; Zhang, W1
Farrow, S; Lea, S; Metryka, A; Plumb, J; Singh, D; Southworth, T1
Beum, PV; Beurskens, FJ; Engelberts, P; Farooqui, M; Lindorfer, MA; Mackus, WJ; Parren, PW; Taylor, RP; Wiestner, A1
Byrd, JC; Gordon, A; Gribben, JG; Heerema, NA; Larson, RA; Lozanski, A; Lozanski, G; Lucas, DM; Marcucci, G; Morrison, VA; Rai, KM; Ruppert, AS1
Gan, SL; Ma, P; Sun, H; Wang, WM; Xie, XS1
Döhner, H; Gribben, JG; Hallek, M; Keating, MJ; Stilgenbauer, S; Zenz, T1
Barisone, E; Berger, M; Fagioli, F; Galletto, C; Manicone, R; Masetti, R; Pession, A; Quarello, P; Rivetti, E1
Elonen, E; Honkanen, T; Jantunen, E; Jyrkkiö, S; Karjalainen-Lindsberg, ML; Kuittinen, O; Lehto, M; Mikkola, M; Poikonen, E; Räsänen, A; Räty, R; Rauhala, A; Rimpiläinen, J; Siitonen, S; Suominen, M; Vapaatalo, M1
Christiansen, H; Griesinger, F; Lederer, K; Nitsche, M; Pradier, O; Schmidberger, H1
Chae, YS; Choi, JY; Kang, BW; Kim, JG; Kim, YK; Lee, SJ; Lee, YJ; Moon, JH; Seo, JW; Shin, HC; Sohn, SK; Suh, JS1
Asami, K; Kato, S; Koike, T; Morimoto, T; Muroi, K; Oshima, K; Shimizu, T; Takakura, H; Takata, M; Tsukamoto, H; Yabe, H; Yabe, M; Yamashita, T1
Blough, DK; Cheng, MM; Devine, EB; Goulart, B; Veenstra, DL1
Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R1
Ba, Y; Hou, Y; Wang, HQ1
Agrawal, S; Auer, RL; Cavenagh, JD; Davies, JK; Gribben, JG; Lister, TA; MacDougall, F; Oakervee, HE; Syndercombe-Court, D; Taussig, D1
Boyiadzis, M; Foon, KA; Kropf, P; Lentzsch, S; Lenzner, D; Marks, S; Mehta, D; Pietragallo, L; Sulecki, M; Tarhini, A1
Cambot, M; Cosset, FL; Costa, C; Dubart-Kupperschmitt, A; Joubert, C; Le Grand, R; Leboulch, P; Legrand, F; Nègre, D; Prost, S; Relouzat, F; Verhoeyen, E1
Bono, M; Bruno, S; Casciaro, S; Decensi, A; Fais, F; Ghiotto, F; Luzzi, P; Mazzarello, AN; Morabito, F; Recchia, A; Tenca, C1
Adachi, S; Fujita, N; Ishii, E; Kanai, R; Nishi, M; Nishimura, R; Ohga, S; Okamura, T; Sato, E; Sawada, A; Suzuki, N; Yano, J; Yasumi, T; Yasutomo, K1
Amsailale, R; Arts, A; Bontemps, F; Smal, C; Starczewska, E; Van Den Neste, E1
Han, W; Wei, Z; Yanxia, Y; Ying, X; Yuhua, J1
Aisa, Y; Kato, J; Mori, T; Nakamura, Y; Nakazato, T; Okamoto, S; Shigematsu, N1
Baurmann, H; Bethge, WA; Bornhauser, M; Bunjes, D; Dittmann, H; Faul, C; Federmann, B; Kanz, L; Stelljes, M; Trenschel, R; Vogel, W; von Harsdorf, S1
Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B1
Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M1
Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D1
Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM1
Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F1
Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C1
Adams, RH; Anderlini, P; Antin, JH; Arai, S; Carter, SL; Confer, DL; Deeg, HJ; Difronzo, NL; Eapen, M; Ewell, M; Gersten, ID; Horowitz, MM; Horwitz, M; Leifer, ES; McCarty, JM; Nakamura, R; Pulsipher, MA; Tolar, J1
Baldelli, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E1
Fathi, AT; Hasserjian, R; Sadrzadeh, H1
Abbenante, MC; Astolfi, A; Baccarani, M; Candoni, A; Cattina, F; Damiani, D; Fanin, R; Ferrari, A; Formica, S; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Lonetti, A; Malagola, M; Martinelli, G; Michelutti, A; Ottaviani, E; Papayannidis, C; Parisi, S; Russo, D; Sazzini, M; Simeone, E1
Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Döhner, H; Elter, T; Engert, A; Fink, AM; Fischer, K; Gassmann, W; Hallek, M; Hasan, I; James, R; Kahl, C; Ritgen, M; Staib, P; Stauch, M; Stilgenbauer, S; Wendtner, CM; Winkler, D1
Baxter-Lowe, LA; Cowan, MJ; Dvorak, CC; Horn, B; Law, J; Long-Boyle, JR; Musick, L1
Ramos, CA1
Fan, L; Fang, C; Hong, M; Li, JY; Liu, P; Miao, KR; Wang, YH; Xu, W; Zhu, DX; Zhu, W; Zou, ZJ1
Ehlert, K; Fruehwald, MC; Groll, AH; Juergens, H; Rossig, C1
Burnett, AK; Fegan, C; Pearce, L; Pepper, C; Walsby, E1
Almazi, JG; Best, OG; Christopherson, RI; Crossett, B; Mactier, S; Mulligan, SP1
Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M1
Best, OG; Mulligan, SP1
Borowiec, M; Błoński, JZ; Franiak-Pietryga, I; Korycka-Wołowiec, A; Maciejewski, H; Mirowski, M; Robak, T; Sałagacka, A1
Kato, J; Kikuchi, T; Kohashi, S; Mori, T; Okamoto, S; Ono, Y; Shimizu, T; Yamane, A1
Adamson, J; Carter, A; Catovsky, D; Dearden, C; Gonzalez, D; Johnson, GG; Lin, K; Matutes, E; Oates, M; Oscier, DG; Pettitt, AR; Richards, S; Wade, R1
Alvarnas, J; Bhatia, R; Cai, JL; Chang, K; Chao, J; Forman, SJ; Maegawa, R; Nakamura, R; O'Donnell, MR; Palmer, JM; Parker, PM; Pullarkat, V; Senitzer, D; Snyder, DS; Stein, AS; Stiller, T; Thomas, SH; Wang, S1
Arima, N; Niino, D; Ohshima, K; Tsuda, H; Tsuji, T; Yamasaki, H1
Andritsos, L; Blum, KA; Byrd, JC; Flynn, JM; Grever, MR; Gupta, SV; Gurcan, M; Herman, SE; Johnson, AJ; Jones, JA; Kong, H; Lehman, A; Lucas, DM; Mahoney, E; Smith, LL; Wagner, AJ; Yeh, YY; Zhang, X1
Denk, U; Egle, A; Greil, R; Hamacher, F; Hofbauer, JP; Kenner, L; Kocher, T; Melchardt, T; Merkel, O; Scheideler, M; Schlederer, M; Sifft, E; Steurer, M; Wacht, N1
Ave, E; Brunati, AM; Cabrelle, A; Carraro, S; Facco, M; Frezzato, F; Gattazzo, C; Martini, V; Semenzato, G; Teramo, A; Tibaldi, E; Trentin, L; Trimarco, V; Zambello, R1
Mitra, S; Pyatt, N1
Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Kantarjian, HM; Pierce, S; Shan, J; Storer, B1
Ariga, T; Hershfield, MS; Imai, K; Kanegane, H; Miyawaki, T; Nomura, K; Santisteban, I; Taneichi, H; Wada, T; Yachie, A1
Bosanquet, AG; Catovsky, D; Else, M; Matutes, E; Richards, SM; Wade, R1
Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A1
Canaani, J; Dezorella, N; Eshel, R; Gepstein, L; Herishanu, Y; Naparstek, E; Perry, C; Polliack, A; Rothman, R; Sarid, N; Shpringer, M; Solar, I1
Bonfim, C; Deeg, HJ; Flowers, ME; Gooley, T; Kiem, HP; O'Donnell, P; Pasquini, R; Ribeiro, L; Sandmaier, BM; Storb, R; Thakar, MS; Woolfrey, AE1
Almazi, JG; Christopherson, RI; Crossett, B; Kohnke, PL; Mactier, S1
Bahlis, N; Brown, C; Chaudhry, A; Daly, A; Duggan, P; Geddes, M; Russell, J; Savoie, ML; Shafey, M; Stewart, D; Storek, J; Turner, AR1
Ambinder, R; Aoki, J; Bolaños-Meade, J; Borowitz, M; Fuchs, E; Jones, R; Kasamon, Y; Luznik, L; Swinnen, L; Symons, H; Zeidan, A1
André, M; Bouabdallah, R; Coiffier, B; Di Raimondo, F; Doorduijn, JK; Dreyling, MH; Feugier, P; Forstpointner, R; Geisler, CH; Hallek, M; Hermine, O; Hiddemann, W; Hoster, E; Kanz, L; Klapper, W; Kluin-Nelemans, HC; Kremers, S; Lepeu, G; Lugtenburg, PJ; Macro, M; Pfreundschuh, M; Procházka, V; Ribrag, V; Sanhes, L; Stilgenbauer, S; Szymczyk, M; Thieblemont, C; Tilly, H; Trneny, M; Unterhalt, M; Uppenkamp, M; Vehling-Kaiser, U; Walewski, J; Zijlstra, JM1
Peterson, A; Shah, BK; Uprety, D1
Bo, L; Chen, F; Fang, Y; Fu, J; Li, Y; Liang, A; Lu, H; Zhang, H; Zhu, D1
Arima, H; Imai, Y; Inoue, D; Kiuchi, M; Maruoka, H; Matsushita, A; Mori, M; Nagano, S; Oita, T; Tabata, S; Takahashi, T; Takiuchi, Y; Yamashiro, A1
Aldred, VL; Bellesso, M; Chamone, DA; Costa, RO; Hallack Neto, AE; Pereira, J; Ruiz, MA1
Rossi, D1
Appelbaum, FR; Belch, A; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Solh, M; Tallman, MS1
Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M1
Bosanquet, AG; Lin, K; Melarangi, T; Oates, M; Pettitt, AR; Rockliffe, N; Slupsky, JR; Zhuang, J1
Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D1
Chevrier, S; Houot, R; Lamy, T; Marchand, T; Poullot, E; Revest, M; Tattevin, P1
Fan, L; Fang, C; Li, JY; Liu, L; Xu, W; Yang, S; Zhang, LN; Zou, ZJ1
Bruyere, H; Chan, MJ; Dalal, CB; Gerrie, AS; Gillan, TL; Huang, SJ; Ramadan, KM; Toze, CL1
Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R1
Ahmed, O; Davies, M; Kottaridis, PD; Narvekar, N; Papageorgiou, SG1
Cacoub, P; Choquet, S; Decaux, O; Hermine, O; Jego, P; Karras, A; Pineton de Chambrun, M; Saadoun, D1
Aker, M; Dray, L; Grisariu, S; Kedmi, M; Or, R; Resnick, IB; Shapira, MY; Stepensky, P1
Ellwanger, S; Gibney, G; Janssen, W; Kudchadkar, R; Kuhn, L; Marzban, S; Mulé, JJ; Pilon-Thomas, S; Royster, E; Sarnaik, AA; Sondak, VK; Weber, J; Zager, J1
Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M1
Bozsó, T; Iványi, JL; Plander, M; Skrapits, J; Szendrei, T1
Fan, L; Li, JY; Liu, L; Wang, DM; Xu, W; Yang, S; Zhang, LN; Zou, ZJ1
Dallas, MH; Hartford, C; Laver, J; Leung, W; Pillai, A; Shook, DR; Srinivasan, A; Triplett, BM1
Andrieux, J; Baranger, L; Barin, C; Bilhou-Nabera, C; Blons, H; Callet-Bauchu, E; Chapiro, E; Chevret, S; Chiesa, J; Daudignon, A; Eclache, V; Gachard, N; Grelier, A; Henry, C; Lambert, J; Leblondon, V; Lejeune, J; Luquet, I; Merle-Beral, H; Mossafa, H; Mould, S; Mozziconacci, MJ; Mugneret, F; Nguyen-Khac, F; Owen, R; Penther, D; Struski, S; Terre, C; Veronese, L1
Borel, C; Bouvet, E; Cazin, B; Compaci, G; Laurent, G; Michallet, AS; Obéric, L; Ysebaert, L1
Cheong, JW; Hong, DS; Joo, YD; Kim, BK; Kim, CS; Kim, DY; Kim, H; Kim, I; Kim, MK; Kim, SH; Koh, Y; Lee, HK; Lee, JH; Lee, KH; Lee, SM; Min, YH; Park, E; Park, MR; Park, S; Park, SK; Sohn, SK; Won, JH; Yoon, SS1
Alchalby, H; Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Fehse, B; Hansen, T; Heinzelmann, M; Klyuchnikov, E; Kröger, N; Schilling, G; Schwarz, S; Stübig, T; Wolschke, C; Zabelina, T; Zander, AR; Zeschke, S1
Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B1
Ahmad, A; Becker, MW; Coppage, M; Iqbal, A1
Helton, KJ; Patay, Z; Triplett, BM1
Catovsky, D; Collins, A; Cross, NC; Else, M; Forster, J; Gardiner, A; Gomez, B; Gonzalez de Castro, D; Oscier, DG; Parker, A; Parker, H; Rose-Zerilli, MJ; Strefford, JC; Winkelmann, N1
Bay, JO; Blaise, D; Bordigoni, P; El-Cheikh, J; Labussière-Wallet, H; Michallet, M; Milpied, N; Mohty, M; Morisset, S; Sobh, M; Socié, G; Tabrizi, R1
Ahmed, G; Davis, Z; Dyer, M; Gonzalez, D; Matutes, E; Moss, P; Oldreive, C; Oscier, D; Parker, A; Richards, S; Skowronska, A; Stankovic, T; Taylor, AM; Thomas, P1
Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Esterni, B; Fürst, S; Granata, A; Oudin, C; Vey, N1
Bhadelia, N; Freedberg, DE; Oster, MW; Poneros, JM1
DeCook, LJ; Hogan, WJ; Holtan, SG; Huneke, T; Johnson, ND; Litzow, MR; Patnaik, MM; Porrata, LF; Thoma, M; Wiegand, RA1
Duszeńko, E; Haus, O; Kałwak, K; Musiał, J; Ussowicz, M1
Autore, F; Chiusolo, P; Innocenti, I; Laurenti, L; Leone, G; Sica, S; Sorà, F; Vannata, B1
Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Kim, SD; Lee, GW; Lee, JH; Lee, KH; Lee, WS; Min, YJ; Park, JH; Ryoo, HM1
Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C1
Forman, SJ; Htut, M; Karanes, C; Krishnan, AY; Murata-Collins, J; Palmer, J; Rincon, A; Sahebi, F; Shen, Y; Somlo, G; Thomas, SH1
Bauer, K; Elter, T; Engert, A; Hallek, M; Rancea, M; Roloff, V; Skoetz, N1
Galaup, A; Paci, A1
Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK1
Bai, LY; Byrd, JC; Chan, KK; Cheney, C; Herman, SE; Jarjoura, D; Jin, Y; Lee, LJ; Lee, RJ; Mao, Y; Marcucci, G; Mo, X; Muthusamy, N; Ramanunni, A; Wang, X; Yu, B1
Bolognia, JL; Cooper, DL; Parker, TL; Seropian, SE1
Brannagan, TH; Leitch, MM; Sherman, WH2
Bellemare, J; Bilban, M; Fleiss, K; Gaiger, A; Gleiss, A; Gruber, M; Guillemette, C; Hoermann, G; Jaeger, U; Le, T; Lévesque, É; Mannhalter, C; Porpaczy, E; Shehata, M; Skrabs, C; Vanura, K; Zehetmayer, S1
Giannakakis, C; Guido, G; Mosillo, G; Rocca, AR; Salviani, C; Serriello, I1
Alhede, M; Bjarnsholt, T; Braendstrup, P; Clasen-Linde, E; Eickhardt, S; Høiby, N; Jensen, KE; Moser, C; Vindeløv, L1
McCormack, C; McCurdy, O; Prince, HM; Ritchie, D1
Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M1
Argnani, L; Baccarani, M; Broccoli, A; Casadei, B; Celli, M; Derenzini, E; Fanti, S; Gandolfi, L; Pellegrini, C; Pileri, S; Poletti, V; Quirini, F; Stefoni, V; Zinzani, PL1
Anderlini, P; Bassett, R; Champlin, R; de Lima, M; Ganesan, P; Giralt, S; Kebriaei, P; Khouri, I; Parmar, S; Rondon, G; Thall, P1
Baker, D; Betz, A; Burke, R; Coffey, G; DeGuzman, F; Druker, BJ; Fletcher, LB; Hollenbach, SJ; Loriaux, MM; Pak, Y; Pandey, A; Sinha, U; Spurgeon, SE; Tyner, JW1
Aljurf, M; Maury, S1
Apollonio, B; Caligaris-Cappio, F; Fazi, C; Fonte, E; Ghia, P; Muzio, M; Ranghetti, P; Scarfò, L1
Blaise, D; Castagna, L1
Blaise, D; Siddiqi, T1
Appelbaum, FR; Belch, AR; Byrd, JC; Geyer, S; Kolitz, J; Larson, RA; Lin, TS; Morrison, VA; Rai, K; Ruppert, AS; Tallman, MS; Woyach, JA1
Chevret, S; Choquet, S; Copplestone, A; Dartigeas, C; Dilhuydy, MS; Ewings, M; Johnson, S; Leblond, V; Lejeune, J; Malphettes, M; Morel, P; Nguyen-Khac, F; Owen, RG; Patmore, RD; Pratt, G; Royer, B; Rule, S; Seymour, JF; Tournilhac, O; Willoughby, S; Wright, D1
Diker-Cohen, T; Lahav, M; Natur, A; Shapira, H; Szyper-Kravitz, M; Uziel, O1
Ichikawa, M; Kurokawa, M; Nakagawa, M; Nakamura, F; Nannya, Y; Yamazaki, S1
du Toit, C; Novitzky, N; Thomas, V1
Chen, LY; Collins, D; Coupland, R; Fung, AT; Gerrie, AS; Maberley, D; Moloney, G; Rossman, D; White, V; Wong, PC1
Fan, ZP; Huang, F; Jiang, QL; Liu, H; Liu, QF; Sun, J; Wu, MQ; Yu, GP; Zhang, X; Zhou, HS1
Ayari, S; Blin, N; Chevallier, P; Clavert, A; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lestang, E; Mahe, B; Mohty, M; Moreau, P; Planche, L; Roland, V; Tessoulin, B1
Barba, P; Carreras, E; Fernández-Avilés, F; Garcia-Cadenas, I; López Corral, L; López-Anglada, L; Martino, R; Novelli, S; Pérez-Simón, JA; Piñana, JL; Rovira, M; Sierra, J; Valcárcel, D1
Cook, G; Craddock, CF; Fielding, AK; Kirkland, KE; Littlewood, TJ; Marks, DI; Medd, PG; Milligan, DW; Pearce, R; Peniket, AJ; Perry, J; Potter, MN; Shaw, BE1
Balleisen, L; Eimermacher, H; Freier, W; Heit, W; Hinke, A; Ibach, S; Knauf, W; Megdenberg, D; Niederle, N; Weiß, J1
Castillo, JJ; Olszewski, AJ1
Boelens, JJ; Raphael, MF; Rottier, BL1
Ajana, F; Ettahar, N; Legout, L; Massongo, M; Patoz, P; Rose, C; Senneville, E1
Bertz, H; Christopoulos, P; Finke, J; Marks, R; Schmoor, C; Wäsch, R; Waterhouse, M1
Fan, Z; Guo, X; Huang, F; Li, Y; Liu, H; Liu, Q; Nie, D; Song, Z; Sun, J; Tu, S; Xiao, Y; Yu, G; Zhai, X; Zhang, Y; Zhou, H1
Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Geyer, MB; Harrison, L; Jin, Z; Morris, E; Radhakrishnan, K1
Azoulay, E; Darmon, M; Epelboin, L; Levy, V; Malphettes, M; Schnell, D; Vincent, F; Xhaard, A1
Abdel-Rahman, F; Abu-Jazar, H; Al-Zaben, A; Frangoul, H; Ghatasheh, L; Hammada, T; Hussein, AA; Najjar, R; Natsheh, A; Sharma, S1
Chiba, S; Fukuda, T; Kako, S; Kanda, Y; Kondo, Y; Kurokawa, M; Miyamoto, T; Miyamura, K; Nagafuji, K; Nakao, S; Ohashi, Y; Okoshi, Y; Oshima, K; Takaue, Y; Taniguchi, S; Uchida, N1
Schmutz, JL; Trechot, P1
Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM1
Alloush, H; Anderson, E; Conway, M; Lamont, J; Martin, A; Mehta, P; Ruddock, M; Salisbury, V; Smith, JG; Smith, MA1
Bogusz, J; Cebula-Obrzut, B; Majchrzak, A; Mędra, A; Robak, T; Smolewski, P1
Baldini, L; Barate', C; Benevolo, G; Frustaci, AM; Gini, G; Goldaniga, MC; Luraschi, A; Morra, E; Motta, M; Nichelatti, M; Pioltelli, P; Ricci, F; Tedeschi, A; Varettoni, M; Vismara, E; Vitolo, U1
Fahrmann, JF; Hardman, WE1
Brychtová, Y; Doubek, M; Lindtnerová, M; Lysák, D; Malčíková, J; Mayer, J; Motyčková, M; Panovská, A; Pospíšilová, Š; Šimkovič, M; Smolej, L; Trbušek, M; Vodárek, P1
Albrecht, M; Bökkerink, J; Claviez, A; Dörffel, W; Holte, H; Karlen, J; Lüders, H; Mann, G; Marciniak, H; Niggli, F; Pötter, R; Rühl, U; Schellong, G; Schmiegelow, K; Schwarze, EW; Wickmann, L1
Busch, R; Cramer, P; Döhner, H; Eichhorst, B; Fingerle-Rowson, G; Fink, AM; Hallek, M; Herling, M; Hopfinger, G; Kandler, G; Pflug, N; Reinart, N; Stilgenbauer, S; Weit, N; Westermann, A; Winkler, D1
Fan, L; Fang, C; Li, JY; Liu, L; Xu, W; Zhang, LN; Zhu, HJ; Zou, ZJ1
Bene, MC; Blin, N; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lode, L; Loirat, M; Mahe, B; Malard, F; Mohr, C; Mohty, M; Moreau, P; Peterlin, P; Planche, L1
Angrilli, F; Arcaini, L; Brugiatelli, M; Carella, AM; Dell'olio, M; Di Raimondo, F; Dondi, A; Federico, M; Franco, V; Gaidano, G; Galimberti, S; Luminari, S; Marcheselli, L; Merli, F; Pulsoni, A; Rigacci, L; Sacchi, S; Stelitano, C; Tucci, A; Vitolo, U1
Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D1
Qin, Q; Xie, Z; Zhu, Y1
Cho, B; Chung, NG; Jang, PS; Jeong, DC; Kim, HK; Lee, JW1
Alyea, EP; Antin, JH; Armand, P; Attar, EC; Ballen, KK; Chen, YB; Coughlin, E; Cutler, C; Dey, BR; Ho, VT; Kennedy, KF; Koreth, J; McAfee, SL; Soiffer, RJ; Spitzer, TR1
Cherne, MK; Jorstad, NL; Keene, CD; Khademi, SB; Montine, KS; Montine, TJ; Shiao, C; Yang, Y1
Dubielecka, PM; Grzybek, M; Korycka, J; Meissner, J; Michalczyk, I; Seweryn, E; Sikorski, AF; Toporkiewicz, M1
Ghavamzadeh, A; Hamdi, A; Hamidieh, AA; Nabavi, M; Pourpak, Z1
Frangoul, H; Hussein, AA1
Bertoni, F; Cavalli, F; Lobetti-Bodoni, C; Stussi, G; Zucca, E1
Banov, L; Calvillo, M; Dufour, C; Fioredda, F; Fischer, A; Gallicola, F; Miano, M; Micalizzi, C; Molinari, AC; Montobbio, G; Parasole, R; Petruzziello, F; Poggi, V; Svahn, J1
Baba, T; Hamanishi, J; Kang, HS; Kharma, B; Konishi, I; Mandai, M; Matsumura, N; Murphy, SK; Yamaguchi, K; Yamanoi, K; Yoshioka, Y1
Bahlo, J; Böttcher, S; Busch, R; Cramer, P; Döhner, H; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Goede, V; Hallek, M; Kneba, M; Langerbeins, P; Mayer, J; Pflug, N; Schubert, F; Stilgenbauer, S; Wendtner, CM1
Boyer, J; Frey, NV; Goldstein, SC; Hexner, EO; June, CH; Kumar, AJ; Levine, BL; Loren, AW; Luger, SM; Porter, DL; Reshef, R; Smith, J; Stadtmauer, EA1
Jiang, H; Liu, L; Ma, Y; Pan, H; Pan, S; Sun, X; Wang, D; Wang, J; Wu, Y; Xu, D; Xu, Z; Zhao, B1
Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Issaragrisil, S; Jetsrisuparb, A; Pakakasama, S; Rujkijyanont, P; Sirachainan, N; Sirireung, S; Songdej, D; Srisala, S; Sruamsiri, R; Ungkanont, A1
Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U1
Broward, MA; Godwin, AK; Pessetto, ZY; Sethi, G; Weir, SJ1
Adams, RH; Betcher, JA; Dueck, AC; Fauble, VD; Khera, N; Klein, JL; Leis, JF; Noel, P; Reeder, CB; Slack, JL; Sproat, LO1
Haeusler, GM; Lingaratnam, S; Seymour, JF; Slavin, MA; Tam, CS; Teh, BW; Thursky, KA; Worth, LJ1
Hashiguchi, M; Imamura, R; Kawaguchi, K; Koteda, S; Makimura, K; Mouri, F; Nagafuji, K; Nakamura, T; Nomura, K; Okamura, T; Oku, E; Osaki, K; Seki, R1
Almasan, A; Hill, BT; Kalaycio, M; Mazumder, S; Sharma, A; Singh, K1
Aquino, S; Avenoso, D; Ballerini, F; Bergamaschi, M; Clavio, M; Colombo, N; Cruciani, F; De Astis, E; Ghiggi, C; Gobbi, M; Grasso, R; Guolo, F; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G1
Li, F; Li, ZJ; Qi, JY; Qiu, LG; Xing, LJ; Xu, Y; Yi, SH; Yu, Z; Zhao, YZ1
De Revel, T; Doghmi, K; Jennane, S; Konopacki, J; Mahtat, el M; Malfuson, JV; Mikdame, M1
Behfar, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hashemi, S; Moin, M; Pourpak, Z; Yari, K1
Beum, PV; Lee, E; Lindorfer, MA; Marti, G; Mo, CC; Njuguna, N; Taylor, RP; Vire, B; Wiestner, A; Wilson, WH1
Brychtova, Y; Doubek, M; Dusek, J; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Racil, Z; Tomiska, M1
Evangelista, M; Lucotti, S; Rainaldi, G; Rizzo, M1
Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Kotkowska, A; Robak, T; Rogalińska, M; Smolewski, P; Wawrzyniak, E; Żołnierczyk, JD1
Berquist, L; Bonavida, B; Chu, P; Clanton, D; Hariharan, K; Ho, SN; Molina, A; Murphy, T; Vega, MI1
Bethge, WA; Bouvier, ME; Bruno, B; Chauncey, TR; Fukuda, T; Hari, P; Hübel, K; Kornblit, B; Maloney, DG; Maziarz, RT; Petersen, FB; Pulsipher, MA; Sandmaier, BM; Storb, R; Storek, J; Storer, BE; Vucinic, V1
Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D1
Azik, F; Emir, S; Erdem, AY; Isik, P; Metin, A; Tavil, B; Tunc, B; Uckan, D1
Daly, A; Kangarloo, SB; Ng, ES1
Choquet, S; Leblond, V; Nguyen, S; Souchet-Compain, L1
Abe, M; Fukuda, S; Kanai, R; Katsube, Y; Mishima, S; Ogushi, H; Tadokoro, M; Taketani, T; Yamaguchi, S; Yuba, S1
Kalaycio, M; Lukenbill, J1
Böttcher, S; Bühler, A; Busch, R; Döhner, H; Eichhorst, B; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hopfinger, G; Kneba, M; Mayer, J; Pflug, N; Ritgen, M; Staib, P; Stilgenbauer, S; Wendtner, CM; Wenger, M; Winkler, D; Zenz, T1
Jaskova, Z; Navrkalova, V; Sebejova, L; Trbusek, M; Zemanova, J1
Faderl, S; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Strati, P; Wierda, W1
Badoux, X; Jones, JA; Kantarjian, H; Keating, MJ; Kipps, TJ; O'Brien, S; Plunkett, W; Tsimberidou, AM; Wen, S; Wierda, WG1
Barrett, J; Childs, RW; Cook, L; Donohue, T; Geller, N; Khuu, H; Kurlander, R; Leitman, S; Pantin, J; Ramos, C; Shah, AA; Stroncek, D; Tian, X; Young, NS1
Bühler, A; Busch, R; Cazzola, M; Döhner, H; Döhner, K; Edelmann, J; Hallek, M; Kless, S; Mack, S; Mertens, D; Paschka, P; Rossi, M; Schnaiter, A; Stilgenbauer, S; Winkler, D; Zenz, T1
Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Lemarie, C; Oudin, C; Saillard, C; Signori, A1
Chen, K; Darcy, PK; Dickinson, M; Gambell, P; Haurat, J; Hönemann, D; Kershaw, MH; Khot, A; Kravets, L; Neeson, PJ; Peinert, S; Prince, HM; Ritchie, DS; Scott, AM; Shin, M; Smyth, MJ; Tai, T; Tainton, K; Trapani, JA; Wall, DM; Westerman, DA; Westwood, JA1
Barré, L; Delamare, J; Deloye, JB; Gourand, F; Guillouet, S; Leporrier, M; Patin, D; Tirel, O1
Atsuta, Y; Goto, H; Inagaki, J; Inoue, M; Ishii, E; Kato, K; Kawa, K; Koike, K; Ohga, S; Okada, K; Sawada, A; Suzuki, N; Suzuki, R; Yabe, H; Yasutomo, K1
Argnani, L; Broccoli, A; Casadei, B; Pellegrini, C; Pileri, S; Zinzani, PL1
Cartron, G; Davies, A; Lei, G; Marcus, R; Morschhauser, F; Radford, J; Salles, G; Vitolo, U; Wassner-Fritsch, E; Wenger, M1
Abbas, A; Barré, L; Dhilly, M; Dumontet, C; Fillesoye, F; Galateau, F; Gourand, F; Guillouet, S; Leporrier, M; MacKenzie, ET; Patin, D; Tirel, O1
Bahlis, NJ; Brown, CB; Chaudhry, MA; Daly, A; Duggan, P; Geddes, M; Kangarloo, SB; Larratt, L; Russell, JA; Savoie, ML; Shafey, M; Stewart, DA; Storek, J; Turner, AR; Williamson, T; Yang, M; Yue, P; Zacarias, N1
Bashir, Q; Champlin, R; Ciurea, S; De Lima, M; Dinh, YT; Giralt, S; Hosing, CM; Jones, R; Kebriaei, P; Khan, H; Liu, P; Nieto, Y; Oran, B; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Rondon, G; Shah, JJ; Shah, N; Shpall, E; Thall, PF1
Bartalucci, G; Bocchia, M; Bosi, A; Cencini, E; Dottori, R; Fabbri, A; Gozzetti, A; Puccini, B; Rigacci, L1
Mapara, MY1
Burke, RT; Druker, BJ; Loriaux, MM; Prins, RC; Spurgeon, SE; Tyner, JW1
Aloyz, R; Assouline, SE; Autexier, C; Chu, TW; Gryaznov, SM; Johnston, JB; Lees-Miller, SP; Martinez-Marignac, V; Shawi, M; Yu, Y1
Burger, J; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Strati, P; Tam, C; Wierda, W1
Goi, K; Hara, T; Kamachi, Y; Kojima, S; Kumaki, S; Morio, T; Muramatsu, H; Sasahara, Y; Sugita, K; Takada, H; Tsuchiya, S; Urabe, T1
Colturato, VA; de Castro, FA; Lanchote, VL; Simões, BP; Voltarelli, JC1
Alvarez De Celis, I; Baldini, L; Bari, A; Boccomini, C; Botto, B; Castellino, C; Chiappella, A; Chiarenza, A; Ciccone, G; De Angelis, F; De Renzo, A; Evangelista, A; Gamba, E; Ladetto, M; Lobetti-Bodoni, C; Parvis, G; Pinto, A; Rossi, G; Tucci, A; Vitolo, U; Zaja, F1
Abel, G; Barthelmes, J; Dueregger, A; Guggenberger, F; Haunschild, J; Intelmann, D; Klocker, H; Ramoner, R; Sampson, N; Schuh, M; Stecher, G1
Agrwal, N; Blair, JE; Carey, EJ; De Petris, G; Kusne, S; Ronan, BA; Seville, MT; Vikram, HR1
Anasetti, C; Ayala, E; Betts, B; Fernandez, H; Field, T; Kharfan-Dabaja, MA; Kunter, G; Locke, F; Nieder, M; Nishihori, T; Ochoa-Bayona, JL; Perez, L; Perkins, JB; Pidala, J; Tomblyn, M1
Byrtek, M; Cerhan, JR; Dawson, K; Flowers, CR; Friedberg, JW; Link, BK; Martin, P; Ziemiecki, R1
Aweeka, F; Huang, L; Lizak, P; Long-Boyle, J1
Arion, C; Coliţă, A; Coliţă, AD; Tanase, A; Varady, Z1
Arakawa, T; Hino, M; Koh, H; Nakamae, H; Nakane, T; Nishimoto, M; Ohsawa, M; Watanabe, K1
Chen, BA; Ding, BH; Ding, JH; Li, YF; Qian, J; Yu, ZP1
Catovsky, D; Dearden, CE; Else, M; Hillmen, P; Richards, S1
Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X1
Eto, T; Fukuda, T; Ikegame, K; Imai, K; Kako, S; Kanamori, H; Kato, H; Minagawa, K; Mizuta, S; Morishima, Y; Nagamura-Inoue, T; Nakamae, H; Nishiwaki, S; Sakamaki, H; Shigematsu, A; Suzuki, R; Tanaka, J; Tanaka, M; Yujiri, T1
Berkahn, L; Bryant, A; Cannell, P; Doocey, R; Fay, K; George, B; Hertzberg, M; Kalff, A; Kennedy, G; Moore, J; Nivison-Smith, I; Patil, S; Pillai, ES; Ritchie, D; Spearing, R; Spencer, A1
Gibson, SB; Graham, BA; Ishdorj, G; Johnston, JB; Yoon, JY1
Bouvet, E; Cazin, B; Coiffier, B; Laurent, G; Michallet, AS; Mosser, L; Oberic, L; Salles, G; Schlaifer, D; Ysebaert, L1
Blaise, D; Bouabdallah, R; Calmels, B; Castagna, L; Chabannon, C; Coso, D; Crocchiolo, R; D'Incan, E; Devillier, R; El-Cheikh, J; Etienne, A; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Picard, C; Schiano, JM; Stoppa, AM; Vey, N1
Bajwa, RP; Rose, MJ; Woods, G1
Abella, E; Abrisqueta, P; Bobillo, S; Bosch, F; Calvo, X; Carbonell, F; Constants, M; Delgado, J; Escoda, L; Ferrà, C; Ferrer, S; García-Marco, JA; González, M; González, Y; González-Barca, E; Jarque, I; Montoro, JB; Montserrat, E; Monzó, E; Muntañola, A; Terol, MJ; Villamor, N1
Carr, DF; Catovsky, D; Cox, TF; Eccles, R; Else, M; Gardiner, LJ; Gonzalez de Castro, D; Johnson, GG; Lin, K; Lloyd, B; Oates, M; Oscier, DG; Pettitt, AR; Pirmohamed, M; Sibson, DR; Strefford, JC1
Caimi, P; Habecker, B; Hill, BT; Kalaycio, M; Kindwall-Keller, T1
Andersson, BS; Champlin, RE; Corn, P; Dominguez, JR; Li, Y; Song, G; Valdez, BC1
Beelen, D; Berdel, WE; Braess, J; Büchner, T; Fiegl, M; Grüneisen, A; Heinecke, A; Hentrich, M; Hiddemann, W; Kern, W; Reichle, A; Rieger, C; Sauerland, C; Schiel, X; Schöndube, D; Serve, H; Spiekermann, K; Staib, P; Unterhalt, M; Wörmann, B1
Ahmad, I; Albert, MH; Belohradsky, BH; Bredius, R; Fasth, A; Fernandes, JF; Fischer, A; Gaspar, HB; Gennery, A; Gruhn, B; Güngör, T; Haddad, E; Hassan, M; Hough, R; Kentouche, K; Lachance, S; Moshous, D; Rentsch, K; Resnick, IB; Schanz, U; Schlegel, PG; Seger, R; Shaw, PJ; Slatter, M; Stepensky, P; Stussi, G; Teira, P; Telles da Cunha, JM; Vermont, C; Veys, P1
Abrams, S; Chen, GL; Hahn, T; Liu, H; McCarthy, PL; Ross, M; Zhang, Y1
Jindra, P; Lysák, D1
Wang, YF; Wang, ZX; Wu, XX; Xu, XX; Yan, B; Yang, HL; Yu, Y; Zhang, YZ; Zhao, DD1
Bluyssen, HA; Czerwoniec, A; Sikorski, K; Szatkowska, K; Szelag, M; Wesoly, J1
Bojarska-Junak, A; Chocholska, S; Dmoszyńska, A; Hus, I; Roliński, J; Tomczak, W; Woś, J1
Eketorp Sylvan, S; Hansson, L; Karlsson, C; Lundin, J; Norin, S; Osterborg, A1
Beckers, MM; Daenen, S; Doorduijn, JK; Doreen Te Raa, G; Eldering, E; Kater, AP; Lankheet, NA; Liu, RD; Luijks, DM; Slinger, E; Spiering, M; Tonino, SH; van Oers, MH1
Huang, XJ; Ji, Y; Liu, DH; Liu, KY; Sun, YQ; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH; Zhang, YY1
Bayhan, T; Ceylaner, S; Demir, HA; Emir, S; Karakuş, E; Kurtulan, O; Özyörük, D; Üner, A1
Amital, H; Davidson, T; Kneller, A; Schiby, G; Twig, G; Yaniv, G; Zavdy, O1
Barth, MJ; Czuczman, MS1
Medeiros, BC2
Aldoss, I; Haider, M; Ji, L; Pullarkat, V1
Autore, F; D'arena, G; De Padua, L; Efremov, DG; Falcucci, P; Innocenti, I; Laurenti, L; Marietti, S; Piccirillo, N; Sica, S; Vannata, B; Za, T1
Albano, F; Angrilli, F; Brugiatelli, M; Carella, AM; Chiarenza, A; Chiaretti, S; Cortelezzi, A; Cuneo, A; De Propris, MS; Del Giudice, I; Della Starza, I; Fazi, P; Foà, R; Gentile, G; Guarini, A; Laurenti, L; Marasca, R; Marinelli, M; Mauro, FR; Molica, S; Musolino, C; Nanni, M; Nobile, F; Piciocchi, A; Vignetti, M; Zaja, F1
Bartelink, IH; Bierings, MB; Boelens, JJ; de Wildt, A; Gerhardt, CE; Lindemans, CA; van Maarseveen, EM; van Reij, EM; Versluys, B1
Barker, JN; Castro-Malaspina, H; Ceberio, I; Devlin, SM; Giralt, S; Goldberg, JD; Jakubowski, AA; Koehne, G; Lechner, L; Moskowitz, CH; Papadopoulos, EB; Perales, MA; Sauter, CS; Zelenetz, AD; Zheng, J1
Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Crocchiolo, R; Devillier, R; El-Cheikh, J; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Mohty, B; Oudin, C; Rey, J; Stoppa, AM; Vey, N1
Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP1
Ahn, KW; Aljurf, MD; Alyea, EP; Arora, M; Brown, JR; Cortes, J; de Lima, M; Gale, RP; Holland, HK; Hsu, JW; Inamoto, Y; Kalaycio, ME; Kamble, RT; Laughlin, MJ; Lewis, ID; Maziarz, RT; Saber, W; Sabloff, M; Seftel, M; Sobecks, RM; Wirk, BM; Zhu, X1
Behfar, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hashemi, S; Moin, M; Movahedi, M; Pourpak, Z; Yari, K1
Cao, F; Feng, B; Gangeswaran, R; Gao, D; Lemoine, NR; Spurrell, E; Tollefson, A; Wang, P; Wang, Y; Wold, W1
Geisler, CH1
Craig, M; Cumpston, A; Evans, K; Goff, L; Hamadani, M; Kanate, AS; Leadmon, S; Rauenzahn, S; Truong, Q; Wen, S; Zhang, J1
Blackford, AL; Carraway, HE; Gojo, I; Gore, SD; Greer, JM; Ivy, SP; Karp, JE; Levis, MJ; McDevitt, MA; Pratz, KW; Smith, BD; Zeidner, JF1
Streu, E2
Agarwal, R; Ball, JB; Hutchinson, SK; Kharbanda, S; Lamb, LS; McKenna, DH; Smith, AR; Wagner, JE; Weinberg, KI1
Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N1
Bo, J; Cai, B; Gao, C; Han, X; Huang, W; Jing, Y; Li, H; Luo, L; Wang, Q; Yu, L; Zhang, L; Zhao, Y; Zhu, H1
Dijkstra, FS; Janssen, JJ; Ossenkoppele, GJ; Visser, OJ; Witte, BI; Wondergem, MJ; Zweegman, S1
Ball, LM; Bredius, RG; Hissink Muller, P; Jol-van der Zijde, EC; Lankester, AC; Vermont, CL; Vossen, AC1
Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B1
Ambrosetti, A; Attolico, I; Barzan, A; Benedetti, F; Bergui, L; Billio, A; Carlo-Stella, C; Chiarenza, A; Devizzi, L; Di Nicola, M; Di Raimondo, F; Gianni, AM; Gueli, A; Guidetti, A; Intermesoli, T; Magni, M; Matteucci, P; Montanari, M; Mulè, A; Olivieri, A; Parvis, G; Patti, C; Rambaldi, A; Scimè, R; Tarella, C; Trentin, L; Valagussa, P; Viero, P; Viviani, S1
Bertaina, A; Brescia, L; Comoli, P; Corbella, F; Giorgiani, G; Locatelli, F; Pagliara, D; Perotti, C; Strocchio, L; Zecca, M1
Chennupati, S; Golla, M; Nalla, S; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S1
Booker, R; Brown, C; Chaudhry, MA; Cox-Kennett, N; Daly, A; Duggan, P; Griffiths, CD; Kangarloo, SB; Ng, ES; Russell, JA; Savoie, L; Storek, J; Williamson, TS; Yue, P1
Advani, P; Akhtar, D; Chanan-Khan, A; Chitta, K; Colon-Otero, G; Foran, J; Khan, AN; Masood, A; Miller, KC; Paulus, A; Rivera, C; Roy, V1
Hafner, J; Kumar, K; Mulligan, S; Ng, K1
Citrin, DE; Rosenberg, SA; Tseng, J; Waldman, M; White, DE; Yang, JC1
Akahoshi, Y; Ashizawa, M; Ishihara, Y; Kako, S; Kanda, J; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, S; Nakano, H; Nakasone, H; Nishida, J; Sakamoto, K; Sato, M; Tanihara, A; Terasako, K; Ugai, T; Wada, H; Yamasaki, R; Yamazaki, R1
Abbas, AY; Bradshaw, TD; Brennan, P; Fegan, C; Fischer, PM; Pepper, C; Pratt, G; Shao, H; Walsby, E; Wang, S1
Chen, H; Fu, HX; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Tang, FF; Wang, FR; Wang, Y; Xu, LP1
Brandberg, Y; Gill, D; Hammerström, J; Hertzberg, M; Johansson, H; Juliusson, G; Jønsson, V; Karlsson, K; Liliemark, J; McLennan, R; Mulligan, SP; Norman, J; Strömberg, M; Sundström, G; Uggla, B; Wallvik, J1
Choi, I; Jang, YJ; Jeon, M; Jung, SJ; Kang, M; Kang, YA; Kim, DY; Kim, H; Kim, HJ; Lee, JH; Lee, JL; Lee, KH; Lee, YS; Park, SY; Seol, M; Yeom, YI; Yoon, SR; Yun, SC1
Appelbaum, FR; Cassaday, RD; Fisher, DR; Gooley, TA; Gopal, AK; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Shields, A1
Chambellan, A; Chevallier, P; Delasalle, B; Delaunay, J; Dirou, S; Germaud, P; Guillaume, T; Lemarchand, P; Malard, F; Mohty, M; Moreau, P1
González-Ramírez, MP; Hernández-Reyes, J; Martagón-Herrera, NA; Rosales-Durón, AD; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Velázquez-Sánchez-de-Cima, S; Zamora-Ortiz, G1
Dave, SS; Kulbacki, E; McKinney, MS; Papalas, JA; Wang, E1
Chae, YK; Estrov, Z; Jain, P; Keating, MJ; Rozovski, U; Trinh, L; Wang, X; Wierda, WG1
Bilmon, I; Bryant, A; Greenwood, M; Hertzberg, M; Kennedy, G; Moore, J; Nivison-Smith, I; Ritchie, D; Spencer, A1
Kawakami, T; Kitano, K; Mimura, Y; Nakazawa, H; Nakazawa, K; Nishina, S; Sakai, K; Senoo, Y1
Aoki, S1
Imamura, Y1
Abrisqueta, P; Bosch, F; Calpe, E; Carabia, J; Carpio, C; Castellví, J; Crespo, M; Palacio, C; Purroy, N1
Blijlevens, NM; de Haan, AF; Donnelly, JP; Herbers, AH; van der Velden, WJ1
Carey, P; Hurst, E; Jayakody Arachchillage, D; Keenan, F; Menne, T; Moses, S; O'Brien, SG; Wallis, JP1
Bekele, N; Borthakur, G; Estey, E; Jabbour, EJ; Kantarjian, H; Keating, MJ; O'Brien, S; Plunkett, WK; Ravandi-Kashani, F; Tsimberidou, AM1
Hoang, KQ; Momin, F; Reyes, C; Satram-Hoang, S; Skettino, S1
Dahllöf, G; Heimdahl, A; Legert, KG; Remberger, M; Ringdén, O1
Chantepie, SP; Gac, AC; Reman, O1
Araoka, H; Asano-Mori, Y; Hayashi, M; Ishiwata, K; Ito, T; Izutsu, K; Kaji, D; Makino, S; Masuoka, K; Matsuno, N; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Uchida, Y; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A1
Chen, T; Fang, J; Huang, Y; Lin, X; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B1
Burger, J; Challagundla, P; Estrov, Z; Faderl, SH; Ferrajoli, A; Jain, N; Jorgensen, J; Keating, MJ; O'Brien, SM; Strati, P; Tambaro, FP; Wierda, WG1
Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L1
Bachanova, V; Blazar, BR; Cooley, S; Curtsinger, J; Defor, TE; Hippen, K; Lewis, D; McGlave, P; McKenna, DH; Miller, JS; Panoskaltsis-Mortari, A; Verneris, MR; Weisdorf, DJ; Zhang, B1
Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY1
Abenhardt, W; Dörfel, S; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Meyer, D; Münz, M1
Abrahamse-Testroote, MC; Doorduijn, J; Geisler, CH; Ghidey Alemayehu, W; Itälä Remes, M; Jurlander, J; Kimby, E; Kozak, T; Polliack, A; Tjønnfjord, G; van Oers, MH; van T' Veer, MB; Walewski, J; Wittebol, S; Wu, KL1
Morgensztern, D; Peddi, PF; Peddi, S; Santos, ES1
Ayres, ML; Baladandayuthapani, V; El-Mabhouh, AA; Gandhi, V; Keating, MJ; Shpall, EJ; Wierda, WG1
Adam, Z; Krejčí, M; Pour, L; Ševčíková, E1
Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; López-Otín, C; Matas-Céspedes, A; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S1
Baker, C; Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Del Toro, G; Garvin, J; George, D; Geyer, MB; Hawks, R; Jin, Z; Lee, MT; Licursi, M; Morris, E; Radhakrishnan, K; Satwani, P; Schwartz, J; Smilow, E; Zuckerman, W1
Aweeka, F; Dvorak, CC; Huang, L; Lizak, P; Long-Boyle, J1
Jiang, C; Liu, Y; Rong, Y; Xu, K; Xu, Q; Yang, C1
Bae, SH; Choi, JH; Joo, YD; Jung, CW; Kim, BS; Kim, H; Kim, HJ; Kim, I; Kim, MK; Kim, SH; Kwak, JY; Lee, KH; Lee, WS; Oh, S; Park, JH; Shin, HJ; Sohn, SK; Won, JH1
Barrett, J; Childs, RW; Cho, E; Cook, L; Donohue, T; Geller, N; Khuu, H; Pantin, J; Ramos, C; Scheinberg, P; Stroncek, D; Tian, X; Vasu, S; Young, NS1
Campos, JG; Carrillo-Cruz, E; Cuadrado, IM; De la Cruz Vicente, F; Galiana, ML; Gonzalez, JF; Marín Niebla, A; Perez-Simón, JA; Rios-Herranz, E; Rodriguez, MS; Tocino, IE1
Brown, JR; O'Brien, SM; Porter, DL1
Assanelli, A; Battaglia, M; Bernardi, M; Bondanza, A; Bonini, C; Bordignon, C; Carbone, MR; Carrabba, M; Ciceri, F; Clerici, D; Corti, C; Crocchiolo, R; Crotta, A; Crucitti, L; Ferraro, A; Fleischhauer, K; Forcina, A; Giglio, F; Guggiari, E; Locatelli, F; Lorusso, A; Lunghi, F; Marcatti, M; Marktel, S; Mastaglio, S; Messina, C; Noviello, M; Olek, S; Oliveira, G; Patriarca, F; Peccatori, J; Roncarolo, MG; Rossini, S; Stanghellini, MT; Tassara, M; Vago, L; Zecca, M1
Duvignaud, JB; Gauchat, D; Godin-Ethier, J; Grandvaux, N; Hanafi, LA; Lapointe, R; Leclerc, D; Possamaï, D1
Bence-Bruckler, I; Benner, A; Bloehdorn, J; Busch, R; Catalano, J; Dmoszynska, A; Döhner, H; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Fink, AM; Fischer, K; Geisler, CH; Hallek, M; Larratt, L; Loscertales, J; Montillo, M; Nguyen, TQ; Palermo, G; Robak, T; Rossiev, VA; Salogub, GN; Shi, X; Solal-Celigny, P; Stilgenbauer, S; Stinson, SY; Valente, N; Warzocha, K; Weisser, M; Wenger, MK; Yeh, RF; Yu, N1
Amadori, S; Bo, MD; Bomben, R; Buccisano, F; Bulian, P; Capelli, G; de Fabritiis, P; Del Poeta, G; Del Principe, MI; Gaidano, G; Gattei, V; Maurillo, L; Niscola, P; Pozzo, F; Ragusa, D; Rossi, D; Rossi, FM; Zucchetto, A1
Bleesing, JJ; Chandrakasan, S; Davies, SM; Filipovich, AH; Jordan, MB; Marsh, RA1
Giannopoulos, K; Jamroziak, K; Robak, T; Szemraj, J; Tukiendorf, A1
Ando, T; Kamachi, K; Kimura, S; Kojima, K; Nishijima, A; Takeshita, M1
Bartalucci, G; Bocchia, M; Candi, V; Cencini, E; Crupi, R; Defina, M; Fabbri, A; Frasconi, A; Gozzetti, A; Lauria, F; Papini, G; Raspadori, D; Schiattone, L1
Almazi, JG; Best, OG; Christopherson, RI; Kohnke, PL; Mactier, S; Mulligan, SP1
Bierne, H; Boulant, S; Cossart, P; Dixit, E; Durbin, AF; Franz, KM; Gehrke, L; Kagan, JC; Odendall, C; Stavru, F1
Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Ugarte-Berzal, E1
Ali, S; Olszewski, AJ; Shafqat, H1
Al-Ahmari, A; Al-Jefri, A; Al-Musa, A; Al-Seraihy, A; Ayas, M; El-Solh, H; Khairy, A; Markiz, S; Shahin, H; Siddiqui, K1
Andreasson, B; Bacigalupo, A; Barosi, G; Boyer, M; Goldberg, JD; Gupta, V; Hoffman, R; Isola, L; Klisovic, RB; Marchioli, R; Mascarenhas, J; Miller, C; Najfeld, V; Orazi, A; Prchal, JT; Price, LS; Prosperini, G; Rambaldi, A; Rondelli, D; Scarano, M; Shore, TB; Silverman, LR; Vannucchi, AM; Weinberg, RS; Wetzler, M1
Hernandez, F; Jaksa, R; Klanova, M; Klener, P; Kulvait, V; Lateckova, L; Lorkova, L; Maswabi, B; Mavis, C; Molinsky, J; Petrak, J; Pospisilova, J; Trneny, M; Vejmelkova, D; Vit, O; Vockova, P; Vokurka, M1
Bittencourt, H; Ceppi, F; Duval, M; Mallette, B; Ovetchkine, P; Teira, P; Therrien, R1
Alam, N; Atenafu, EG; Gupta, V; Kim, DH; Kuruvilla, J; Lipton, JH; Messner, HA; Seftel, M; Shanavas, M; Uhm, J1
Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH1
Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL1
Awan, FT; Clemmons, AB; DeRemer, DL; Evans, S1
Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R1
Borthakur, G; Brandt, M; Cortes, JE; Estey, EE; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Koller, C; Luthra, R; O'Brien, S; Patel, K; Ravandi, F; Wang, X1
Bae, SH; Bang, SM; Cheong, JW; Han, BR; Jo, DY; Joo, YD; Kim, DY; Kim, HJ; Kim, KH; Kim, SJ; Kim, SY; Kim, YK; Kwak, JY; Lee, JH; Lee, JO; Lee, KH; Lee, MH; Lee, NR; Lee, WS; Maeng, CH; Min, YH; Moon, JH; Park, J; Ryoo, HM; Sohn, SK; Song, IC; Won, JH; Yoon, HJ; Zang, DY1
Elmore, L; Khawaja, MR; Mumaw, CL; Nelson, RP; Orschell, C; Paczesny, S; Perkins, SM1
Afrough, A; Hamdi, A; Hosing, CM; Lu, G; Muzzafar, T; Popat, UR; Qazilbash, MH1
Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP1
Ding, K; Geng, L; Liu, H; Liu, X; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zheng, C; Zhu, X1
Alati, C; Console, G; Cuzzola, M; Dattola, A; Fedele, R; Gallo, GA; Irrera, G; Martinello, T; Martino, M; Messina, G; Molica, S; Moscato, T; Pontari, A; Princi, D; Ronco, F1
Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lee, HJ; O'Brien, S; Qiao, W; Wierda, W1
Abedin, S; Choi, S; Couriel, DR; Levine, JE; Peres, E; Yanik, G1
Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA1
Almasan, A; Erzurum, SC; Hill, BT; Janocha, AJ; Sharma, A; Smith, MR1
Andersson, BS; Anurathapan, U; Charoenkwan, P; Chuansumrit, A; Hongeng, S; Issaragrisil, S; Jetsrisuparb, A; Meekaewkunchorn, A; Mekjaruskul, P; Pakakasama, S; Pongtanakul, B; Rujkijyanont, P; Sanpakit, K; Sirachainan, N; Songdej, D; Sruamsiri, R; Ungkanont, A1
Avni, B; Grisariu, S; Or, R; Resnick, IB; Shapira, MY; Stepensky, P; Tsirigotis, PD1
Chang, TY; Chen, SH; Hsueh, C; Hung, IJ; Jaing, TH; Yang, CP1
Russo, GL; Russo, M; Spagnuolo, C1
Gupta, V; Hamad, N; Kim, DD; Kuruvilla, J; Lipton, JH; Messner, HA; Michelis, FV; Seftel, M; Shanavas, M; Uhm, J1
Calvo, K; Cole, K; Cuellar-Rodriguez, J; Freeman, A; Gea-Banacloche, J; Grossman, J; Hakim, F; Hickstein, DD; Holland, SM; Hughes, T; Parta, M; Zerbe, C1
Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC1
Castellano, G; Dominguez, N; Fernandez, I; Manzano, ML; Martin, A; Muñoz, R1
Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C1
Guzailinuer, W; Li, Y; Liu, H; Maimaitili, Y; Wang, X; Xiao, M1
Fan, L; Li, JY; Min, K; Wang, L; Wu, JZ; Xu, J; Xu, W1
Awan, FT; Byrd, JC; Flinn, IW; Hellmann, A; Hillmen, P; Hughes, SG; Robak, T; Shannon, M; Trone, D1
Fu, Y; Fuchs, EJ; Lin, Q; Maeda, H; Montgomery, RA; Shen, ZY; Sun, Z; Wang, Y; Warren, DS; Williams, GM1
Ahmed, S; Alousi, A; Anderlini, P; Bassett, RL; Ciurea, S; Gulbis, A; Jabbour, E; Khouri, IF; Korbling, M; Oran, B; Popat, UR; Rondon, G; Turturro, F; Wei, W1
Chen, T; Du, Q; Huang, Y; Lin, X; Lu, Z; Song, C; Sun, C; Tao, Y; Tu, S; Wu, B1
Carpenter, RO; Chen, CC; Dudley, ME; Feldman, S; Feldman, T; Goy, A; Hughes, MS; Kassim, SH; Kochenderfer, JN; Kranick, SM; Li, YF; Lu, L; Morton, KE; Nath, A; Nathan, DA; Ngo, LT; Phan, GQ; Raffeld, M; Rosenberg, SA; Sherry, RM; Somerville, RP; Spaner, DE; Stetler-Stevenson, M; Toomey, MA; Wang, ML; Yang, JC1
Bunin, N; Heimall, J; Morsheimer, M; Oshrine, B1
Blin, N; Brissot, E; Chevallier, P; Delaunay, J; Dubruille, V; Gastinne, T; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Lodé, L; Mahé, B; Mohty, M; Moreau, P; Peterlin, P1
Anghel, AG; Badea, M; Bleotu, C; Bordei, E; Crantea, G; Gavrilă, RI; Grecu, A; Grumezescu, AM; Holban, AM; Jercan, DA; Nicolae, BC; Tchinda, K; Vochiţoaia, GC; Voicu, G1
Hiroshima, Y; Ichikawa, N; Kirihara, T; Kobayashi, H; Kurihara, T; Mori, Y; Sato, K; Shibazaki, M; Sumi, M; Takeda, W; Ueki, T; Ueno, M1
Anheier, N; Bergmann, M; Busch, R; Cramer, P; Döhner, H; Dürig, J; Eichhorst, B; Fink, AM; Fischer, K; Goebeler, ME; Hallek, M; Hurtz, HJ; Langerbeins, P; Stauch, MB; Stilgenbauer, S; Wendtner, CM1
Baker, KS; Burroughs, LM; Deeg, HJ; Delaney, C; Domm, J; Englund, JA; Flowers, ME; Giller, RH; Nemecek, ER; Rawlings, DJ; Shimamura, A; Skoda-Smith, S; Storb, R; Storer, BE; Talano, JA; Thakar, MS; Torgerson, TR; Woolfrey, AE1
Rule, S; Seymour, JF; Shah, N; Tam, C1
Coiteux, V; de Berranger, E; Duhamel, A; Duléry, R; Gauthier, J; Gomez, E; Langlois, C; Magro, L; Terriou, L; Yakoub-Agha, I1
Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K1
Ahn, HS; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Kim, S; Lee, JW; Lee, SH; Park, JD; Park, KD; Shin, HY; Song, SH; Yu, KS1
Andersson, BS; Champlin, RE; de Lima, MJ; Furlong, T; Jones, RJ; Kanakry, CG; Luznik, L; Medeot, M; Mielcarek, M; O'Donnell, PV; Thall, PF; Wei, W1
Cortes, J; Do, KA; Ferrajoli, A; Kantarjian, H; Keating, MJ; Khouri, I; Lerner, S; O'Brien, S; Plunkett, W; Tam, CS; Wang, X; Wierda, W1
Blaise, D; Chevallier, P; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Le Gouill, S; Malard, F; Milpied, N; Mohty, M; Moreau, P; Tabrizi, R; Vigouroux, S1
Dinur-Schejter, Y; Erlich, O; Gorelik, N; Krauss, AC; Porat, I; Stein, J; Stepensky, P; Weintraub, M; Yahel, A; Zaidman, I1
Chen, XC; Huang, XO; Li, JJ; Liu, T; Liu, ZG; Lu, ZP; Tang, Y1
Nishikawa, H1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH1
Divoka, M; Faber, E; Indrak, K; Langova, K; Pikalova, Z; Raida, L; Rohon, P; Rusinakova, Z; Skoumalova, I; Szotkowska, R1
Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lerner, S; O'Brien, S; Qiao, W; Strom, SS; Trinh, L; Wang, X; Wierda, W1
Chen, HR; Guo, Z; He, XP; Liu, XD; Lou, JX; Zhang, Y1
Chen, HR; Chen, P; Guo, Z; He, XP; Liu, XD; Lou, JX; Yang, K; Zhang, Y2
Cox, EA; Cripe, LD; Farag, SS; Khawaja, MR; Kiel, PJ; Nelson, RP; Perkins, SM; Robertson, MJ; Sayar, H; Schwartz, JE; Vance, GH1
Asselineau, J; Blaise, D; Bouabdallah, K; Bouabdallah, R; Ceballos, P; Chevalier, P; Doussau, A; Furst, S; Le Gouill, S; Milpied, N; Mohty, M; Tabrizi, R; Tournilhac, O; Vigouroux, S1
Derks, IA; Eldering, E; Geisler, CH; Hüllein, J; Jethwa, A; Kater, AP; Lodén, M; Malcikova, J; Moerland, PD; Monsuur, H; Navrkalova, V; Oldreive, C; Pospisilova, S; Skowronska, A; Stankovic, T; Te Raa, GD; Trbusek, M; van Laar, J; van Oers, MH; Zenz, T1
Hirabayashi, K; Koike, K; Kurata, T; Nakazawa, Y; Saito, S; Sakashita, K; Tanaka, M; Yanagisawa, R; Yoshikawa, K1
Accornero, E; Algeri, M; Baio, A; Comoli, P; Corbella, F; Cugno, C; Del Fante, C; Giorgiani, G; Gurrado, A; Perotti, C; Pession, A; Strocchio, L; Zecca, M1
Becker, HJ; Beckmann, L; Brinkmann, K; Fandrey, J; Frenzel, LP; Hallek, M; Huelsemann, MF; Kashkar, H; Otto, T; Pallasch, CP; Patz, M; Reinhardt, HC; Theurich, S; von Bergwelt-Baildon, M; Wendtner, CM; Zahedi, RP1
Afanasyev, B; Baron, F; Deconinck, E; Jindra, P; Labopin, M; Mohty, M; Nagler, A; Peniket, A; Sanz, MA1
Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Guthrie, KA; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Rezvani, AR; Sandmaier, BM; Sorror, ML; Storb, RF; Storer, BE1
Avraham, GP; Brammer, JE; Curtin, P; Frires, R; Gajewski, J; Hayes-Lattin, B; Kovacsovics, T; Leis, JF; Maziarz, RT; Meyers, G; Nemecek, E; Palmbach, G; Slater, S; Stentz, A; Subbiah, N1
Donaldson, SL; McGonagle, DG; Owen, RG1
Alberti, N; Crombe, A; De Roquefeuil, E; Dousset, V; Gilles, M; Guy, A; Tourdias, T1
Choi, YS; Jeon, YW; Kim, DY; Kim, HJ; Kim, JH; Kim, YJ; Lee, JH; Lee, JW; Lee, KH; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH1
Bay, JO; Bilger, K; Bulabois, CE; Buzyn, A; Ceballos, P; Chevallier, P; Chevret, S; Clement, L; Cornillon, J; Dauriac, C; Françoise, S; Fürst, S; Gluckman, E; Huynh, A; Legrand, F; Maillard, N; Margueritte, G; Maury, S; Michallet, M; Michel, G; Milpied, N; Nguyen, S; Rio, B; Rocha, V; Ruggeri, A; Simon, T; Sirvent, A; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I1
Bleesing, JJ; Davies, SM; Filipovich, AH; Haines, HL; Hornung, L; Jordan, MB; Marsh, RA1
Assanelli, A; Bernardi, M; Carrabba, M; Ciceri, F; Claudiani, S; Corti, C; De Freitas, T; Giglio, F; Guggiari, E; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Peccatori, J; Piemontese, S1
Guilcher, GM; Lewis, VA; Moorjani, R; Truong, TH1
Byrd, JC; Gordon, A; Guinn, D; Hertlein, E; Jaglowski, S; Johnson, AJ; Larson, R; Lin, TS; Maddocks, K; Marcucci, G; Ruppert, AS; Woyach, J1
Aldrin, A; Andersson, PO; Björkstrand, B; Häggström, J; Hansson, L; Norin, S; Rommel, F; Timberg, L1
Chen, C; Chen, Y; Ding, Y; Fu, J; Liang, A; Lu, H; Wang, W; Wu, H; Zhang, W; Zou, S1
Hasegawa, K; Hirayama, Y; Ishihara, T; Kanagawa, M; Koyama, J; Suzuki, T; Terui, T1
Inagaki, J; Kakuda, H; Kudo, K; Kurosawa, H; Manabe, A; Ohtsuka, Y; Sakashita, K; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N1
Foltynski, P; Ladyzynski, P; Molik, M1
Champlin, RE; Eapen, M; Horowitz, MM; Lee, SJ; Logan, BR; Perales, MA; Rocha, V; Soiffer, RJ; Zhong, X1
Adachi, S; Atsuta, Y; Goto, H; Hasegawa, D; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kawa, K; Koh, K; Kudo, K; Okamoto, Y; Yabe, H1
Azzi, N; De Ville, A; Dedeken, L; Devalck, C; Ferster, A; Huybrechts, S; Massin, M; Rooze, S; Roufosse, F; Sanoussi, I; Sauvage, D1
Błoński, JZ; Góralski, P; Hartman, M; Kiliańska, ZM; Koceva-Chyła, A; Piekarski, H; Robak, P; Robak, T; Rogalińska, M; Rogalska, A; Wawrzyniak, E1
Chan, TS; Cheung, CY; Gill, H; Hwang, YY; Kwong, YL; Wong, IY; Yeung, IY1
Chen, F; Chen, S; Fu, Z; Han, Y; Jin, S; Jin, Z; Liu, L; Ma, X; Miao, M; Qiu, H; Sun, A; Tang, X; Wang, X; Wu, D; Zhang, X1
Benajiba, L; Dalle, JH; Galambrun, C; Jubert, C; Peffault de Latour, R; Salvado, C; Socié, G; Soulier, J1
Chen, H; Huang, XJ; Liu, DH; Liu, KY; Sun, YQ; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH; Zhang, YY1
Abraham, A; Benton, M; Brown, C; Chiang, KY; Dioguardi, JL; Grizzle, A; Haight, A; Hale, G; Horan, JT; Kanter, J; Kasow, KA; Nieder, M; Shelman, C1
Araoka, H; Asano-Mori, Y; Ikebe, T; Ishiwata, K; Izutsu, K; Kon, A; Makino, S; Masuoka, K; Matsuno, N; Nakano, N; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A1
Aljurf, MD; Arat, M; Bader, P; Boelens, JJ; Duarte, R; Faraci, M; Lawitschka, A; Peters, C; Socie, G; Tichelli, A; Veys, P; Wachowiak, J; Yaniv, I1
Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C1
Bollard, C; Cuellar-Rodriguez, J; Freeman, AF; Gea-Banacloche, J; Grossman, J; Hickstein, DD; Holland, SM; Kong, HH; Moutsopoulos, N; Murdock, H; Parta, M; Shah, N; Stone, K; Su, H1
Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L1
Baron, F; Beguin, Y; De Becker, A; Emonds, MP; Graux, C; Kerre, T; Lewalle, P; Maertens, J; Ory, A; Seidel, L; Theunissen, K; Van Gelder, M; Willems, E; Zachée, P1
Allegrini, S; Camici, M; Chaloin, L; Cividini, F; Cros-Perrial, E; Dumontet, C; Jordheim, LP; Pesi, R; Tozzi, MG1
Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B1
Ariel, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shapiro, M; Shvidel, L; Tadmor, T1
Ahmed, S; Al Atrash, G; Alousi, AM; Andersson, B; Brammer, JE; Champlin, RE; Chen, J; Ciurea, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Nieto, Y; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saliba, RM; Shah, N; Shpall, EJ1
Iida, H; Imahashi, N; Kasai, M; Kato, C; Kato, T; Kiyoi, H; Kohno, A; Kurahashi, S; Miyamura, K; Miyao, K; Murata, M; Naoe, T; Nishida, T; Ohashi, H; Ozawa, Y; Sakemura, R; Sawa, M; Terakura, S; Watamoto, K; Yokohata, E1
Arthur, C; Fay, K; Gifford, G; Greenwood, M; Kerridge, I; Stevenson, W; Wong, K1
Li, BL; Li, J; Li, SX; Liu, Y; Wang, HT; Wang, TM; Zhai, B; Zhu, HL1
Azzollini, K; Bejot, C; Bhattacharyya, PK; Chow, KF; Feldman, T; Foon, KA; Gadaleta, G; Goy, A; Howlett, C; Kdiry, S; Mato, AR; Mrkulic, M; Pascual, LN; Porter, D; Schuster, SJ; Strelec, L; Svoboda, J; Valentinetti, M; Yannotti, K; Zenreich, J1
Brunet, S; Clapés, V; Guardia, R; Oriol, A; Piernas, S; Ribera, JM; Sierra, J; Subirà, M; Vives, S1
Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC1
Alonzo, TA; Arceci, RJ; Balis, FM; Bunin, NJ; Castleberry, RP; Cheng, JW; Cooper, TM; Emanuel, PD; Gerbing, RB; Jayaprakash, N; Liu, YL; Loh, ML; Stieglitz, E; Ward, AF; Widemann, BC1
Aldenhoven, M; Bierings, MB; Boelens, JJ; Bonney, D; Borrill, RE; Coussons, M; Jones, SA; Mercer, J; van der Ploeg, AT; van Hasselt, PM; Versluys, B; Wijburg, FA; Wynn, RF1
Bosman, WM; Langenberg, JC; Ritchie, ED; van den Bremer, J1
Butler, AC; Chan, G; Fang, L; Jewell, RC; Kipps, TJ; Laubscher, KH; Lewis, E; Lindeman, R; Patton, WN; Sedoti, D; Witman, P; Zhou, YY1
Appelbaum, FR; Bennett, JM; Byrd, JC; Claus, R; Dewald, GW; Flinn, IW; Grever, MR; Gribben, JG; Hussein, MA; Jelinek, DF; Larson, RA; Lozanski, A; Lozanski, G; Lucas, DM; Moore, DF; Neuberg, DS; Paietta, EM; Plass, C; Ruppert, AS; Tallman, MS1
Fujieda, A; Imai, H; Katayama, N; Masuya, M; Miyazami, K; Nagaharu, K; Sugimoto, Y; Tamura, A; Umino, A; Yamaguchi, M1
Dyer, MJ; Furman, RR; Goldstein, N; Gupta, IV; Hellmann, A; Hillmen, P; Jewell, RC; Kipps, TJ; Kozak, T; Lisby, S; Losic, N; Mayer, J; Österborg, A; Padmanabhan-Iyer, S; Phillips, JL; Piotrowska, M; Robak, T; Stilgenbauer, S; Struemper, H; Trnêný, M; Wierda, WG; Williams, CD1
Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; Lymp, J; O'Brien, S; Pagel, JM1
Baron, F; Beguin, Y; Daulne, C; de Bock, M; Ehx, G; Fillet, M; Gothot, A; Graux, C; Hannon, M; Humblet-Baron, S; Kerre, T; Maertens, J; Ory, A; Seidel, L; Servais, S; Willems, E1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Yoon, JH1
Bixby, D; Braun, T; Choi, S; Churay, T; Couriel, DR; Frame, D; Goldstein, SC; Harris, A; Kitko, C; Levine, J; Li, Y; Magenau, JM; Mineishi, S; Parkin, B; Pawarode, A; Reddy, P; Riwes, MM; Yanik, G1
Champagne, C; Farrant, P; Taylor, M1
da Silva, AS; de Mello, LM; Koury, Cde N; Nunes, AA; Souza, KM1
Bashey, A; Brown, SL; Connor, K; Hilton, S; Holland, HK; Morris, LE; Sanacore, M; Solomon, SR; Zhang, X1
Andritsos, L; Brown, JR; Bühler, A; Byrd, JC; Caligaris-Cappio, F; Devin, J; Gabrilove, J; Ghia, P; Grever, MR; Hallek, M; Heerema, NA; Janssens, A; Johnson, AJ; Kipps, TJ; Lanasa, MC; Larson, RA; Leblond, V; Milligan, DW; Stilgenbauer, S1
Best, OG; Crassini, K; Mulligan, SP; Stevenson, WS1
Alvarez, I; Anastasia, A; Arcari, A; Bari, A; Botto, B; Carella, AM; Chiarenza, A; Dondi, A; Federico, M; Marcheselli, L; Puccini, B; Salvi, F1
Huang, P; Li, S; Liu, Q; Wang, J; Xu, N; Zhang, F; Zhao, X1
Blazar, BR; DeFor, TE; Dusenbery, KE; MacMillan, ML; Slungaard, A; Wagner, JE; Weisdorf, DJ; Young, JA; Zierhut, H1
Beck, C; Dreyfus, B; Dyer, MJ; Gupta, IV; Hellman, A; Hess, G; Hillmen, P; Jewell, RC; Kozlowski, P; Lisby, S; Mayer, J; Nebot, N; Österborg, A; Pfreundschuh, M; Phillips, JL; Rizzi, R; Schetelig, J; Schuh, A; Smolej, L; Spacek, M; Wierda, WG; Williams, V1
Bergmann, M; Wendtner, CM1
Tsukasaki, K1
Davis, J; Haut, P; Hayashi, R; Kothari, A; Loechelt, BJ; Murray, L; Ngwube, A; Shenoy, S1
Iliakis, G; Magin, S; Papaioannou, M; Saha, J; Staudt, C1
Abdel-Azim, H; Kapoor, N; Mahadeo, K; Mehta, B1
Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ1
Chen, P; Chen, Y; Hu, W; Li, N; Li, X; Yang, W1
Allegrini, S; Camici, M; Cividini, F; Filoni, DN; Pesi, R; Tozzi, MG1
Bellman, D; Bleesing, JJ; Chandra, S; Dandoy, C; Davies, SM; El-Bietar, J; Filipovich, AH; Gefen, A; Grimley, M; Jodele, S; Jordan, MB; Khandelwal, P; Kumar, AR; Leemhuis, T; Marsh, RA; Mehta, PA; Myers, KC; Rao, MB; Zhang, K1
Alousi, A; Anderlini, P; Andreeff, M; Benton, CB; Champlin, R; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Kebriaei, P; Konopleva, M; Lu, H; McMullin, B; Nieto, Y; Parmar, S; Popat, U; Qiao, W; Rondon, G; Schober, W; Shpall, E; Thall, PF; Wang, RY; Woodworth, G; Zeng, Z1
Amigo-Jiménez, I; García-Marco, JA; García-Pardo, A; Lozano-Santos, C; Nova-Gurumeta, S; Pérez-Sanz, N1
Fan, X; Hu, J; Tang, W; Wang, L2
Bae, SH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, KH; Lee, WS; Ryoo, HM1
Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A1
Allan, PW; Carroll, WR; Chung, TK; Clemons, L; Conry, RM; Hong, J; Hunt, FR; Lowman, D; Mannion, K; Nabell, L; Parker, WB; Richman, J; Rosenthal, EL; Sorscher, EJ1
Assouline, S; Badoux, X; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Hourcade-Potelleret, F; McIntyre, C; Sayyed, P1
Boyraz, MS; Çağdaş, D; Güçer, Ş; Tezcan, İ; Uçkan Çetinkaya, D; Ünal, Ş1
Brennig, S; Czarnecki, K; Dilloo, D; Heinz, N; Heise, M; Heuser, M; Kaever, V; Kempf, H; Lachmann, N; Moritz, T; Phaltane, R; Schambach, A1
Daimon, T; Ikegame, K; Ishii, S; Kaida, K; Kanda, Y; Kaya, H; Kodera, Y; Kurokawa, T; Maeda, Y; Ogawa, H; Okada, M; Okumura, H; Shimizu, H; Tamaki, H; Taniguchi, K; Taniguchi, S; Ueda, Y; Yoshida, T; Yoshihara, S1
Aulitzky, W; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Lange, T; Maschmeyer, G; Morgner, A; Neugebauer, S; Niederwieser, D; Peter, N; Pönisch, W; Schäfer-Eckart, K; Schetelig, J; Schulze, A; Thiel, A; Wilhelm, M1
Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C1
Brenner, MK; Dotti, G; Heslop, HE; Huye, L; Narala, N; Ninomiya, S; Ramos, CA; Rooney, CM; Savoldo, B; Yagyu, S1
Groeneveld, ON; Kersten, MJ; Kraan, W; Linn, C; Minnema, MC; Pals, ST; Vos, JM1
Baranovsky, A; Bogushevich, S; Golubeva, M; Kalinichenko, E; Kulak, T; Kuzmitsky, B; Tsybulskaya, I1
Deng, L; Guo, KY; He, YZ; Huang, YX; Lin, X; Long, H; Lu, ZG; Song, CY; Tu, SF; Wu, BY; Xu, JH1
Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L1
Bemer, MJ; Heimfeld, S; Mager, DE; McCune, JS; Sandmaier, BM; Storer, BE1
Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G1
Treon, SP1
Bazarbachi, A; Beelen, D; Bermudez, A; Blaise, D; Fegueux, N; Hamladji, RM; Kharfan-Dabaja, MA; Kroeger, N; Labopin, M; Lioure, B; Mohty, M; Nagler, A; Or, R; Socie, G; Veelken, H1
Abramson, J; Antin, JH; Armand, P; Barnes, J; Brown, J; Chen, YB; Cutler, C; Del Rio, C; Driscoll, J; El-Jawahri, A; Fisher, DC; Ho, VT; Hochberg, E; Jacobsen, E; Li, S; McAfee, S; Soiffer, R; Spitzer, TR; Takvorian, R1
Asma, S; Boga, C; Kasar, M; Kozanoglu, I; Maytalman, E; Ozdogu, H; Yeral, M1
Baba, J; Ichikawa, K; Igarashi, N; Ishikawa, D; Kagamu, H; Kondo, R; Koshio, J; Koya, T; Miura, S; Nakata, K; Narita, I; Nozaki, K; Okajima, M; Saida, Y; Sato, K; Shoji, S; Tanaka, J; Tanaka, T; Watanabe, S; Yoshizawa, H1
Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Chammas, MJ; Cutler, CS; Glotzbecker, B; Ho, VT; Kim, HT; Koreth, J; Lange, PB; Nikiforow, S; Reynolds, CG; Ritz, J; Soiffer, RJ1
Boga, C; Kasar, M; Kozanoglu, I; Ozdogu, H; Sariturk, C; Yeral, M1
Mamorska-Dyga, A; Seiter, K1
Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J1
Bodzenta-Lukaszyk, A; Bolkun, L; Dabrowska, M; Eljaszewicz, A; Jasiewicz, M; Kaminski, K; Kloczko, J; Lapuc, I; Luksza, E; Miklasz, P; Moniuszko, M; Piszcz, J; Ptaszynska-Kopczynska, K; Rusak, M; Singh, P1
Chocholska, S; Dmoszynska, A; Hus, M; Klimek, P; Kowal, M; Macheta, A; Podhorecka, M; Szymczyk, A1
Baxter-Lowe, L; Bruckner, A; Cairo, MS; Chen, M; Christiano, AM; Fabricatore, S; Geyer, MB; Giller, R; Harel, S; Kandel, J; Kiuru, M; LeBoeuf, N; McGrath, J; Morel, KD; Radhakrishnan, K; Uitto, J; Umegaki, N; Woodley, D1
Blaise, D; Ceballos, P; Chevallier, P; Cornelissen, J; Einsele, H; Gluckman, E; Holler, E; Kenzey, C; Linkesch, W; Maillard, N; Pagliuca, A; Pascal, L; Petersen, E; Rocha, V; Ruggeri, A; Sengeloev, H; Tabrizi, R; Tucunduva, L; Yakoub-Agha, I1
Hu, W; Huang, Q; Liu, J; Qiu, L; Wang, Z; Zhou, Y1
Anacak, Y; Aydinok, Y; Balkan, C; Delcastello, BE; Kamer, SA; Karadaş, N; Karapinar, DY; Kavakli, K1
Alatrash, G; Andersson, BS; Champlin, R; Charafeddine, Y; Chen, J; Ciurea, S; Kebriaei, P; Lee, HC; Medeiros, LJ; Oran, B; Popat, U; Rondon, G; Saliba, RM; Shpall, E1
Iida, S; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Masaki, A; Masuda, A; Narita, T; Ri, M; Totani, H; Yoshida, T1
Cassin, R; Cortelezzi, A; Gaidano, G; Giannarelli, D; Orofino, N; Reda, G; Rossi, D; Sciumè, M; Vincenti, D1
Armistead, P; Chung, Y; Coghill, J; Comeau, T; Gabriel, D; Ivanova, A; Rao, K; Sarantopoulos, S; Serody, J; Shea, TC; Sheets, J; Walko, C; Wood, W1
Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Short, NJ; Smith, SC; Wierda, WG1
Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S1
Avigdor, A; Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R1
Du, Q; Jiang, X; Li, Q; Meng, F; Mo, W; Wei, Y; Yu, B; Zhou, M1
Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q1
Derks, IA; Eldering, E; Hoogendoorn, M; Kater, AP; Laddach, N; Leeksma, AC; Loden-van Straaten, M; Luijks, DM; Moerland, PD; Navrkalova, V; Skowronska, A; Stankovic, T; te Raa, GD; Trbusek, M; van Oers, MH; Yigittop, H; Zenz, T1
Hirano, T; Tsuji, T; Tuda, H; Yamasaki, H1
Chan, TY; Soon, AK1
Bulian, P; Cerri, M; Chiarenza, A; Cortelezzi, A; Coscia, M; Cuneo, A; De Paoli, L; Del Giudice, I; Del Poeta, G; Foà, R; Forconi, F; Gaidano, G; Gattei, V; Gentile, M; Ghilardi, G; Laurenti, L; Marasca, R; Massaia, M; Mauro, FR; Montillo, M; Morabito, F; Moreno, C; Motta, M; Neri, A; Perbellini, O; Rigolin, GM; Rossi, D; Tedeschi, A; Terzi-di-Bergamo, L; Vincelli, I; Visco, C; Zaja, F; Zinzani, PL1
Alam, M; Arrey, TN; Doktorova, E; Klanova, M; Klener, P; Lorkova, L; Maswabi, B; Petrak, J; Pospisilova, J; Scigelova, M; Vit, O; Vockova, P1
Bahlo, J; Busch, R; Chataline, V; Goede, V; Hallek, M; Kremers, S; Müller, L; Reschke, D; Schlag, R; Schmidt, B; Stilgenbauer, S; Vehling-Kaiser, U; Wedding, U1
Bucur, S; Cohen, JB; Colbert, A; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; King, N; Langston, AA; Lechowicz, MJ; Lonial, S; Sinha, R; Waller, EK; Winton, EF1
Ai, HS; Dong, Z; Guo, M; Hu, KX; Huang, XM; Huang, YJ; Liu, ZQ; Qiao, JH; Sun, QY; Wang, SF; Wang, Y; Yu, CL; Zuo, HL1
Buño, I; Martinez-Laperche, C; Muñoz-Calleja, C; Perez-Chacon, G; Rebolleda, N; Somovilla-Crespo, B; Zapata, JM1
Cramer, P; Eichhorst, B; Hallek, M; Langerbeins, P1
Conlon, KC; Jaffe, ES; Kreitman, RJ; Pastan, I; Steinberg, SM; Stetler-Stevenson, M; Waldmann, TA; Wilson, W1
Brown, JR; Cohen, JB; Flowers, CR; Jaye, DL; Katzen, HI; Lakhanpal, S; Leis, JF; Rosenthal, H; Sinha, R; Stock, W; Waller, EK1
Jallad, B; Mawri, S; Nabi, S; Won, J1
Ali, M; Chellapandian, D; Gassas, A; Krueger, J; Naqvi, A; Schechter, T; Weitzman, S1
Boztug, H; Cant, A; Glogova, E; Lankester, A; Peters, C; Pötschger, U; Skinner, R; Slatter, M; Sykora, KW; Veys, P; Wachowiak, J; Zecca, M1
Bruce, AJ; Chaudhry, HM; Hashmi, SK; Hogan, WJ; Kremers, WK; Litzow, MR; Patnaik, MS; Phillips, GL; Wolf, RC1
Bethge, WA; Buechele, C; Faul, C; Federmann, B; Helwig, A; Kanz, L; Schmohl, J; Schneidawind, D; Vogel, W1
Byrne, WL; Cummins, J; Lehouritis, P; McCarthy, FO; Murphy, CT; Reid, G; Stanton, M; Tangney, M; Urbaniak, C1
Dai, B; Qiu, M; Su, W; Zhang, H; Zhu, M1
Al-Ali, HK; Behre, G; Franke, GN; Hochhaus, A; Jentzsch, M; Klink, A; Niederwieser, D; Pfrepper, C; Sayer, HG; Schenk, T; Schwind, S1
Jeon, M; Kang, YA; Kim, DY; Lee, JH; Lee, KH; Lee, YS; Seol, M1
Alessandrino, EP; Arcese, W; Bacigalupo, A; Boschini, C; Bosi, A; Bruno, B; Busca, A; Carella, AM; Cavattoni, I; Chiusolo, P; Corradini, P; Grassi, A; Guidi, S; Marfisi, RM; Marotta, G; Masciulli, A; Micò, MC; Milone, G; Montanari, M; Mordini, N; Nagler, A; Oldani, E; Pastore, D; Patriarca, F; Pini, M; Raimondi, R; Rambaldi, A; Risitano, AM; Russo, D; Santarone, S; Saporiti, G; Scimè, R; Terruzzi, E; Torelli, GF1
Barrett, M; Dornan, D; Duchateau-Nguyen, G; Dufour, A; Maisel, D; Nguyen, T; Palermo, G; Robak, T; Smith, H; Weisser, M; Yeh, RF1
Byrne, JA; Earl, JW; Fraser, CJ; Koyyalamudi, SR; Kuzhiumparambil, U; Nath, CE; O'Brien, TA; Shaw, PJ1
Iida, H; Kato, T; Kawashima, N; Kohno, A; Kusumoto, S; Kuwatsuka, Y; Miyamura, K; Miyao, K; Mizuta, S; Morishita, Y; Murata, M; Naito, K; Nakase, K; Nishida, T; Ozawa, Y; Sao, H; Sawa, M; Taji, H; Tsurumi, H1
Avivi, I; Ben-Barouch, S; Cohen, O; Ram, R; Vidal, L1
Catovsky, D; Else, M; Oscier, D; Wade, R1
Bazargan, A; Carney, DA; Cheah, CY; Filshie, R; Januszewicz, EH; Lew, TE; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M1
Bagarolo, ML; Cacciapuoti, G; Marabotti, A; Martino, E; Porcelli, M; Scafuri, B1
Drozdinsky, G; Erlich, O; Gorelik, N; Lamdan, R; Natsheh, J; Or, R; Simanovsky, N; Stepensky, P; Weintraub, M1
Bahlo, J; Böttcher, S; Cramer, P; Döhner, H; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Ghia, P; Goede, V; Hallek, M; Herling, CD; Herling, M; Kneba, M; Kovacs, G; Kreuzer, KA; Langerbeins, P; Marlton, P; Maurer, C; Seymour, JF; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM1
Delgado, D; Hege, K; Quigg, T1
Freireich, EJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Plunkett, W; Smith, SC; Stingo, F; Tam, CS; Thompson, PA; Wierda, WG1
Zhang, L; Zou, W1
Ave, E; Castelli, M; Chiodin, G; Facco, M; Frezzato, F; Gattazzo, C; Giorgi, CA; Lessi, F; Martini, V; Piazza, F; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A; Zambello, R1
Fujisawa, S; Ishibashi, D; Ishigatsubo, Y; Kawasaki, R; Koharazawa, H; Matsumoto, K; Nakajima, Y; Tachibana, T; Tanaka, M; Yamamoto, E1
Gergis, U; Mayer, S; Parmar, S; Patel, K; Shah, S; Shore, T; van Besien, K1
Alyea, EP; Blum, W; Carter, S; Champlin, RE; Chen, YB; Devine, SM; Giralt, S; Hars, V; Horowitz, MM; Hsu, JW; Larson, RA; Linker, C; Mulkey, F; Owzar, K; Shea, TC; Sibley, AB; Slack, J; Soiffer, RJ; Stone, RM; Vij, R1
Annechini, G; Capria, S; D'Elia, GM; De Angelis, F; Foà, R; Pulsoni, A; Russo, E; Stefanizzi, C; Tosti, ME1
Fuji, S; Fukuda, T; Hagiwara, S; Hatanaka, K; Hidaka, M; Ito, T; Kim, SW; Kurosawa, S; Nakamae, H; Ohashi, K; Takami, A; Yamaguchi, T; Yamashita, T; Yano, S1
Alomari, M; Best, OG; Christopherson, RI; Haynes, PA; Jenkins, Y; Kaufman, KL; Mactier, S; Mirzaei, M; Mulligan, SP; Pascovici, D1
Amadori, S; Bittolo, T; Bomben, R; Buccisano, F; Cefalo, M; Dal Bo, M; de Fabritiis, P; De Santis, G; Del Poeta, G; Del Principe, MI; Gaidano, G; Gattei, V; Maurillo, L; Rossi, D; Rossi, FM; Venditti, A; Zucchetto, A1
Bahlo, J; Borsi, L; Civello, D; Eichhorst, B; Fingerle-Rowson, G; Fischer, K; Hallek, M; Kaiser, P; Kellermann, L; Mensch, A; Müller, D; Reiser, M; Stock, S; Walshe, R1
Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L1
Behfar, M; Faghihi-Kashani, S; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Hosseini, AS; Moin, M; Movahedi, M; Mozafari, M; Pourpak, Z1
Bolam, S; Follows, G; Gambell, J; Hillmen, P; Jack, A; Johnson, PW; Johnson, S; Kirkwood, AA; Kruger, A; Linch, D; Pocock, C; Rule, S; Seymour, JF; Smith, P; Toncheva, M; Walewski, J1
Bhargava, S; Chakrabarti, A; Chakrabarti, S; Chatterjee, S; Jaiswal, SR; O'Donnell, P; Ray, K1
Berrebi, A; Shvidel, L1
Davies, SM; Filipovich, AH; Jodele, S; Lane, A; Marsh, RA; Mehta, PA; Neumeier, L1
Balser, C; Barth, J; Blau, W; Boeck, HP; Brugger, W; Hahn, L; Hinke, A; Kaiser, U; Kauff, F; Losem, C; Mueller, L; Niederle, N; Rummel, M; Sandherr, M; Stauch, M; Vereshchagina, J; von Gruenhagen, U; Weidmann, E; Welslau, M1
Agathangelidis, A; Baliakas, P; Belessi, C; Blakemore, SJ; Chiorazzi, N; Clifford, R; Cortese, D; Davi, F; Gaidano, G; Ghia, P; Höglund, M; Juliusson, G; Kotaskova, J; Langerak, AW; Ljungström, V; Mansouri, L; Ntoufa, S; Oscier, D; Panagiotidis, P; Pandzic, T; Plevova, K; Pospisilova, S; Pott, C; Rosenquist, R; Rossi, D; Schuh, A; Sjöblom, T; Smedby, KE; Stamatopoulos, K; Stavroyianni, N; Strefford, JC; Sutton, LA; Trentin, L; Young, E1
Biemond, BJ; Cornelissen, JJ; Graux, C; Hazenberg, CL; Kuball, J; Löwenberg, B; Maertens, J; Ossenkoppele, G; Pabst, T; Passweg, JR; Schouten, HC; Theobald, M; van Putten, WL; Vellenga, E; Versluis, J1
Andronescu, E; Geanaliu-Nicolae, RE; Iordache, F; Pîrvan, AA; Voicu, G1
Aytaç Eyüboğlu, S; Bayhan, T; Çetin, M; Gümrük, F; Kuşkonmaz, B; Tavil, B; Uçkan Çetinkaya, D; Ünal, Ş1
Barkholt, L; Ericzon, BG; Mattsson, J; Omazic, B; Potácová, Z; Remberger, M; Ringdén, O; Söderdahl, G; Wersäll, P1
Ahmadzadeh, A; Khodadadi, A; Saki, G; Teimoori, A; Valizadeh, A1
Du, H; Jing, Y; Lu, W; Luan, Z; Tang, X; Wu, N; Xu, S; Zhang, B1
Chen, J; Ding, L; Li, B; Li, Q; Luo, C; Wang, J1
Breuer, A; Dürig, J; Gigel, C; Herling, M; Mayer, P; Möllmann, M; Stiefelhagen, M; Vasyutina, E1
Chang, W; Chen, F; Fu, C; Jin, Z; Ma, X; Miao, M; Qiu, H; Ruan, C; Sun, A; Tang, X; Wu, D; Xue, S1
Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE1
Andersson, PO; Chang, CN; Daly, S; Gorczyca, M; Grosicki, S; Gupta, I; Kaplan, P; Kryachok, I; Kulyaba, Y; Lisby, S; Mazur, G; Middeke, JM; Montillo, M; Österborg, A; Rekhtman, G; Schuh, A; Steurer, M; Udvardy, M; Zaritskey, A1
Baxter-Lowe, LA; Bhatia, M; Cairo, MS; Cooney-Qualter, E; Fabricatore, S; Harrison, L; Kletzel, M; Luisi, P; Militano, O; Morris, E; Ricci, A; Roy, S; van de Ven, C; Wolownik, K; Zahler, S1
Adachi, K; Hirabayashi, K; Koike, K; Nakazawa, Y; Nanba, E; Saito, S; Sakai, N; Sakashita, K; Shibazaki, T; Shigemura, T; Shiohara, M; Takagi, M1
Aoki, J; Fujii, E; Ishigatsubo, Y; Kanamori, H; Matsumoto, K; Tanaka, M; Yamamoto, E; Yamamoto, W1
Brown, M; Myers, D; Radhi, M; Rahmetullah, R; Shreve, N1
Li, H; Li, Z; Liu, H; Liu, W; Lü, R; Qiu, L; Xiong, W; Yi, S; Zou, D1
Chen, J; Hu, J; Huang, H; Huang, X; Jin, J; Li, J; Li, Y; Liang, Y; Ma, J; Sun, Y; Wang, C; Wang, J; Wang, L; Wu, D; Xiao, Y; Yu, K1
Abramovici, O; Carlos Molano, L; Cuvelier, A; Darmon, A; Duval-Modeste, AB; Louvel, JP; Muir, JF; Piton, N1
Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R1
Hoshino, A; Ikegame, K; Imai, K; Inoue, T; Kaida, K; Kanegane, H; Morio, T; Ogawa, H; Okada, M; Soma, T; Tamaki, H; Yamashita, M1
Ishiyama, K; Kawabata, H; Kitano, T; Kondo, T; Sugimoto, N; Takaori-Kondo, A; Takeda, J1
Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ1
Goto, H; Goto, S; Yokosuka, T1
Ichinohe, T; Iida, H; Kako, S; Kanamori, H; Kanda, Y; Kato, C; Koh, H; Maeda, T; Mori, T; Nakao, S; Onishi, Y; Onizuka, M; Ozawa, Y; Suzuki, R; Yamazaki, H1
Han, HJ; Lu, YW; Xia, RX1
Calvieri, S; Cantisani, C; Giustini, S; Iacovino, C; Miraglia, E1
Ding, K; Geng, L; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zhang, L; Zhang, X; Zheng, C; Zhu, X1
Assouline, S; Badoux, X; Berthillon, N; Brewster, M; Buccheri, V; Catalani, O; Delmer, A; Gaidano, G; Li, S; McIntyre, C; Sayyed, P; Trneny, M1
Bermúdez, A; Caballero, MD; Cabrero, M; Conde, E; De La Serna, J; Gómez, V; Lahuerta, JJ; Moraleda, JM; Perez, SG; Sanz, G; Sanz, J; Serrano, D; Vallejo, C1
Akhtar-Ali, M; Ban, K; Baumann, T; Blakemore, SJ; Campo, E; Clifford, R; He, L; Hellström, AR; Hellström, M; Kundu, S; Larsson, J; Ljungström, V; Lopez-Guillermo, A; Mansouri, L; Pandzic, T; Rosenquist, R; Schuh, A; Sjöblom, T; Strefford, JC1
Alchalby, H; Ayuk, F; Cassinat, B; Christopeit, M; Kröger, N; Peffault de Latour, R; Porcher, R; Robin, M; Sicre de Fontbrune, F; Socié, G; Wolschke, C; Zabelina, T1
Becker, U; Hautala, A; Kyttälä, M; Martikainen, J; Poikonen, E; Soini, E1
Alexandrova, IY; Grishina, GV; Kozlov, VA; Makarov, SV; Minaev, YL; Mishchenko, OV; Rossiev, VA; Semagina, OV1
Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH1
Appelhans, D; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Kowalczyk, P; Maciejewski, H; Misiewicz, M; Ostrowska, K; Voit, B1
Annechini, G; Argnani, L; Broccoli, A; Casadei, B; De Renzo, A; Gandolfi, L; Morigi, A; Pellegrini, C; Pulsoni, A; Quirini, F; Stefoni, V; Tonialini, L; Zinzani, PL1
Chadwick, H; Counsell, N; Evans, K; Johnson, RJ; Pottinger, BT; Rudin, CE; Smith, P; Townsend, W; Wickham, C1
Hong, DS; Ji, YS; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MS; Min, CW; Park, SK; Won, JH; Yun, J1
Böhme, A; Dreyling, M; Fries, S; Höhler, T; Kellermann, L; Kiewe, P; Zoellner, AK1
Alousi, AM; Anderlini, P; Champlin, RE; Fanale, MA; Hagemeister, FB; Hosing, CM; Khouri, IF; Ledesma, C; Neelapu, S; Nieto, Y; Oki, Y; Plair, T; Popat, UR; Romaguera, JE; Saliba, RM; Shpall, EJ; Younes, A1
Barré, L; Dhilly, M; Guillouet, S; Hovhannisyan, N; Leporrier, M1
Bacigalupo, A; Ballerini, F; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Miglino, M; Minetto, P; Pastori, G; Rebesco, B; Sessarego, M1
Ahn, HS; Cho, B; Chung, NG; Hong, KT; Im, HJ; Jung, HJ; Kang, HJ; Kim, H; Kim, HK; Kim, SY; Koh, KN; Koo, HH; Lee, JH; Lee, JW; Lee, SH; Lee, YH; Lim, YJ; Lim, YT; Park, JA; Park, JE; Park, KD; Park, SK; Ryu, KH; Seo, JJ; Shin, HY; Sung, KW; Yoo, ES; Yoo, KH1
Brundage, R; Brunstein, CG; Cao, Q; Jacobson, PA; Jensen, K; Kirstein, MN; Kurtzweil, A; Long-Boyle, J; Rogosheske, J; Sanghavi, K; Wagner, J; Warlick, ED; Weisdorf, DJ; Wiseman, A1
Castejon, R; Losada-Fernandez, I; Martinez, A; Morado, M; Perez-Aciego, P; Perez-Chacon, G; Rebolleda, N; Rosado, S; Vallejo-Cremades, MT; Vargas-Nuñez, JA1
Choi, EJ; Jeon, M; Kang, YA; Kim, DY; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M1
Campion, L; Chevallier, P; Delaunay, J; Duquesne, A; Guillaume, T; Le Bourgeois, A; Le Gouill, S; Mohty, M; Moreau, P; Peterlin, P1
Bachanova, V; Devine, SM; Fenske, T; Gersten, I; Horowitz, M; Hosing, C; Laport, GG; Lazarus, HM; Logan, B; Longo, W; Nademanee, A; Riches, ML; Wu, J1
Bahlo, J; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kovacs, G; Langerbeins, P; Maurer, C; Müller, L; Pflug, N; Ritgen, M; Seiler, T; Stilgenbauer, S; von Tresckow, J; Wendtner, CM1
Boubaya, M; Choquet, S; Delmer, A; Dupuis, J; Le Gouill, S; Leblond, V; Levy, V; Ouzegdouh, M; Pégourié-Bandelier, B; Souchet, L; Tamburini, J; Tournilhac, O; Vargaftig, J1
Deng, L; Huang, QX; Huang, R; Huang, YX; Li, YH; Song, CY; Tu, SF; Wu, BY1
Gao, ZY; Li, WD; Lu, DP; Lu, DY; Yu, XJ1
Artz, A; Bredeson, C; Burkart, J; DiPersio, J; Fernandez, HF; Kamishohara, M; Le-Rademacher, J; Mehta, J; Mineishi, S; Nakamura, Y; Pasquini, MC; Ratanatharathorn, V; Sobecks, R; Zhu, X1
Aye, Y; Blessing, WA; Fletcher, EA; Li, M; Long, MJ; Weiss, RS; Wisitpitthaya, S; Zhao, Y1
Choi, ES; Im, HJ; Jang, S; Koh, KN; Kwon, SW; Lee, SW; Park, CJ; Seo, JJ; Suh, JK1
Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC1
Chan, KW; Chaudhury, S; Douglas, D; Gilman, AL; Hale, GA; Haut, P; Hayashi, RJ; Kasow, KA; Madden, LM; Murray, LM; Pulsipher, MA; Shenoy, S1
Bahlo, J; Böttcher, S; Busch, R; Döhner, H; Eichhorst, B; Fink, AM; Fischer, K; Gregor, M; Hallek, M; Kiehl, M; Klapper, W; Kneba, M; Köchling, G; Köppler, H; Kovacs, G; Kreuzer, KA; Lange, E; Maurer, C; Plesner, T; Plöger, C; Schlag, R; Sökler, M; Stilgenbauer, S; Trneny, M; Vehling-Kaiser, U; Wendtner, CM1
Arana Echarri, A; Beyaert, M; Bol, V; Bontemps, F; Michaux, L; Saussoy, P; Smal, C; Starczewska, E; Van Den Neste, E; Vekemans, MC1
Bendell, J; Brown, JR; Derks, IA; Eichhorst, B; Eldering, E; Fernandes, SM; Filvaroff, EH; Garrick, B; Hallek, M; Hege, K; Kater, AP; Kersten, MJ; Michot, JM; Reinhardt, HC; Rodríguez, MS; Ter Burg, J; Thijssen, R; Trowe, T; van Bochove, GG; van Kampen, RJ1
Adams, S; Allwood, Z; Amrolia, P; Chiesa, R; Lucchini, G; Qasim, W; Rao, K; Silva, J; Veys, P; Worth, A1
Akiyama, K; Aoki, T; Arakawa, Y; Hanada, R; Ikeda, Y; Koh, K; Mori, M; Sekinaka, Y1
Brown, JR; Hallek, MJ; Pagel, JM1
Aleric, I; Bakovic, M; Bilic, E; Ceovic, R; Curtis, LM; Delimar, V; Desnica, L; Milos, O; Nemet, D; Pavletic, SZ; Pulanic, D; Pulanic, TK; Seiwerth, RS; Stipetic, MM; Vrhovac, R1
Kay, BK; Koduvayur, SP; Lavie, A; Su, Y1
Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Li, Y; Liu, Y; Murray, D; Nieto, Y; Teo, EC; Valdez, BC1
Baxter-Lowe, LA; Cairo, MS; Dalal, R; Dozor, AJ; Fabricatore, S; Harrison, L; Jin, Z; Majzner, R; Morris, E; Sandoval, C; van de Ven, C; Wolownik, K1
Becker, U; Briggs, AH; Moreno, SG; Ngo, P; Ray, JA; Samanta, K1
Asano-Mori, Y; Ishiwata, K; Izutsu, K; Kageyama, K; Kaji, D; Makino, S; Masuoka, K; Nishida, A; Ota, H; Takagi, S; Taniguchi, S; Tsuji, M; Uchida, N; Wake, A; Yamamoto, G; Yamamoto, H; Yoneyama, A; Yuasa, M1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH1
Appelhans, D; Borowiec, M; Bryszewska, M; Cebula-Obrzut, B; Franiak-Pietryga, I; Kaczmarek, A; Klajnert-Maculewicz, B; Maciejewski, H; Robak, T; Smolewski, P; Voit, B; Ziemba, B; Ziółkowska, E1
Ayala, E; Kharfan-Dabaja, MA; LaFave, D; Nishihori, T1
Bahlo, J; Busch, R; Eichhorst, B; Fischer, K; Hallek, M; Hensel, M; Hess, G; Hopfinger, G; Kutsch, N; Maria Fink, A; Mayer, J; von Grünhagen, U; Wendtner, CM1
Altenhofer, P; Andel, J; Burcoveanu, C; Burgstaller, S; Doubek, M; Egle, A; Flochová, E; Fridrik, M; Gercheva, L; Girschikofsky, M; Greil, R; Hrubiško, M; Jäger, U; Klingler, A; Kozák, T; Králiková, E; Ladická, M; Mayer, J; Melchardt, T; Mihaylov, G; Mikušková, E; Nösslinger, T; Obrtlíková, P; Oexle, H; Palášthy, S; Papajík, T; Pecherstorfer, M; Petzer, A; Pleyer, L; Raynov, J; Smolej, L; Spasov, E; Stehlíková, O; Steurer, M; Zabernigg, A1
Andou, T; Fujisawa, S; Hagihara, M; Ishii, Y; Itabashi, M; Koyama, S; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W1
Chinratanalab, W; Engelhardt, BG; Goodman, SA; Greer, JP; Jagasia, M; Kassim, AA; Kennedy, VE; Savani, BN; Sengsayadeth, S1
Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL1
Vargas Núñez, JA1
Hogan, JJ; Weiss, BM1
Hawkes, N2
Katsanis, E; Kopp, LM; Pelayo-Katsanis, L; Sapp, LN; Whitney, K; Zeng, Y1
Antin, JH; Armand, P; Caballero, D; Cabrero, M; Esquirol, A; Kekre, N; Lopez-Corral, L; Marquez-Malaver, FJ; Martino, R; Pérez-Simon, JA; Piñana, J; Soiffer, RJ; Solano, C; Terol, MJ1
Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY1
Hey, SP; Kesselheim, AS1
Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J1
Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J1
Cao, H; Chen, G; Ding, J; Li, J; Pang, N; Qu, J; Wang, L; Yuan, H; Zhang, R; Zhang, Z; Zhao, F1
Ahmed, S; Alatrash, G; Anderlini, P; Bassett, RL; Burger, JA; Ciurea, SO; Ferrajoli, A; Gulbis, AM; Jabbour, EJ; Jorgensen, JL; Kadia, TM; Khouri, IF; Ledesma, C; Marin, D; Medeiros, LJ; Olson, A; Oran, B; Patel, KK; Popat, UR; Samuels, BI; Sui, D; Turturro, F1
Berger, C; Chaney, C; Chen, X; Cherian, S; Hanafi, LA; Hawkins, R; Heimfeld, S; Hudecek, M; Li, D; Maloney, DG; Pender, B; Riddell, SR; Robinson, E; Soma, L; Turtle, CJ; Wood, B1
Allsup, D; Bloor, A; Collett, L; Hillmen, P; Hockaday, A; Howard, DR; Munir, T; Oughton, JB; Phillips, D; Rawstron, AC1
Ayres, ML; Balakrishnan, K; Burger, JA; Cortes, JE; Ferrajoli, A; Gandhi, V; Jain, N; Kadia, TM; Keating, MJ; O'Brien, SM; Tambaro, FP; Wierda, WG1
Cheng, H; Hu, X; Li, R; Lv, S; Song, X; Wang, J; Wang, L; Yang, J; Zhang, W1
Chen, YY; Fan, L; Hong, M; Li, JY; Miao, KR; Miao, YQ; Qian, SX; Wang, L; Wu, W; Xia, Y; Xie, Y; Xu, W; Yu, H; Zhao, HH; Zhu, H; Zhu, HY; Zhu, Y1
Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z1
Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kastritis, E; Kyrtsonis, MC; Migkou, M; Mpakiri, M; Roussou, M; Tasidou, A; Terpos, E; Vassilakopoulos, TP1
Abdulkadyrov, K; Błoński, JZ; Carey, JL; Chang, CN; Gorczyca, MM; Govind Babu, K; Grosicki, S; Gupta, IV; Homenda, W; Kryachok, I; Kuliczkowski, K; Kulyaba, Y; Kłoczko, J; Lisby, S; Loscertales, J; McKeown, A; Rekhtman, G; Robak, T; Warzocha, K1
Bay, JO; Beckerich, F; Blaise, D; Bourhis, JH; Bulabois, CE; Chevallier, P; Contentin, N; Daguindau, E; de La Tour, RP; Delage, J; Detrait, M; François, S; Guillaume, T; Guillerm, G; Huynh, A; Labopin, M; Legrand, F; Lioure, B; Maillard, N; Mohty, M; Turlure, P; Vigouroux, S; Yakoub-Agha, I1
Choe, HK; Gergis, U; Mayer, SA; Nagar, H; Phillips, AA; Shore, TB; Smith, MJ; van Besien, K1
Babu, V; Biersack, B; Bloehdorn, J; Chessa, L; Crispatzu, G; Efremov, DG; Hallek, M; Herling, CD; Herling, M; Knittel, G; Lohmann, G; Mayer, P; Muenzner, JK; Prinz, C; Reinart, N; Reinhardt, HC; Schneider, JI; Schobert, R; Schumacher, B; Stilgenbauer, S; Vasyutina, E1
Bonfigli, S; Careddu, MG; Coppola, L; Dessì, L; Dore, F; Dore, S; Fozza, C; Giannico, DB; Longinotti, M; Longu, F; Nieddu, RM; Pardini, S; Podda, L; Sotgiu, G1
Bittenbring, J; Ganser, A; Hallek, M; Huynh, A; Kröger, N; Labopin, M; Malard, F; Michallet, M; Mohty, M; Nagler, A; Savani, BN; Schmid, C; Stuhler, G; Tischer, J1
Abdulkadyrov, K; Bal, V; Błoński, JZ; Chang, CN; Govind Babu, K; Grosicki, S; Gupta, IV; Homenda, W; Kryachok, I; Kuliczkowski, K; Kulyaba, Y; Kłoczko, J; Lisby, S; Loscertales, J; McKeown, A; Rekhtman, G; Robak, T; Warzocha, K1
Beyer, M; Dietrich, S; Göder, A; Heinzel, T; Kiweler, N; Krämer, OH; Linnebacher, M; Mahboobi, S; Mahendrarajah, N; Nikolova, T; Rauch, A; Reich, TR; Schäfer, C; Schneider, G; Sellmer, A; Sonnemann, J; Stojanovic, N; Tomicic, MT; Wieczorek, M1
Aurran-Schleinitz, T; Birsen, R; Bonnet, C; Boubaya, M; Choquet, S; Cymbalista, F; Delarue, R; Dietrich, PY; Dupuis, J; Fahri, J; Lamy, T; Leblond, V; Lemal, R; Lepretre, S; Levy, V; Michallet, AS; Re, D; Troussard, X; Wanquet, A; Ysebaert, L1
Belsito, V; Carella, AM; Cortellezzi, A; Cuneo, A; De Propris, MS; Ferretti, A; Foà, R; Guarini, AR; Liberati, AM; Marinelli, M; Mauro, FR; Molica, S; Nanni, M; Orlando, SM; Paoloni, F; Rizzi, R; Spriano, M; Tosi, P; Vignetti, M; Zaja, F1
Crazzolara, R; Haas, OA; Kager, L; Kropshofer, G; Matthes-Martin, S1
Appelhans, D; Bednarek, M; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Maciejewski, H; Misiewicz, M; Ostrowska, K; Ziemba, B1
Ikegame, K; Inoue, T; Ishii, S; Kaida, K; Kojima, H; Kusunoki, Y; Ogawa, H; Okada, M; Saji, H; Soma, T; Tamaki, H; Yoshihara, K; Yoshihara, S1
Celeghin, A; De Rossi, A; Dolcetti, R; Freguja, R; Giunco, S; Nalio, S; Zangrossi, M1
Coelho, R; Flagg, A; Gonzalez, BE; Hanna, R; Harrington, S; Kusick, K; Ondrejka, S; Procop, GW; Stempak, LM; Zembillas, A1
Bruzzese, D; Busiello, T; Cesaro, E; Chiurazzi, F; Ciano, M; Costanzo, P; Fiammetta Romano, M; Garofalo, O; Romano, S; Simeone, L; Sodaro, G1
Damiani, D; Geromin, A; Tiribelli, M1
Chandra, S; Emoto, C; Fukuda, T; Khandelwal, P; Marsh, RA; Mehta, PA; Neumeier, L; Teusink-Cross, A; Vinks, AA1
Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; Domingo-Domenech, E; Escoda, L; Estany, C; Fernández de Sevilla, A; Gardella, S; González-Barca, E; López-Guillermo, A; Magnano, L; Montoto, S; Moreno, C; Muntañola, A; Oriol, A; Pedro, C; Ribera, JM; Salar, A; Sancho, JM; Vivancos, P1
Abounader, DM; Andresen, S; Bolwell, BJ; Dean, R; Ferraro, C; Gerds, AT; Hamilton, BK; Hanna, R; Hill, BT; Kalaycio, M; Liu, H; Majhail, NS; Mustafa Ali, M; Pohlman, B; Rybicki, LA; Sobecks, RM; Starn, J; Winslow, V; Yurch, MA1
Blaise, D; D'Aveni-Piney, M; Daguindeau, E; Diez-Martin, JL; Hamladji, RM; Irrera, G; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Richard, C; Rubio, MT; Santarone, S; Sanz, MA; Savani, BN; Yakoub-Agha, I; Yeshurun, M1
Clavio, M; Gobbi, M; Guolo, F; Lemoli, RM; Miglino, M; Minetto, P1
Baker, KS; Boulad, F; Davies, SM; Guinan, E; Kernan, NA; Lane, A; Leemhuis, T; Lehmann, L; Margolis, D; Mehta, PA; Myers, K; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Williams, DA1
Daly, A; Geddes, M; Lam, W; Li, H; Storek, J1
Bigley, V; Collin, M; Craddock, C; Dickinson, AM; Green, K; Jackson, G; Jardine, L; Mackinnon, S; Nagra, S; Nicolson, PLR; Pearce, K; Peggs, KS; Sellar, RS; Thomson, K1
Bloor, A; Blundell, J; Fegan, C; Gribben, JG; Hamblin, M; Hillmen, P; Hockaday, A; Howard, DR; McParland, L; Munir, T; Pettitt, A; Phillips, D; Pocock, C; Rawstron, AC; Varghese, A1
Cairoli, R; Greco, R; Grillo, G; Mancini, V; Marbello, L; Molteni, A; Ravano, E; Riva, M; Zucchetti, E1
Ali, M; Courtney, S; Krueger, J; Lowry, J; Ramzan, M; Schechter Finkelstein, T1
Ball, LM; Bresters, D; Fiocco, M; Louwerens, M; van Doorn, R; Wanders, DCM1
Bendall, L; Bradstock, KF; Hart, D; Hsu, WH; Mattar, Z; Shahin, K; Silveira, P1
Ayala, A; Cabanillas, F; Fanale, MA; Fayad, L; Feng, L; Fowler, NH; Goy, AH; Hagemeister, FB; McLaughlin, P; Nastoupil, LJ; Neal, E; Neelapu, SS; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, M; Westin, JR1
Becker, U; Miguel, LS; Paquete, AT; Pereira, C; Pinto, CG1
Go, RS; Kay, NE; Winters, JL1
Arechaga, I; Bravo-Navas, S; Cabezas, M; Cabezón, E; Pipaón, C; Sánchez-Carrera, D; Yáñez, L1
Jin, JG1
Alyea, EP; Bashey, A; Deeg, HJ; Devine, SM; Fernandez, HF; Geller, NL; Giralt, S; Hamadani, M; Horowitz, MM; Horwitz, ME; Le-Rademacher, J; Leifer, E; Logan, BR; Maziarz, RT; Mendizabal, AM; Pasquini, MC; Porter, DL; Scott, BL; Warlick, ED; Wu, J1
Ashida, A; Ashida, T; Enomoto, A; Hamada, S; Matsunaga, K; Miki, H; Mukai, T; Torihata, S; Uchihashi, T; Yasumoto, M; Yasutake, N1
Abedi-Valugerdi, M; Benkessou, F; Hassan, M; Zhao, Y; Zheng, W1
Cros-Perrial, E; Dumontet, C; Jordheim, LP; Lefebvre-Tournier, I; Peyrottes, S; Puy, JY1
Boelens, JJ; Egas, AC; Langenhorst, JB; Punt, AM; van Kesteren, C; van Maarseveen, EM1
Afanasyev, B; Bethge, W; Brand, R; de Witte, T; Deliliers, GL; Dreger, P; Franke, GN; Guidi, S; Günther, A; Heim, D; Hübel, K; Iacobelli, S; Kobbe, G; Kröger, N; Onida, F; Pini, M; Platzbecker, U; Poiré, X; Robin, M; Scheid, C; Stelljes, M; Uddin, R; van Os, M; Volin, L; Weber, T1
Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE1
Barré, L; Dhilly, M; Fidalgo, M; Fillesoye, F; Guillouet, S; Hovhannisyan, N; Sola, B1
Chaudhry, HM; Mauermann, ML; Rajkumar, SV1
Abraham, A; Balasubramanian, P; Edison, ES; Fouzia, NA; George, B; Korula, A; Lakshmi, KM; Mathews, V; Mohanan, E; Panetta, JC; Srivastava, A; Viswabandya, A1
Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, HM; Ohanian, M; Oran, B; Pemmaraju, N; Ragon, BK; Ravandi, F1
Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP2
Alousi, A; Burke, E; Cao, K; Champlin, R; Chen, J; de Lima, M; Hosing, C; Kaur, I; Kebriaei, P; Marin, D; Mehta, RS; Olson, A; Oran, B; Parmar, S; Popat, U; Rezvani, K; Saliba, RM; Shah, N; Shpall, EJ; Skerrett, D1
Chaiwangyen, W; Daher, S; Markert, UR; Morales-Prieto, DM; Ospina-Prieto, S; Pereira de Sousa, FL; Photini, SM; Sass, N; Schleussner, E; Weber, M1
Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC1
Baculea, S; Cote, S; Diels, J; Van Sanden, S1
Abraham, A; Cluster, A; Delgado, D; Hulbert, ML; Jacobsohn, D; Kukadiya, D; Murray, L; Shenoy, S1
Chauffaille, MLLF; Fonseca, ARBMD; Goncalves, MV; Guedes, NR; Lacerda, MP; Pereira, AD; Rodrigues, CA; Yamakawa, PE; Yamamoto, M1
Cheng, L; Feng, Z; Li, H; Ni, W; Pan, X; Tang, Q; Zheng, W1
Curry, JL; Khan, M; Naqvi, K; Siddiqi, R1
Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R1
Brierley, CK; Eyre, TA1
Austin, E; Burt, DJ; Byatte, AJ; Chester, KA; Gilham, DE; Guest, RD; Halford, SER; Hawkins, RE; Kirillova, N; Nabarro, S; Pillai, M; Rothwell, DG; Sharma, SK; Thistlethwaite, FC; Valle, JW; Wan, S; Westwood, NB1
Aweeka, F; Chan, D; Cowan, MJ; Dvorak, CC; Huang, L; Ivaturi, V; Jennissen, C; Liu, T; Long-Boyle, J; Orchard, PJ; Pai, SY; Stricherz, M; Tolar, J; Wahlstrom, J1
Chan, KW; De Oliveira, S; Eapen, M; Fei, M; Hattersely, G; Horowitz, MM; Kurtzberg, J; Mendizabal, A; Schultz, KR; Wagner, JE; Wall, D; Zhang, MJ1
Buxhofer-Ausch, V; Geissler, K; Girschikofsky, M; Gleixner, K; Herndlhofer, S; Hoermann, G; Jaeger, U; Knoebl, P; Kundi, M; Machherndl-Spandl, S; Poehnl, R; Sliwa, T; Sperr, WR; Strecker, K; Valent, P; Weltermann, A1
Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L2
Barker, JN; Boulad, F; Castro-Malaspina, H; Fuller, K; Hilden, PD; Hsu, KC; Jakubowski, AA; Kernan, NA; Koehne, G; O'Reilly, RJ; Papadopoulos, EB; Perales, MA; Prockop, SE; Scaradavou, A; Spitzer, B; van den Brink, MR; Young, JW1
Billingham, L; Brock, K; Copland, M; Siddique, S; Sirovica, M; Yap, C1
Anand, S; Chao, NJ; Corbet, K; Gasparetto, C; Horwitz, ME; Long, GD; Lopez, R; Morris, AK; Rizzieri, DA; Sarantopoulos, S; Sullivan, KM; Sung, AD; Thomas, S1
Appelhans, D; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Jander, M; Maciejewski, H; Robak, T; Treliński, J; Voit, B; Ziemba, B1
Delaney, C; Gammill, H; Kanaan, SB; Milano, F; Nelson, JL; Oliver, DC1
Connolly, EC; Dhere, V; Edelman, S; Esiashvili, N; Graiser, M; Khan, MK; Langston, A; Switchenko, JM; Waller, EK1
Chen, X; Guo, N; Liu, Y; Lou, B; Tian, Y; Wu, Y; You, H; Yuan, Z; Zhang, Y; Zhao, Q; Zhou, D; Zhou, J1
Bot, A; Feldman, SA; Kochenderfer, JN; Lam, N; Lu, T; McIntyre, L; Rosenberg, SA; Rossi, J; Sherry, RM; Somerville, RPT; Yang, JC1
Abenhardt, W; Bahlo, J; Bentz, M; Blau, I; Bühler, A; Busch, R; Döhner, H; Eckart, MJ; Eichhorst, B; Emmerich, B; Fischer, K; Freier, W; Fuss, H; Goebeler, M; Hallek, M; Hartmann, F; Hoechstetter, MA; Hopfinger, G; Hurtz, HJ; Jäger, U; Müller, L; Schimke, H; Stilgenbauer, S; Vehling-Kaiser, U; Wendtner, CM; Winkler, D1
Chen, B; Gao, C; Ge, Z; Liu, R; Zhang, X1
Björklund, A; Garming-Legert, K; Hassan, M; Ljungman, P; Mattsson, J; Remberger, M; Serafi, IE; Sundin, M; Törlen, J1
Aoki, J; Atsuta, Y; Eto, T; Fukuda, T; Ichinohe, T; Ishiyama, K; Iwato, K; Kahata, K; Kako, S; Kanamori, H; Kanda, Y; Kawamura, K; Kondo, T; Mizuta, S; Ozawa, Y; Sawa, M; Uchida, N; Yano, S1
Chen, ZB; Li, ZY; Liang, YB; Ma, ZF; Tang, H; Wu, JG; Yang, W; Zeng, LJ1
Bay, JO; Blaise, D; Bulabois, CE; Ceballos, P; Chantepie, S; Charbonnier, A; Chevallier, P; Contentin, N; Cornillon, J; Daguindau, E; Deconinck, E; Labopin, M; Le Bourgeois, A; Maillard, N; Marçais, A; Marchand, T; Mercier, M; Mohty, M; N'Guyen, S; Peffault de Latour, R; Rorhlich, PS; Turlure, P; Vigouroux, S; Yakoub-Agha, I1
Appleby, N; Cahill, MR; Crotty, G; Enright, H; Hayat, A; Hennessy, B; Hodgson, A; Kelly, J; Leahy, M; O'Brien, D; O'Dwyer, M; O'Leary, H; Parker, I; Quinn, FM; Scott, K; Smyth, L; Vandenberghe, EA1
Bell, AD; Cheng, JC; Gutierrez, L; Karras, NA; Pawlowska, AB; Rosenthal, J; Sun, W; Wang, LD1
Hosokawa, I; Hosokawa, Y; Matsuo, T; Ozaki, K1
Brown, JR; Chai-Adisaksopha, C1
Damlaj, M; Patnaik, MM1
Ahmed, S; Ahn, KW; Armand, P; Epperla, N; Fenske, TS; Hamadani, M; Jagasia, M; Jaglowski, S; Kenkre, VP; Savani, B; Shah, NN; Smith, SM; Sureda, A1
Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M1
Aurran-Schleinitz, T; Benchikh, R; Cymbalista, F; Defoi, Y; Feugier, P; Godmer, P; Guillermin, Y; Herbaux, C; Jardel, H; Laribi, K; Leblond, V; Leprêtre, S; Letestu, R; Lévy, V; Michallet, AS; Orsini, F; Pegourié, B; Salles, G; Subtil, F; Vallais, F; Vaudaux, S1
Abu-Arja, R; Guilcher, GMT; Pai, V; Rangarajan, HG; Soni, S1
Ahn, JS; Choi, Y; Lee, HS; Lee, JH; Lee, JO; Lee, WS; Moon, JH; Park, S; Shin, DY; Shin, HJ; Song, IC; Yoon, SS1
Angelucci, E; Angrilli, F; Arcaini, L; Bertoldero, G; Cascavilla, N; Chiarenza, A; Dondi, A; Federico, M; Ferrari, A; Ferreri, AJM; Gaidano, G; Kovalchuk, S; Luminari, S; Manni, M; Marcheselli, L; Merli, F; Pulsoni, A; Rusconi, C; Salvi, F; Stelitano, C; Tarantino, V; Tucci, A; Vallisa, D; Vitolo, U1
Brown, JR; Kay, NE1
Hawkes, EA; Opat, S1
Bentz, M; Binnenhei, M; Bohl, SR; Bullinger, L; Bunjes, D; Döhner, H; Döhner, K; Drognitz, K; Kuchenbauer, F; Kündgen, L; Moulin, JC; Nguyen, TM; Ringhoffer, M; Schlenk, RF; Teleanu, V; von Harsdorf, S; Wais, V1
Coyne, CP; Narayanan, L1
Abd Hamid, IJ; Abinun, M; Amrolia, P; Cant, AJ; Chiesa, R; Elfeky, R; Flood, T; Gaspar, HB; Gennery, AR; Hambleton, S; Nademi, Z; Pearce, MS; Qasim, W; Rao, K; Slatter, MA; Veys, P; Worth, A1
Burger, J; Cortes, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, H; Keating, MJ; Luthra, R; Nogueras González, GM; O'Brien, S; Quesada, A; Rozovski, U; Sanchez-Petitto, G; Sarwari, N; Tam, C; Thompson, PA; Wierda, WG1
Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I1
Abraham, RS; Chadha, R; Kohli, S; Nivargi, S; Prakash Yadav, S; Rastogi, N; Thakkar, D1
Cao, Q; Dusenbery, KE; Gao, RW; Smith, AR; Yuan, J1
Gladstone, DE; Gocke, CD1
Baculea, S; Côté, S; Diels, J; Dorman, E; Fahrbach, K; Sanden, SV; Xu, Y1
Baer, MR; Ding, J; Hess, JR; Zimrin, AB1
Schmidt, C1
Ahmadi, AR; Akpinarli, B; Brandacher, G; Budihardjo, J; Etra, JW; Fidder, SAJ; Furtmüller, GJ; Lee, WPA; Lopez, J; Lough, DM; Miller, DT; Montgomery, RA; Nägele, F; Quan, A; Raimondi, G; Sun, Z; Vasilic, D; Wang, HD1
Albano, F; Chiurazzi, F; Cimmino, C; Fiume, G; Frieri, C; Golino, G; Iaccino, E; Mallardo, M; Mimmi, S; Pastore, A; Pisano, A; Quinto, I; Scala, G; Vecchio, E1
Han, TT; Huang, XJ; Mo, XD; Sun, YQ; Tang, FF; Wang, JZ; Wang, WJ; Xu, LP; Zhang, XH1
Altiparmak, D; Cetin-Atalay, R; Guven, EB; Kucukdumlu, A; Tuncbilek, M1
Li, H; Li, ZJ; Liu, HM; Lü, R; Qiu, LG; Wang, TY; Xiong, WJ; Yi, SH; Yu, Z1
Bruce, K; Domm, J; Evans, M; Frangoul, H; Isbell, J1
Ballerini, F; Cagnetta, A; Carminati, E; Cea, M; Clavio, M; Colombo, N; Di Grazia, C; Fugazza, G; Gobbi, M; Guardo, D; Guolo, F; Kunkl, A; Lemoli, RM; Matarese, S; Miglino, M; Minetto, P; Raiola, AM1
Cherry, MA; Crew, RM; Kim, YM; Li, S; Liu, G; Liu, Y; Lu, X; Wang, X; Wen, Z1
Benavente, C; Bergua, J; Boluda, B; Cordón, L; Díaz-Beyá, M; Esteve, J; Garrido, A; Jiménez-Ubieto, A; Martínez, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Pérez-Simón, JA; Prieto-Delgado, J; Rodríguez-Veiga, R; Salamero, O; Sanz, MA; Sempere, A; Serrano, J; Vidriales, B; Vives, S1
Baccarani, M; Candoni, A; Fanin, R; Gherlinzoni, F; Gottardi, M; Iacobucci, I; Martinelli, G; Papayannidis, C; Simeone, E; Visani, G1
Algeri, M; Aricò, M; Basso, G; Caniglia, M; Cesaro, S; Di Bartolomeo, P; Fagioli, F; Favre, C; Giardino, S; Locatelli, F; Marzollo, A; Merli, P; Messina, C; Pillon, M; Porta, F; Prete, A; Rabusin, M; Ripaldi, M; Rovelli, A; Saglio, F; Sieni, E; Zecca, M; Ziino, O1
Boulad, F; Curran, K; Kernan, NA; O'Reilly, RJ; Prockop, SE; Ruggiero, J; Scaradavou, A; Takpradit, C; Zakak, N1
Bund, C; De Seze, J; Kremer, S; Lhermitte, B; Namer, IJ1
Avni, B; Grisariu, S; Hussein, F; Lokshin, E; NaserEddin, A; Oron, HC; Shadur, B; Stepensky, P; Zaidman, I1
Asma, S; Aytan, P; Boga, C; Gereklioglu, C; Kozanoglu, I; Maytalman, E; Ozdogu, H; Sariturk, C; Yeral, M1
Aurran, T; Banos, A; Cartron, G; Dartigeas, C; de Guibert, S; Delmer, A; Dupuis, J; Ferrant, E; Feugier, P; Gagez, AL; Guiu, B; Leblond, V; Leprêtre, S; Letestu, R; Letuan, P; Mahé, B; Orsini-Piocelle, F; Rouillé, V; Ternant, D; Tournilhac, O; Tout, M; Villemagne, B1
Abuelgasim, KA; Al Atwi, N; Al Balwi, M; Almughairi, A; Alshieban, S; Alsubaie, M; Rehan, H1
Cairo, MS; Cooper, T; Dang, H; Dvorak, CC; Gao, Y; Grupp, SA; Hirsch, B; Kahwash, S; Loh, ML; Mazor, T; Mehta, PA; Olshen, AB; Parker, JS; Patel, N; Pei, Q; Raimondi, S; Satwani, P; Skeens, M; Stieglitz, E; Wall, D1
Choo, S; Cole, T; Mechinaud, F; Richards, S1
Claxton, D; Miki, K; Mineishi, S; Naik, S; Rakszawski, K; Shike, H; Wagner, H1
Aurran, T; Béné, MC; Casasnovas, O; Cazin, B; Chevret, S; Corront, B; Cymbalista, F; Delépine, R; Delmer, A; Feugier, P; Leblond, V; Leprêtre, S; Letestu, R; Mahé, B; Maisonneuve, H; Nguyen-Khac, F; Ross-Weil, D; Royer, B; Tournilhac, O; Van Den Neste, E; Vaudaux, S1
Alyea, EP; Antin, JH; Armand, P; Cutler, CS; Glotzbecker, BE; Gooptu, M; Ho, VT; Kim, HT; Koreth, J; Nageshwar, P; Nikiforow, S; Ritz, J; Soiffer, RJ1
Alani, M; Baugier de Materre, A; Besançon, A; Denizon, N; Farhi, J; Ghnaya, H; Laribi, K1
Bancaud, A; Bradbury, A; Cazaux, C; Filleron, T; Fournié, JJ; Gilhodes, J; Grgurevic, S; Hoffmann, JS; Laurent, G; Montilla-Perez, P; Pelofy, S; Queille, S; Quillet-Mary, A; Récher, C; Ysebaert, L1
Antoniou, MN; Biswas, A; Buckley, SMK; Chan, JKY; Choolani, M; Dighe, NM; Johana, N; Mattar, CNZ; Sandikin, D; Shaw, SSW; Tan, KW; Tan, LG; Tan, YW; Waddington, SN1
Feng, S; Li, J; Liu, R; Shi, X; Song, Z; Yue, Y1
Becktell, K; Burke, MJ; Houser, K1
Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J1
Calip, G; Oh, A; Patel, P; Rondelli, D; Sweiss, K1
Chen, L; Chen, M; Chen, W; Zhang, B; Zhang, L; Zhang, Y1
Chen, H; Chen, Y; Huang, XJ; Liu, KY; Qin, J; Wang, FR; Xu, LP; Yang, YL; Zhang, XH1
Ding, W; Feng, X; He, Y; Li, C; Lin, G; Liu, H; Pei, F; Peng, Z; Wu, X; Yang, M; Yi, W; Zhang, C1
Borthakur, G; Burger, JA; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Jabbour, E; Jain, N; Jorgensen, J; Kadia, TM; Keating, MJ; O'Brien, SM; Peterson, CB; Strati, P; Thompson, PA; Wierda, WG1
Amado, R; Binder, G; Jakobsen, BK; Lowe, KL; Mackall, CL; Norry, E1
Fang, X; Jiang, Y; Li, Y; Liu, X; Sui, X; Wang, X; Xu, H; Zhang, L1
Bredius, RGM; Bresters, D; Jacobse, J; Kollen, WJW; Mensink, H; van der Stoep-Yap, MYEC1
Fauble, V; Hogan, WJ; Jain, T; Khera, N; Kunze, KL; Leis, JF; Mesa, RA; Noel, P; Palmer, J; Partain, DK; Patnaik, MS; Roy, V; Slack, JL; Sproat, LZ; Temkit, M1
Abraham, A; Ahn, KW; Artz, A; Boelens, JJ; Dvorak, C; Fei, M; Frangoul, H; Freytes, C; Gale, RP; Harris, AC; Hong, S; Lazarus, HM; Levine, JE; Loren, A; Mineishi, S; Nishihori, T; O'Brien, T; Pasquini, MC; Williams, K1
Catakovic, K; Egle, A; Gassner, FJ; Geisberger, R; Girschikofsky, M; Greil, R; Hartmann, TN; Lang, A; Melchardt, T; Petzer, A; Pleyer, L; Steurer, M; Thaler, J; Voskova, D; Weiss, L; Zaborsky, N1
Biondi, A; Corsi, A; Dazzi, F; Granata, V; Michelozzi, IM; Pievani, A; Rambaldi, B; Serafini, M1
Hamilton, BK1
Chung, H; Hong, KT; Kang, HJ; Kim, S; Lee, JW; Rhee, SJ; Yoon, SH; Yu, KS1
Tam, CS; Thompson, PA1
Deotare, U; Khalil, MMI; Kim, DD; Lipton, JH; Messner, HA; Michelis, FV; Thyagu, S; Viswabandya, A1
Arad, A; Aviv, A; Bairey, O; Braester, A; Fineman, R; Goldschmidt, N; Greenbaum, U; Herishanu, Y; Joffe, E; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T1
Chen, X; Huang, Y; Huang, Z; Lan, H; Ma, X; Meng, F; Sun, Q; Wu, B; Wu, S; Xu, J; Yao, Q; Zhu, Z1
Aktan, M; Bosch, F; Dartigeas, C; Ferra Coll, CM; Foà, R; Gresko, E; Kisro, J; Leblond, V; Merot, JL; Montillo, M; Raposo, J; Robson, S; Stilgenbauer, S1
Allen, CE; Andolina, JR; Baker, KS; Bollard, CM; Bryant, C; Burroughs, L; Connelly, J; Dawson, P; Eapen, M; Hanna, R; Kean, L; Marsh, R; Pai, SY; Pulsipher, MA; Ramirez, A; Roehrs, P; Schultz, KR; Shenoy, S; Stenger, EO; Talano, JA1
Blaise, D; Brecht, A; Cahn, JY; Heinicke, T; Hicheri, Y; Huynh, A; Labopin, M; Ledoux, MP; Milpied, N; Mohty, M; Mufti, GJ; Nagler, A; Polge, E; Savani, BN; Scheid, C; Schmid, C; Socié, G1
Della Pepa, R; Giordano, C; Grimaldi, F; Mortaruolo, C; Pane, F; Picardi, M; Pugliese, N; Raimondo, M; Salvatore, P; Sirignano, C; Trastulli, F; Zacheo, I1
Aljurf, M; Arcese, W; Beohou, E; Bonifazi, F; Bruno, B; Labopin, M; Lanza, F; Mohty, M; Nagler, A; Passweg, J; Pioltelli, P; Santarone, S; Saraceni, F; Savani, BN; Sociè, G; Stepensky, P; Yakoub-Agha, I1
Al-Agil, A; Al-Ahmari, A; Al-Seraihi, A; Ayas, M; Ayas, MF; Ghemlas, I1
Ashkenazi, M; Avni, B; Grisariu, S; Or, R; Shapira, MY; Sheth, V; Stepensky, P1
Blaise, D; Decroocq, J; Devillier, R; Fan, X; Fürst, S; Hu, J; Tian, L; Vey, N; Wan, M; Wang, L; Wang, LN1
Bittenbring, J; Brecht, A; Canaani, J; Ganser, A; Labopin, M; Labussière-Wallet, H; Mayer, J; Mohty, M; Nagler, A; Savani, B; Sheth, V; Shouval, R; Volin, L1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yahng, SA; Yoon, JH1
Arigoni, M; Benes, V; Brychtova, Y; Calogero, RA; Cerna, K; Chochola, V; Doubek, M; Mayer, J; Mraz, M; Musilova, K; Oppelt, J; Pavlasova, G; Pospisilova, S; Radova, L; Seda, V; Trbusek, M1
Baker, L; Holder, K; Kanellopoulos, A; Kaparou, M; Kishore, B; Lovell, R; Nikolousis, E; Paneesha, S; Ryan, L; Suhr, J; Xenou, E1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Park, SS; Yoon, JH1
Anderson, E; Bone, H; Heywood, J; Mayer, L; Mehta, P; Rees, B; Reynolds, D; Robinson, G; Salisbury, V1
Appelhans, D; Borowiec, M; Bryszewska, M; Franiak-Pietryga, I; Jander, M; Maciejewski, H; Ostrowska, K; Treliński, J; Voit, B; Ziemba, B1
Ross Reichard, R; Vaubel, RA1
Abou Mourad, Y; Abuhaleeqa, M; Daly, A; Nitta, J; Paulson, K; Seftel, MD; Speziali, C1
Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J1
Barré, L; Fillesoye, F; Gourand, F; Guillouet, S; Hovhannisyan, N; Ibazizene, M; Plancoulaine, B; Toutain, J; Valable, S1
Bahlo, J; Cramer, P; Dürig, J; Eichhorst, B; Fink, AM; Hallek, M; Herling, M; Hopfinger, G; Kreuzer, KA; Mayer, P; Oberbeck, S; Pflug, N; Robrecht, S; Schrader, A; Seiler, T; Stilgenbauer, S; Westermann, A; Zenz, T1
Boelens, JJ; Dorlo, TPC; Huitema, ADR; Kuball, J; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM1
Byun, JE; Choi, I; Huy, H; Jung, H; Kim, DO; Kim, MJ; Kim, TD; Kim, WS; Lee, J; Lee, KH; Noh, JY; Park, YJ; Yoon, SR1
Chen, J; Chen, L; Cheng, H; Gao, L; Hu, XX; Li, HM; Luo, YR; Ni, X; Song, XM; Tang, GS; Wang, JM; Wang, ZW; Xia, XX; Yang, D; Yang, JM; Zhang, WP; Zhou, H1
Luo, W; Ni, X; Wei, J; Yu, H; Zou, X1
Levin-Epstein, R; Oliai, C; Schiller, G1
Kanda, Y1
Ahmed, S; Al-Atrash, G; Alousi, AM; Anderlini, P; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, SO; Hosing, CM; Im, JS; Jones, R; Kawedia, J; Kebriaei, P; Khouri, I; Marin, D; Mehta, RS; Nieto, Y; Olson, A; Oran, B; Parmar, S; Popat, UR; Qazilbash, MH; Rezvani, K; Shah, N; Shpall, EJ; Srour, SA; Valdez, BC1
Tian, C; Yu, Y; Zhang, Y1
Arroyo, DS; Bussi, C; Heller, V; Iribarren, P; Rodriguez, CM; Sastre, D; Slavutsky, I; Stanganelli, C1
Blumenthal, GM; Bouchkouj, N; Bryan, W; de Claro, RA; George, B; Kasamon, YL; Lee, S; Lin, X; McKee, AE; Pazdur, R1
Crispino, JD; Fu, C; Gong, Y; Marinaccio, C; Shi, H; Shi, X; Sun, Z; Wan, Y; Wang, Z; Xu, K1
Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Maloney, DG; Press, OW; Puronen, CE; Sandmaier, BM; Stevenson, PA; Storb, RF1
Bakala, J; Declercq, H; Delette, C; Drumez, E; Duhamel, A; Guidez, S; Hivert, B; Labreuche, J; Marolleau, JP; Morel, P; Protin, C; Verlay, M; Ysebaert, L1
Andersson, PO; Asklid, A; Bjellvi, J; Hansson, L; Johansson, H; Karlsson, C; Karlsson, K; Kimby, E; Klintman, J; Lauri, B; Mattsson, M; Norin, S; Österborg, A; Sandstedt, AB; Strandberg, M; Sylvan, SE; Tolvgård, S1
Alahdab, F; Almader-Douglas, D; Firwana, B; Jain, T; Palmer, J; Sonbol, MB1
Jain, N1
Chen, K; Feng, Z; Li, X; Lin, J; Pan, X; Qi, W; Yan, Y1
Adachi, S; Atsuta, Y; Hashii, Y; Imai, K; Inoue, M; Kato, K; Kobayashi, M; Koga, Y; Morio, T; Okada, K; Sasahara, Y; Sato, M; Takahashi, Y; Umeda, K; Yabe, H; Yoshida, N1
Alatrash, G; Andersson, BS; Champlin, RE; Chen, J; Crain, AK; Di Stasi, A; Jones, RB; Kidwell, KM; Popat, U; Shpall, EJ; Thall, PF; Zope, M1
Alessandrino, EP; Bacigalupo, A; Bonifazi, F; Bosi, A; Bregante, S; Bruno, B; Carella, AM; Fanin, R; Finazzi, MC; Mammoliti, S; Masciulli, A; Messina, G; Milone, G; Narni, F; Patriarca, F; Pavoni, C; Rambaldi, A; Russo, D1
Brown, JR; Eradat, H; Hirata, J; Kingsley, CD; Kipps, TJ; McIver, T; Morariu-Zamfir, R; O'Brien, S; Pagel, JM1
Basu, O; Döring, M; Ebinger, M; Gruhn, B; Handgretinger, R; Heinzelmann, F; Holzer, U; Lang, P; Paulsen, F; Teltschik, HM; Wegener, D; Weidner, N; Wittig, A; Zips, D1
Calip, GS; Oh, AL; Patel, PR; Rondelli, D; Sweiss, K1
Stanford, M; Virgo, J; Williams, G1
Baird, DM; Fegan, CD; Hillmen, P; Hills, R; Norris, K; Pepper, C; Rawstron, A1
Appelhans, D; Danani, A; Deriu, MA; Gorzkiewicz, M; Grasso, G; Janaszewska, A; Klajnert-Maculewicz, B; Pułaski, Ł; Studzian, M1
Li, Y; Wang, X; Xu, Y; Zhang, Y; Zhou, X1
Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T1
Hatsumi, N; Hoshino, T; Sakura, T; Takada, S1
Aviv, A; Bairey, O; Braester, A; Fineman, R; Herishanu, Y; Levi, I; Polliack, A; Rahimi-Levene, N; Ruchlemer, R; Shvidel, L; Tadmor, T; Yuklea, M1
Araujo, C; Banos, A; Compaci, G; Despas, F; Larcher, M; Laurent, G; Oberic, L; Sahnes, L; Sommet, A; Ysebaert, L1
Antic, D; Dencic-Fekete, M; Djurasinovic, V; Karan-Djurasevic, T; Kostic, T; Marjanovic, I; Mihaljevic, B; Pavlovic, S; Tosic, N; Vukovic, V1
Acharya, UH; Cassaday, RD; Chapuis, AG; Chen, X; Cherian, S; Dhawale, TM; Gauthier, J; Gooley, T; Hawkins, RM; Hay, KA; Hendrie, PC; Hirayama, AV; Kiem, HP; Li, D; Lynch, RC; Maloney, DG; Pender, BS; Ramos, J; Riddell, SR; Shadman, M; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A; Voutsinas, JM; Wu, Q1
Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A1
Ariznavarreta, GD; Carbonell, F; Champ, D; Costa, MAA; De La Serna Torroba, J; De Marcos, NS; De Oteyza, JP; De Paz Arias, R; Díaz, MG; Fernández, IP; Ferrer, S; García-Marco, JA; García-Vela, JA; González-Barca, E; Guinaldo, MAR; Jarque, I; Jiménez, JL; Llanos, EB; Malo, MDG; Martin, EMD; Martinez, RM; Parraga, FJP; Persona, EP; Ramírez, MJ; Recasens, V; Suarez, JG; Tatay, AC; Valle, MDCF; Yañez, L; Zarzoso, MF1
Li, LJ; Yu, K; Zhang, JY1
Ahmed, S; Al-Atrash, G; Alousi, AM; Anderlini, P; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, SO; Hosing, CM; Im, JS; Kebriaei, P; Khouri, I; Marin, D; Mehta, RS; Molldrem, JJ; Nieto, Y; Olson, A; Oran, B; Popat, UR; Qazilbash, MH; Rezvani, K; Shpall, EJ; Srour, SA1
Chen, Y; Feng, J; Lin, F; Lu, N; Ma, Y; Shi, Y; Sun, L; Tang, L; Wang, N; Xing, C; Yu, K1
Bačíková, A; Kozubek, S; Lukášová, E; Řezáčová, M; Šebejová, L; Vávrová, J1
Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J1
Chung, Y; Han, B; Kim, HY; Kim, M; Lee, J; Lee, YK; Park, JY1
Brychtova, Y; Brzobohata, A; Doubek, M; Mayer, J; Mraz, M; Panovska, A; Pavlova, S; Pospisilova, S; Skuhrova Francova, H; Spunarova, M; Tom, N; Trbusek, M1
Baggerly, KA; Benton, CB; Champlin, R; Chen, J; Konoplev, S; Konopleva, M; Liu, W; Lu, H; Shpall, E; Wang, RY; Zeng, Z1
Blaise, D; Bramanti, S; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Devillier, R; Faucher, C; Fürst, S; Granata, A; Harbi, S; Hospital, MA; Legrand, F; Lemarie, C; Lining, W; Maisano, V; Mokart, D; Pagliardini, T; Porta, MD; Rey, J; Saillard, C; Vey, N; Weiller, PJ1
Aiyer, HM; Bansal, S; Bhakuni, P; Bhargava, S; Chakrabarti, S; Jaiswal, SR1
Audisio, E; Boccadoro, M; Bruno, B; Candoni, A; Cerrano, M; Crisà, E; D'Ardia, S; Dubbini, MV; Ferrero, D; Zannier, ME1
Wierda, WG1
Imanaga, H; Ohno, Y; Ohta, T; Oku, S; Sugio, Y1
Wendtner, CM1
Artz, A; Bishop, MR; Champlin, RE; Chen, J; Ciurea, SO; Gergis, U; Guarneri, D; Liu, H; Mayer, SA; Rondon, G; Shore, T; Srour, SA; Stock, W; van Besien, K1
Chen, B; Fang, Q; He, Z; Li, P; Ma, D; Ren, M; Wang, J; Zhe, N; Zhong, Q; Zhou, Z1
Burgess, M; Cheung, C; Gill, D; McMillan, NA; Mollee, P; Saunders, NA; Tate, C1
Bashey, A; Holland, HK; Morris, LE; Solh, M; Solomon, SR; Zhang, X1
Chua, KYL; Holmes, NE; Meher-Homji, Z; Phillips, EJ; Seymour, JF; Siderov, J; Slavin, MA; Tam, CS; Trubiano, JA1
Al-Ahmari, A; Al-Jefri, A; Al-Saedi, H; Al-Seraihi, A; Alanazi, A; Ayas, M; Ayas, MF; Ghemlas, I; Jafri, R; Siddiqui, K1
Cao, J; Chen, W; Cheng, H; Jing, G; Li, H; Qi, K; Qiao, J; Shi, M; Wang, G; Wu, Q; Xu, K; Zeng, L; Zhao, J; Zheng, J1
Alonso Caballero, C; Barrenetxea Lekue, C; D'Amore, F; Grasso Cicala, S; Herráez Rodríguez, S; Jørgensen, JM; Leal Martínez, I; Leppä, S; Stauffer Larsen, T; Toldbod, H1
Barr, PM; Barrientos, J; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Jelinek, DF; Kay, NE; Leis, JF; Little, RF; Litzow, M; Mato, AR; Mullane, MP; O'Brien, S; Shanafelt, TD; Singh, AK; Stone, RM; Tallman, M; Wang, XV; Zhang, CC1
Facco, M; Frezzato, F; Gurrieri, C; Imbergamo, S; Martini, V; Pagnin, E; Piazza, F; Pravato, S; Raggi, F; Scomazzon, E; Semenzato, G; Severin, F; Trentin, L; Trimarco, V; Visentin, A1
Chen, J; Cheng, H; Gao, L; Hu, X; Luo, Y; Tang, G; Wang, J; Yang, D; Yang, J; Zhang, W1
Stirrups, R1
Bijou, F; Durrieu, F; Filleron, T; Gauthier, M; Martin, E; Obéric, L; Peres, M; Quillet Mary, A; Vergez, F; Ysebaert, L1
Bosch, F; Böttcher, S; Cantin, G; Cortelezzi, A; Foà, R; Gresko, E; Knauf, W; Leblond, V; Merot, JL; Robson, S; Stilgenbauer, S; Tausch, E; Tiab, M; Trunzer, K; Turgut, M; Zaritskey, A1
Czyż, A; Danylesko, I; Fein, JA; Nagler, A; Shem Tov, N; Shimoni, A; Shouval, R; Sobas, M; Vega, Y; Yerushalmi, R1
Holzer, S; Jenkyn-Bedford, M; Kilkenny, ML; Pellegrini, L; Rzechorzek, NJ; Short, IR1
Behre, G; Döhring, C; Franke, GN; Grimm, J; Hille, A; Jentzsch, M; Linke, R; Niederwieser, D; Pönisch, W; Schwind, S; Vucinic, V1
Burger, JA; Estrov, Z; Ferrajoli, A; Hether, T; Jain, N; Jorgensen, JL; Keating, MJ; O'Brien, SM; Peterson, C; Srivastava, J; Strati, P; Thompson, PA; Wierda, WG1
Abrams, ZB; Abruzzo, LV; Bahlo, J; Barron, LL; Benner, A; Bloehdorn, J; Bondaruk, JE; Coombes, KR; Czerniak, BA; Ferrajoli, A; Fischer, K; Hallek, M; Herling, CD; Keating, MJ; Majewski, T; Oakes, CC; Stilgenbauer, S1
Arthur, C; Fay, K; Greenwood, M; Kerridge, I; Lindsay, J; Lwin, Y; Reid, C; Stevenson, W; Wong, K1
Al-Atrash, G; Alousi, A; Bashir, Q; Betul, O; Bittencourt, MCB; Champlin, RE; Ciurea, SO; Daver, N; Hosing, C; Jabbour, E; Kantarjian, H; Kebriaei, P; Khouri, I; Kongtim, P; Konopleva, M; Masarova, L; Mehta, R; Olson, A; Perez, JMR; Popat, U; Ravandi, F; Saliba, RM; Short, N; Srour, SA1
Bednarski, JJ; Bhatt, ST; Hente, M; Murray, L; Schulz, G; Shenoy, S; Slater, A1
Shimoni, A1
Shen, YF; Sun, HL; Zhou, X; Zou, ZJ1
Fujita, N; Fukano, R; Fukuda, T; Hashii, Y; Inagaki, J; Inoue, M; Kato, K; Kobayashi, R; Maseki, N; Mitsui, T; Mori, T; Okada, K; Sato, A; Shimoyama, T; Shindo, M; Suzuki, R; Suzumiya, J; Tabuchi, K1
Bolwell, B; Gerds, AT; Hamilton, BK; Hanna, R; Kalaycio, M; Majhail, NS; Patel, SS; Pohlman, B; Rybicki, L; Sobecks, R1
Blaise, D; Choi, G; Cornelissen, J; Heinicke, T; Kuball, J; Labopin, M; Mohty, M; Nagler, A; Niederwieser, D; Paul, F; Platzbecker, U; Polge, E; Potter, V; Savani, BN; Schaap, N; Sengelov, H; van Gorkom, G1
Battiwalla, M; Brazauskas, R; Buchbinder, D; Cahoon, EK; Curtis, RE; Engels, EA; Flowers, ME; Herr, MM; Morton, LM; Shaw, BE; Tecca, HR; Tucker, MA1
Dührsen, U; Flasshove, M; Hanoun, M; Noppeney, R; Schmitz, C; Westhus, J1
Beutel, G; Dammann, E; Eder, M; Eggers, H; Ehrlich, S; Gabdoulline, R; Ganser, A; Göhring, G; Hambach, L; Heuser, M; Klement, P; Koenecke, C; Markel, D; Neziri, B; Rehberg, A; Reuter, M; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Wichmann, M1
Jayakumar, I; Patel, S; Raj, R; Ramakrishnan, B; Ramanan, KM; Ravichandran, N; Swaminathan, VV; Uppuluri, R1
Appelhans, D; Borowiec, M; Bryszewska, M; Danilewicz, M; Franiak-Pietryga, I; Jander, M; Kuncman, W; Sikorska, H; Ziemba, B1
Gennery, AR; Hoenig, M; Lum, SH; Slatter, MA1
Brinda, BJ; Foxworthy Scott, S; Karr, AH; Kiel, PJ; Nelson, RP; Podichetty, JT; Prasad, NK; Quinney, S1
Bachy, E; Baseggio, L; Besson, H; Callet-Bauchu, E; Diels, J; Doubek, M; Garside, J; Healy, N; Hermans, R; Iraqi, W; Lundbom, J; Lysak, D; Panovska, A; Pick-Lauer, C; Salles, G; Simkovic, M; Smolej, L; Spacek, M; Urbanova, R1
Anagnostopoulos, A; Bhoi, S; Duran-Ferrer, M; Ghia, P; Kollia, P; Ljungström, V; Malousi, A; Mansouri, L; Martin-Subero, JI; Moysiadis, T; Oscier, D; Papakonstantinou, N; Plevova, K; Pospisilova, S; Pott, C; Queirós, AC; Ritgen, M; Rosenquist, R; Stamatopoulos, K; Stavroyianni, N; Trentin, L; Tsagiopoulou, M1
Agar, S; Altay, F; Gölcü, A; Sayin, VO; Şenel, P; Yurtsever, M1
Aotsuka, N; Hangaishi, A; Hoshino, T; Kako, S; Kanda, Y; Kato, J; Kobayashi, T; Matsumoto, K; Mori, T; Najima, Y; Okamoto, S; Onizuka, M; Shimizu, H; Shono, K; Tachibana, T; Tanaka, M; Tsukamoto, S; Usuki, K; Watanabe, R; Yamazaki, E; Yano, S1
Doorduijn, JK; Dreyling, MH; Feugier, P; Geisler, CH; Hermine, O; Hoster, E; Kaiser, F; Kanz, L; Klapper, W; Kluin-Nelemans, HC; Pott, C; Ribrag, V; Salles, G; Schmidt, C; Stilgenbauer, S; Szymczyk, M; Thieblemont, C; Tilly, H; Trneny, M; Unterhalt, M; Walewski, J; Zijlstra, JM1
Alousi, A; Bashir, Q; Champlin, RE; Chen, J; Ciurea, SO; Daver, N; Hosing, C; Kongtim, P; Konopleva, M; Mehta, R; Olson, A; Oran, B; Popat, U; Rondon, G; Srour, S; Varma, A1
Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I1
Briones, J; Brunet, S; Caballero, A; Esquirol, A; Garcia-Cadenas, I; Garrido, A; Granell, M; Martino, R; Moreno, C; Novelli, S; Querol, S; Saavedra, S; Sierra, J1
Angelucci, E; Bacigalupo, A; Bregante, S; Bruno, B; Chiusolo, P; Grazia, CD; Grisariu, S; Iori, AP; Mordini, N; Olivieri, A; Patriarca, F; Raiola, AM; Rambaldi, A; Sica, S; Sora, F; Terruzzi, E1
Cai, Y; Jiang, J; Wan, L; Wang, C; Yang, J1
Achyut, BR; Allan, PW; Behbahani, T; Ealick, SE; Gilbert-Ross, M; Hong, J; Joshi, D; Parker, WB; Rab, R; Sorscher, EJ; Waud, WR1
Boelens, JJ; de Witte, MA; Dorlo, TPC; Huitema, ADR; Langenhorst, JB; Nierkens, S; van Kesteren, C; van Maarseveen, EM1
Melarcode Ramanan, K; Patel, S; Raj, R; Ravichandran, N; Uppuluri, R; Vellaichamy Swaminathan, V1
Chhabra, S; D'Souza, A; Dhakal, B; Drobyski, WR; Fenske, TS; George, G; Hamadani, M; Hari, PN; Jerkins, JH; Michaelis, LC; Narra, RK; Pasquini, MC; Rizzo, RD; Saber, W; Shah, NN; Shaw, BE; Szabo, A; Wu, R1
Govindaraju, S; Grosicki, S; Kryachok, I; Lewerin, C; Mazur, G; Middeke, JM; Miklos, U; Montillo, M; Österborg, A; Rekhtman, G; Stefanelli, T; Steurer, M; Strugov, V; Vincent, G1
Higashi, T; Hirosawa, M; Kominato, Y; Morimoto, H; Tanaka, A; Tsukada, J; Yamaguchi, T1
Antoniou, P; Blakemore, SJ; Bryant, D; Carr, L; Catovsky, D; Chan, J; Clifford, R; Colins, A; Cragg, MS; Davis, Z; Else, M; Forster, J; Kadalyayil, L; Larrayoz, M; McCarthy, H; Morilla, R; Oscier, DG; Parker, H; Robbe, P; Rose-Zerilli, MJJ; Schuh, A; Speight, G; Stankovic, T; Stec-Dziedzic, E; Steele, AJ; Strefford, JC; Vavoulis, D; Walewska, RJ1
Bąbol-Pokora, K; Dąbrowska-Leonik, N; Frączkiewicz, J; Gul, K; Janeczko-Czarnecka, M; Kałwak, K; Martuszewski, A; Mielcarek-Siedziuk, M; Młynarski, W; Nowak, M; Paluszkiewicz, P; Salamonowicz-Bodzioch, M; Sierżęga-Staykov, K; Ussowicz, M; Wawrzyniak-Dzierżek, E; Wolska-Kuśnierz, B1
Dreger, P; Hegenbart, U; Herfarth, K; Luft, T; Müller-Tidow, C; Radujkovic, A1
Al-Sawaf, O; Bahlo, J; Böttcher, S; Busch, R; Cazin, B; Cymbalista, F; Döhner, H; Dreyfus, B; Eichhorst, B; Fink, AM; Fischer, K; Groß-Ophoff-Müller, C; Hallek, M; Herling, CD; Hoechstetter, MA; Ibach, S; Kaiser, F; Kneba, M; Langerbeins, P; Leblond, V; Leprêtre, S; Letestu, R; Levy, V; Porcher, R; Robrecht, S; Stilgenbauer, S; Wentner, CM1
Beckerleg, W; Milman, N; van der Jagt, R1
Al-Chami, F; Angelucci, E; Bazarbachi, A; Bonifazi, F; Bruno, B; Carella, AM; Castagna, L; El-Cheikh, J; Iori, AP; La Nasa, G; Labopin, M; Mohty, M; Nagler, A; Santarone, S; Savani, B1
Andersen, NS; Friis, LS; Grønbæk, K; Hansen, JW; Kornblit, B; Petersen, SL; Schjødt, I; Sengeløv, H; Wedge, E1
Fujita, N; Fukano, R; Hashimoto, H; Kada, A; Kamei, M; Kobayashi, R; Koga, Y; Mitsui, T; Mori, T; Ohki, K; Osumi, T; Saito, AM; Sekimizu, M; Tanaka, F; Ueyama, J1
Banerjee, H; Blonski, J; Govind Babu, K; Grosicki, S; Homenda, W; Kriachok, I; Kłoczko, J; Lech-Maranda, E; Litvinskaya, E; Loscertales, J; Rekhtman, G; Robak, T; Rybka, J; Stefanelli, T; Vincent, G1
Al Tourah, AJ; Bruyere, H; Dueck, G; Galbraith, P; Gerrie, AS; Hardy, E; Hrynchak, M; Huang, SJ; Noble, MC; Ramadan, KM; Sehn, L; Toze, CL; Tsang, P; Tucker, T; Young, S1
Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Mizuno, T; Nakadate, H; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yoshimura, S1
Chen, K; Han, X; Hao, H; Huang, T; Lei, J; Li, Q; Liu, C; Liu, Y; Yu, F1
Bishton, MJ; Clifton-Hadley, L; Haynes, A; Lush, R; McMillan, A; Patmore, R; Rule, S; Turner, D; Wilson, W1
Ahn, KW; Awan, FT; Chow, VA; Eghtedar, A; Fenske, TS; Hamadani, M; Karmali, R; Khanal, M; Kharfan-Dabaja, MA; Litovich, C; Sauter, C; Winter, A1
Chevassut, T; Milne, K; Sturrock, B1
Akasaka, T; Atsuta, Y; Eto, T; Fukuda, T; Hidaka, M; Kanda, J; Kondo, T; Miyakoshi, S; Ota, S; Shiratori, S; Takami, A; Uchida, N; Yamashita, T; Yano, S1
Chen, X; Chen, Y; Li, J; Li, Z; Liu, F; Liu, L; Pui, CH; Ruan, M; Wang, J; Wang, S; Wang, Y; Yang, JJ; Zhong, M; Zhu, X1
Gordiienko, I; Ivanivska, T; Shcherbina, V; Shlapatska, L; Sidorenko, S1
Beitinjaneh, A; Flinn, IW; Fung, H; Goy, A; Hill, BT; Holmes, H; Houot, R; Jacobson, CA; Jaglowski, S; Jain, RK; Kersten, MJ; Locke, FL; McSweeney, PA; Miklos, DB; Milpied, N; Munoz, J; Pagel, JM; Peng, W; Rao, AV; Reagan, PM; Rossi, JM; Timmerman, JM; Topp, MS; Wang, M; Zheng, L1
Asher, N; Ben-Betzalel, G; Ben-Nun, A; Besser, MJ; Brezinger, K; Itzhaki, O; Kubi, A; Levi, M; Markel, G; Nagler, A; Nissani, A; Schachter, J; Shapira-Frommer, R; Shimoni, A; Zeltzer, LA; Zikich, D; Zippel, DB1
Suzumiya, J; Takizawa, J1
Agrawal, N; Agrawal, P; Ahmed, R; Bhurani, D; Kapoor, J; Khushoo, V; Mirgh, SP; Naim, F; Pramanik, SK1
Ahluwalia, MS; Alban, TJ; Bayik, D; Cheng, F; Grabowski, MM; Hong, C; Horbinski, C; Hwang, TH; Khalil, AM; Kristensen, BW; Lathia, JD; Lauko, A; Lo, A; McGraw, M; Otvos, B; Park, C; Roversi, G; Silver, DJ; Sorensen, M; Vail, D; Vogelbaum, MA; Watson, DC; Zhou, Y1
Byrd, JC; Lee, DA; Mani, R; Mo, X; Muthusamy, N; Nunes, J; Rajgolikar, G; Vasu, S; Wasmuth, R; Zapolnik, K1
Bertrand, Y; Girard, S; Marceau-Renaut, A; Penel-Page, M; Plesa, A; Renard, C1
Bloehdorn, J; Döhner, H; Lichter, P; Mertens, D; Stilgenbauer, S; Yosifov, DY1
Barcellini, W; Berentsen, S; Brudevold, R; D'Sa, S; Dahm, AEA; Dalgaard, J; Fattizzo, B; Frøen, H; Hallstensen, RF; Haukås, E; Hjorth-Hansen, H; Jæger, PH; Kell, M; Małecka, A; Oksman, M; Randen, U; Rolke, J; Sekhar, M; Sørbø, JH; Tjønnfjord, E; Tjønnfjord, GE; Tsykunova, G; Tvedt, THA1
Bernardi, R; Bongiovanni, L; Coltella, N; Ghia, P; Magliulo, D; Ponzoni, M; Scarfò, L; Valsecchi, R1
Al Malki, MM; Aldoss, I; Ali, H; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; Pullarkat, V; Salhotra, A; Sandhu, K; Smith, E; Snyder, D; Stein, A; Tsai, NC1
Allain, EP; Bat, V; Caron, P; Demirtas, D; Droit, A; Guillemette, C; Hubmann, R; Jäger, U; Joly-Beauparlant, C; Labriet, A; Le, T; Lévesque, E; Rouleau, M; Schnabl, S; Shehata, M; Staber, PB; Tremblay, S; Turcotte, V; Vaillancourt, J; Vanura, K; Villeneuve, L1
Atsuta, Y; Fujita, N; Goto, H; Inoue, M; Kato, K; Kawaguchi, H; Kobayashi, R; Koh, K; Kojima, S; Kudo, K; Miyamura, T; Okada, K; Okamoto, Y; Suzuki, R; Takahashi, Y; Watanabe, K; Yabe, H; Yabe, M; Yoshida, N1
Cheah, R; Dendle, C; Gregory, G; Mohan, B; Tey, A1
Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L1
Choi, Y; Do, YR; Jung, SH; Kim, DS; Koh, Y; Lee, JH; Lee, S; Lee, SS; Lee, WS; Moon, JH; Mun, YC; Park, HS; Park, Y; Yang, DH; Yhim, HY; Yi, JH1
Baron, F; Hsu, J; Van Besien, K1
Ahmed, S; Ahn, KW; Aljurf, M; Bacher, VU; Bredeson, C; Epperla, N; Farhadfar, N; Freytes, CO; Ganguly, S; Ghosh, N; Hamadani, M; Haverkos, B; Inwards, D; Kamble, RT; Khanal, M; Kharfan-Dabaja, MA; Lazarus, HM; Lekakis, L; Litovich, C; Murthy, HS; Nishihori, T; Ramakrishnan, P; Rizzieri, DA; Sureda, A; Yared, JA1
Ussowicz, M1
Andrés, AM; Arreola, NM; González-Navarro, P; Hernández-Oliveros, F; Machuca, M; Mestre, C; Navarro-Zapata, A; Papa-Gobbi, R; Pascual-Miguel, B; Pérez-Martínez, A; Pires-Lobo, SC; Stringa, P; Vela, M1
Daly, A; Dharmani-Khan, P; Duggan, PR; Jamani, K; Jimenez-Zepeda, V; Kalra, A; Khan, FM; Ousia, S; Prokopishyn, N; Russell, JA; Storek, J; Williamson, TS1
Bertz, H; Duque-Afonso, J; Finke, J; Ihorst, G; Köhler, T; Marks, R; Müller-Quernheim, J; Wäsch, R; Waterhouse, M; Yücel, M; Zeiser, R1
Kolb, HJ; Schmid, C1
Cao, J; Cheng, H; Gao, X; Jiao, J; Li, D; Li, W; Li, Z; Liu, H; Ma, Y; Qin, Y; Sang, T; Sang, W; Shi, M; Song, X; Sun, C; Sun, H; Sun, K; Wang, Y; Wu, M; Xu, K; Xu, L; Yan, D; Yan, Z; Yang, J; Yao, M; Zeng, L; Zhang, B; Zheng, J; Zhu, F1
Anagnostopoulos, A; Chatzidimitriou, A; Galigalidou, C; Gemenetzi, K; Ghia, P; Ioannou, N; Iskas, M; Koravou, E; Kotouza, M; Kotta, K; Kouvatsi, A; Papazoglou, D; Pasentsis, K; Psomopoulos, F; Ramsay, AG; Scarfó, L; Stamatopoulos, K; Stavroyianni, N; Vardi, A; Vlachonikola, E1
Cho, BS; Cho, SG; Eom, KS; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yoon, JH1
de Castro, DG; Dietrich, S; Dreger, P; Dreyling, M; Grabe, N; Hermine, O; Hoster, E; Hüttl, K; Klapper, W; Kluin-Nelemans, HC; Müller-Tidow, C; Ott, G; Pott, C; Roider, T; Rosenwald, A; Stewart, JP; Wang, X1
Bruce, AAK; Desai, S; Guilcher, GMT; Le, D; Leaker, MT; Lewis, V; Shah, RM; Steele, M; Truong, TH; Wright, NAM1
Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G1
Akashi, K; Eto, T; Fujishima, N; Harada, M; Hidaka, M; Kishimoto, J; Maeda, Y; Matsumoto, K; Miyamoto, T; Mori, SI; Morita, K; Murayama, T; Sakura, T; Taniguchi, S; Teshima, T; Uchida, N; Yamashita, T; Yoshimoto, G1
Slater, H1
Callander, N; D'Angelo, CR; Hall, A; Hematti, P; Juckett, M; Kenkre, VP; Kim, K; Longo, W; Mattison, R; Woo, KM1
Appelhans, D; Borowiec, M; Bryszewska, M; Danilewicz, M; Franiak-Pietryga, I; Jander, M; Kuncman, W; Lewkowicz, P; Ostrowska, K; Sikorska, H; Ziemba, B1
Beaven, AW; Brenner, MK; Buchanan, FB; Cheng, CJ; Dittus, C; Dotti, G; Eldridge, PW; Gee, AP; Grilley, BJ; Grover, NS; Heslop, HE; Ivanova, A; Lulla, PD; McKay, KL; Mehta, B; Morrison, K; Park, SI; Ramos, CA; Rooney, CM; Savoldo, B; Serody, JS; Shea, TC; Wang, T; Wu, MF1
Ahmed, P; Anwer, F; Chaudhry, QUN; Farhan, M; Ghafoor, T; Humayun, S; Iftikhar, R; Khan, MA; Khattak, TA; Mahmood, SK; Rehman, J; Risalat, A; Satti, HS; Satti, TM; Shahbaz, N; Shamshad, GU; Wahab, A1
Ahn, IE; Fleisher, T; Gaglione, E; Lotter, J; Maric, I; Mu, R; Pittaluga, S; Pleyer, C; Rampertaap, S; Rosenzweig, S; Soto, S; Stetler-Stevenson, M; Sun, C; Superata, J; Tian, X; Wiestner, A; Yuan, CM1
Armand, P; Arnason, J; Brown, JR; Davids, MS; Fisher, DC; Francoeur, K; Hanna, J; Lee, B; McDonough, M; Montegaard, J; Odejide, O; Tyekucheva, S1
Ali, T; Behfar, M; Farajifard, H; Hamidieh, AA; Hkima Abou Fakher, F; Kheder, M1
Hino, Y; Kato, J; Kikuchi, T; Koda, Y; Matsumoto, K; Mishina, T; Mori, T; Morita, K; Nagao, Y; Ohwada, C; Okamoto, S; Onizuka, M; Onoda, M; Sakaida, E; Shimizu, H; Shono, K; Takeda, Y; Yokota, A; Yokoyama, H1
Brochstein, J; Sahdev, I; Stiles, J; Werther, N1
Beelen, DW; Blaise, D; Bornhäuser, M; Byrne, JL; Fegueux, N; Giebel, S; Karadogan, I; Labopin, M; Mohty, M; Nagler, A; Rovira, M; Savani, BN; Sobczyk-Kruszelnicka, M; Spyridonidis, A; Stelljes, M1
An, Y; Gao, X; Jingquan, G; Xiao, K; Xie, W; Yang, L1
Aanei, C; Baseggio, L; Béné, MC; Boubaya, M; Campos, L; Cartron, G; Chatelain, B; Cymbalista, F; Dahmani, A; Dartigeas, C; Debliquis, A; Delepine, R; Drénou, B; Feugier, P; Jacob, MC; Katsahian, S; Le Garff-Tavernier, M; Leblond, V; Legac, E; Leprêtre, S; Letestu, R; Lévy, V; Lhoumeau, AC; Quiney, C; Robillard, N; Rouillé, V; Ticchioni, M; Van Den Neste, E; Vaudaux, S1
Cao, R; Chen, M; Dong, Z; Su, Q; Wang, F1
Cavo, M; Curti, A; Iannarone, C; Ocadlikova, D; Redavid, AR1
Bar, M; Bezerra, ED; Cassaday, RD; Chapuis, AG; Chou, CK; Cowan, AJ; Fiorenza, S; Gauthier, J; Green, DJ; Hawkins, RM; Hirayama, AV; Jamieson, AW; Kiem, HP; Kimble, EL; Maloney, DG; Milano, F; Pender, BS; Phi, TD; Riddell, SR; Shadman, M; Sheih, A; Steinmetz, RN; Till, BG; Turtle, CJ; Vakil, A1
Ata, O; Inci, TG; Kocer, S; Mutlu, O; Sariyer, E; Turgut-Balik, D; Ugurel, E; Ugurel, OM1
Adachi, S; Goto, H; Hasegawa, D; Iwamoto, S; Kakuda, H; Koh, K; Miyamura, T; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D; Yuza, Y1
Cao, L; Du, XY; Fan, L; Li, JY; Wang, F; Wang, L; Xu, W; Zhu, HY1
Chu, X; Fang, X; Geng, L; Liu, H; Qiang, P; Song, K; Sun, G; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, X; Zhu, X1
Banet, A; Battipaglia, G; Belhocine, R; Bianchessi, A; Bonnin, A; Boussaroque, A; Brissot, E; Duléry, R; Favale, F; Hirsch, P; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Memoli, M; Mohty, M; Paviglianiti, A; Sestili, S; Van de Wyngaert, Z; Vekhoff, A1
Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I1
Arabi, A; Bazarbachi, A; Bekadja, MA; Bouhass, R; Brahimi, M; Osmani, S; Serradj, F; Yafour, N1
Bejar, J; Garty-Ofir, M; Kreiniz, N; Polliack, A; Tadmor, T1
Chauvin-Fleurence, CN; Courtney, AN; Dakhova, O; Di Pierro, EJ; Dotti, G; Ghatwai, N; Heczey, A; Li, M; Liu, B; Liu, K; Metelitsa, LS; Montalbano, A; Ngai, H; Raveh-Sadka, T; Robinson, S; Savoldo, B; Xu, X1
Angelucci, E; Beauvais, D; Beelen, D; Bornhäuser, M; Castagna, L; Chevallier, P; Czerw, T; de Wreede, L; Finke, J; Hayden, P; Helbig, G; Hernández-Boluda, JC; Karakasis, D; Kröger, N; Maertens, J; Mauff, K; McLornan, D; Mear, JB; Mohty, M; Passweg, J; Polverelli, N; Reményi, P; Rifòn, J; Robin, M; Rubio, MT; Russo, D; Sirait, T; Vrhovac, R; Yakoub-Agha, I1
Bansal, M; Bhargava, R; Chakraborty, S; Dua, V; Hamal, S; Sachdev, M1
Cui, Q; Hu, Y; Huang, H; Liang, Z; Shao, M; Wu, Z; Xiao, L; Zhang, H1
Albano, F; Angelucci, E; Battistini, R; Coscia, M; Cuneo, A; De Propris, MS; Del Giudice, I; Del Poeta, G; Della Starza, I; Foà, R; Gozzetti, A; Guarini, AR; Ilariucci, F; Liberati, AM; Mauro, FR; Molica, S; Musolino, C; Nanni, M; Neri, A; Piciocchi, A; Pietrasanta, D; Raponi, S; Re, F; Reda, G; Soddu, S; Tedeschi, A; Vignetti, M; Zaja, F1
Ahmed, P; Ansar, I; Anwer, F; Ashraf, R; Chaudhry, QUN; Farhan, M; Ghafoor, T; Iftikhar, R; Khan, M; Khan, MA; Khattak, TA; Mahmood, SK; Marsh, J; Neupane, K; Rafae, A; Rehman, J; Satti, TM; Shahbaz, N; Shamshad, GU1
Brammer, JE; Choe, H; Dickerson, T; Elder, P; Jaglowski, S; Larkin, K; Mims, A; Penza, S; Puto, M; Rasor, B; Roddy, JVF; Saad, A; Vasu, S; Wall, SA; William, B; Zhao, Q1
Kapoor, R; Rastogi, N; Yadav, SP1
Fukuhara, S; Izutsu, K; Kinoshita, T; Ohashi, Y; Suzumiya, J; Takizawa, J; Tobinai, K; Yamamoto, G1
Moreno, C1
Barbarino, M; Bottaro, M; Cipollini, M; Corrado, A; Dell'Anno, I; Gemignani, F; Giordano, A; Landi, S; Luzzi, L; Martin, SA; Melaiu, O; Melani, A; Paolicchi, E; Silvestri, R1
Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A1
Clement, NF; Dietrich, J; Hochberg, EP; Martinez-Lage, M; Winter, SF1
Mathews, W; Muldoon, D; Tolar, J; Vanden Oever, M1
El-Sharkawi, D; Stewart, A; Williams, R1
Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K1
Chan, W; Ding, H; Hao, L; Li, J; Liu, J; Ren, J; Wang, J; Wang, M; Wei, W; Yang, Q; Yue, Y1
Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I1
Aoki, Y; Ashiarai, M; Endo, A; Hiroki, H; Hoshino, A; Ichimura, T; Imai, K; Inoue, K; Inoue, M; Ishiwata, Y; Isoda, T; Kajiwara, M; Kamiya, T; Kanegane, H; Kawahara, Y; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Miyawaki, R; Mizutani, S; Morio, T; Nagasawa, M; Nishimura, A; Okano, T; Okawa, T; Ono, S; Ono, T; Takagi, M; Tanaka-Kubota, M; Tezuka, M; Tomizawa, D; Tomoda, T; Ueyama, J; Yamagishi, C; Yamashita, M; Yanagimachi, M; Yasuhara, M1
Chen, A; Hayes-Lattin, B; Maziarz, RT; Murphree, C; Nagle, SJ; Nemecek, E; Raess, PW; Schachter, L1
Atalay, RC; Guven, EB; Kucukdumlu, A; Tuncbilek, M1
Andersen, MA; da Cunha-Bang, C; Frederiksen, H; Grønbaek, K; Hjalgrim, H; Niemann, CU; Rostgaard, K; Rotbain, EC1
Ayash, L; Deol, A; Kim, S; Modi, D; Ratanatharathorn, V; Singh, V; Uberti, JP1
Edahiro, T; Fujii, T; Fujino, K; Fukushima, N; Hirata, Y; Ichinohe, T; Kawase, T; Mino, T; Miyama, T; Morioka, T; Nagoshi, H; Nishizawa, M; Noma, M; Toishigawa, K; Yoshida, T1
Chamo, M; Gazit, R; Goldstein, O; Ilic, S; Keinan, N; Scharff, Y1
Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M1
Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM1
Campbell, TB; Jagannath, S; Madduri, D; Neumann, F; Parekh, S; Petrocca, F1
Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S1
Algarra, L; Amador Barciela, ML; Barragán, E; Bergua Burgues, J; Colorado, M; Falantes, JF; Fernández, MÁ; Foncillas, MÁ; García, O; Gascón, A; Gil, C; Herrera, P; Labrador, J; Lavilla, E; López-Lorenzo, JL; Martínez-Cuadrón, D; Martínez-López, J; Martínez-Sánchez, MP; Montesinos, P; Olave, MT; Paiva, B; Pérez-Encinas, MM; Ramos, F; Rodríguez-Veiga, R; Salamero, O; Sanz, MÁ; Sayas, MJ; Serrano, A; Serrano, J; Simiele, A; Tormo, M; Vidriales, B; Vives, S1
Ashida, T; Atsuta, Y; Fukuda, T; Hara, M; Ichinohe, T; Ikeda, T; Ishikawa, T; Kawakita, T; Maruyama, Y; Morishige, S; Shimomura, Y; Takada, S; Takanashi, M; Uchida, N; Wake, A; Yamamoto, H1
DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA1
Demsky, C; Gorfinkel, L; Kupfer, G; Pashankar, F; Shah, NC1
Cuesta, M; Esquirol, A; Ferrà, C; Garcia-Cadenas, I; Herruzo, B; Martino, R; Pascual, MJ; Pérez, A; Sierra, J; Torio, A; Torrent, A1
Ding, H; Gao, C; Gao, S; Li, Z; Lin, S; Wen, C; Xing, Z; Yu, Y; Zou, P1
Abraham, A; Abubacker, FN; Devasia, AJ; George, B; Korula, A; Kulkarni, U; Lakshmi, KM; Lionel, S; Mathews, V; Selvarajan, S; Sindhuvi, E1
Asher, N; Ben-Betzalel, G; Besser, MJ; Itzhaki, O; Jacoby, E; Lev-Ari, S; Markel, G; Meirson, T; Nissani, A; Schachter, J; Shapira-Frommer, R1
Cho, HW; Hyun, JK; Ju, HY; Koo, HH; Lee, JW; Lim, DH; Sung, KW; Yoo, KH1
Cheng, Z; Feng, L; He, F; Wei, R; Wu, Y; Xiao, M; Zhao, G1
Ayala, A; Borthakur, G; Bose, P; Burger, J; Estrov, Z; Ferrajoli, A; Gandhi, V; Garg, N; Jabbour, E; Jain, N; Jorgensen, J; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Keating, M; Konopleva, M; Lopez, W; O'Brien, S; Patel, K; Pemmaraju, N; Plunkett, W; Sasaki, K; Takahashi, K; Thompson, P; Wang, S; Wang, W; Wang, X; Wierda, WG1
Chaudhury, S; Duerst, RE; Jacobsohn, D; Kletzel, M; Kwon, S; Rossoff, J; Schneiderman, J; Tse, WT1
Isobe, M; Konuma, T; Monna-Oiwa, M; Okabe, M; Takahashi, S; Tojo, A1
Allsup, D; Bloor, A; Emmerson, J; Hillmen, P; Hockaday, A; Howard, D; Munir, T; Nathwani, A; Oughton, JB; Paneesha, S; Phillips, D; Rawstron, A; Turner, D1
Adeoti, M; Alvarado, Y; Andreeff, M; Borthakur, G; Daver, N; DiNardo, CD; Garcia-Manero, G; Issa, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, MY; Kornblau, S; Lachowiez, CA; Loghavi, S; Maiti, A; Masarova, L; Montalban Bravo, G; Pemmaraju, N; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Wang, S; Xiao, L; Yilmaz, M1
Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S1
Bai, S; Cai, Z; Gong, J; Huang, H; Huang, T; Peng, Y; Xiong, G; Xiu, H; Zhang, G; Zhang, S1
Amagai, M; Fujita, T; Fukuda, K; Funakoshi, T; Handa, M; Hirai, I; Iwata, T; Kamijuku, H; Kato, J; Kawakami, Y; Koda, Y; Mori, M; Mori, T; Noji, S; Ohta, S; Okamoto, S; Sakurai, M; Tanosaki, R; Watanabe, N; Yaguchi, T1
Ahmed, SO; Alahmari, A; Alfraih, F; Alhakim, A; Alhayli, S; Aljurf, M; Almohareb, F; Alsadi, H; Alshaibani, A; Alsharif, F; Alshomar, A; Alzahrani, H; Assiri, A; Babiker, F; Balbaid, A; Chaudhri, N; El Fakih, R; Elhassan, T; Ghabashi, E; Hanbali, A; Kotb, A; Rasheed, W; Samarkandi, H; Shaheen, M1
Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S1
Allsup, D; Baird, DM; Bomben, R; Bulian, P; Catovsky, D; Fegan, CD; Gattei, V; Hillmen, P; Hockaday, A; Norris, K; Ow, PL; Pepper, AGS; Pepper, C; Polesel, J; Rawstron, A; Soe, Z; Tissino, E; Zucchetto, A1
Atsuta, Y; Eto, T; Fukuda, T; Hara, M; Hirabayashi, S; Ichinohe, T; Kanda, Y; Kawakita, T; Kimura, T; Kondo, T; Maruyama, Y; Mizuno, S; Mukae, J; Nakano, N; Ota, S; Ozawa, Y; Shimomura, Y; Tanaka, M; Uchida, N; Yanada, M1
Araqi Houssaini, L; Chiheb, S; Hali, F; Marnissi, F; Quessar, A1
Illés, Á; Szász, R; Telek, B1
Barhoom, D; Behfar, M; Hamidieh, AA; Mohseni, R2
Amini, R; Ashofteh, N; Baazm, M; Karami, H; Molaee, N1
Cai, QQ; Cao, JN; Feng, JF; Gao, Y; Huang, HQ; Jiang, WQ; Jin, J; Li, ZM; Wang, HQ; Wang, XX; Zhang, HL1
Agrawal, V; Ahn, KW; Aljurf, M; Bacher, U; Bashey, A; Beitinjaneh, A; Bredeson, C; Cerny, J; Chhabra, S; Copelan, E; Diaz, MA; Farhadfar, N; Farhan, S; Fretham, C; Gale, RP; Ganguly, S; Grunwald, MR; Hale, GA; Hashmi, S; Hildebrandt, GC; Jain, T; Kalaycio, M; Kharfan-Dabaja, MA; Lazarus, HM; Liesveld, JL; Litzow, M; Majhail, NS; Marks, DI; Murthy, HS; Nakamura, R; Nathan, S; Nishihori, T; Olsson, RF; Oran, B; Pawarode, A; Popat, U; Reshef, R; Rizzieri, D; Saber, W; Sabloff, M; Savani, BN; Scott, BL; Seo, S; Szer, J; van der Poel, M; Verdonck, LF; Weisdorf, D; Wirk, B; Yared, JA; Yves-Cahn, J1
Barr, PM; Barrientos, JC; Braggio, E; Cashen, AF; Coutre, SE; Erba, H; Hanson, CA; Kay, NE; Leis, JF; Lesnick, CE; Litzow, MR; Mato, AR; Mullane, MP; O'Brien, S; Paietta, EM; Shanafelt, TD; Singh, AK; Stone, R; Tallman, MS; Tschumper, RC; Wang, XV; Zhang, CC1
Al-Ammari, M; Albtoosh, BM; Alfayez, M; AlGhamdi, MS; Alnoamani, MS; AlShehry, NF; Altaf, SY; Aoun, SMA; Iqbal, S; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ1
Ansari, M; Ben Hassine, K; Bittencourt, H; Bredius, RGM; Daali, Y; Kassir, N; Krajinovic, M; Lewis, V; Nath, CE; Nava, T; Shaw, PJ; Théoret, Y; Uppugunduri, CRS1
Adams, JM; Anderson, MA; Blombery, P; Carney, DA; Chen, X; Dengler, MA; Handunnetti, SM; Huang, DCS; Lew, TE; Lin, VS; Nguyen, T; Panigrahi, A; Roberts, AW; Seymour, JF; Tam, CS; Thompson, ER; Wei, AH; Westerman, DA1
Aoki, J; Atsuta, Y; Fukuda, T; Imada, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y1
Dong, J; Meng, G; Wei, J; Wu, J; Zhang, H; Zhang, Y; Zuo, S1
Atanackovic, D; Bukhari, A; Dahiya, S; Gahres, N; Gottlieb, D; Hardy, NM; Holtzman, NG; Kansagra, AJ; Kim, DW; Kocoglu, MH; Law, JY; Lee, ST; Lutfi, F; Matsumoto, LR; Mohindra, P; Molitoris, J; Mustafa Ali, M; Rapoport, AP; Ruehle, K; Samanta, S; Yan, J; Yared, JA1
Alcoceba, M; Andreu, MÁ; Anguita, E; Collado, R; Córdoba, R; de la Serna, J; de Oteyza, JP; Deben, G; Fernández, MC; Fernández-Cuevas, B; Fernández-Zarzoso, M; García-Malo, MD; García-Marco, JA; Garcia-Vela, JA; Gómez, S; González, M; González-Barca, E; González-Rincón, J; López-Jiménez, J; Navarro-Matilla, B; Nova-Gurumeta, S; Paz-Arias, R; Peñalver, FJ; Pérez-Persona, E; Pérez-Sanz, N; Recasens, V; Ruíz-Guinaldo, MÁ; Sánchez-Beato, M; Yáñez, L1
Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I1
Bağrıaçık, EÜ; Gökçen, S; Kayhan, H; Yağcı, M1
Avivi, I; Bot, A; Bouabdallah, K; Dong, J; Dührsen, U; Houot, R; Kerber, A; Kersten, MJ; Kim, JJ; Kuruvilla, J; Lugtenburg, PJ; Minnema, MC; Plaks, V; Rossi, JM; Sherman, M; Song, KW; Thieblemont, C; Topp, MS; van Meerten, T; Vardhanabhuti, S; Wermke, M; Zheng, Y1
Akiyama, M; Goto, H; Hasegawa, D; Honda, T; Kumamoto, T; Ogawa, S; Takagi, M; Terao, YM; Yamaoka, M; Yoshida, K1
Antin, JH; Brock, J; Cutler, CS; DeAngelo, DJ; Fell, G; Garcia, JS; Gooptu, M; Ho, VT; Karp, HQ; Kim, AS; Kim, HT; Koreth, J; Letai, A; Lindsley, RC; Loschi, F; Lucas, F; Mashaka, T; Murdock, HM; Nikiforow, S; Potter, D; Romee, R; Ryan, J; Shapiro, R; Soiffer, RJ; Stone, RM1
DiNardo, C; Gibson, A; Khazal, S; Mahadeo, KM; Petropoulos, D; Ragoonanan, D; Rodriguez, N; Tewari, P1
Adachi, H; Atsuta, Y; Doki, N; Igarashi, A; Ikegawa, S; Inamoto, K; Kaito, S; Kishida, Y; Kobayashi, T; Konishi, T; Konuma, R; Marumo, A; Mukae, J; Nagata, A; Nagata, R; Najima, Y; Noguchi, Y; Ohashi, K; Sakamaki, H; Toya, T; Wada, A; Yamada, Y1
Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S1
Appelbaum, FR; Cooper, JP; Deeg, HJ; Doney, K; Flowers, MED; Gooley, T; Martin, PJ; McCune, JS; McFarland, C; O'Donnell, PV; Schoch, G; Sorror, ML; Storer, BE; Yeh, AC1
Armand, P; Arnason, J; Brown, JR; Davids, MS; Fernandes, SM; Fisher, DC; Gadi, D; Griffith, A; Lederer, JA; Lee, B; Lehmberg, TZ; Machado, JH; Martindale, SP; Odejide, O; Rai, V; Thrash, E; Tyekucheva, S; Vartanov, A; Wang, Z1
Geng, L; Li, G; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, L; Zhang, S; Zhang, X; Zhu, X1
Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB1
Baggott, C; Boelens, JJ; Brown, PA; Chinnabhandar, V; Curran, KJ; Egeler, E; Fabrizio, VA; Goksenin, AY; Hermiston, M; Karras, NA; Keating, AK; Krupski, C; Kunicki, M; Laetsch, TW; Mackall, CL; Margossian, SP; Mauguen, A; Mavroukakis, S; Moskop, A; Myers, GD; Pacenta, H; Phillips, CL; Prabhu, S; Qayed, M; Rabik, CA; Rossoff, J; Satwani, P; Schultz, LM; Stefanski, HE; Talano, JA; Verneris, MR; Wilcox, R1
Abboud, R; Andolina, JR; DiPersio, JF; Eastburg, L; Fountaine, T; Huselton, E; Russler-Germain, DA1
Almazi, JG; Alomari, M; Belov, L; Best, OG; Christopherson, RI; Graham, ME; Mulligan, SP; Shen, Y1
Alimoghaddam, K; Badalzadeh, M; Fazlollahi, MR; Ghavamzadeh, A; Hamidieh, AA; Mahdaviani, SA; Pourpak, Z; Setarehdan, SA; Souri, M; Tajik, S; Vaezi, M1
Algeri, M; Alseraihy, A; Angelucci, E; Corbacioglu, S; Cseh, A; de la Fuente, J; Fisgin, T; Galimard, JE; Isgrò, A; Kleinschmidt, K; La La Nasa, G; Lankester, A; Locatelli, F; Lüftinger, R; Peters, C; Salzer, E; Smiers, FJ; Unal, E; Yesilipek, A; Zecca, M; Zubarovskaya, N1
Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A1
Cen, S; Dong, D; Guo, F; Guo, S; Li, Q; Li, X; Liu, Q; Liu, Z; Ma, L; Wei, T; Yi, D; Zhang, Y; Zhao, J1
Allsup, DJ; Bloor, A; Cairns, D; Clifford, R; Craig, Z; Gattei, V; Hillmen, P; Hockaday, A; Howard, D; Munir, T; Pepper, C; Rawstron, A; Robbe, P; Schuh, A; Soe, Z; Zucchetto, A1
Admiraal, R; Bierings, M; Blok, H; Calkoen, FG; De Koning, C; Dekker, L; Hoogerbrugge, P; Huitema, ADR; Jiang, Y; Lindemans, CA; Nierkens, S; Nijstad, AL; Pieters, R; Spoon, M; Van Der Elst, KCM; Van Der Vlugt, M; Van Tinteren, H; Veldkamp, SR; Visscher, H; Vormoor, B; Vormoor, HJ1
Andersson, BS; Murray, D; Nieto, Y; Popat, U; Valdez, BC; Yuan, B1
Asquith, KL; Barr, I; Chen, L; Foster, PS; Hsu, AC; Laurie, K; Li, X; Liu, C; Liu, X; Yang, M1
Atsuta, Y; Fukuda, T; Imada, K; Ishiyama, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kimura, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y1
Bowornruangrit, P; Kumkate, S; Leardkamolkarn, V; Sirigulpanit, W1
Bassermann, F; Braitsch, K; Götze, KS; Herhaus, P; Hubbuch, M; Keller, U; Koch, K; Menzel, H; Schwarz, A; Verbeek, M1
Bazarbachi, A; Bethge, W; Blau, IW; Bondarenko, S; Brecht, A; Brissot, E; Bulabois, CE; Eder, M; Einsele, H; Forcade, E; Giebel, S; Huynh, A; Labopin, M; Mohty, M; Nagler, A; Rodríguez-Arbolí, E; Savani, B; Schmid, C; Spyridonidis, A; Stölzel, F; Tischer, J; Verbeek, M1
Baj, G; Bortolussi, G; de Alencastro, G; Jang, H; Kay, MA; Muro, AF; Pekrun, K; Stephens, CJ; Tsuji, S; Zhang, F1
Arpinati, M; Baronciani, D; Bernasconi, P; Bonifazi, F; Brunello, L; Bruno, B; Busca, A; Carella, AM; Carluccio, P; Casini, M; Chiusolo, P; Ciceri, F; Cilloni, D; Cupri, A; Di Grazia, C; Gheorghiu, A; Giglio, F; Girmenia, C; Grassi, A; Grillo, G; Iori, AP; Luppi, M; Martino, M; Masciulli, A; Musso, M; Nozzoli, C; Oldani, E; Onida, F; Palazzo, G; Parma, M; Patriarca, F; Pavoni, C; Peccatori, J; Picardi, A; Proia, A; Rambaldi, A; Sacchi, N; Santarone, S; Sorasio, R; Tringali, S; Vacca, A; Vallisa, D1
Ali, N; Bal, SK; Boughan, KM; Caimi, PF; Cooper, BW; de Lima, M; de Rezende, ACP; Gallogly, M; Hamerschlak, N; Kerbauy, L; Kerbauy, MN; Latif, BM; Malek, E; Mansur, D; Metheny, L; Otegbeye, F; Pereira, G; Ribeiro, AF; Sakuraba, R; Sanchez, G; Sekaly, RP; Sharma, AA; Tomlinson, BK; Weltman, E1
Azarnoush, S; Dhunputh, C; Ducassou, S; Leverger, G; Merched, M; Pasquet, M; Petit, A; Strullu, M1
Derlon, JM; Gourand, F; Guillouet, S; Kalaeva, D; Khokholova, E; Kobyakov, G; Maryashev, S; Pitskhelauri, D; Postnov, A; Potapov, A; Pronin, I; Pyzhik, E; Rizhova, M; Toutain, J; Usachev, D; Valable, S; Vikhrova, N1
Afanasyev, B; Beynarovich, A; Borzenkova, E; Kondakova, E; Kozlov, A; Kulagin, A; Lepik, K; Mikhailova, N; Moiseev, I; Pirogova, O; Stelmakh, L; Volkov, N; Zalyalov, Y; Zubarovskaya, L1
Alkhateeb, HB; Barreto, EF; Bartoo, GT; Hogan, WJ; Kutzke, JL; Leung, N; Litzow, MR; Mangaonkar, AA; Mara, KC; Merten, JA; Pawlenty, AG; Shah, MV1
Crodel, CC; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Linke, P; Miethke, J; Schnetzke, U; Scholl, S1
Abraham, A; Balasubramanian, P; Devasia, AJ; Fouzia, NA; George, B; Kavitha, ML; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; Pai, AA; Selvarajan, S; Sindhuvi, E; Srivastava, A1
Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC1
Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC1
AlRiyami, L; Grunebaum, E; Hook, R; Rao, H; Schechter, T; Wall, DA; Xu, M1
Babushok, DV; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Loren, AW; Luger, SM; Maity, A; Martin, ME; Plastaras, JP; Porter, DL1
Arora, S; Di Stasi, A; Jamy, O; Meredith, R; Minagawa, K; Mineishi, S; Saad, A; Salzman, D1
Diaz, A; Maziarz, RT; Miklos, DB; Shah, NN1
Bertz, H; Bornhäuser, M; Burchert, A; Dreger, P; Finke, J; Glass, B; Grishina, O; Hegenbart, U; Kobbe, G; Reicherts, C; Schmoor, C; Schub, N; Sohlbach, K; Stelljes, M; Wagner-Drouet, EM1
Brissot, E; Clement, L; Dalle, JH; Gandemer, V; Grain, A; Jubert, C; Labopin, M; Michel, G; Mohty, M; Paillard, C; Plantaz, D; Pochon, C; Rialland, F; Rohrlich, PS; Sirvent, A1
Alvarado, Y; Borthakur, G; Brandt, M; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, H; Ohanian, M; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Wang, X1
Cioccio, J; Claxton, DF; Ehmann, WC; Minagawa, K; Mineishi, S; Naik, S; Nickolich, M; Pizzola, CJ; Rakszawski, KL; Rybka, WB; Shike, H; Silar, B; Wirk, B; Zheng, H; Zhou, S1
Dimitrova, D; Kanakry, JA1
Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z1
Ling, Y; Qi, Y; Xu, W; Xu, X; Yang, S; Ye, H; Zhao, Y1
Chen, J; Hu, S; Huang, X; Jiang, E; Jiang, H; Lan, M; Li, C; Li, F; Lin, F; Liu, S; Lu, P; Lu, Y; Luo, C; Sun, S; Sun, Y; Tang, Y; Wan, D; Wang, S; Wu, X; Xu, L; Xu, Y1
Aviv, A; Bairey, O; Bomben, R; Braester, A; Bronstein, Y; Chiarenza, A; Coscia, M; Cuneo, A; Del Poeta, G; Del Principe, MI; Fineman, R; Foà, R; Gaidano, G; Gattei, V; Gentile, M; Goldschmidt, N; Gutwein, O; Herishanu, Y; Laurenti, L; Levi, S; Loseto, G; Mauro, FR; Morabito, F; Murru, R; Neri, A; Olivieri, J; Perry, C; Pietrasanta, D; Reda, G; Rossi, D; Ruchlemer, R; Shvidel, L; Sportoletti, P; Tadmor, T; Trentin, L; Varettoni, M; Visentin, A; Ziv-Baran, T; Zucchetto, A1
Gale, RP; Halahleh, KA; Ma'koseh, M; Muradi, I; Rimawi, DH; Sultan, I1
Do Nascimento, J; Domingo-Domenech, E; Encuentra, M; Ferrá, C; Gallardo, D; González-Barca, E; López, P; Oliveira, AC; Ribera, JM; Rodriguez-Luaces, M; Roncero, JM; Sarrá, J; Sureda, A1
Arat, M; Berceanu, A; Giebel, S; Hamladji, RM; Kröger, N; Labopin, M; Mohty, M; Nagler, A; Ozdogu, H; Potter, V; Rambaldi, A; Sanz, J; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R; Yakoub-Agha, I1
Abuasab, T; Alvarado, Y; Borthakur, G; Brandt, MA; Daver, N; DiNardo, C; Haddad, FG; Kadia, T; Kantarjian, H; Pemmaraju, N; Ravandi, F; Senapati, J1
Ara, T; Ashida, T; Atsuta, Y; Fukuda, T; Kamijo, K; Kanaya, M; Kim, SW; Kondo, E; Kuriyama, T; Kusumoto, S; Maseki, N; Matsuoka, KI; Mizuno, I; Mizuno, S; Nakazawa, H; Onizuka, M; Shimomura, Y; Shinohara, A; Usui, Y; Yamaguchi, M1
Chan, WYK; Cheuk, DKL; Cheung, C; Ha, SY; Kan, EYL; Lee, PPW; Leung, W; Shelia, WSN; Tso, WWY; Yeung, WL1
Bazarbachi, A; Bethge, W; Bug, G; Carlson, K; Hilgendorf, I; Kaare, A; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Niittyvuopio, R; Reinhardt, HC; Savani, BN; Schäfer-Eckart, K; Spyridonidis, A; Stelljes, M; Verbeek, M1
Hanke, C; Shah, M; Wald, J1
Fan, Z; Guo, Z; Huang, F; Jin, H; Liang, X; Lin, R; Ling, Y; Liu, C; Liu, H; Liu, Q; Liu, X; Ou, R; Qu, H; Sun, J; Wu, M; Xu, N; Xu, X; Xuan, L; Yu, S; Zhai, X; Zhang, H; Zhang, Y; Zhao, Y1
Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F1
Dai, L; Ding, C; Fan, L; Jiang, R; Li, J; Miao, Y; Qin, S; Qiu, J; Qiu, T; Sha, Y; Shen, H; Wu, W; Wu, Y; Xia, Y; Xu, W; Yang, Y; Zhu, H1
Bazinet, A; Keating, MJ; O'Brien, SM; Peterson, CB; Plunkett, W; Saha, S; Tam, CS; Thompson, PA; Wierda, WG1
Boubaya, M; Bravetti, C; Chapiro, E; Davi, F; Dehgane, L; Doualle, C; Garnier, D; Grange, B; Jondreville, L; Lerner, LK; Nguyen-Khac, F; Roos-Weil, D; Smagghe, L; Susin, SA; Tournilhac, O1
Carlow, DC; Schofield, RC; Scordo, M; Shah, G1

Reviews

317 review(s) available for fludarabine and vidarabine

ArticleYear
New antimetabolites in the treatment of human malignancies.
    Seminars in oncology, 1992, Volume: 19, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Cladribine; Clinical Trials as Topic; Drugs, Investigational; Forecasting; Humans; Immunosuppression Therapy; Leukemia; Lymphoma; Pentostatin; Purines; Vidarabine

1992
[New analogs of deoxyadenosine for treatment of lymphoid malignancies].
    Przeglad lekarski, 1992, Volume: 49, Issue:10

    Topics: Antineoplastic Agents; Cladribine; Deoxyadenosines; Formycins; Humans; Leukemia; Lymphoma; Vidarabine

1992
A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities.
    Mayo Clinic proceedings, 1992, Volume: 67, Issue:5

    Topics: 2-Chloroadenosine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Chlorambucil; Deoxyadenosines; Dose-Response Relationship, Drug; Histocompatibility Testing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prednisone; Prognosis; Survival Rate; Vidarabine

1992
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
    Leukemia, 1992, Volume: 6 Suppl 2

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine

1992
New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.
    Cancer, 1992, Aug-15, Volume: 70, Issue:4 Suppl

    Topics: Antineoplastic Agents; Humans; Interferon-alpha; Lymphoma, Non-Hodgkin; Multiple Myeloma; Vidarabine

1992
New purine analogues for the treatment of chronic B-cell malignancies.
    Henry Ford Hospital medical journal, 1991, Volume: 39, Issue:2

    Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine

1991
Fludarabine: a review.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:5

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Neoplasms; Remission Induction; Vidarabine

1991
[Treatment with cyclosporin A of the anemia associated with chronic lymphatic leukemia].
    Sangre, 1990, Volume: 35, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclosporins; Erythropoiesis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; T-Lymphocytes, Regulatory; Thrombocytopenia; Vidarabine

1990
Membrane transport and the antineoplastic action of nucleoside analogues.
    Cancer metastasis reviews, 1987, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Membrane; Humans; Nucleosides; Vidarabine

1987
Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.
    Drugs, 1994, Volume: 47 Suppl 6

    Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Cladribine; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine

1994
Evolution of the arabinosides and the pharmacology of fludarabine.
    Drugs, 1994, Volume: 47 Suppl 6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cytarabine; Humans; Leukemia; Vidarabine

1994
Clinical experience with fludarabine in leukaemia.
    Drugs, 1994, Volume: 47 Suppl 6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine

1994
Fludarabine in the management of malignant lymphomas.
    Drugs, 1994, Volume: 47 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Incidence; Lymphoma; Lymphoma, Non-Hodgkin; Mycoses; Vidarabine; Waldenstrom Macroglobulinemia

1994
Potential immunological action of purine nucleoside analogues.
    Drugs, 1994, Volume: 47 Suppl 6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cladribine; Humans; Immunosuppressive Agents; Leukemia; Pentostatin; Purine Nucleosides; Vidarabine

1994
The expanding role of fludarabine in hematologic malignancies.
    Leukemia & lymphoma, 1994, Volume: 14 Suppl 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine; Waldenstrom Macroglobulinemia

1994
The optimal management of hairy cell leukaemia.
    Drugs, 1995, Volume: 49, Issue:6

    Topics: Antineoplastic Agents; Cladribine; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Leukemia, Hairy Cell; Pentostatin; Splenectomy; Vidarabine

1995
Modulation of arabinosylcytosine metabolism during leukemia therapy.
    Advances in experimental medicine and biology, 1994, Volume: 370

    Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Biotransformation; Cytarabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia; Vidarabine

1994
Infectious and immunosuppressive complications of purine analog therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Humans; Immune Tolerance; Infections; Pentostatin; Purines; Vidarabine

1995
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine

1995
Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
    Blood, 1995, Oct-01, Volume: 86, Issue:7

    Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance; Humans; Lymphoproliferative Disorders; Pentostatin; Purine Nucleosides; Vidarabine

1995
Advances in therapy for hairy cell leukemia. A review.
    Cancer, 1993, Jul-01, Volume: 72, Issue:1

    Topics: 2-Chloroadenosine; Deoxyadenosines; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Leukemia, Hairy Cell; Male; Pentostatin; Splenectomy; Vidarabine

1993
Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.
    Drugs, 1993, Volume: 45, Issue:5

    Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Neoplasms, Experimental; Vidarabine

1993
Antimetabolites.
    Cancer chemotherapy and biological response modifiers, 1994, Volume: 15

    Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; Drug Resistance; Fluorouracil; Humans; Mercaptopurine; Methotrexate; Vidarabine

1994
Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.
    Blood, 1995, Jan-15, Volume: 85, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Chlorambucil; Chromosome Aberrations; Cladribine; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Vidarabine

1995
The role of fludarabine in hematological malignancies.
    Blood reviews, 1994, Volume: 8, Issue:3

    Topics: Adult; Aged; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

1994
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias.
    Leukemia & lymphoma, 1994, Volume: 14 Suppl 2

    Topics: Acute Disease; Animals; Antineoplastic Agents; DNA Replication; Humans; Leukemia; Leukemia, Experimental; Mice; Vidarabine

1994
The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies.
    Cancer, 1993, Dec-01, Volume: 72, Issue:11 Suppl

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma; Pentostatin; Vidarabine

1993
Purine analogs in lymphoproliferative disorders.
    Leukemia & lymphoma, 1993, Volume: 11 Suppl 2

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Multiple Myeloma; Pentostatin; Vidarabine

1993
Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
    Seminars in hematology, 1993, Volume: 30, Issue:4 Suppl 6

    Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia; Lymphoma; Molecular Structure; Pentostatin; Purine Nucleosides; Vidarabine

1993
Neurotoxicity of purine analogs: a review.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Male; Middle Aged; Nervous System; Nervous System Diseases; Pentostatin; Purine Nucleosides; Vidarabine

1994
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
    Leukemia & lymphoma, 1993, Volume: 10 Suppl

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Survival Rate; Vidarabine

1993
Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL).
    Leukemia & lymphoma, 1993, Volume: 10, Issue:4-5

    Topics: Antigens, Neoplasm; Biomarkers, Tumor; Cell Division; DNA Repair; Drug Resistance; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Prognosis; Proliferating Cell Nuclear Antigen; Vidarabine

1993
Fludarabine for treatment of adult acute myelogenous leukemia.
    Leukemia & lymphoma, 1993, Volume: 11 Suppl 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine

1993
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 2

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Molecular Structure; Multicenter Studies as Topic; Radiation-Sensitizing Agents; Remission Induction; Tumor Cells, Cultured; Vidarabine; Waldenstrom Macroglobulinemia

1994
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
    Seminars in oncology, 1993, Volume: 20, Issue:5 Suppl 7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Neoplasms; Vidarabine

1993
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Leukemia & lymphoma, 1993, Volume: 10 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Vidarabine

1993
Fludarabine in the treatment of lymphoproliferative malignancies.
    Cancer investigation, 1993, Volume: 11, Issue:3

    Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Vidarabine

1993
[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
    Acta haematologica Polonica, 1995, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Remission Induction; Vidarabine

1995
[Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia].
    Bulletin du cancer, 1995, Volume: 82, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Hematopoietic Cell Growth Factors; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Vidarabine

1995
New chemotherapeutic agents in acute myeloid leukemia.
    Leukemia, 1996, Volume: 10 Suppl 1

    Topics: Acute Disease; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotoxins; Leukemia, Myeloid; Oligonucleotides, Antisense; Retinoids; Vidarabine

1996
Key issues in the treatment of chronic lymphocytic leukaemia (CLL)
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:13-14

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Hematopoietic Cell Growth Factors; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Risk Factors; Vidarabine

1995
Intracellular pharmacodynamics in leukemia therapy.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1996, Volume: 37, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Mitoxantrone; Vidarabine

1996
Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
    Seminars in hematology, 1996, Volume: 33, Issue:1 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prospective Studies; Vidarabine

1996
The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia.
    Seminars in hematology, 1996, Volume: 33, Issue:1 Suppl 1

    Topics: Alkylation; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1996
[Current therapeutic methods in onco-hematology].
    Annales pharmaceutiques francaises, 1996, Volume: 54, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cladribine; Docetaxel; Humans; Keratolytic Agents; Leukemia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tretinoin; Vidarabine

1996
Radiosensitizing nucleosides.
    Journal of the National Cancer Institute, 1996, Sep-04, Volume: 88, Issue:17

    Topics: Animals; Deoxycytidine; Gemcitabine; Humans; Hydroxyurea; Nucleosides; Pyrimidines; Radiation-Sensitizing Agents; Thymidine; Vidarabine

1996
[Antileukemic agents--new drugs and attempts of rational administration].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1996, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Drug Administration Schedule; Humans; Idarubicin; Leukemia; Vidarabine

1996
Purine analogues in the management of lymphoproliferative diseases.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1996, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Cladribine; Humans; Lymphoproliferative Disorders; Pentostatin; Vidarabine

1996
[Treatment of chronic lymphatic leukemia].
    Vnitrni lekarstvi, 1996, Volume: 42, Issue:8

    Topics: Antineoplastic Agents; Cladribine; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Vidarabine

1996
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7 Suppl 6

    Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purine Nucleosides; Vidarabine; Waldenstrom Macroglobulinemia

1996
2-Chlorodeoxyadenosine treatment of lymphoma.
    Cancer treatment and research, 1996, Volume: 85

    Topics: Adenosine Deaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Pentostatin; Vidarabine; Waldenstrom Macroglobulinemia

1996
Pharmacology of purine nucleoside analogues.
    Hematology and cell therapy, 1996, Volume: 38 Suppl 2

    Topics: Animals; Antineoplastic Agents; Cladribine; Hematologic Neoplasms; Humans; Pentostatin; Purine Nucleosides; Vidarabine

1996
Adverse and beneficial immunological effects of purine nucleoside analogues.
    Hematology and cell therapy, 1996, Volume: 38 Suppl 2

    Topics: Animals; Antineoplastic Agents; Cladribine; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Purine Nucleosides; Vidarabine

1996
Clinical experience with fludarabine in hemato-oncology.
    Hematology and cell therapy, 1996, Volume: 38 Suppl 2

    Topics: Antineoplastic Agents; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Vidarabine

1996
Perspectives on purine analogues.
    Hematology and cell therapy, 1996, Volume: 38 Suppl 2

    Topics: Antineoplastic Agents; Cladribine; Forecasting; Humans; Leukemia; Pentostatin; Purines; Vidarabine

1996
Purine analogs in the treatment of chronic lymphocytic leukemia.
    Leukemia, 1997, Volume: 11 Suppl 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1997
Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
    Leukemia, 1997, Volume: 11 Suppl 2

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Recurrence; Remission Induction; Vidarabine

1997
Is there a place for 2-CDA in the treatment of B-CLL?
    Leukemia, 1997, Volume: 11 Suppl 2

    Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thrombocytopenia; Vidarabine

1997
Prophylactic strategies to meet infectious complications in fludarabine-treated CLL.
    Leukemia, 1997, Volume: 11 Suppl 2

    Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Immunoglobulins, Intravenous; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Opportunistic Infections; Salvage Therapy; Vidarabine

1997
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.
    Drugs, 1997, Volume: 53, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Synergism; Drug Tolerance; Hematologic Neoplasms; Humans; Vidarabine

1997
[A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
    Vnitrni lekarstvi, 1997, Volume: 43, Issue:1

    Topics: Antineoplastic Agents; Hematologic Neoplasms; Humans; Vidarabine

1997
Complications in the treatment of CLL with purine analogues.
    Hematology and cell therapy, 1997, Volume: 39 Suppl 1

    Topics: Anemia, Hemolytic, Autoimmune; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Purine Nucleosides; Vidarabine

1997
[Current principles of diagnosis and treatment of chronic lymphocytic B-cell leukemia].
    Orvosi hetilap, 1998, Mar-15, Volume: 139, Issue:11

    Topics: Alkylating Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine

1998
Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9 Suppl 1

    Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Combined Modality Therapy; Cytokines; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunotherapy, Adoptive; Interleukin-2; Lymphoma; Neoplasm Recurrence, Local; Neoplasm, Residual; Recombinant Proteins; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine

1998
Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.
    Seminars in hematology, 1998, Volume: 35, Issue:3 Suppl 3

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine

1998
Clinical challenges in chronic lymphocytic leukemia.
    Seminars in hematology, 1998, Volume: 35, Issue:3 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Splenectomy; Vidarabine

1998
Chronic lymphocytic leukemia in the next decade: where do we go from here?
    Seminars in hematology, 1998, Volume: 35, Issue:3 Suppl 3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1998
Hairy cell leukemia. What is new forty years after the first description?
    Hematology and cell therapy, 1998, Volume: 40, Issue:4

    Topics: 2-Chloroadenosine; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; B-Lymphocytes; Bone Marrow; Clinical Trials as Topic; Deoxyadenosines; Humans; Immunologic Factors; Interferon Type I; Leukemia, Hairy Cell; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Recombinant Proteins; Splenectomy; Vidarabine

1998
[Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Przeglad lekarski, 1998, Volume: 55, Issue:7-8

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Neoplasm, Residual; Pentostatin; Remission Induction; Splenectomy; Vidarabine

1998
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:11A

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Humans; Idarubicin; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Topotecan; Vidarabine

1998
Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk-adapted therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:5

    Topics: Bacterial Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine

1999
[Multiple myeloma and other plasma cell dyscrasias].
    Revista clinica espanola, 1999, Volume: 199 Suppl 1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; Diagnosis, Differential; Heavy Chain Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Prognosis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia

1999
Eosinophilia during fludarabine treatment of chronic lymphocytic leukemia.
    Annals of hematology, 1999, Volume: 78, Issue:10

    Topics: Aged; Antineoplastic Agents; Eosinophilia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1999
Current treatment of follicular low-grade lymphomas.
    Seminars in oncology, 1999, Volume: 26, Issue:5 Suppl 14

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Lymphoma, Follicular; Vidarabine

1999
CD40 and B chronic lymphocytic leukemia cell response to fludarabine: the influence of NF-kappaB/Rel transcription factors on chemotherapy-induced apoptosis.
    Leukemia & lymphoma, 2000, Volume: 36, Issue:3-4

    Topics: Antineoplastic Agents; Apoptosis; CD40 Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Oncogene Proteins v-rel; Tumor Cells, Cultured; Vidarabine

2000
Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.
    Haematologica, 2000, Volume: 85, Issue:3

    Topics: Antineoplastic Agents; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2000
Follicular lymphoma: have we made any progress?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11 Suppl 1

    Topics: Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Lymphoma, Follicular; Male; Prognosis; Recurrence; Survival Rate; Vidarabine

2000
Non myeloablative "mini transplants".
    Cancer treatment and research, 1999, Volume: 101

    Topics: Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Vidarabine

1999
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Seminars in oncology, 2000, Volume: 27, Issue:2 Suppl 5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Remission Induction; Vidarabine

2000
Chronic lymphocytic leukemia.
    Current opinion in hematology, 2000, Volume: 7, Issue:4

    Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; CD79 Antigens; Chromosome Aberrations; Chromosomes, Human; Cladribine; Combined Modality Therapy; Cytokines; Female; Genes, Immunoglobulin; Genes, p53; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Stem Cells; Prognosis; Risk Factors; Vidarabine

2000
Combination therapy with purine nucleoside analogs.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:6 Suppl 2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxyadenosines; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferons; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Pentostatin; Purine Nucleosides; Treatment Outcome; Vidarabine

2000
Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
    Haematologica, 1999, Volume: 84 Suppl EHA-4

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Vidarabine

1999
Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations.
    The oncologist, 2000, Volume: 5, Issue:6

    Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2000
Clinical trials review: idiopathic inflammatory myopathy.
    Current rheumatology reports, 2000, Volume: 2, Issue:3

    Topics: Azathioprine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Methotrexate; Myositis; Vidarabine

2000
Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies.
    Hematological oncology, 2000, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine

2000
Bilateral breast relapse in acute myelogenous leukemia.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine

2001
Novel treatment strategies in chronic lymphocytic leukemia.
    Current oncology reports, 2001, Volume: 3, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pentostatin; Randomized Controlled Trials as Topic; Sex Factors; Vidarabine

2001
[Mantle cell lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2001, Volume: 42, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Rituximab; Vidarabine

2001
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
    Leukemia, 2001, Volume: 15, Issue:6

    Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine

2001
Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:5-6

    Topics: Antineoplastic Agents; Autoimmunity; Cladribine; Humans; Immunosuppressive Agents; Neoplasms; Neoplasms, Second Primary; Vidarabine

2001
[Chronic lymphocytic leukemia. 2. Therapy].
    Deutsche medizinische Wochenschrift (1946), 2001, Jun-08, Volume: 126, Issue:23

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Chlorambucil; Dose-Response Relationship, Radiation; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunization, Passive; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Risk Factors; Splenectomy; Steroids; Transplantation, Autologous; Vidarabine

2001
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
    Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:2-3

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Leukemia, B-Cell; Prednisolone; Prognosis; Recurrence; Risk Factors; Salvage Therapy; Vidarabine; Vincristine

2001
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Annals of the New York Academy of Sciences, 2001, Volume: 938

    Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Disease Progression; Dogs; Forecasting; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Methotrexate; Middle Aged; Mycophenolic Acid; Neoplasms; Prednisone; Radiation Chimera; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2001
Non-myeloablative hematopoietic stem cell transplantation.
    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2001, Volume: 8, Issue:3

    Topics: Animals; Bone Marrow; Chimera; Cyclosporine; Dogs; Drug Administration Schedule; Graft Rejection; Graft Survival; Graft vs Host Reaction; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Models, Animal; Mycophenolic Acid; Safety; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2001
Combination chemotherapy and rituximab.
    Anti-cancer drugs, 2001, Volume: 12 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Doxorubicin; Flow Cytometry; Humans; Immunotherapy; Lymphoma, Non-Hodgkin; Prednisolone; Proto-Oncogene Proteins c-bcl-2; Rituximab; Time Factors; Translocation, Genetic; Treatment Outcome; Vidarabine; Vincristine

2001
Therapeutic options for acute myelogenous leukemia.
    Cancer, 2001, Sep-01, Volume: 92, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Cytogenetics; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Prognosis; Topotecan; Vidarabine

2001
Nucleoside analogues in the treatment of haematological malignancies.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:6

    Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine

2001
Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:6

    Topics: Alkylating Agents; Antimetabolites; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Guidelines as Topic; Humans; Middle Aged; Pentostatin; Plasmapheresis; Purine Nucleosides; Quality of Life; Vidarabine; Waldenstrom Macroglobulinemia

2001
[Drug-induced hemolytic anemia].
    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2001, Volume: 8, Issue:4

    Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cephalosporins; Cyclosporine; Hemolytic-Uremic Syndrome; Humans; Isoantibodies; Leukemia, Lymphocytic, Chronic, B-Cell; Methyldopa; Procainamide; Purpura, Thrombocytopenic; Quinine; Rho(D) Immune Globulin; Thrombocytopenia; Vidarabine

2001
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
    The Journal of rheumatology. Supplement, 2001, Volume: 64

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2001
Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies.
    The oncologist, 2001, Volume: 6 Suppl 5

    Topics: Angiogenesis Inhibitors; Apoptosis; Cytokines; Fibroblast Growth Factor 2; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2001
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2001
[Chronic lymphocytic leukemias].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 7

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Sex Factors; Survival Rate; Vidarabine

2001
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vidarabine; Vincristine

2002
Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2002
Cellular and clinical pharmacology of fludarabine.
    Clinical pharmacokinetics, 2002, Volume: 41, Issue:2

    Topics: Antineoplastic Agents; Biological Availability; Deoxycytidine Kinase; DNA (Cytosine-5-)-Methyltransferases; Drug Evaluation, Preclinical; Humans; Leukemia; Lymphoma; Phosphorylation; Vidarabine; Vidarabine Phosphate

2002
Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer.
    Cancer treatment and research, 2002, Volume: 110

    Topics: Breast Neoplasms; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2002
Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation.
    Cancer treatment and research, 2002, Volume: 110

    Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Pentostatin; Transplantation, Homologous; Vidarabine

2002
Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
    Health technology assessment (Winchester, England), 2002, Volume: 6, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cost of Illness; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical; Treatment Outcome; United Kingdom; Vidarabine

2002
Fludarabine-induced eosinophilia: case report.
    Annals of hematology, 2002, Volume: 81, Issue:5

    Topics: Antineoplastic Agents; Eosinophilia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine

2002
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
    Leukemia, 2002, Volume: 16, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Nucleosides; Survival Rate; Treatment Failure; Vidarabine

2002
Immunochemotherapy in indolent non-Hodgkin's lymphoma.
    Seminars in oncology, 2002, Volume: 29, Issue:2 Suppl 6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vidarabine; Vincristine

2002
Waldenström's macroglobulinemia.
    Current treatment options in oncology, 2000, Volume: 1, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; beta 2-Microglobulin; Chlorambucil; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Humans; Interferon-alpha; Neoplasm Recurrence, Local; Plasmapheresis; Rituximab; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia

2000
Challenges in treating hematologic malignancies.
    Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 8

    Topics: Anemia; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epoetin Alfa; Erythropoietin; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Prognosis; Quality of Life; Recombinant Proteins; Vidarabine

2002
[Nucleoside analogues--new drugs for the treatment of lymphatic cancers].
    Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphoid; Lymphoma; Nucleosides; Pentostatin; Vidarabine

2001
Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.
    American journal of hematology, 2002, Volume: 70, Issue:3

    Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases; Prednisone; Tomography, X-Ray Computed; Vidarabine

2002
[Experience with fludarabine treatment and review of the literature].
    Orvosi hetilap, 2002, Jun-16, Volume: 143, Issue:24

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Remission Induction; Treatment Outcome; Vidarabine

2002
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Clinical lymphoma, 2002, Volume: 3, Issue:1

    Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine

2002
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
    Clinical lymphoma, 2002, Volume: 3, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bleomycin; Bone Marrow; Bone Marrow Diseases; Chemotherapy, Adjuvant; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Paraproteins; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine

2002
Current and developing chemotherapy for CLL.
    Medical oncology (Northwood, London, England), 2002, Volume: 19 Suppl

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Survival Rate; Vidarabine

2002
Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
    Blood, 2002, Sep-15, Volume: 100, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine

2002
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.
    British journal of haematology, 2002, Volume: 119, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Male; Melphalan; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.
    Blood, 2002, Dec-15, Volume: 100, Issue:13

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Bone Marrow; Busulfan; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Europe; Female; Genetic Heterogeneity; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Infections; Inflammation; Male; Melphalan; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Waldenström's macroglobulinemia: a review of therapy.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:8

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Plasma Exchange; Rituximab; Splenectomy; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia

2002
[Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].
    Polskie Archiwum Medycyny Wewnetrznej, 2001, Volume: 105 Suppl

    Topics: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Host vs Graft Reaction; Humans; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
[Clinical pharmacology of nucleoside analogues].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antimetabolites; Antimetabolites, Antineoplastic; Biotransformation; Cytarabine; Cytidine Deaminase; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Half-Life; Humans; Male; Metabolic Clearance Rate; Neoplasm Proteins; Phosphorylation; Prodrugs; Vidarabine

2002
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Bone marrow transplantation, 2002, Volume: 30, Issue:12

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine

2002
Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.
    Bone marrow transplantation, 2002, Volume: 30, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytokines; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunotherapy, Adoptive; Kidney Neoplasms; Melphalan; Multicenter Studies as Topic; Nephrectomy; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2002
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
    Cancer treatment and research, 2002, Volume: 112

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Capecitabine; Cell Membrane; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Tumor Cells, Cultured; Vidarabine

2002
Advances in the treatment of hairy-cell leukaemia.
    The Lancet. Oncology, 2003, Volume: 4, Issue:2

    Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Cell Adhesion Molecules; Cladribine; Humans; Interferon-alpha; Lectins; Leukemia, Hairy Cell; Neoplasm, Residual; Neoplasms, Second Primary; Pancytopenia; Pentostatin; Receptors, Interleukin-2; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Spleen; Splenectomy; Splenomegaly; Treatment Outcome; Vidarabine

2003
Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.
    American journal of hematology, 2003, Volume: 72, Issue:3

    Topics: Aged; Antineoplastic Agents; Blood Urea Nitrogen; Calcium; Creatinine; Fatal Outcome; Fluid Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Phosphorus; Potassium; Renal Dialysis; Tumor Lysis Syndrome; Uric Acid; Vidarabine

2003
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
    Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine

2003
Rituximab in chronic lymphocytic leukemia.
    Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2003
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
    American journal of hematology, 2003, Volume: 72, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Fatal Outcome; Female; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lomustine; Male; Middle Aged; Mitoxantrone; Neoplasms, Multiple Primary; Neoplastic Stem Cells; Prednisone; Prognosis; Reed-Sternberg Cells; Remission Induction; Skin Neoplasms; Splenectomy; Tumor Virus Infections; Vidarabine; Vinblastine; Vincristine

2003
Purine nucleoside analogues in the treatment of myleoid leukemias.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:3

    Topics: Aging; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Y; Clone Cells; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pancytopenia; Trisomy; Tumor Cells, Cultured; Vidarabine

2003
Fludarabine in Waldenstrom's macroglobulinemia.
    Seminars in oncology, 2003, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Vidarabine; Waldenstrom Macroglobulinemia

2003
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
    Leukemia, 2003, Volume: 17, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2003
Mechanism of action of purine analogues in chronic lymphocytic leukaemia.
    British journal of haematology, 2003, Volume: 121, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Division; Cladribine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Phosphorylation; Tumor Suppressor Protein p53; Vidarabine

2003
[Evidence-based therapy for chronic leukemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Jun-10, Volume: 92, Issue:6

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Transplantation, Homologous; Vidarabine

2003
A novel t(15;17) translocation in acute myeloid leukaemia not associated with PML/RARalpha rearrangement.
    Clinical and laboratory haematology, 2003, Volume: 25, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Breakage; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Core Binding Factor Alpha 2 Subunit; Cytarabine; Daunorubicin; DNA-Binding Proteins; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Acute; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins; Remission Induction; Salvage Therapy; Thioguanine; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Vidarabine

2003
[Non-myeloablative or reduced intensity stem cell transplantation preparative regimens].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Alemtuzumab; Alkylating Agents; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Radiotherapy Dosage; T-Lymphocytes; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2003
[Mini-transplantation from HLA-mismatched donors].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
[Mini-transplantation from cord blood].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Busulfan; Cyclophosphamide; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2003
[Reduced-intensity stem cell transplantation (RIST) for lymphoproliferative diseases].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Busulfan; Cause of Death; Clinical Trials as Topic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Transplantation Conditioning; Vidarabine

2003
[Non-myeloablative stem cell transplantation for non-malignant hematologic disorders].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hemochromatosis; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2003
[Nonmyeloablative allogeneic peripheral blood stem cell transplantation of renal cell carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Aged; Carcinoma, Renal Cell; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Kidney Neoplasms; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Oral fludarabine.
    Drugs, 2003, Volume: 63, Issue:21

    Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Biological Availability; Clinical Trials as Topic; Half-Life; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2003
[Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
    MMW Fortschritte der Medizin, 2003, Jul-10, Volume: 145, Issue:27-28

    Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Combined Modality Therapy; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitrogen Mustard Compounds; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Time Factors; Vidarabine

2003
Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:10

    Topics: Antineoplastic Agents; Diagnosis, Differential; DNA, Viral; Fatal Outcome; Humans; Immunosuppression Therapy; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Polymerase Chain Reaction; Vidarabine

2003
Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
    Current hematology reports, 2004, Volume: 3, Issue:1

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Synergism; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rituximab; Vidarabine

2004
Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
    Seminars in oncology, 2004, Volume: 31, Issue:1 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2004
Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
    Leukemia research, 2004, Volume: 28, Issue:5

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Rituximab; Vidarabine

2004
Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine

2004
Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine

2004
Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Administration, Oral; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine

2004
Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Treatment Outcome; Vidarabine

2004
Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2004
Use of fludarabine in the treatment of acute myeloid leukemia.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid; Salvage Therapy; Treatment Outcome; Vidarabine

2004
Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Future prospects for fludarabine-containing regimens in the treatment of hematological cancers.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Treatment Outcome; Vidarabine

2004
Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2004, Volume: 18, Issue:3

    Topics: Aged; Biopsy, Needle; Fluorescent Antibody Technique, Indirect; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycophenolic Acid; Paraneoplastic Syndromes; Pemphigus; Risk Assessment; Severity of Illness Index; Stomatitis; Treatment Outcome; Vidarabine

2004
Treatment of chronic lymphocytic leukemia.
    Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 4

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2004
[Waldenstrom macroglobulinemia].
    Praxis, 2004, Mar-31, Volume: 93, Issue:14

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Blood Transfusion; Chlorambucil; Diagnosis, Differential; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Plasmapheresis; Prednisone; Prognosis; Recurrence; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia

2004
Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Cancer, 2004, May-15, Volume: 100, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine

2004
Reconstructing immunity after allogeneic transplantation.
    Immunologic research, 2004, Volume: 29, Issue:1-3

    Topics: Animals; Bone Marrow Transplantation; Dendritic Cells; Gamma Rays; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hyaluronan Receptors; Mice; Mice, Inbred C57BL; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation, Homologous; Vidarabine

2004
The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
    Cancer, 2004, Sep-01, Volume: 101, Issue:5

    Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Vidarabine

2004
Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Safety; Survival Rate; Treatment Outcome; Vidarabine

2004
Blastic natural killer (NK)-cell lymphoma: report of an unusual CD4 negative case and review of the CD4 negative neoplasms with blastic features in the literature.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:10

    Topics: Adult; Blast Crisis; Bone Marrow Neoplasms; CD4 Antigens; Diagnosis, Differential; Fatal Outcome; Humans; Immunophenotyping; In Situ Hybridization; Killer Cells, Natural; Lymphoma, Non-Hodgkin; Male; Neoplasm Invasiveness; RNA, Viral; Skin Neoplasms; Vidarabine

2004
Purine analogs in leukemia.
    Advances in pharmacology (San Diego, Calif.), 2004, Volume: 51

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Pentostatin; Purines; Stem Cell Transplantation; Vidarabine

2004
[New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia].
    Orvosi hetilap, 2004, Aug-29, Volume: 145, Issue:35

    Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Mutation; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Recurrence; Remission Induction; Rituximab; Stem Cell Transplantation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2004
Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:11

    Topics: Alkylating Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MEDLINE; Neutrophils; Risk; Time Factors; Treatment Outcome; Vidarabine

2004
The role of mitoxantrone in the treatment of indolent lymphomas.
    The oncologist, 2005, Volume: 10, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Survival Analysis; Vidarabine

2005
Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2005, Volume: 32, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Cladribine; Clinical Trials as Topic; Glycoproteins; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Random Allocation; Rituximab; Time Factors; Vidarabine

2005
[Current and new therapeutic strategies in acute myeloid leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine

2005
[Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
    Bulletin du cancer, 2005, Volume: 92, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nucleoside Transport Proteins; Nucleosides; Phosphorylation; Vidarabine

2005
[News in therapeutic management of chronic lymphoid leukemia].
    Bulletin du cancer, 2005, Volume: 92, Issue:3

    Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine

2005
Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
    Cancer treatment reviews, 2005, Volume: 31, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vidarabine

2005
Economic assessment on the management of chronic lymphocytic leukaemia.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Health Care Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Vidarabine

2005
Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature.
    American journal of hematology, 2005, Volume: 79, Issue:3

    Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mycobacterium tuberculosis; Tomography, X-Ray Computed; Tuberculosis; Vidarabine

2005
Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:9

    Topics: Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Time Factors; Transplantation Conditioning; Vidarabine

2005
Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).
    International journal of oncology, 2005, Volume: 27, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Membrane; Cell Proliferation; Cell Survival; Cladribine; DNA; DNA Damage; DNA Repair; DNA-Directed DNA Polymerase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Models, Biological; Models, Chemical; Nucleosides; RNA; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine

2005
[T-large granular lymphocyte leukaemia. An important differential diagnosis to Felty's syndrome].
    Zeitschrift fur Rheumatologie, 2006, Volume: 65, Issue:5

    Topics: Antirheumatic Agents; Antiviral Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Felty Syndrome; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Leukemia, T-Cell; Methotrexate; Vidarabine

2006
Guidelines on the management of Waldenström macroglobulinaemia.
    British journal of haematology, 2006, Volume: 132, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Plasma Exchange; Prognosis; Rituximab; Stem Cell Transplantation; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia

2006
[Progress and perspectives in the treatment of systemic lupus erythematosus].
    Przeglad lekarski, 2005, Volume: 62, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antineoplastic Agents, Alkylating; Azathioprine; Cladribine; Cyclophosphamide; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mycophenolic Acid; Vidarabine

2005
Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.
    Seminars in hematology, 2006, Volume: 43, Issue:2 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Purine Nucleosides; Risk Assessment; Treatment Outcome; Vidarabine

2006
[State of the art in the treatment of chronic leukemias].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:4

    Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine

2006
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
    Cancer treatment reviews, 2006, Volume: 32, Issue:5

    Topics: Anemia, Hemolytic; Antineoplastic Agents; Cladribine; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vidarabine

2006
Purine antagonists for chronic lymphocytic leukaemia.
    The Cochrane database of systematic reviews, 2006, Jul-19, Issue:3

    Topics: Antineoplastic Agents; Chlorambucil; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine

2006
Fludarabine in chronic lymphocytic leukaemia.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:12

    Topics: Administration, Oral; Aged; Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Survival Analysis; Vidarabine

2006
[Reduced-intensity cord blood transplantation for adult hematological diseases].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:7

    Topics: Adult; Age Factors; Antigens, CD34; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Diseases; Hematologic Neoplasms; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2006
Role of fludarabine in hematological malignancies.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:9

    Topics: Animals; Antineoplastic Agents; Hematologic Neoplasms; Humans; Prodrugs; Vidarabine

2006
Management of symptomatic, untreated chronic lymphocytic leukemia.
    Blood reviews, 2007, Volume: 21, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Risk Assessment; Treatment Outcome; Vidarabine

2007
Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:11 Suppl 2

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosomes, Human, Pair 12; Cyclophosphamide; Disease-Free Survival; Drug Screening Assays, Antitumor; Flow Cytometry; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Polymerase Chain Reaction; Risk Factors; Survival Rate; Trisomy; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2006
Current treatment options in prolymphocytic leukemia.
    Medical science monitor : international medical journal of experimental and clinical research, 2007, Volume: 13, Issue:4

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Drug Therapy; Humans; Leukemia, Prolymphocytic; Pentostatin; Purine Nucleosides; Rituximab; Splenectomy; Stem Cell Transplantation; Vidarabine

2007
Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.
    Haematologica, 2007, Volume: 92, Issue:4

    Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Lymphocyte Depletion; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Oncogene, 2007, May-28, Volume: 26, Issue:25

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; CD52 Antigen; Cyclophosphamide; Glycoproteins; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2007
Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:6

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Vidarabine

2007
Fludarabine: a review of its use in non-Hodgkin's lymphoma.
    Drugs, 2007, Volume: 67, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Vidarabine

2007
Chemoimmunotherapy of chronic lymphocytic leukemia.
    Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:3

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Rituximab; Vidarabine

2007
Minimal residual disease assessment in chronic lymphocytic leukaemia.
    Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:3

    Topics: Alleles; Antibodies, Monoclonal; Antigens, CD19; CD5 Antigens; Combined Modality Therapy; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Polymerase Chain Reaction; Sensitivity and Specificity; Stem Cell Transplantation; Vidarabine

2007
[Chronic lymphoid leukemia and intravenous immunoglobulins].
    La Revue de medecine interne, 2007, Volume: 28 Spec No 2

    Topics: Agammaglobulinemia; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multicenter Studies as Topic; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome; Vidarabine

2007
Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
    British journal of haematology, 2008, Volume: 140, Issue:6

    Topics: Adolescent; Adult; Child; Child, Preschool; Fanconi Anemia; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine

2008
Antibody therapy for chronic lymphocytic leukemia.
    Seminars in hematology, 2008, Volume: 45, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drugs, Investigational; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Pentostatin; Rituximab; Vidarabine

2008
Nelarabine: a new purine analog in the treatment of hematologic malignancies.
    Reviews on recent clinical trials, 2006, Volume: 1, Issue:3

    Topics: Arabinonucleosides; Clinical Trials as Topic; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Leukemia-Lymphoma, Adult T-Cell; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Vidarabine

2006
Non-MALT marginal zone lymphomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19 Suppl 4

    Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Italy; L-Lactate Dehydrogenase; Lymph Nodes; Lymphocytosis; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prognosis; Splenectomy; Splenic Neoplasms; Survival Analysis; Vidarabine

2008
[Novel medical treatment modalities in hematology].
    Ugeskrift for laeger, 2008, Jun-09, Volume: 170, Issue:24

    Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine

2008
Pentostatin in chronic lymphocytic leukemia.
    Expert opinion on drug metabolism & toxicology, 2008, Volume: 4, Issue:9

    Topics: Adenosine Deaminase Inhibitors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine

2008
[Chronic lymphocytic leukemia and the related disorders].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chromosome Aberrations; Gene Rearrangement; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Recombination, Genetic; Rituximab; Time Factors; Vidarabine

2008
Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia.
    Bone marrow transplantation, 2008, Volume: 42 Suppl 2

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Child; Child, Preschool; Donor Selection; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Living Donors; Lymphocyte Depletion; Male; Peripheral Blood Stem Cell Transplantation; Risk Adjustment; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Alkylating agents for Waldenstrom's macroglobulinaemia.
    The Cochrane database of systematic reviews, 2009, Jan-21, Issue:1

    Topics: Alkylating Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Prednisone; Randomized Controlled Trials as Topic; Vidarabine; Waldenstrom Macroglobulinemia

2009
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
    American journal of hematology, 2009, Volume: 84, Issue:4

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Complement Activation; Complement System Proteins; Cyclophosphamide; Cytokines; Drug Eruptions; Female; Fever; Humans; Leukopenia; Lymphoma, Mantle-Cell; Mitoxantrone; Risk Factors; Rituximab; Splenomegaly; Thrombocytopenia; Vidarabine

2009
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lymphoma; Neutropenia; Opportunistic Infections; Randomized Controlled Trials as Topic; Rituximab; Vidarabine

2009
Rituximab-based treatments in Waldenström's macroglobulinemia.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Doxorubicin; Humans; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2009
Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Vidarabine; Waldenstrom Macroglobulinemia

2009
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
    Current opinion in hematology, 2009, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine

2009
Treatment of fludarabine-refractory chronic lymphocytic leukemia.
    Cancer, 2009, Jul-01, Volume: 115, Issue:13

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Salvage Therapy; Stem Cell Transplantation; Vidarabine

2009
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
    Cancer, 2009, Sep-01, Volume: 115, Issue:17

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retreatment; Transplantation, Homologous; Vidarabine

2009
Pentostatin treatment combinations in chronic lymphocytic leukemia.
    Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:6

    Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Pentostatin; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine

2009
Update in the management of chronic lymphocytic leukemia.
    Journal of hematology & oncology, 2009, Jul-20, Volume: 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Congresses as Topic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Patient Selection; Vidarabine

2009
Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.
    Journal of hepatology, 2009, Volume: 51, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Recurrence; Rituximab; Vidarabine

2009
Tumor lysis syndrome following chlorambucil therapy for chronic lymphocytic leukemia: case report and review of the literature.
    Tennessee medicine : journal of the Tennessee Medical Association, 2009, Volume: 102, Issue:10

    Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Risk Factors; Tumor Lysis Syndrome; Vidarabine

2009
Immune hemolytic anemia--selected topics.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Blood Group Incompatibility; Cladribine; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lymphocyte Subsets; Lymphoproliferative Disorders; Postoperative Complications; Rituximab; Splenectomy; Transfusion Reaction; Transplantation; Transplantation, Homologous; Venous Thromboembolism; Vidarabine

2009
State-of-the-art treatment of chronic lymphocytic leukemia.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Combined Modality Therapy; Cytostatic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Salvage Therapy; Thionucleotides; Transplantation, Homologous; Vidarabine

2009
Novel therapeutic approaches in systemic lupus erythematosus.
    Frontiers in bioscience (Scholar edition), 2010, 01-01, Volume: 2, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Cyclophosphamide; Cytokines; Humans; Immunotherapy; Interferons; Lupus Erythematosus, Systemic; Rituximab; Signal Transduction; Stem Cell Transplantation; T-Lymphocytes; Vidarabine

2010
Cutaneous Richter's syndrome, prognosis, and clinical, histological and immunohistological patterns: report of four cases and review of the literature.
    Dermatology (Basel, Switzerland), 2010, Volume: 220, Issue:3

    Topics: Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD5 Antigens; Cell Transformation, Viral; Epstein-Barr Virus Infections; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Ki-1 Antigen; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Skin Neoplasms; Vidarabine

2010
Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
    American journal of hematology, 2010, Volume: 85, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Decision Support Techniques; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Markov Chains; Prednisone; Quality-Adjusted Life Years; Rituximab; Vidarabine; Vincristine

2010
Regulatory T cell as a target for cancer therapy.
    Archivum immunologiae et therapiae experimentalis, 2010, Volume: 58, Issue:3

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine

2010
Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:3

    Topics: Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Posterior Leukoencephalopathy Syndrome; Prodrugs; Vidarabine

2011
Advances in the treatment of chronic lymphocytic leukemia.
    Current hematologic malignancy reports, 2006, Volume: 1, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drugs, Investigational; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Rituximab; Salvage Therapy; Vidarabine

2006
Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.
    Current hematologic malignancy reports, 2007, Volume: 2, Issue:4

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Graft vs Tumor Effect; Humans; Immunologic Factors; Immunotherapy; Lymphocyte Transfusion; Lymphoma, Follicular; Melphalan; Methotrexate; Middle Aged; Multicenter Studies as Topic; Rituximab; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Vidarabine

2007
Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:7

    Topics: Antineoplastic Agents; Clinical Trials as Topic; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Salvage Therapy; Vidarabine

2010
[Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:3

    Topics: Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2010
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
    Environmental and molecular mutagenesis, 2010, Volume: 51, Issue:6

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Clofarabine; Cross-Linking Reagents; Hematologic Neoplasms; Humans; Preoperative Care; Stem Cell Transplantation; Vidarabine

2010
Chemoimmunotherapy of chronic lymphocytic leukemia.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Disease Progression; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Failure; Vidarabine

2010
Ofatumumab in the treatment of chronic lymphocytic leukemia.
    Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cyclophosphamide; Evidence-Based Medicine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Rituximab; Treatment Outcome; Vidarabine

2010
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2010
[Bone marrow failure due to telomere associated gene mutation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:8

    Topics: Animals; Cell Cycle Proteins; Dyskeratosis Congenita; Genes, Dominant; Genes, Recessive; Genes, X-Linked; Hematopoietic Stem Cell Transplantation; Humans; Mice; Mutation; Nuclear Proteins; Oxymetholone; RNA; Telomerase; Telomere; Telomere-Binding Proteins; Transplantation Conditioning; Vidarabine

2010
Current immunochemotherapy strategies in follicular lymphoma.
    Advances in therapy, 2010, Volume: 27, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Nitrogen Mustard Compounds; Prednisone; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Vidarabine; Vincristine

2010
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Expert review of anticancer therapy, 2010, Volume: 10, Issue:10

    Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Mice; Rituximab; Vidarabine

2010
The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:Suppl. 2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; United Kingdom; Vidarabine

2010
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
    The oncologist, 2011, Volume: 16, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Approval; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Randomized Controlled Trials as Topic; Rituximab; United States; United States Food and Drug Administration; Vidarabine

2011
Refractory chronic lymphocytic leukemia--new therapeutic strategies.
    Oncotarget, 2010, Volume: 1, Issue:7

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Survival Analysis; Therapies, Investigational; Vidarabine

2010
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    Expert review of anticancer therapy, 2011, Volume: 11, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Cytotoxicity, Immunologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Vidarabine

2011
[Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
    Actas dermo-sifiliograficas, 2011, Volume: 102, Issue:4

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Cyclophosphamide; Diagnosis, Differential; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Mitoxantrone; Palate, Soft; Red-Cell Aplasia, Pure; Rituximab; Vidarabine

2011
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:2

    Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Vidarabine

2011
How I manage cold agglutinin disease.
    British journal of haematology, 2011, Volume: 153, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Immunosuppressive Agents; Middle Aged; Rituximab; Vidarabine

2011
Purine analog toxicity in patients with hairy cell leukemia.
    Leukemia & lymphoma, 2011, Volume: 52 Suppl 2

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Purines; Vidarabine

2011
Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
    Health technology assessment (Winchester, England), 2011, Volume: 15 Suppl 1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality-Adjusted Life Years; Vidarabine

2011
[Practical considerations and questions in the treatment of chronic lymphocytic leukemia].
    Orvosi hetilap, 2011, Jun-12, Volume: 152, Issue:24

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Prognosis; Recurrence; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2011
Allogeneic stem cell transplantation in follicular lymphoma.
    Best practice & research. Clinical haematology, 2011, Volume: 24, Issue:2

    Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Lymphoma, Follicular; Mice; Myeloablative Agonists; Recurrence; Remission Induction; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2011
Rituximab in chronic lymphocytic leukemia.
    Advances in therapy, 2011, Volume: 28, Issue:7

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2011
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Leukemia & lymphoma, 2012, Volume: 53, Issue:3

    Topics: Agammaglobulinemia; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2012
Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.
    Expert review of anticancer therapy, 2011, Volume: 11, Issue:9

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Rituximab; Vidarabine

2011
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Salvage Therapy; Vidarabine

2012
The treatment of relapsed refractory chronic lymphocytic leukemia.
    Hematology. American Society of Hematology. Education Program, 2011, Volume: 2011

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Vidarabine

2011
Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.
    Blood reviews, 2012, Volume: 26, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Contraindications; Cryoglobulins; Drug Combinations; Erythrocyte Transfusion; Female; Humans; Middle Aged; Precision Medicine; Remission Induction; Rituximab; Vidarabine

2012
Alemtuzumab for patients with chronic lymphocytic leukaemia.
    The Cochrane database of systematic reviews, 2012, Feb-15, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Vidarabine

2012
A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia.
    Cancer treatment reviews, 2012, Volume: 38, Issue:8

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Randomized Controlled Trials as Topic; Rituximab; Vidarabine

2012
Late graft failure in FA--case report and review of the literature.
    Pediatric transplantation, 2012, Volume: 16, Issue:8

    Topics: Antigens, CD34; Antineoplastic Agents; Child; Fanconi Anemia; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Neutrophils; Risk Factors; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2012
Renal failure secondary to leukemic infiltration of kidneys in CLL--a case report and review of literature.
    Annals of hematology, 2013, Volume: 92, Issue:2

    Topics: Acute Kidney Injury; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Delayed Diagnosis; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Lymph Nodes; Male; Renal Dialysis; Rituximab; Vidarabine

2013
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
    The Cochrane database of systematic reviews, 2012, Nov-14, Volume: 11

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Vidarabine

2012
Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Liver; Myeloablative Agonists; Ovarian Neoplasms; Vidarabine; Whole-Body Irradiation

2013
Fludarabine in chronic lymphocytic leukemia with membranous nephropathy.
    Renal failure, 2013, Volume: 35, Issue:2

    Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Follow-Up Studies; Glomerulonephritis, Membranous; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proteinuria; Rare Diseases; Risk Assessment; Treatment Outcome; Vidarabine

2013
Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning.
    Bone marrow transplantation, 2013, Volume: 48, Issue:2

    Topics: Adult; Anemia, Aplastic; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine

2013
Do different conditioning regimens really make a difference?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunotherapy; Medical Oncology; Middle Aged; Neoplasms; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2012
Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?
    Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012

    Topics: Adult; Antilymphocyte Serum; Child; Comorbidity; Cyclophosphamide; Cyclosporine; Graft vs Leukemia Effect; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2012
[Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
    Journal de mycologie medicale, 2013, Volume: 23, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Cutaneous Fistula; Cyclophosphamide; Diabetes Mellitus, Type 2; Female; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Neutropenia; Opportunistic Infections; Osteolysis; Osteomyelitis; Rituximab; Vidarabine

2013
The changing paradigm of chronic lymphocytic leukemia management.
    European journal of internal medicine, 2013, Volume: 24, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Rituximab; Vidarabine

2013
Fludarabine: a review of the clear benefits and potential harms.
    Leukemia research, 2013, Volume: 37, Issue:9

    Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Vidarabine

2013
Fulminant hepatitis due to human adenovirus.
    Infection, 2014, Volume: 42, Issue:1

    Topics: Adenovirus Infections, Human; Adenoviruses, Human; Aged; Antibodies, Monoclonal, Murine-Derived; Biopsy; Female; Hepatitis, Viral, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Liver; Rituximab; Vidarabine

2014
Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature.
    Pediatric transplantation, 2014, Volume: 18, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Blood Platelets; Congenital Bone Marrow Failure Syndromes; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Melphalan; Methylprednisolone; Mucositis; Neutrophils; Thrombocytopenia; Transplantation Conditioning; Vidarabine

2014
[Chronic lymphocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:2

    Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Piperidines; Practice Guidelines as Topic; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vidarabine; Vincristine

2014
[Hemophagocytic lymphohistiocytosis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease Progression; Doxorubicin; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Methotrexate; Multiple Organ Failure; Prednisolone; Prednisone; Rituximab; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Vincristine

2014
Central nervous system toxicities of chemotherapeutic agents.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:7

    Topics: Antineoplastic Agents; Central Nervous System Diseases; Cisplatin; Cytarabine; Fluorouracil; Humans; Ifosfamide; Methotrexate; Neurotoxicity Syndromes; Posterior Leukoencephalopathy Syndrome; Vidarabine; Vincristine

2014
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
    Vnitrni lekarstvi, 2014, Volume: 60, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia

2014
Novel treatments for chronic lymphocytic leukemia and moving forward.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2014

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Small Molecule Libraries; Sulfonamides; Vidarabine

2014
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
    Blood, 2014, Aug-28, Volume: 124, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2014
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Sep-20, Volume: 32, Issue:27

    Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine

2014
The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia.
    Food & function, 2014, Volume: 5, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrophenols; Phytochemicals; Piperazines; Protein Kinase Inhibitors; Quercetin; Sulfonamides; Vidarabine

2014
Plasmablastic lymphoma following combination treatment with fludarabine and rituximab for nongastric mucosa-associated lymphoid tissue lymphoma: a case report and review of literature.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:7

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasms, Second Primary; Rituximab; Vidarabine

2014
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?
    Leukemia & lymphoma, 2015, Volume: 56, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoproliferative Disorders; Rituximab; Vidarabine

2015
[Regulatory T cells in cancer immunotherapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Antibodies, Monoclonal; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; Cyclophosphamide; Humans; Immune Tolerance; Immunosuppressive Agents; Immunotherapy; Ipilimumab; Molecular Targeted Therapy; Neoplasms; Programmed Cell Death 1 Receptor; Receptors, CCR4; T-Lymphocytes, Regulatory; Vidarabine

2014
A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Cancer treatment reviews, 2015, Volume: 41, Issue:2

    Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Nitrogen Mustard Compounds; Pentostatin; Physical Fitness; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rituximab; Vidarabine

2015
Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Critical reviews in oncology/hematology, 2015, Volume: 94, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2015
Richter syndrome: an aggressive transformation.
    Oncology nursing forum, 2015, Volume: 42, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Hospice and Palliative Care Nursing; Humans; Hypercalcemia; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Neoplastic Stem Cells; Organoplatinum Compounds; Palliative Care; Prednisone; Prognosis; Risk Factors; Rituximab; Salvage Therapy; Syndrome; Vidarabine; Vincristine

2015
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    American journal of hematology, 2015, Volume: 90, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers; CD5 Antigens; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Cyclophosphamide; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2015
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6

    Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine

2015
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
    Clinical interventions in aging, 2015, Volume: 10

    Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Chlorambucil; Clinical Trials as Topic; Comorbidity; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2015
[Acquired pure red cell aplasia in a patient with B cell chronic lymphocytic leukemia after fludarabine therapy].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:6

    Topics: Aged; Antineoplastic Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Red-Cell Aplasia, Pure; Treatment Outcome; Vidarabine

2015
Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).
    European journal of haematology, 2016, Volume: 96, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Practice Guidelines as Topic; Rituximab; Tumor Suppressor Protein p53; Vidarabine

2016
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4

    Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Methotrexate; Mouth Mucosa; Myeloablative Agonists; Severity of Illness Index; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2016
Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis.
    Bone marrow transplantation, 2016, Volume: 51, Issue:2

    Topics: Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Randomized Controlled Trials as Topic; Survival Rate; Transplantation Conditioning; Vidarabine

2016
Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?
    Expert review of hematology, 2016, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Prognosis; Rituximab; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine

2016
[Treatment of Gaucher disease with allogeneic hematopoietic stem cell transplantation: report of three cases and review of literatures].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2015, Volume: 53, Issue:11

    Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Gaucher Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mycophenolic Acid; Retrospective Studies; Transplantation Conditioning; Vidarabine

2015
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016, Volume: 35

    Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Rituximab; Sulfonamides; Vidarabine

2016
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
    Clinical journal of the American Society of Nephrology : CJASN, 2016, 09-07, Volume: 11, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine

2016
Mycobacterium genavense-induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:2

    Topics: Abdomen; Adolescent; Alemtuzumab; Antibiotic Prophylaxis; Antibiotics, Antitubercular; Antibodies, Monoclonal, Humanized; Bone Marrow Transplantation; Bronchoalveolar Lavage Fluid; Cyclosporine; Diabetes Mellitus, Type 1; Diarrhea; Genetic Diseases, X-Linked; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Immune System Diseases; Immunosuppressive Agents; Lymph Nodes; Male; Melphalan; Mycobacterium Infections, Nontuberculous; Mycophenolic Acid; Nontuberculous Mycobacteria; Photopheresis; Polymerase Chain Reaction; Transplantation Conditioning; Vidarabine

2017
How I treat autoimmune hemolytic anemia.
    Blood, 2017, 06-01, Volume: 129, Issue:22

    Topics: Aged; Algorithms; Anemia, Hemolytic, Autoimmune; Coombs Test; Erythrocyte Transfusion; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Serologic Tests; Splenectomy; Vidarabine

2017
Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.
    Mayo Clinic proceedings, 2017, Volume: 92, Issue:5

    Topics: Administration, Intravenous; Biomarkers; Demyelinating Autoimmune Diseases, CNS; Diagnosis, Differential; Glycoproteins; Humans; Immunoglobulins; Immunologic Factors; Monoclonal Gammopathy of Undetermined Significance; Myeloablative Agonists; Peripheral Nervous System Diseases; Plasmapheresis; Prognosis; Rituximab; Vidarabine

2017
Efficacy and safety evaluation of fludarabine-based chemotherapy regimen for patients with non-Hodgkin lymphoma: A meta-analysis.
    Medicine, 2017, Volume: 96, Issue:33

    Topics: Antineoplastic Combined Chemotherapy Protocols; Lymphoma, Non-Hodgkin; Odds Ratio; Remission Induction; Vidarabine

2017
FCR achieves long-term durable remissions in patients with
    Blood, 2017, 11-23, Volume: 130, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Remission Induction; Rituximab; Time Factors; Vidarabine

2017
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
    Bulletin du cancer, 2017, Volume: 104, Issue:12S

    Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2017
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
    Journal of comparative effectiveness research, 2018, Volume: 7, Issue:5

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Network Meta-Analysis; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Vidarabine

2018
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
    Journal of medical case reports, 2018, Mar-11, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Chromosomes, Human, Pair 12; Cyclin D1; Cyclophosphamide; Disease Progression; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Treatment Outcome; Trisomy; Vidarabine

2018
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia.
    Current treatment options in oncology, 2018, 10-25, Volume: 19, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2018
Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:4

    Topics: Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2019
Selecting Frontline Therapy for CLL in 2018.
    Hematology. American Society of Hematology. Education Program, 2018, 11-30, Volume: 2018, Issue:1

    Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine

2018
Pixantrone beyond monotherapy: a review.
    Annals of hematology, 2019, Volume: 98, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, B-Cell; Mitoxantrone; Prednisone; Rituximab; Salvage Therapy; Vidarabine; Vincristine

2019
Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency.
    Current allergy and asthma reports, 2019, 11-18, Volume: 19, Issue:11

    Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Primary Immunodeficiency Diseases; Transplantation Conditioning; Vidarabine

2019
Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.
    Current oncology reports, 2020, 03-14, Volume: 22, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Tumor Suppressor Protein p53; Vidarabine

2020
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    International journal of hematology, 2020, Volume: 111, Issue:5

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Immunotherapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Neoplasm, Residual; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Vidarabine

2020
The FLAMSA concept-past and future.
    Annals of hematology, 2020, Volume: 99, Issue:9

    Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2020
Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies.
    Blood reviews, 2021, Volume: 47

    Topics: Age Factors; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclosporine; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Methotrexate; Risk Factors; Transplantation Conditioning; Unrelated Donors; Vidarabine

2021
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Cancer, 2021, 04-15, Volume: 127, Issue:8

    Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine

2021
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
    Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:1

    Topics: B-Cell Maturation Antigen; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin D; Immunologic Factors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Receptors, Chimeric Antigen; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine

2022
A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.
    Annals of hematology, 2022, Volume: 101, Issue:4

    Topics: Adult; Child; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine

2022

Trials

796 trial(s) available for fludarabine and vidarabine

ArticleYear
Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
    The New England journal of medicine, 1992, Oct-08, Volume: 327, Issue:15

    Topics: 2-Chloroadenosine; Adult; Antineoplastic Agents; Cladribine; Deoxyadenosines; Drug Resistance; Female; Haptoglobins; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Remission Induction; Vidarabine

1992
Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Evaluation; Female; Glioblastoma; Humans; Isoxazoles; Magnetic Resonance Imaging; Male; Middle Aged; Recurrence; Tomography, X-Ray Computed; Vidarabine

1991
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
    British journal of cancer, 1991, Volume: 64, Issue:1

    Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine; Vidarabine Phosphate

1991
Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine

1992
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
    The American journal of medicine, 1991, Volume: 90, Issue:2

    Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Chromosome Aberrations; Chromosome Disorders; Female; Humans; Immunoglobulin M; Karyotyping; Leukemia, Prolymphocytic; Male; Middle Aged; Prednisone; Remission Induction; Vidarabine

1991
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
    Leukemia & lymphoma, 1993, Volume: 11 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine

1993
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyt
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Regression Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine

1994
FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
    Leukemia, 1994, Volume: 8, Issue:11

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine

1994
Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.
    Acta haematologica, 1995, Volume: 93, Issue:2-4

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fatal Outcome; Female; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pilot Projects; Prednisolone; Prednisone; Remission Induction; Staining and Labeling; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vidarabine; Vinca Alkaloids; Vincristine

1995
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
    European journal of haematology, 1995, Volume: 55, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Vidarabine

1995
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
    Leukemia, 1995, Volume: 9, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Rate; Vidarabine

1995
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
    Blood, 1995, Aug-15, Volume: 86, Issue:4

    Topics: Adult; Aged; CD4 Lymphocyte Count; Female; Humans; Immunity, Cellular; Immunoglobulin G; Interferon Type I; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recombinant Proteins; Skin; Survival Analysis; Vidarabine

1995
Fludarabine treatment in resistant Waldenstrom's macroglobulinemia.
    European journal of haematology, 1995, Volume: 54, Issue:2

    Topics: Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Vidarabine; Waldenstrom Macroglobulinemia

1995
[Treatment with fludarabine of chronic refractory lymphoid leukemia].
    Sangre, 1995, Volume: 40, Issue:2

    Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Vidarabine

1995
A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials.
    Controlled clinical trials, 1994, Volume: 15, Issue:6

    Topics: Antineoplastic Agents; Bayes Theorem; Drug Therapy; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Research Design; Tretinoin; Vidarabine

1994
Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma--the Jerusalem experience.
    Leukemia & lymphoma, 1994, Volume: 15, Issue:1-2

    Topics: Adult; Aged; Bone Marrow Transplantation; Combined Modality Therapy; Female; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine

1994
Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
    Leukemia & lymphoma, 1994, Volume: 14 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B-Lymphocytes; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; T-Lymphocytes; Vidarabine

1994
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
    Leukemia & lymphoma, 1993, Volume: 11 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Humans; Middle Aged; Remission Induction; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia

1993
Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mycosis Fungoides; Recombinant Proteins; Remission Induction; Sezary Syndrome; Skin Neoplasms; Vidarabine

1994
Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine.
    Acta oncologica (Stockholm, Sweden), 1994, Volume: 33, Issue:6

    Topics: Aged; Antineoplastic Agents; Blotting, Southern; DNA, Neoplasm; Flow Cytometry; Gene Rearrangement; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction; Vidarabine

1994
Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
    Blood, 1994, Nov-15, Volume: 84, Issue:10

    Topics: Antineoplastic Agents; B-Lymphocytes; Camptothecin; Cell Survival; Cells, Cultured; Chlorambucil; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine

1994
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
    The New England journal of medicine, 1993, Mar-18, Volume: 328, Issue:11

    Topics: Antineoplastic Agents; Cladribine; Drug Resistance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1993
Chronic lymphocytic leukemia--correlation of response and survival.
    Leukemia & lymphoma, 1993, Volume: 11 Suppl 2

    Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Survival Rate; Vidarabine

1993
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
    Leukemia & lymphoma, 1993, Volume: 10, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Gastrointestinal Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine

1993
Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group
    Seminars in oncology, 1993, Volume: 20, Issue:5 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Prednisone; Remission Induction; Survival Rate; Vidarabine; Vincristine

1993
Fludarabine in low-grade lymphoma.
    Seminars in oncology, 1993, Volume: 20, Issue:5 Suppl 7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Vidarabine

1993
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
    Seminars in oncology, 1993, Volume: 20, Issue:5 Suppl 7

    Topics: Adult; Aged; Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Remission Induction; Survival Rate; Vidarabine

1993
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Vidarabine

1993
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
    Leukemia & lymphoma, 1993, Volume: 10, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Agents; Arabinonucleotides; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Vidarabine

1993
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
    Cancer, 1993, Oct-01, Volume: 72, Issue:7

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine

1993
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
    Leukemia & lymphoma, 1993, Volume: 9, Issue:4-5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Conjunctivitis; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pancreatitis; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine

1993
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
    Blood, 1993, Sep-15, Volume: 82, Issue:6

    Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD4 Antigens; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisone; Prognosis; Regression Analysis; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine

1993
When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L.
    Hematological oncology, 1993, Volume: 11 Suppl 1

    Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multivariate Analysis; Neoplasm Staging; Peptichemio; Prednisone; Sex Factors; Vidarabine; Vincristine

1993
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
    Blood, 1993, Jun-01, Volume: 81, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vidarabine

1993
Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas.
    Leukemia & lymphoma, 1995, Volume: 18, Issue:5-6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; CD4 Lymphocyte Count; Female; Humans; Immunosuppression Therapy; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Platelet Count; Survival Analysis; Vidarabine

1995
Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.
    Leukemia & lymphoma, 1995, Volume: 18, Issue:5-6

    Topics: Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cladribine; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Survival Analysis; Vidarabine

1995
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leukemia, 1996, Volume: 10, Issue:4

    Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Drug Resistance, Neoplasm; Female; Hemorrhage; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Remission Induction; Sepsis; Treatment Failure; Vidarabine

1996
Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.
    American journal of clinical oncology, 1996, Volume: 19, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine

1996
Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
    Lancet (London, England), 1996, May-25, Volume: 347, Issue:9013

    Topics: Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Time Factors; Vidarabine

1996
A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1996, Volume: 86, Issue:5

    Topics: Aged; Antineoplastic Agents; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Sleep Wake Disorders; Thrombocytopenia; Vidarabine

1996
Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia.
    Leukemia & lymphoma, 1996, Volume: 21, Issue:3-4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Vidarabine

1996
[Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
    Medicina clinica, 1996, Jun-15, Volume: 107, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Vidarabine

1996
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
    Leukemia & lymphoma, 1996, Volume: 22, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Vidarabine

1996
Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
    Leukemia, 1997, Volume: 11, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Middle Aged; Pentostatin; Vidarabine

1997
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
    Blood, 1997, Jun-15, Volume: 89, Issue:12

    Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine

1997
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vidarabine

1997
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 1997, Volume: 26, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Vidarabine

1997
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:8

    Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine

1997
Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    European journal of haematology, 1997, Volume: 59, Issue:2

    Topics: Adult; Aged; Female; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Vidarabine

1997
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
    Leukemia, 1997, Volume: 11, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fever; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neutropenia; Vidarabine

1997
Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Child; Child, Preschool; Cytarabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine

1998
Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
    American journal of hematology, 1998, Volume: 58, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Retreatment; Risk Factors; Survival Rate; Transplantation, Autologous; Vidarabine

1998
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
    Blood, 1998, Aug-15, Volume: 92, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4 Lymphocyte Count; Disease Progression; Disease-Free Survival; Female; Fever; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisolone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine

1998
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
    British journal of haematology, 1998, Volume: 102, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Vidarabine

1998
High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
    The Journal of rheumatology, 1998, Volume: 25, Issue:9

    Topics: Antigens, CD; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Lymphocyte Count; Male; Middle Aged; Phenotype; Platelet Count; Time Factors; Treatment Outcome; Vidarabine

1998
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Blast Crisis; Cell Cycle; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; In Vitro Techniques; Infusions, Intravenous; Kinetics; Leukemia, Myeloid, Acute; Pilot Projects; Vidarabine

1995
A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
    The Journal of rheumatology, 1999, Volume: 26, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents; Dermatomyositis; Edema; Female; Flow Cytometry; Hematologic Tests; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Pilot Projects; Polymyositis; Prednisone; Treatment Outcome; Vidarabine

1999
Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; CD4 Lymphocyte Count; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine

1999
Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate; Vidarabine

1999
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Blood, 1999, Apr-15, Volume: 93, Issue:8

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine

1999
Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
    Hematological oncology, 1998, Volume: 16, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Vidarabine

1998
Multi-drug resistance in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 1999, Volume: 34, Issue:1-2

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dexamethasone; Doxorubicin; Drug Resistance, Multiple; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine; Vincristine

1999
Autologous transplantation with peripheral blood stem cells in chronic lymphocytic leukemia. A phase III, randomized, multicenter study. GIMEMA. Gruppo Italiano per le Malattie Ematologiche dell'Adulto. GITMO-Gruppo Italiano Trapianto di Midollo Osseo.
    Hematology and cell therapy, 1999, Volume: 41, Issue:3

    Topics: Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophosphamide; Drug Therapy; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Phenotype; Pilot Projects; Prospective Studies; Statistics as Topic; Survival Rate; Toxicity Tests; Transplantation, Autologous; Vidarabine

1999
A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. EORTC Leukemia Cooperative Group.
    Hematology and cell therapy, 1999, Volume: 41, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chlorambucil; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Pilot Projects; Vidarabine

1999
Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.
    Haematologica, 1999, Volume: 84, Issue:11

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Idarubicin; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Recurrence; Risk Factors; Survival Rate; Treatment Outcome; Vidarabine

1999
Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study.
    Bone marrow transplantation, 1999, Volume: 24, Issue:9

    Topics: Adult; Antineoplastic Agents; Base Sequence; Combined Modality Therapy; Disease-Free Survival; DNA Primers; Female; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation Conditioning; Vidarabine

1999
Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Interferons; Lymphoma, Follicular; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Survival Analysis; Teniposide; Vidarabine

1999
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Cancer, 1999, Dec-01, Volume: 86, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine

1999
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
    Leukemia & lymphoma, 1999, Volume: 36, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1999
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine

2000
Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases.
    Bone marrow transplantation, 2000, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Ambulatory Care; beta-Thalassemia; Blood Component Transfusion; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Remission Induction; Survival Rate; Thrombocytopenia; Transplantation Conditioning; Treatment Outcome; Vidarabine

2000
Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Rate; Treatment Outcome; Vidarabine

2000
Measures of treatment effectiveness on tumour response and survival: a multi-state model approach.
    Statistics in medicine, 2000, Mar-30, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Vidarabine

2000
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine

2000
Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Survival Analysis; Vidarabine

2000
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
    Blood, 2000, Jul-01, Volume: 96, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2000
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
    Leukemia, 2000, Volume: 14, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine

2000
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; DNA, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Treatment Outcome; Vidarabine

2000
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
    Blood, 2000, Oct-01, Volume: 96, Issue:7

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Microsatellite Repeats; Middle Aged; Nuclear Family; Polymerase Chain Reaction; Recurrence; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2000
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Bone marrow transplantation, 2000, Volume: 26, Issue:6

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Melphalan; Pilot Projects; Transplantation Conditioning; Vidarabine

2000
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-01, Volume: 18, Issue:23

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine

2000
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    The New England journal of medicine, 2000, Dec-14, Volume: 343, Issue:24

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cross-Over Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Analysis; Vidarabine

2000
Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis.
    Clinical rheumatology, 2000, Volume: 19, Issue:6

    Topics: Arthritis, Rheumatoid; Disease Progression; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Prednisone; Treatment Failure; Vidarabine

2000
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
    Blood, 2001, Feb-01, Volume: 97, Issue:3

    Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
    Seminars in oncology, 2000, Volume: 27, Issue:6 Suppl 12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Staging; Neutropenia; Rituximab; Vidarabine

2000
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Flow Cytometry; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine

2001
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Haematologica, 2001, Volume: 86, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Treatment Outcome; Vidarabine

2001
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arabinonucleotides; Biomarkers; Female; Guanosine Triphosphate; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Prolymphocytic; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Treatment Outcome; Vidarabine

2001
Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis.
    Pharmacotherapy, 2001, Volume: 21, Issue:5

    Topics: Adult; Antineoplastic Agents; Confidence Intervals; Cross-Over Studies; Cyclophosphamide; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lupus Nephritis; Male; Middle Aged; Statistics, Nonparametric; Vidarabine

2001
Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2001, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Chimera; Combined Modality Therapy; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2001
A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
    The British journal of dermatology, 2001, Volume: 144, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; Mycosis Fungoides; Pilot Projects; Sezary Syndrome; Skin Neoplasms; Treatment Outcome; Vidarabine

2001
Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
    Blood, 2001, Jul-01, Volume: 98, Issue:1

    Topics: Age Factors; Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Cohort Studies; Disease-Free Survival; Female; Hemoglobins; Humans; Immunoglobulin M; Male; Models, Biological; Multivariate Analysis; Odds Ratio; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia

2001
Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:3-4

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Salvage Therapy; Sex Factors; Vidarabine

2001
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:3-4

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Survival Rate; Vidarabine

2001
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Vidarabine

2001
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:3-4

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Pancytopenia; Pilot Projects; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Vidarabine

2001
Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.
    Journal of clinical epidemiology, 2001, Volume: 54, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine

2001
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
    Annals of hematology, 2001, Volume: 80, Issue:6

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Humans; Leukemia; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine

2001
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Bone marrow transplantation, 2001, Volume: 27, Issue:8

    Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine

2001
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasms; Pneumonia; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2001
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Aug-15, Volume: 19, Issue:16

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Ontario; Respiratory Tract Infections; Skin Diseases, Infectious; Treatment Outcome; United States; Vidarabine

2001
Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
    Leukemia, 2001, Volume: 15, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Health Status Indicators; Humans; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia

2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
    British journal of haematology, 2001, Volume: 114, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome; Vidarabine

2001
Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
    Haematologica, 2001, Volume: 86, Issue:9

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Methylprednisolone; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Onkologie, 2001, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Rate; Vidarabine

2001
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
    Cancer, 2001, Oct-15, Volume: 92, Issue:8

    Topics: Aged; Anemia; Antineoplastic Agents; Cyclosporine; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Splenectomy; Thrombocytopenia; Vidarabine

2001
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
    Haematologica, 2001, Volume: 86, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Lineage; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloid Cells; Prospective Studies; Transplantation Chimera; Vidarabine

2001
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Bone marrow transplantation, 2001, Volume: 28, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2001
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
    Blood, 2001, Nov-01, Volume: 98, Issue:9

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Male; Middle Aged; Mouth Mucosa; Prednisone; Recurrence; Salvage Therapy; Stomatitis; Survival Analysis; Therapeutic Equivalency; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
    Blood, 2001, Dec-15, Volume: 98, Issue:13

    Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prognosis; Recurrence; Remission Induction; Survival Rate; Time Factors; Topotecan; Treatment Failure; Vidarabine

2001
Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.
    Blood, 2001, Dec-15, Volume: 98, Issue:13

    Topics: Adult; Aged; Busulfan; Cyclophosphamide; Erythrocyte Transfusion; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Nuclear Family; Platelet Transfusion; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2001
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
    Blood, 2001, Dec-15, Volume: 98, Issue:13

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Rituximab; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine

2001
The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
    Bone marrow transplantation, 2001, Volume: 28, Issue:8

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Gastric Mucosa; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Middle Aged; Permeability; Prospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2001
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
    Blood, 2002, Feb-01, Volume: 99, Issue:3

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Melphalan; Middle Aged; Survival Analysis; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 2

    Topics: Actins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Dexamethasone; DNA; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mitoxantrone; Neoplasm, Residual; Polymerase Chain Reaction; Rituximab; Translocation, Genetic; Vidarabine

2002
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
    Cancer, 2002, Feb-01, Volume: 94, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine

2002
Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1

    Topics: Adult; Drug Resistance, Neoplasm; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Middle Aged; Recurrence; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.
    Blood, 2002, Mar-15, Volume: 99, Issue:6

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Resistance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Therapeutic Equivalency; Treatment Outcome; Vidarabine

2002
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
    Blood, 2002, Mar-15, Volume: 99, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Primary Myelofibrosis; Splenomegaly; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Vidarabine

2002
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Leukemia, 2002, Volume: 16, Issue:4

    Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Clinical lymphoma, 2002, Volume: 2, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Tumor Burden; Vidarabine; Vincristine

2002
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Blood, 2002, May-15, Volume: 99, Issue:10

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Demography; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine

2002
[Fludarabine as primary therapeutic drug in chronic lymphatic leukemia].
    Der Internist, 2002, Volume: 43, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate; Treatment Outcome; Vidarabine

2002
A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2002, Volume: 63, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Otorhinolaryngologic Neoplasms; Radiation Injuries; Vidarabine

2002
Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
    Haematologica, 2002, Volume: 87, Issue:7

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Therapeutic Equivalency; Treatment Outcome; Vidarabine

2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Mass Index; Creatinine; Disease-Free Survival; Female; Hematologic Tests; Humans; Kidney Function Tests; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neutrophils; Vidarabine

2002
Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    American journal of hematology, 2002, Volume: 70, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Remission Induction; Vidarabine; Vincristine

2002
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine

2002
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Cytotherapy, 2001, Volume: 3, Issue:3

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
    Blood, 2002, Sep-15, Volume: 100, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Vidarabine

2002
Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
    Bone marrow transplantation, 2002, Volume: 30, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Lymphoma; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
    Haematologica, 2002, Volume: 87, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors; Vidarabine

2002
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Vidarabine

2002
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Neutropenia; Opportunistic Infections; Pilot Projects; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine

2002
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Bone marrow transplantation, 2002, Volume: 30, Issue:6

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2002, Volume: 8, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cerebral Hemorrhage; Chills; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine

2002
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
    Blood, 2003, Jan-01, Volume: 101, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Leukemia, B-Cell; Male; Middle Aged; Risk Factors; Rituximab; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vidarabine

2003
Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
    Blood, 2002, Dec-01, Volume: 100, Issue:12

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
    Blood, 2002, Dec-15, Volume: 100, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine

2002
The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.
    Anti-cancer drugs, 2002, Volume: 13, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclophosphamide; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Vidarabine

2002
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Deutsche medizinische Wochenschrift (1946), 2002, Oct-25, Volume: 127, Issue:43

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine

2002
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
    International journal of hematology, 2002, Volume: 76 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Mycophenolic Acid; Tissue Donors; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2002
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
    British journal of haematology, 2002, Volume: 119, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Vidarabine

2002
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-15, Volume: 20, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Quality of Life; Survival Rate; Treatment Outcome; Vidarabine; Vincristine

2002
Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
    Clinical lymphoma, 2002, Volume: 3, Issue:3

    Topics: Antineoplastic Agents; Bryostatins; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Vidarabine

2002
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; Esophagitis; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Metabolic Clearance Rate; Middle Aged; Recurrence; Stomatitis; Vidarabine

2003
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Leukemia, 2003, Volume: 17, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Patient Selection; Survival Rate; Time Factors; Vidarabine

2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
    Cancer, 2003, Mar-15, Volume: 97, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival; Treatment Outcome; Vidarabine

2003
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
    Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine

2003
Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:3

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Mycophenolic Acid; Radiotherapy, Adjuvant; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
    Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vidarabine

2003
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
    Blood, 2003, Aug-01, Volume: 102, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Follow-Up Studies; Graft Survival; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma.
    Haematologica, 2003, Volume: 88, Issue:4

    Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2003
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Follow-Up Studies; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2003
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-15, Volume: 21, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Living Donors; Male; Melphalan; Middle Aged; Prognosis; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
    Seminars in oncology, 2003, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Follow-Up Studies; Humans; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Vidarabine; Waldenstrom Macroglobulinemia

2003
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Middle Aged; Mycophenolic Acid; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2003
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Annals of hematology, 2003, Volume: 82, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine

2003
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
    Blood, 2003, Sep-01, Volume: 102, Issue:5

    Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2003
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Survival Analysis; Treatment Outcome; United States; Vidarabine

2003
Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.
    European journal of haematology, 2003, Volume: 70, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clone Cells; Cytarabine; Dexamethasone; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplastic Cells, Circulating; Remission Induction; Vidarabine; Vincristine

2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:3

    Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Radiation-Protective Agents; Sepsis; Survival Rate; Vidarabine

2003
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
    Blood, 2003, Sep-15, Volume: 102, Issue:6

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Lymphocyte Transfusion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Tissue Donors; Vidarabine; Whole-Body Irradiation

2003
Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
    European journal of haematology, 2003, Volume: 71, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine

2003
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
    Bone marrow transplantation, 2003, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Graft Survival; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Histocompatibility; Humans; Middle Aged; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2003
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:6

    Topics: Aged; Aged, 80 and over; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Analysis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia

2003
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
    Leukemia research, 2003, Volume: 27, Issue:10

    Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Drug Resistance, Neoplasm; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Platelet Count; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Vidarabine

2003
Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:7

    Topics: Adult; Aged; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:7

    Topics: Adult; Aged; Animals; Antilymphocyte Serum; Bone Marrow Diseases; Bone Marrow Transplantation; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Radiotherapy Dosage; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2003
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.
    Blood, 2003, Nov-15, Volume: 102, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Renal Cell; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Male; Melphalan; Middle Aged; Neoplasm Metastasis; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria.
    European journal of haematology, 2003, Volume: 71, Issue:2

    Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
    Annals of hematology, 2003, Volume: 82, Issue:9

    Topics: Adult; Antigens, CD34; Cyclophosphamide; Female; Hematologic Diseases; Hematologic Neoplasms; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutrophils; Peripheral Blood Stem Cell Transplantation; Platelet Count; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Rate; Vidarabine

2003
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:8

    Topics: Adult; Anemia, Sickle Cell; beta-Thalassemia; Bone Marrow Transplantation; Child; Child, Preschool; Female; Graft Survival; Hematopoiesis; Humans; Immunocompetence; Kinetics; Male; Pilot Projects; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2003
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
    Bone marrow transplantation, 2003, Volume: 32, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
    Blood, 2004, Jan-15, Volume: 103, Issue:2

    Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
    Bone marrow transplantation, 2003, Volume: 32, Issue:6

    Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Patient Selection; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-01, Volume: 9, Issue:10 Pt 1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Diphtheria Toxin; Drug Resistance, Neoplasm; Female; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Recombinant Fusion Proteins; Time Factors; Tomography, Emission-Computed; Treatment Outcome; Vidarabine

2003
[Modified FLAG regimen in the management of refractory acute myeloid leukemia].
    Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2003, Volume: 23, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine

2003
The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Bone marrow transplantation, 2003, Volume: 32, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Transplantation, Isogeneic; Treatment Outcome; Vidarabine

2003
Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects.
    Annals of the rheumatic diseases, 2003, Volume: 62, Issue:11

    Topics: Adult; Anti-Inflammatory Agents; Arthritis, Psoriatic; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; DNA-Binding Proteins; E-Selectin; Endothelial Cells; Female; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Lymphocyte Depletion; Male; Middle Aged; P-Selectin; Phosphorylation; Prednisone; STAT1 Transcription Factor; Synovial Membrane; Trans-Activators; Vidarabine

2003
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
    Clinical and laboratory haematology, 2003, Volume: 25, Issue:6

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Incidence; Leukocyte Transfusion; Life Tables; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2003
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.
    Leukemia research, 2004, Volume: 28, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; STAT1 Transcription Factor; Survival Analysis; Trans-Activators; Treatment Outcome; Vidarabine

2004
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
    British journal of haematology, 2004, Volume: 124, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine

2004
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Haematologica, 2003, Volume: 88, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Disease Progression; Drug Administration Schedule; Female; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine

2003
Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Neoplasma, 2003, Volume: 50, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Vidarabine

2003
[Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Vidarabine

2003
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:1

    Topics: Adult; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Opportunistic Infections; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
Nonmyeloablative stem cell transplantation for lymphoma.
    Seminars in oncology, 2004, Volume: 31, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma; Middle Aged; Recurrence; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine

2004
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
    Bone marrow transplantation, 2004, Volume: 33, Issue:9

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.
    Blood, 2004, Sep-15, Volume: 104, Issue:6

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vidarabine

2004
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
    Bone marrow transplantation, 2004, Volume: 33, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents; Disease Progression; Drug Therapy; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
    Bone marrow transplantation, 2004, Volume: 33, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mycophenolic Acid; Opportunistic Infections; Premedication; Prospective Studies; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2004
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
    Blood, 2004, Apr-15, Volume: 103, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Risk Factors; Survival Rate; Vidarabine

2004
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
    Leukemia research, 2004, Volume: 28, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Topotecan; Treatment Outcome; Vidarabine

2004
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
    Annals of hematology, 2004, Volume: 83 Suppl 1

    Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
    Bone marrow transplantation, 2004, Volume: 34, Issue:1

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphocyte Transfusion; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
    Blood, 2004, Sep-01, Volume: 104, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Radiation, Ionizing; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine

2004
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Survival Analysis; Time Factors; Vidarabine

2004
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Cancer, 2004, Jun-15, Volume: 100, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Vidarabine

2004
Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:9

    Topics: Adult; Aged; Aging; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine

2004
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
    Leukemia & lymphoma, 2004, Volume: 45, Issue:9

    Topics: Adult; Aged; Bendamustine Hydrochloride; Female; Germany; Hematology; Humans; Lymphoma; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Societies, Medical; Time Factors; Vidarabine

2004
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.
    Bone marrow transplantation, 2004, Volume: 34, Issue:2

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Nervous System Diseases; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Diseases

2004
Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
    European journal of haematology, 2004, Volume: 73, Issue:2

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell
    Blood, 2004, Nov-15, Volume: 104, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine

2004
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Vidarabine

2004
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
    Blood, 2004, Dec-01, Volume: 104, Issue:12

    Topics: Adult; Aged; Combined Modality Therapy; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppression Therapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2004
Cytopenia and hematopoietic recovery after low intensity conditioning transplants.
    Croatian medical journal, 2004, Volume: 45, Issue:4

    Topics: Adult; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Analysis; Thrombocytopenia; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2004
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Annals of hematology, 2004, Volume: 83, Issue:11

    Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine

2004
Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.
    European journal of haematology, 2004, Volume: 73, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Rituximab; Vidarabine

2004
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2004, Volume: 10, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
    Blood, 2005, Jan-15, Volume: 105, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Nucleoside Transport Proteins; RNA, Messenger; Treatment Outcome; Vidarabine

2005
Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
    Bone marrow transplantation, 2004, Volume: 34, Issue:12

    Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2004
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-15, Volume: 10, Issue:20

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Topotecan; Vidarabine

2004
Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2004, Volume: 10, Issue:11

    Topics: Adult; Aged; Antilymphocyte Serum; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2004
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
    Bone marrow transplantation, 2004, Volume: 34, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
    Bone marrow transplantation, 2005, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Combined Modality Therapy; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunosuppressive Agents; Infections; Male; Pancytopenia; Thalassemia; Transfusion Reaction; Transplantation Chimera; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2005
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Treatment Outcome; Vidarabine

2004
Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).
    Bone marrow transplantation, 2005, Volume: 35, Issue:3

    Topics: Antigens, CD34; Antilymphocyte Serum; Busulfan; Child, Preschool; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Infant; Lymphocyte Transfusion; Mucopolysaccharidosis I; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-01, Volume: 10, Issue:23

    Topics: Adenocarcinoma, Clear Cell; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Renal Cell; Cells, Cultured; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Middle Aged; Minor Histocompatibility Antigens; Mycophenolic Acid; Myeloid Cells; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2004
Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Haematologica, 2004, Volume: 89, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vidarabine

2004
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
    Haematologica, 2004, Volume: 89, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Infections; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:12

    Topics: Adult; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Liposomes; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Treatment Outcome; Vidarabine

2004
Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.
    Bone marrow transplantation, 2005, Volume: 35, Issue:5

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cyclophosphamide; Graft Survival; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppression Therapy; Incidence; Tissue Donors; Treatment Outcome; Vidarabine

2005
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Flow Cytometry; Genes, bcl-2; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; T-Lymphocyte Subsets; Vidarabine

2005
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Risk Factors; Vidarabine; Vindesine

2005
Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
    Haematologica, 2005, Volume: 90, Issue:2

    Topics: Aged; Antineoplastic Agents; Cohort Studies; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia

2005
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
    Blood, 2005, Jun-15, Volume: 105, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 7; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; DNA Damage; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Remission Induction; Rituximab; Time Factors; Vidarabine

2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2005
Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
    European journal of haematology, 2005, Volume: 74, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine

2005
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
    Clinical lymphoma, 2005, Volume: 5, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Female; Humans; Lymphoma; Male; Middle Aged; Prospective Studies; Splenic Neoplasms; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2005
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10

    Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Treatment Outcome; Vidarabine

2005
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
    Leukemia, 2005, Volume: 19, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Radiation Dosage; Siblings; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2005
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.
    Bone marrow transplantation, 2005, Volume: 35, Issue:12

    Topics: Adult; Age Distribution; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; CD52 Antigen; Combined Modality Therapy; Female; Glycoproteins; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Leukocyte Common Antigens; Lymphocyte Depletion; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2005
Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
    Neoplasma, 2005, Volume: 52, Issue:3

    Topics: Adult; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2005
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:7

    Topics: Adult; Age Factors; Aged; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myelopoiesis; Neoplasms; Neutrophils; Risk Factors; Sex Factors; Syndrome; Transplantation Conditioning; Vidarabine

2005
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
    Clinical lymphoma, 2005, Volume: 6, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Staging; Neutropenia; Patient Selection; Recurrence; Treatment Outcome; Vidarabine

2005
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine

2005
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Blood, 2005, Nov-01, Volume: 106, Issue:9

    Topics: Adult; Aged; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2005
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
    Blood, 2005, Nov-15, Volume: 106, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vidarabine

2005
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
    British journal of haematology, 2005, Volume: 130, Issue:4

    Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes

2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Prospective Studies; Radioimmunotherapy; Treatment Outcome; Vidarabine

2005
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine

2005
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:10

    Topics: Acute Disease; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Siblings; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2005
Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.
    Leukemia, 2005, Volume: 19, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine

2005
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    British journal of haematology, 2005, Volume: 131, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine

2005
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2

    Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Gemtuzumab; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunotherapy; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.
    Bone marrow transplantation, 2005, Volume: 36, Issue:11

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cause of Death; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine

2005
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
    Blood, 2006, Feb-01, Volume: 107, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Remission Induction; Retrospective Studies; Thrombocytopenia; Vidarabine

2006
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:12

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Time Factors; Treatment Outcome; Vidarabine

2005
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
    Cancer, 2005, Dec-15, Volume: 104, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Probability; Prognosis; Prospective Studies; Risk Assessment; Rituximab; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2005
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosphamide; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Follicular; Male; Middle Aged; Vidarabine

2005
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
    Bone marrow transplantation, 2006, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survival; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infusions, Intravenous; Living Donors; Male; Myeloablative Agonists; Prospective Studies; Rabbits; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2006
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Bone marrow transplantation, 2006, Volume: 37, Issue:4

    Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2006
Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
    Bone marrow transplantation, 2006, Volume: 37, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Combined Modality Therapy; Diarrhea; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Mouth Mucosa; Stomatitis; Survival Rate; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2006
Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Living Donors; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Stem Cell Transplantation; Survival Rate; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2006
Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Aged; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Remission Induction; Survival Rate; Transplantation Conditioning; Vidarabine

2006
Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.
    European journal of haematology, 2006, Volume: 77, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sepsis; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2006
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-20, Volume: 24, Issue:15

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD34; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus Infections; Feasibility Studies; Female; Ganciclovir; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Treatment Outcome; Vidarabine

2006
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
    International journal of hematology, 2006, Volume: 83, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Myeloablative Agonists; Podophyllotoxin; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2006
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
    Leukemia research, 2007, Volume: 31, Issue:2

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Thalidomide; Treatment Failure; Tumor Necrosis Factor-alpha; Vidarabine

2007
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Cancer, 2006, Sep-01, Volume: 107, Issue:5

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protease Inhibitors; Pyrazines; Treatment Outcome; Vidarabine

2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:8

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Melphalan; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2006
Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:8

    Topics: Adult; Anemia, Aplastic; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2006
High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    American journal of hematology, 2006, Volume: 81, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2006
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.
    Bone marrow transplantation, 2006, Volume: 38, Issue:6

    Topics: Adult; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Risk Factors; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2006
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
    British journal of haematology, 2006, Volume: 135, Issue:2

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Epidemiologic Methods; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2006
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular
    Blood, 2006, Dec-15, Volume: 108, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Vidarabine

2006
Preclinical assessment of curcumin as a potential therapy for B-CLL.
    American journal of hematology, 2007, Volume: 82, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; NF-kappa B; NF-kappaB-Inducing Kinase; PPAR gamma; Protein Serine-Threonine Kinases; Rolipram; Signal Transduction; Tumor Cells, Cultured; Vidarabine; Vincristine

2007
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
    Blood, 2006, Dec-15, Volume: 108, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Adducts; DNA Repair; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Vidarabine

2006
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
    Bone marrow transplantation, 2006, Volume: 38, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutropenia; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2006
Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
    Blood, 2007, Jan-01, Volume: 109, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Child; Child, Preschool; Colitis; Endocrine System Diseases; Food Hypersensitivity; Forkhead Transcription Factors; Genes, X-Linked; Graft Survival; Humans; Ichthyosis, X-Linked; Immunologic Deficiency Syndromes; Infant; Leukocyte Count; Melphalan; Postoperative Complications; Reoperation; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Macrolides; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Vidarabine

2006
Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.
    Annals of hematology, 2007, Volume: 86, Issue:1

    Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Middle Aged; Myeloablative Agonists; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2007
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
    Leukemia research, 2007, Volume: 31, Issue:7

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Lymphoid; Leukemia, T-Cell; Male; Middle Aged; Pentostatin; Retrospective Studies; Vidarabine

2007
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vidarabine

2006
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
    British journal of haematology, 2007, Volume: 136, Issue:1

    Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Multivariate Analysis; Remission Induction; Respiratory Tract Infections; Risk Factors; Survival Rate; Vidarabine

2007
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10

    Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; Cytokines; Disease-Free Survival; Family; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2006
Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.
    Neurology, 2006, Dec-12, Volume: 67, Issue:11

    Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Immunoglobulin M; Male; Middle Aged; Paraproteinemias; Polyneuropathies; Prospective Studies; Vidarabine

2006
Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation.
    Journal of clinical pharmacology, 2007, Volume: 47, Issue:1

    Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Cyclophosphamide; Cyclosporine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Mycophenolic Acid; Statistics, Nonparametric; Vidarabine; Whole-Body Irradiation

2007
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
    Bone marrow transplantation, 2007, Volume: 39, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Interactions; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
    Bone marrow transplantation, 2007, Volume: 39, Issue:3

    Topics: Abnormalities, Multiple; Adolescent; Bone Marrow Diseases; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Pilot Projects; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Bone marrow transplantation, 2007, Volume: 39, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:1

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Female; Graft Survival; Graft vs Host Disease; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2007
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-01, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Vidarabine

2007
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-20, Volume: 25, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotides, Antisense; Proportional Hazards Models; Recurrence; Thionucleotides; Time Factors; Treatment Failure; Treatment Outcome; Vidarabine

2007
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Matched-Pair Analysis; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
    Rheumatology (Oxford, England), 2007, Volume: 46, Issue:6

    Topics: Adult; Aged; CD4 Lymphocyte Count; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lupus Nephritis; Lymphopenia; Male; Middle Aged; Neutropenia; Pilot Projects; Proteinuria; Treatment Outcome; Vidarabine

2007
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survivors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fatigue; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Nausea; Quality of Life; Surveys and Questionnaires; Vidarabine; Vomiting

2007
A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:5

    Topics: Acute Disease; Adult; Chimerism; Cyclophosphamide; Disease-Free Survival; Female; Fertility; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
    Journal of Korean medical science, 2007, Volume: 22, Issue:2

    Topics: Adolescent; Adult; Aged; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; International Cooperation; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.
    British journal of haematology, 2007, Volume: 137, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers, Tumor; Chi-Square Distribution; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Statistics, Nonparametric; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2007
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Cancer, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thrombocytopenia; Time Factors; Treatment Outcome; Vidarabine

2007
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
    Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mexico; Middle Aged; Recurrence; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine

2007
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
    International journal of hematology, 2007, Volume: 85, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.
    Blood, 2007, Oct-15, Volume: 110, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2007
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    American journal of hematology, 2007, Volume: 82, Issue:10

    Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison
    British journal of haematology, 2007, Volume: 138, Issue:2

    Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Vidarabine

2007
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
    Bone marrow transplantation, 2007, Volume: 40, Issue:5

    Topics: Adult; Aged; Antilymphocyte Serum; Feasibility Studies; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Salvage Therapy; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2007
Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
    American journal of hematology, 2007, Volume: 82, Issue:10

    Topics: Aged; Agranulocytosis; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Reoperation; Siblings; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol
    Leukemia research, 2008, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Recurrence; Thiosemicarbazones; Treatment Outcome; Vidarabine

2008
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
    Lancet (London, England), 2007, Jul-21, Volume: 370, Issue:9583

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Vidarabine

2007
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Haematologica, 2007, Volume: 92, Issue:10

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Endothelial Cell Adhesion Molecule-1; Vidarabine

2007
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2007, Volume: 40, Issue:11

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine

2007
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    British journal of haematology, 2007, Volume: 139, Issue:1

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Melphalan; Methotrexate; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma.
    British journal of haematology, 2007, Volume: 139, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate; Vidarabine

2007
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:10

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine

2007
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:11

    Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Child, Preschool; Chimerism; Drug Therapy, Combination; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukocyte Reduction Procedures; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Vidarabine

2007
Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
    Experimental hematology, 2007, Volume: 35, Issue:11

    Topics: Adult; Bone Marrow Examination; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Primary Myelofibrosis; Remission Induction; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
    Leukemia, 2008, Volume: 22, Issue:2

    Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gemtuzumab; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Transplantation, Homologous; Vidarabine

2008
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
    Blood, 2008, Feb-01, Volume: 111, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; Idarubicin; Infant; Infant, Newborn; Interleukin-2; Leukemia, Myeloid, Acute; Male; Prognosis; Survival Rate; Treatment Outcome; Vidarabine

2008
Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen.
    Bone marrow transplantation, 2008, Volume: 41, Issue:4

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Mucopolysaccharidosis I; Pilot Projects; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
    International journal of hematology, 2007, Volume: 86, Issue:4

    Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine

2007
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
    Blood, 2008, Feb-15, Volume: 111, Issue:4

    Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Coombs Test; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome; Vidarabine

2008
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Annals of hematology, 2008, Volume: 87, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Poland; Remission Induction; Vidarabine

2008
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-01, Volume: 14, Issue:1

    Topics: ADP-ribosyl Cyclase 1; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2008
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    European journal of haematology, 2008, Volume: 80, Issue:4

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Salvage Therapy; Vidarabine

2008
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Research Design; Rituximab; Statistics, Nonparametric; Survival Analysis; Syndrome; Treatment Outcome; Vidarabine

2008
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
    Cancer, 2008, Feb-15, Volume: 112, Issue:4

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Vidarabine; Yttrium Radioisotopes

2008
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Cancer, 2008, Mar-15, Volume: 112, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Rituximab; Survival Rate; Vidarabine

2008
High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.
    Bone marrow transplantation, 2008, Volume: 41, Issue:8

    Topics: Cord Blood Stem Cell Transplantation; Female; Graft Survival; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Transplantation Conditioning; Treatment Failure; Vidarabine

2008
Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Remission Induction; Treatment Outcome; Vidarabine

2008
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
    Bone marrow transplantation, 2008, Volume: 41, Issue:10

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Vidarabine

2008
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:2

    Topics: Adult; Age Factors; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2008
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Monitoring; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2008
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:2

    Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2008
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
    Haematologica, 2008, Volume: 93, Issue:2

    Topics: Adult; Disease-Free Survival; Female; Follow-Up Studies; Hodgkin Disease; Hospitals, University; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Pilot Projects; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
    Haematologica, 2008, Volume: 93, Issue:2

    Topics: Adult; Aged; Anesthesia Recovery Period; CD8-Positive T-Lymphocytes; Cyclosporine; Female; Flow Cytometry; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms; Peripheral Blood Stem Cell Transplantation; Receptors, Antigen, T-Cell, alpha-beta; Thymus Gland; Time Factors; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2008
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
    Haematologica, 2008, Volume: 93, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Survival Rate; Vidarabine

2008
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Bone marrow transplantation, 2008, Volume: 41, Issue:11

    Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Phase I trial of nelarabine in indolent leukemias.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Arabinonucleotides; DNA (Cytosine-5-)-Methyltransferases; Drug Therapy, Combination; Female; Guanosine Triphosphate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine

2008
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunotherapy; Infection Control; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Rituximab; Salvage Therapy; Vidarabine

2008
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    The Lancet. Oncology, 2008, Volume: 9, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Probability; Radioimmunotherapy; Risk Assessment; Survival Analysis; Vidarabine; Yttrium Radioisotopes

2008
Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:5

    Topics: Adult; Busulfan; Cell Count; Cord Blood Stem Cell Transplantation; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myeloid; Myeloablative Agonists; Transplantation Conditioning; Treatment Failure; Vidarabine

2008
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
    Blood, 2008, Aug-15, Volume: 112, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
    Blood, 2008, Jun-15, Volume: 111, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Rituximab; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
    Blood, 2008, Jul-15, Volume: 112, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:6

    Topics: Adult; Aged; Blood Component Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Filgrastim; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Postoperative Care; Postoperative Complications; Recombinant Proteins; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2008
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:6

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bayes Theorem; Busulfan; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2008
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
    British journal of haematology, 2008, Volume: 142, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2008
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
    Annals of hematology, 2008, Volume: 87, Issue:11

    Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neutropenia; Remission Induction; Vidarabine

2008
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Leukemia research, 2008, Volume: 32, Issue:12

    Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Vidarabine; Young Adult

2008
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
    American journal of hematology, 2008, Volume: 83, Issue:9

    Topics: Adolescent; Adult; Aged; Busulfan; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Comorbidity; Digestive System Diseases; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Reoperation; Risk; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Middle Aged; Myeloablative Agonists; Risk Assessment; Siblings; Survival Analysis; Survival Rate; Vidarabine

2008
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Premedication; Sirolimus; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
    Hematological oncology, 2008, Volume: 26, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Immune Tolerance; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Recurrence; Vidarabine

2008
Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia.
    Current oncology reports, 2008, Volume: 10, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease-Free Survival; Flow Cytometry; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2008
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Annals of hematology, 2009, Volume: 88, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Time Factors; Vidarabine

2009
[Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Vidarabine

2008
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Half-Life; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Salvage Therapy; Tissue Distribution; Vidarabine

2008
Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.
    Leukemia, 2009, Volume: 23, Issue:3

    Topics: Adult; Aged; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2009
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32

    Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chemotherapy, Adjuvant; Child; Cyclophosphamide; Female; Humans; Interleukin-15; Interleukin-2; Interleukin-7; Kaplan-Meier Estimate; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Myeloablative Agonists; Neoadjuvant Therapy; Neoplasm Metastasis; Pilot Projects; Radiotherapy Dosage; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Vidarabine

2008
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
    Blood, 2009, Mar-19, Volume: 113, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cell Cycle; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Inactivation, Metabolic; Infusions, Intravenous; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Piperidines; Protein Kinase Inhibitors; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Lysis Syndrome; Uridine Diphosphate Glucuronic Acid; Vidarabine

2009
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
    British journal of haematology, 2008, Volume: 143, Issue:4

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2008
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an his
    Leukemia, 2009, Volume: 23, Issue:2

    Topics: Adult; Aged; Cell Count; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Recombinant Proteins; Stem Cell Factor; Treatment Outcome; Vidarabine

2009
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.
    Bone marrow transplantation, 2009, Volume: 43, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Female; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Leukemia, Myeloid, Acute; Lymphocytes; Male; Melphalan; Middle Aged; Neoplastic Cells, Circulating; Transplantation Conditioning; Transplantation, Homologous; Tumor Burden; Vidarabine

2009
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
    Blood, 2009, Apr-16, Volume: 113, Issue:16

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neutropenia; Pneumonia; Prospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia

2009
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
    British journal of haematology, 2009, Volume: 144, Issue:1

    Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Treatment Outcome; Vidarabine

2009
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
    Blood, 2009, Apr-02, Volume: 113, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Genes, Immunoglobulin Heavy Chain; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Receptors, Fc; Rituximab; Survival Analysis; Vidarabine; Young Adult

2009
Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
    Bone marrow transplantation, 2009, Volume: 43, Issue:10

    Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Lymphocyte Depletion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2009
Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Family; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Middle Aged; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2009
A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:1

    Topics: Adult; Aged; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Premedication; Reoperation; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine

2009
Allogeneic hematopoietic stem cell transplantation of patients with FA and high risk features using fludarabine without radiation.
    Pediatric blood & cancer, 2009, Volume: 52, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Fanconi Anemia; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Radiation; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2009
Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Aged; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Humans; Immunosuppression Therapy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycophenolic Acid; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2009
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
    Leukemia research, 2009, Volume: 33, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Salvage Therapy; Survival Rate; Tretinoin; Vidarabine

2009
Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
    American journal of hematology, 2009, Volume: 84, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult

2009
Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Vidarabine

2009
Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Rituximab; Vidarabine

2009
A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Leukemia, 2009, Volume: 23, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etanercept; Female; Humans; Immunoglobulin G; Infusions, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Tumor Necrosis Factor; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Tumor Necrosis Factor-alpha; Vidarabine

2009
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Cancer, 2009, May-01, Volume: 115, Issue:9

    Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Genes, bcl-2; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Rituximab; Survival Analysis; Vidarabine; Vincristine

2009
Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
    PloS one, 2009, Volume: 4, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cytokines; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Humans; Immunotherapy, Adoptive; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine

2009
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2009, Volume: 32, Issue:4

    Topics: Acyclovir; Adult; Aged; Antifungal Agents; Antineoplastic Agents, Alkylating; Antiviral Agents; Cyclophosphamide; Cytotoxicity, Immunologic; Female; Fluconazole; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Skin Neoplasms; Vidarabine

2009
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
    British journal of haematology, 2009, Volume: 145, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies; Rituximab; Survival Rate; Vidarabine

2009
Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:3

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine

2009
[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine

2009
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
    Bone marrow transplantation, 2009, Volume: 44, Issue:12

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2009
Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
    Leukemia, 2009, Volume: 23, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2009
[Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine

2009
Better posttransplant outcome with fludarabine based conditioning in multitransfused fanconi anemia patients who underwent peripheral blood stem cell transplantation.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:7

    Topics: Adolescent; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Humans; Male; Peripheral Blood Stem Cell Transplantation; Radiotherapy; Transplantation Conditioning; Treatment Outcome; Vidarabine

2009
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
    Cancer science, 2009, Volume: 100, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine

2009
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-20, Volume: 27, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Vidarabine

2009
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
    Blood, 2009, Oct-15, Volume: 114, Issue:16

    Topics: Aged; Antineoplastic Agents, Alkylating; Chlorambucil; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Survival Rate; Vidarabine

2009
HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer.
    Bone marrow transplantation, 2010, Volume: 45, Issue:3

    Topics: Adult; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2010
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Blood, 2009, Sep-24, Volume: 114, Issue:13

    Topics: Administration, Cutaneous; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p21; DNA Mutational Analysis; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Signal Transduction; Treatment Failure; Tumor Suppressor Protein p53; Vidarabine

2009
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
    Leukemia research, 2010, Volume: 34, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cell Separation; Cyclophosphamide; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Pilot Projects; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2010
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
    British journal of haematology, 2009, Volume: 147, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine

2009
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
    Bone marrow transplantation, 2010, Volume: 45, Issue:3

    Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2010
Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Cancer, 2009, Nov-15, Volume: 115, Issue:22

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Rituximab; Vidarabine

2009
Rituximab for polyneuropathy with IgM monoclonal gammopathy.
    Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:9

    Topics: Age of Onset; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; B-Lymphocytes; Bone Marrow Cells; Cyclophosphamide; Disability Evaluation; Female; Humans; Immunoglobulin M; Immunologic Factors; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Muscle Strength; Neural Conduction; Paraproteinemias; Prednisone; Prospective Studies; Rituximab; Sensation; Treatment Outcome; Vidarabine

2009
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
    Lancet (London, England), 2009, Sep-12, Volume: 374, Issue:9693

    Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunologic Factors; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Leukocyte Common Antigens; Male; Rats; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2009
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
    American journal of hematology, 2009, Volume: 84, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Remission Induction; Vidarabine; Young Adult

2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-01, Volume: 27, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Thionucleotides; Vidarabine

2009
The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase
    Leukemia & lymphoma, 2009, Volume: 50, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Rituximab; Severity of Illness Index; Survival; Treatment Outcome; Vidarabine

2009
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Blood, 2009, Dec-24, Volume: 114, Issue:27

    Topics: Acute Disease; Aged; Antibodies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Leukemia, Myeloid; Leukocyte Common Antigens; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Analysis; Survival Rate; Tissue Distribution; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Blood, 2009, Dec-17, Volume: 114, Issue:26

    Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2009
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11

    Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infection Control; Infections; Male; Medical Audit; Methotrexate; Middle Aged; Myeloablative Agonists; Patient Isolation; Postoperative Complications; Rabbits; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2009
[Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine; Young Adult

2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Blood, 2010, Jan-21, Volume: 115, Issue:3

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Vidarabine

2010
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:10

    Topics: Adult; Aged; Alemtuzumab; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Bone Marrow Diseases; CD52 Antigen; Cohort Studies; Cytomegalovirus Infections; Feasibility Studies; Female; Glycoproteins; Humans; Hypotension; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Survival Analysis; Vidarabine

2009
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genes, p53; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Somatic Hypermutation, Immunoglobulin; Survival Analysis; Tumor Suppressor Protein p53; Vidarabine; Young Adult; ZAP-70 Protein-Tyrosine Kinase

2009
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
    British journal of haematology, 2010, Volume: 148, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD52 Antigen; Cyclophosphamide; Disease Progression; Epidemiologic Methods; Female; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prognosis; Rituximab; Vidarabine

2010
Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:3

    Topics: Adolescent; Adult; Aged; Blood Cell Count; Cell Count; Communicable Diseases; Dendritic Cells; Disease-Free Survival; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Lymphocytes; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Recurrence; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2010
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
    Blood, 2010, Feb-04, Volume: 115, Issue:5

    Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult

2010
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-20, Volume: 28, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Rituximab; Vidarabine

2010
[FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult

2009
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:3

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine

2010
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-01, Volume: 28, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Quality of Life; Retreatment; Rituximab; Vidarabine

2010
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-01, Volume: 28, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

2010
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-10, Volume: 28, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Cytogenetic Analysis; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine

2010
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-10, Volume: 28, Issue:14

    Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Melphalan; Methotrexate; Middle Aged; Mycosis Fungoides; Myeloablative Agonists; Recurrence; Sezary Syndrome; Tacrolimus; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2010
[Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
    Terapevticheskii arkhiv, 2010, Volume: 82, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mitoxantrone; Myeloablative Agonists; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2010
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
    Bone marrow transplantation, 2011, Volume: 46, Issue:1

    Topics: Adult; Aged; Drug Monitoring; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Neutrophil Infiltration; Prodrugs; Renal Insufficiency; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Vidarabine Phosphate; Young Adult

2011
Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.
    Bone marrow transplantation, 2011, Volume: 46, Issue:1

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Peripheral Blood Stem Cell Transplantation; Pulmonary Fibrosis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2011
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
    Blood, 2010, Aug-12, Volume: 116, Issue:6

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Apoptosis; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Phosphoric Monoester Hydrolases; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Pyrimidinones; Severity of Illness Index; Vidarabine

2010
Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.
    Blood, 2010, Jul-29, Volume: 116, Issue:4

    Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Survival; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2010
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
    Molecular cancer, 2010, May-26, Volume: 9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Vidarabine

2010
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult
    Cancer, 2010, Sep-15, Volume: 116, Issue:18

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Rituximab; Tumor Burden; Vidarabine

2010
Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.
    Bone marrow transplantation, 2011, Volume: 46, Issue:4

    Topics: Child; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2011
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
    Blood, 2010, Oct-21, Volume: 116, Issue:16

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Female; Glycoproteins; Graft vs Host Disease; HLA Antigens; Humans; Male; Melphalan; Middle Aged; Siblings; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine

2010
Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:1

    Topics: Adult; Aged; Busulfan; Dose-Response Relationship, Drug; Drug Interactions; Female; Glutathione; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Pharmacokinetics; Precision Medicine; Reproducibility of Results; Vidarabine; Young Adult

2011
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.
    Blood, 2010, Oct-28, Volume: 116, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Rituximab; Vidarabine

2010
Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia.
    International journal of cancer, 2011, May-01, Volume: 128, Issue:9

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Plasma; Rituximab; Salvage Therapy; Vidarabine

2011
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2010, Volume: 33, Issue:7

    Topics: Aged; Busulfan; Cancer Vaccines; CD8 Antigens; Cell Proliferation; Cyclophosphamide; Cytokines; Female; Freund's Adjuvant; Humans; Immunotherapy, Adoptive; Lymphocyte Depletion; Male; MART-1 Antigen; Melanoma; Middle Aged; Peptide Fragments; Skin Neoplasms; T-Lymphocytes; Vidarabine

2010
Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:11

    Topics: Adolescent; Adult; Anemia, Aplastic; Antibodies, Monoclonal; Antilymphocyte Serum; Bone Marrow Transplantation; Cell Count; Child; Child, Preschool; Cyclophosphamide; Cytomegalovirus Infections; Erythrocyte Transfusion; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Leukocyte Count; Lymphoproliferative Disorders; Male; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prognosis; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2011
Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
    International journal of hematology, 2010, Volume: 92, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neoplasm, Residual; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Young Adult

2010
TP53 mutation and survival in chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multivariate Analysis; Mutation; Prognosis; Proportional Hazards Models; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine

2010
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.
    Bone marrow transplantation, 2011, Volume: 46, Issue:6

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2011
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.
    Leukemia, 2010, Volume: 24, Issue:11

    Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Thrombocytopenia; Vidarabine

2010
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Annals of hematology, 2011, Volume: 90, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Italy; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine; Young Adult

2011
Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.
    Blood, 2011, Jan-06, Volume: 117, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
    Lancet (London, England), 2010, Oct-02, Volume: 376, Issue:9747

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Rituximab; Severity of Illness Index; Treatment Outcome; Vidarabine

2010
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:12

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2010
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6

    Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busulfan; Cell Line, Tumor; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Rabbits; Remission Induction; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2011
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Living Donors; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2011
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Rad51 Recombinase; Recombination, Genetic; Treatment Outcome; Vidarabine

2011
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
    Lancet (London, England), 2010, Dec-11, Volume: 376, Issue:9757

    Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine

2010
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
    Hematological oncology, 2010, Volume: 28, Issue:4

    Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Transplantation, Autologous; Treatment Outcome; Vidarabine

2010
Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Cyclophosphamide; Drug Administration Schedule; Female; Glutathione Transferase; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Isoenzymes; Male; Middle Aged; Polymorphism, Genetic; Transplantation Conditioning; Vidarabine; Young Adult

2011
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    British journal of haematology, 2011, Volume: 152, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2011
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
    Blood, 2011, Mar-17, Volume: 117, Issue:11

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Proportional Hazards Models; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine

2011
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
    Leukemia & lymphoma, 2011, Volume: 52, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cooperative Behavior; Cyclophosphamide; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoadjuvant Therapy; Rituximab; Spain; Treatment Outcome; Vidarabine; Young Adult

2011
Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine

2011
A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8

    Topics: Adult; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Bone marrow transplantation, 2011, Volume: 46, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Apr-01, Volume: 29, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Disease-Free Survival; Genes, Immunoglobulin Heavy Chain; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; London; Mutation; Proportional Hazards Models; Risk Assessment; Risk Factors; Rituximab; Survival Rate; Time Factors; Treatment Outcome; United States; Vidarabine

2011
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:10

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.
    Bone marrow transplantation, 2012, Volume: 47, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Cutaneous; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Skin Neoplasms; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
    Bone marrow transplantation, 2012, Volume: 47, Issue:1

    Topics: Abnormal Karyotype; Acute Disease; Adolescent; Adult; Amsacrine; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Pilot Projects; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
[Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine

2011
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16

    Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; DNA Mutational Analysis; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Proportional Hazards Models; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine

2011
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
    Blood, 2011, Jun-16, Volume: 117, Issue:24

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine

2011
⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
    Blood, 2011, Jul-28, Volume: 118, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Humans; Lymphoma, B-Cell; Middle Aged; Radioimmunotherapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
    Blood, 2011, Aug-25, Volume: 118, Issue:8

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2011
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.
    British journal of haematology, 2011, Volume: 154, Issue:2

    Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine

2011
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
    American journal of hematology, 2011, Volume: 86, Issue:5

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Medical Records; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2011
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prospective Studies; Radioimmunotherapy; Rituximab; Treatment Outcome; Vidarabine; Yttrium Radioisotopes

2012
Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.
    American journal of hematology, 2011, Volume: 86, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Immunotherapy, Active; Lymphoma, Follicular; Middle Aged; Prednisone; Treatment Outcome; Vidarabine; Vincristine; Young Adult

2011
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
    Bone marrow transplantation, 2012, Volume: 47, Issue:4

    Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Time Factors; Transplantation, Autologous; Vidarabine

2012
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
    Haematologica, 2011, Volume: 96, Issue:9

    Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
    Blood, 2011, Aug-25, Volume: 118, Issue:8

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Salvage Therapy; Smith-Magenis Syndrome; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine

2011
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
    Cancer, 2011, Nov-15, Volume: 117, Issue:22

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Vidarabine

2011
The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study.
    Hematological oncology, 2012, Volume: 30, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Double-Blind Method; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucositis; Transplantation Conditioning; Vidarabine; Zinc Sulfate

2012
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Radiopharmaceuticals; Rituximab; Survival Analysis; Vidarabine; Yttrium Radioisotopes

2011
Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cytomegalovirus Infections; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Vidarabine

2011
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
    Cancer, 2012, Jan-15, Volume: 118, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Immunosuppression Therapy; Male; Middle Aged; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2012
Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
    European journal of haematology, 2011, Volume: 87, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Middle Aged; Prospective Studies; Rituximab; Vidarabine

2011
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
    Blood, 2011, Aug-25, Volume: 118, Issue:8

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Risk Factors; Rituximab; Smith-Magenis Syndrome; Thrombocytopenia; Vidarabine

2011
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
    Blood, 2011, Oct-13, Volume: 118, Issue:15

    Topics: Administration, Oral; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Survival Rate; Time Factors; Vidarabine

2011
Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome; Vidarabine; Vomiting

2012
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
    Blood, 2011, Sep-22, Volume: 118, Issue:12

    Topics: Antigens, CD; Cell Separation; Cyclophosphamide; Flow Cytometry; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunophenotyping; Immunosuppressive Agents; Immunotherapy, Adoptive; Interleukin-2; Killer Cells, Natural; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, KIR; Recurrence; Remission Induction; Risk Factors; Transplantation, Homologous; Vidarabine

2011
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.
    Blood, 2011, Sep-29, Volume: 118, Issue:13

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Time Factors; United States; Vidarabine

2011
Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Quality-Adjusted Life Years; Rituximab; Survival Rate; Vidarabine

2012
A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine

2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Sep-10, Volume: 29, Issue:26

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Nitrogen Mustard Compounds; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine

2011
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
    Blood, 2011, Nov-10, Volume: 118, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Vidarabine

2011
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2012
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:3

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine

2012
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:3

    Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Salvage Therapy; Vidarabine; Virus Activation

2012
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Rituximab; Treatment Outcome; Vidarabine

2012
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:3

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2012
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Melphalan; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2012
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:13

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; North America; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vidarabine

2011
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine

2012
Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia.
    British journal of haematology, 2012, Volume: 157, Issue:1

    Topics: Adolescent; Adult; Anemia, Aplastic; Antigens, CD19; Antilymphocyte Serum; Antineoplastic Agents; CD3 Complex; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphocyte Depletion; Male; Myeloablative Agonists; Prospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2012
Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Models, Statistical; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Treatment Outcome; Vidarabine

2012
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6

    Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Ethnicity; Graft vs Host Disease; Histocompatibility Testing; HLA-C Antigens; Humans; Killer Cells, Natural; Leukemia, Myeloid; Lymphocyte Depletion; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Receptors, KIR; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2012
Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.
    Bone marrow transplantation, 2012, Volume: 47, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2012
Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine; Vomiting

2012
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.
    Cancer, 2012, Aug-15, Volume: 118, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine

2012
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Drug Administration Schedule; Drug Dosage Calculations; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2012
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cyclophosphamide; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Biological; Retrospective Studies; Rituximab; Vidarabine

2012
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Follicular; Mitoxantrone; Radioimmunotherapy; Vidarabine

2012
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
    Bone marrow transplantation, 2012, Volume: 47, Issue:10

    Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Myeloablative Agonists; Neoplasm Staging; Recovery of Function; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine

2012
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
    Bone marrow transplantation, 2012, Volume: 47, Issue:10

    Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-20, Volume: 30, Issue:9

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Prognosis; Prospective Studies; Rituximab; Survival Rate; Vidarabine

2012
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
    Blood, 2012, May-31, Volume: 119, Issue:22

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Time Factors; Vidarabine

2012
[The comparison of fludarabine or antithymocyte globulin based non-myeloablative conditioning regimen for haematologic diseases with graft-versus-host disease].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:8

    Topics: Adult; Antilymphocyte Serum; Female; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2011
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
    Journal of immunology (Baltimore, Md. : 1950), 2012, Apr-01, Volume: 188, Issue:7

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Cell Line, Tumor; Combined Modality Therapy; Complement Activation; Complement C3b; Complement C4b; Complement System Proteins; Cyclophosphamide; Cytotoxicity, Immunologic; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Opsonin Proteins; Rituximab; Vidarabine

2012
[Clinical study on efficiency of fludarabine-based regimen for the patients with chronic lymphocytic leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine

2012
Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study
    Leukemia & lymphoma, 2012, Volume: 53, Issue:10

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine

2012
Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Neoplasm Staging; Radiation-Sensitizing Agents; Radiotherapy Dosage; Vidarabine

2012
Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
    Bone marrow transplantation, 2012, Volume: 47, Issue:11

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Dose-Response Relationship, Radiation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radioimmunotherapy; Radiopharmaceuticals; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Yttrium Radioisotopes

2012
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult

2012
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
    Haematologica, 2012, Volume: 97, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Prognosis; Prospective Studies; Remission Induction; Rituximab; Sex Factors; Survival Rate; Tissue Distribution; Vidarabine

2012
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2012, Volume: 47, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult

2012
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
    Annals of hematology, 2012, Volume: 91, Issue:9

    Topics: Adolescent; Adult; Anemia, Aplastic; Antibiotic Prophylaxis; Antilymphocyte Serum; Antiviral Agents; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Postoperative Complications; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2012
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult

2012
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cyclophosphamide; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2012
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
    Leukemia, 2012, Volume: 26, Issue:12

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Vidarabine

2012
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:11

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Busulfan; Child; Child, Preschool; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infant; Myeloablative Agonists; Neutrophils; Prospective Studies; Secondary Prevention; Severity of Illness Index; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2012
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
    Blood, 2012, Jul-12, Volume: 120, Issue:2

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2012
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
    Haematologica, 2013, Volume: 98, Issue:1

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2013
Treatment of older patients with mantle-cell lymphoma.
    The New England journal of medicine, 2012, Aug-09, Volume: 367, Issue:6

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Prospective Studies; Remission Induction; Rituximab; Survival Rate; Vidarabine; Vincristine

2012
Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
    Die Pharmazie, 2012, Volume: 67, Issue:7

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytarabine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Indicators and Reagents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Vidarabine

2012
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2013
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2013
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2012, Volume: 35, Issue:8

    Topics: Adult; Aged; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Lymphopenia; Male; Melanoma; Middle Aged; Pilot Projects; Skin Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Vidarabine

2012
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
    Annals of hematology, 2013, Volume: 92, Issue:2

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation

2013
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
    Haematologica, 2013, Volume: 98, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 6; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotype; Male; Middle Aged; Prognosis; Prospective Studies; Trisomy; Vidarabine; Waldenstrom Macroglobulinemia

2013
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
    American journal of hematology, 2013, Volume: 88, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Survival Rate; Time Factors; Vidarabine

2013
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
    Blood, 2013, Jan-17, Volume: 121, Issue:3

    Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Chromosomes, Human, Pair 12; Cyclophosphamide; Education, Medical, Continuing; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Middle Aged; Phosphoproteins; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Trisomy; Tumor Suppressor Protein p53; Vidarabine

2013
Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
    Experimental hematology, 2013, Volume: 41, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2013
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Dec-20, Volume: 30, Issue:36

    Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclophosphamide; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Protein Serine-Threonine Kinases; Survival Analysis; Tumor Suppressor Proteins; United Kingdom; Vidarabine

2012
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Gastroenteritis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2013
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine

2012
Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Administration, Oral; Aged; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3

    Topics: Aged; Antineoplastic Agents; Chlorambucil; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Proportional Hazards Models; Vidarabine; Waldenstrom Macroglobulinemia

2013
Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.
    Bone marrow transplantation, 2013, Volume: 48, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sex Factors; Societies, Medical; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine

2013
Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
    Annals of hematology, 2013, Volume: 92, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Survival Analysis; Treatment Outcome; Vidarabine

2013
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicen
    Journal of hematology & oncology, 2013, Feb-08, Volume: 6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2013
Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major.
    Pediatric blood & cancer, 2013, Volume: 60, Issue:8

    Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Infant; Male; Myeloablative Agonists; Retrospective Studies; Risk Factors; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
    European journal of haematology, 2013, Volume: 90, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Vidarabine

2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
    Cancer, 2013, Jun-15, Volume: 119, Issue:12

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mitoxantrone; Proto-Oncogene Proteins; Remission Induction; Treatment Outcome; Vidarabine

2013
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-20, Volume: 31, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine

2013
Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:8

    Topics: Adolescent; Antilymphocyte Serum; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Male; Risk Factors; Thalassemia; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7

    Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.
    Haematologica, 2013, Volume: 98, Issue:8

    Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cohort Studies; Female; Humans; Immunotherapy; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Metabolic Clearance Rate; Middle Aged; Rituximab; Time Factors; Treatment Outcome; Vidarabine

2013
In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
    Pharmacological reports : PR, 2013, Volume: 65, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cladribine; Cyclophosphamide; DNA Fragmentation; Electrophoresis, Agar Gel; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Vidarabine

2013
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunophenotyping; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2013
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    British journal of haematology, 2013, Volume: 162, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2013
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine; Young Adult

2014
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
    American journal of hematology, 2013, Volume: 88, Issue:10

    Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Chronic Disease; Cyclosporine; Female; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Risk Factors; Salvage Therapy; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
    Blood, 2013, Aug-15, Volume: 122, Issue:7

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Phosphoproteins; Prognosis; Prospective Studies; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Survival Rate; Tumor Suppressor Protein p53; Vidarabine

2013
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2013, Volume: 21, Issue:11

    Topics: Aged; Bone Marrow; Female; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Lewis Blood Group Antigens; Male; Middle Aged; Receptors, Antigen, T-Cell; Remission Induction; T-Lymphocytes; Transplantation Conditioning; Vidarabine

2013
Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan.
    International journal of hematology, 2013, Volume: 98, Issue:2

    Topics: Adolescent; Allografts; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Infant; Japan; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Myeloablative Agonists; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine

2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
    Blood, 2013, Aug-15, Volume: 122, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Prognosis; Vidarabine; Vincristine

2013
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine

2014
Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation.
    Journal of clinical pharmacology, 2013, Volume: 53, Issue:11

    Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Cyclophosphamide; Drug Interactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Young Adult

2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Lin
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-20, Volume: 31, Issue:27

    Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Dexamethasone; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Rituximab; Vidarabine

2013
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
    Blood, 2013, Dec-05, Volume: 122, Issue:24

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine

2013
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
    Blood, 2013, Dec-19, Volume: 122, Issue:26

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cyclophosphamide; Cytochrome P-450 CYP2B6; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pharmacogenetics; Prognosis; Remission Induction; Vidarabine

2013
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
    Leukemia, 2014, Volume: 28, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Survival Analysis; Vidarabine; Young Adult

2014
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Lancet (London, England), 2014, Feb-01, Volume: 383, Issue:9915

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Graft Survival; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2014
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
    Leukemia research, 2014, Volume: 38, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Fatigue; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Nausea; NF-kappa B; Pneumonia; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Vidarabine

2014
Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study.
    International journal of hematology, 2013, Volume: 98, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Child; Cyclophosphamide; Drug Substitution; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Pneumonia; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2013
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
    Leukemia research, 2014, Volume: 38, Issue:2

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome; Vidarabine

2014
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prospective Studies; Rituximab; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2014
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:5

    Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vomiting; Young Adult

2014
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
    Haematologica, 2014, Volume: 99, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Outcome; Vidarabine

2014
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4

    Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; beta-Thalassemia; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Unrelated Donors; Vidarabine

2014
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2014
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
    Bone marrow transplantation, 2014, Volume: 49, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine

2014
Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation.
    Cancer, 2014, May-01, Volume: 120, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Pilot Projects; Radiation Injuries; Recombinant Proteins; Thrombotic Microangiopathies; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2014
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:12

    Topics: Aged; Antineoplastic Agents; Chlorambucil; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Quality of Life; Retreatment; Treatment Outcome; Vidarabine

2014
Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Disease Progression; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:6

    Topics: Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Prognosis; Radioimmunotherapy; Radiopharmaceuticals; Transplantation, Autologous; Vidarabine

2014
Oral versus intravenous fludarabine as part of a reduced-intensity conditioning for allogeneic stem cell transplantation.
    Acta haematologica, 2014, Volume: 132, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Allografts; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Male; Mexico; Middle Aged; Myeloablative Agonists; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2014
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine; Young Adult

2014
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
    Blood, 2014, Jun-12, Volume: 123, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Time Factors; Vidarabine; Withholding Treatment

2014
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine

2014
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
    Blood, 2014, Jun-19, Volume: 123, Issue:25

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Child; Child, Preschool; Coculture Techniques; Combined Modality Therapy; Cyclophosphamide; Diphtheria Toxin; Female; Humans; Interleukin-2; K562 Cells; Killer Cells, Natural; Leukemia, Myeloid; Lymphocyte Depletion; Male; Middle Aged; Recombinant Fusion Proteins; Remission Induction; T-Lymphocytes, Regulatory; Treatment Outcome; Vidarabine; Young Adult

2014
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
    International journal of radiation oncology, biology, physics, 2014, May-01, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2014
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
    Blood, 2014, May-22, Volume: 123, Issue:21

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

2014
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
    Bone marrow transplantation, 2014, Volume: 49, Issue:7

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Pilot Projects; Prospective Studies; Siblings; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult

2014
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
    Leukemia, 2015, Volume: 29, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Neutrophils; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2015
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
    Blood, 2014, Jul-17, Volume: 124, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Focal Adhesion Kinase 1; Gene Expression; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Proportional Hazards Models; Recurrence; Retrospective Studies; Rituximab; RNA, Messenger; RNA, Neoplasm; Vidarabine

2014
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
    Blood, 2014, Aug-14, Volume: 124, Issue:7

    Topics: Adult; Aged; Analysis of Variance; Antilymphocyte Serum; Blood Donors; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Janus Kinase 2; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prospective Studies; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2014
How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:8

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prospective Studies; Risk Factors; Rituximab; Treatment Outcome; Vidarabine

2014
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Pilot Projects; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2014
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Allografts; Antineoplastic Agents; Bone Marrow Transplantation; Child; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; GATA2 Transcription Factor; Genetic Diseases, Inborn; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2014
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch
    British journal of haematology, 2014, Volume: 167, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Rituximab; Vidarabine

2014
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
    Blood, 2014, Oct-02, Volume: 124, Issue:14

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Combinations; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2014
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Feb-20, Volume: 33, Issue:6

    Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Immunotherapy, Adoptive; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Receptors, Antigen, T-Cell; T-Lymphocytes; Transplantation Conditioning; Vidarabine

2015
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
    American journal of hematology, 2014, Volume: 89, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hemoglobins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Rituximab; Survival Analysis; Treatment Failure; Vidarabine; Vincristine

2014
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Myeloablative Agonists; Prospective Studies; Tacrolimus; Transplantation Conditioning; Unrelated Donors; Vidarabine

2014
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
    Cancer, 2015, Jan-15, Volume: 121, Issue:2

    Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine

2015
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-01, Volume: 32, Issue:31

    Topics: Adult; Aged; Bayes Theorem; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine

2014
Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.
    Cancer, 2015, Feb-15, Volume: 121, Issue:4

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:1

    Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2015
Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies.
    Scientific reports, 2014, Nov-06, Volume: 4

    Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Gamma Rays; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Quality of Life; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult

2014
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Yttrium Radioisotopes

2015
Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Agents; Busulfan; Cyclosporine; Female; Frail Elderly; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Prospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2015
Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Allografts; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2015
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study.
    Leukemia research, 2015, Volume: 39, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Rituximab; Sweden; Vidarabine

2015
Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
    International journal of oncology, 2015, Volume: 46, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Cells, Cultured; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Treatment Outcome; Vidarabine

2015
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:5

    Topics: Adolescent; Allografts; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine

2015
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
    Hematological oncology, 2016, Volume: 34, Issue:1

    Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2016
Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Busulfan; Child; Female; Graft Survival; Graft vs Host Disease; Guanine Nucleotide Exchange Factors; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunophenotyping; Immunosuppressive Agents; Male; Methotrexate; Mutation; Myeloablative Agonists; Pilot Projects; Severe Combined Immunodeficiency; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2015
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
    Journal of hematology & oncology, 2015, Feb-06, Volume: 8

    Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Antineoplastic Agents; Chemoradiotherapy; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Maltose; Middle Aged; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2015
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:5

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine

2015
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
    American journal of hematology, 2015, Volume: 90, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Thalidomide; Vidarabine

2015
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Isotretinoin; Leukemia, Myelomonocytic, Juvenile; Male; Middle Aged; Quinolones; Survival Rate; Vidarabine

2015
An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arrhythmias, Cardiac; B-Lymphocytes; Biomarkers; Cardiotoxicity; Complement System Proteins; Cytokines; Drug Resistance, Neoplasm; Electrocardiography; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Retreatment; Treatment Outcome; Vidarabine

2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergr
    Leukemia & lymphoma, 2015, Volume: 56, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Mutational Analysis; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2015
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
    Blood, 2015, Apr-30, Volume: 125, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine

2015
Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jul-15, Volume: 21, Issue:14

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Male; Middle Aged; Radiotherapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning.
    Bone marrow transplantation, 2015, Volume: 50, Issue:6

    Topics: Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Middle Aged; Prospective Studies; Rabbits; Survival Rate; Transplantation Conditioning; Vidarabine

2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
    Leukemia research, 2015, Volume: 39, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Flavonoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Recurrence; Survival Analysis; Treatment Failure; Vidarabine

2015
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
    British journal of haematology, 2015, Volume: 169, Issue:4

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Monocytes; Prednisone; Prospective Studies; Rituximab; Survival Rate; Vidarabine; Vincristine

2015
Frontline therapy of severe aplastic anaemia with fludarabine, cyclophosphamide and ciclosporin.
    British journal of haematology, 2015, Volume: 171, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Vidarabine

2015
Alternative donor hematopoietic cell transplantation for Fanconi anemia.
    Blood, 2015, Jun-11, Volume: 125, Issue:24

    Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Enzyme Inhibitors; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Opportunistic Infections; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2015
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
    British journal of haematology, 2015, Volume: 170, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Retreatment; Vidarabine

2015
Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:7

    Topics: Acute Disease; Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Melphalan; Myeloablative Agonists; Neutropenia; Prospective Studies; Risk; Siblings; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2015
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
    European journal of haematology, 2016, Volume: 96, Issue:2

    Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine

2016
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
    Medicine, 2015, Volume: 94, Issue:15

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult

2015
A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
    European journal of haematology, 2016, Volume: 96, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Idarubicin; Induction Chemotherapy; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine

2016
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7

    Topics: Adenoviridae; Aged; Aged, 80 and over; Combined Modality Therapy; Dose-Response Relationship, Drug; Escherichia coli; Female; Follow-Up Studies; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Purine-Nucleoside Phosphorylase; Tumor Cells, Cultured; Vidarabine

2015
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.
    British journal of clinical pharmacology, 2015, Volume: 80, Issue:5

    Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Preference; Rituximab; Vidarabine

2015
Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Stu
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:8

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Male; Middle Aged; Prospective Studies; Recurrence; Steroids; Transplantation Conditioning; Vidarabine

2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult

2015
Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies.
    Bone marrow transplantation, 2015, Volume: 50, Issue:8

    Topics: Adolescent; Adult; Allografts; Busulfan; Child; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphocyte Depletion; Male; Middle Aged; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Vidarabine

2015
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine

2015
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:10

    Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Adhesion Molecules; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Radioimmunotherapy; Radioisotopes; Rhenium; T-Lymphocytes; Transplantation Conditioning; Vidarabine

2015
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:9

    Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Sirolimus; Stem Cell Transplantation; Survival Rate; Tacrolimus; Vidarabine

2015
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11

    Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2015
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:12

    Topics: Adult; Area Under Curve; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2015
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Cancer, 2015, Nov-01, Volume: 121, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Treatment Outcome; Vidarabine

2015
Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Bone marrow transplantation, 2015, Volume: 50, Issue:12

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine

2015
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
    Blood, 2015, Oct-15, Volume: 126, Issue:16

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Smith-Magenis Syndrome; Survival Rate; Vidarabine

2015
Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Darbepoetin alfa; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Treatment Outcome; Vidarabine

2016
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Rituximab; Vidarabine

2015
Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Exotoxins; Female; Humans; Immunotoxins; Interleukin-2 Receptor alpha Subunit; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine

2016
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retreatment; Treatment Outcome; Vidarabine

2015
A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.
    Blood cancer journal, 2015, Oct-02, Volume: 5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Inositol Polyphosphate 5-Phosphatases; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Prognosis; Proportional Hazards Models; Transcriptome; Vidarabine

2015
The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
    British journal of haematology, 2016, Volume: 172, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine

2016
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
    Blood, 2016, Jan-14, Volume: 127, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2016
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-10, Volume: 33, Issue:35

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2015
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F.
    Bone marrow transplantation, 2016, Volume: 51, Issue:3

    Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine

2016
Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study
    Bone marrow transplantation, 2016, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Allografts; Antilymphocyte Serum; Child; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Male; Melphalan; Prospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine

2016
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
    Haematologica, 2016, Volume: 101, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Opportunistic Infections; Rituximab; Survival Analysis; Vidarabine

2016
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine

2016
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Infections; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Survival Rate; Treatment Outcome; Vidarabine

2016
Successful Outcome With Fludarabine-Based Conditioning Regimen for Hematopoietic Stem Cell Transplantation From Related Donor in Fanconi Anemia: A Single Center Experience From Turkey.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:4

    Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Tissue Donors; Transplantation Conditioning; Turkey; Vidarabine

2016
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.
    Blood, 2016, Mar-17, Volume: 127, Issue:11

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Risk; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2016
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine

2016
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4

    Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Drug Administration Schedule; Female; Gemtuzumab; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy; Immunotoxins; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Sialic Acid Binding Ig-like Lectin 3; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine; Young Adult

2016
[Clinical Efficacy and Safety of Rituximab Combined with Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine

2016
Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:3

    Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine

2016
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
    Bone marrow transplantation, 2016, Volume: 51, Issue:7

    Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mucositis; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2016
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Hydroxamic Acids; Infusions, Intravenous; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Quality of Life; Recurrence; Vidarabine; Vorinostat

2016
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Survival Analysis; Thalidomide; Vidarabine

2016
Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Prospective Studies; Republic of Korea; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult

2016
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Immunological; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2016
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
    Leukemia, 2016, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Case-Control Studies; Cell Transformation, Neoplastic; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Registries; Risk Assessment; Risk Factors; Vidarabine

2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; International Agencies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine

2016
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
    Blood, 2016, 07-28, Volume: 128, Issue:4

    Topics: Bridged Bicyclo Compounds, Heterocyclic; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Proteins; Nuclear Proteins; Purines; Pyrazines; Quinazolinones; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured; Vidarabine

2016
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medication Adherence; Middle Aged; Quality of Life; Rituximab; Sex Factors; Surveys and Questionnaires; Treatment Outcome; Vidarabine

2017
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Rituximab; Survival Rate; Vidarabine

2016
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
    Science translational medicine, 2016, 09-07, Volume: 8, Issue:355

    Topics: Adult; Aged; Biomarkers, Tumor; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cyclophosphamide; Female; Humans; Immunotherapy; Lymphocyte Depletion; Lymphocyte Subsets; Lymphoma, Non-Hodgkin; Male; Middle Aged; Receptors, Antigen, T-Cell; Syndrome; Transgenes; Treatment Outcome; Vidarabine; Young Adult

2016
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
    Trials, 2016, 09-20, Volume: 17, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Protocols; Cyclophosphamide; Drug Dosage Calculations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Research Design; Time Factors; Treatment Outcome; United Kingdom; Vidarabine

2016
A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.
    Oncotarget, 2017, Mar-28, Volume: 8, Issue:13

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Rituximab; Survival Rate; Vidarabine

2017
Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    American journal of hematology, 2017, Volume: 92, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Prospective Studies; Proto-Oncogene Proteins c-kit; Translocation, Genetic; Vidarabine; Young Adult

2017
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Recurrence; Retreatment; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2017
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Treatment Outcome; Vidarabine

2017
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome; Vidarabine

2017
Trial of novel leukaemia drug is stopped for second time after two more deaths.
    BMJ (Clinical research ed.), 2016, Nov-25, Volume: 355

    Topics: Antineoplastic Agents; Brain Edema; Early Termination of Clinical Trials; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; United States; United States Food and Drug Administration; Vidarabine

2016
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.
    Annals of hematology, 2017, Volume: 96, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Survival Rate; Time Factors; Treatment Outcome; Vidarabine

2017
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
    Blood, 2017, 04-20, Volume: 129, Issue:16

    Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Siblings; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2017
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
    Leukemia, 2017, Volume: 31, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine

2017
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
    British journal of haematology, 2017, Volume: 177, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Interferons; Lymphoma, Non-Hodgkin; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Remission Induction; Rituximab; Vidarabine; Young Adult

2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-01, Volume: 35, Issue:19

    Topics: Adult; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2017
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
    American journal of hematology, 2017, Volume: 92, Issue:9

    Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Decitabine; Disease-Free Survival; Epigenesis, Genetic; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Translocation, Genetic; Vidarabine

2017
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
    Stem cells and development, 2017, 08-01, Volume: 26, Issue:15

    Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Prognosis; Quality of Life; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine; Young Adult

2017
Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:8

    Topics: Aged; Allografts; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Melphalan; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Middle Aged; Neutrophils; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2017
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine

2017
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:9

    Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Hydroxyurea; Male; Melphalan; Mycophenolic Acid; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2017
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
    Cancer immunology, immunotherapy : CII, 2017, Volume: 66, Issue:11

    Topics: Abdominal Pain; Adult; Aged; Anemia; Carcinoembryonic Antigen; Cohort Studies; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-6; Lung; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Treatment Outcome; Vidarabine; Vomiting

2017
Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:10

    Topics: Adolescent; Arabinonucleotides; Biomarkers, Pharmacological; Child; Child, Preschool; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Metabolic Clearance Rate; Patient-Specific Modeling; Precision Medicine; Prospective Studies; Transplant Recipients; Transplantation Conditioning; Vidarabine

2017
Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:10

    Topics: Acute Disease; Adolescent; Child; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Infant; Leukemia; Male; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
    American journal of hematology, 2017, Volume: 92, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Vidarabine

2017
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Cancer, 2017, Nov-15, Volume: 123, Issue:22

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult

2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2018
Implementing the EffTox dose-finding design in the Matchpoint trial.
    BMC medical research methodology, 2017, Jul-20, Volume: 17, Issue:1

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blast Crisis; Cytarabine; Humans; Idarubicin; Imidazoles; Models, Statistical; Outcome Assessment, Health Care; Pyridazines; Research Design; Vidarabine

2017
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(
    Leukemia & lymphoma, 2018, Volume: 59, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 17; Cyclophosphamide; DNA Mutational Analysis; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2018
Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Alemtuzumab; Allografts; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Infant; Male; Risk Factors; Survival Rate; Transplantation Conditioning; United Kingdom; Vidarabine

2018
Augmenting Total Body Irradiation with a Cranial Boost before Stem Cell Transplantation Protects Against Post-Transplant Central Nervous System Relapse in Acute Lymphoblastic Leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Allografts; Central Nervous System Neoplasms; Child; Child, Preschool; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Annals of hematology, 2018, Volume: 97, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Vidarabine; Young Adult

2018
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
    American journal of hematology, 2018, Volume: 93, Issue:5

    Topics: Adolescent; Adult; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine; Young Adult

2018
Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
    Hematology/oncology and stem cell therapy, 2018, Volume: 11, Issue:3

    Topics: Adult; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Siblings; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Vidarabine

2018
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
    Haematologica, 2018, Volume: 103, Issue:8

    Topics: Adolescent; Adult; Aged; Antigens, CD20; Cyclophosphamide; Dose-Response Relationship, Drug; Female; France; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine; Young Adult

2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:7

    Topics: Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Myeloablative Agonists; Prognosis; Transplantation Conditioning; Vidarabine

2018
Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen.
    Bone marrow transplantation, 2018, Volume: 53, Issue:9

    Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Survival Rate; Vidarabine

2018
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.
    Blood advances, 2018, 06-12, Volume: 2, Issue:11

    Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine

2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
    Annals of hematology, 2018, Volume: 97, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Hematologic Diseases; Humans; Immunity, Cellular; Immunologic Memory; Immunotherapy; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Rituximab; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Vidarabine

2018
Haploidentical haematopoietic stem cell transplantation for thalassaemia major based on an FBCA conditioning regimen.
    British journal of haematology, 2018, Volume: 182, Issue:4

    Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine

2018
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
    Haematologica, 2018, Volume: 103, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

2018
Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.
    Blood, 2018, 09-27, Volume: 132, Issue:13

    Topics: Adolescent; Adult; Alemtuzumab; Antineoplastic Agents; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2018
Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine

2019
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:3

    Topics: Adult; Aged; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Incidence; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Prolymphocytic, T-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Treatment Outcome; Vidarabine

2019
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.
    Bone marrow transplantation, 2019, Volume: 54, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Vidarabine; Young Adult

2019
Is pharmacokinetic guidance a must in busulfan regimens?
    The Lancet. Haematology, 2018, Volume: 5, Issue:11

    Topics: Area Under Curve; Busulfan; Cyclophosphamide; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Male; Randomized Controlled Trials as Topic; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2018
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
    The Lancet. Haematology, 2018, Volume: 5, Issue:11

    Topics: Adolescent; Adult; Aged; Busulfan; Child; Comorbidity; Dose-Response Relationship, Drug; Drug Interactions; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Time Factors; Treatment Outcome; Vidarabine; Young Adult

2018
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 03-15, Volume: 25, Issue:6

    Topics: Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy; Cyclophosphamide; Drug Approval; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunotherapy, Adoptive; Leukapheresis; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine; Young Adult

2019
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
    Haematologica, 2019, Volume: 104, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Registries; Retrospective Studies; Rituximab; Survival Rate; Sweden; Vidarabine

2019
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:5

    Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine

2019
Renal dysfunction within 90 days of FluBu4 predicts early and late mortality.
    Bone marrow transplantation, 2019, Volume: 54, Issue:7

    Topics: Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Retrospective Studies; Survival Rate; Vidarabine

2019
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
    International journal of hematology, 2019, Volume: 109, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine

2019
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
    Hematological oncology, 2019, Volume: 37, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Israel; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Survival Rate; Vidarabine

2019
Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
    Annals of hematology, 2019, Volume: 98, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oncology Nursing; Risk Factors; Rituximab; Survival Rate; Vidarabine

2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
    Blood, 2019, 04-25, Volume: 133, Issue:17

    Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Cell- and Tissue-Based Therapy; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; Lymphocyte Depletion; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Survival Rate; Vidarabine

2019
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:7

    Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine

2019
Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:11

    Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Risk; Single-Blind Method; Treatment Failure; Vidarabine

2019
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.
    Haematologica, 2019, Volume: 104, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine

2019
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:8

    Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Infant; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine

2019
Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.
    Acta haematologica, 2019, Volume: 142, Issue:3

    Topics: Adult; Allografts; Benzylamines; Busulfan; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Proteomics; Signal Transduction; Transplantation Conditioning; Vidarabine

2019
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:9

    Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine

2019
Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.
    International journal of hematology, 2019, Volume: 110, Issue:3

    Topics: Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine

2019
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
    Blood advances, 2019, 06-25, Volume: 3, Issue:12

    Topics: Adult; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Enzyme Inhibitors; Female; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neutrophils; Recovery of Function; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2019
Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:11

    Topics: Acute Disease; Adult; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2019
Successful Outcome in Patients with Fanconi Anemia Undergoing T Cell-Replete Mismatched Related Donor Hematopoietic Cell Transplantation Using Reduced-Dose Cyclophosphamide Post-Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:11

    Topics: Adolescent; Allografts; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Mycophenolic Acid; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Vidarabine

2019
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
    The New England journal of medicine, 2019, 08-01, Volume: 381, Issue:5

    Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunotherapy; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine

2019
Ibrutinib and rituximab for chronic lymphocytic leukaemia.
    The Lancet. Oncology, 2019, Volume: 20, Issue:9

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Rituximab; Vidarabine

2019
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.
    Leukemia, 2020, Volume: 34, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Progression-Free Survival; Remission Induction; Vidarabine

2020
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
    Blood, 2019, 11-28, Volume: 134, Issue:22

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Rituximab; Vidarabine

2019
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    The Lancet. Oncology, 2019, Volume: 20, Issue:11

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Gene Expression Profiling; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Risk Assessment; Risk Factors; Rituximab; Texas; Time Factors; Transcriptome; Treatment Outcome; Vidarabine

2019
A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:1

    Topics: Alemtuzumab; Child; Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infant; Melphalan; Myeloablative Agonists; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Hematology/oncology and stem cell therapy, 2020, Volume: 13, Issue:3

    Topics: Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine

2020
FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
    British journal of haematology, 2020, Volume: 188, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Recurrence; Salvage Therapy; Sulfonamides; Vidarabine

2020
Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine.
    Pharmacotherapy, 2020, Volume: 40, Issue:1

    Topics: Adult; Basiliximab; Cyclophosphamide; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Vidarabine

2020
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
    American journal of hematology, 2020, Volume: 95, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2020
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 01-20, Volume: 38, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Progression-Free Survival; Rituximab; Time; Vidarabine; Vincristine

2020
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
    British journal of haematology, 2020, Volume: 189, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Vidarabine

2020
Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.
    Annals of hematology, 2020, Volume: 99, Issue:3

    Topics: Aged; Allografts; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Female; Follow-Up Studies; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Vidarabine; Viral Load; Whole-Body Irradiation

2020
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.
    Leukemia, 2020, Volume: 34, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Baculoviral IAP Repeat-Containing 3 Protein; Biomarkers, Tumor; Cohort Studies; Cyclophosphamide; Extracellular Signal-Regulated MAP Kinases; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Signaling System; Mutation; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine

2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.
    Leukemia, 2020, Volume: 34, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prospective Studies; Rituximab; Vidarabine

2020
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:5

    Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine

2020
A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children.
    Acta medica Okayama, 2020, Volume: 74, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Melphalan; Transplantation Conditioning; Vidarabine

2020
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
    British journal of haematology, 2020, Volume: 190, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Progression-Free Survival; Prospective Studies; Survival Rate; United Kingdom; Vidarabine; Young Adult

2020
Treatment of Testicular Relapse of B-cell Acute Lymphoblastic Leukemia With CD19-specific Chimeric Antigen Receptor T Cells.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Humans; Immunotherapy, Adoptive; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Testicular Neoplasms; Vidarabine

2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
    The New England journal of medicine, 2020, 04-02, Volume: 382, Issue:14

    Topics: Adult; Aged; Antigens, CD19; Antineoplastic Agents; Combined Modality Therapy; Humans; Immunotherapy, Adoptive; Infusions, Intravenous; Leukapheresis; Lymphoma, Mantle-Cell; Middle Aged; Receptors, Chimeric Antigen; Recurrence; Survival Analysis; T-Lymphocytes; Vidarabine

2020
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
    Cytotherapy, 2020, Volume: 22, Issue:7

    Topics: Aged; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Cell Line, Tumor; Cell Membrane; Cytotoxicity, Immunologic; Female; Humans; Immunoglobulin Fc Fragments; Interleukin-2; Interleukins; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Activation; Male; Mice; Middle Aged; Protein Binding; Protein Engineering; Sialic Acid Binding Ig-like Lectin 3; Vidarabine

2020
Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Vidarabine

2020
Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
    Blood, 2020, 07-23, Volume: 136, Issue:4

    Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Rituximab; Vidarabine

2020
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study.
    Frontiers of medicine, 2021, Volume: 15, Issue:1

    Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Peripheral Blood Stem Cell Transplantation; Pharmaceutical Preparations; Prospective Studies; Transplantation Conditioning; Vidarabine

2021
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Cancer medicine, 2020, Volume: 9, Issue:16

    Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 Ratio; Confidence Intervals; Cyclophosphamide; Cytokine Release Syndrome; Female; Glycolysis; Humans; Ifosfamide; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Progression-Free Survival; Receptors, Chimeric Antigen; Recurrence; T-Lymphocytes; Thrombocytopenia; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2020
Outcomes of Haploidentical Stem Cell Transplantation using Total Body Irradiation (600 cGy) and Fludarabine with Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia: A Prospective Phase II Study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:10

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2020
The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    International journal of cancer, 2021, 01-01, Volume: 148, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Oxaliplatin; Prednisone; Primary Cell Culture; Rituximab; SAM Domain and HD Domain-Containing Protein 1; Tissue Array Analysis; Vidarabine; Vincristine

2021
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
    Leukemia research, 2020, Volume: 96

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine

2020
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Epitopes; Female; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Ki-1 Antigen; Lymphocyte Depletion; Male; Middle Aged; Stem Cell Transplantation; Vidarabine; Young Adult

2020
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
    American journal of hematology, 2020, Volume: 95, Issue:11

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Survival Rate; Vidarabine

2020
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
    Leukemia, 2021, Volume: 35, Issue:4

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Induction Chemotherapy; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Purines; Rituximab; Treatment Outcome; Vidarabine

2021
Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
    Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:8

    Topics: Adolescent; Alemtuzumab; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Prognosis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood, 2021, 01-21, Volume: 137, Issue:3

    Topics: Adult; Aged; Antigens, CD19; Cell Proliferation; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Progression-Free Survival; T-Lymphocytes; Treatment Outcome; Vidarabine

2021
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
    Nature medicine, 2020, Volume: 26, Issue:11

    Topics: Bone Neoplasms; Child; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Immunity; Immunotherapy, Adoptive; Lymphocyte Activation; Male; Natural Killer T-Cells; Neuroblastoma; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Vidarabine

2020
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EB
    American journal of hematology, 2021, Volume: 96, Issue:1

    Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Organ Size; Primary Myelofibrosis; Registries; Retrospective Studies; Spleen; Splenectomy; Survival Rate; Vidarabine

2021
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
    Japanese journal of clinical oncology, 2021, Mar-03, Volume: 51, Issue:3

    Topics: Aged; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease Progression; Endpoint Determination; Female; Humans; Immunosuppression Therapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2021
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 02-01, Volume: 39, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation

2021
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7

    Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult

2021
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    British journal of haematology, 2021, Volume: 193, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine

2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
    Cancer, 2021, 06-15, Volume: 127, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome; Vidarabine

2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Leukemia, 2021, Volume: 35, Issue:12

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Vidarabine

2021
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
    British journal of haematology, 2021, Volume: 194, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine

2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 09-01, Volume: 39, Issue:25

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Sulfonamides; Survival Rate; Vidarabine; Young Adult

2021
Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Cancer science, 2021, Volume: 112, Issue:8

    Topics: Administration, Intravenous; Cell Culture Techniques; Cyclophosphamide; Feasibility Studies; Gene Regulatory Networks; Humans; Immune Checkpoint Inhibitors; Immunotherapy, Adoptive; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Pilot Projects; Transplantation Conditioning; Treatment Outcome; Vidarabine

2021
Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
    Annals of hematology, 2021, Volume: 100, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Female; Humans; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vidarabine

2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Blood, 2021, 12-30, Volume: 138, Issue:26

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Rituximab; Treatment Outcome; Vidarabine

2021
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
    Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:10

    Topics: Adolescent; Adult; Azacitidine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult

2021
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
    Blood, 2022, 02-24, Volume: 139, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Myelopoiesis; Myeloproliferative Disorders; Neoplasms, Second Primary; Sulfonamides; Vidarabine

2022
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    British journal of haematology, 2021, Volume: 195, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Biological Products; Biomarkers; Cyclophosphamide; Cytokine Release Syndrome; Drug Therapy, Combination; Female; Humans; Immunotherapy, Adoptive; Leukapheresis; Levetiracetam; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nervous System Diseases; Neutropenia; Propensity Score; Vidarabine; Young Adult

2021
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.
    Blood advances, 2021, 12-28, Volume: 5, Issue:24

    Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Transplantation, Homologous; Vidarabine

2021
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
    Leukemia, 2022, Volume: 36, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Cyclophosphamide; Cytokines; Humans; Inflammation; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Rituximab; T-Lymphocytes; Vidarabine

2022
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
    Bone marrow transplantation, 2022, Volume: 57, Issue:6

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Vidarabine

2022
Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:7

    Topics: Adolescent; Adult; Aged; Bone Marrow; Busulfan; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine

2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
    Bone marrow transplantation, 2022, Volume: 57, Issue:8

    Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine

2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:8

    Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat

2022
Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 Gy.
    Bone marrow transplantation, 2022, Volume: 57, Issue:10

    Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2022
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
    Bone marrow transplantation, 2022, Volume: 57, Issue:11

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine

2022
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial.
    Bone marrow transplantation, 2022, Volume: 57, Issue:11

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2022
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderso
    American journal of hematology, 2022, Volume: 97, Issue:11

    Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Prospective Studies; Retrospective Studies; Vidarabine

2022
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-10, Volume: 41, Issue:29

    Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Transplantation Conditioning; Vidarabine; Young Adult

2023

Other Studies

2193 other study(ies) available for fludarabine and vidarabine

ArticleYear
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
    Journal of medicinal chemistry, 1995, Mar-31, Volume: 38, Issue:7

    Topics: Adenosine; Animals; Cell Membrane; CHO Cells; Corpus Striatum; Cricetinae; In Vitro Techniques; Magnetic Resonance Spectroscopy; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Radioligand Assay; Rats; Recombinant Proteins; Ribose; Structure-Activity Relationship

1995
The purine analogs--a therapeutic beauty contest.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:3

    Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine

1992
The purine analogs--a therapeutic beauty contest.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:5

    Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Pentostatin; Vidarabine

1992
Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone.
    Annals of internal medicine, 1992, Sep-15, Volume: 117, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Listeriosis; Male; Middle Aged; Prednisone; Retrospective Studies; Vidarabine

1992
Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
    The Medical letter on drugs and therapeutics, 1992, Sep-18, Volume: 34, Issue:879

    Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine

1992
New drugs in the treatment of chronic lymphocytic leukemia.
    Leukemia, 1992, Volume: 6 Suppl 4

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine

1992
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
    Blood, 1992, Jul-01, Volume: 80, Issue:1

    Topics: Adult; Aged; Antigens, CD; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; CD5 Antigens; Female; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Gene Rearrangement, B-Lymphocyte, Light Chain; Genes, Immunoglobulin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Male; Middle Aged; Prednisone; Survival Analysis; Vidarabine

1992
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
    British journal of haematology, 1992, Volume: 81, Issue:3

    Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine

1992
Fludarabine and acute tumor lysis in chronic lymphocytic leukemia.
    The New England journal of medicine, 1992, Nov-05, Volume: 327, Issue:19

    Topics: Acute Kidney Injury; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Lysis Syndrome; Vidarabine

1992
Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment.
    Annals of hematology, 1992, Volume: 65, Issue:5

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1992
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:1

    Topics: Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cell Cycle; Cytarabine; Deoxycytidine Kinase; Drug Synergism; G1 Phase; G2 Phase; Humans; Intracellular Fluid; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Metaphase; Nucleotides; S Phase; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine

1992
Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Hindlimb; Leukemia L1210; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Nervous System Diseases; Paralysis; Prodrugs; Thioinosine; Thionucleotides; Vidarabine

1992
Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:3

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Cytarabine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Time Factors; Vidarabine

1992
A quantitative assay for fragmented DNA in apoptotic cells.
    Analytical biochemistry, 1992, Nov-15, Volume: 207, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA; DNA, Circular; Ethidium; Gemcitabine; Humans; Microchemistry; Phosphorus Radioisotopes; Plasmids; T-Lymphocytes; Time Factors; Vidarabine

1992
Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine.
    American journal of hematology, 1992, Volume: 39, Issue:4

    Topics: Antineoplastic Agents; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Pneumonia, Pneumocystis; Tuberculosis; Vidarabine

1992
Fludarabine-induced cytogenetic remission in prolymphocytic leukemia.
    American journal of hematology, 1992, Volume: 40, Issue:1

    Topics: Aged; Chromosome Aberrations; Chromosome Disorders; Humans; Karyotyping; Leukemia, Prolymphocytic; Male; Vidarabine

1992
Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:2

    Topics: Adult; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1992
Two views of the immunologic effects of fludarabine.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:2

    Topics: Antineoplastic Agents; Burkitt Lymphoma; CD4-Positive T-Lymphocytes; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; T-Lymphocytes, Regulatory; Vidarabine

1991
Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
    The Journal of biological chemistry, 1990, Sep-25, Volume: 265, Issue:27

    Topics: Aphidicolin; Arabinonucleotides; Cell Line; Cell Survival; Clone Cells; Diterpenes; DNA Replication; DNA-Directed DNA Polymerase; Guanosine Monophosphate; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Vidarabine; Vidarabine Phosphate

1990
Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Seminars in oncology, 1990, Volume: 17, Issue:5 Suppl 8

    Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Drug Evaluation; Humans; Injections, Intravenous; Multivariate Analysis; Neoplasms; Vidarabine; Vidarabine Phosphate

1990
Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.
    Molecular pharmacology, 1991, Volume: 39, Issue:4

    Topics: Antineoplastic Agents; Cell-Free System; Poly A; Protein Biosynthesis; RNA; Temperature; Transcription, Genetic; Vidarabine

1991
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Cancer research, 1992, Feb-15, Volume: 52, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Synergism; Female; Humans; Hydroxyurea; Infusions, Intravenous; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Vidarabine

1992
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
    American journal of hospital pharmacy, 1991, Volume: 48, Issue:10

    Topics: Anti-Infective Agents; Antineoplastic Agents; Drug Compounding; Drug Incompatibility; Infusions, Intravenous; Solutions; Vidarabine

1991
Fludarabine approved for use in chronic lymphocytic leukemia.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:6

    Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1991
Sustained response of refractory prolymphocytic leukemia to fludarabine.
    Acta haematologica, 1991, Volume: 85, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Humans; Leukemia, Prolymphocytic; Leukocyte Count; Male; Remission Induction; Spleen; Vidarabine

1991
Fludarabine.
    The Medical letter on drugs and therapeutics, 1991, Sep-20, Volume: 33, Issue:853

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine

1991
Fludarabine therapy in hairy cell leukemia.
    Cancer, 1991, Mar-01, Volume: 67, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Leukemia, Hairy Cell; Male; Remission Induction; Vidarabine

1991
Interaction of arabinosyl nucleotides in K562 human leukemia cells.
    Biochemical pharmacology, 1989, Oct-15, Volume: 38, Issue:20

    Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleosides; Arabinonucleotides; Cytarabine; Deoxyribonucleotides; Drug Interactions; Guanosine Triphosphate; Humans; Leukemia; Phosphorylation; Phosphotransferases; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate

1989
Fludarabine shows promise for some leukemia patients.
    Oncology (Williston Park, N.Y.), 1989, Volume: 3, Issue:3

    Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine; Vidarabine Phosphate

1989
Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay.
    Cancer drug delivery, 1986,Spring, Volume: 3, Issue:2

    Topics: Cell Survival; Cells, Cultured; Cladribine; Colony-Forming Units Assay; Deoxyadenosines; Drug Evaluation, Preclinical; Female; Humans; Kinetics; Neoplasms; Vidarabine

1986
Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides.
    Mutation research, 1989, Volume: 210, Issue:2

    Topics: Animals; Blotting, Southern; Cell Line; Chromosome Deletion; Cricetinae; Hypoxanthine Phosphoribosyltransferase; Mutation; RNA, Messenger; Vidarabine

1989
Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production.
    Biochemical pharmacology, 1987, Sep-15, Volume: 36, Issue:18

    Topics: Adenine; Adenosine; Adenosine Triphosphate; Animals; Binding, Competitive; Cell Line; Escherichia coli; Humans; Kidney; Kinetics; Leukemia; Liver; Mice; Phosphates; Purine Nucleosides; Rats; Vidarabine

1987
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Cancer research, 1988, Jan-15, Volume: 48, Issue:2

    Topics: Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine

1988
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Leukemia, 1987, Volume: 1, Issue:9

    Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine

1987
Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
    Journal of chromatography, 1987, Jan-23, Volume: 413

    Topics: Cells, Cultured; Chromatography, High Pressure Liquid; Cytarabine; Humans; Kinetics; Leukemia; Nucleotides; Vidarabine

1987
Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
    Cancer research, 1987, Feb-01, Volume: 47, Issue:3

    Topics: Animals; Biological Transport; Epithelium; Intestine, Small; Kinetics; Leukemia L1210; Mice; Mice, Inbred Strains; Organ Specificity; Phosphorylation; Tritium; Vidarabine

1987
The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
    Advances in enzyme regulation, 1985, Volume: 23

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; Deoxyadenosines; Deoxyguanosine; Hydroxyurea; Isoquinolines; Leukemia L1210; Models, Biological; Nucleic Acid Synthesis Inhibitors; Phosphorylases; Pyrazoles; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Thymidine; Vidarabine

1985
Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA.
    Biochemical pharmacology, 1986, Jan-15, Volume: 35, Issue:2

    Topics: Carboxylesterase; Carboxylic Ester Hydrolases; Cell Differentiation; Cell Division; Cell Line; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; RNA, Neoplasm; Time Factors; Vidarabine

1986
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
    Cancer research, 1984, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate

1984
Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts.
    Cancer research, 1980, Volume: 40, Issue:5

    Topics: Cell Survival; Cells, Cultured; Deoxycytidine; DNA, Neoplasm; Humans; Leukemia, Lymphoid; Phosphotransferases; Vidarabine

1980
Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Cancer research, 1980, Volume: 40, Issue:10

    Topics: Animals; Cell Line; Chromatography, DEAE-Cellulose; Deoxycytidine Kinase; DNA; Electrophoresis, Polyacrylamide Gel; Leukemia L1210; Mice; Mutation; Oxidative Phosphorylation; Phosphotransferases; Vidarabine

1980
Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
    Cancer research, 1984, Volume: 44, Issue:8

    Topics: Animals; Cell Survival; Cytidine; Deferoxamine; Deoxyadenosines; Deoxycytidine; Drug Synergism; Hydroxyurea; Kinetics; Leukemia L1210; Mice; Pyrazoles; Vidarabine

1984
Specificity of systems mediating transport of adenosine, 9-beta-d-arabinofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells.
    Cancer research, 1983, Volume: 43, Issue:1

    Topics: Adenosine; Animals; Biological Transport; Kinetics; Leukemia L1210; Mice; Purine Nucleosides; Temperature; Time Factors; Vidarabine

1983
Initial rate kinetics and evidence for duality of mediated transport of adenosine, related purine nucleosides, and nucleoside analogues in L1210 cells.
    Cancer research, 1983, Volume: 43, Issue:1

    Topics: Adenosine; Animals; Biological Transport; Cell Membrane; Kinetics; Leukemia L1210; Mice; Purine Nucleosides; Temperature; Time Factors; Vidarabine

1983
2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine.
    Biochemical and biophysical research communications, 1983, May-31, Volume: 113, Issue:1

    Topics: Adenine; Adenosine Triphosphate; Animals; Arabinonucleotides; Cell Line; Chromatography, High Pressure Liquid; Leukemia P388; Leukemia, Experimental; Mice; Vidarabine

1983
Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells.
    Cancer research, 1980, Volume: 40, Issue:7

    Topics: Adenosine Deaminase Inhibitors; Adenosine Triphosphate; Antineoplastic Agents; Cells, Cultured; Coformycin; DNA; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphoid; T-Lymphocytes; Vidarabine

1980
Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
    Cancer research, 1982, Volume: 42, Issue:6

    Topics: Adenosylhomocysteinase; Animals; DNA Polymerase I; DNA Polymerase II; DNA Replication; Hydrolases; Leukemia L1210; Mice; Nucleic Acid Synthesis Inhibitors; Ribonucleotide Reductases; Vidarabine

1982
In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.
    Molecular pharmacology, 1982, Volume: 21, Issue:2

    Topics: Antiviral Agents; Arabinonucleotides; Binding, Competitive; Cell Survival; Deoxycytidine Kinase; HeLa Cells; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Phosphorylation; Ribonucleotide Reductases; Vidarabine

1982
Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
    Cancer research, 1982, Volume: 42, Issue:7

    Topics: Animals; Bone Marrow; Female; Intestinal Mucosa; Kinetics; Leukemia P388; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Vidarabine

1982
Identification of metabolites of 9-beta-D-arabinofuranosyl-2-fluoroadenine, an antitumor and antiviral agent.
    Biochemical pharmacology, 1982, Jun-01, Volume: 31, Issue:11

    Topics: Animals; Antineoplastic Agents; Antiviral Agents; Chemical Phenomena; Chemistry; Dogs; Female; Leukemia L1210; Macaca mulatta; Male; Mice; Vidarabine

1982
Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro.
    Leukemia, 1995, Volume: 9, Issue:11

    Topics: Antineoplastic Agents; Biological Transport; Bone Marrow; Cell Survival; Cells, Cultured; Chlorambucil; Cladribine; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1995
[Fludarabine and fatal hemolytic anemia].
    Sangre, 1995, Volume: 40, Issue:4

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine

1995
Acute leukemia complicating bone marrow hypoplasia in an adult with Shwachman's syndrome.
    Leukemia & lymphoma, 1993, Volume: 12, Issue:1-2

    Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Neutropenia; Pancreatic Diseases; Syndrome; Vidarabine

1993
CD23 antigen density is related to serum gamma globulin level, bone marrow reticulin pattern, and treatment in B chronic lymphocytic leukemia.
    Leukemia & lymphoma, 1994, Volume: 13, Issue:1-2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Flow Cytometry; Fluorescent Antibody Technique; gamma-Globulins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Prednisolone; Receptors, IgE; Reticulin; Vidarabine; Vincristine

1994
Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
    Leukemia, 1994, Volume: 8, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cytarabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Vidarabine

1994
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
    Leukemia & lymphoma, 1995, Volume: 16, Issue:5-6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality Therapy; Cytarabine; Factor VIII; Female; Granulocyte Colony-Stimulating Factor; Hemophilia A; Hemorrhage; Hodgkin Disease; Humans; Immunologic Factors; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Plasmapheresis; Prednisone; Procarbazine; Prothrombin; Remission Induction; Thrombocytopenia; Vidarabine; Vincristine

1995
In vitro sensitivity of B-CLL cells to fludarabine and interferons.
    Leukemia & lymphoma, 1995, Volume: 17, Issue:5-6

    Topics: Aged; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cells, Cultured; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Interferon-alpha; Interferon-beta; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1995
Remission of leukaemic meningitis after fludarabine.
    Lancet (London, England), 1995, Oct-07, Volume: 346, Issue:8980

    Topics: Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Meningitis, Aseptic; Remission Induction; Vidarabine

1995
Adaptation of the TdT assay for semi-quantitative flow cytometric detection of DNA strand breaks.
    Cytometry, 1995, Jul-01, Volume: 20, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cells, Cultured; Cladribine; DNA Damage; DNA Nucleotidylexotransferase; Flow Cytometry; Humans; Lymphocytes; Ultraviolet Rays; Vidarabine

1995
Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:3

    Topics: Anemia, Hemolytic; Antineoplastic Agents; Autoimmune Diseases; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Recurrence; Vidarabine

1995
Developments in the treatment of leukaemias and lymphomas.
    Annals of hematology, 1995, Volume: 68, Issue:3 Suppl

    Topics: Animals; Antineoplastic Agents; Humans; Leukemia; Lymphoma; Vidarabine

1995
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
    Leukemia, 1995, Volume: 9, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Bacteremia; Drug Administration Schedule; Female; Fever of Unknown Origin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pneumonia; Remission Induction; Survival Rate; Vidarabine

1995
Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia.
    Leukemia, 1995, Volume: 9, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Humans; Interferon-alpha; Interleukin-1; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Necrosis Factor-alpha; Vidarabine

1995
Acute renal failure as a consequence of urine stop flow in a patient with chronic lymphocytic leukemia after treatment with fludarabine.
    American journal of hematology, 1995, Volume: 50, Issue:1

    Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Insufficiency; Urinary Retention; Vidarabine

1995
Renal failure in a patient with chronic lymphocytic leukaemia treated with fludarabine.
    Journal of clinical pathology, 1995, Volume: 48, Issue:2

    Topics: Acute Kidney Injury; Antineoplastic Agents; Glomerulonephritis, Membranoproliferative; Humans; Kidney Glomerulus; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1995
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
    Molecular pharmacology, 1995, Volume: 47, Issue:5

    Topics: Antineoplastic Agents; Cell Survival; Cisplatin; Cross-Linking Reagents; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Drug Synergism; Genome, Human; Humans; Thiourea; Tumor Cells, Cultured; Vidarabine

1995
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
    Blood, 1995, Jun-01, Volume: 85, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation

1995
Gentamicin and fludarabine ototoxicity.
    The Annals of pharmacotherapy, 1995, Volume: 29, Issue:2

    Topics: Aged; Antineoplastic Agents; Deafness; Dose-Response Relationship, Drug; Gentamicins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pneumonia; Vidarabine

1995
Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis.
    American journal of hematology, 1995, Volume: 49, Issue:2

    Topics: Antineoplastic Agents; Biopsy; Bronchoscopy; Humans; Lung; Lung Diseases; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine

1995
Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Aphidicolin; Apoptosis; Cell Cycle; Cell Line; Cell Membrane; Deoxycytidine; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; T-Lymphocytes; Time Factors; Tumor Cells, Cultured; Vidarabine

1995
Fludarabine and plasma cell leukemia.
    European journal of haematology, 1995, Volume: 54, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Vidarabine

1995
Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia.
    British journal of haematology, 1994, Volume: 88, Issue:3

    Topics: Antineoplastic Agents; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Transfusion Reaction; Vidarabine

1994
First report of fludarabine in gamma-heavy chain disease.
    British journal of haematology, 1994, Volume: 88, Issue:3

    Topics: Aged; Antineoplastic Agents; Follow-Up Studies; Heavy Chain Disease; Humans; Male; Vidarabine

1994
Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 1994, Volume: 15, Issue:1-2

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Purpura, Thrombocytopenic, Idiopathic; Recurrence; T-Lymphocyte Subsets; Vidarabine

1994
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Diploidy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine

1995
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
    Blood, 1995, 03-15, Volume: 85, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Chromosome Aberrations; Chromosomes, Human, Pair 17; Female; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Sequence Data; Pentostatin; Polymorphism, Single-Stranded Conformational; Survival Rate; Vidarabine

1995
Defective apoptosis due to Bcl-2 overexpression may explain why B-CLL cells accumulate in G0.
    Current topics in microbiology and immunology, 1995, Volume: 194

    Topics: Apoptosis; B-Lymphocytes; Gene Expression Regulation, Leukemic; Humans; Interphase; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine

1995
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
    The New England journal of medicine, 1994, Feb-03, Volume: 330, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine

1994
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
    The New England journal of medicine, 1994, Jun-23, Volume: 330, Issue:25

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1994
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
    The New England journal of medicine, 1994, Jun-23, Volume: 330, Issue:25

    Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1994
Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.
    Leukemia & lymphoma, 1994, Volume: 14, Issue:1-2

    Topics: 2-Chloroadenosine; Anemia; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Deoxyadenosines; Fatal Outcome; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Male; Methotrexate; Middle Aged; Neoplastic Stem Cells; Prednisone; Salvage Therapy; Vidarabine; Vincristine; Zidovudine

1994
Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation.
    International journal of radiation oncology, biology, physics, 1994, Sep-30, Volume: 30, Issue:2

    Topics: Animals; Antineoplastic Agents; Male; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage; Vidarabine

1994
Neurological illness following treatment with fludarabine.
    British journal of cancer, 1994, Volume: 70, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nervous System Diseases; Vidarabine

1994
Late listeriosis after fludarabine plus prednisone treatment.
    British journal of haematology, 1994, Volume: 87, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Male; Opportunistic Infections; Prednisone; Time Factors; Vidarabine

1994
The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo.
    Cancer research, 1994, Dec-01, Volume: 54, Issue:23

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; DNA; Dose-Response Relationship, Drug; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Radiation Tolerance; S Phase; Vidarabine

1994
Secondary neoplasms in two patients treated with purine analogues.
    Nouvelle revue francaise d'hematologie, 1994, Volume: 36, Issue:4

    Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia

1994
Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
    Postgraduate medical journal, 1994, Volume: 70, Issue:827

    Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Tumor Lysis Syndrome; Vidarabine

1994
Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells.
    American journal of hematology, 1994, Volume: 47, Issue:4

    Topics: Aged; Apoptosis; Cladribine; DNA Damage; Female; Humans; In Vitro Techniques; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Tumor Cells, Cultured; Vidarabine

1994
Fludarabine causing tumour lysis syndrome in chronic lymphocytic leukaemia.
    Australian and New Zealand journal of medicine, 1994, Volume: 24, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Tumor Lysis Syndrome; Vidarabine

1994
Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance.
    Leukemia & lymphoma, 1994, Volume: 13, Issue:1-2

    Topics: 2-Chloroadenosine; Aged; Chlorambucil; Drug Resistance; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Time Factors; Vidarabine

1994
Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.
    Leukemia & lymphoma, 1994, Volume: 13, Issue:1-2

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Survival; Cells, Cultured; Cyclophosphamide; Cytotoxicity, Immunologic; Humans; Immunophenotyping; Interferon-alpha; Interleukin-2; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Tumor Cells, Cultured; Vidarabine

1994
Kaposi's sarcoma in an HIV-negative CLL patient as the cause of thrombocytopenia.
    Annals of hematology, 1994, Volume: 68, Issue:6

    Topics: Aged; Antineoplastic Agents; Biopsy; Blood Platelets; HIV Seronegativity; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Subsets; Radionuclide Imaging; Sarcoma, Kaposi; Skin; Technetium Compounds; Thrombocytopenia; Vidarabine

1994
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
    Leukemia, 1994, Volume: 8, Issue:8

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Count; Recurrence; Vidarabine

1994
Effectiveness of fludarabine in end-stage prolymphocytic leukemia.
    Leukemia, 1994, Volume: 8, Issue:8

    Topics: Aged; Anemia; Antigens, CD; Antineoplastic Agents; Blood Transfusion; Chlorambucil; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Neoplasm Staging; Splenectomy; Thrombocytopenia; Vidarabine

1994
Prolonged bone marrow aplasia of refractory prolymphocytoid variant of B-cell chronic lymphocytic leukemia related to fludarabine treatment.
    European journal of haematology, 1994, Volume: 53, Issue:1

    Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukopenia; Male; Middle Aged; Neutropenia; Vidarabine

1994
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
    Blood, 1993, Jan-01, Volume: 81, Issue:1

    Topics: Adenosine Triphosphate; Apoptosis; Cladribine; Cycloheximide; Dactinomycin; DNA, Neoplasm; Egtazic Acid; Guanosine Triphosphate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Microscopy, Electron; Puromycin; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Uridine Triphosphate; Vidarabine

1993
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
    The New England journal of medicine, 1993, Mar-18, Volume: 328, Issue:11

    Topics: Antineoplastic Agents; Cladribine; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1993
Listeriosis after 2-chlorodeoxyadenosine treatment.
    The New England journal of medicine, 1993, Mar-18, Volume: 328, Issue:11

    Topics: Aged; Antineoplastic Agents; Cladribine; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Vidarabine

1993
Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia.
    Lancet (London, England), 1993, Aug-28, Volume: 342, Issue:8870

    Topics: Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Red-Cell Aplasia, Pure; Vidarabine

1993
Cytopenia and fludarabine.
    Lancet (London, England), 1993, Oct-23, Volume: 342, Issue:8878

    Topics: Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia; Vidarabine

1993
Cytopenia and fludarabine.
    Lancet (London, England), 1993, Oct-23, Volume: 342, Issue:8878

    Topics: Adult; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Red-Cell Aplasia, Pure; Vidarabine

1993
Fludarabine and psoriasis.
    The New England journal of medicine, 1994, May-26, Volume: 330, Issue:21

    Topics: Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Psoriasis; Vidarabine

1994
Case report: fatal Staphylococcus aureus sepsis from single-donor platelet transfusion.
    The American journal of the medical sciences, 1994, Volume: 307, Issue:5

    Topics: Aged; Antineoplastic Agents; Bacteremia; Blood Donors; Carcinoma, Squamous Cell; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Platelet Transfusion; Skin Neoplasms; Staphylococcal Infections; Staphylococcus aureus; Thrombocytopenia; Vidarabine

1994
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Administration Schedule; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vidarabine

1994
Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
    Acta haematologica Polonica, 1994, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Female; Follow-Up Studies; Hemoglobins; Humans; Immunoglobulin M; Middle Aged; Remission Induction; Vidarabine; Waldenstrom Macroglobulinemia

1994
Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine.
    Leukemia & lymphoma, 1993, Volume: 11, Issue:1-2

    Topics: Aged; Anemia, Hemolytic, Autoimmune; CD4-CD8 Ratio; Coombs Test; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Vidarabine

1993
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
    Bone marrow transplantation, 1993, Volume: 12, Issue:3

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Synergism; Etoposide; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Pentostatin; Prednisone; Rats; Rats, Inbred Lew; Salvage Therapy; Shock, Cardiogenic; Ventricular Fibrillation; Vidarabine; Vincristine

1993
Listerial brain abscess in a patient with chronic lymphocytic leukemia treated with fludarabine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1993, Volume: 17, Issue:4

    Topics: Aged; Antineoplastic Agents; Brain Abscess; Cefotaxime; Drug Therapy, Combination; Gentamicins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Male; Prednisone; Tomography, X-Ray Computed; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine

1993
Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
    Cancer research, 1994, Jan-15, Volume: 54, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Division; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Sarcoma, Experimental; Vidarabine

1994
Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia.
    Connecticut medicine, 1993, Volume: 57, Issue:10

    Topics: Acute Disease; Aged; Antineoplastic Agents; Fatal Outcome; Female; Humans; Leukemia, Prolymphocytic; Tumor Lysis Syndrome; Vidarabine

1993
Response criteria with fludarabine therapy in chronic lymphocytic leukemia.
    Blood, 1994, Feb-01, Volume: 83, Issue:3

    Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1994
A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside.
    Leukemia, 1993, Volume: 7, Issue:7

    Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Methylcellulose; Vidarabine

1993
Fludarabine therapy in Waldenström's macroglobulinemia.
    The American journal of medicine, 1993, Volume: 95, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

1993
Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Immunosuppressive Agents; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Vidarabine

1993
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia.
    European journal of haematology, 1993, Volume: 51, Issue:2

    Topics: Adult; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Platelet Count; Remission Induction; Vidarabine

1993
Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia.
    Annals of internal medicine, 1993, Jan-15, Volume: 118, Issue:2

    Topics: Antineoplastic Agents; Brain Diseases; Combined Modality Therapy; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Vidarabine

1993
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Treatment Outcome; Vidarabine

1993
Complete remission after fludarabine for chronic lymphocytic leukemia.
    Blood, 1993, Jan-15, Volume: 81, Issue:2

    Topics: Antigens, CD; Antineoplastic Agents; Blotting, Southern; Bone Marrow; DNA, Neoplasm; Drug Administration Schedule; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Time Factors; Vidarabine

1993
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
    Leukemia, 1993, Volume: 7, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine

1993
Treatment of low grade non-Hodgkin's lymphomas with fludarabine.
    Leukemia & lymphoma, 1993, Volume: 10 Suppl

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine

1993
Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1995, Volume: 36, Issue:1

    Topics: Animals; Antineoplastic Agents; Cobalt Radioisotopes; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Hindlimb; Injections, Intraperitoneal; Paresis; Radiation Dosage; Radiation Injuries, Experimental; Radiation Tolerance; Radioisotope Teletherapy; Rats; Rats, Inbred F344; Spinal Cord; Time Factors; Vidarabine

1995
Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1995, Volume: 14, Issue:9

    Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Vidarabine

1995
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
    British journal of haematology, 1995, Volume: 91, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1995
Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia.
    British journal of haematology, 1995, Volume: 91, Issue:2

    Topics: Antineoplastic Agents; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Polymerase Chain Reaction; Transfusion Reaction; Vidarabine

1995
Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine.
    Blood, 1996, Feb-01, Volume: 87, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factor 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Fluorescence; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Tumor Cells, Cultured; Vidarabine

1996
Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenström's macroglobulinemia.
    International journal of hematology, 1995, Volume: 62, Issue:2

    Topics: Aged; Gastroenteritis; Humans; Immunization, Passive; Immunocompromised Host; Immunoglobulins, Intravenous; Male; Mamastrovirus; Opportunistic Infections; Peptic Ulcer; Vidarabine; Virus Diseases; Waldenstrom Macroglobulinemia

1995
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:5

    Topics: Adult; Antineoplastic Agents; Cytotoxicity, Immunologic; Flow Cytometry; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocyte Subsets; Tumor Cells, Cultured; Vidarabine

1996
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
    British journal of haematology, 1996, Volume: 92, Issue:3

    Topics: Adult; Anemia, Hemolytic, Autoimmune; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine

1996
In vivo oxygen consumption rate of DS sarcoma cells on inhibition of DNA synthesis.
    Cancer research, 1996, May-01, Volume: 56, Issue:9

    Topics: Animals; Antineoplastic Agents; Ascites; Cell Division; Depression, Chemical; DNA, Neoplasm; Lovastatin; Male; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Sarcoma, Experimental; Vidarabine

1996
Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
    Cancer research, 1996, May-15, Volume: 56, Issue:10

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biotransformation; Breast Neoplasms; Carcinoma, Small Cell; Cladribine; Colonic Neoplasms; Cytarabine; Deoxycytidine Kinase; DNA, Complementary; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genetic Vectors; Humans; Lung Neoplasms; Moloney murine leukemia virus; Phosphorylation; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vidarabine

1996
Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.
    Leukemia research, 1996, Volume: 20, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Survival; Cytarabine; Deoxycytidine; Drug Interactions; Gemcitabine; HL-60 Cells; Humans; Thymidine; Vidarabine

1996
Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
    European journal of haematology, 1996, Volume: 56, Issue:4

    Topics: Antigens, CD19; Apoptosis; B-Lymphocytes; Carrier Proteins; CD5 Antigens; Cladribine; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Neoplasm Proteins; Nucleoside Transport Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; S Phase; Tumor Cells, Cultured; Vidarabine

1996
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3

    Topics: Antineoplastic Agents; Cell Cycle; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Binding; Tumor Cells, Cultured; Vidarabine

1996
Transfusion-associated graft-versus-host disease (TA-GVHD) in fludarabine-treated patients: is it time to irradiate blood component?
    British journal of haematology, 1996, Volume: 93, Issue:3

    Topics: Antineoplastic Agents; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Transfusion Reaction; Vidarabine

1996
Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine

1995
2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
    Leukemia, 1996, Volume: 10, Issue:7

    Topics: Antineoplastic Agents; Cladribine; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1996
Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA.
    The Journal of biological chemistry, 1996, Aug-09, Volume: 271, Issue:32

    Topics: Base Sequence; DNA; DNA Polymerase II; Exodeoxyribonuclease V; Exodeoxyribonucleases; Humans; Kinetics; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; Tumor Cells, Cultured; Vidarabine

1996
Fludarabine treatment and transfusion-associated graft-versus-host disease.
    Lancet (London, England), 1996, Aug-17, Volume: 348, Issue:9025

    Topics: Antineoplastic Agents; Fatal Outcome; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transfusion Reaction; Vidarabine

1996
Fludarabine treatment and transfusion-associated graft-versus-host disease.
    Lancet (London, England), 1996, Aug-17, Volume: 348, Issue:9025

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine

1996
Type II mixed cryoglobulinemia treated with fludarabine.
    The Journal of rheumatology, 1996, Volume: 23, Issue:4

    Topics: Antineoplastic Agents; Cryoglobulinemia; Humans; Male; Middle Aged; Remission Induction; Sjogren's Syndrome; Vidarabine

1996
T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure.
    Bone marrow transplantation, 1996, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; HLA Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Living Donors; Lymphocyte Depletion; Male; Middle Aged; Pancytopenia; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

1996
Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role?
    Leukemia & lymphoma, 1995, Volume: 20, Issue:1-2

    Topics: Adult; Antigens, CD; Antineoplastic Agents; Cyclosporine; Flow Cytometry; Follow-Up Studies; Hemoglobins; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Vidarabine

1995
Isolated leukemia cutis and CNS involvement in combination with cytogenetic findings of trisomy 8--two case reports.
    Leukemia & lymphoma, 1995, Volume: 20, Issue:1-2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Central Nervous System Neoplasms; Chromosomes, Human, Pair 8; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin Neoplasms; Trisomy; Vidarabine

1995
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
    Journal of immunology (Baltimore, Md. : 1950), 1996, Apr-01, Volume: 156, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; DNA, Neoplasm; Endonucleases; Glucocorticoids; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Mitoxantrone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine

1996
Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Cladribine; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Remission Induction; Retreatment; Survival Rate; Treatment Outcome; Vidarabine

1996
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine.
    Blood, 1996, Sep-15, Volume: 88, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunoblastic Lymphadenopathy; Male; Middle Aged; Prednisone; Vidarabine; Vincristine

1996
Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies.
    British journal of haematology, 1996, Volume: 94, Issue:4

    Topics: Aged; Antineoplastic Agents; Cladribine; Eosinophilia; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Vidarabine

1996
[Fludarabine and severe autoimmune hemolytic anemia: a new case].
    La Revue de medecine interne, 1996, Volume: 17, Issue:8

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Male; Vidarabine

1996
Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia.
    Hematology and cell therapy, 1996, Volume: 38, Issue:4

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Fatal Outcome; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine

1996
Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine.
    Radiation research, 1996, Volume: 146, Issue:5

    Topics: Animals; Antineoplastic Agents; Indomethacin; Male; Mice; Mice, Inbred C3H; Prostaglandin Antagonists; Sarcoma, Experimental; Vidarabine

1996
Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
    Biochimica et biophysica acta, 1996, Oct-24, Volume: 1291, Issue:2

    Topics: Adenosine Diphosphate; Adenosine Triphosphate; Antimetabolites, Antineoplastic; Drug Carriers; Drug Delivery Systems; Erythrocytes; Humans; Kinetics; Phosphorylation; Vidarabine; Vidarabine Phosphate

1996
Fludarabine in the treatment of essential mixed cryoglobulinaemia.
    European journal of haematology, 1996, Volume: 57, Issue:3

    Topics: Antineoplastic Agents; Cryoglobulinemia; Humans; Vidarabine

1996
Crescentic glomerulonephritis associated with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1996, Volume: 11, Issue:11

    Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Antineoplastic Agents; Female; Glomerulonephritis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1996
Cold agglutinin hemolysis responding to fludarabine therapy.
    American journal of hematology, 1996, Volume: 53, Issue:4

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Antimetabolites; Cyclophosphamide; Drug Resistance; Humans; Male; Vidarabine

1996
Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results.
    Transplantation proceedings, 1996, Volume: 28, Issue:6

    Topics: Animals; Bone Marrow Transplantation; Cells, Cultured; Cyclophosphamide; Immunosuppressive Agents; Mice; Mice, Inbred C3H; Spleen; T-Lymphocytes; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

1996
Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:10

    Topics: Antineoplastic Agents; Cisplatin; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Melanoma; Ovarian Neoplasms; Tumor Cells, Cultured; Vidarabine

1996
Seeking the nucleoside transporter.
    Nature medicine, 1997, Volume: 3, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus

1997
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs.
    Nature medicine, 1997, Volume: 3, Issue:1

    Topics: Adenosine; Amino Acid Sequence; Animals; Antineoplastic Agents; Carrier Proteins; Cladribine; Cloning, Molecular; Cytarabine; Databases, Factual; DNA, Complementary; Equilibrative Nucleoside Transporter 1; Humans; Membrane Proteins; Molecular Sequence Data; Nucleosides; Oocytes; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Tissue Distribution; Uridine; Vidarabine; Xenopus

1997
Purine analogues for treatment of refractory essential mixed cryoglobulinemia.
    Mayo Clinic proceedings, 1997, Volume: 72, Issue:1

    Topics: 2-Chloroadenosine; Cryoglobulinemia; Deoxyadenosines; Humans; Purines; Vidarabine

1997
Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.
    Leukemia, 1997, Volume: 11, Issue:2

    Topics: Apoptosis; B-Lymphocytes; Cell Line, Transformed; Dactinomycin; DNA Fragmentation; Fibroblast Growth Factor 2; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Vidarabine

1997
Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients.
    Leukemia research, 1997, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Melphalan; Middle Aged; Tumor Cells, Cultured; Vidarabine

1997
Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
    British journal of haematology, 1997, Volume: 96, Issue:3

    Topics: Administration, Cutaneous; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Recurrence; Vidarabine

1997
Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia.
    American journal of hematology, 1997, Volume: 54, Issue:4

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine

1997
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
    Cancer research, 1997, Apr-15, Volume: 57, Issue:8

    Topics: Adenosine Monophosphate; Adenosine Triphosphate; Antineoplastic Agents; Cisplatin; Cytidine Monophosphate; DNA Adducts; DNA Repair; High Mobility Group Proteins; Humans; Plasmids; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured; Vidarabine

1997
Chronic lymphocytic leukemia in the elderly population.
    Clinics in geriatric medicine, 1997, Volume: 13, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prednisone; United States; Vidarabine

1997
Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:5

    Topics: Affinity Labels; Animals; Anti-HIV Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Cells, Cultured; Drug Interactions; Ducks; Hepadnaviridae Infections; Hepatitis B Virus, Duck; Humans; Thioinosine; Thymidine; Tumor Cells, Cultured; Vidarabine; Zalcitabine

1997
Fludarabine-induced tumour lysis in low-grade non-Hodgkin's lymphoma.
    Clinical and laboratory haematology, 1997, Volume: 19, Issue:1

    Topics: Acute Disease; Aged; Humans; Lymphoma, Non-Hodgkin; Male; Renal Dialysis; Tumor Lysis Syndrome; Vidarabine

1997
Steroid-responsive interstitial pneumonitis after fludarabine therapy.
    Chest, 1997, Volume: 111, Issue:5

    Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Cough; Fatal Outcome; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Male; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Respiratory Distress Syndrome; Respiratory Insufficiency; Vidarabine

1997
[A nidulans bronchial aspergillosis after treatment of low-grade lymphoma with fludarabine].
    La Revue de medecine interne, 1997, Volume: 18, Issue:3

    Topics: Antineoplastic Agents; Aspergillosis; Bronchial Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Vidarabine

1997
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.
    British journal of haematology, 1997, Volume: 97, Issue:2

    Topics: Adult; Antineoplastic Agents; Blood Transfusion, Autologous; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine

1997
Listeriosis after fludarabine treatment for chronic lymphocytic leukemia.
    Hematology and cell therapy, 1997, Volume: 39, Issue:2

    Topics: Aged; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Prednisone; Sulfamethoxazole; Trimethoprim; Vidarabine; Vincristine

1997
Topical treatment of psoriasis with fludarabine.
    Cutis, 1997, Volume: 59, Issue:5

    Topics: Administration, Topical; Antineoplastic Agents; Dermatologic Agents; Humans; Male; Psoriasis; Vidarabine

1997
Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience.
    Leukemia & lymphoma, 1996, Volume: 21, Issue:5-6

    Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Cause of Death; Drug Evaluation; Fever; Graft vs Host Disease; Hematologic Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Remission Induction; Retrospective Studies; Salvage Therapy; Spain; Survival Analysis; Transfusion Reaction; Treatment Outcome; Vidarabine

1996
Chemotherapeutic purine analogs alter the level of interferon-beta mRNA induced by poly I-poly C in cultured osteosarcoma cells.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 1997, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Cladribine; Dose-Response Relationship, Drug; eIF-2 Kinase; Gene Expression; Humans; Interferon-beta; Neoplastic Stem Cells; Pentostatin; Poly I-C; Protein Serine-Threonine Kinases; RNA, Messenger; Vidarabine

1997
In vivo 'purging' of residual disease in CLL with Campath-1H.
    British journal of haematology, 1997, Volume: 97, Issue:3

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Pentostatin; Vidarabine

1997
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
    Blood, 1997, Jul-01, Volume: 90, Issue:1

    Topics: Antineoplastic Agents; Binding Sites; Cytarabine; Deoxycytidine; DNA Repair; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine

1997
Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation.
    Blood, 1997, Jul-01, Volume: 90, Issue:1

    Topics: Animals; Bone Marrow Transplantation; Graft vs Host Disease; Immunosuppressive Agents; Mice; Transplantation, Homologous; Vidarabine

1997
Flare-up of squamous cell carcinoma of the skin following fludarabine therapy for chronic lymphocytic leukemia.
    Acta haematologica, 1997, Volume: 98, Issue:1

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; CD4 Lymphocyte Count; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Skin Neoplasms; Vidarabine

1997
Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy.
    Cancer letters, 1997, Jun-24, Volume: 116, Issue:2

    Topics: Adult; Cladribine; Cytarabine; Deoxycytidine; Deoxycytosine Nucleotides; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine

1997
Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.
    Clinical and laboratory haematology, 1997, Volume: 19, Issue:2

    Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 8; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia; Trisomy; Vidarabine

1997
[Nocardia nova pulmonary infection under treatment with fludarabine].
    Presse medicale (Paris, France : 1983), 1997, Jul-05, Volume: 26, Issue:23

    Topics: Aged; Antineoplastic Agents; Humans; Lung Diseases; Male; Nocardia Infections; Vidarabine

1997
Third space sequestration increases toxicity of fludarabine--a case report.
    Acta oncologica (Stockholm, Sweden), 1997, Volume: 36, Issue:4

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drainage; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pleural Effusion; Sepsis; Vidarabine

1997
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
    Cancer research, 1997, Aug-15, Volume: 57, Issue:16

    Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Doxorubicin; Fas Ligand Protein; fas Receptor; Humans; Leukemia-Lymphoma, Adult T-Cell; Ligands; Membrane Glycoproteins; Signal Transduction; Tumor Cells, Cultured; Up-Regulation; Vidarabine

1997
Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis.
    Cancer research, 1997, Aug-15, Volume: 57, Issue:16

    Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Cell Fusion; Cell Line; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Electrophoresis, Gel, Pulsed-Field; Gemcitabine; Humans; In Vitro Techniques; Molecular Weight; Nucleosomes; Vidarabine

1997
Bayesian interim analysis of phase II cancer clinical trials.
    Statistics in medicine, 1997, Aug-30, Volume: 16, Issue:16

    Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid; Models, Statistical; Research Design; Vidarabine

1997
Role of splenectomy in chronic lymphocytic leukemia.
    Journal of the American College of Surgeons, 1997, Volume: 185, Issue:3

    Topics: Antineoplastic Agents; Case-Control Studies; Female; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Neoplasm Staging; Retrospective Studies; Splenectomy; Survival Analysis; Treatment Outcome; Vidarabine

1997
Fludarabine and autoimmune hemolytic anemia in chronic lymphocytic leukemia.
    European journal of haematology, 1997, Volume: 59, Issue:2

    Topics: Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1997
Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.
    Leukemia & lymphoma, 1997, Volume: 26, Issue:3-4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Drug Interactions; Drug Screening Assays, Antitumor; Female; Guanosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine

1997
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
    Molecular pharmacology, 1997, Volume: 52, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Southern; Cell Count; Cisplatin; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine; Xeroderma Pigmentosum

1997
Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations.
    British journal of haematology, 1997, Volume: 99, Issue:1

    Topics: Aged; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD5 Antigens; Down-Regulation; Female; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymerase Chain Reaction; Tumor Cells, Cultured; Vidarabine

1997
Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes.
    British journal of haematology, 1997, Volume: 99, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma; Male; Splenic Neoplasms; Vidarabine

1997
Quantification of CMV viraemia in a case of transfusion-related graft-versus-host disease associated with purine analogue treatment.
    British journal of haematology, 1997, Volume: 99, Issue:1

    Topics: Acute Disease; Adult; Antineoplastic Agents; Cytomegalovirus Infections; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Leukemia, Myeloid; Lymphopenia; T-Lymphocytes; Transfusion Reaction; Vidarabine; Viremia

1997
[Successful treatment for advanced and refractory chronic lymphocytic leukemia with fludarabine phosphate].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1997, Volume: 38, Issue:9

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine

1997
[Selective aplasia of the red-cell series after fludarabine administration in a patient with chronic B-cell lymphatic leukemia].
    Sangre, 1997, Volume: 42, Issue:3

    Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Chlorambucil; Cyclophosphamide; Cyclosporine; Doxorubicin; Humans; Hydrocortisone; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Red-Cell Aplasia, Pure; Vidarabine; Vincristine

1997
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Cytokines and molecular therapy, 1995, Volume: 1, Issue:1

    Topics: Adult; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Confidence Intervals; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Environment, Controlled; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Middle Aged; Platelet Count; Probability; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine

1995
Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 1997, Volume: 10, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Viral; Antineoplastic Agents; CD4 Lymphocyte Count; Cell Transformation, Neoplastic; DNA Primers; Female; Herpesvirus 4, Human; Humans; In Situ Hybridization; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Vidarabine; Viral Matrix Proteins

1997
P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 1997, Volume: 26, Issue:5-6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; bcl-2-Associated X Protein; Chlorambucil; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nuclear Proteins; Polymorphism, Single-Stranded Conformational; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine

1997
Evans syndrome complicating fludarabine treatment for advanced B-CLL.
    British journal of haematology, 1997, Volume: 99, Issue:3

    Topics: Anemia, Hemolytic; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Syndrome; Thrombocytopenia; Vidarabine

1997
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas.
    European journal of haematology, 1997, Volume: 59, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Vidarabine

1997
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
    British journal of haematology, 1997, Volume: 99, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine

1997
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
    British journal of haematology, 1998, Volume: 100, Issue:1

    Topics: Adult; Apoptosis; Blood Platelets; CD40 Ligand; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Membrane Glycoproteins; Up-Regulation; Vidarabine

1998
A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia.
    Bone marrow transplantation, 1997, Volume: 20, Issue:12

    Topics: Antineoplastic Agents; Child; Cyclophosphamide; Fanconi Anemia; Female; Humans; Leukemia, Myeloid; Male; Preleukemia; Remission Induction; Risk Factors; Transplantation Conditioning; Vidarabine

1997
Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma.
    Vox sanguinis, 1998, Volume: 74, Issue:2

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Autoantibodies; Coombs Test; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Temperature; Vidarabine

1998
Association of myelodysplastic changes with purine analogues.
    British journal of haematology, 1998, Volume: 100, Issue:4

    Topics: 2-Chloroadenosine; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxyadenosines; Female; Humans; Lymphoproliferative Disorders; Male; Myelodysplastic Syndromes; Pentostatin; Vidarabine

1998
Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine.
    Bone marrow transplantation, 1998, Volume: 21, Issue:6

    Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytomegalovirus Infections; Doxorubicin; Drug Synergism; Female; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Pneumonia, Viral; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Vincristine; Viral Load

1998
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
    Haematologica, 1998, Volume: 83, Issue:3

    Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Risk Factors; Time Factors; Vidarabine

1998
Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1998
Effect of Cladribine, fludarabine, and 5-aza-deoxycytidine on S-adenosylmethionine (SAM) and nucleotides pools in stimulated human lymphocytes.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Adenine Nucleotides; Adenine Phosphoribosyltransferase; Antineoplastic Agents; Azacitidine; Cells, Cultured; Cladribine; Cytidine Triphosphate; Decitabine; Guanine Nucleotides; Humans; Kinetics; Lymphocyte Activation; Lymphocytes; NAD; Ribonucleotides; S-Adenosylmethionine; Uracil Nucleotides; Vidarabine

1998
Does 2-chlorodeoxyadenosine contribute to alteration of DNA methyltransferase activity?
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Adenosylhomocysteinase; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cladribine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Hydrolases; Kinetics; Leukemia L1210; Mice; Tumor Cells, Cultured; Vidarabine

1998
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.
    Leukemia & lymphoma, 1998, Volume: 28, Issue:5-6

    Topics: 2-Chloroadenosine; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Deoxyadenosines; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proto-Oncogene Proteins c-bcl-2; Vidarabine

1998
Tuberculosis-associated fatal hemophagocytic syndrome in a patient with lymphoma treated with fludarabine.
    Leukemia & lymphoma, 1998, Volume: 28, Issue:5-6

    Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Tuberculosis; Vidarabine

1998
Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom's macroglobulinemia treated with fludarabine.
    Leukemia & lymphoma, 1998, Volume: 28, Issue:5-6

    Topics: Antineoplastic Agents; Brain Diseases; Female; Humans; Immunosuppressive Agents; Meningitis, Cryptococcal; Middle Aged; Opportunistic Infections; Tuberculoma; Vidarabine; Waldenstrom Macroglobulinemia

1998
Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Drug Resistance; Humans; Immunoglobulin M; Immunosuppressive Agents; Middle Aged; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

1998
Simple, fast method of detection apoptosis in lymphoid cells.
    Cytometry, 1998, Jun-01, Volume: 32, Issue:2

    Topics: Apoptosis; Blood Cell Count; Cells, Cultured; Chlorambucil; Flow Cytometry; Humans; Immunohistochemistry; Interleukin-4; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Reference Values; Scattering, Radiation; Theophylline; Vidarabine

1998
Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresi
    International journal of radiation biology, 1998, Volume: 73, Issue:5

    Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA Repair; DNA, Neoplasm; Electrophoresis, Gel, Pulsed-Field; Fibrosarcoma; Gemcitabine; Mice; Mice, Inbred C3H; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vidarabine

1998
Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tumor Lysis Syndrome; Vidarabine

1998
Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.
    Annals of hematology, 1998, Volume: 76, Issue:5

    Topics: Administration, Inhalation; Adult; Antineoplastic Agents; Antiviral Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin; Vidarabine

1998
New prospects in the treatment of indolent lymphomas with purine analogues.
    The cancer journal from Scientific American, 1998, Volume: 4 Suppl 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine

1998
Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.
    Blood, 1998, Aug-01, Volume: 92, Issue:3

    Topics: Antibodies, Monoclonal; Apoptosis; CD40 Antigens; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Oligonucleotides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-rel; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine

1998
Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy.
    Clinical and laboratory haematology, 1998, Volume: 20, Issue:3

    Topics: Aged; Allantoin; Antimetabolites, Antineoplastic; Diuresis; Drug Evaluation; Female; Humans; Kidney Calculi; Kidney Diseases; Kidney Tubules; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oliguria; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine

1998
Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy.
    European journal of haematology, 1998, Volume: 61, Issue:1

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Bone Marrow Cells; Cell Count; Cell Differentiation; Cell Division; Clone Cells; Colony-Forming Units Assay; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Vidarabine

1998
In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia.
    British journal of haematology, 1998, Volume: 102, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Lethal Dose 50; Lymphoma, B-Cell; Male; Middle Aged; Vidarabine

1998
Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four cases.
    British journal of haematology, 1998, Volume: 102, Issue:2

    Topics: Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Vidarabine; Vincristine

1998
In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues--correlation with clinical course.
    Leukemia, 1998, Volume: 12, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Cladribine; DNA Nucleotidylexotransferase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Phenotype; Proto-Oncogene Proteins c-bcl-2; Vidarabine

1998
Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
    Hematology and cell therapy, 1998, Volume: 40, Issue:3

    Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Dose-Response Relationship, Drug; Erythrocyte Transfusion; Hemolysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Survival Rate; Time Factors; Vidarabine

1998
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Enhancement, Immunologic; Graft vs Host Disease; Graft vs Host Reaction; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine

1998
When prognosis is poor, does false hope add to leukemia patients' pain?
    Journal of the National Cancer Institute, 1998, Aug-19, Volume: 90, Issue:16

    Topics: Adaptation, Psychological; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine

1998
Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:7

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Leukemia, Hairy Cell; Mice; Tumor Cells, Cultured; Vidarabine

1998
Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines.
    The international journal of biochemistry & cell biology, 1998, Volume: 30, Issue:7

    Topics: Adenosine Deaminase Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Division; Cladribine; Deoxyribonucleotides; Enzyme Inhibitors; Humans; Kinetics; Leukemia, T-Cell; Lymphoma, B-Cell; Pentostatin; Ribonucleotides; Tumor Cells, Cultured; Vidarabine

1998
In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy.
    British journal of haematology, 1998, Volume: 102, Issue:4

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Vidarabine

1998
Chronic lymphocytic leukemia in a patient with sickle cell anemia.
    The Western journal of medicine, 1998, Volume: 169, Issue:2

    Topics: Anemia, Sickle Cell; Antineoplastic Agents; Chronic Disease; Fatal Outcome; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

1998
Fludarabine and hemolytic anemia in chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1998
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.
    European journal of haematology, 1998, Volume: 61, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Chronic Disease; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm, Residual; Treatment Outcome; Vidarabine

1998
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
    Annals of internal medicine, 1998, Oct-01, Volume: 129, Issue:7

    Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Neoplasm Staging; Opportunistic Infections; Prednisone; Retrospective Studies; Risk Factors; Vidarabine

1998
Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia.
    Haematologica, 1998, Volume: 83, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine

1998
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
    Blood, 1998, Nov-15, Volume: 92, Issue:10

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Cycle Proteins; Chromosomes, Human, Pair 17; Cyclin-Dependent Kinase Inhibitor p27; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Precursors; Flavonoids; Gene Deletion; Genes, p53; Growth Inhibitors; Humans; In Situ Hybridization, Fluorescence; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Microtubule-Associated Proteins; Neoplasm Proteins; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

1998
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:9

    Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Time Factors; Vidarabine

1997
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Apoptosis; Chelating Agents; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Egtazic Acid; Enzyme Inhibitors; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Tumor Cells, Cultured; Vidarabine

1995
Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; DNA Fragmentation; DNA Repair; Flow Cytometry; Humans; Lymphocytes; Ultraviolet Rays; Vidarabine

1996
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:4

    Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; K562 Cells; Vidarabine

1996
Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders.
    American journal of hematology, 1998, Volume: 59, Issue:4

    Topics: Aged; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Humans; Immunosuppressive Agents; Incidence; Infection Control; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Prednisone; Retrospective Studies; Vidarabine

1998
Quantification of apoptosis by the Abbott CD4000 hematology analyzer.
    Hematology and cell therapy, 1998, Volume: 40, Issue:5

    Topics: Apoptosis; Autoanalysis; Cells, Cultured; Female; Flow Cytometry; Hematology; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Theophylline; Vidarabine

1998
Phenotypic changes of leukemic cells in a patient with prolympho-plasmacytic leukaemia after treatment with fludarabine.
    European journal of histochemistry : EJH, 1997, Volume: 41 Suppl 2

    Topics: Aged; Antigens, CD; Antineoplastic Agents; Humans; Immunophenotyping; Immunosuppressive Agents; Leukemia, Plasma Cell; Leukemia, Prolymphocytic; Lymphocytes; Male; Phenotype; Vidarabine

1997
Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.
    Haematologica, 1998, Volume: 83, Issue:11

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pancytopenia; Prednisone; Primary Myelofibrosis; Vidarabine; Vincristine

1998
In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia.
    Haematologica, 1998, Volume: 83, Issue:11

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Drug Interactions; Drug Screening Assays, Antitumor; Gene Expression Regulation, Leukemic; Humans; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine

1998
Leukemic pleural effusion in B-cell prolymphocytic leukemia.
    Hematology and cell therapy, 1998, Volume: 40, Issue:6

    Topics: Aged; Antibodies; Antigens, CD20; Antineoplastic Agents; Humans; Immunohistochemistry; Leukemia, B-Cell; Leukemia, Prolymphocytic; Male; Pleural Effusion, Malignant; Remission Induction; Tomography Scanners, X-Ray Computed; Vidarabine

1998
Re: V.I. Avramis et al., Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin. Can
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Leukemia; Terminology as Topic; Vidarabine; Vidarabine Phosphate

1999
Refractory pure red cell aplasia associated with B-CLL: successful treatment with a combination of fludarabine, cyclosporin A and erythropoietin.
    Leukemia, 1999, Volume: 13, Issue:1

    Topics: Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4-CD8 Ratio; Cyclosporine; Erythropoietin; Hemoglobins; Humans; Immunoglobulins, Intravenous; Immunophenotyping; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Red-Cell Aplasia, Pure; Vidarabine

1999
Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia.
    Leukemia research, 1999, Volume: 23, Issue:3

    Topics: Antineoplastic Agents; Cells, Cultured; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1999
Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1999, Volume: 33, Issue:2

    Topics: Antineoplastic Agents; Biopsy; Female; Glomerulonephritis, Membranous; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

1999
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Bone marrow transplantation, 1999, Volume: 23, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine

1999
Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders.
    British journal of haematology, 1999, Volume: 104, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine

1999
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
    Annals of hematology, 1999, Volume: 78, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine

1999
Irreversible renal failure in a patient with chronic lymphocytic leukemia treated with fludarabine.
    Annals of hematology, 1999, Volume: 78, Issue:2

    Topics: Acute Kidney Injury; Antimetabolites, Antineoplastic; Autoantibodies; Erythrocytes; Fatal Outcome; Glomerulonephritis; Humans; Immune Complex Diseases; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Dialysis; Salvage Therapy; Vidarabine

1999
Two cases of toxoplasmic encephalitis in patients with acute T-cell leukaemia and lymphoma.
    The Journal of infection, 1999, Volume: 38, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; HIV Seronegativity; Humans; Immunocompromised Host; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; Male; Meningoencephalitis; Methotrexate; Middle Aged; Toxoplasmosis; Vidarabine

1999
Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Haematologica, 1999, Volume: 84, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Analysis; Vidarabine

1999
Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine.
    British journal of haematology, 1999, Volume: 104, Issue:4

    Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Vidarabine

1999
Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells.
    Leukemia & lymphoma, 1999, Volume: 33, Issue:1-2

    Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Guanosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Cells, Cultured; Vidarabine

1999
Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
    Leukemia & lymphoma, 1999, Volume: 33, Issue:1-2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Vidarabine

1999
Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.
    Bone marrow transplantation, 1999, Volume: 23, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Stem Cell Transplantation; Stem Cells; Vidarabine

1999
Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
    International journal of oncology, 1999, Volume: 14, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bryostatins; Cell Division; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured; Vidarabine

1999
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.
    Nature medicine, 1999, Volume: 5, Issue:4

    Topics: Alternative Splicing; Antineoplastic Agents; Cyclosporine; Cytokines; DNA-Binding Proteins; Gene Expression Regulation; Humans; Immune Tolerance; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Signal Transduction; STAT1 Transcription Factor; Trans-Activators; Vidarabine

1999
Association between chronic lymphocytic leukemia and sarcoidosis: clinical value of bronchoalveolar lavage.
    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 1999, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte Count; Comorbidity; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Middle Aged; Sarcoidosis; Vidarabine

1999
Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.
    Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 66, Issue:5

    Topics: Aged; Aged, 80 and over; Female; Humans; Immunoglobulin M; Immunosuppressive Agents; Male; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Vidarabine

1999
Fever after cytotoxic therapy of chronic lymphocytic leukemia.
    Cancer investigation, 1999, Volume: 17, Issue:4

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Aztreonam; Candidiasis; Female; Fever; Glycopeptides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Metronidazole; Middle Aged; Monobactams; Vidarabine

1999
Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism.
    Oncogene, 1999, Apr-15, Volume: 18, Issue:15

    Topics: Amidohydrolases; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Death; Ceramidases; Enzyme Inhibitors; Gamma Rays; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Myristates; Propanolamines; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sphingosine; Vidarabine

1999
Fludarabine-based preparative protocol for unrelated donor cord blood transplantation in children: successful engraftment with minimal toxicity.
    Bone marrow transplantation, 1999, Volume: 23, Issue:8

    Topics: Adolescent; Child; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

1999
Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study.
    British journal of haematology, 1999, Volume: 105, Issue:2

    Topics: Aged; Female; Herpesviridae Infections; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Prospective Studies; Vidarabine

1999
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients.
    British journal of haematology, 1999, Volume: 105, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Vidarabine

1999
Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Vidarabine

1999
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
    European journal of haematology, 1999, Volume: 62, Issue:5

    Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine

1999
Evan's syndrome precipitated by fludarabine therapy in a case of CLL.
    American journal of hematology, 1999, Volume: 61, Issue:3

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Female; Humans; Immune Tolerance; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Thrombocytopenia; Vidarabine

1999
Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1.
    Leukemia, 1999, Volume: 13, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Bryostatins; Cell Differentiation; Cell Division; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Lactones; Leukemia, Myelomonocytic, Acute; Macrolides; U937 Cells; Vidarabine

1999
Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution.
    Bone marrow transplantation, 1999, Volume: 23, Issue:12

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

1999
Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.
    British journal of haematology, 1999, Volume: 106, Issue:1

    Topics: Ambulatory Care; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cyclophosphamide; Doxorubicin; Humans; Length of Stay; Lymphoma, B-Cell; Middle Aged; Prednisone; Recurrence; Retrospective Studies; Rituximab; Vidarabine; Vincristine

1999
Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.
    British journal of haematology, 1999, Volume: 106, Issue:1

    Topics: Aged; Antineoplastic Agents; Cause of Death; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Survival Rate; Therapeutics; Vidarabine

1999
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
    British journal of haematology, 1999, Volume: 106, Issue:1

    Topics: Antineoplastic Agents; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Phenotype; Vidarabine

1999
Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia.
    Leukemia, 1999, Volume: 13, Issue:8

    Topics: Aged; Antibodies; Chronic Disease; Cyclophosphamide; Factor VIII; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Vidarabine

1999
Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: complete remission of lymphoma with control of autoimmune complications.
    Bone marrow transplantation, 1999, Volume: 24, Issue:2

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Combined Modality Therapy; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation, Autologous; Vidarabine

1999
Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells.
    Leukemia research, 1999, Volume: 23, Issue:8

    Topics: Antigens, CD34; Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured; Vidarabine

1999
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
    Haematologica, 1999, Volume: 84, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine

1999
[Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Orvosi hetilap, 1999, Aug-01, Volume: 140, Issue:31

    Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Treatment Outcome; Vidarabine

1999
Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia.
    British journal of haematology, 1999, Volume: 106, Issue:3

    Topics: Antineoplastic Agents; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Vidarabine

1999
In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells.
    Haematologica, 1999, Volume: 84, Issue:9

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Leukemic; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Vidarabine

1999
A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
    Clinical nephrology, 1999, Volume: 52, Issue:2

    Topics: Adult; Alkylating Agents; Anti-Inflammatory Agents; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephritis, Membranous; Humans; Immunoglobulin G; Immunologic Memory; Immunosuppressive Agents; Lupus Nephritis; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Pilot Projects; Prednisone; Proteinuria; Renal Plasma Flow, Effective; Sinusitis; Vidarabine

1999
Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia.
    Leukemia & lymphoma, 1999, Volume: 34, Issue:5-6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Middle Aged; Remission Induction; Vidarabine

1999
Resolution of psoriatic skin lesions with fludarabine.
    The American journal of medicine, 1999, Volume: 107, Issue:3

    Topics: Antineoplastic Agents; CD4-Positive T-Lymphocytes; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Vidarabine

1999
Inhibition of FAS/FAS-ligand does not block chemotherapy-induced apoptosis in drug sensitive and resistant cells.
    Advances in experimental medicine and biology, 1999, Volume: 457

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Cycle; Clone Cells; Drug Resistance, Multiple; Etoposide; Fas Ligand Protein; fas Receptor; HL-60 Cells; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Tumor Cells, Cultured; Vidarabine; Vinblastine

1999
Effects of PARP inhibition on drug and Fas-induced apoptosis in leukaemic cells.
    Advances in experimental medicine and biology, 1999, Volume: 457

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Drug Resistance, Multiple; Enzyme Inhibitors; Etoposide; fas Receptor; Genes, MDR; HL-60 Cells; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Microtubules; Phenanthrenes; Poly(ADP-ribose) Polymerase Inhibitors; Tumor Cells, Cultured; Vidarabine; Vinblastine

1999
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
    Blood, 1999, Oct-15, Volume: 94, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; bcl-X Protein; CD3 Complex; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine

1999
The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.
    British journal of haematology, 1999, Volume: 106, Issue:4

    Topics: Antineoplastic Agents; Cell Survival; Cladribine; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine

1999
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia.
    Annals of hematology, 1999, Volume: 78, Issue:9

    Topics: Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine

1999
Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP).
    Hematology and cell therapy, 1999, Volume: 41, Issue:4

    Topics: Antineoplastic Agents; Demyelinating Diseases; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine

1999
Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.
    British journal of haematology, 1999, Volume: 105, Issue:4

    Topics: Animals; Cell Death; Cladribine; Coformycin; Dexamethasone; Drug Resistance; Etoposide; Genes, p53; Lymphocytes; Mice; Mice, Knockout; Spleen; Vidarabine

1999
Treatment of red cell aplasia in CLL with fludarabine.
    Leukemia, 1999, Volume: 13, Issue:11

    Topics: Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Red-Cell Aplasia, Pure; Vidarabine

1999
Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:7

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cyclophosphamide; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

1999
Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8

    Topics: Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Pentostatin; Vidarabine

1999
Use of novel plasmid constructs to demonstrate fludarabine triphosphate inhibition of nucleotide excision repair of a site-specific 1,2-d(GpG) intrastrand cisplatin adduct.
    International journal of oncology, 1999, Volume: 15, Issue:6

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Base Sequence; Binding Sites; Cisplatin; DNA; DNA Adducts; DNA Repair; DNA, Recombinant; Dose-Response Relationship, Drug; Humans; Molecular Sequence Data; Oligonucleotides; Plasmids; Substrate Specificity; Tumor Cells, Cultured; Vidarabine

1999
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes.
    Cancer, 1999, Nov-15, Volume: 86, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Vidarabine

1999
Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
    Leukemia research, 1999, Volume: 23, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chlorambucil; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins c-bcl-2; Vidarabine

1999
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus.
    The British journal of dermatology, 1999, Volume: 141, Issue:4

    Topics: Adult; CD8-Positive T-Lymphocytes; Drug Eruptions; Epidermis; Female; Histocompatibility Antigens Class II; Humans; Immunohistochemistry; Immunophenotyping; Immunosuppressive Agents; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Lymphoma, Non-Hodgkin; Pemphigus; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine

1999
Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect.
    British journal of haematology, 1999, Volume: 107, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine

1999
Refractory pure red-cell aplasia associated with B chronic lymphocytic leukemia successfully treated by fludarabine.
    Haematologica, 1999, Volume: 84, Issue:12

    Topics: Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; Vidarabine

1999
Successful treatment of lupus with fludarabine.
    Lupus, 1999, Volume: 8, Issue:9

    Topics: Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Male; Middle Aged; Vidarabine

1999
Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
    Cancer research, 1999, Dec-01, Volume: 59, Issue:23

    Topics: Antineoplastic Agents; Biological Transport; Biotransformation; Cell Survival; Cladribine; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Phosphorylation; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Vidarabine

1999
The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
    British journal of haematology, 1999, Volume: 107, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Viral; Cyclophosphamide; Dexamethasone; Epstein-Barr Virus Infections; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Opportunistic Infections; Vidarabine; Virus Activation

1999
Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.
    Medical oncology (Northwood, London, England), 1999, Volume: 16, Issue:4

    Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Autoradiography; Brain; Cladribine; Clofarabine; Cytarabine; Lipid Metabolism; Mice; Mice, Inbred C57BL; Thymus Gland; Tissue Distribution; Tritium; Vidarabine

1999
[Chronic lymphatic leukemia and Hodgkin's disease].
    Sangre, 1999, Volume: 44, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasms, Second Primary; Prednisone; Remission Induction; Vidarabine; Vinblastine

1999
Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.
    Leukemia research, 2000, Volume: 24, Issue:1

    Topics: Acute Disease; Adenosine Deaminase Inhibitors; Antimetabolites, Antineoplastic; Calcitriol; Cell Differentiation; Cladribine; Deoxyadenosines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Monocytes; Neoplasm Proteins; Neoplastic Stem Cells; Pentostatin; Tretinoin; Tumor Cells, Cultured; U937 Cells; Vidarabine

2000
Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair.
    Leukemia, 2000, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cyclophosphamide; Dexamethasone; DNA Repair; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine

2000
Second treatment with fludarabine in a Waldenström's macroglobulinemia patient.
    Leukemia, 2000, Volume: 14, Issue:1

    Topics: Adult; CD4-CD8 Ratio; Humans; Immunosuppressive Agents; Male; Vidarabine; Waldenstrom Macroglobulinemia

2000
Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin.
    Hematology and cell therapy, 1999, Volume: 41, Issue:5

    Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Humans; Lymphoma; Splenectomy; Splenic Neoplasms; Treatment Outcome; Vidarabine

1999
Fludarabine containing regimen followed by autologous peripheral blood stem cell transplantation in unselected patients with acute myeloid leukemia: a single center experience.
    Haematologica, 2000, Volume: 85, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Transplantation, Autologous; Treatment Outcome; Vidarabine

2000
Oochroconis gallopava endophthalmitis in fludarabine treated chronic lymphocytic leukaemia.
    The British journal of ophthalmology, 2000, Volume: 84, Issue:1

    Topics: Aged; Antineoplastic Agents; Endophthalmitis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mitosporic Fungi; Opportunistic Infections; Vidarabine

2000
Determination of fludarabine in a pharmaceutical formulation by LC.
    Journal of pharmaceutical and biomedical analysis, 1999, Volume: 21, Issue:5

    Topics: Antineoplastic Agents; Buffers; Calibration; Chromatography, High Pressure Liquid; Methanol; Pharmaceutical Preparations; Phosphates; Reproducibility of Results; Sensitivity and Specificity; Vidarabine

1999
Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene.
    Hepatology (Baltimore, Md.), 2000, Volume: 31, Issue:3

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Combined Modality Therapy; Escherichia coli; Ganciclovir; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Liver Neoplasms, Experimental; Luminescent Proteins; Mice; Mice, Nude; Orotate Phosphoribosyltransferase; RNA, Messenger; Thymidine Kinase; Tumor Cells, Cultured; Vidarabine

2000
Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
    International journal of molecular medicine, 2000, Volume: 5, Issue:4

    Topics: Aged; Antineoplastic Agents; Biological Transport, Active; Bryostatins; Carrier Proteins; Cladribine; Deoxycytidine Kinase; Dipyridamole; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Male; Membrane Proteins; Nucleoside Transport Proteins; Phosphorylation; Thioinosine; Tumor Cells, Cultured; Vidarabine

2000
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Leukemia, 2000, Volume: 14, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine

2000
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Factor Analysis, Statistical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Regression Analysis; Survival Analysis; Vidarabine

2000
Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:1-2

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Vidarabine

2000
New treatment protocol including lympholytic and antiretroviral drugs to inhibit murine AIDS.
    Journal of acquired immune deficiency syndromes (1999), 2000, Feb-01, Volume: 23, Issue:2

    Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Flow Cytometry; Mice; Murine Acquired Immunodeficiency Syndrome; Vidarabine; Viral Load; Zidovudine

2000
Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia.
    Human reproduction (Oxford, England), 2000, Volume: 15, Issue:4

    Topics: Antineoplastic Agents; DNA Damage; Female; Follicle Stimulating Hormone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Luteinizing Hormone; Male; Middle Aged; Oligospermia; Spermatozoa; Testicular Diseases; Testis; Testosterone; Time Factors; Vidarabine

2000
Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes.
    Cytometry, 2000, May-01, Volume: 40, Issue:1

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Membrane; DNA Fragmentation; Flow Cytometry; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Phosphatidylserines; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Vidarabine

2000
Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias
    British journal of haematology, 2000, Volume: 108, Issue:3

    Topics: Antineoplastic Agents; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2000
[The heart in air].
    La Revue de medecine interne, 2000, Volume: 21, Issue:3

    Topics: Aged; Antineoplastic Agents; Cardiac Tamponade; Fatal Outcome; Humans; Lymphoma; Male; Pericardiocentesis; Pneumopericardium; Rupture, Spontaneous; Stomach Ulcer; Tomography, X-Ray Computed; Vidarabine

2000
Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.
    Leukemia, 2000, Volume: 14, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Vidarabine

2000
Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia.
    Leukemia, 2000, Volume: 14, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Cladribine; Comorbidity; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pentostatin; Prednisolone; Prognosis; Staining and Labeling; Tumor Cells, Cultured; Vidarabine; Vincristine

2000
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia.
    Leukemia, 2000, Volume: 14, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Cells; Bone Marrow Cells; DNA Primers; DNA, Neoplasm; Gene Duplication; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Hodgkin Disease; Humans; Immunization, Passive; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Oligonucleotide Probes; Polymerase Chain Reaction; Reference Standards; Rituximab; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine

2000
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
    Blood, 2000, May-01, Volume: 95, Issue:9

    Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Prednisolone; Probability; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Survival Analysis; Time Factors; Vidarabine

2000
Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines.
    Journal of cancer research and clinical oncology, 2000, Volume: 126, Issue:4

    Topics: Antineoplastic Agents, Alkylating; DNA Repair; Drug Interactions; Guanine; Humans; Lung Neoplasms; Platinum Compounds; Tumor Cells, Cultured; Vidarabine

2000
Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage.
    International journal of molecular medicine, 2000, Volume: 5, Issue:6

    Topics: Antineoplastic Agents; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; DNA Damage; Gemcitabine; Thymidine; Tumor Suppressor Protein p53; Vidarabine

2000
An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:2A

    Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Lineage; Cyclophosphamide; Disease Models, Animal; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cells; Histocompatibility; Immunosuppressive Agents; Lymphocyte Depletion; Mice; Mice, Inbred C57BL; Transplantation Chimera; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2000
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Bone marrow transplantation, 2000, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Life Tables; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2000
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
    British journal of haematology, 2000, Volume: 109, Issue:2

    Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Administration Schedule; Enzyme Inhibitors; Gemcitabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Ribonucleotide Reductases; Vidarabine

2000
Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia.
    American journal of hematology, 2000, Volume: 64, Issue:3

    Topics: Antineoplastic Agents; Female; Hepatitis B virus; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Vidarabine; Virus Activation; Virus Replication

2000
Cryptococcal infection associated with fludarabine therapy.
    The American journal of medicine, 2000, Apr-15, Volume: 108, Issue:6

    Topics: Antineoplastic Agents; CD4-CD8 Ratio; Cryptococcosis; Fatal Outcome; Fungemia; Humans; Immunocompromised Host; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine

2000
Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation.
    Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:3

    Topics: Adult; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Vidarabine

1999
Fludarabine and high dose cytarabine (FLA): a well tolerated salvage regimen in acute myeloid leukaemia.
    Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:4

    Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Vidarabine

1999
Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
    Seminars in oncology, 2000, Volume: 27, Issue:2 Suppl 5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Pentostatin; Sezary Syndrome; Survival Rate; Vidarabine

2000
[Efficacy of fludarabine in the treatment of angioimmunoblastic lymphoma (AIL)].
    Annales de medecine interne, 2000, Volume: 151, Issue:3

    Topics: Humans; Immunoblastic Lymphadenopathy; Immunosuppressive Agents; Male; Middle Aged; Remission Induction; Vidarabine

2000
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
    Haematologica, 2000, Volume: 85, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Infant, Newborn; Leukemia; Leukemia, Myeloid, Acute; Lung Diseases; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Distress Syndrome, Newborn; Staphylococcal Infections; Vidarabine

2000
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
    Experimental hematology, 2000, Volume: 28, Issue:7

    Topics: Adult; Antineoplastic Agents; Arthritis, Psoriatic; Autoimmunity; Busulfan; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Psoriasis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine

2000
Fludarabine induced intestinal pseudo-obstruction: case report and literature review.
    European journal of gastroenterology & hepatology, 2000, Volume: 12, Issue:6

    Topics: Aged; Antineoplastic Agents; Humans; Intestinal Pseudo-Obstruction; Lymphoma, Non-Hodgkin; Male; Radiography; Vidarabine

2000
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
    Bone marrow transplantation, 2000, Volume: 26, Issue:2

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Male; Middle Aged; Neoplasms; Nuclear Family; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2000
A brief history of the brief history of low-dose transplants.
    Journal of the National Cancer Institute, 2000, Aug-02, Volume: 92, Issue:15

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; History, 20th Century; Humans; Immunosuppressive Agents; Neoplasms; United States; Vidarabine

2000
Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia.
    British journal of haematology, 2000, Volume: 109, Issue:4

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Membrane; Cell Size; Cells, Cultured; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2000
Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine.
    Clinical and laboratory haematology, 2000, Volume: 22, Issue:3

    Topics: Antineoplastic Agents; Autoantibodies; Autoimmunity; Contusions; Hemophilia A; Hemorrhage; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine

2000
Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders.
    Clinical and laboratory haematology, 2000, Volume: 22, Issue:3

    Topics: Adult; Aged; Anemia, Hemolytic; Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Male; Purpura, Thrombocytopenic, Idiopathic; Vidarabine

2000
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
    Leukemia, 2000, Volume: 14, Issue:8

    Topics: Antineoplastic Agents; DNA Fragmentation; DNA Repair; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; RNA, Neoplasm; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine

2000
Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
    Haematologica, 2000, Volume: 85, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium; Calcium Channel Blockers; Calcium Signaling; Chlorambucil; Cisplatin; Cladribine; Cyclosporine; DNA Fragmentation; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nifedipine; Prednisolone; Tumor Cells, Cultured; Verapamil; Vidarabine; Vincristine

2000
Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
    Cancer research, 2000, Aug-01, Volume: 60, Issue:15

    Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Membrane; Cell Size; Cladribine; DNA Fragmentation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tumor Suppressor Protein p53; Vidarabine

2000
What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
    Seminars in oncology, 2000, Volume: 27, Issue:4

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Treatment Failure; Vidarabine

2000
Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone.
    The British journal of dermatology, 2000, Volume: 143, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Mitoxantrone; Panniculitis; Skin Neoplasms; Vidarabine

2000
Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia.
    Annals of hematology, 2000, Volume: 79, Issue:7

    Topics: Administration, Oral; Antineoplastic Agents; Biopsy; Brain; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Stereotaxic Techniques; Vidarabine

2000
CD8 expression on B cells in chronic lymphocytic leukemia: a case report and review of the literature.
    Archives of pathology & laboratory medicine, 2000, Volume: 124, Issue:9

    Topics: Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Bone Marrow Cells; CD5 Antigens; CD8 Antigens; Fatal Outcome; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, IgE; Vidarabine

2000
Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring.
    Haematologica, 2000, Volume: 85, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Treatment Outcome; Vidarabine

2000
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation.
    Haematologica, 2000, Volume: 85, Issue:9

    Topics: Antineoplastic Agents; B-Lymphocytes; Clone Cells; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Transplantation, Autologous; Vidarabine

2000
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
    Bone marrow transplantation, 2000, Volume: 26, Issue:4

    Topics: Adult; Anemia, Sickle Cell; Fatal Outcome; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Nuclear Family; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2000
Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes.
    FEBS letters, 2000, Sep-15, Volume: 481, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antiviral Agents; Carrier Proteins; Cytidine; Deoxycytidine; Electric Conductivity; Gemcitabine; Gene Expression; Humans; Membrane Potentials; Membrane Proteins; Nucleoside Transport Proteins; Nucleosides; Oocytes; Sodium; Substrate Specificity; Uridine; Vidarabine; Xenopus laevis

2000
[Fludarabine treatment of chronic lymphoid leukemia].
    Terapevticheskii arkhiv, 2000, Volume: 72, Issue:8

    Topics: Adult; Antineoplastic Agents; Bone Marrow; Disease Progression; Female; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Retrospective Studies; Vidarabine

2000
Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin's lymphoma.
    Haematologica, 2000, Volume: 85, Issue:10

    Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Acute; Neoplasms, Second Primary; Translocation, Genetic; Vidarabine

2000
Concomitant presentation of Hashimoto's thyroiditis and maltoma of the thyroid in a twenty-year-old man with a rapidly growing mass in the neck.
    Thyroid : official journal of the American Thyroid Association, 2000, Volume: 10, Issue:9

    Topics: Adult; Antineoplastic Agents; Autoantibodies; Humans; Iodide Peroxidase; Lymphoma, B-Cell, Marginal Zone; Male; Thyroglobulin; Thyroid Neoplasms; Thyroidectomy; Thyroiditis, Autoimmune; Thyrotropin; Thyroxine; Triiodothyronine; Vidarabine

2000
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.
    Journal of chromatography. B, Biomedical sciences and applications, 2000, Aug-18, Volume: 745, Issue:2

    Topics: Arabinonucleotides; Calibration; Chromatography, High Pressure Liquid; Guanosine Triphosphate; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tumor Cells, Cultured; Vidarabine

2000
Sight-threatening varicella zoster virus infection after fludarabine treatment.
    British journal of haematology, 2000, Volume: 110, Issue:4

    Topics: Acyclovir; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Eye Infections, Viral; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Lymphoma, Follicular; Male; Middle Aged; Polymerase Chain Reaction; Retinal Necrosis Syndrome, Acute; Vidarabine; Waldenstrom Macroglobulinemia

2000
Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia.
    Haematologica, 2000, Volume: 85, Issue:11

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine

2000
Fludarabine therapy in chronic lymphocytic leukemia-associated severe nephrotic syndrome.
    Haematologica, 2000, Volume: 85, Issue:11

    Topics: Antineoplastic Agents; Diagnosis, Differential; Female; Glomerulonephritis, Membranous; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nephrotic Syndrome; Proteinuria; Remission Induction; Treatment Outcome; Vidarabine

2000
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.
    Blood, 2000, Nov-15, Volume: 96, Issue:10

    Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Arabinonucleosides; B-Lymphocytes; Cell Survival; Cladribine; Clofarabine; Comet Assay; Deoxyadenosines; DNA Damage; DNA, Mitochondrial; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Potentials; Microinjections; Mitochondria; Time Factors; Tumor Cells, Cultured; Vidarabine

2000
Fludarabine therapy in Waldenström's macroglobulinemia.
    Annals of hematology, 2000, Volume: 79, Issue:10

    Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Therapeutic Equivalency; Vidarabine; Waldenstrom Macroglobulinemia

2000
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
    Cancer research, 2000, Nov-15, Volume: 60, Issue:22

    Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Caspases; DNA; DNA Damage; Enzyme Activation; Humans; Leukemia, Myeloid; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; S Phase; Tumor Cells, Cultured; U937 Cells; Vidarabine; Vidarabine Phosphate

2000
[Cryptococcus neoformans infection in hematologic malignancies].
    La Revue de medecine interne, 2000, Volume: 21, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Cryptococcus neoformans; Female; France; Hematologic Neoplasms; Humans; Immunity, Cellular; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Vidarabine

2000
Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Haematologica, 2000, Volume: 85, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine

2000
When and how to treat chronic lymphocytic leukemia.
    The New England journal of medicine, 2000, Dec-14, Volume: 343, Issue:24

    Topics: Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Vidarabine

2000
Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells.
    Toxicology, 2000, Nov-23, Volume: 154, Issue:1-3

    Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Caspase 3; Caspase Inhibitors; Caspases; Ceramides; Chromatography, Thin Layer; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fumonisins; Glutathione; Humans; Image Processing, Computer-Assisted; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylserines; Sphingomyelins; Tumor Cells, Cultured; Vidarabine

2000
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic l
    British journal of haematology, 2000, Volume: 111, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Clone Cells; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Vidarabine

2000
The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.
    British journal of clinical pharmacology, 2000, Volume: 50, Issue:6

    Topics: Anti-HIV Agents; Cell Survival; Cytidine Triphosphate; Deoxycytosine Nucleotides; Dideoxynucleotides; Drug Interactions; Humans; Hydroxyurea; Lamivudine; Methotrexate; Phosphorylation; Tumor Cells, Cultured; Vidarabine

2000
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma.
    Leukemia research, 2001, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Chromosome Aberrations; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Myelodysplastic Syndromes; Vidarabine

2001
[Progressive multifocal leukoencephalopathy in a patient with chronic lymphatic leukemia treated with fludarabine].
    Medicina clinica, 2000, Nov-04, Volume: 115, Issue:15

    Topics: Aged; Antineoplastic Agents; Biopsy; Brain; Diagnosis, Differential; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Vidarabine

2000
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2000
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
    Haematologica, 2001, Volume: 86, Issue:1

    Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Topotecan; Vidarabine

2001
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.
    British journal of haematology, 2000, Volume: 111, Issue:4

    Topics: Child, Preschool; Cyclophosphamide; Fanconi Anemia; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lymphocyte Depletion; Male; Recombinant Proteins; T-Lymphocytes; Tacrolimus; Vidarabine

2000
Red swollen nail folds and nail deformity as presenting findings in chronic lymphocytic leukaemia.
    British journal of haematology, 2001, Volume: 112, Issue:1

    Topics: Aged; Antineoplastic Agents; Fingers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Nails; Nails, Malformed; Skin; Toes; Vidarabine

2001
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment.
    British journal of haematology, 2001, Volume: 112, Issue:2

    Topics: Adult; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Recombinant Proteins; Remission Induction; Time Factors; Vidarabine

2001
Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation.
    British journal of haematology, 2001, Volume: 112, Issue:2

    Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Immunosuppressive Agents; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment.
    British journal of haematology, 2001, Volume: 112, Issue:2

    Topics: Female; Humans; Immunosuppressive Agents; Middle Aged; Red-Cell Aplasia, Pure; Vidarabine

2001
Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT.
    Bone marrow transplantation, 2000, Volume: 26, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Graft Rejection; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vidarabine

2000
Reactivation of hepatitis B virus infection during cytotoxic chemotherapy.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:2

    Topics: Acute Disease; Aged; Antineoplastic Agents; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine

2001
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:2

    Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Arabinonucleotides; Blotting, Western; Drug Interactions; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Lymphoma; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Staurosporine; U937 Cells; Vidarabine

2001
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
    Leukemia, 2001, Volume: 15, Issue:1

    Topics: Adult; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; HL-60 Cells; Humans; Hydroxyurea; Leukemia; Vidarabine

2001
Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.
    British journal of haematology, 2001, Volume: 112, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD4-Positive T-Lymphocytes; Cells, Cultured; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2001
Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
    Blood, 2001, Apr-01, Volume: 97, Issue:7

    Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Clone Cells; Cyclophosphamide; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Immunoglobulin Heavy Chains; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Lymph Nodes; Neoplasm Proteins; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction; Sensitivity and Specificity; Treatment Outcome; Vidarabine

2001
New drug combinations for the treatment of murine AIDS and macrophage protection.
    European journal of clinical investigation, 2001, Volume: 31, Issue:3

    Topics: Animals; Anti-HIV Agents; Antiviral Agents; Drug Combinations; Female; Macrophages; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Vidarabine; Zidovudine

2001
Immunoablation followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune disease.
    Haematologica, 2000, Volume: 85, Issue:11 Suppl

    Topics: Adolescent; Adult; Antilymphocyte Serum; Autoimmune Diseases; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation, Autologous; Treatment Outcome; Vidarabine

2000
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.
    Experimental hematology, 2001, Volume: 29, Issue:3

    Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cell Count; Child; Cohort Studies; Disease-Free Survival; Female; Graft Survival; Histocompatibility; Humans; Leukemia; Life Tables; Lymphoma, Large-Cell, Anaplastic; Male; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
    American journal of hematology, 2001, Volume: 66, Issue:4

    Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Methotrexate; Middle Aged; Neural Tube Defects; Program Evaluation; Recurrence; Survival Analysis; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001
Fludarabine in the treatment of an active phase of a familial haemophagocytic lymphohistiocytosis.
    Archives of disease in childhood, 2001, Volume: 84, Issue:4

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; Histiocytosis, Non-Langerhans-Cell; Humans; Infant; Male; Remission Induction; Vidarabine

2001
A fludarabine-based conditioning regimen for severe aplastic anemia.
    Bone marrow transplantation, 2001, Volume: 27, Issue:2

    Topics: Anemia, Aplastic; Child; Child, Preschool; Combined Modality Therapy; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Transplantation Chimera; Transplantation, Homologous; Vidarabine

2001
Fludarabine for chronic lymphocytic leukemia.
    The New England journal of medicine, 2001, Apr-12, Volume: 344, Issue:15

    Topics: Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Value of Life; Vidarabine

2001
Fludarabine for chronic lymphocytic leukemia.
    The New England journal of medicine, 2001, Apr-12, Volume: 344, Issue:15

    Topics: Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine

2001
Fludarabine for chronic lymphocytic leukemia.
    The New England journal of medicine, 2001, Apr-12, Volume: 344, Issue:15

    Topics: Age Factors; Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Palliative Care; Remission Induction; Vidarabine

2001
Fludarabine for chronic lymphocytic leukemia.
    The New England journal of medicine, 2001, Apr-12, Volume: 344, Issue:15

    Topics: Antineoplastic Agents; Chlorambucil; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2001
Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.
    Bone marrow transplantation, 2001, Volume: 27, Issue:5

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.
    Bone marrow transplantation, 2001, Volume: 27, Issue:6

    Topics: Adult; Arthritis; Aspergillosis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Knee Joint; Male; Middle Aged; Vidarabine

2001
Fatal legionella pneumonia after fludarabine treatment in chronic lymphocytic leukaemia.
    Journal of clinical pathology, 2001, Volume: 54, Issue:5

    Topics: Antineoplastic Agents; Fatal Outcome; Humans; Immunocompromised Host; Legionnaires' Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Vidarabine

2001
[Molecular biology examination in chronic lymphocytic leukemia].
    Orvosi hetilap, 2001, Apr-22, Volume: 142, Issue:16

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Time Factors; Vidarabine

2001
Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.
    Leukemia & lymphoma, 2000, Volume: 39, Issue:5-6

    Topics: Antineoplastic Agents; Cytotoxicity, Immunologic; DNA, Antisense; Down-Regulation; Drug Resistance, Neoplasm; Genes, bcl-2; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine

2000
Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 2001, Volume: 41, Issue:1-2

    Topics: Actuarial Analysis; Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vidarabine

2001
Reversal of fludarabine induced testicular damage in a patient with chronic lymphocytic leukaemia (CLL), by suppression of pituitary-testicular axis using gonadotrophin releasing hormone (GnRH).
    Leukemia & lymphoma, 2001, Volume: 41, Issue:1-2

    Topics: Antineoplastic Agents; Endocrine System; Gonadotropin-Releasing Hormone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pituitary Gland; Sperm Count; Testicular Diseases; Testis; Testosterone; Vidarabine

2001
Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.
    International journal of hematology, 2001, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells.
    Biochemical pharmacology, 2001, Jul-01, Volume: 62, Issue:1

    Topics: Antineoplastic Agents; Cytarabine; DNA Replication; DNA, Neoplasm; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine

2001
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
    Experimental hematology, 2001, Volume: 29, Issue:6

    Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Multiple; Genes, bcl-2; Humans; Interleukin-4; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Prednisone; Proto-Oncogene Proteins c-bcl-2; Spleen; Staurosporine; Thymus Gland; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine

2001
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
    Leukemia & lymphoma, 2001, Volume: 41, Issue:3-4

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine

2001
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
    Acta haematologica, 2001, Volume: 105, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine

2001
Paraneoplastic pemphigus: an association with fludarabine?
    The British journal of dermatology, 2001, Volume: 144, Issue:6

    Topics: Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Fluorescent Antibody Technique; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine

2001
Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.
    Leukemia & lymphoma, 2001, Volume: 40, Issue:5-6

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Leukemia, Myeloid; Lymphoma; Neoplasms, Multiple Primary; Remission Induction; Vidarabine

2001
Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Prognosis; Retrospective Studies; Survival Analysis; Thymidine Kinase; Treatment Outcome; Vidarabine

2001
Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine.
    Onkologie, 2001, Volume: 24, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Synergism; Female; Humans; Killer Cells, Natural; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prognosis; Treatment Outcome; Vidarabine

2001
[Chronic lymphatic leukemia. 3. The concrete case].
    Deutsche medizinische Wochenschrift (1946), 2001, Jun-08, Volume: 126, Issue:23

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Prognosis; Vidarabine

2001
Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
    British journal of haematology, 2001, Volume: 114, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Drug Resistance, Neoplasm; Flavonoids; Flow Cytometry; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Piperidines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine

2001
Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?
    Transplantation, 2001, Jul-27, Volume: 72, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenograstim; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nuclear Family; Psoriasis; Recombinant Proteins; T-Lymphocyte Subsets; Transplantation Chimera; Vidarabine

2001
Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning.
    Bone marrow transplantation, 2001, Volume: 28, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Family Health; Female; Graft Survival; Humans; Immunophenotyping; Infant; Lymphocyte Activation; Metabolism, Inborn Errors; Pregnancy; Purine-Nucleoside Phosphorylase; T-Lymphocytes; Transplantation Conditioning; Transplantation, Isogeneic; Vidarabine

2001
Acute left ventricular failure following melphalan and fludarabine conditioning.
    Bone marrow transplantation, 2001, Volume: 28, Issue:1

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Homologous; Ventricular Dysfunction, Left; Vidarabine

2001
Unrelated cord blood transplantation in a Fanconi anemia patient using fludarabine-based conditioning.
    Bone marrow transplantation, 2001, Volume: 28, Issue:1

    Topics: Antineoplastic Agents; Child, Preschool; Fanconi Anemia; Female; Fetal Blood; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine

2001
Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.
    Bone marrow transplantation, 2001, Volume: 28, Issue:2

    Topics: Adult; Chediak-Higashi Syndrome; Cyclosporine; Fatal Outcome; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; T-Lymphocytes; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Failure; Vidarabine; Whole-Body Irradiation

2001
Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.
    International journal of hematology, 2001, Volume: 74, Issue:1

    Topics: Adenoviridae Infections; Adenoviruses, Human; Antilymphocyte Serum; Bronchoalveolar Lavage Fluid; Busulfan; Cystitis; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Methylprednisolone; Middle Aged; Pneumonia, Viral; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
    Bone marrow transplantation, 2001, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studies; Cell Culture Techniques; Child; Child, Preschool; Cytotoxicity, Immunologic; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Infections; Killer Cells, Lymphokine-Activated; Lymphocyte Activation; Male; Middle Aged; Phytohemagglutinins; T-Lymphocyte Subsets; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin's lymphoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2001, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Vidarabine

2001
Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis.
    Journal of neuropathology and experimental neurology, 2001, Volume: 60, Issue:9

    Topics: Adult; Antineoplastic Agents; Apoptosis; Biopsy; Cathepsin B; Cathepsin L; Cathepsins; Cell Cycle; Cells, Cultured; Cysteine Endopeptidases; Dermatomyositis; DNA Primers; DNA-Binding Proteins; Gene Expression; Humans; Immunohistochemistry; Interferon-gamma; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Regeneration; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Trans-Activators; Vidarabine

2001
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
    British journal of haematology, 2001, Volume: 114, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Northern; Cisplatin; Complement System Proteins; Cytotoxicity Tests, Immunologic; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vidarabine

2001
Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.
    Leukemia, 2001, Volume: 15, Issue:10

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Antineoplastic Agents; Apoptosis; Caspases; Cyclic Nucleotide Phosphodiesterases, Type 4; Down-Regulation; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rolipram; Tumor Cells, Cultured; Vidarabine

2001
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
    Cancer, 2001, Oct-15, Volume: 92, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Survival Analysis; Topotecan; Vidarabine

2001
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.
    Annals of hematology, 2001, Volume: 80, Issue:9

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001
Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report.
    Annals of hematology, 2001, Volume: 80, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rituximab; Vidarabine; Virus Activation

2001
Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:4

    Topics: Adult; Autoantibodies; Factor VIII; Female; Hemorrhagic Disorders; Humans; Interferon-alpha; Male; Middle Aged; Neoplasms; Partial Thromboplastin Time; Vidarabine

2001
Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease.
    Haematologica, 2001, Volume: 86, Issue:11

    Topics: Antineoplastic Agents; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Salvage Therapy; Transplantation, Homologous; Vidarabine

2001
Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Haematologica, 2001, Volume: 86, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Retrospective Studies; Treatment Outcome; Vidarabine; Vincristine

2001
Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intensity conditioning regimens.
    Leukemia & lymphoma, 2001, Volume: 42, Issue:1-2

    Topics: Adolescent; Adult; Antigens, CD34; Blood Cell Count; Child; Child, Preschool; Female; Graft Survival; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Male; Middle Aged; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia.
    Leukemia & lymphoma, 2001, Volume: 42, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cyclophosphamide; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Male; Pancytopenia; Prednisone; Red-Cell Aplasia, Pure; Rituximab; Treatment Outcome; Vidarabine; Vincristine

2001
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell Count; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Karyotyping; Methotrexate; Middle Aged; Monosomy; Myelodysplastic Syndromes; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2001
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:11

    Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Arabinonucleotides; Clofarabine; Cyclophosphamide; DNA; DNA Repair; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nucleosides; Time Factors; Vidarabine

2001
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
    Blood, 2001, Dec-01, Volume: 98, Issue:12

    Topics: Animals; Cyclophosphamide; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Immunosuppressive Agents; Mice; Mice, Inbred AKR; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; T-Lymphocytes, Cytotoxic; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2001
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
    British journal of haematology, 2001, Volume: 115, Issue:1

    Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine

2001
Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.
    British journal of haematology, 2001, Volume: 115, Issue:3

    Topics: Adolescent; Adult; Aged; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Karyotyping; Lymphoproliferative Disorders; Male; Middle Aged; Prognosis; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
    Leukemia, 2001, Volume: 15, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitric Oxide; Triazenes; Vidarabine

2001
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
    Blood, 2002, Jan-01, Volume: 99, Issue:1

    Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome.
    Blood, 2002, Jan-15, Volume: 99, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Cyclophosphamide; Cyclosporine; Feasibility Studies; Ganciclovir; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infection Control; Leukemia, Myeloid; Prednisone; Premedication; Recurrence; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine; Viral Load

2002
Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure.
    Bone marrow transplantation, 2001, Volume: 28, Issue:8

    Topics: Adult; Anabolic Agents; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Cyclosporine; Diabetes Complications; Female; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Iron Overload; Methylprednisolone; T-Lymphocytes; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2001
Analysis of recurrent failure times data: should the baseline hazard be stratified?
    Statistics in medicine, 2001, Dec-30, Volume: 20, Issue:24

    Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rhinitis; Treatment Failure; Vidarabine

2001
Evidence of inhibition of DNA methylation by fludarabine.
    Advances in experimental medicine and biology, 2000, Volume: 486

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cell Line; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Vidarabine

2000
Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease.
    Experimental hematology, 2002, Volume: 30, Issue:1

    Topics: Adult; Anemia, Sickle Cell; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes.
    Toxicology, 2002, Feb-28, Volume: 171, Issue:2-3

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cells, Cultured; Chromosome Aberrations; DNA Fragmentation; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Idarubicin; Lymphocytes; Mutagens; Vidarabine

2002
Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
    Haematologica, 2002, Volume: 87, Issue:2

    Topics: 2-Chloroadenosine; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium Channel Blockers; Chlorambucil; Deoxyadenosines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Palatine Tonsil; Protein Kinase C; Staurosporine; Tumor Cells, Cultured; Verapamil; Vidarabine

2002
Hematopoietic cell transplantation beyond first remission.
    Leukemia, 2002, Volume: 16, Issue:2

    Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Nuclear Family; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndrome.
    British journal of haematology, 2002, Volume: 116, Issue:2

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cyclophosphamide; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Penicillin V; Transplantation Chimera; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine; Wiskott-Aldrich Syndrome

2002
Toxoplasmic encephalitis in a non-HIV patient with follicular lymphoma.
    International journal of hematology, 2002, Volume: 75, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Interferon-alpha; Lymphoma, Follicular; Opportunistic Infections; Prednisone; Salvage Therapy; Teniposide; Toxoplasmosis, Cerebral; Vidarabine

2002
Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.
    British journal of haematology, 2001, Volume: 115, Issue:4

    Topics: Adult; Aged; Bone Marrow Cells; Busulfan; Cell Count; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2001
Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
    Journal of leukocyte biology, 2002, Volume: 71, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; bcl-X Protein; Drug Resistance, Neoplasm; Female; Fibronectins; Humans; Integrin alpha4beta1; Integrins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Peptide Fragments; Proto-Oncogene Proteins c-bcl-2; Receptors, Lymphocyte Homing; Tumor Cells, Cultured; Vidarabine

2002
[Lupus nephritis: treatments for today and tomorrow].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2001, Volume: 21, Issue:6

    Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal; Bone Marrow Transplantation; CD40 Ligand; Cladribine; Drug Administration Schedule; Drug Therapy, Combination; Forecasting; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid; Oligonucleotides; Plasmapheresis; Vidarabine

2001
High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma.
    British journal of haematology, 2002, Volume: 116, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine

2002
CD80 antigen expression as a predictor of ex vivo chemosensitivity in chronic lymphocytic leukemia.
    Leukemia research, 2002, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; B7-1 Antigen; Deoxyadenosines; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2002
Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.
    The hematology journal : the official journal of the European Haematology Association, 2000, Volume: 1, Issue:6

    Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Vidarabine

2000
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Cancer, 2002, Apr-01, Volume: 94, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Retrospective Studies; Risk Factors; Survival Rate; Vidarabine

2002
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
    European journal of haematology, 2002, Volume: 68, Issue:1

    Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine

2002
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
    The American journal of surgical pathology, 2002, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Ribosomal Proteins; RNA-Binding Proteins; Vidarabine

2002
Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
    Bone marrow transplantation, 2002, Volume: 29, Issue:7

    Topics: Adult; Cohort Studies; Disease Progression; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Recurrence; Retrospective Studies; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2002
Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.
    American journal of hematology, 2002, Volume: 70, Issue:1

    Topics: 2-Chloroadenosine; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nucleosides; Vidarabine

2002
Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.
    American journal of hematology, 2002, Volume: 70, Issue:1

    Topics: Aged; Antineoplastic Agents; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine

2002
Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:2

    Topics: Aged; Cladribine; Drug Evaluation; Humans; Immunoglobulin M; Immunosuppressive Agents; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2002
Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:2

    Topics: Aged; Diagnosis, Differential; DNA, Viral; Humans; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Polymerase Chain Reaction; Vidarabine

2002
Membranoproliferative glomerulonephritis in association with chronic lymphocytic leukaemia: a report of three cases.
    Pathology, 2002, Volume: 34, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Chlorambucil; Drug Therapy, Combination; Female; Glomerular Mesangium; Glomerulonephritis, Membranoproliferative; Humans; Kidney Glomerulus; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Fluorescence; Middle Aged; Paraproteinemias; Prednisolone; Treatment Outcome; Vidarabine

2002
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Cancer, 2002, May-01, Volume: 94, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Renal Cell; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Pilot Projects; Sarcoma; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
    Annals of hematology, 2002, Volume: 81, Issue:5

    Topics: Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Computer Systems; DNA, Neoplasm; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Cells, Circulating; Polymerase Chain Reaction; Rituximab; Vidarabine

2002
Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
    Haematologica, 2002, Volume: 87, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Staining and Labeling; Survival Analysis; Vidarabine

2002
Inhibition of nucleotide excision repair by fludarabine in normal lymphocytes in vitro, measured by the alkaline single cell gel electrophoresis (Comet) assay.
    Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:5

    Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Comet Assay; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Kinetics; Lymphocytes; Time Factors; Ultraviolet Rays; Vidarabine

2002
Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication?
    European journal of haematology, 2002, Volume: 68, Issue:2

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Follow-Up Studies; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasms, Second Primary; Rituximab; Time Factors; Vidarabine

2002
Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Leukemia, 2002, Volume: 16, Issue:6

    Topics: Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Chlorambucil; Cladribine; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine

2002
Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.
    European journal of haematology, 2002, Volume: 68, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Carcinoma, Merkel Cell; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Rituximab; Salvage Therapy; Vidarabine

2002
Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide.
    Blood, 2002, Jul-01, Volume: 100, Issue:1

    Topics: Apoptosis; Cytotoxicity Tests, Immunologic; Drug Interactions; Endothelium, Vascular; Epithelial Cells; Humans; Immunity; Intercellular Adhesion Molecule-1; Leukocytes; Polydeoxyribonucleotides; Protective Agents; Tumor Cells, Cultured; Vidarabine

2002
Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells.
    Oncogene, 2002, Jul-04, Volume: 21, Issue:29

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Blotting, Western; Cell Line; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Humans; Polymerase Chain Reaction; Protein Binding; RNA, Messenger; STAT1 Transcription Factor; Trans-Activators; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine

2002
Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine.
    Haematologica, 2002, Volume: 87, Issue:7

    Topics: Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Male; Middle Aged; Opportunistic Infections; Time Factors; Vidarabine

2002
Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning.
    British journal of haematology, 2002, Volume: 118, Issue:1

    Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Lymphoma, B-Cell; Middle Aged; Multiple Myeloma; Remission Induction; Reoperation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2002
Cast nephropathy in a case of Waldenström's macroglobulinemia.
    Nephron, 2002, Volume: 91, Issue:3

    Topics: Aged; Biopsy; Female; Humans; Immunoglobulin A; Immunohistochemistry; Immunosuppressive Agents; Kidney Diseases; Kidney Glomerulus; Renal Dialysis; Vidarabine; Waldenstrom Macroglobulinemia

2002
[Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2002, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Transplantation Conditioning; Transplantation Tolerance; Vidarabine

2002
Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
    The Netherlands journal of medicine, 2002, Volume: 60, Issue:4

    Topics: Adult; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine

2002
Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.
    Blood, 2002, Sep-01, Volume: 100, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Count; Cyclophosphamide; Dexamethasone; Enzyme Activation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; Mitoxantrone; Protein Conformation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine

2002
Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.
    Molecular pharmacology, 2002, Volume: 62, Issue:3

    Topics: Alkaloids; CDC2-CDC28 Kinases; cdc25 Phosphatases; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA Damage; Enzyme Activation; Enzyme Inhibitors; Humans; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Vidarabine

2002
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation.
    Cytotherapy, 2002, Volume: 4, Issue:3

    Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
    Leukemia, 2002, Volume: 16, Issue:9

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Case-Control Studies; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Ribonucleotide Reductases; Vidarabine

2002
Fludarabine treatment of cryoglobulinemic glomerulonephritis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 40, Issue:3

    Topics: Adult; Cryoglobulinemia; Disease-Free Survival; Fatal Outcome; Female; Follow-Up Studies; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; RNA, Viral; Vidarabine; Viral Load

2002
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.
    Journal of hematotherapy & stem cell research, 2002, Volume: 11, Issue:4

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Agents; Dendritic Cells; Flow Cytometry; Fluorescent Antibody Technique; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Neoplasms; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Vidarabine

2002
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
    American journal of hematology, 2002, Volume: 71, Issue:1

    Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine

2002
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.
    Chest, 2002, Volume: 122, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cause of Death; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Interstitial; Lymphoproliferative Disorders; Male; Middle Aged; Risk Factors; Vidarabine

2002
Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin.
    Bone marrow transplantation, 2002, Volume: 30, Issue:6

    Topics: Adolescent; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoiesis; Histocompatibility; Humans; Immunosuppressive Agents; Male; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia.
    European journal of haematology, 2002, Volume: 69, Issue:1

    Topics: Antineoplastic Agents; Antiviral Agents; Cyclophosphamide; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Respiratory Syncytial Virus Infections; Ribavirin; Vidarabine

2002
The triterpenoid CDDO induces apoptosis in refractory CLL B cells.
    Blood, 2002, Oct-15, Volume: 100, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Caspases; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitric Oxide; Oleanolic Acid; Vidarabine

2002
CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?
    American journal of hematology, 2002, Volume: 71, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Neoplasms, Second Primary; Time Factors; Vidarabine

2002
Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications.
    Clinical and laboratory haematology, 2002, Volume: 24, Issue:5

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Female; Fractures, Bone; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Intellectual Disability; Male; Methylprednisolone; Mycophenolic Acid; Obesity; Peripheral Blood Stem Cell Transplantation; Prednisolone; Remission Induction; Siblings; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2002
Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes.
    European journal of haematology, 2002, Volume: 69, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphocytes; Lymphoma; Remission Induction; Splenic Neoplasms; Vidarabine

2002
Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma.
    Annals of hematology, 2002, Volume: 81, Issue:9

    Topics: Antineoplastic Agents; Aortic Valve Stenosis; Female; Heart Failure; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Middle Aged; Pulmonary Eosinophilia; Vidarabine

2002
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Infections; Life Tables; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Spain; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; United Kingdom; Vidarabine

2002
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce dura
    Blood, 2003, Feb-15, Volume: 101, Issue:4

    Topics: Adult; Aged; Child; Cyclosporine; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Remission Induction; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2003
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.
    Blood, 2003, Jan-15, Volume: 101, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Homologous; Vidarabine

2003
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
    Blood, 2002, Dec-15, Volume: 100, Issue:13

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:8

    Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cecal Diseases; Colitis; Cytarabine; Cytomegalovirus Infections; Female; Humans; Middle Aged; Mitoxantrone; Vidarabine

2002
Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen.
    British journal of haematology, 2002, Volume: 119, Issue:2

    Topics: Antimetabolites; Child, Preschool; Cord Blood Stem Cell Transplantation; Dyskeratosis Congenita; Humans; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.
    Blood, 2003, Mar-15, Volume: 101, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adult; Aged; Aged, 80 and over; Biological Transport; Carrier Proteins; Cell Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Male; Melphalan; Membrane Transport Proteins; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured; Vidarabine

2003
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine.
    Haematologica, 2002, Volume: 87, Issue:11

    Topics: Female; Guillain-Barre Syndrome; Herpes Zoster; Herpesvirus 3, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine; Virus Activation

2002
Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.
    Bone marrow transplantation, 2002, Volume: 30, Issue:10

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2002
Haploidentical stem cell transplantation for acute leukemia.
    International journal of hematology, 2002, Volume: 76 Suppl 1

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Survival; Haplotypes; Histocompatibility; Humans; Killer Cells, Natural; Leukemia; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2002
Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
    British journal of haematology, 2002, Volume: 119, Issue:3

    Topics: Adult; Busulfan; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Severe hypoglycemia in a patient with acute renal failure due to tumor lysis syndrome.
    The Israel Medical Association journal : IMAJ, 2002, Volume: 4, Issue:9

    Topics: Acute Kidney Injury; Antineoplastic Agents; Female; Humans; Hypoglycemia; Leukemia, Lymphoid; Middle Aged; Severity of Illness Index; Tumor Lysis Syndrome; Vidarabine

2002
Repeated cycles of alternate administration of fludarabine and Zidovudine plus Didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels.
    Virology, 2002, Oct-25, Volume: 302, Issue:2

    Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Didanosine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Leukemia Virus, Murine; Lymph Nodes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Proviruses; Reverse Transcriptase Inhibitors; Treatment Outcome; Vidarabine; Zidovudine

2002
[Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia].
    Revue neurologique, 2002, Volume: 158, Issue:11

    Topics: Aged; Antineoplastic Agents; Biopsy; Brain; Chronic Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Polymerase Chain Reaction; Vidarabine

2002
Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
    Bone marrow transplantation, 2002, Volume: 30, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Factor VIIa; Fatal Outcome; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Acute; Lung Diseases; Pneumothorax; Pulmonary Alveoli; Recombinant Proteins; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2002
The effects of cladribine and fludarabine on DNA methylation in K562 cells.
    Biochemical pharmacology, 2003, Jan-15, Volume: 65, Issue:2

    Topics: Adenosine; Antineoplastic Agents; Cell Survival; Cladribine; CpG Islands; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Humans; K562 Cells; Tumor Cells, Cultured; Vidarabine

2003
Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
    Biochemical pharmacology, 2003, Jan-15, Volume: 65, Issue:2

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Cell Line; Cladribine; Clofarabine; Cytogenetics; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Leukemia; Phenotype; Phosphorylation; Ribonucleotide Reductases; Vidarabine

2003
[Successful treatment with fludarabine of chronic lymphocytic leukemia associated with nephrotic syndrome].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2002, Volume: 43, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nephrotic Syndrome; Vidarabine

2002
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Medical oncology (Northwood, London, England), 2002, Volume: 19, Issue:4

    Topics: Adenoviridae Infections; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

2002
Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission.
    British journal of haematology, 2003, Volume: 120, Issue:2

    Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Siblings; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2003
Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML.
    Haematologica, 2002, Volume: 87, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Stem Cell Transplantation; Vidarabine; Whole-Body Irradiation

2002
Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
    American journal of hematology, 2003, Volume: 72, Issue:2

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Histiocytosis, Non-Langerhans-Cell; Humans; Infant; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.
    Blood, 2003, Mar-01, Volume: 101, Issue:5

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cytomegalovirus; Cytomegalovirus Infections; Humans; Incidence; Melphalan; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation; Whole-Body Irradiation

2003
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
    Statistics in medicine, 2003, Mar-15, Volume: 22, Issue:5

    Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine

2003
Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity.
    British journal of haematology, 2003, Volume: 120, Issue:4

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, T-Cell; Male; Middle Aged; Neutropenia; Vidarabine

2003
The relevance of nonmyeloablative transplants in developing countries: lessons from the UK experience.
    Transplantation proceedings, 2003, Volume: 35, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cohort Studies; Cross-Cultural Comparison; Developing Countries; Graft vs Host Disease; Histocompatibility Testing; Humans; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; United Kingdom; Vidarabine

2003
[Whipple's disease as a complication of chronic lymphocytic leukemia treated with fludarabine].
    Polskie Archiwum Medycyny Wewnetrznej, 2002, Volume: 108, Issue:3

    Topics: Antineoplastic Agents; Fatal Outcome; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Vidarabine; Whipple Disease

2002
CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
    Haematologica, 2003, Volume: 88, Issue:2

    Topics: Aged; Aged, 80 and over; Apoptosis; Autocrine Communication; B-Lymphocytes; CD40 Antigens; CD40 Ligand; Female; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha; Up-Regulation; Vidarabine

2003
Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.
    Haematologica, 2003, Volume: 88, Issue:2

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine

2003
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.
    Annals of hematology, 2002, Volume: 81 Suppl 2

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; Survival Rate; Transplantation Conditioning; Vidarabine

2002
Facial paresis after fludarabine treatment for advanced chronic lymphocytic leukaemia.
    Haematologia, 2002, Volume: 32, Issue:3

    Topics: Aged; Facial Paralysis; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Shock, Septic; Vidarabine

2002
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
    Leukemia research, 2003, Volume: 27, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia

2003
Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.
    Bone marrow transplantation, 2003, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Aged; Breast Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2003
Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia.
    Bone marrow transplantation, 2003, Volume: 31, Issue:1

    Topics: Animals; Apoptosis; Crosses, Genetic; Cyclophosphamide; Drug Therapy, Combination; Graft vs Host Disease; Leukemia, B-Cell; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Skin; Spleen; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine

2003
Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
    Acta haematologica, 2003, Volume: 109, Issue:2

    Topics: Antineoplastic Agents; Female; Humans; Hypergammaglobulinemia; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Middle Aged; Remission Induction; Vidarabine

2003
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Journal of experimental & clinical cancer research : CR, 2002, Volume: 21, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine

2002
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
    Blood, 2003, Jul-15, Volume: 102, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2003
Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC).
    Haematologica, 2003, Volume: 88, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Treatment Outcome; Vidarabine

2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Cancer, 2003, Apr-01, Volume: 97, Issue:7

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubicin; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Vidarabine; Vincristine

2003
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
    Blood, 2003, Jul-15, Volume: 102, Issue:2

    Topics: Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Intestines; Life Tables; Liver; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Organ Specificity; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Severity of Illness Index; Skin; Survival Analysis; Time Factors; Tissue Donors; Transplantation Conditioning; Vidarabine; Washington; Whole-Body Irradiation

2003
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-01, Volume: 21, Issue:7

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pentostatin; Thrombocytopenia; Treatment Outcome; Vidarabine

2003
Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation.
    Bone marrow transplantation, 2003, Volume: 31, Issue:6

    Topics: Child; Fanconi Anemia; Female; Haploidy; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2003
Bilateral orbital masses in a patient with B-cell chronic lymph.
    Haematologica, 2003, Volume: 88, Issue:4

    Topics: Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Orbital Neoplasms; Treatment Outcome; Vidarabine

2003
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Salvage Therapy; Time Factors; Vidarabine

2002
Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:9

    Topics: Annexin A5; Apoptosis; Apoptosis Regulatory Proteins; Caenorhabditis elegans Proteins; Cell Cycle; Cell Division; Cell Line, Tumor; Coloring Agents; Cyclin D3; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Down-Regulation; Fluorescein-5-isothiocyanate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Vidarabine

2002
Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:3

    Topics: 2-Chloroadenosine; Antineoplastic Agents; Apoptosis; Cisplatin; Cytarabine; Deoxyadenosines; DNA Fragmentation; Doxorubicin; Endodeoxyribonucleases; Etoposide; Humans; In Situ Nick-End Labeling; Leukemia, Mast-Cell; Microscopy, Electron; Neoplasm Proteins; Tumor Cells, Cultured; Vidarabine; Vincristine

2003
Evaluation of thymic output by measurement of T-cell-receptor gene rearrangement excisional circles (TREC) in patients who have received fludarabine.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:2

    Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Gene Rearrangement, T-Lymphocyte; Humans; Immune System; Male; Middle Aged; Polymerase Chain Reaction; T-Lymphocyte Subsets; Thymus Gland; Vidarabine

2003
The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
    Archivum immunologiae et therapiae experimentalis, 2003, Volume: 51, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Colony-Forming Units Assay; Cyclosporine; Enzyme Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Vidarabine

2003
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
    British journal of haematology, 2003, Volume: 121, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2003
Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine.
    Annals of hematology, 2003, Volume: 82, Issue:4

    Topics: Aged; Antineoplastic Agents; Humans; Lymphoma, T-Cell; Male; Necrosis; Panniculitis; Vidarabine

2003
Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:5

    Topics: Aged; Antineoplastic Agents; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Time Factors; Vidarabine

2003
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.
    Cell death and differentiation, 2003, Volume: 10, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Chlorambucil; Cyclophosphamide; DNA Damage; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gamma Rays; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Risk Factors; Survival Rate; Tumor Suppressor Protein p53; Vidarabine

2003
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
    Hematology (Amsterdam, Netherlands), 2003, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
    Bone marrow transplantation, 2003, Volume: 31, Issue:10

    Topics: Adenocarcinoma; Cyclophosphamide; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Living Donors; Middle Aged; Pancreatic Neoplasms; Siblings; Stem Cell Transplantation; Time Factors; Tomography, X-Ray Computed; Transplantation Conditioning; Treatment Outcome; Vidarabine

2003
Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation.
    Bone marrow transplantation, 2003, Volume: 31, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Stem Cell Transplantation; Transplantation, Autologous; Vidarabine

2003
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
    Leukemia, 2003, Volume: 17, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine

2003
Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab.
    The hematology journal : the official journal of the European Haematology Association, 2003, Volume: 4, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Vidarabine

2003
Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
    Leukemia, 2003, Volume: 17, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase Inhibitors; Caspases; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cyclin D2; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Subcellular Fractions; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vidarabine

2003
Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hepatitis B; Humans; Liver Cirrhosis; Lymphoma, T-Cell; Male; Middle Aged; Time Factors; Vidarabine

2003
Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:4

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Humans; Interleukin-2; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cell Transplantation; Prednisone; Recombinant Fusion Proteins; Remission Induction; Rituximab; Time Factors; Vidarabine; Vincristine

2003
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.
    Bone marrow transplantation, 2003, Volume: 31, Issue:11

    Topics: Adult; Anemia, Sideroblastic; Antilymphocyte Serum; Fatal Outcome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2003
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
    British journal of haematology, 2003, Volume: 121, Issue:5

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase 3; Caspases; Cytarabine; Daunorubicin; Drug Interactions; Humans; Leukemia, Myeloid; Membrane Glycoproteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine

2003
Fludarabine versus cyclophosphamide, vincristine, and prednisone in recurrent low-grade lymphomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-01, Volume: 21, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma, Non-Hodgkin; Prednisone; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Reproducibility of Results; Social Behavior; Survival; Vidarabine; Vincristine

2003
Bilateral optic disc swelling as the presenting sign of Waldenström's macroglobulinaemia.
    Acta ophthalmologica Scandinavica, 2003, Volume: 81, Issue:4

    Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Optic Disk; Papilledema; Prednisone; Vidarabine; Waldenstrom Macroglobulinemia

2003
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-15, Volume: 21, Issue:14

    Topics: Adult; Aged; Busulfan; Child; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Probability; Retrospective Studies; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness.
    Bone marrow transplantation, 2003, Volume: 32, Issue:4

    Topics: Adult; Blood Transfusion; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunosuppressive Agents; Jehovah's Witnesses; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Religion and Medicine; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Refusal; Vidarabine

2003
Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8

    Topics: Aphidicolin; Apoptosis; Caspase 3; Caspase 8; Caspases; Cell Survival; Cells, Cultured; DNA Repair; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; fas Receptor; Humans; Immunoblotting; Lymphocytes; Membrane Glycoproteins; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Signal Transduction; Time Factors; Tumor Suppressor Protein p53; Ultraviolet Rays; Vidarabine

2003
Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:7

    Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Vidarabine; Virus Activation

2003
Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.
    Haematologica, 2003, Volume: 88, Issue:8

    Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Amino Acid Chloromethyl Ketones; Antibodies; Antibodies, Monoclonal; Antigens, CD; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin A; Immunoglobulin D; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Neprilysin; Palatine Tonsil; Vidarabine

2003
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
    Blood, 2004, Jan-15, Volume: 103, Issue:2

    Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Disease Progression; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia.
    Blood, 2003, Sep-15, Volume: 102, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2003
Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression.
    Journal of leukocyte biology, 2003, Volume: 74, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Acute-Phase Proteins; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Cell Survival; Cells, Cultured; Disease Reservoirs; DNA-Binding Proteins; Erythrocytes; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages; Proviruses; STAT3 Transcription Factor; Trans-Activators; Vidarabine; Viral Load; Virus Replication

2003
Early reappearance of primary solid cancer in patients treated with purine analogs.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Colic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Purines; Remission Induction; Treatment Outcome; Vidarabine

2003
Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.
    Blood, 2004, Jan-01, Volume: 103, Issue:1

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Platelet Count; Transplantation, Autologous; Vidarabine

2004
Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.
    Bone marrow transplantation, 2003, Volume: 32, Issue:7

    Topics: Adolescent; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft Survival; Graft vs Host Disease; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Kinetics; Male; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6

    Topics: Acute Disease; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Vidarabine

2003
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
    British journal of haematology, 2003, Volume: 123, Issue:1

    Topics: Aged; Antineoplastic Agents; Case-Control Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Frequency; Genes, bcl-2; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Vidarabine

2003
Fludarabine-related myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-01, Volume: 21, Issue:19

    Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Flow Cytometry; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Vidarabine

2003
Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin.
    Leukemia, 2003, Volume: 17, Issue:10

    Topics: Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2003
[Gastrointestinal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Adult; Aged; Cyclophosphamide; Female; Gastrointestinal Neoplasms; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
Oral fludarabine: a viewpoint by Dieter Huhn.
    Drugs, 2003, Volume: 63, Issue:21

    Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Clinical Trials as Topic; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2003
Oral fludarabine: a viewpoint by David Oscier.
    Drugs, 2003, Volume: 63, Issue:21

    Topics: Administration, Oral; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2003
Oral fludarabine: a viewpoint by Bruce D. Cheson.
    Drugs, 2003, Volume: 63, Issue:21

    Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2003
Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.
    Journal of pediatric hematology/oncology, 2003, Volume: 25, Issue:10

    Topics: Bone Marrow Transplantation; Busulfan; Chediak-Higashi Syndrome; Child, Preschool; Graft vs Host Disease; Humans; Injections, Intravenous; Male; Siblings; Time Factors; Vidarabine

2003
Effects of etoposide and fludarabine in subtoxic doses on karyotype of human malignant lymphoid Namalwa cells.
    Bulletin of experimental biology and medicine, 2003, Volume: 136, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatids; Chromosome Aberrations; Chromosomes; Culture Media; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Humans; Karyotyping; Lymphoma; Mutagens; Vidarabine

2003
Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases.
    Experimental hematology, 2003, Volume: 31, Issue:10

    Topics: Adult; Aged; Cyclosporine; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Myeloid Cells; Prospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2003
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Complement Membrane Attack Complex; Complement System Proteins; Cysteine Endopeptidases; Cytochromes c; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Activation; Glucocorticoids; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Multienzyme Complexes; Neoplasm Recurrence, Local; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Tumor Cells, Cultured; Vidarabine; X-Linked Inhibitor of Apoptosis Protein

2003
The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Division; Cladribine; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines; Tumor Stem Cell Assay; Vidarabine

2003
Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2003, Volume: 9, Issue:10

    Topics: Animals; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; Graft vs Host Disease; Graft vs Leukemia Effect; Histocompatibility; Hyaluronan Receptors; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Mice; Mice, Inbred Strains; T-Lymphocytes; Transplantation, Homologous; Vidarabine

2003
Post-transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions.
    Leukemia, 2004, Volume: 18, Issue:1

    Topics: Aged; Aged, 80 and over; Alternative Splicing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Base Sequence; Caspase 3; Caspases; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Interleukin-4; Isoenzymes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Sequence Data; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; RNA Processing, Post-Transcriptional; RNA, Messenger; Sequence Deletion; Sequence Homology, Nucleic Acid; Signal Transduction; Transcription, Genetic; Vidarabine

2004
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs.
    Blood, 2004, Mar-01, Volume: 103, Issue:5

    Topics: Antibiotics, Antineoplastic; Antigens, CD34; Apoptosis; Benzoquinones; Blotting, Western; Bone Marrow Cells; Cell Separation; Chlorambucil; Down-Regulation; Enzyme Inhibitors; Flow Cytometry; HSP70 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinones; Rifabutin; RNA, Messenger; T-Lymphocytes; Time Factors; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2004
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.
    Leukemia, 2004, Volume: 18, Issue:1

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes; Male; Middle Aged; Time Factors; Transplantation, Autologous; Vidarabine

2004
Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Haematologica, 2003, Volume: 88, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carrier State; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Hepatitis C Antibodies; Humans; Lamivudine; Liver Failure; Lymphoma, Non-Hodgkin; Male; Middle Aged; Sequence Homology; Vidarabine; Virus Activation

2003
In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine.
    Biochemical pharmacology, 2003, Dec-01, Volume: 66, Issue:11

    Topics: Aged; Aged, 80 and over; Apoptosis; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Survival; Cells, Cultured; Chronic Disease; Female; Humans; Immunosuppressive Agents; Leukemia, B-Cell; Male; Middle Aged; Statistics, Nonparametric; Vidarabine

2003
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
    Oncogene, 2003, Nov-13, Volume: 22, Issue:51

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Chlorambucil; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Protein Binding; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine

2003
Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.
    British journal of haematology, 2003, Volume: 123, Issue:4

    Topics: Adult; Aged; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infections; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Viremia

2003
Successful allogeneic stem cell transplantation with fludarabine-based conditioning regimen in severe aplastic anemia.
    The Journal of the Association of Physicians of India, 2003, Volume: 51

    Topics: Adult; Anemia, Aplastic; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Transplantation Conditioning; Vidarabine

2003
Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine.
    Biochemical and biophysical research communications, 2003, Nov-21, Volume: 311, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Adhesion; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Humans; Immunoblotting; Integrin alpha4beta1; Leukemia, B-Cell; Ligands; Lysine; Proto-Oncogene Proteins c-bcl-2; Sequence Analysis, DNA; Signal Transduction; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine

2003
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
    Annals of hematology, 2004, Volume: 83, Issue:4

    Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine

2004
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus.
    Transfusion, 2003, Volume: 43, Issue:12

    Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Erythrocyte Transfusion; Fatal Outcome; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Platelet Transfusion; Risk Factors; Vidarabine

2003
[Seventeen cases of nonmyeloablative stem cell transplantation using a conditioning regimen containing fludarabine].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:8

    Topics: Adult; Female; Follow-Up Studies; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
[Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:8

    Topics: Adolescent; Adult; Female; Follow-Up Studies; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2003
[Pressure pain in the left epigastrium: blood picture provides diagnosis. Chronic lymphatic leukemia].
    MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytosis; Lymphocyte Count; Male; Middle Aged; Prednisone; Splenomegaly; Time Factors; Ultrasonography; Vidarabine

2003
Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, Jan-05, Volume: 799, Issue:1

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Leukemia; Reproducibility of Results; Sensitivity and Specificity; Vidarabine

2004
Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
    International journal of clinical oncology, 2003, Volume: 8, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Intestinal Polyposis; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Prednisone; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine

2003
[Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Nederlands tijdschrift voor geneeskunde, 2003, Nov-22, Volume: 147, Issue:47

    Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Risk Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2003
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells.
    British journal of haematology, 2004, Volume: 124, Issue:2

    Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Albuterol; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Calcium; Cell Line, Tumor; Chlorambucil; Cyclic AMP; Ethanolamines; Female; Formoterol Fumarate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Vidarabine

2004
Fatal fludarabine-induced extensive bone marrow necrosis in a patient with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:10

    Topics: Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Diseases; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Necrosis; Vidarabine

2003
Fludarabine induced immune thrombocytopenia in a patient with CD5 positive B cell chronic lymphocytic leukemia.
    JPMA. The Journal of the Pakistan Medical Association, 2003, Volume: 53, Issue:10

    Topics: Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Vidarabine

2003
B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen.
    Transplantation proceedings, 2003, Volume: 35, Issue:8

    Topics: Adult; Antigens, CD; Antigens, CD20; Antilymphocyte Serum; B-Lymphocytes; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphoproliferative Disorders; Male; Middle Aged; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine

2003
[Hairy cell leukemia: report on one case with survival for 10 years].
    Zhongguo shi yan xue ye xue za zhi, 2003, Volume: 11, Issue:6

    Topics: Aged; Humans; Immunophenotyping; Interferon alpha-2; Interferon-alpha; Leukemia, Hairy Cell; Male; Recombinant Proteins; Vidarabine

2003
45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
    Clinical lymphoma, 2003, Volume: 4, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Prednisone; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Vincristine

2003
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Bone marrow transplantation, 2004, Volume: 33, Issue:5

    Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine

2004
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.
    Blood, 2004, May-01, Volume: 103, Issue:9

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Drug Evaluation; Drug Resistance; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Sequence Deletion; Treatment Outcome; Vidarabine

2004
Reversible acute renal failure following single administration of fludarabine.
    Bone marrow transplantation, 2004, Volume: 33, Issue:6

    Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Combined Modality Therapy; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine

2003
Fludarabine-induced hemolytic anemia: successful treatment by rituximab.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:1

    Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Blood Transfusion; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Treatment Outcome; Vidarabine

2004
Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.
    Gynecologic oncology, 2004, Volume: 92, Issue:1

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Female; Graft vs Tumor Effect; Humans; Melphalan; Ovarian Neoplasms; Vidarabine

2004
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2004, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Child; Child, Preschool; Cladribine; Female; Fever; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Transplantation Conditioning; Vidarabine

2004
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
    Bone marrow transplantation, 2004, Volume: 33, Issue:7

    Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cladribine; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Cyclophosphamide; Disease Progression; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Second Primary; Syndrome; Time Factors; Vidarabine

2003
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
    International journal of hematology, 2004, Volume: 79, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
Hypoxia/re-oxygenation-induced, redox-dependent activation of STAT1 (signal transducer and activator of transcription 1) confers resistance to apoptotic cell death via hsp70 induction.
    The Biochemical journal, 2004, May-15, Volume: 380, Issue:Pt 1

    Topics: Acetylcysteine; Animals; Apoptosis; Cell Hypoxia; Cells, Cultured; DNA-Binding Proteins; Enzyme Inhibitors; Fibroblasts; Gene Expression Regulation; Hepatocytes; HSP70 Heat-Shock Proteins; Janus Kinase 2; Male; MAP Kinase Signaling System; Oxidation-Reduction; Oxidative Stress; Oxygen; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Lew; STAT1 Transcription Factor; Trans-Activators; Tyrphostins; Vidarabine

2004
Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine.
    Leukemia, 2004, Volume: 18, Issue:5

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Vidarabine

2004
[Drug-resistant B cell chronic lymphocytic leukemia safely treated with rituximab to control leukemic cell increment and platelet transfusion dependence].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm; Hepatomegaly; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytosis; Male; Middle Aged; Platelet Transfusion; Rituximab; Vidarabine

2004
Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Rituximab; Treatment Failure; Vidarabine

2004
Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium.
    Leukemia research, 2004, Volume: 28, Issue:5

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chlorambucil; Complement System Proteins; Culture Media, Serum-Free; Humans; Immunoglobulin Fab Fragments; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
    Blood, 2004, Aug-01, Volume: 104, Issue:3

    Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
Aspergillus fumigatus: a rare cause of vertebral osteomyelitis.
    Haematologica, 2004, Volume: 89, Issue:4

    Topics: Aspergillus fumigatus; Humans; Leukemia, B-Cell; Opportunistic Infections; Osteomyelitis; Purine Nucleosides; Spinal Diseases; Vidarabine

2004
Fludarabine in chronic lymphocytic leukemia and other hematological malignancies: progress in treatment. Fludarabine supplement.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine

2004
[Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine

2004
Transient absence of hepatic uptake on gallium-67 scintigraphy following fludarabine therapy.
    Clinical nuclear medicine, 2004, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; Citrates; Gallium; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liver; Male; Metabolic Clearance Rate; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Spleen; Time Factors; Vidarabine

2004
High dose chlorambucil in the treatment of lymphoid malignancies.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vidarabine

2004
The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
    Leukemia, 2004, Volume: 18, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Division; Cell Line, Transformed; Clone Cells; Drug Synergism; Humans; Immunotoxins; N-Glycosyl Hydrolases; Plant Proteins; Ribosome Inactivating Proteins, Type 1; Rituximab; Saporins; Tumor Cells, Cultured; Vidarabine

2004
Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
    Croatian medical journal, 2004, Volume: 45, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Apoptosis; B-Lymphocytes; Biomarkers, Tumor; Cell Cycle; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Microfilament Proteins; Muscle Proteins; Rituximab; Sensitivity and Specificity; Tumor Protein, Translationally-Controlled 1; Vidarabine

2004
[Reduced intensity stem cell transplantation for metastatic renal cell carcinoma].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2004, Volume: 95, Issue:3

    Topics: Adult; Busulfan; Carcinoma, Renal Cell; Cyclosporine; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kidney Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Salvage Therapy; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2004
Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection.
    The American journal of surgical pathology, 2004, Volume: 28, Issue:5

    Topics: Aged; Antineoplastic Agents; Clone Cells; DNA, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Deletion; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasms, Second Primary; Polymerase Chain Reaction; Reed-Sternberg Cells; Vidarabine

2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
    Blood, 2005, Jan-01, Volume: 105, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Treatment Outcome; Vidarabine

2005
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
    Cancer, 2004, May-15, Volume: 100, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; Female; Gastrointestinal Neoplasms; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Survival Rate; Treatment Outcome; Vidarabine; Vincristine

2004
Fludarabine combination regimen severely affected peripheral blood stem cell mobilization.
    Acta haematologica, 2004, Volume: 111, Issue:4

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Humans; Kinetics; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine

2004
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
    Blood, 2004, Jun-01, Volume: 103, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Graft Rejection; Granulocyte Precursor Cells; Hematologic Diseases; Humans; Immunosuppressive Agents; Melphalan; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine

2004
Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin.
    Leukemia research, 2004, Volume: 28, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Ionomycin; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleotides; Pentostatin; Prognosis; Tumor Cells, Cultured; Vidarabine

2004
Fludarabine as the possible cause of acute myelofibrosis.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:3

    Topics: Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Primary Myelofibrosis; Vidarabine

2004
Fludarabine- and cyclophosphamide-based nonmyeloablative conditioning regimen for transplantation of chronic granulomatous disease: possible correlation with prolonged pure red cell aplasia.
    International journal of hematology, 2004, Volume: 79, Issue:3

    Topics: ABO Blood-Group System; Adolescent; Blood Group Incompatibility; Cyclophosphamide; Graft Survival; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Male; Neutrophils; Red-Cell Aplasia, Pure; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jun-01, Volume: 10, Issue:11

    Topics: Adult; Aged; Blood Platelets; Cyclosporine; Feasibility Studies; Female; Fetal Blood; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neutrophils; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2004
Severe T-mediated bone marrow aplasia in a patient with splenic lymphoma with villous lymphocytes (SLVL) previously treated with fludarabine regimen.
    Haematologica, 2004, Volume: 89, Issue:6 Suppl

    Topics: Antineoplastic Agents; Bone Marrow Diseases; Humans; Lymphoma, B-Cell; Splenic Neoplasms; T-Lymphocytes; Vidarabine

2004
Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
    Bone marrow transplantation, 2004, Volume: 34, Issue:4

    Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegalovirus Infections; Drug Therapy, Combination; Fanconi Anemia; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Living Donors; Male; Postoperative Complications; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
    Journal of the American Society of Nephrology : JASN, 2004, Volume: 15, Issue:7

    Topics: Acute Kidney Injury; Adult; Aged; Behavior Therapy; Cohort Studies; Cyclosporine; Female; Glomerular Filtration Rate; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Stem Cell Transplantation; Tacrolimus; Time Factors; Vidarabine

2004
9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells.
    Molecular pharmacology, 2004, Volume: 66, Issue:1

    Topics: Antineoplastic Agents; Aryl Hydrocarbon Receptor Nuclear Translocator; DNA-Binding Proteins; Enzyme Activation; Female; Gene Expression; Gene Silencing; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Aryl Hydrocarbon; RNA, Messenger; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured; Vascular Endothelial Growth Factors; Vidarabine

2004
Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells.
    Blood, 2004, Oct-15, Volume: 104, Issue:8

    Topics: Apoptosis; B-Lymphocytes; Cell Cycle; Cell Division; Cell Line; DNA-Binding Proteins; Down-Regulation; Gene Expression; Genetic Vectors; Green Fluorescent Proteins; Humans; Nuclear Proteins; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; STAT1 Transcription Factor; Trans-Activators; Tumor Suppressor Protein p53; Vidarabine

2004
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    Blood, 2004, Oct-15, Volume: 104, Issue:8

    Topics: Adolescent; Adult; Age Factors; Aged; Child; Chimera; Disease Progression; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.
    Bone marrow transplantation, 2004, Volume: 34, Issue:2

    Topics: Aged; Busulfan; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2004
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
    Leukemia, 2004, Volume: 18, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mycophenolic Acid; Neoplasm Recurrence, Local; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2004
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
    Cancer biology & therapy, 2004, Volume: 3, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Cycle Proteins; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia; Pyridines; Reactive Oxygen Species; Vidarabine

2004
Fatal peripheral neuropathy following FLA chemotherapy.
    Clinical and laboratory haematology, 2004, Volume: 26, Issue:4

    Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Interactions; Fatal Outcome; Humans; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrimidines; Triazoles; Vidarabine; Voriconazole

2004
Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia.
    British journal of haematology, 2004, Volume: 126, Issue:4

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2004
Reversible paraneoplastic neuropathy associated with T-cell large granular lymphocyte leukemia.
    Neurology, 2004, Aug-10, Volume: 63, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclosporine; Dexamethasone; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Male; Middle Aged; Mitoxantrone; Nerve Degeneration; Paraneoplastic Polyneuropathy; Paresthesia; Sural Nerve; T-Lymphocytes; Urinary Retention; Vidarabine

2004
Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:8

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antirheumatic Agents; Arthritis, Rheumatoid; CD3 Complex; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Transplantation Chimera; Vidarabine

2004
Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Fever of Unknown Origin; Filgrastim; Granulocyte Colony-Stimulating Factor; Guillain-Barre Syndrome; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous; Vidarabine

2004
Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Safety; Survival Rate; Treatment Outcome; Vidarabine

2004
High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    The Korean journal of internal medicine, 2004, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasm Staging; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Vidarabine

2004
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
    Cancer, 2004, Nov-01, Volume: 101, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia; Lymphoma; Male; Middle Aged; Neoplasm Staging; Opportunistic Infections; Risk Factors; Vidarabine

2004
The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
    Cancer research, 2004, Sep-15, Volume: 64, Issue:18

    Topics: Apoptosis; B-Lymphocytes; Benzodiazepines; Benzodiazepinones; Case-Control Studies; Caspase 3; Caspases; Cross-Linking Reagents; DNA Damage; DNA Repair; Enzyme Activation; Humans; K562 Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrroles; T-Lymphocytes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine

2004
Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update.
    Leukemia, 2004, Volume: 18, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphocytes; Lymphoma; Middle Aged; Splenectomy; Splenic Neoplasms; Vidarabine

2004
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
    Blood, 2005, Mar-01, Volume: 105, Issue:5

    Topics: Adamantane; Apoptosis; B-Lymphocytes; Cells, Cultured; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Hydroquinones; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Vidarabine

2005
Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:5

    Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Contraindications; Cyclosporine; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infection Control; Infections; Leukemia, Myeloid; Male; Middle Aged; Mycophenolic Acid; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes.
    Biochemical pharmacology, 2004, Nov-01, Volume: 68, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Carboplatin; Cell Proliferation; DNA Damage; DNA Repair; Drug Interactions; Humans; Lymphocytes; Tumor Cells, Cultured; Vidarabine

2004
Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-01, Volume: 39, Issue:7

    Topics: Antilymphocyte Serum; Busulfan; Epstein-Barr Virus Infections; Guillain-Barre Syndrome; Humans; Male; Middle Aged; Samarium; Stem Cell Transplantation; Vidarabine; Virus Activation

2004
Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
    Oncogene, 2004, Nov-25, Volume: 23, Issue:55

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Coloring Agents; Cyclophosphamide; DNA Damage; Enzyme Inhibitors; Flow Cytometry; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Membrane Potentials; Mitochondria; Mitoxantrone; Proteins; Reactive Oxygen Species; Staurosporine; Time Factors; Translocation, Genetic; Tumor Suppressor Protein p53; Vidarabine

2004
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
    Leukemia, 2004, Volume: 18, Issue:12

    Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Mitochondrial Proteins; Nitric Oxide; Nuclear Proteins; Nuclear Respiratory Factor 1; Organelle Biogenesis; Transcription Factors; Tumor Cells, Cultured; Vidarabine

2004
Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.
    Bone marrow transplantation, 2004, Volume: 34, Issue:11

    Topics: Adolescent; Anemia, Aplastic; Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Transplantation Conditioning; Vidarabine

2004
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.
    British journal of haematology, 2004, Volume: 127, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2004
[Establishment of nonmyeloablative allogeneic stem cell transplantation model in H-2 haploidentical mice and its related study].
    Zhongguo shi yan xue ye xue za zhi, 2004, Volume: 12, Issue:5

    Topics: Animals; Female; Graft vs Host Disease; H-2 Antigens; Haplotypes; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Male; Mice; Mice, Inbred C57BL; Transplantation Chimera; Transplantation, Homologous; Vidarabine

2004
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.
    International journal of cancer, 2005, Feb-20, Volume: 113, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Culture Media, Serum-Free; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Oligonucleotide Array Sequence Analysis; Phenotype; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation; Vidarabine

2005
Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
    Leukemia, 2005, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Blotting, Western; Equilibrative-Nucleoside Transporter 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vidarabine

2005
Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:11

    Topics: Aged; Annexin A5; Antigens, CD19; Antineoplastic Agents; Apoptosis; CD5 Antigens; Cell Death; Cell Survival; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Monocytes; Time Factors; Vidarabine

2004
Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway.
    Oncogene, 2004, Dec-16, Volume: 23, Issue:58

    Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Caspase 8; Caspases; Cell Line, Tumor; Cladribine; Fas-Associated Death Domain Protein; Humans; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Vidarabine

2004
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
    European journal of haematology, 2004, Volume: 73, Issue:6

    Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine

2004
The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
    European journal of haematology, 2004, Volume: 73, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Middle Aged; Quinolones; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine

2004
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
    International journal of oncology, 2004, Volume: 25, Issue:6

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Tumor Cells, Cultured; Vidarabine

2004
Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:6

    Topics: Acute Kidney Injury; Administration, Oral; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Lysis Syndrome; Vidarabine

2004
Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
    Nucleosides, nucleotides & nucleic acids, 2004, Volume: 23, Issue:8-9

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Coloring Agents; Cytarabine; Deoxycytidine; DNA; Gemcitabine; HL-60 Cells; Humans; Inhibitory Concentration 50; Nucleosides; Tetrazolium Salts; Thiazoles; Vidarabine

2004
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.
    Blood, 2005, Mar-15, Volume: 105, Issue:6

    Topics: Adult; Aged; Antigens, CD; CD8-Positive T-Lymphocytes; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility Testing; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2005
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
    Haematologica, 2004, Volume: 89, Issue:12

    Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Burkitt Lymphoma; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunophenotyping; In Situ Hybridization, Fluorescence; Interphase; Life Tables; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Solubility; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2004
Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
    Annals of hematology, 2005, Volume: 84, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine

2005
Effect of fludarabine on leukocyte functions.
    Chemotherapy, 2004, Volume: 50, Issue:6

    Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Degranulation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; HL-60 Cells; Humans; Hypochlorous Acid; Neutrophils; Peroxidase; Vidarabine

2004
Conditioning regimen of melphalan, fludarabine and total body irradiation in unmanipulated HLA haploidentical stem cell transplantation based on feto-maternal tolerance.
    Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:11

    Topics: Adult; Antineoplastic Agents, Alkylating; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2004
Genistein induces G2 arrest in malignant B cells by decreasing IL-10 secretion.
    Cell cycle (Georgetown, Tex.), 2004, Volume: 3, Issue:12

    Topics: Apoptosis; Apoptosis Regulatory Proteins; B-Lymphocytes; Cell Cycle Proteins; Cell Proliferation; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Flow Cytometry; G2 Phase; Genistein; Humans; Interferon-gamma; Interleukin-10; Receptors, Interleukin; Receptors, Interleukin-10; RNA, Messenger; Tumor Cells, Cultured; Vidarabine

2004
Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB.
    The Journal of biological chemistry, 2005, Mar-11, Volume: 280, Issue:10

    Topics: Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lysophospholipids; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Lysophosphatidic Acid; Tumor Cells, Cultured; Vidarabine

2005
Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:3

    Topics: Aged; Aged, 80 and over; Apoptosis; Cell Survival; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; STAT1 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Tyrphostins; Vidarabine

2005
Effects of fludarabine treatment on murine lupus nephritis.
    Lupus, 2004, Volume: 13, Issue:12

    Topics: Animals; Cyclophosphamide; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Immunosuppressive Agents; Kidney Glomerulus; Lupus Nephritis; Lymphocyte Count; Male; Mice; Spleen; Vidarabine

2004
Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
    Haematologica, 2005, Volume: 90, Issue:1

    Topics: Acute Kidney Injury; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chronic Disease; Disseminated Intravascular Coagulation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Renal Dialysis; Transplantation Conditioning; Vidarabine

2005
PNP with Waldenström's macroglobulinaemia.
    Clinical and experimental dermatology, 2005, Volume: 30, Issue:1

    Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Eruptions; Fatal Outcome; Humans; Male; Paraneoplastic Syndromes; Pemphigus; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia

2005
Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia.
    Bone marrow transplantation, 2005, Volume: 35, Issue:6

    Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Salvage Therapy; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Successful bone marrow transplantation in a patient with c-mpl-mutated congenital amegakaryocytic thrombocytopenia from a carrier donor.
    Pediatric transplantation, 2005, Volume: 9, Issue:1

    Topics: Bone Marrow Purging; Bone Marrow Transplantation; Child; Female; Heterozygote; Humans; Immunosuppressive Agents; Megakaryocytes; Point Mutation; Thrombocytopenia; Thrombopoietin; Vidarabine

2005
Fludarabine: risk factor for aggressive behaviour of squamous cell carcinoma of the skin?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Lymphoma, B-Cell; Male; Skin Neoplasms; T-Lymphocytes; Vidarabine

2005
Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
    Haematologica, 2005, Volume: 90, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2005
Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
    Saudi medical journal, 2004, Volume: 25, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prednisolone; Retreatment; Survival Analysis; Turkey; Vidarabine

2004
The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia.
    Folia morphologica, 2004, Volume: 63, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Vidarabine

2004
[Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
    Voprosy onkologii, 2004, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Treatment Outcome; Vidarabine

2004
Fludarabine-based conditioning used in successful bone marrow transplantation from an unrelated donor in a heavily transfused patient with severe aplastic anemia.
    International journal of hematology, 2005, Volume: 81, Issue:1

    Topics: Adolescent; Anemia, Aplastic; Blood Transfusion; Bone Marrow Transplantation; Female; Humans; Immunosuppressive Agents; Severity of Illness Index; Tissue Donors; Transplantation Conditioning; Vidarabine

2005
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.
    British journal of haematology, 2005, Volume: 128, Issue:5

    Topics: Adult; Antilymphocyte Serum; Blood Transfusion, Autologous; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Middle Aged; Pilot Projects; Primary Myelofibrosis; Prospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2005
Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis.
    Leukemia research, 2005, Volume: 29, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Disease Progression; Female; Herpesvirus 4, Human; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Reed-Sternberg Cells; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine

2005
Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia.
    Stem cells and development, 2005, Volume: 14, Issue:1

    Topics: Antigens, CD34; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine

2005
Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
    Annals of hematology, 2005, Volume: 84, Issue:5

    Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Cell Fractionation; Cohort Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Opportunistic Infections; Pneumonia, Bacterial; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
    Blood, 2005, Jun-01, Volume: 105, Issue:11

    Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Middle Aged; Multiple Myeloma; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.
    Bone marrow transplantation, 2005, Volume: 35, Issue:8

    Topics: Adolescent; Adult; Anemia, Aplastic; Blood Transfusion; Bone Marrow Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; T-Lymphocytes; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2005
Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).
    The pharmacogenomics journal, 2005, Volume: 5, Issue:3

    Topics: Adenosine; Animals; Antineoplastic Agents; Cation Transport Proteins; Cladribine; Conserved Sequence; DNA; Ethnicity; Genetic Variation; Haplotypes; Humans; Membrane Transport Proteins; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Oocytes; Vidarabine; Xenopus laevis

2005
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
    Neoplasma, 2005, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine

2005
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3

    Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Patient Selection; Postoperative Complications; Recurrence; Renal Dialysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2005
Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2005, Volume: 35, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Pharmacokinetics; Transplantation, Homologous; Vidarabine

2005
Analysis of 1H NMR-detectable mobile lipid domains for assessment of apoptosis induced by inhibitors of DNA synthesis and replication.
    Cell biology international, 2005, Volume: 29, Issue:1

    Topics: Apoptosis; Cell Line, Tumor; Cell Membrane; DNA Replication; Etoposide; Humans; Hydrogen; Magnetic Resonance Spectroscopy; Membrane Lipids; Quercetin; Vidarabine

2005
Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
    Bone marrow transplantation, 2005, Volume: 35, Issue:9

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mycophenolic Acid; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2005
Changing the way we think about chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Rituximab; Vidarabine

2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2005
Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.
    Annals of hematology, 2005, Volume: 84, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Vidarabine

2005
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Comorbidity; Female; Graft Rejection; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Middle Aged; Probability; Transplantation Conditioning; Treatment Outcome; Vidarabine

2005
Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity.
    Bone marrow transplantation, 2005, Volume: 35, Issue:9

    Topics: Antineoplastic Agents; Cell Line; Cell Movement; Endothelial Cells; Endothelium, Vascular; Oligodeoxyribonucleotides; Polydeoxyribonucleotides; Transplantation Conditioning; Vascular Diseases; Vidarabine

2005
Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF.
    Bone marrow transplantation, 2005, Volume: 35, Issue:7

    Topics: Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Leukemia, Lymphocytic, Chronic, B-Cell; Peripheral Blood Stem Cell Transplantation; Treatment Failure; Vidarabine

2005
Lymphoma: diagnosis, staging, natural history, and treatment strategies.
    Seminars in oncology, 2005, Volume: 32, Issue:1 Suppl 1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Vidarabine

2005
p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
    British journal of haematology, 2005, Volume: 129, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Female; Genes, p53; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Treatment Outcome; Vidarabine

2005
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
    Blood, 2005, Jul-15, Volume: 106, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Caspases; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; In Vitro Techniques; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lignans; Magnolia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phytotherapy; Proto-Oncogene Proteins c-bcl-2; Vidarabine

2005
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Whole-Body Irradiation

2005
Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.
    British journal of haematology, 2005, Volume: 129, Issue:2

    Topics: Antineoplastic Agents; Cell Transformation, Viral; Clone Cells; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Hodgkin Disease; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Micromanipulation; Middle Aged; Reed-Sternberg Cells; Vidarabine

2005
Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:4

    Topics: Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Female; Graft vs Host Disease; Granulocytes; Humans; Leukemia, Myelomonocytic, Acute; Melphalan; Neoplasm Recurrence, Local; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway.
    Biochemical and biophysical research communications, 2005, Jun-03, Volume: 331, Issue:2

    Topics: Apoptosis; Caspases; Cell Line, Tumor; Chromones; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; MAP Kinase Signaling System; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; U937 Cells; Vidarabine

2005
Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.
    European journal of haematology, 2005, Volume: 74, Issue:6

    Topics: Acute Kidney Injury; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Renal Dialysis; Vidarabine

2005
A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, Jun-25, Volume: 820, Issue:2

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Jurkat Cells; Leukemia; Mass Spectrometry; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Vidarabine

2005
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
    Blood, 2005, Sep-01, Volume: 106, Issue:5

    Topics: Actins; Apoptosis; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Chemotaxis; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Molecular Weight; Oligopeptides; Peptides; Receptors, CXCR4; Stromal Cells; Structure-Activity Relationship; Time Factors; Vidarabine

2005
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
    Stem cells and development, 2005, Volume: 14, Issue:2

    Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine

2005
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
    European journal of pharmacology, 2005, May-09, Volume: 514, Issue:2-3

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; B-Lymphocytes; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Caspase 9; Caspases; Cell Aggregation; Cell Survival; Cells, Cultured; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Vidarabine

2005
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
    Blood, 2005, Sep-15, Volume: 106, Issue:6

    Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation; Case-Control Studies; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; DNA-Binding Proteins; Forkhead Transcription Factors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Interleukin-10; L-Selectin; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Receptors, Interleukin-2; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; T-Lymphocyte Subsets; Transforming Growth Factor beta; Transforming Growth Factor beta1; Vidarabine

2005
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
    British journal of haematology, 2005, Volume: 129, Issue:5

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Graft vs Host Disease; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Proportional Hazards Models; Receptors, Immunologic; Receptors, KIR; Recurrence; Risk; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy.
    Haematologica, 2005, Volume: 90, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microcirculation; Middle Aged; Neoplasm, Residual; Neovascularization, Pathologic; Vidarabine

2005
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Haematologica, 2005, Volume: 90, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Disease Susceptibility; Female; Herpesviridae Infections; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia, Pneumocystis; Risk; Rituximab; Vidarabine

2005
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-01, Volume: 11, Issue:11

    Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine

2005
Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:6

    Topics: Administration, Oral; Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
    Bone marrow transplantation, 2005, Volume: 36, Issue:3

    Topics: Female; Graft Survival; Graft vs Host Disease; Histiocytosis, Langerhans-Cell; Humans; Infant; Langerhans Cells; Male; Melphalan; Prognosis; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
    Clinical and laboratory haematology, 2005, Volume: 27, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Disease Progression; Female; Humans; Pleural Effusion; Recurrence; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2005
Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature.
    Annals of diagnostic pathology, 2005, Volume: 9, Issue:3

    Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Treatment Outcome; Vidarabine; Vincristine

2005
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
    Cancer, 2005, Jul-15, Volume: 104, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dexamethasone; Female; Humans; Immunosuppression Therapy; Infections; Interferons; Lymphoma; Male; Middle Aged; Mitoxantrone; Neutropenia; Vidarabine

2005
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
    Haematologica, 2005, Volume: 90, Issue:6

    Topics: Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Treatment Outcome; Vidarabine

2005
An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2005
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Middle Aged; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine

2005
Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome; Vidarabine

2005
Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myasthenia Gravis; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine

2005
Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
    British journal of haematology, 2005, Volume: 130, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Disease Progression; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Sirolimus; Survival Analysis; Treatment Outcome; Vidarabine

2005
Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
    American journal of hematology, 2005, Volume: 79, Issue:4

    Topics: Acute Disease; Aged; Antineoplastic Agents; Bone Marrow; Chromosomes, Human, Pair 7; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Monosomy; Neoplasms, Second Primary; Vidarabine

2005
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    JPMA. The Journal of the Pakistan Medical Association, 2005, Volume: 55, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine

2005
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Annals of hematology, 2005, Volume: 84, Issue:12

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukocyte Count; Liver; Male; Middle Aged; Mucositis; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
    Pediatric blood & cancer, 2006, May-01, Volume: 46, Issue:5

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Female; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Treatment Outcome; Vidarabine

2006
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2005, Aug-18, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Teniposide; Treatment Outcome; Vidarabine

2005
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Diagnosis, Differential; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Vidarabine

2005
Richter's syndrome--the downside of fludarabine?
    Leukemia research, 2005, Volume: 29, Issue:10

    Topics: Antineoplastic Agents; Epstein-Barr Virus Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Syndrome; Vidarabine

2005
Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
    Leukemia research, 2005, Volume: 29, Issue:10

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Cyclophosphamide; Cyclosporine; Dexamethasone; Drug Resistance, Neoplasm; Humans; Leukemia, T-Cell; Male; Mitoxantrone; Prednisolone; Red-Cell Aplasia, Pure; Remission Induction; Vidarabine

2005
'Specific' cutaneous infiltrate of B-cell chronic lymphocytic leukemia at the site of a florid herpes simplex infection.
    Journal of cutaneous pathology, 2005, Volume: 32, Issue:8

    Topics: Aged; Antineoplastic Agents; Herpes Zoster; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Neoplasm Staging; Skin Neoplasms; Treatment Outcome; Vidarabine

2005
Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning.
    British journal of haematology, 2005, Volume: 130, Issue:5

    Topics: Adolescent; Adult; Child; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Survival Rate; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2005
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
    Leukemia, 2005, Volume: 19, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Hemoglobins; Humans; Immunoglobulin M; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2005
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.
    Blood, 2006, Jan-01, Volume: 107, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; B-Lymphocytes; Brefeldin A; Cells, Cultured; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Golgi Apparatus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Middle Aged; Multiple Myeloma; Protein Transport; Tumor Necrosis Factor Ligand Superfamily Member 13; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vidarabine

2006
Apoptosis of peripheral human blood lymphocytes induced by physical-chemical influences and generation of reactive oxygen species.
    Annals of the New York Academy of Sciences, 2005, Volume: 1048

    Topics: Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Lymphocytes; Microscopy, Fluorescence; Radiation, Ionizing; Reactive Oxygen Species; Temperature; Vidarabine

2005
Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.
    International journal of hematology, 2005, Volume: 81, Issue:5

    Topics: Animals; Binding, Competitive; Biotransformation; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; DNA; Drug Interactions; Drug Resistance, Neoplasm; Hydroxyurea; Mice; Nucleosides; Vidarabine

2005
Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:7

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Disease Management; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Rituximab; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine

2004
Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:10

    Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Drug Administration Schedule; Humans; Male; Monosomy; Myelodysplastic Syndromes; Vidarabine; Waldenstrom Macroglobulinemia

2005
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Deutsche medizinische Wochenschrift (1946), 2005, Sep-23, Volume: 130, Issue:38

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Recurrence; Regression Analysis; Remission Induction; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.
    British journal of haematology, 2005, Volume: 131, Issue:1

    Topics: Adolescent; Adult; Aged; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Nephrotic Syndrome; Proteinuria; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine

2005
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma.
    Bone marrow transplantation, 2005, Volume: 36, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Risk Assessment; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2005
[Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].
    Orvosi hetilap, 2005, Aug-21, Volume: 146, Issue:34

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulins; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myeloablative Agonists; Rituximab; Severity of Illness Index; Thrombocytopenia; Treatment Outcome; Vidarabine

2005
Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2.
    Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:1

    Topics: Animals; Equilibrative-Nucleoside Transporter 2; Female; Haplotypes; Humans; Inosine; Mutation; Oocytes; Polymorphism, Genetic; Tritium; Uridine; Vidarabine; Xenopus laevis

2006
Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
    Clinical lymphoma & myeloma, 2005, Volume: 6, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Vidarabine; Waldenstrom Macroglobulinemia

2005
A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
    Molecular pharmacology, 2006, Volume: 69, Issue:1

    Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Biological Transport; Cell Line; Cladribine; Clofarabine; Humans; Membrane Transport Proteins; Recombinant Proteins; Vidarabine; Xenopus laevis

2006
Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Cerebrospinal Fluid; Drug Evaluation; Female; Humans; Injections, Intravenous; Injections, Spinal; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate; Vidarabine

2005
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Journal of cellular physiology, 2006, Volume: 207, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carrier Proteins; Cell Survival; Chlorambucil; Flow Cytometry; Gene Expression; Glycoproteins; Humans; Immunoglobulin G; Interleukin-1; Interleukin-8; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Oligonucleotide Array Sequence Analysis; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation; Vidarabine

2006
Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
    Rapid communications in mass spectrometry : RCM, 2005, Volume: 19, Issue:24

    Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cladribine; Cyclophosphamide; Humans; Molecular Structure; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Vidarabine

2005
Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.
    Leukemia research, 2006, Volume: 30, Issue:4

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Vidarabine

2006
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    European journal of haematology, 2005, Volume: 75, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Creatinine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nitrogen Mustard Compounds; Recombinant Proteins; Renal Insufficiency; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid; Vidarabine

2005
Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen.
    Clinical transplantation, 2005, Volume: 19, Issue:6

    Topics: Adrenoleukodystrophy; Busulfan; Child; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Male; Myeloablative Agonists; Transplantation Conditioning; Vidarabine

2005
An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning.
    Transplantation, 2005, Nov-15, Volume: 80, Issue:9

    Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Cell Transplantation; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Lymphocyte Count; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Spleen; T-Lymphocytes; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2005
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:1

    Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Radioimmunotherapy; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Yttrium Radioisotopes

2006
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Haematologica, 2005, Volume: 90, Issue:12

    Topics: Acyclovir; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cohort Studies; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dexamethasone; Diphtheria Toxin; DNA, Viral; Doxorubicin; Female; Fever; Follow-Up Studies; Ganciclovir; Hematologic Neoplasms; Humans; Interleukin-2; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Transplantation, Autologous; Valacyclovir; Valine; Vidarabine; Vincristine; Viremia; Virus Activation

2005
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action.
    Journal of the National Cancer Institute, 2005, Dec-07, Volume: 97, Issue:23

    Topics: Antineoplastic Agents; Apoptosis; Calcium Channels; Cell Line, Tumor; Cholestenones; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopy, Electron; Mitochondrial Membranes; Saponins; Vidarabine

2005
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
    Annals of the New York Academy of Sciences, 2005, Volume: 1054

    Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical Protocols; Combined Modality Therapy; Comorbidity; Deferoxamine; Disease-Free Survival; Erythrocyte Transfusion; Erythropoietin; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Hemosiderosis; Humans; Hydroxyurea; Immunosuppressive Agents; Iron Chelating Agents; Life Tables; Liver Cirrhosis; Male; Phlebotomy; Postoperative Complications; Survival Analysis; Thalassemia; Transfusion Reaction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2005
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    European journal of haematology, 2006, Volume: 76, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2006
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Female; Gene Deletion; Genes, Immunoglobulin Heavy Chain; Genetic Predisposition to Disease; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rituximab; Tumor Suppressor Protein p53; Vidarabine

2006
[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Dexamethasone; Doxorubicin; Female; Hemoglobins; Humans; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Remission Induction; Vidarabine; Vincristine

2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
    Cancer, 2006, Jan-15, Volume: 106, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2006
Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma.
    Clinical lymphoma & myeloma, 2005, Volume: 6, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Fatal Outcome; Humans; Lymphoma, Follicular; Middle Aged; Remission Induction; Rituximab; Vidarabine; West Nile Fever; West Nile virus

2005
Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
    Roczniki Akademii Medycznej w Bialymstoku (1995), 2005, Volume: 50

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Case-Control Studies; Cyclophosphamide; Fas Ligand Protein; fas Receptor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Solubility; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors; Vidarabine

2005
Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter.
    Gene, 2006, Apr-12, Volume: 371, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; ATPases Associated with Diverse Cellular Activities; Bone Marrow; Bone Resorption; Cell Differentiation; Cell Line; Electrophoretic Mobility Shift Assay; Gene Expression Regulation; Interferon-gamma; LIM Domain Proteins; Mice; Osteoclasts; Proteasome Endopeptidase Complex; Response Elements; Signal Transduction; STAT1 Transcription Factor; Transcription Factors; Vidarabine

2006
The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Dose-Response Relationship, Radiation; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2006
Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.
    Bone marrow transplantation, 2006, Volume: 37, Issue:3

    Topics: Adult; Biomarkers, Tumor; Bone Marrow; Bone Marrow Neoplasms; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Female; Gene Expression Regulation, Neoplastic; Graft Survival; Graft vs Tumor Effect; Humans; Mammaglobin A; Middle Aged; Myeloablative Agonists; Neoplasm Proteins; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Uteroglobin; Vidarabine

2006
Significance of VH genes mutation status for prognosis of CLL patients.
    Experimental oncology, 2005, Volume: 27, Issue:4

    Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Flow Cytometry; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine

2005
Resistant pure red cell aplasia after allogeneic bone marrow transplantation with major ABO mismatch treated by purified CD34+ cell infusion.
    European journal of haematology, 2006, Volume: 76, Issue:2

    Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Bone Marrow Transplantation; Erythropoietin; Female; Humans; Leukocyte Transfusion; Medical Errors; Red-Cell Aplasia, Pure; Rituximab; Transplantation, Homologous; Vidarabine

2006
Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Costs and Cost Analysis; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Living Donors; Melphalan; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study.
    Acta haematologica, 2006, Volume: 115, Issue:1-2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Health Services; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Retrospective Studies; United Kingdom; Vidarabine; Vincristine

2006
Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
    Clinical and laboratory haematology, 2006, Volume: 28, Issue:1

    Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Hemolysis; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Vidarabine

2006
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Cancer, 2006, Mar-01, Volume: 106, Issue:5

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Topotecan; Vidarabine

2006
Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.
    International journal of hematology, 2006, Volume: 83, Issue:1

    Topics: Adult; Bone Marrow; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2006
Fludarabine induced autoimmune haemolytic anaemia in a patient with chronic lymphocytic leukaemia.
    JPMA. The Journal of the Pakistan Medical Association, 2006, Volume: 56, Issue:1

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Vidarabine

2006
[Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:1

    Topics: Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative.
    The Journal of biological chemistry, 2006, Apr-14, Volume: 281, Issue:15

    Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Barbiturates; bcl-2-Associated X Protein; Benzophenanthridines; Benzopyrans; Caspase 9; Caspases; Cell Line; Cell Line, Tumor; Cell Survival; Chlorambucil; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; HeLa Cells; Humans; Ligands; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; Phenanthridines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Rats, Wistar; RNA, Small Interfering; Staurosporine; Time Factors; Vidarabine

2006
PS exposure increases the susceptibility of cells to fusion with DOTAP liposomes.
    Chemico-biological interactions, 2006, Mar-25, Volume: 160, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Membrane; Chlorides; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluorescent Dyes; HeLa Cells; Humans; Jurkat Cells; Liposomes; Manganese Compounds; Membrane Fusion; Mitoxantrone; Phosphatidylserines; Phospholipid Transfer Proteins; Quaternary Ammonium Compounds; Staurosporine; Vidarabine

2006
Positron emission tomography--positive distal femur following fludarabine, dexamethasone and mitoxantrone chemotherapy.
    British journal of haematology, 2006, Volume: 132, Issue:6

    Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Femur; Humans; Injections, Intravenous; Male; Middle Aged; Mitoxantrone; Osteonecrosis; Positron-Emission Tomography; Vidarabine

2006
Exacerbation of chronic epidural abscess following a fludarabine-based preparative regimen.
    American journal of hematology, 2006, Volume: 81, Issue:3

    Topics: Acetamides; Anemia, Aplastic; Anti-Infective Agents; Epidural Abscess; Graft vs Host Disease; Humans; Linezolid; Male; Middle Aged; Myeloablative Agonists; Oxazolidinones; Radiography; Staphylococcal Infections; Stem Cell Transplantation; Vidarabine

2006
Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    American journal of hematology, 2006, Volume: 81, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Male; Mexico; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2006, Volume: 39, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Transcription Factors; Tumor Suppressor Protein p53; Vidarabine

2006
Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia.
    Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:2

    Topics: Adult; Aged; Annexin A5; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cytotoxicity Tests, Immunologic; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

2006
[Second nonmyeloablative allogeneic peripheral blood stem cell transplantation with more immunosuppressive conditioning regimen for the late graft failure of the patient with acute myeloid leukemia].
    Fukuoka igaku zasshi = Hukuoka acta medica, 2005, Volume: 96, Issue:11

    Topics: Antineoplastic Agents; Cyclophosphamide; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2005
Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
    Bone marrow transplantation, 2006, Volume: 37, Issue:8

    Topics: Adolescent; Adult; Anemia, Aplastic; Animals; Antigens, CD34; Antilymphocyte Serum; Cyclophosphamide; Female; Graft vs Host Disease; Horses; Humans; Immunosuppressive Agents; Male; Micropore Filters; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2006
DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
    Leukemia, 2006, Volume: 20, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; CD40 Antigens; Cell Line, Tumor; Cell Survival; Cyclohexanones; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine

2006
The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia.
    Haematologica, 2006, Volume: 91, Issue:4

    Topics: Anemia, Hemolytic, Autoimmune; Case-Control Studies; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Vidarabine

2006
[Fever and dyspnea in a patient with chronic lymphatic leukemia under treatment with fludarabine].
    Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:1

    Topics: Aged; Antineoplastic Agents; Dyspnea; Female; Fever; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vidarabine

2006
Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
    Leukemia research, 2006, Volume: 30, Issue:12

    Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease Progression; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prednisolone; Remission Induction; Risk Factors; Rituximab; Treatment Outcome; Vidarabine

2006
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Blood, 2006, Aug-01, Volume: 108, Issue:3

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cells, Cultured; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Transcription, Genetic; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2006
Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway.
    International immunopharmacology, 2006, Volume: 6, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Extracellular Signal-Regulated MAP Kinases; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interleukin-8; Monocytes; Transcription Factor AP-1; U937 Cells; Vidarabine

2006
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
    European journal of haematology, 2006, Volume: 76, Issue:6

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine

2006
Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    American journal of hematology, 2006, Volume: 81, Issue:4

    Topics: Adult; Amyloidosis; Diarrhea; Drug Therapy, Combination; Heart Diseases; Humans; Hypotension; Japan; Kidney Diseases; Male; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
The infectious consequences of rituximab addition to fludarabine-containing regimens.
    Blood, 2006, Apr-01, Volume: 107, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Drug Interactions; Humans; Lymphoma, AIDS-Related; Rituximab; Vidarabine

2006
[Inhibition effect of fludarabine on the growth of myelodysplastic syndrome cell line MUTZ-1 and its mechanism].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2006, Volume: 35, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Survivin; Vidarabine

2006
Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient.
    Leukemia research, 2007, Volume: 31, Issue:1

    Topics: Aged; Antifungal Agents; Antineoplastic Agents; Cryptococcosis; Fluconazole; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Male; Opportunistic Infections; Radiography, Thoracic; Tomography, X-Ray Computed; Treatment Outcome; Vidarabine

2007
F-ara-AMP is a substrate of cytoplasmic 5'-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation.
    Nucleosides, nucleotides & nucleic acids, 2006, Volume: 25, Issue:3

    Topics: 5'-Nucleotidase; Chromatography, High Pressure Liquid; Cytoplasm; Humans; Kinetics; Magnetic Resonance Spectroscopy; Vidarabine; Vidarabine Phosphate

2006
[Effect of inhibitors of signal transducer and activator of transcription-1/3 on expression of tumor necrosis factor-alpha induced by high mobility group box-1 protein inflammatory response in rat peritoneal macrophages].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2006, Feb-01, Volume: 44, Issue:3

    Topics: Animals; Cells, Cultured; Drug Interactions; HMGB1 Protein; Macrophages, Peritoneal; Male; Rats; Rats, Wistar; Signal Transduction; Sirolimus; STAT1 Transcription Factor; STAT3 Transcription Factor; Transcription, Genetic; Tumor Necrosis Factor-alpha; Vidarabine

2006
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
    British journal of haematology, 2006, Volume: 133, Issue:3

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Bone Marrow Diseases; Child; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine

2006
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Cancer, 2006, Jun-01, Volume: 106, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2006
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
    Blood, 2006, Aug-15, Volume: 108, Issue:4

    Topics: Animals; Antineoplastic Agents; CD5 Antigens; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Neoplasm Proteins; Proto-Oncogene Proteins; Tumor Cells, Cultured; Vidarabine

2006
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
    American journal of hematology, 2006, Volume: 81, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine

2006
Another case of myelodysplasia with monosomy 7 following fludarabine-based chemotherapy.
    American journal of hematology, 2006, Volume: 81, Issue:6

    Topics: Antineoplastic Agents; Chromosomes, Human, Pair 7; Female; Humans; Lymphoma, Follicular; Middle Aged; Monosomy; Myelodysplastic Syndromes; Vidarabine

2006
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:7

    Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Stem Cell Transplantation; Vidarabine

2006
Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.
    British journal of haematology, 2006, Volume: 133, Issue:6

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mucositis; Opportunistic Infections; Pilot Projects; Quality of Life; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2006
[Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisolone; Rituximab; Vidarabine; Vincristine

2005
Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: rituximab as the treatment of choice?
    Leukemia research, 2007, Volume: 31, Issue:2

    Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Hepatitis B; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine

2007
Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
    International journal of hematology, 2006, Volume: 83, Issue:4

    Topics: Adult; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma.
    Onkologie, 2006, Volume: 29, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; European Union; Fees and Charges; Germany; Health Care Costs; Humans; Lymphoma, Follicular; Male; Models, Economic; Prednisone; Reproducibility of Results; Rituximab; Sensitivity and Specificity; Vidarabine; Vincristine

2006
Hemophagocytosis during fludarabine-based SCT for systemic juvenile idiopathic arthritis.
    Bone marrow transplantation, 2006, Volume: 38, Issue:3

    Topics: Adolescent; Arthritis, Juvenile; Child; Female; Humans; Macrophage Activation; Male; Myeloablative Agonists; Stem Cell Transplantation; Syndrome; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2006
Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:7

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine

2006
Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
    International journal of hematology, 2006, Volume: 83, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Neoplasms, Second Primary; Prednisone; Recurrence; Remission Induction; Time Factors; Vidarabine; Vincristine

2006
Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine.
    Journal of medical virology, 2006, Volume: 78, Issue:8

    Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Female; Hepatitis B; Hepatitis B Surface Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phylogeny; Vidarabine

2006
Diagnosis of a primary testicular lymphoma by echography and magnetic resonance imaging.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:6

    Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Methotrexate; Neoplasm Proteins; Orchiectomy; Prednisone; Prognosis; Rituximab; Testicular Neoplasms; Ultrasonography; Vidarabine; Vincristine

2006
Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
    Experimental hematology, 2006, Volume: 34, Issue:7

    Topics: Animals; Bone Marrow Transplantation; Flow Cytometry; Graft vs Leukemia Effect; Mice; Mice, Inbred C57BL; Spleen; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
Graft failure and severe autoimmune haemolysis following fludarabine-based reduced-intensity matched unrelated donor bone marrow transplantation for severe aplastic anaemia: salvage by second transplant with conventional dose conditioning.
    Bone marrow transplantation, 2006, Volume: 38, Issue:4

    Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic, Autoimmune; Bone Marrow Transplantation; Female; Graft Rejection; Humans; Salvage Therapy; Tissue Donors; Vidarabine

2006
Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia.
    British journal of haematology, 2006, Volume: 134, Issue:2

    Topics: Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Pilot Projects; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2006
High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
    British journal of haematology, 2006, Volume: 134, Issue:2

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematologic Neoplasms; Humans; Leukemia; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine

2006
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
    Cancer, 2006, Aug-15, Volume: 107, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Risk Factors; Rituximab; Vidarabine

2006
Central line-related bacteraemia due to Roseomonas mucosa in a neutropenic patient with acute myeloid leukaemia in Piraeus, Greece.
    Journal of medical microbiology, 2006, Volume: 55, Issue:Pt 8

    Topics: Acute Disease; Adult; Amikacin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bacteremia; Base Sequence; Catheterization, Central Venous; Cytarabine; Humans; Leukemia, Myeloid; Male; Methylobacteriaceae; Molecular Sequence Data; Neutropenia; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; RNA, Bacterial; RNA, Ribosomal, 16S; Vidarabine

2006
Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
    European journal of haematology, 2006, Volume: 77, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Family; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine

2006
Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus- positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia.
    Archives of pathology & laboratory medicine, 2006, Volume: 130, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Humans; Immunoglobulin A; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Tumor Lysis Syndrome; Vidarabine

2006
Preparation of a fludarabine intermediate via selective alkylation of 2-fluoroadenine.
    Nucleosides, nucleotides & nucleic acids, 2006, Volume: 25, Issue:7

    Topics: Adenine; Alkylation; Arabinose; Nucleic Acid Conformation; Pentanols; Stereoisomerism; Vidarabine

2006
[Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Cyclosporine; Graft vs Host Disease; Humans; Infant; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tissue Donors; Transplantation Conditioning; Vidarabine

2006
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:7

    Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Signal Transduction; T-Lymphocytes; Time Factors; Vidarabine

2006
[Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
    Terapevticheskii arkhiv, 2006, Volume: 78, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine

2006
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:9

    Topics: Adult; Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bacterial Infections; Causality; Female; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Rituximab; Vidarabine

2006
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.
    British journal of haematology, 2006, Volume: 135, Issue:3

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Middle Aged; Postoperative Complications; Primary Myelofibrosis; Spleen; Time Factors; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2006
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
    Leukemia research, 2007, Volume: 31, Issue:3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Remission Induction; T-Lymphocytes, Regulatory; Thalidomide; Treatment Failure; Tumor Necrosis Factor-alpha; Vidarabine

2007
Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
    Bone marrow transplantation, 2006, Volume: 38, Issue:7

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Czech Republic; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hospital Costs; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Philadelphia Chromosome; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cladribine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Kidney Neoplasms; Oxidoreductases; Transfection; Vidarabine

2007
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
    Cancer research, 2006, Oct-01, Volume: 66, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Melanoma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protease Inhibitors; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Ultraviolet Rays; Vidarabine

2006
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.
    Medical oncology (Northwood, London, England), 2006, Volume: 23, Issue:3

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Recurrence; Remission Induction; Stem Cells; Treatment Outcome; Vidarabine

2006
Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine.
    Pediatric transplantation, 2006, Volume: 10, Issue:7

    Topics: Antineoplastic Agents; Bone Neoplasms; Child; Disease Progression; Fatal Outcome; Female; Humans; Immunosuppression Therapy; Magnetic Resonance Imaging; Myeloablative Agonists; Osteosarcoma; Pleural Neoplasms; Radiography, Thoracic; Vidarabine

2006
Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
    Transplantation, 2006, Oct-15, Volume: 82, Issue:7

    Topics: Acute Disease; Antifungal Agents; Cause of Death; Chronic Disease; Cyclosporine; Cytomegalovirus Infections; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Mycoses; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine

2006
Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.
    Journal of virology, 2006, Volume: 80, Issue:21

    Topics: Adenine; Animals; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cercocebus atys; Drug Carriers; Erythrocytes; Female; Humans; Macrophages; Male; Myeloablative Agonists; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; STAT1 Transcription Factor; T-Lymphocyte Subsets; Tenofovir; Vidarabine; Viremia; Virus Replication

2006
Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine.
    European journal of haematology, 2006, Volume: 77, Issue:5

    Topics: Acyclovir; Aged; Antineoplastic Agents; Antiviral Agents; Female; Gene Expression Profiling; Gene Expression Regulation, Viral; Herpesviridae Infections; Herpesvirus 1, Human; Herpesvirus 2, Human; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphadenitis; Vidarabine

2006
Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.
    Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Flow Cytometry; Gene Expression; Gene Expression Profiling; Genistein; Humans; Interleukin-10; Leukemia, B-Cell; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2007
Flow cytometric evaluation of red blood cell chimerism after bone marrow transplantation in Iranian patients: a preliminary study.
    Archives of Iranian medicine, 2006, Volume: 9, Issue:4

    Topics: ABO Blood-Group System; Adolescent; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Child; Erythrocytes; Female; Flow Cytometry; Fluorescein-5-isothiocyanate; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Iran; Male; Vidarabine

2006
Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:9

    Topics: Aged; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2006
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
    Nucleosides, nucleotides & nucleic acids, 2006, Volume: 25, Issue:9-11

    Topics: Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; Estrogen Receptor alpha; Genes, APC; Genes, BRCA1; Humans; K562 Cells; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Vidarabine

2006
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10

    Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Reoperation; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2006
STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines.
    International journal of cancer, 2007, Jan-01, Volume: 120, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cross Reactions; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Radiation; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gamma Rays; Gene Expression Profiling; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Radiation Tolerance; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT1 Transcription Factor; Tumor Cells, Cultured; Vidarabine

2007
Treatment-related myelodysplasia following fludarabine combination chemotherapy.
    Haematologica, 2006, Volume: 91, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Vidarabine

2006
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2006
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
    Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lichenoid Eruptions; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mucositis; Paraneoplastic Syndromes; Pemphigus; Prednisone; Recurrence; Rituximab; T-Lymphocytes; Vidarabine; Vincristine

2007
MicroRNAs in leukemia.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8

    Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia; Mice; MicroRNAs; Piperidines; Prognosis; Vidarabine

2006
Conditioning with fludarabine alone and allogeneic transplantation as a successful rescue therapy for persistent, severe iatrogenic aplasia after relapse of acute myeloid leukemia.
    Bone marrow transplantation, 2007, Volume: 39, Issue:1

    Topics: Anemia, Aplastic; Female; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Leukemia, Myeloid; Middle Aged; Myeloablative Agonists; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Chemical and Drug Induced Liver Injury; Cholangitis; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Hematologic Diseases; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Incidence; Infant, Newborn; Liver Diseases; Liver Function Tests; Male; Melphalan; Middle Aged; Postoperative Complications; Risk Factors; Tacrolimus; Tissue Donors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2006
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:12

    Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2006
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:12

    Topics: Alemtuzumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cladribine; Etodolac; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Purines; Rituximab; Spectrometry, Fluorescence; Vidarabine

2006
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.
    Haematologica, 2006, Volume: 91, Issue:12 Suppl

    Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Immunotherapy; Leukopenia; Lymphoma, Follicular; Middle Aged; Parvoviridae Infections; Parvovirus B19, Human; Prednisolone; Recurrence; Rituximab; Vidarabine; Vincristine; Viremia

2006
Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
    American journal of hematology, 2007, Volume: 82, Issue:6

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chimerism; Chronic Disease; Cohort Studies; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Injections, Intravenous; Lymphocyte Transfusion; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2007
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
    Leukemia, 2007, Volume: 21, Issue:3

    Topics: Aged; Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; CD52 Antigen; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Drug Resistance; Glycoproteins; Hemoglobins; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Splenectomy; Treatment Outcome; Vidarabine; Vincristine

2007
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
    Leukemia, 2007, Volume: 21, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine

2007
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
    British journal of haematology, 2007, Volume: 136, Issue:1

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chi-Square Distribution; Disease-Free Survival; Drug Resistance, Multiple; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Phenotype; Prognosis; Remission Induction; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Vidarabine

2007
Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
    Cytometry. Part B, Clinical cytometry, 2007, Volume: 72, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Deletion; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Toxicity Tests; Treatment Outcome; Vidarabine

2007
Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.
    Clinical and experimental dermatology, 2007, Volume: 32, Issue:2

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Skin; Treatment Outcome; Vidarabine

2007
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; Injections, Intraperitoneal; Leukemia L1210; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Sulfonamides; Survival Analysis; Time Factors; Tumor Burden; Vidarabine; Weight Loss; Xenograft Model Antitumor Assays

2007
Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.
    Onkologie, 2007, Volume: 30, Issue:1-2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclosporine; Demyelinating Diseases; Fatal Outcome; Female; Humans; Immunosuppressive Agents; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment; Stem Cell Transplantation; Vidarabine

2007
Improved outcome after relapse in children with acute myeloid leukaemia.
    British journal of haematology, 2007, Volume: 136, Issue:2

    Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Cytogenetics; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Recurrence; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate; Sweden; Treatment Outcome; Vidarabine

2007
Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 292, Issue:6

    Topics: Angioplasty, Balloon; Animals; Aorta; Cardiovascular Agents; Carotid Artery Injuries; Carotid Stenosis; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Feasibility Studies; Hyperplasia; Janus Kinase 2; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Prosthesis Design; Rabbits; Rats; Rats, Wistar; RNA, Antisense; STAT1 Transcription Factor; Stents; Time Factors; Transfection; Tunica Intima; Vidarabine

2007
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
    Bone marrow transplantation, 2007, Volume: 39, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.
    Bone marrow transplantation, 2007, Volume: 39, Issue:7

    Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Agents; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinopathies; Humans; Immunologic Deficiency Syndromes; Infant; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2007
Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2007, Volume: 9, Issue:1

    Topics: Academies and Institutes; Antineoplastic Agents; Aspergillosis; Cyclophosphamide; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Michigan; Middle Aged; Myeloablative Agonists; Neoplasms; Opportunistic Infections; Retrospective Studies; Review Literature as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
    European journal of haematology, 2007, Volume: 78, Issue:2

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Burkitt Lymphoma; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 8; Chromosomes, Human, X; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Genes, myc; Humans; Karyotyping; Lymph Nodes; Lymphoma, AIDS-Related; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Mutagenesis, Insertional; Pleural Effusion, Malignant; Prednisone; Rituximab; Translocation, Genetic; Trisomy; Vidarabine; Vincristine

2007
Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    European journal of haematology, 2007, Volume: 78, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Blast Crisis; Chimera; Cord Blood Stem Cell Transplantation; Disease Progression; Fatal Outcome; Female; Graft Rejection; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Immunity, Maternally-Acquired; Isoantigens; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine

2007
Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:3

    Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child, Preschool; Cyclophosphamide; Dyskeratosis Congenita; Female; Humans; Vidarabine

2007
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:3

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine

2008
Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    International journal of hematology, 2007, Volume: 85, Issue:2

    Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Vidarabine

2007
17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:2

    Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Chromosome Deletion; Chromosomes, Human, Pair 17; DNA (Cytosine-5-)-Methyltransferases; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine

2007
Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: a study of 25 consecutive patients and a literature review.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:2

    Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; DNA (Cytosine-5-)-Methyltransferases; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors.
    Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Renal Cell; Colonic Neoplasms; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Rectal Neoplasms; Sarcoma; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2006
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.
    Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3

    Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Anti-Inflammatory Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisolone; Remission Induction; Sweet Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2006
Allogeneic bone marrow transplantation for Pearson's syndrome.
    Bone marrow transplantation, 2007, Volume: 39, Issue:9

    Topics: Antifungal Agents; Antilymphocyte Serum; Antineoplastic Agents; Aspergillosis, Allergic Bronchopulmonary; Base Sequence; Bone Marrow Transplantation; DNA, Mitochondrial; Electron Transport; Female; Genetic Diseases, Inborn; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Leukemia, Myeloid; Melphalan; Mitochondrial Diseases; Myeloablative Agonists; Sequence Deletion; Syndrome; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine

2007
Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation.
    Haematologica, 2007, Volume: 92, Issue:3

    Topics: Adult; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Registries; Remission Induction; Retrospective Studies; Sarcoma; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Advances in CLL.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:1

    Topics: Antibodies, Monoclonal; Biomarkers; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Therapy, Combination; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine

2007
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
    British journal of haematology, 2007, Volume: 136, Issue:6

    Topics: Adolescent; Adult; Aged; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Red-Cell Aplasia, Pure; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2007
Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway.
    Leukemia, 2007, Volume: 21, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cells, Cultured; Human T-lymphotropic virus 1; Humans; Lymphocyte Activation; NF-kappa B; Signal Transduction; T-Lymphocytes; Vidarabine

2007
Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.
    Oncogene, 2007, Aug-23, Volume: 26, Issue:39

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Caspases; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, B-Cell; Minor Histocompatibility Antigens; Proto-Oncogene Proteins c-bcl-2; Rituximab; RNA, Small Interfering; Tumor Cells, Cultured; Vidarabine; Vincristine

2007
Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine.
    Annals of hematology, 2007, Volume: 86, Issue:8

    Topics: Cell Transformation, Neoplastic; Female; Genes, Immunoglobulin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Vidarabine

2007
Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
    International journal of radiation oncology, biology, physics, 2007, Jul-15, Volume: 68, Issue:4

    Topics: Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lung; Male; Melphalan; Myeloablative Agonists; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
    Acta haematologica, 2007, Volume: 118, Issue:1

    Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemtuzumab; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; Vidarabine

2007
Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
    Haematologica, 2007, Volume: 92, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Female; Graft Survival; Histiocytosis, Langerhans-Cell; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Melphalan; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vinblastine

2007
Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.
    Haematologica, 2007, Volume: 92, Issue:1

    Topics: Agammaglobulinemia; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Humans; Immunocompromised Host; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Opportunistic Infections; Skin Diseases, Bacterial; Vidarabine

2007
Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.
    Haematologica, 2007, Volume: 92, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Cell Activating Factor; B-Lymphocytes; Bone Marrow; Cell Lineage; Cells, Cultured; Cyclophosphamide; Cytokines; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lymphopoiesis; Middle Aged; Myelopoiesis; Neutropenia; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia

2007
Gene expression signatures that predict radiation exposure in mice and humans.
    PLoS medicine, 2007, Volume: 4, Issue:4

    Topics: Animals; Cyclophosphamide; DNA; DNA Damage; Dose-Response Relationship, Radiation; Environmental Exposure; Female; Gene Expression; Gene Expression Profiling; Gene Regulatory Networks; Genes; Humans; Leukocytes, Mononuclear; Mass Screening; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Particle Accelerators; Radiation Dosage; Radiation Injuries, Experimental; Radiation, Ionizing; Sensitivity and Specificity; Single-Blind Method; Species Specificity; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia.
    Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:5 Suppl

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Fluorescent Antibody Technique, Direct; Humans; Immunoglobulin A; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Paraneoplastic Syndromes; Pemphigus; Rituximab; Vidarabine

2007
Dictyostelium discoideum salvages purine deoxyribonucleosides by highly specific bacterial-like deoxyribonucleoside kinases.
    Journal of molecular biology, 2007, Jun-08, Volume: 369, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Differentiation; Deoxyribonucleosides; Dictyostelium; Gene Expression Regulation; Kinetics; Models, Molecular; Molecular Sequence Data; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Recombinant Proteins; Substrate Specificity; Vidarabine

2007
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
    Leukemia research, 2008, Volume: 32, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasms, Second Primary; Rituximab; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2008
Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation.
    Bone marrow transplantation, 2007, Volume: 40, Issue:1

    Topics: Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine

2007
Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    Bone marrow transplantation, 2007, Volume: 40, Issue:1

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Enzyme Inhibitors; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; India; Male; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Hematology (Amsterdam, Netherlands), 2007, Volume: 12, Issue:2

    Topics: ABO Blood-Group System; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; beta-Thalassemia; Blood Group Incompatibility; Busulfan; Child, Preschool; Cyclosporine; Epstein-Barr Virus Infections; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Lymphoproliferative Disorders; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Plasma Exchange; Red-Cell Aplasia, Pure; Remission, Spontaneous; Retrospective Studies; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2007
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:4

    Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Stem Cell Transplantation; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation.
    Bone marrow transplantation, 2007, Volume: 40, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Combined Modality Therapy; Erythema Infectiosum; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Parvovirus B19, Human; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiography, Thoracic; Recurrence; Thiotepa; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Bone marrow transplantation, 2007, Volume: 40, Issue:2

    Topics: Adolescent; Adult; Busulfan; Child; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia; Male; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Annals of hematology, 2007, Volume: 86, Issue:8

    Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.
    International journal of hematology, 2007, Volume: 85, Issue:3

    Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
In vitro effect of fludarabine, cyclophosphamide, and cytosine arabinoside on chromosome breakage in Fanconi anemia patients: relevance to stem cell transplantation.
    International journal of hematology, 2007, Volume: 85, Issue:4

    Topics: Antimetabolites, Antineoplastic; Cells, Cultured; Chromosome Breakage; Chromosome Fragility; Cyclophosphamide; Cytarabine; Fanconi Anemia; Female; Humans; Male; Myeloablative Agonists; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine

2007
Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine.
    International journal of oncology, 2007, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Electrochemotherapy; Electroporation; Gene Transfer Techniques; Genes, Bacterial; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Neoplasms, Experimental; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Rats; Rats, Inbred Lew; RNA, Messenger; Vidarabine; Xenograft Model Antitumor Assays

2007
Acquired hemophilia in chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:5

    Topics: Aged; Autoantibodies; Cyclophosphamide; Factor VIII; Female; Hemophilia A; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Time Factors; Treatment Outcome; Vidarabine

2007
Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.
    Haematologica, 2007, Volume: 92, Issue:5

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cause of Death; Chi-Square Distribution; Child; Child, Preschool; Cohort Studies; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Hepatitis; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Kaplan-Meier Estimate; Living Donors; Lymphocyte Depletion; Male; Middle Aged; Proportional Hazards Models; Reoperation; Retrospective Studies; Statistics, Nonparametric; Survival Analysis; Survival Rate; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Haematologica, 2007, Volume: 92, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2007
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
    Blood, 2007, Aug-15, Volume: 110, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prognosis; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
[Ulcers in a patient with chronic lymphocytic leukemia].
    Actas dermo-sifiliograficas, 2007, Volume: 98, Issue:4

    Topics: Antimetabolites, Antineoplastic; Ear Diseases; Ear, External; Hand Dermatoses; Herpes Simplex; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Skin Ulcer; Vidarabine

2007
Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
    Leukemia, 2007, Volume: 21, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, T-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Medical Oncology; Mitoxantrone; Treatment Outcome; Vidarabine

2007
Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11

    Topics: B-Lymphocytes; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Models, Biological; Polymerase Chain Reaction; Protein Tyrosine Phosphatases; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Reverse Transcriptase Polymerase Chain Reaction; Sulfites; Vidarabine

2007
Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.
    Blood, 2007, Oct-15, Volume: 110, Issue:8

    Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Factor VIII; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Hemophilia A; Humans; Mice; Swine; Transgenes; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
    British journal of cancer, 2007, Jul-16, Volume: 97, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cross-Linking Reagents; DNA; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pyrroles; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine

2007
Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Agents; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:7

    Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2007
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.
    Gene therapy, 2007, Volume: 14, Issue:17

    Topics: Animals; Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cytarabine; Directed Molecular Evolution; Drosophila melanogaster; Genes, Transgenic, Suicide; Genetic Therapy; Glioblastoma; Humans; Lethal Dose 50; Mutation; Neoplasms; Osteosarcoma; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Substrate Specificity; Transduction, Genetic; Vidarabine

2007
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.
    Experimental hematology, 2007, Volume: 35, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation; CD2 Antigens; CTLA-4 Antigen; Forkhead Transcription Factors; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Interferon-gamma; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Transplantation Chimera; Vidarabine

2007
Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.
    Leukemia, 2007, Volume: 21, Issue:12

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Alkylator-free conditioning regimen for patients with acquired aplastic anemia, transplanted from genetically identical twins.
    Pediatric transplantation, 2007, Volume: 11, Issue:5

    Topics: Alkylating Agents; Anemia, Aplastic; Antineoplastic Agents; Contraindications; Female; Follow-Up Studies; Humans; Male; Myeloablative Agonists; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Twins, Monozygotic; Vidarabine

2007
[Reactivation of familial hemophagocytic lymphohistiocytosis after non-myeloablative cord blood stem cell transplantation resulted in the early graft failure].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:6

    Topics: Antilymphocyte Serum; Child, Preschool; Cord Blood Stem Cell Transplantation; DNA; Female; Graft Rejection; Histocompatibility Testing; Humans; Killer Cells, Natural; Lymphocyte Activation; Lymphohistiocytosis, Hemophagocytic; Recurrence; T-Lymphocytes; Transplantation Conditioning; Vidarabine

2007
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Bone marrow transplantation, 2007, Volume: 40, Issue:6

    Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infections; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
    Blood, 2007, Nov-01, Volume: 110, Issue:9

    Topics: Adolescent; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Combination therapies for previously untreated CLL.
    Lancet (London, England), 2007, Jul-21, Volume: 370, Issue:9583

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Vidarabine

2007
Regurgitation of esophageal mucosa.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:8

    Topics: Adult; Busulfan; Esophagitis; Esophagus; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucositis; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine; Vomiting

2007
Paraneoplastic pemphigus associated with fludarabine use.
    Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:1

    Topics: Antineoplastic Agents; Humans; Immunoglobulin G; Keratinocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Vidarabine

2007
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal
    Leukemia, 2007, Volume: 21, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:9

    Topics: Adolescent; Adult; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Fanconi Anemia; Female; Graft Survival; Histocompatibility Testing; Humans; Infant; Male; Middle Aged; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine

2007
Diffuse large B-cell lymphoma developing following treatment of Waldenstrom's macroglobulinaemia: spontaneous resolution upon cessation of fludarabine.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:8

    Topics: Aged; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2007
Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Pediatric hematology and oncology, 2007, Volume: 24, Issue:6

    Topics: Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Living Donors; Lymphocyte Depletion; Male; Melphalan; Multiple Organ Failure; Postoperative Complications; Reoperation; Retrospective Studies; Spain; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome

2007
[Visual cortes--is it a concern?].
    Bulletin de la Societe belge d'ophtalmologie, 2007, Issue:304

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Blindness, Cortical; Carmustine; Cathartics; Cholinergic Antagonists; Cisplatin; Cyclosporine; Dopamine Agents; Drug-Related Side Effects and Adverse Reactions; Hallucinations; Humans; Interferons; Serotonin Agents; Tacrolimus; Vidarabine; Vincristine; Visual Cortex

2007
Fludarabine delivery by autologous red blood cells induces macrophage depletion in chronically SIV-infected Sooty Mangabeys.
    Journal of controlled release : official journal of the Controlled Release Society, 2006, Nov-28, Volume: 116, Issue:2

    Topics: Animals; Cercocebus atys; Dialysis; Drug Administration Schedule; Drug Delivery Systems; Erythrocytes; Macrophages; Phosphorylation; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Vidarabine; Viral Load

2006
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
    Journal of pharmaceutical sciences, 2008, Volume: 97, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemistry, Pharmaceutical; Drug Stability; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Mitoxantrone; Solubility; Vidarabine

2008
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.
    Bone marrow transplantation, 2007, Volume: 40, Issue:9

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Child; Dyskeratosis Congenita; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Male; Transplantation Conditioning; Vidarabine

2007
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Bone marrow transplantation, 2007, Volume: 40, Issue:9

    Topics: Adult; Aged; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Extramedullary, extranodal lymphoplasmacytic lymphoma with macroglobulinemia: long-term complete remission with fludarabine.
    Annals of hematology, 2008, Volume: 87, Issue:2

    Topics: Aged; Antineoplastic Agents; Humans; Lung Neoplasms; Male; Vidarabine; Waldenstrom Macroglobulinemia

2008
Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.
    British journal of cancer, 2007, Sep-17, Volume: 97, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation; Vidarabine

2007
Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine.
    Leukemia, 2008, Volume: 22, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Genes, p53; Humans; Isoelectric Point; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Mutation; Neoplasm Proteins; Peptide Fragments; Peptide Hydrolases; Phosphorylation; Protein Processing, Post-Translational; Protein Structure, Tertiary; Tumor Suppressor Protein p53; Vidarabine

2008
CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.
    British journal of haematology, 2007, Volume: 138, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; CD40 Ligand; Cell Proliferation; Cell Survival; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Mice; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; Tumor Cells, Cultured; Vidarabine

2007
Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.
    Haematologica, 2007, Volume: 92, Issue:9

    Topics: Aged; Epstein-Barr Virus Infections; Everolimus; Fatal Outcome; Female; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Vidarabine

2007
Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine.
    British journal of haematology, 2007, Volume: 139, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Opportunistic Infections; Toxoplasmosis, Cerebral; Vidarabine

2007
[Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies].
    Terapevticheskii arkhiv, 2007, Volume: 79, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Myeloablative Agonists; Risk; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
[Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
    Terapevticheskii arkhiv, 2007, Volume: 79, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Treatment Outcome; Vidarabine

2007
Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
    Bone marrow transplantation, 2007, Volume: 40, Issue:10

    Topics: Adolescent; Adult; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Graft vs Host Disease; Humans; Male; Middle Aged; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
A novel regimen incorporating the concomitant administration of fludarabine and alemtuzumab for the treatment of refractory adult acute lymphoblastic leukaemia: a report of three cases.
    British journal of haematology, 2007, Volume: 139, Issue:1

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Female; Humans; Male; Middle Aged; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Vidarabine

2007
Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.
    Cancer genetics and cytogenetics, 2007, Volume: 177, Issue:2

    Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; DNA-Binding Proteins; Female; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Rituximab; Transcriptional Elongation Factors; Translocation, Genetic; Vidarabine

2007
Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    International journal of radiation oncology, biology, physics, 2008, Feb-01, Volume: 70, Issue:2

    Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Disease-Free Survival; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphatic Irradiation; Middle Aged; Muromonab-CD3; Peripheral Blood Stem Cell Transplantation; Pneumonia; Retreatment; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.
    Leukemia research, 2008, Volume: 32, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Middle Aged; Rituximab; Vidarabine

2008
Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.
    Transplantation, 2007, Sep-15, Volume: 84, Issue:5

    Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2007
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
    British journal of haematology, 2007, Volume: 139, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Prognosis; Purine Nucleotides; Risk Factors; Vidarabine

2007
Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardy.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:10

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Prognosis; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:10

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Male; Middle Aged; Models, Biological; Rituximab; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine

2007
Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    The Netherlands journal of medicine, 2007, Volume: 65, Issue:9

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Aspergillosis; CD52 Antigen; Drug Evaluation; Drug Resistance, Neoplasm; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Records; Netherlands; Opportunistic Infections; Pneumonia, Pneumocystis; Remission Induction; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine

2007
[Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:5

    Topics: Aged; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Treatment Outcome; Vidarabine

2007
[Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
    Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:5

    Topics: Animals; Cyclophosphamide; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Animal; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2007
BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism.
    Blood, 2008, Jan-15, Volume: 111, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-bcl-2; Regulatory Elements, Transcriptional; RNA, Messenger; RNA, Neoplasm; Time Factors; Translocation, Genetic; Vidarabine

2008
Fludarabine reduces survivability of HepG2 cells through VEGF under hypoxia.
    Archives of biochemistry and biophysics, 2007, Dec-01, Volume: 468, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Oxygen; Vascular Endothelial Growth Factor A; Vidarabine

2007
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Dec-01, Volume: 25, Issue:34

    Topics: Aged; Alleles; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Cyclophosphamide; DNA Breaks, Double-Stranded; DNA-Binding Proteins; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine

2007
Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis.
    Bone marrow transplantation, 2008, Volume: 41, Issue:3

    Topics: Adult; Aged; Cohort Studies; Colony-Stimulating Factors; Cyclophosphamide; Female; Finland; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Transplantation, Autologous; Treatment Failure; Vidarabine

2008
Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo.
    European journal of haematology, 2007, Volume: 79, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Neoplasms; Vidarabine

2007
Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy.
    British journal of haematology, 2007, Volume: 139, Issue:4

    Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2007
Have we forgotten the purpose of phase III studies?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Dec-10, Volume: 25, Issue:35

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD52 Antigen; Chlorambucil; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Research Design; Vidarabine

2007
Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.
    International journal of hematology, 2007, Volume: 86, Issue:3

    Topics: Adolescent; Adult; Age Factors; Antilymphocyte Serum; Busulfan; Child; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Sex Factors; Survival Rate; Transplantation Conditioning; Vidarabine

2007
Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.
    Cell death and differentiation, 2008, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Brefeldin A; Cell Line, Tumor; Cisplatin; Dactinomycin; Doxorubicin; Humans; Imatinib Mesylate; Interferons; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-mdm2; Pyrimidines; STAT1 Transcription Factor; Tumor Suppressor Protein p53; Vidarabine

2008
Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor kappaB.
    Bone marrow transplantation, 2008, Volume: 41, Issue:3

    Topics: Apoptosis; Humans; Immunosuppressive Agents; Jurkat Cells; Leukocytes, Mononuclear; NF-kappa B; Signal Transduction; T-Lymphocytes; Th1 Cells; Tumor Necrosis Factor-alpha; Vidarabine

2008
CD-34 selected hematopoetic stem cell transplantation from HLA identical family members for fanconi anemia.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:5

    Topics: Adolescent; Antigens, CD34; Antineoplastic Agents; Child; DNA (Cytosine-5-)-Methyltransferases; Fanconi Anemia; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Lymphocyte Depletion; Male; Recombinant Proteins; T-Lymphocytes; Transplantation Conditioning; Vidarabine

2008
Cannabinoid receptors expression in bone marrow trephine biopsy of chronic lymphocytic leukaemia patients treated with purine analogues.
    Experimental oncology, 2007, Volume: 29, Issue:3

    Topics: Antineoplastic Agents; B-Lymphocytes; Biopsy; Bone Marrow Cells; Cladribine; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Receptors, Cannabinoid; Vidarabine

2007
Imatinib inhibition of fludarabine uptake in T-lymphocytes.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:4

    Topics: Antineoplastic Agents; Benzamides; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dose-Response Relationship, Drug; Drug Interactions; Humans; Imatinib Mesylate; In Vitro Techniques; Piperazines; Pyrimidines; Thioinosine; Vidarabine

2008
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.
    Cancer research, 2007, Nov-15, Volume: 67, Issue:22

    Topics: Animals; Antigens, CD20; Antineoplastic Agents; Chlorocebus aethiops; Drug Therapy; Humans; Lymphoma; Measles virus; Membrane Cofactor Protein; Mice; Mice, Transgenic; Prodrugs; Purine-Nucleoside Phosphorylase; Vero Cells; Vidarabine

2007
Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2007, Volume: 13, Issue:12

    Topics: Adult; Anemia, Sickle Cell; Directed Tissue Donation; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Kidney Failure, Chronic; Male; Myeloablative Agonists; Siblings; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group.
    Haematologica, 2007, Volume: 92, Issue:10

    Topics: Adolescent; Adult; Child; Child, Preschool; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Male; Probability; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine

2007
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
    Blood, 2008, Feb-01, Volume: 111, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase Inhibitors; Caspases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Mice; Mitochondria; Mitochondrial Proteins; Protease Inhibitors; Receptors, IgE; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Vidarabine; Xenograft Model Antitumor Assays

2008
[MALT (mucosa-associated lymphoid tissue) lymphoma of the lacrimal gland].
    Journal francais d'ophtalmologie, 2007, Volume: 30, Issue:9

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Eye Neoplasms; Humans; Lacrimal Apparatus; Lymphoma, B-Cell, Marginal Zone; Male; Mitoxantrone; Rituximab; Vidarabine

2007
Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients.
    British journal of haematology, 2008, Volume: 140, Issue:3

    Topics: Adolescent; Antigens, CD34; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft vs Leukemia Effect; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Probability; Prospective Studies; Recurrence; Stem Cells; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.
    Nucleosides, nucleotides & nucleic acids, 2007, Volume: 26, Issue:8-9

    Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Genes, APC; Genes, BRCA1; Genes, Tumor Suppressor; Humans; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Receptors, Retinoic Acid; Vidarabine

2007
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:12

    Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.
    Biochemical pharmacology, 2008, Feb-15, Volume: 75, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Equilibrative Nucleoside Transporter 1; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Tetradecanoylphorbol Acetate; Vidarabine

2008
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
    Leukemia, 2008, Volume: 22, Issue:3

    Topics: Apoptosis; B-Lymphocytes; Drug Screening Assays, Antitumor; Drug Synergism; Fatty Acids, Nonesterified; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lipid Metabolism; Lipoprotein Lipase; Multigene Family; Neoplasm Proteins; Orlistat; Phospholipases; Proto-Oncogene Proteins c-bcr; Tumor Cells, Cultured; Vidarabine

2008
Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    Pediatric transplantation, 2008, Volume: 12, Issue:1

    Topics: Adolescent; Anemia, Aplastic; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Transplantation Conditioning; Vidarabine

2008
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4

    Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Journal of cellular biochemistry, 2008, May-15, Volume: 104, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Blast Crisis; Cell Cycle; Cell Line, Tumor; Chlorambucil; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperazines; Proto-Oncogene Proteins c-mdm2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine

2008
Invasive fungal sinusitis in patients treated with fludarabine.
    The Journal of infection, 2008, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus flavus; Aspergillus fumigatus; Child; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mucormycosis; Rhizopus; Sinusitis; Vidarabine

2008
Therapeutic experience of Bing-Neel Syndrome associated with Waldenstrom's macroglobulinemia.
    Journal of Korean medical science, 2007, Volume: 22, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Brain; Central Nervous System Diseases; Cranial Irradiation; Female; Humans; Middle Aged; Rituximab; Syndrome; Vidarabine; Waldenstrom Macroglobulinemia

2007
Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.
    Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:3

    Topics: Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Serum Globulins; Vidarabine

2008
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
    Blood, 2008, May-01, Volume: 111, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cytotoxicity, Immunologic; Humans; Interleukins; Membrane Proteins; Proto-Oncogene Proteins; Rituximab; STAT1 Transcription Factor; STAT5 Transcription Factor; Up-Regulation; Vidarabine

2008
Switching of donor cells after urgent second cord blood transplantation for suspected graft failure.
    International journal of hematology, 2007, Volume: 86, Issue:5

    Topics: Adult; Anti-Inflammatory Agents; Bone Marrow; Cord Blood Stem Cell Transplantation; Delayed Graft Function; Donor Selection; Female; Ferritins; Graft Survival; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Macrophages; Methylprednisolone; Myeloablative Agonists; Tissue Donors; Transplantation Conditioning; Vascular Diseases; Vidarabine

2007
Graft-versus-myeloma effects in reduced-intensity cord blood transplantation.
    International journal of hematology, 2007, Volume: 86, Issue:5

    Topics: Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Remission Induction; Retrospective Studies; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2007
Long-term donor-specific tolerance in rat cardiac allografts by intrabone marrow injection of donor bone marrow cells.
    Transplantation, 2008, Jan-15, Volume: 85, Issue:1

    Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Radiation; Graft Survival; Heart Transplantation; Injections; Rats; Rats, Inbred BN; Rats, Inbred F344; Time Factors; Transplantation Tolerance; Transplantation, Homologous; Treatment Outcome; Vidarabine

2008
Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
    Transplant infectious disease : an official journal of the Transplantation Society, 2008, Volume: 10, Issue:4

    Topics: Adolescent; Adult; Aged; Aspergillosis; Bacteremia; Busulfan; Catheterization, Central Venous; Chronic Disease; Communicable Diseases; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pneumonia, Bacterial; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2008
Successful treatment of chronic granulomatous disease with fludarabine-based reduced-intensity conditioning and unrelated bone marrow transplantation.
    International journal of hematology, 2008, Volume: 87, Issue:1

    Topics: Bone Marrow Transplantation; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; Humans; Male; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2008
Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
    Bone marrow transplantation, 2008, Volume: 41, Issue:10

    Topics: Adult; Aged; Denmark; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Hospitalization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Outpatient Clinics, Hospital; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2008
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Caspase 3; Cell Line, Tumor; Child; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Killer Cells, Natural; Leukemia; Stem Cells; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Vidarabine

2008
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:9

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thrombocytopenia; Vidarabine

2007
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine

2008
[Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Vnitrni lekarstvi, 2007, Volume: 53, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fibroblast Growth Factor 2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vascular Endothelial Growth Factor A; Vidarabine

2007
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
    Journal of molecular medicine (Berlin, Germany), 2008, Volume: 86, Issue:5

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Chromosome Deletion; Chromosomes, Human, Pair 17; Drug Resistance, Neoplasm; Enzyme Activation; Female; Free Radical Scavengers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxidative Stress; Oxides; Poly(ADP-ribose) Polymerases; Prognosis; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine

2008
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Acute Disease; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine

2008
Successful bone marrow transplantation in a girl with Fanconi anemia and preterminal renal failure.
    Bone marrow transplantation, 2008, Volume: 42, Issue:1

    Topics: Bone Marrow Transplantation; Child, Preschool; Directed Tissue Donation; Fanconi Anemia; Female; Graft Survival; Graft vs Host Disease; Hemibody Irradiation; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Mycophenolic Acid; Siblings; Transplantation Chimera; Transplantation Conditioning; Vesico-Ureteral Reflux; Vidarabine

2008
Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records.
    Leukemia, 2008, Volume: 22, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine

2008
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
    British journal of haematology, 2008, Volume: 141, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Chromosome Aberrations; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Furans; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Membrane Proteins; Mutation; Nerve Tissue Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine

2008
Potential role of a mismatched HLA-specific CTL clone developed pre-transplant in graft rejection following cord blood transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:4

    Topics: Clone Cells; Cord Blood Stem Cell Transplantation; Electroporation; Female; Graft Rejection; Histocompatibility Testing; HLA Antigens; HLA-A Antigens; HLA-B Antigens; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Leukemia, Myelomonocytic, Acute; Male; Melphalan; Middle Aged; Polymerase Chain Reaction; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic; Transfection; Transplantation Chimera; Vidarabine

2008
Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Experimental hematology, 2008, Volume: 36, Issue:5

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; France; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Registries; Remission Induction; Retrospective Studies; Risk Factors; Survival Analysis; Time; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2008
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-15, Volume: 14, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukocytes; Oligonucleotide Array Sequence Analysis; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; TCF Transcription Factors; Vidarabine; Waldenstrom Macroglobulinemia

2008
Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2008, Volume: 29, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Brain; Female; Gadolinium; Humans; Image Enhancement; Leukoencephalopathy, Progressive Multifocal; Lymphoproliferative Disorders; Magnetic Resonance Imaging; Middle Aged; Rituximab; Time; Vidarabine

2008
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2008, Volume: 31, Issue:4

    Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Immunologic Memory; Interferon-gamma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Vidarabine; Whole-Body Irradiation

2008
Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma.
    Pharmacy world & science : PWS, 2008, Volume: 30, Issue:4

    Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Granulocytes; Humans; Hypoglycemic Agents; Leukocyte Count; Lymphoma, B-Cell, Marginal Zone; Male; Metformin; Neutropenia; Splenic Neoplasms; Vidarabine

2008
Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.
    Cellular signalling, 2008, Volume: 20, Issue:6

    Topics: Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoproliferative Disorders; Lysophospholipids; Multiple Myeloma; Mutagens; NF-kappa B; RNA, Messenger; Vascular Endothelial Growth Factor A; Vidarabine

2008
A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
    Pediatric transplantation, 2008, Volume: 12, Issue:8

    Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Female; History, Ancient; Humans; Immunosuppressive Agents; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Pilot Projects; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Chromatography, Liquid; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Male; Mass Spectrometry; Middle Aged; Phenotype; T-Lymphocytes; Vidarabine

2009
Use of TAGVHD warnings in patients receiving purine analogue chemotherapy.
    Transfusion medicine (Oxford, England), 2008, Volume: 18, Issue:2

    Topics: Blood Transfusion; Enzyme Inhibitors; Graft vs Host Disease; Health Policy; Humans; Retrospective Studies; Risk Factors; Transfusion Reaction; Vidarabine

2008
Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future.
    Onkologie, 2008, Volume: 31, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Lysis Syndrome; Vidarabine

2008
Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.
    Onkologie, 2008, Volume: 31, Issue:4

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Treatment Outcome; Tumor Lysis Syndrome; Urate Oxidase; Vidarabine

2008
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
    Leukemia, 2008, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.
    International journal of hematology, 2008, Volume: 87, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Recurrence; Risk Factors; Survival Rate; Transplantation, Homologous; Vidarabine

2008
Comparable engraftment and chimerism kinetics using oral and intravenous fludarabine as part of a reduced intensity conditioning regimen.
    Bone marrow transplantation, 2008, Volume: 42, Issue:2

    Topics: Administration, Oral; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Kinetics; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Retreatment with fludarabine and cyclosporine for one case of refractory pure red cell aplasia.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2008, Volume: 23, Issue:1

    Topics: Adult; Cyclosporine; Female; Humans; Immunosuppressive Agents; Red-Cell Aplasia, Pure; Vidarabine

2008
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.
    Cancer investigation, 2008, Volume: 26, Issue:4

    Topics: Adult; Agammaglobulinemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; CD4 Lymphocyte Count; Cyclophosphamide; Female; Humans; Immunocompromised Host; Immunoglobulin Class Switching; Immunoglobulins, Intravenous; Immunologic Memory; Immunophenotyping; Lymphoma, Follicular; Rituximab; Sinusitis; Vidarabine

2008
Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:6

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Hypertension, Pulmonary; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2008
Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols.
    Saudi medical journal, 2008, Volume: 29, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Saudi Arabia; Survival Rate; Treatment Outcome; Vidarabine

2008
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
    American journal of hematology, 2008, Volume: 83, Issue:8

    Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Vidarabine

2008
Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:5

    Topics: Databases, Factual; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine

2008
[Treatment of refractory severe autoimmune disease by combined therapy with Chinese drug and autohemopoietic stem cell transplantation].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2008, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Antilymphocyte Serum; Autoimmune Diseases; Combined Modality Therapy; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hematopoietic Stem Cell Transplantation; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Phytotherapy; Transplantation, Autologous; Treatment Outcome; Vidarabine; Young Adult

2008
Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome.
    Bone marrow transplantation, 2008, Volume: 42, Issue:3

    Topics: Abnormalities, Multiple; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft vs Host Disease; Humans; Male; Melphalan; Pancreatic Diseases; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine

2008
Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:2

    Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Humans; Immunoblotting; Inhibitory Concentration 50; Kidney Tubules, Proximal; Membrane Transport Proteins; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine

2009
Selective killing of Mycobacterium avium-infected macrophages by inhibition of phosphorylated signal transducer and activator of transcription type 1.
    The Journal of infectious diseases, 2008, Jul-01, Volume: 198, Issue:1

    Topics: Antineoplastic Agents; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Macrophages; Mycobacterium avium; Phosphorylation; STAT1 Transcription Factor; Time Factors; Vidarabine

2008
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
    Blood, 2008, Aug-15, Volume: 112, Issue:4

    Topics: bcl-X Protein; Caspases; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Thiazoles; Tumor Cells, Cultured; Vidarabine

2008
Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
    Pathobiology : journal of immunopathology, molecular and cellular biology, 2008, Volume: 75, Issue:3

    Topics: Antineoplastic Agents; Cell Division; Cells, Cultured; Coculture Techniques; Cytokines; Cytotoxicity Tests, Immunologic; Dose-Response Relationship, Drug; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Vidarabine

2008
Irreversible visual loss and optic nerve dysfunction associated with central retinal vein occlusion in Waldenstrom Macroglobulinemia.
    The Medical journal of Malaysia, 2007, Volume: 62, Issue:4

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Male; Optic Nerve; Optic Nerve Diseases; Plasmapheresis; Prognosis; Retinal Vein; Risk Factors; Rituximab; Vidarabine; Vision, Low; Visual Acuity; Waldenstrom Macroglobulinemia

2007
Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.
    Chemotherapy, 2008, Volume: 54, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Female; Humans; Immune Tolerance; Lymphatic Diseases; Middle Aged; Rituximab; Vidarabine

2008
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
    Blood, 2008, Sep-01, Volume: 112, Issue:5

    Topics: Antineoplastic Agents; Caspase 3; Cell Death; Cytochromes c; Drug Resistance, Neoplasm; Glutathione; Glutathione Peroxidase; Humans; In Vitro Techniques; Isothiocyanates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oxidation-Reduction; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Vidarabine

2008
Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403.
    Haematologica, 2008, Volume: 93, Issue:7

    Topics: Aged; Antineoplastic Agents; Databases, Factual; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Neoplasms, Second Primary; Research Design; Sex Factors; Time Factors; Treatment Outcome; Vidarabine

2008
Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-01, Volume: 14, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Research Design; Treatment Outcome; Vidarabine

2008
Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization.
    Leukemia, 2008, Volume: 22, Issue:11

    Topics: Antineoplastic Agents; Bone Marrow; Cell Movement; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Endothelium, Vascular; Hematopoietic Stem Cells; Humans; Mesenchymal Stem Cells; Stromal Cells; Vidarabine

2008
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
    Blood, 2008, Nov-01, Volume: 112, Issue:9

    Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Immunoglobulin Heavy Chains; In Vitro Techniques; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Prognosis; Proto-Oncogene Proteins c-bcl-2; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2008
Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells.
    Nucleosides, nucleotides & nucleic acids, 2008, Volume: 27, Issue:6

    Topics: Animals; Antibodies; Antigens, CD; Apoptosis; Cattle; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Lymphoma; Tumor Suppressor Protein p53; Vidarabine

2008
Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2008, Volume: 21, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Single-Blind Method; Vidarabine

2008
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.
    European journal of haematology, 2008, Volume: 81, Issue:5

    Topics: Adult; Antineoplastic Agents; Bacteremia; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Retrospective Studies; Risk Factors; Survival Rate; Vidarabine

2008
Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cord Blood Stem Cell Transplantation; Cytarabine; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Kinetics; Male; Middle Aged; Risk Assessment; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2008
Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease.
    Haematologica, 2008, Volume: 93, Issue:9

    Topics: Adult; Aged; Biomarkers, Tumor; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Vidarabine; Virus Activation

2008
A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
    Annals of hematology, 2009, Volume: 88, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Rituximab; Vidarabine

2009
Fludarabine based treatment caused improvement of anemia in a patient with T-cell LGL leukemia despite evidence of the persistence of the abnormal T-cell clone.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Aged; Anemia; Clone Cells; Female; Humans; Leukemia, T-Cell; Treatment Outcome; Vidarabine

2008
Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
    Leukemia research, 2009, Volume: 33, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Calorimetry, Differential Scanning; Cell Survival; Cells, Cultured; Cladribine; Cyclophosphamide; DNA Damage; Drug Combinations; Drug Monitoring; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myeloid Cell Leukemia Sequence 1 Protein; Phase Transition; Proto-Oncogene Proteins c-bcl-2; Vidarabine

2009
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
    Blood, 2008, Nov-01, Volume: 112, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; Benzothiazoles; Chlorambucil; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitochondria; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Toluene; Transcription, Genetic; Tumor Suppressor Protein p53; Vidarabine

2008
Massive swelling of the cervical region: an uncommon manifestation of B cell chronic lymphocytic leukemia.
    Oral and maxillofacial surgery, 2008, Volume: 12, Issue:4

    Topics: Adipose Tissue; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lipectomy; Lipomatosis, Multiple Symmetrical; Lymph Nodes; Middle Aged; Neck; Vidarabine

2008
Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.
    Annals of hematology, 2009, Volume: 88, Issue:3

    Topics: Aged; Combined Modality Therapy; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Renal Dialysis; Transplantation Conditioning; Vidarabine

2009
Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose.
    Bone marrow transplantation, 2008, Volume: 42, Issue:11

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Female; Hematopoietic Stem Cells; HLA Antigens; Humans; Leukemia; Male; Middle Aged; Recurrence; Siblings; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine

2008
Images in haematology. Cerebral nocardiosis in a patient with lymphoplasmacytic lymphoma treated with fludarabine.
    British journal of haematology, 2008, Volume: 143, Issue:4

    Topics: Aged, 80 and over; Antineoplastic Agents; Central Nervous System Bacterial Infections; Humans; Male; Nocardia Infections; Opportunistic Infections; Tomography, X-Ray Computed; Vidarabine; Waldenstrom Macroglobulinemia

2008
400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Bone marrow transplantation, 2008, Volume: 42, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine

2008
Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:2

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Blood Component Removal; Bone Marrow Cells; Cell Culture Techniques; Cell Survival; Colony-Forming Units Assay; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Models, Biological; Nitrogen Mustard Compounds; Reference Values; Stem Cells; Vidarabine

2009
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.
    Leukemia, 2008, Volume: 22, Issue:11

    Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Myeloablative Agonists; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine

2008
Leptin inhibits rosiglitazone-induced adipogenesis in murine primary adipocytes.
    Molecular and cellular endocrinology, 2008, Nov-06, Volume: 294, Issue:1-2

    Topics: Adipocytes; Adipogenesis; Animals; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation; Leptin; Mice; Mice, Inbred C57BL; Phosphorylation; PPAR gamma; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; Thiazolidinediones; Time Factors; Vidarabine

2008
Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
    Haematologica, 2008, Volume: 93, Issue:11

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytomegalovirus Infections; Diagnosis, Differential; Disease Progression; Epstein-Barr Virus Infections; Female; Genome, Viral; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Monitoring, Physiologic; Vidarabine

2008
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
    Bone marrow transplantation, 2009, Volume: 43, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult

2009
Umbilical cord-blood transplantations from unrelated donors in patients with inherited metabolic diseases: Single-institute experience.
    Pediatric transplantation, 2008, Volume: 12, Issue:6

    Topics: Administration, Oral; Busulfan; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Lysosomal Storage Diseases; Male; Methotrexate; Peroxisomal Disorders; Vidarabine

2008
Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells.
    Mutation research, 2008, Nov-10, Volume: 646, Issue:1-2

    Topics: Adult; Androstadienes; Animals; Benzaldehydes; Cell Line; Cell Proliferation; Cell Survival; CHO Cells; Chromosome Aberrations; Cricetinae; Cricetulus; DNA; DNA Breaks, Double-Stranded; DNA Ligases; DNA Repair; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fibroblasts; Foreskin; Humans; Lymphocytes; Male; Mitotic Index; S Phase; Vidarabine; Wortmannin

2008
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
    Blood, 2009, Jan-01, Volume: 113, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; B-Lymphocytes; Cell Communication; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gossypol; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Stromal Cells; Tumor Cells, Cultured; Vidarabine

2009
Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease.
    Immunologic research, 2009, Volume: 44, Issue:1-3

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Chimerism; Cyclophosphamide; Follow-Up Studies; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Kaplan-Meier Estimate; Male; Melphalan; Postoperative Complications; Pulmonary Aspergillosis; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult

2009
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:10

    Topics: Acetylation; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Caspase 2; Cell Line, Tumor; Cytosol; DNA Damage; DNA Repair; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Leukemia; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine

2008
Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Transplantation, 2008, Oct-15, Volume: 86, Issue:7

    Topics: Animals; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Injections, Intraperitoneal; Kinetics; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2008
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:11

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Living Donors; Lymphocyte Transfusion; Male; Metabolic Diseases; Prospective Studies; Retrospective Studies; Severe Combined Immunodeficiency; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2008
Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Cyclosporine; Disease-Free Survival; Female; Glomerular Filtration Rate; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Diseases; Male; Middle Aged; Mycophenolic Acid; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2008
Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
    Haematologica, 2008, Volume: 93, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Equilibrative-Nucleoside Transporter 2; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Tumor Cells, Cultured; Vidarabine

2008
Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.
    American journal of clinical dermatology, 2008, Volume: 9, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mitoxantrone; Panniculitis; Skin Neoplasms; Vidarabine

2008
Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures.
    Leukemia research, 2009, Volume: 33, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Culture Techniques; Drug Synergism; Fluorescent Antibody Technique; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Phosphorylation; Thalidomide; Tumor Cells, Cultured; Vidarabine

2009
Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.
    Bone marrow transplantation, 2009, Volume: 43, Issue:6

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Female; Graft Rejection; Humans; Immunosuppressive Agents; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine

2009
Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT.
    Leukemia research, 2009, Volume: 33, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Fetal Blood; Humans; Male; Recurrence; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2009
Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
    Haematologica, 2009, Volume: 94, Issue:1

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Recurrence; Vidarabine

2009
[First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].
    Presse medicale (Paris, France : 1983), 2009, Volume: 38, Issue:1

    Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cyclophosphamide; Drug Costs; Frail Elderly; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloablative Agonists; Opportunistic Infections; Risk Factors; Rituximab; Vidarabine

2009
Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
    British journal of haematology, 2009, Volume: 144, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Blotting, Western; Cladribine; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Confocal; Middle Aged; Reactive Oxygen Species; Tumor Cells, Cultured; Valproic Acid; Vidarabine

2009
Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma.
    European journal of medical research, 2008, Oct-27, Volume: 13, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Hepatitis B, Chronic; Humans; Liver; Liver Failure, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Rituximab; Vidarabine

2008
Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    European journal of haematology, 2009, Volume: 82, Issue:2

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2009
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
    British journal of haematology, 2008, Volume: 143, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Survival; Chlorambucil; Cytotoxicity Tests, Immunologic; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Statistics, Nonparametric; Thiazoles; Tumor Suppressor Protein p53; Vidarabine

2008
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-20, Volume: 27, Issue:3

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2009
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-10, Volume: 27, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia

2009
Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
    Molecular cancer research : MCR, 2008, Volume: 6, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Cell Communication; Cell Division; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hedgehog Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligodeoxyribonucleotides, Antisense; Signal Transduction; Stromal Cells; Transcription Factors; Vidarabine; Zinc Finger Protein GLI1

2008
Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Feb-01, Volume: 27, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine

2009
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Feb-01, Volume: 27, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Treatment Outcome; Vidarabine

2009
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Feb-01, Volume: 27, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Flow Cytometry; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymerase Chain Reaction; Remission Induction; Rituximab; Vidarabine

2009
The combined use of Flu/ATG in nonmyeloablative SCT for severe aplastic anemia with multiple earlier transfusions.
    Bone marrow transplantation, 2009, Volume: 43, Issue:11

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine; Young Adult

2009
Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    Chinese medical journal, 2008, Sep-20, Volume: 121, Issue:18

    Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous; Vidarabine

2008
The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-15, Volume: 14, Issue:24

    Topics: Antineoplastic Agents; CD40 Ligand; Cytoprotection; DNA; Drug Synergism; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Prognosis; Sesquiterpenes; Vidarabine

2008
Radiosensitization by inhibiting STAT1 in renal cell carcinoma.
    International journal of radiation oncology, biology, physics, 2009, Jan-01, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Humans; Kidney Neoplasms; Radiation-Sensitizing Agents; STAT1 Transcription Factor; Vidarabine

2009
HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling.
    Microvascular research, 2009, Volume: 77, Issue:2

    Topics: AIDS Dementia Complex; Blood-Brain Barrier; Brain; Cell Adhesion; Cell Movement; Cells, Cultured; Chromones; Cytokines; Endothelial Cells; Enzyme Inhibitors; Flavonoids; HIV Envelope Protein gp120; HIV-1; Humans; Interleukin-6; Interleukin-8; Microvessels; Mitogen-Activated Protein Kinase Kinases; Models, Neurological; Monocytes; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; STAT1 Transcription Factor; Vidarabine

2009
Oxidative stress and delta-ALA-D activity in different conditioning regimens in allogeneic bone marrow transplantation patients.
    Clinical biochemistry, 2009, Volume: 42, Issue:7-8

    Topics: Adult; Antioxidants; Ascorbic Acid; Bone Marrow Transplantation; Catalase; Cyclophosphamide; Enzyme Activation; Female; Humans; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Porphobilinogen Synthase; Superoxide Dismutase; Vidarabine

2009
Dasatinib induces a response in chronic lymphocytic leukemia.
    Blood, 2009, Jan-08, Volume: 113, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine

2009
Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:1

    Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cyclosporine; Female; Glomerular Filtration Rate; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Premedication; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult

2009
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
    Cytotherapy, 2009, Volume: 11, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Injections, Intravenous; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2009
Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.
    American journal of hematology, 2009, Volume: 84, Issue:3

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Myeloablative Agonists; Ovary; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2009
Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
    Pediatric transplantation, 2009, Volume: 13, Issue:6

    Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Leukemia; Male; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2009
Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Cytarabine; Cytochrome P-450 CYP3A; Drug Delivery Systems; Infusions, Intravenous; Liver; Liver Neoplasms; Male; Mice; Nucleosides; Prodrugs; Thymidine; Tissue Distribution; Vidarabine

2009
Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.
    European journal of pharmacology, 2009, May-01, Volume: 609, Issue:1-3

    Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Cell Line, Tumor; Chlorambucil; Cytotoxins; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Formazans; Glucosyltransferases; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Chemical; Molecular Structure; Tetrazolium Salts; Vidarabine

2009
Chronic lymphocytic leukaemia: current first-line therapy.
    Internal medicine journal, 2009, Volume: 39, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2009
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
    Leukemia research, 2009, Volume: 33, Issue:10

    Topics: Adrenal Cortex Hormones; Annexin A5; Apoptosis; Chlorambucil; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Enzymologic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Plasmids; Prognosis; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Syk Kinase; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2009
T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Prednisone; Vidarabine; Vincristine

2010
IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
    Annals of hematology, 2009, Volume: 88, Issue:12

    Topics: ADAM Proteins; Antineoplastic Agents; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; DNA Mutational Analysis; Gene Expression Regulation, Neoplastic; Genes, Immunoglobulin Heavy Chain; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lipoprotein Lipase; Mutation; Remission Induction; Treatment Outcome; Vidarabine

2009
Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.
    Bone marrow transplantation, 2009, Volume: 44, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Transplantation Conditioning; Vidarabine; Young Adult

2009
Assessment of bone marrow response in Waldenström's macroglobulinemia.
    Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Flow Cytometry; Humans; Immunoglobulin M; Immunohistochemistry; Male; Vidarabine; Waldenstrom Macroglobulinemia

2009
Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Chlorambucil; Cladribine; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prognosis; Time Factors; Tumor Cells, Cultured; Vidarabine

2009
Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
    Journal of clinical pathology, 2009, Volume: 62, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pancytopenia; Vidarabine

2009
A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
    Internal medicine journal, 2009, Volume: 39, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Conflict of Interest; Cost-Benefit Analysis; Cross-Over Studies; Cyclophosphamide; Disease-Free Survival; Drug Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Practice Guidelines as Topic; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Vidarabine

2009
Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
    Leukemia, 2009, Volume: 23, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Receptors, Tumor Necrosis Factor; Risk Factors; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha; Vidarabine

2009
Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antigens, Viral; Bone Marrow Transplantation; Busulfan; Cytomegalovirus Infections; Disease Susceptibility; Female; Humans; Immunosuppressive Agents; Incidence; Intestinal Mucosa; Japan; Male; Middle Aged; Myeloablative Agonists; Postoperative Complications; Radiation Injuries; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult

2009
Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.
    Bone marrow transplantation, 2010, Volume: 45, Issue:1

    Topics: Adult; Aged; Anthracyclines; Arrhythmias, Cardiac; Busulfan; Female; Heart Diseases; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2010
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
    Immunologic research, 2009, Volume: 44, Issue:1-3

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Autoimmune Diseases; Bone Marrow Transplantation; Forkhead Transcription Factors; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin E; Infant; Interleukin-7 Receptor alpha Subunit; Male; Melphalan; T-Lymphocytes, Regulatory; Transplantation Conditioning; Vidarabine; X-Linked Combined Immunodeficiency Diseases

2009
Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma.
    Pediatric transplantation, 2010, Volume: 14, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Myeloablative Agonists; Positron-Emission Tomography; Severity of Illness Index; Time Factors; Transplantation, Homologous; Treatment Outcome; Vidarabine

2010
Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia.
    Irish journal of medical science, 2009, Volume: 178, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2009
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting.
    Blood transfusion = Trasfusione del sangue, 2009, Volume: 7, Issue:2

    Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Donors; Busulfan; Catheter Ablation; Cost-Benefit Analysis; Cyclophosphamide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mexico; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2009
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
    Blood, 2009, Aug-20, Volume: 114, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bendamustine Hydrochloride; Cyclophosphamide; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Mitochondria; Nitrogen Mustard Compounds; Nuclear Proteins; Proto-Oncogene Proteins; Purine Nucleosides; Pyrimidinones; Rituximab; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2009
Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.
    Bone marrow transplantation, 2010, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Clinical Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2010
Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.
    Bone marrow transplantation, 2010, Volume: 45, Issue:2

    Topics: Adolescent; Adult; Area Under Curve; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2010
The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
    Journal of Korean medical science, 2009, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine

2009
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
    Cancer research, 2009, Jul-01, Volume: 69, Issue:13

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Caspase 3; Cell Line, Tumor; Curcumin; Gene Expression Profiling; Humans; Immunoglobulin Variable Region; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Oxazines; Phosphorylation; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Syk Kinase; Vidarabine

2009
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:8

    Topics: Adult; Aged; Alleles; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Early Termination of Clinical Trials; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Haplotypes; Humans; Infections; Lymphoma, Follicular; Lymphopenia; Male; Mannose-Binding Lectin; Middle Aged; Multicenter Studies as Topic; Neutropenia; Prospective Studies; Risk; Rituximab; Spain; Vidarabine; Young Adult

2009
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.
    Current opinion in oncology, 2009, Volume: 21 Suppl 1

    Topics: Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Cohort Studies; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Rabbits; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2009
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
    Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 1

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality of Life; Survival Analysis; Technology Assessment, Biomedical; Vidarabine

2009
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jul-15, Volume: 15, Issue:14

    Topics: Animals; CD4-Positive T-Lymphocytes; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Cytotoxicity, Immunologic; Female; Flow Cytometry; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Mice; Middle Aged; Minor Histocompatibility Antigens; Myeloablative Agonists; NIH 3T3 Cells; T-Lymphocytes; Transplantation, Homologous; Treatment Outcome; Vidarabine

2009
Diagnosis by sheer coincidence.
    The international journal of cardiovascular imaging, 2009, Volume: 25, Issue:7

    Topics: Aged; Antineoplastic Agents; Diuretics; Echocardiography, Doppler; Female; Heart Failure; Hodgkin Disease; Humans; Incidental Findings; Pulmonary Subvalvular Stenosis; Tomography, X-Ray Computed; Transposition of Great Vessels; Vidarabine

2009
Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.
    International journal of clinical oncology, 2009, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2009
Successful allo-SCT in a Fanconi anemia patient with renal impairment using reduced doses of CY and fludarabine.
    Bone marrow transplantation, 2010, Volume: 45, Issue:2

    Topics: Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Humans; Renal Insufficiency; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine

2010
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancytopenia; Prevalence; Retrospective Studies; Thrombocytopenia; Time Factors; Vidarabine

2010
Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?
    British journal of haematology, 2009, Volume: 146, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bone Marrow Diseases; Cell Lineage; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Rituximab; Vidarabine

2009
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
    Leukemia, 2009, Volume: 23, Issue:11

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; bcl-X Protein; Biphenyl Compounds; Dexamethasone; Doxorubicin; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Mimicry; Nitrophenols; Piperazines; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Vidarabine

2009
A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
    Biomedical chromatography : BMC, 2010, Volume: 24, Issue:4

    Topics: 1-Propanol; Acetonitriles; Antimetabolites, Antineoplastic; Capecitabine; Chemical Precipitation; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Floxuridine; Fluorouracil; Furans; Humans; Linear Models; Pyrimidines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Trichloroacetic Acid; Uracil; Vidarabine

2010
Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Experimental hematology, 2009, Volume: 37, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Diseases; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Interferon-alpha; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Retrospective Studies; Rituximab; Vidarabine; Vincristine

2009
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:9

    Topics: Acute Kidney Injury; Adult; Aged; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2009
Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer.
    Pancreas, 2009, Volume: 38, Issue:7

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Male; Middle Aged; Mycophenolic Acid; Pancreatic Neoplasms; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Tumor Necrosis Factor-alpha; Vidarabine; Whole-Body Irradiation

2009
Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; DNA Mutational Analysis; Frameshift Mutation; Gene Expression Regulation, Leukemic; Genes, p53; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Proteins; Prognosis; Rituximab; Survival Analysis; Tumor Suppressor Protein p53; Vidarabine

2009
Lymphoplasmacytic lymphoma with IgA hypergammaglobulinemia and liver involvement.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2009, Volume: 92 Suppl 3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antirheumatic Agents; Cyclophosphamide; Female; Humans; Hypergammaglobulinemia; Immunoglobulin A; Immunologic Factors; Liver Diseases; Rituximab; Thailand; Vidarabine; Waldenstrom Macroglobulinemia

2009
Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
    Annals of the New York Academy of Sciences, 2009, Volume: 1171

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cell Survival; Cells, Cultured; Cladribine; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Synergism; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Vidarabine

2009
Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.
    Haematologica, 2009, Volume: 94, Issue:9

    Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Living Donors; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2009
Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.
    Acta dermato-venereologica, 2009, Volume: 89, Issue:5

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Examination; Dermatitis, Exfoliative; Diagnostic Errors; Erythema; Fatal Outcome; Humans; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Leukemic Infiltration; Male; Prednisone; Skin; T-Lymphocytes; Treatment Failure; Vidarabine

2009
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Child; Chronic Disease; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2009
Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:10

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Feasibility Studies; Humans; Immunotherapy; Infections; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2009
Renal dysfunction due to leukemic infiltration of kidneys in a case of chronic lymphocytic leukemia.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2010, Volume: 14, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Middle Aged; Prednisolone; Renal Dialysis; Renal Insufficiency; Ultrasonography; Vidarabine

2010
Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
    British journal of haematology, 2009, Volume: 147, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Death; Cladribine; Cohort Studies; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Up-Regulation; Vidarabine

2009
[Brucella bacteremia reactivation 70 years after the primary infection].
    Medecine et maladies infectieuses, 2010, Volume: 40, Issue:4

    Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Brucella melitensis; Brucellosis; Combined Modality Therapy; Cyclophosphamide; Doxycycline; Drug Therapy, Combination; Female; France; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Lymphoma, Non-Hodgkin; Recurrence; Rifampin; Rituximab; Spain; Time Factors; Vidarabine

2010
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    American journal of hematology, 2009, Volume: 84, Issue:11

    Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult

2009
Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia.
    Leukemia, 2010, Volume: 24, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents; Disease-Free Survival; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2010
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2009
The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
    Cancer research, 2009, Nov-01, Volume: 69, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Caspase 8; DNA (Cytosine-5-)-Methyltransferases; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunoblotting; Immunoglobulin Heavy Chains; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microtubules; Middle Aged; Oxazepines; Prognosis; Pyrroles; Tubulin; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2009
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Chemotherapy, Adjuvant; Dasatinib; Humans; Immunosuppressive Agents; Leukemia; Male; Philadelphia Chromosome; Pyrimidines; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2010
[Clinical analysis of 14 patients with lymphoma associated hemophagocytic syndrome].
    Zhongguo shi yan xue ye xue za zhi, 2009, Volume: 17, Issue:5

    Topics: Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Prognosis; Retrospective Studies; Treatment Outcome; Vidarabine

2009
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
    Blood, 2009, Dec-17, Volume: 114, Issue:26

    Topics: Antineoplastic Agents; Blotting, Western; DNA Damage; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gene Silencing; Genes, p53; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine

2009
Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:12

    Topics: Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Cell Survival; Cells, Cultured; Female; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysophospholipids; Male; Middle Aged; Receptors, Lysophosphatidic Acid; Receptors, Purinergic P2; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor A; Vidarabine

2009
Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
    Biopharmaceutics & drug disposition, 2010, Volume: 31, Issue:1

    Topics: Administration, Oral; Adult; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Half-Life; Heart Rate; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Chemical; Vidarabine; Vidarabine Phosphate

2010
Keratotic vascular papules over the feet: a case of Waldenström's macroglobulinaemia-associated cutaneous macroglobulinosis.
    Clinical and experimental dermatology, 2010, Volume: 35, Issue:3

    Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Diagnosis, Differential; Fluorescent Antibody Technique, Direct; Foot Diseases; Humans; Immunoglobulin M; Keratosis; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2010
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
    Journal of cellular biochemistry, 2010, Jan-01, Volume: 109, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Survival; Cells, Cultured; Cladribine; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Cyclophosphamide; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Purines; Roscovitine; Vidarabine

2010
Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
    British journal of haematology, 2010, Volume: 148, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Recurrence; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Young Adult

2010
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine

2010
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:8

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine

2009
Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    Bone marrow transplantation, 2010, Volume: 45, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation; Young Adult

2010
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
    British journal of haematology, 2010, Volume: 148, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Rituximab; Vidarabine

2010
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2010
[Conditioning regimen containing fludarabine instead of cyclophosphamide for haploidentical hematopoietic stem cell transplantation].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:8

    Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2009
R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.
    Leukemia, 2010, Volume: 24, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Tumor Suppressor Protein p53; Vidarabine

2010
Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:1

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Blotting, Western; Caspase 3; Caspase 9; Cell Separation; Drug Synergism; Enzyme Activation; Female; Flow Cytometry; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Vidarabine

2010
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Cyclophosphamide; Drug Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Risk; Rituximab; Thalidomide; Treatment Outcome; Vidarabine

2010
Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2009, Volume: 50, Issue:11

    Topics: Female; Graft vs Host Disease; Humans; Janus Kinase 2; Melphalan; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine

2009
CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.
    Experimental hematology, 2010, Volume: 38, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autoimmunity; CD40 Ligand; Cells, Cultured; Cladribine; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Vidarabine

2010
Progressive multifocal leukencephalopathy and cerebral toxoplasmosis in a patient with CLL.
    American journal of hematology, 2010, Volume: 85, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Humans; Immunocompromised Host; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Toxoplasmosis, Cerebral; Vidarabine; Virus Activation

2010
Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells.
    Molecular and cellular biochemistry, 2010, Volume: 339, Issue:1-2

    Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Caspase Inhibitors; Cytoskeleton; Dexamethasone; Flow Cytometry; Fluorescent Antibody Technique; HL-60 Cells; Humans; Isoenzymes; Jurkat Cells; Mitoxantrone; Octoxynol; Protein Kinase C; Protein Kinase C-theta; Protein Multimerization; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrin; Vidarabine; Vimentin

2010
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
    Bone marrow transplantation, 2010, Volume: 45, Issue:8

    Topics: Adolescent; Adult; Age Factors; Aged; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2010
Inhibition of STAT1 accelerates bone fracture healing.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2010, Volume: 28, Issue:7

    Topics: Animals; Bony Callus; Calcification, Physiologic; Chlorocebus aethiops; Core Binding Factor Alpha 1 Subunit; COS Cells; Disease Models, Animal; Enzyme Inhibitors; Fracture Healing; Gene Expression; Mice; Mice, Mutant Strains; Osteoblasts; Osteogenesis; Sp7 Transcription Factor; STAT1 Transcription Factor; Tibial Fractures; Transcription Factors; Vidarabine

2010
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.
    Leukemia, 2010, Volume: 24, Issue:3

    Topics: Adult; Aged; Antigens, CD19; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cancer Vaccines; CD40 Ligand; CD5 Antigens; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Humans; Hyaluronan Receptors; Immunization; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; T-Lymphocytes, Cytotoxic; Vidarabine

2010
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:6

    Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine

2010
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Feasibility Studies; Female; Haplotypes; Humans; Immunotherapy; Infant; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prognosis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2010
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.
    Leukemia research, 2010, Volume: 34, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Remission Induction; Vidarabine; Young Adult

2010
Natural pregnancy and delivery after unrelated bone marrow transplantation using fludarabine-based regimen in a Fanconi anemia patient.
    International journal of hematology, 2010, Volume: 91, Issue:2

    Topics: Bone Marrow Transplantation; Child; Delivery, Obstetric; Fanconi Anemia; Female; Fertility; Humans; Myeloablative Agonists; Pregnancy; Pregnancy Outcome; Vidarabine; Young Adult

2010
[Correlation of deoxycytidine kinase gene expression with fludarabine resistance in patients with chronic lymphocytic leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:1

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

2010
Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
    American journal of hematology, 2010, Volume: 85, Issue:4

    Topics: Adult; Aged; Aging; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2010
Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.
    American journal of hematology, 2010, Volume: 85, Issue:4

    Topics: Adult; Aged; Aging; Antilymphocyte Serum; beta 2-Microglobulin; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2010
All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.
    The Journal of biological chemistry, 2010, Apr-30, Volume: 285, Issue:18

    Topics: Antineoplastic Agents; Autocrine Communication; Cell Membrane; Cytosol; Enzyme Activation; HeLa Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Membrane Transport Proteins; Mitogen-Activated Protein Kinase 3; Protein Transport; rhoA GTP-Binding Protein; Transcription, Genetic; Transforming Growth Factor beta1; Tretinoin; Vidarabine

2010
Clinical and imaging features of fludarabine neurotoxicity.
    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2010, Volume: 30, Issue:1

    Topics: Adult; Antineoplastic Agents; Brain; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurotoxicity Syndromes; Vidarabine

2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
    Bone marrow transplantation, 2010, Volume: 45, Issue:12

    Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult

2010
Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
    Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:3

    Topics: Adolescent; Antigens, CD19; Antineoplastic Agents; CD3 Complex; Child; Child, Preschool; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2010
Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression.
    Acta haematologica, 2010, Volume: 123, Issue:3

    Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; Biomarkers; Bone Marrow Cells; Caspase 3; Chronic Disease; Cladribine; Disease Progression; Enzyme Activation; Humans; Leukemia, Lymphoid; Membrane Glycoproteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2010
Rapid vision loss associated with fludarabine administration.
    Retina (Philadelphia, Pa.), 2010, Volume: 30, Issue:8

    Topics: Antineoplastic Agents; Blindness; Brain Diseases; Electroretinography; Evoked Potentials, Visual; Fatal Outcome; Female; Humans; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Myeloablative Agonists; Retina; Retinal Diseases; Retrospective Studies; Vidarabine; Young Adult

2010
In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia.
    Internal medicine journal, 2009, Volume: 39, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine

2009
Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.
    Bone marrow transplantation, 2011, Volume: 46, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Chimerism; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Myeloablative Agonists; T-Lymphocytes; Transplantation Conditioning; Transplantation, Heterologous; Vidarabine; Whole-Body Irradiation; Young Adult

2011
Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    The Egyptian journal of immunology, 2008, Volume: 15, Issue:1

    Topics: Aged; Apoptosis; Female; Hemoglobins; Humans; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Leukocytes, Mononuclear; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Platelet Count; Vidarabine

2008
Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
    Cancer investigation, 2010, Volume: 28, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caspase 3; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mitochondria; Piperazines; Pyrimidines; Vidarabine

2010
Haemophagocytic syndrome and Hodgkin's disease variant of Richter's syndrome after fludarabine for CLL.
    European journal of haematology, 2010, Volume: 85, Issue:1

    Topics: Aged; Antineoplastic Agents; Epstein-Barr Virus Infections; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Vidarabine

2010
Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:10

    Topics: Adult; Aged; Cohort Studies; Female; Follow-Up Studies; Genotype; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Minor Histocompatibility Antigens; Polymorphism, Single Nucleotide; Proportional Hazards Models; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2010
Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab.
    Chemotherapy, 2010, Volume: 56, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Diseases; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Severity of Illness Index; Vidarabine

2010
A rare occurrence of hairy cell leukemia in the Thai population: a case report.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2010, Volume: 93 Suppl 1

    Topics: Adult; Antineoplastic Agents; Asian People; Bone Marrow; Cyclophosphamide; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Hairy Cell; Male; Splenectomy; Treatment Outcome; Vidarabine

2010
Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease.
    The Journal of allergy and clinical immunology, 2010, Volume: 125, Issue:4

    Topics: Age of Onset; Anti-Bacterial Agents; Antibodies, Monoclonal; Child; Drug Therapy, Combination; Gene Deletion; Granulomatous Disease, Chronic; Humans; Inflammatory Bowel Diseases; Male; NADPH Oxidases; Steroids; Treatment Outcome; Vidarabine

2010
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
    Blood, 2010, Jun-24, Volume: 115, Issue:25

    Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chronic Disease; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Living Donors; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2010
Drug-induced immune hemolytic anemia.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2

    Topics: Anemia, Hemolytic; Anti-Bacterial Agents; Antineoplastic Agents; Cefotetan; Ceftriaxone; Coombs Test; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperacillin; Vidarabine

2010
Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells.
    European journal of pharmacology, 2010, Jul-25, Volume: 638, Issue:1-3

    Topics: Adenosine; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cholecalciferol; Cladribine; DNA Methylation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Receptors, Retinoic Acid; Resveratrol; Stilbenes; Transcriptional Activation; Tretinoin; Vidarabine

2010
Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia.
    The American journal of the medical sciences, 2010, Volume: 340, Issue:1

    Topics: Actinomycetales Infections; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte Count; Chronic Disease; Female; Humans; Leukemia, Lymphoid; Lymphopenia; Opportunistic Infections; Pneumonia, Bacterial; Rhodococcus equi; Vidarabine

2010
Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.
    Leukemia, 2010, Volume: 24, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunomodulation; Immunotherapy; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Rituximab; Survival Rate; Vidarabine

2010
[Female case of successful engraftment after PBSCT from her HLA-haploidentical son for severe aplastic anemia during maintenance peritoneal dialysis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:4

    Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclophosphamide; Female; Graft Survival; Haploidy; HLA Antigens; Humans; Immunosuppressive Agents; Middle Aged; Nuclear Family; Peripheral Blood Stem Cell Transplantation; Peritoneal Dialysis, Continuous Ambulatory; Rabbits; Severity of Illness Index; Tacrolimus; Transplantation Conditioning; Vidarabine

2010
Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
    Molecular cancer, 2010, May-20, Volume: 9

    Topics: Aged; Antineoplastic Agents; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Genes, myc; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Vidarabine

2010
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.
    Haematologica, 2010, Volume: 95, Issue:6

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Europe; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2010
Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Adolescent; Adult; Busulfan; Drug Therapy, Combination; Feasibility Studies; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2010
Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.
    Annals of hematology, 2010, Volume: 89, Issue:11

    Topics: ADP-ribosyl Cyclase 1; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Simvastatin; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2010
Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy.
    Muscle & nerve, 2010, Volume: 41, Issue:6

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Chromosome Mapping; Chromosomes, Human, X; Cyclophosphamide; Dystrophin; Follow-Up Studies; Gene Deletion; Gene Expression Regulation; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Male; Muscular Dystrophy, Duchenne; Reoperation; Transplantation, Homologous; Treatment Outcome; Vidarabine

2010
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
    Human antibodies, 2010, Volume: 19, Issue:1

    Topics: Adult; Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine; Vindesine

2010
Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement.
    International journal of radiation oncology, biology, physics, 2011, May-01, Volume: 80, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Confidence Intervals; Cranial Irradiation; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Transplantation Conditioning; Vidarabine; Young Adult

2011
Choice of immunosuppression influences cytomegalovirus DNAemia in cynomolgus monkey (Macaca fascicularis) islet allograft recipients.
    Cell transplantation, 2010, Volume: 19, Issue:12

    Topics: Analgesics, Non-Narcotic; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus; Daclizumab; DNA, Viral; Ganciclovir; Humans; Immunoglobulin G; Immunosuppressive Agents; Islets of Langerhans Transplantation; Leukocytes; Macaca fascicularis; Organometallic Compounds; Organophosphorus Compounds; Retrospective Studies; Sirolimus; T-Lymphocytes; Tacrolimus; Transplantation, Homologous; Valganciclovir; Vidarabine

2010
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Sep-01, Volume: 16, Issue:17

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Fever; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neutropenia; Pneumonia; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine

2010
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.
    Leukemia, 2010, Volume: 24, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Boron Compounds; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Purines; Tumor Necrosis Factor-alpha; Vidarabine

2010
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
    Annals of hematology, 2011, Volume: 90, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Female; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Treatment Outcome; Vidarabine

2011
High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:12

    Topics: Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine

2010
Auer rod-like inclusions in a low-grade B-cell leukemia.
    Annals of diagnostic pathology, 2010, Volume: 14, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Separation; Cyclophosphamide; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Inclusion Bodies; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Electron, Transmission; Middle Aged; Rituximab; Vidarabine

2010
HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus.
    Journal of hepatology, 2010, Volume: 53, Issue:4

    Topics: Antineoplastic Agents; Blood Transfusion; Disease Transmission, Infectious; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine; Virus Activation

2010
Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.
    The Journal of allergy and clinical immunology, 2010, Volume: 126, Issue:5

    Topics: Adolescent; Cell Separation; Child; Cyclosporine; Flow Cytometry; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Immunosuppressive Agents; Infant; Male; Mycophenolic Acid; Myeloablative Agonists; Reverse Transcriptase Polymerase Chain Reaction; Syndrome; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2010
Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.
    British journal of cancer, 2010, Aug-24, Volume: 103, Issue:5

    Topics: Adult; Aged, 80 and over; Apoptosis; Cells, Cultured; Drug Synergism; fas Receptor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Quercetin; Receptors, Death Domain; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Vidarabine

2010
Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
    American journal of hematology, 2010, Volume: 85, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine; Young Adult

2010
[Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].
    Orvosi hetilap, 2010, Aug-01, Volume: 151, Issue:31

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Humans; Immunophenotyping; Leukemia, Prolymphocytic, B-Cell; Male; Prognosis; Rituximab; Treatment Outcome; Vidarabine

2010
Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
    Bone marrow transplantation, 2011, Volume: 46, Issue:5

    Topics: Adult; Aged; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2011
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
    Bone marrow transplantation, 2011, Volume: 46, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Prednisone; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine

2011
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Pediatric hematology and oncology, 2010, Volume: 27, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Treatment Outcome; Vidarabine

2010
Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.
    Gene therapy, 2010, Volume: 17, Issue:12

    Topics: Animals; Antigens, CD20; Antineoplastic Agents; Cells, Cultured; Chlorocebus aethiops; Cyclophosphamide; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Measles virus; Mice; Mice, SCID; Molecular Targeted Therapy; Oncolytic Viruses; Salvage Therapy; Tumor Burden; Vero Cells; Vidarabine; Xenograft Model Antitumor Assays

2010
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
    Bone marrow transplantation, 2011, Volume: 46, Issue:5

    Topics: Adult; Aged; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Middle Aged; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine

2011
Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT.
    Bone marrow transplantation, 2011, Volume: 46, Issue:5

    Topics: Adult; Aged; Cyclosporine; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Male; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2011
Effect of FCGR2A and FCGR3A variants on CLL outcome.
    Blood, 2010, Nov-18, Volume: 116, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Genotype; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Receptors, IgG; Rituximab; Treatment Outcome; Vidarabine

2010
Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).
    Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Czech Republic; Disease Management; Female; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

2010
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.
    Bone marrow transplantation, 2011, Volume: 46, Issue:5

    Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Treatment Outcome; Vidarabine

2011
Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
    Annals of hematology, 2011, Volume: 90, Issue:2

    Topics: ADP-ribosyl Cyclase 1; Adult; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Drug Therapy, Combination; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Membrane Glycoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Resveratrol; Stilbenes; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2011
Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:5

    Topics: Administration, Oral; Adult; Animals; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Female; Forced Expiratory Volume; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lung; Male; Middle Aged; Myeloablative Agonists; Pulmonary Diffusing Capacity; Rabbits; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vital Capacity

2011
Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Agents; Blood Platelets; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Neutrophils; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
    British journal of haematology, 2010, Volume: 151, Issue:2

    Topics: Adjuvants, Immunologic; Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Apoptosis; Cell Communication; Coculture Techniques; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Proteins; Receptors, CXCR4; Rituximab; Stromal Cells; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Vidarabine

2010
Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
    Leukemia, 2010, Volume: 24, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Repair; Drug Synergism; Humans; Hydroxylamines; Leukemia, Lymphocytic, Chronic, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Uracil-DNA Glycosidase; Vidarabine

2010
B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.
    Leukemia, 2010, Volume: 24, Issue:11

    Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Separation; Coloring Agents; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Phenotype; Recombinant Proteins; Rituximab; Vidarabine

2010
Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Thailand; Vidarabine; Young Adult

2010
What's new in Waldenström macroglobulinemia.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2010
Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6

    Topics: Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Humans; Longitudinal Studies; Lymphocyte Count; Male; Melphalan; Multivariate Analysis; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine

2011
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.
    Experimental hematology, 2010, Volume: 38, Issue:12

    Topics: Adolescent; Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine

2010
Biclonal follicular lymphoma: histological, clinical and molecular characteristics.
    Pathology, 2010, Volume: 42, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosome Breakpoints; Clone Cells; Dexamethasone; Female; Gene Rearrangement; Genes, bcl-2; Humans; Lymphoma, Follicular; Mitoxantrone; Molecular Sequence Data; Neoplasm Staging; Polymerase Chain Reaction; Vidarabine

2010
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
    Cancer immunology, immunotherapy : CII, 2011, Volume: 60, Issue:1

    Topics: Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Male; Middle Aged; Myeloablative Agonists; T-Lymphocyte Subsets; T-Lymphocytes; Vidarabine

2011
Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
    Leukemia & lymphoma, 2010, Volume: 51, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Assessment; Vidarabine

2010
Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6

    Topics: Adult; Cord Blood Stem Cell Transplantation; Cryopreservation; Disease-Free Survival; Female; Graft Rejection; Graft vs Host Disease; HLA Antigens; Humans; Lymphocyte Count; Male; Middle Aged; Prospective Studies; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2011
Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative dis
    Human pathology, 2010, Volume: 41, Issue:12

    Topics: Aged; Antineoplastic Agents; B-Lymphocytes; Cell Transformation, Neoplastic; Clone Cells; Epstein-Barr Virus Infections; Fatal Outcome; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large-Cell, Immunoblastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Plasma Cells; Vidarabine

2010
Chronic lymphocytic leukaemia--moving towards cure?
    Lancet (London, England), 2010, Oct-02, Volume: 376, Issue:9747

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Time Factors; Treatment Outcome; Vidarabine

2010
Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution.
    American journal of hematology, 2010, Volume: 85, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Survival Rate; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2010
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2010
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
    Journal of hematology & oncology, 2010, Oct-06, Volume: 3

    Topics: Area Under Curve; Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2010
Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:12

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Disorders; Cyclophosphamide; Humans; Male; Middle Aged; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2010
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2011
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
    Biochemical pharmacology, 2011, Jan-15, Volume: 81, Issue:2

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Clofarabine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine

2011
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age.
    Haematologica, 2011, Volume: 96, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Survival Rate; T-Lymphocytes; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult

2011
ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.
    Oncogene, 2011, Feb-10, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; CD40 Antigens; Cisplatin; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Tumor Cells, Cultured; Up-Regulation; Vidarabine

2011
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2010
Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Prognosis; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vidarabine; Young Adult

2011
Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia.
    Journal of medical microbiology, 2011, Volume: 60, Issue:Pt 1

    Topics: Aged; Angiomatosis, Bacillary; Anti-Bacterial Agents; Antineoplastic Agents; Bacteriological Techniques; Bartonella quintana; Drug Therapy; Female; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Microscopy; Osteomyelitis; Treatment Failure; Vidarabine

2011
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
    Leukemia, 2010, Volume: 24, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine

2010
High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Antiviral Agents; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Neuralgia, Postherpetic; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Activation

2011
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
    Leukemia research, 2011, Volume: 35, Issue:4

    Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine Kinase; DNA Mutational Analysis; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Vidarabine

2011
Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita.
    Acta haematologica, 2010, Volume: 124, Issue:4

    Topics: Antilymphocyte Serum; Cyclosporine; Dyskeratosis Congenita; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Mycophenolic Acid; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2010
Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients.
    Leukemia research, 2011, Volume: 35, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine Kinase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Treatment Outcome; Vidarabine

2011
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.
    Bone marrow transplantation, 2011, Volume: 46, Issue:8

    Topics: Age Factors; Aged; Antilymphocyte Serum; Busulfan; Comorbidity; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Stem cell transplantation using non-myeloablative conditioning regimen with fludarabine for hematological malignancies.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2010, Volume: 77, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Vidarabine

2010
Alloreactive natural killer cells promote haploidentical hematopoietic stem cell transplantation by expansion of recipient-derived CD4(+) CD25(+) regulatory T cells.
    Transplant international : official journal of the European Society for Organ Transplantation, 2011, Volume: 24, Issue:2

    Topics: Animals; CD4-Positive T-Lymphocytes; Cyclophosphamide; Dendritic Cells; Female; Hematopoietic Stem Cell Transplantation; Immunotherapy, Adoptive; Interleukin-2 Receptor alpha Subunit; Killer Cells, Natural; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred C57BL; T-Lymphocytes, Regulatory; Thymus Gland; Transplantation Conditioning; Transplantation Tolerance; Transplantation, Homologous; Vidarabine

2011
Unrelated donor transplantation for acute myelogenous leukemia in first remission.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Salvage Therapy; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2011
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
    Leukemia research, 2011, Volume: 35, Issue:6

    Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Flow Cytometry; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Receptors, CXCR4; Survival Analysis; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2011
Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Transplantation proceedings, 2010, Volume: 42, Issue:9

    Topics: Adult; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recurrence; Reoperation; Republic of Korea; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vidarabine

2010
Diagnostic and therapeutic challenges.
    Retina (Philadelphia, Pa.), 2011, Volume: 31, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymph Nodes; Male; Middle Aged; Retinal Neoplasms; Rituximab; Splenomegaly; Tomography, X-Ray Computed; Vidarabine; Vision, Low; Visual Acuity; Vitreoretinopathy, Proliferative; Vitreous Hemorrhage

2011
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
    European journal of haematology, 2011, Volume: 86, Issue:3

    Topics: Antineoplastic Agents; Aza Compounds; Base Sequence; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Genes, p53; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mutation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Vidarabine

2011
The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:5

    Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Drug Synergism; Female; Graft Survival; Graft vs Host Disease; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Lymphocyte Depletion; Mice; Mice, Inbred BALB C; Pentostatin; Transplantation Chimera; Transplantation, Homologous; Vidarabine

2011
Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.
    Bone marrow transplantation, 2011, Volume: 46, Issue:11

    Topics: Adult; Aged; Area Under Curve; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine

2011
Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).
    Bone marrow transplantation, 2011, Volume: 46, Issue:10

    Topics: Adolescent; Adult; Busulfan; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:12

    Topics: Busulfan; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Maximum Tolerated Dose; Monitoring, Physiologic; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2010
EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab.
    Journal of neurology, 2011, Volume: 258, Issue:5

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immune System; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine

2011
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medi
    The oncologist, 2010, Volume: 15, Issue:12

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; European Union; Female; Health Services; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Practice Guidelines as Topic; Survival Rate; Treatment Outcome; Vidarabine

2010
Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.
    Biochemical pharmacology, 2011, Mar-01, Volume: 81, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Enzyme Activation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proliferating Cell Nuclear Antigen; Proteasome Endopeptidase Complex; Purine Nucleosides; Tumor Suppressor Protein p53; Ubiquitination; Up-Regulation; Vidarabine

2011
Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma.
    Journal of proteome research, 2011, Mar-04, Volume: 10, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cladribine; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Humans; Lymphoma, B-Cell; Mitochondria; Molecular Chaperones; Proteome; Purines; Vidarabine

2011
Synthesis and biological properties of the cytotoxic 14-membered macrolides aspergillide A and B.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2011, Jan-10, Volume: 17, Issue:2

    Topics: Antineoplastic Agents; Aspergillus; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Inhibitory Concentration 50; Macrolides; Marine Biology; Molecular Structure; Stereoisomerism; Vidarabine

2011
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.
    Annals of hematology, 2011, Volume: 90, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:8

    Topics: Adult; Aged; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Nod2 Signaling Adaptor Protein; Polymorphism, Single Nucleotide; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2011
Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:9

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Graft Survival; Humans; Infant; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2011
Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Cord Blood Stem Cell Transplantation; Cyclosporine; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Mycophenolic Acid; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2011
The RNA activator ds-p21 potentiates the cytotoxicity induced by fludarabine in Dohh2 cells.
    Oligonucleotides, 2011, Volume: 21, Issue:1

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation; Humans; Lymphoma, Non-Hodgkin; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-6; RNA, Double-Stranded; RNA, Messenger; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53; Vidarabine

2011
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.
    International journal of hematology, 2011, Volume: 93, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Retrospective Studies; Rituximab; Transplantation Conditioning; Vidarabine

2011
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
    Journal of the National Cancer Institute, 2011, Feb-16, Volume: 103, Issue:4

    Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine

2011
Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID.
    Bone marrow transplantation, 2011, Volume: 46, Issue:12

    Topics: Acute Disease; Antineoplastic Agents; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Female; Fetal Blood; Graft vs Host Disease; Histocompatibility Testing; Humans; Infant; Lung Diseases, Fungal; Male; Pneumonia, Bacterial; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; X-Linked Combined Immunodeficiency Diseases

2011
DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
    Experimental oncology, 2010, Volume: 32, Issue:4

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; ATP Binding Cassette Transporter, Subfamily B; Benzaldehydes; Blotting, Western; Caffeine; Cell Cycle Proteins; Cell Line, Tumor; Chromones; Cyclosporine; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine

2010
A transient IgE monoclonal protein in a child.
    Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 1

    Topics: Adrenoleukodystrophy; Antibodies, Monoclonal; Busulfan; Child; Cyclosporine; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Immunoglobulin E; Immunosuppressive Agents; Vidarabine; Virus Activation

2011
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2011
Antithymocyte globulin-induced acute lung injury during transplantation for aplastic anemia.
    Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:2

    Topics: Acute Lung Injury; Anemia, Aplastic; Animals; Anti-Bacterial Agents; Antilymphocyte Serum; Bacterial Infections; Bone Marrow Transplantation; Child; Cyclophosphamide; Horses; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Transplantation Conditioning; Vancomycin; Vidarabine

2011
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).
    Pediatric blood & cancer, 2011, Volume: 57, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Female; Graft Rejection; Heart Transplantation; Humans; Liver Transplantation; Lymphoproliferative Disorders; Male; Remission Induction; Rituximab; Vidarabine

2011
FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
    Journal of experimental & clinical cancer research : CR, 2011, Feb-08, Volume: 30

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Feasibility Studies; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radioimmunotherapy; Retrospective Studies; Rituximab; Vidarabine; Yttrium Radioisotopes

2011
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
    Leukemia research, 2011, Volume: 35, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2011
Personalizing treatment for chronic lymphocytic leukemia.
    Expert review of hematology, 2011, Volume: 4, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Receptors, CXCR4; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2011
Early initial therapy of advanced follicular lymphoma: the need for vigilance.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Follow-Up Studies; Humans; Lymphoma, Follicular; Neoadjuvant Therapy; Population Surveillance; Rituximab; Vidarabine

2011
STAT1-mediated signal integration between IFNγ and LPS leads to increased EC and SMC activation and monocyte adhesion.
    American journal of physiology. Cell physiology, 2011, Volume: 300, Issue:6

    Topics: Antineoplastic Agents; Atherosclerosis; Cell Adhesion; Cell Line; Endothelial Cells; Gene Expression; Humans; Interferon-gamma; Lipopolysaccharides; Monocytes; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Signal Transduction; STAT1 Transcription Factor; Toll-Like Receptor 4; Vidarabine

2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
    Hematological oncology, 2011, Volume: 29, Issue:4

    Topics: Adult; Aged; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Opportunistic Infections; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2011
[A preliminary study on efficacy of allogeneic hematopoietic stem cell transplantation by myeloablative conditioning regimen with fludarabine for high risk leukemia patients].
    Zhongguo shi yan xue ye xue za zhi, 2011, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2011
[Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].
    Methods and findings in experimental and clinical pharmacology, 2010, Volume: 32 Suppl A

    Topics: Adolescent; Adult; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2010
Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
    Haematologica, 2011, Volume: 96, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Humans; International Classification of Diseases; Male; Middle Aged; Prognosis; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2011
Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.
    International journal of hematology, 2011, Volume: 93, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chimerism; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Vidarabine; Young Adult

2011
Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
    Bone marrow transplantation, 2012, Volume: 47, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2012
Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic 'sensor/effector' compounds.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Catalysis; Cell Survival; Drug Synergism; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Organic Chemicals; Oxidation-Reduction; Reactive Oxygen Species; Vidarabine

2011
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
    Bone marrow transplantation, 2012, Volume: 47, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2012
Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.
    Bone marrow transplantation, 2012, Volume: 47, Issue:3

    Topics: Adult; Animals; Antilymphocyte Serum; Carotid Arteries; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Probability; Rabbits; Retrospective Studies; Salvage Therapy; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine

2012
Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.
    Journal of immunology (Baltimore, Md. : 1950), 2011, May-15, Volume: 186, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Case-Control Studies; Female; Humans; Immunoglobulin M; Immunologic Memory; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza, Human; Lymphoma, Non-Hodgkin; Male; Middle Aged; Orthomyxoviridae; Rituximab; Tumor Necrosis Factor Receptor Superfamily, Member 7; Vidarabine

2011
Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2011, Volume: 34, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follicle Stimulating Hormone; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasms; Ovary; Primary Ovarian Insufficiency; Radiotherapy; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult

2011
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
    American journal of hematology, 2011, Volume: 86, Issue:7

    Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Journal of hematology & oncology, 2011, Apr-23, Volume: 4

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Flow Cytometry; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Myeloid; Leukocytes, Mononuclear; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Thymus Gland; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2011
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
    Cancer, 2011, May-15, Volume: 117, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Prognosis; Recurrence; Remission Induction; Tandem Repeat Sequences; Vidarabine

2011
Immune hemolysis after fludarabine-based reduced intensity conditioning and allogeneic PBSC transplantation for CML with minor ABO incompatibility.
    Annals of hematology, 2012, Volume: 91, Issue:2

    Topics: Antineoplastic Agents; Blood Group Incompatibility; Female; Hemolysis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
    Hematological oncology, 2012, Volume: 30, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:11

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
Waldenström's macroglobulinemia and nephrotic syndrome with membranous nephropathy.
    Scandinavian journal of urology and nephrology, 2011, Volume: 45, Issue:6

    Topics: Adult; Angiotensin Receptor Antagonists; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Glomerulonephritis, Membranous; Humans; Immunoglobulin lambda-Chains; Immunoglobulin M; Male; Nephrotic Syndrome; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2011
Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
    Annals of hematology, 2011, Volume: 90, Issue:10

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Drug Monitoring; Female; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pilot Projects; Recombinant Proteins; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine

2011
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-15, Volume: 17, Issue:14

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line; Cell Survival; CHO Cells; Cricetinae; Cricetulus; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Organoplatinum Compounds; Oxaliplatin; Signal Transduction; Vidarabine

2011
Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:8

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Glomerulonephritis, Membranoproliferative; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine

2011
Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.
    Cancer gene therapy, 2011, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Chlorocebus aethiops; Combined Modality Therapy; Female; GPI-Linked Proteins; Humans; Male; Measles virus; Mice; Mice, SCID; Neoplasm Proteins; Oncolytic Virotherapy; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Vero Cells; Vidarabine; Xenograft Model Antitumor Assays

2011
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:10

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Risk; Transplantation Conditioning; Treatment Outcome; Vidarabine

2011
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
    Leukemia research, 2011, Volume: 35, Issue:8

    Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Primary Myelofibrosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2011
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
    Blood, 2011, Sep-01, Volume: 118, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Infections; Kaplan-Meier Estimate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2011
Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab.
    BMC nephrology, 2011, Jul-05, Volume: 12

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Glomerulosclerosis, Focal Segmental; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Rituximab; Vidarabine

2011
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-01, Volume: 29, Issue:22

    Topics: Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prospective Studies; Recurrence; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine

2011
Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Neoplasma, 2011, Volume: 58, Issue:5

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2011
Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.
    British journal of haematology, 2011, Volume: 154, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Berlin; beta-Lactams; Case-Control Studies; Ciprofloxacin; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lorazepam; Male; Middle Aged; Odds Ratio; Piperacillin; Population Surveillance; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine; Young Adult

2011
Treatment strategies in patients with core-binding factor acute myeloid leukemia.
    Current oncology reports, 2011, Volume: 13, Issue:5

    Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Daunorubicin; Disease-Free Survival; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Vidarabine

2011
Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:1

    Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult

2012
Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Clinical Trials as Topic; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2012
Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2011, Volume: 65, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 5; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Translocation, Genetic; Vidarabine

2011
Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT.
    Bone marrow transplantation, 2012, Volume: 47, Issue:5

    Topics: Adult; Aged; Cryotherapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms.
    The Journal of investigative dermatology, 2011, Volume: 131, Issue:12

    Topics: Animals; Cell Line; Enzyme Inhibitors; Humans; Interleukin-17; Keratin-17; Keratinocytes; Mice; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Stilbenes; Vidarabine

2011
Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2012, Volume: 47, Issue:5

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Reoperation; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Hemianopsia; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Rituximab; Vidarabine

2012
Gastric mucosa-associated lymphoid tissue lymphoma: how to attack the T… for two?
    Leukemia & lymphoma, 2011, Volume: 52, Issue:12

    Topics: Antineoplastic Agents; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Tumor Microenvironment; Vidarabine

2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Oligonucleotides; Prognosis; Risk Factors; Rituximab; Survival Rate; Tumor Suppressor Protein p53; Vidarabine

2012
Successful cord blood transplantation with reduced-intensity conditioning for childhood cerebral X-linked adrenoleukodystrophy at advanced and early stages.
    Pediatric transplantation, 2012, Volume: 16, Issue:2

    Topics: Adrenoleukodystrophy; Brain; Child; Cord Blood Stem Cell Transplantation; Humans; Male; Melphalan; Myeloablative Agonists; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2012
Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with fludarabine: effect on tumor microenvironment.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; T-Lymphocyte Subsets; Tumor Microenvironment; Vidarabine

2011
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
    British journal of haematology, 2011, Volume: 155, Issue:2

    Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Genetic Diseases, Inborn; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Melphalan; Myeloablative Agonists; Neoplasms; Neutrophils; Recombinant Proteins; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2011
Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.
    Clinical immunology (Orlando, Fla.), 2011, Volume: 141, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cell Survival; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft Enhancement, Immunologic; Graft Survival; Humans; Immunologic Deficiency Syndromes; Infant; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Male; Melphalan; Point Mutation; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thiotepa; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:4

    Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cystitis; Disease-Free Survival; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Male; Prospective Studies; Saudi Arabia; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2012
Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen.
    Medical science monitor : international medical journal of experimental and clinical research, 2011, Volume: 17, Issue:9

    Topics: Acute Disease; Adult; Aged; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Mouth Diseases; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2011
Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

    Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Female; Flow Cytometry; Genes, Immunoglobulin Heavy Chain; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2012
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
    Investigational new drugs, 2012, Volume: 30, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Death; Cell Survival; Cyclophosphamide; Depsipeptides; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Monocytes; Peptides, Cyclic; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Vidarabine

2012
Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide.
    Annals of hematology, 2012, Volume: 91, Issue:5

    Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Cyclophosphamide; Female; Humans; Immunoglobulin M; Livedo Reticularis; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Rituximab; Vidarabine

2012
Atypical cytogenetics in therapy-related myelodysplastic syndrome secondary to indolent B-cell lymphoma.
    Clinical laboratory science : journal of the American Society for Medical Technology, 2011,Summer, Volume: 24, Issue:3

    Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 20; Female; Flow Cytometry; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Middle Aged; Myelodysplastic Syndromes; Vidarabine

2011
The effects of chemotherapeutic agents on differentiated chordoma cells.
    Journal of neurosurgery. Spine, 2011, Volume: 15, Issue:6

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Chordoma; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Imatinib Mesylate; Methotrexate; Piperazines; Pyrimidines; Vidarabine; Vincristine

2011
Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings.
    Journal of medical virology, 2011, Volume: 83, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine; Viral Load; Viremia; Virus Activation

2011
Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.
    International journal of hematology, 2011, Volume: 94, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia; Lymphoma; Salvage Therapy; Vidarabine

2011
Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
    Cytometry. Part B, Clinical cytometry, 2011, Volume: 80, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; B-Lymphocytes; CD5 Antigens; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Neoplasm, Residual; Reference Values; ROC Curve; Sensitivity and Specificity; Vidarabine

2011
Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44.
    Journal of clinical immunology, 2012, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Busulfan; CD3 Complex; Child; Down-Regulation; Female; Forkhead Transcription Factors; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Hyaluronan Receptors; Immunosuppression Therapy; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Leukocytes, Mononuclear; Lymphocyte Culture Test, Mixed; Male; Middle Aged; Myeloablative Agonists; Protein Binding; Rabbits; Radiation Tolerance; T-Lymphocytes, Regulatory; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2012
Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients.
    Hematology/oncology and stem cell therapy, 2011, Volume: 4, Issue:3

    Topics: Adolescent; Adult; Cause of Death; Child; Child, Preschool; Fanconi Anemia; Female; Graft Rejection; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2011
Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.
    Clinical and experimental immunology, 2011, Volume: 166, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes; Cells, Cultured; Coculture Techniques; Flow Cytometry; Forkhead Transcription Factors; Humans; Immunomodulation; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tumor Necrosis Factor Receptor Superfamily, Member 7; Vidarabine

2011
Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.
    Onkologie, 2011, Volume: 34, Issue:10

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukocyte Count; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Myelodysplastic Syndromes; Platelet Count; Statistics as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2011
CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.
    Haematologica, 2012, Volume: 97, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers, Tumor; Cohort Studies; Female; Humans; Lectins, C-Type; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Vidarabine

2012
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine

2012
Comment on research report by Gruson and colleagues, this issue.
    Journal of the peripheral nervous system : JPNS, 2011, Volume: 16, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Female; Humans; Immunologic Factors; Male; Polyradiculoneuropathy; Rituximab; Vidarabine

2011
Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.
    Journal of the peripheral nervous system : JPNS, 2011, Volume: 16, Issue:3

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Autoantigens; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoglobulin M; Immunologic Factors; Male; Middle Aged; Myelin-Associated Glycoprotein; Paraproteinemias; Polyradiculoneuropathy; Rituximab; Vidarabine

2011
FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
    American journal of hematology, 2012, Volume: 87, Issue:1

    Topics: Aged; Aged, 80 and over; Ambulatory Care; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Treatment Outcome; Vidarabine

2012
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.
    PloS one, 2011, Volume: 6, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; B-Lymphocytes; Biomarkers, Tumor; Cell Line, Tumor; Female; Humans; Hydrogen Peroxide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Proteome; Reactive Oxygen Species; Signal Transduction; Single-Cell Analysis; Vidarabine

2011
Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:5

    Topics: Antineoplastic Agents; Cell Death; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; Tumor Cells, Cultured; Vidarabine

2012
Fludarabine versus chlorambucil: is the debate over?
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Remission Induction; Vidarabine

2011
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
    Blood, 2011, Dec-22, Volume: 118, Issue:26

    Topics: Amino Acid Sequence; Antineoplastic Agents; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Sequence Data; Mutation; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Polymorphism, Single Nucleotide; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Sequence Homology, Amino Acid; Spliceosomes; Tumor Suppressor Protein p53; Vidarabine

2011
Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome.
    The American Journal of dermatopathology, 2011, Volume: 33, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biopsy; Cyclophosphamide; Drug Therapy, Combination; Eyelids; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Necrobiotic Xanthogranuloma; Paraproteinemias; Rituximab; Sjogren's Syndrome; Treatment Outcome; Vidarabine

2011
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
    JAMA, 2011, Nov-02, Volume: 306, Issue:17

    Topics: Age Factors; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Radiation Dosage; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2011
Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go.
    JAMA, 2011, Nov-02, Volume: 306, Issue:17

    Topics: Antineoplastic Agents; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2011
Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.
    Leukemia, 2012, Volume: 26, Issue:5

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine

2012
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

    Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Apoptosis; CD40 Ligand; Cell Proliferation; Crotonates; Drug Resistance, Neoplasm; Humans; Hydroxybutyrates; Interleukin-4; Isoxazoles; Janus Kinases; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitriles; Signal Transduction; STAT Transcription Factors; Toluidines; Tumor Cells, Cultured; Vidarabine

2012
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
    Leukemia research, 2012, Volume: 36, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Down-Regulation; Drug Synergism; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxamic Acids; Indoles; Leukemia; MAP Kinase Kinase 4; Mice; Mice, Nude; NF-kappa B; Panobinostat; Vidarabine; X-Linked Inhibitor of Apoptosis Protein

2012
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
    Journal of pediatric surgery, 2011, Volume: 46, Issue:11

    Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine

2011
Anti-CD20: tales of identical twins?
    Blood, 2011, Nov-10, Volume: 118, Issue:19

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Vidarabine

2011
Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2012, Volume: 25, Issue:2

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Rituximab; Vidarabine

2012
Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Roscovitine; Vidarabine

2012
Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
    European journal of haematology, 2012, Volume: 88, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Mucositis; Myeloablative Agonists; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biphenyl Compounds; CD40 Antigens; CD40 Ligand; Coculture Techniques; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Mice; Middle Aged; Minor Histocompatibility Antigens; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; NIH 3T3 Cells; Nitrophenols; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Tumor Cells, Cultured; Vidarabine

2012
Fludarabine nucleoside modulates nuclear "survival and death" proteins in resistant chronic lymphocytic leukemia cells.
    Nucleosides, nucleotides & nucleic acids, 2011, Volume: 30, Issue:12

    Topics: Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nuclear Proteins; Nucleosides; Protein Processing, Post-Translational; Vidarabine

2011
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
    Haematologica, 2012, Volume: 97, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine

2012
Chemotherapy: New FluCam combination therapy has familiar limitations.
    Nature reviews. Clinical oncology, 2011, Dec-06, Volume: 9, Issue:1

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Cyclophosphamide; Drug Therapy, Combination; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2011
The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzamides; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2012
Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart.
    The Journal of biological chemistry, 2012, Jan-20, Volume: 287, Issue:4

    Topics: Animals; Antineoplastic Agents; Butadienes; Cardiomegaly; Cells, Cultured; Collagen; Disease Models, Animal; Down-Regulation; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Humans; Imidazoles; Interleukin-6; Male; MAP Kinase Signaling System; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Rats; Rats, Wistar; STAT1 Transcription Factor; STAT3 Transcription Factor; Vidarabine

2012
Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.
    Haematologica, 2012, Volume: 97, Issue:6

    Topics: Aged; Aged, 80 and over; Annexin A5; Antineoplastic Agents; Apoptosis; Biological Transport; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Primary Cell Culture; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tretinoin; Tritium; Vidarabine

2012
Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.
    Haematologica, 2012, Volume: 97, Issue:6

    Topics: Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD18 Antigens; Cell Adhesion; Cell Communication; Coculture Techniques; Culture Media, Conditioned; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Integrin beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Primary Cell Culture; Signal Transduction; Vascular Cell Adhesion Molecule-1; Vidarabine

2012
Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient.
    Experimental oncology, 2011, Volume: 33, Issue:4

    Topics: Antineoplastic Agents; Brain; DNA, Viral; Herpesvirus 7, Human; Humans; JC Virus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Vidarabine

2011
Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.
    Blood, 2012, Mar-01, Volume: 119, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Recurrence; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2012
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
    American journal of hematology, 2012, Volume: 87, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Remission Induction; Retrospective Studies; Translocation, Genetic; Vidarabine

2012
Fludarabine may overcome resistance to rituximab in IgM-related neuropathy.
    Journal of the neurological sciences, 2012, Apr-15, Volume: 315, Issue:1-2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Drug Resistance; Female; Humans; Immunoglobulin M; Male; Middle Aged; Polyneuropathies; Rituximab; Vidarabine

2012
Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival.
    Bone marrow transplantation, 2012, Volume: 47, Issue:9

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft Rejection; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2012
A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.
    Bone marrow transplantation, 2012, Volume: 47, Issue:9

    Topics: Adult; Antilymphocyte Serum; Combined Modality Therapy; Cyclophosphamide; Dyskeratosis Congenita; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2012
Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.
    Naunyn-Schmiedeberg's archives of pharmacology, 2012, Volume: 385, Issue:5

    Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Binding, Competitive; CHO Cells; Cladribine; Clofarabine; Cricetinae; Cricetulus; Cytotoxins; Humans; Purinergic P1 Receptor Agonists; Radioligand Assay; Receptors, Purinergic P1; Vidarabine

2012
Individualized fludarabine-based regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Advances in therapy, 2012, Volume: 29, Issue:2

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2012
Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
    Annals of hematology, 2012, Volume: 91, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Serologic Tests; Titrimetry; Vidarabine; Vincristine; Virus Activation

2012
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:8

    Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Area Under Curve; Biopsy; Busulfan; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Liver; Male; Middle Aged; Stem Cell Transplantation; Time Factors; Vidarabine

2012
[Modern times: back to past, back to future].
    Medicina clinica, 2012, Jul-07, Volume: 139, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine

2012
Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2012, Volume: 20, Issue:5

    Topics: Animals; Animals, Newborn; Busulfan; Genes, Reporter; Genetic Vectors; Graft Survival; Green Fluorescent Proteins; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Immune Tolerance; Immunosuppressive Agents; Lentivirus; Macaca mulatta; Simian Immunodeficiency Virus; Transduction, Genetic; Transgenes; Transplantation Conditioning; Vidarabine

2012
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
    Bone marrow transplantation, 2012, Volume: 47, Issue:5

    Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Rabbits; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine

2012
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
    Blood, 2012, Mar-22, Volume: 119, Issue:12

    Topics: Aged; Antineoplastic Agents; Baculoviral IAP Repeat-Containing 3 Protein; Blotting, Western; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization, Fluorescence; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; NF-kappa B; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Vidarabine

2012
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-10, Volume: 30, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-15; Interleukin-7; Lymphocyte Depletion; Lymphoma; Male; Middle Aged; Prednisone; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine; Vincristine

2012
[Classic Hodgkin's lymphoma in post-treatment hairy cell leukemia: report of a case].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2011, Volume: 40, Issue:12

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Leukemia, Hairy Cell; Male; Mitoxantrone; Neoplasms, Multiple Primary; Rituximab; Splenectomy; Vidarabine; Vinblastine

2011
Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2011, Volume: 155, Issue:4

    Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2011
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.
    Nature cell biology, 2012, Feb-19, Volume: 14, Issue:3

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Marrow Cells; Cell Communication; Cell Line; Cell Survival; Coculture Techniques; Culture Media, Conditioned; Cysteine; Cystine; Drug Resistance, Neoplasm; Flow Cytometry; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Organoplatinum Compounds; Oxaliplatin; Reactive Oxygen Species; Stromal Cells; Tumor Cells, Cultured; Vidarabine

2012
IFN-γ synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation.
    British journal of pharmacology, 2012, Volume: 166, Issue:7

    Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; Cytokines; Dexamethasone; Drug Resistance; Female; Humans; Interferon-gamma; Janus Kinases; Lipopolysaccharides; Macrophages, Alveolar; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Toll-Like Receptor 2; Toll-Like Receptor 4; Vidarabine

2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Mutation, Missense; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Serine-Threonine Kinases; Rituximab; Tumor Suppressor Proteins; Vidarabine

2012
Risk categories and refractory CLL in the era of chemoimmunotherapy.
    Blood, 2012, May-03, Volume: 119, Issue:18

    Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Forecasting; Genes, p53; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Prognosis; Risk Assessment; Rituximab; Terminology as Topic; Treatment Failure; Vidarabine

2012
FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Salvage Therapy; Survival Rate; Vidarabine

2012
Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
    The Korean journal of internal medicine, 2012, Volume: 27, Issue:1

    Topics: Adolescent; Adult; Busulfan; Chi-Square Distribution; Disease-Free Survival; Drug Therapy, Combination; Feasibility Studies; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2012
Matched sibling donor stem cell transplantation for Fanconi anemia patients with T-cell somatic mosaicism.
    Pediatric transplantation, 2012, Volume: 16, Issue:4

    Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chimerism; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Fanconi Anemia; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infant; Male; Mosaicism; Stem Cell Transplantation; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2012
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:9

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisolone; Rituximab; Teniposide; Vidarabine

2012
T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.
    British journal of haematology, 2012, Volume: 157, Issue:5

    Topics: Adult; Aged; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Middle Aged; Recurrence; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.
    Blood, 2012, Mar-29, Volume: 119, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Middle Aged; Neoadjuvant Therapy; Rituximab; Survival Analysis; Time Factors; Vidarabine

2012
Stem cell factor-displaying simian immunodeficiency viral vectors together with a low conditioning regimen allow for long-term engraftment of gene-marked autologous hematopoietic stem cells in macaques.
    Human gene therapy, 2012, Volume: 23, Issue:7

    Topics: Animals; Antigens, CD34; Chimerism; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; HEK293 Cells; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hemophilia A; Humans; Lymphocyte Count; Macaca fascicularis; Male; Myeloablative Agonists; Radiation-Sensitizing Agents; Recombinant Proteins; Simian Immunodeficiency Virus; Stem Cell Factor; Transduction, Genetic; Transplantation Conditioning; Transplantation, Autologous; Vidarabine; Whole-Body Irradiation

2012
N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
    Leukemia, 2012, Volume: 26, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Proliferation; Drug Synergism; Fenretinide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sulfonamides; Vidarabine

2012
Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.
    American journal of hematology, 2012, Volume: 87, Issue:6

    Topics: Blood Component Transfusion; Blood Donors; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Humans; Infant; Infant, Newborn; Japan; Lymphohistiocytosis, Hemophagocytic; Male; Melphalan; Reoperation; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2012
Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
    Biochemical pharmacology, 2012, Jul-01, Volume: 84, Issue:1

    Topics: Antineoplastic Agents; Aphidicolin; Biotransformation; Cell Line, Tumor; Cell Survival; Cladribine; Deoxycytidine; Deoxycytidine Kinase; Enzyme Activation; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Kinetics; Mutation; Phosphorylation; Purine Nucleosides; Pyrimidine Nucleosides; Serine; Structure-Activity Relationship; Substrate Specificity; Vidarabine

2012
Splenic re-irradiation for waldenstrőm's macroglobulinemia.
    Radiation oncology (London, England), 2012, Apr-12, Volume: 7

    Topics: Aged; Antineoplastic Agents; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Radiotherapy, Conformal; Spleen; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia

2012
[Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:3

    Topics: Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2012
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
    Gene, 2012, Jun-15, Volume: 501, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine

2012
The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Atherosclerosis; Cell Line; Cell Separation; gag Gene Products, Human Immunodeficiency Virus; Gene Expression Regulation; GTP-Binding Proteins; HIV Antigens; HIV Infections; HIV-1; Humans; Inflammation; Isoxazoles; Janus Kinases; Lipid Metabolism; Lipopolysaccharide Receptors; Macrophages; Monocytes; Neoplasm Proteins; Neutralization Tests; Phenotype; Phosphorylation; PPAR gamma; Receptors for Activated C Kinase; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; Thiazolidinediones; Vaccination; Vidarabine

2012
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.
    American journal of hematology, 2013, Volume: 88, Issue:3

    Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Fatal Outcome; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Prednisone; Vidarabine; Vincristine

2013
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:4

    Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Enzymes; Female; Gemtuzumab; Genetic Heterogeneity; Genotype; Humans; Idarubicin; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sialic Acid Binding Ig-like Lectin 3; Treatment Outcome; Vidarabine

2013
Striking the right balance: optimizing conditioning regimens for unrelated donor bone marrow transplant for severe aplastic anemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:7

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Cyclophosphamide; Female; Humans; Male; Transplantation Conditioning; Vidarabine

2012
miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
    Carcinogenesis, 2012, Volume: 33, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Vidarabine

2012
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
    Oncotarget, 2012, Volume: 3, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; CASP8 and FADD-Like Apoptosis Regulating Protein; Cells, Cultured; Cytoprotection; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Resorcinols; Signal Transduction; Survivin; Tumor Microenvironment; Vidarabine

2012
Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.
    Proteomics. Clinical applications, 2012, Volume: 6, Issue:5-6

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cytosol; DNA-Binding Proteins; Humans; Membrane Proteins; Nuclear Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2012
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:11

    Topics: Animals; Apoptosis; CD40 Antigens; CD40 Ligand; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunophenotyping; Isoxazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phenotype; Receptor Tyrosine Kinase-like Orphan Receptors; Resorcinols; STAT3 Transcription Factor; Stromal Cells; Vidarabine

2012
Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study.
    Pharmacological reports : PR, 2012, Volume: 64, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cladribine; DNA, Complementary; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Transcriptome; Tumor Cells, Cultured; Vidarabine

2012
Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.
    American journal of hematology, 2012, Volume: 87, Issue:9

    Topics: Adult; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2012
Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Aug-01, Volume: 18, Issue:15

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclin-Dependent Kinase Inhibitor p21; Cyclophosphamide; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Prognosis; Protein Serine-Threonine Kinases; Randomized Controlled Trials as Topic; Signal Transduction; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2012
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
    Leukemia research, 2012, Volume: 36, Issue:9

    Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Sirolimus; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2012
Epstein-Barr virus-negative classical Hodgkin's lymphoma in a patient with T-cell prolymphocytic leukemia treated with fludarabine.
    Journal of clinical and experimental hematopathology : JCEH, 2012, Volume: 52, Issue:1

    Topics: Antineoplastic Agents; Female; Herpesvirus 4, Human; Hodgkin Disease; Humans; Leukemia, Prolymphocytic, T-Cell; Middle Aged; Neoplasms, Second Primary; Vidarabine

2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
    Blood, 2012, Aug-09, Volume: 120, Issue:6

    Topics: Antineoplastic Agents; Autophagy; Cell Culture Techniques; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Signal Transduction; Starvation; Tumor Cells, Cultured; Vidarabine

2012
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
    Leukemia, 2012, Volume: 26, Issue:12

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Dactinomycin; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Mice, Transgenic; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine

2012
HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Blood Proteins; Cell Nucleus; Cyclophosphamide; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Receptors, Antigen, B-Cell; RNA, Messenger; src-Family Kinases; Subcellular Fractions; Substrate Specificity; Vidarabine

2012
Cytomegalovirus oesophagitis following treatment with fludarabine for refractory lymphoplasmacytic lymphoma.
    BMJ case reports, 2012, Jul-05, Volume: 2012

    Topics: Antineoplastic Agents; Antiviral Agents; Biopsy; Cytomegalovirus Infections; Diagnosis, Differential; Endoscopy, Digestive System; Esophagitis; Ganciclovir; Humans; Immunocompromised Host; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Valganciclovir; Vidarabine; Waldenstrom Macroglobulinemia

2012
Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.
    Pediatric transplantation, 2013, Volume: 17, Issue:1

    Topics: Adenosine Deaminase; Agammaglobulinemia; Bone Marrow Transplantation; Busulfan; Child, Preschool; Humans; Living Donors; Male; Severe Combined Immunodeficiency; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2013
The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
    Leukemia, 2013, Volume: 27, Issue:2

    Topics: Antineoplastic Agents; Biological Assay; Drug Monitoring; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Patient Selection; Predictive Value of Tests; Prognosis; Random Allocation; Randomized Controlled Trials as Topic; Survival Rate; Vidarabine

2013
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2013
Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.
    European journal of haematology, 2012, Volume: 89, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cyclophosphamide; DNA Probes; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Rituximab; Translocation, Genetic; Vidarabine

2012
Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.
    Pediatric hematology and oncology, 2012, Volume: 29, Issue:6

    Topics: Adolescent; Antineoplastic Agents; Child; Combined Modality Therapy; Fanconi Anemia; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Lymphocyte Depletion; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity.
    Journal of proteome research, 2012, Sep-07, Volume: 11, Issue:9

    Topics: Antigens, CD; Apoptosis; B-Lymphocytes; Burkitt Lymphoma; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Survival; Cladribine; Drug Resistance, Neoplasm; Flow Cytometry; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Reproducibility of Results; Signal Transduction; Up-Regulation; Vidarabine

2012
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:12

    Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Comorbidity; Disease-Free Survival; Humans; Incidence; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2012
Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:3

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytic Sarcoma; Histocompatibility; Histocompatibility Testing; HLA Antigens; Humans; Male; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2013
Successful treatment of γ-heavy-chain disease with rituximab and fludarabine.
    Acta haematologica, 2012, Volume: 128, Issue:3

    Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Heavy Chain Disease; Humans; Lymphoma, B-Cell; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2012
T-cell large granular lymphocytic leukemia: treatment experience with fludarabine.
    Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult

2012
Richter syndrome and fludarabine: a controversial relationship.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:2

    Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Vidarabine

2013
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011).
    Leukemia & lymphoma, 2013, Volume: 54, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Vidarabine

2013
Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.
    Cell death & disease, 2012, Aug-16, Volume: 3

    Topics: Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Immunoprecipitation; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; NF-kappa B; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine

2012
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
    Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:6

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia

2013
Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:3

    Topics: Aged; Amphotericin B; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcus neoformans; Cyclophosphamide; Drug Therapy, Combination; Fatal Outcome; Flucytosine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Meningitis, Cryptococcal; Rituximab; Time Factors; Vidarabine

2013
S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
    Cancer science, 2012, Volume: 103, Issue:12

    Topics: Aged; Animals; Antineoplastic Agents; Cell Cycle Proteins; Female; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Nuclear Proteins; Piperazines; Prognosis; Protein Splicing; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Suppressor Protein p53; Vidarabine

2012
Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality.
    Cancer genetics, 2012, Volume: 205, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Cytogenetics; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Time Factors; Translocation, Genetic; Vidarabine

2012
Preservation of fertility in women undergoing reduced-intensity conditioning allogeneic transplantation with a fludarabine-based regime.
    Transplantation, 2012, Sep-15, Volume: 94, Issue:5

    Topics: Adult; Biomarkers; Estradiol; Female; Fertility Preservation; Follicle Stimulating Hormone, Human; Hematopoietic Stem Cell Transplantation; Humans; Infertility, Female; Luteinizing Hormone; Myeloablative Agonists; Ovary; Pregnancy; Pregnancy Rate; Retrospective Studies; Risk Assessment; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Ultrasonography; Vidarabine; Young Adult

2012
Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma.
    Arthritis care & research, 2013, Volume: 65, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cryoglobulinemia; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2013
The effect of cyclosporine initiation time on the outcome of matched allogeneic stem-cell transplantation following fludarabine-based conditioning.
    Transplant international : official journal of the European Society for Organ Transplantation, 2012, Volume: 25, Issue:12

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2012
[Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].
    Orvosi hetilap, 2012, Oct-14, Volume: 153, Issue:41

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Flow Cytometry; Hospitals, County; Humans; Hungary; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prednisolone; Remission Induction; Treatment Outcome; Vidarabine; Vincristine

2012
Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
    Cancer biology & therapy, 2012, Volume: 13, Issue:14

    Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Female; Humans; Imidazoles; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleoproteins; Oncogene Proteins; Piperazines; Poly-ADP-Ribose Binding Proteins; Prognosis; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2012
Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Chimerism; Hematopoietic Stem Cell Transplantation; Humans; Neoplasms; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult

2013
Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.
    Haematologica, 2013, Volume: 98, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2013
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adult; Cytogenetic Analysis; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prognosis; Prospective Studies; Remission Induction; Translocation, Genetic; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
    Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2012
Leukemia specific loss of heterozygosity of MHC in a CLL patient: disease state impacts timing of confirmatory typing.
    Human immunology, 2013, Volume: 74, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Histocompatibility Testing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Loss of Heterozygosity; Male; Middle Aged; Myeloablative Agonists; Rituximab; Time Factors; Transplantation Conditioning; Unrelated Donors; Vidarabine

2013
Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation.
    Bone marrow transplantation, 2013, Volume: 48, Issue:5

    Topics: Adolescent; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Male; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine

2013
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases.
    Cancer, 2013, Mar-01, Volume: 119, Issue:5

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Drug Administration Schedule; Female; Graft vs Host Reaction; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult

2013
Visceral varicella in a patient with chronic lymphocytic leukemia treated with fludarabine: a case report.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Chickenpox; Herpesvirus 3, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine; Virus Activation

2013
Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning.
    Bone marrow transplantation, 2013, Volume: 48, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocytes; Male; Melphalan; Middle Aged; Monocytes; Prognosis; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2013
Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL.
    Bone marrow transplantation, 2013, Volume: 48, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia; Busulfan; Child, Preschool; Humans; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Vidarabine

2013
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia.
    American journal of hematology, 2012, Volume: 87, Issue:12

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Vidarabine

2012
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.
    British journal of haematology, 2013, Volume: 160, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Living Donors; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2013
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:3

    Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
    Blood, 2013, Jan-03, Volume: 121, Issue:1

    Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cell Line, Tumor; CpG Islands; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Rituximab; RNA, Small Interfering; Thionucleotides; Toll-Like Receptor 9; Vidarabine; Xenograft Model Antitumor Assays

2013
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant.
    Bone marrow transplantation, 2013, Volume: 48, Issue:5

    Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Erythema; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2013
Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide.
    Muscle & nerve, 2013, Volume: 47, Issue:2

    Topics: Cyclophosphamide; Disease Progression; Female; Humans; Immunosuppressive Agents; Middle Aged; Neural Conduction; Peripheral Nerves; Polyneuropathies; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Treatment Outcome; Vidarabine

2013
Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia.
    Blood, 2013, Feb-14, Volume: 121, Issue:7

    Topics: Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Disease-Free Survival; Female; Gene Dosage; Gene Knockdown Techniques; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Prognosis; Risk Factors; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Transcriptome; Up-Regulation; Vidarabine

2013
A non-fatal case of invasive zygomycete (Lichtheimia corymbifera) infection in an allogeneic haematopoietic cell transplant recipient.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2013, Volume: 121, Issue:5

    Topics: Antifungal Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Mucorales; Mucormycosis; Peripheral Blood Stem Cell Transplantation; Triazoles; Vidarabine

2013
Exacerbation of lymphomatoid papulosis during rituximab therapy.
    The Australasian journal of dermatology, 2014, Volume: 55, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphomatoid Papulosis; Male; Middle Aged; Prednisolone; Rituximab; Vidarabine; Vincristine

2014
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
    Acta haematologica, 2013, Volume: 129, Issue:2

    Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum

2013
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.
    Hematological oncology, 2013, Volume: 31, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Mitoxantrone; Radionuclide Imaging; Retrospective Studies; Treatment Outcome; Vidarabine

2013
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 344, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, Inbred BALB C; Mice, SCID; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Spleen; Syk Kinase; Vidarabine; Xenograft Model Antitumor Assays

2013
In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jan-15, Volume: 19, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphotoxin-alpha; MicroRNAs; Prognosis; Toll-Like Receptors; Vidarabine

2013
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-01, Volume: 31, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2013
The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Fluorouracil; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotype; Male; Middle Aged; Neoplasms; Telomere; Vidarabine

2013
Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:24

    Topics: Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Time Factors; Vidarabine

2012
Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Cells, Cultured; Child; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Myeloablative Agonists; Secondary Prevention; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy.
    European journal of haematology, 2013, Volume: 90, Issue:3

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Humans; Hypergammaglobulinemia; Immunoglobulin G; Immunologic Factors; Lacrimal Apparatus; Lymph Nodes; Lymphatic Diseases; Male; Retinal Degeneration; Rituximab; Vasculitis; Vidarabine

2013
[A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
    Zhonghua nei ke za zhi, 2012, Volume: 51, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult

2012
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
    European journal of haematology, 2013, Volume: 90, Issue:3

    Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Innate; Leukemia; Lymphoma; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Recovery of Function; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:4

    Topics: Adult; Aged; Blood Platelets; Female; Ferritins; Follow-Up Studies; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Medicare; Middle Aged; Risk Factors; Rituximab; SEER Program; Survival Rate; Treatment Outcome; United States; Vidarabine

2013
Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation.
    The European respiratory journal, 2013, Volume: 41, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Child, Preschool; Female; Humans; Immunosuppressive Agents; Infant; Inflammation; Lung Injury; Lymphocyte Count; Male; Stem Cell Transplantation; Steroids; T-Lymphocytes; Vidarabine

2013
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
    Bone marrow transplantation, 2013, Volume: 48, Issue:7

    Topics: Adult; Aged; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Time Factors; Transplantation Conditioning; Vidarabine

2013
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:4

    Topics: Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Graft Rejection; Graft Survival; Humans; Infant; Male; Myeloablative Agonists; Transplantation Conditioning; Unrelated Donors; Vidarabine

2013
Outcomes in critically ill chronic lymphocytic leukemia patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:7

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Female; Hospital Mortality; Humans; Intensive Care Units; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Rituximab; Treatment Outcome; Vidarabine

2013
In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
    American journal of hematology, 2013, Volume: 88, Issue:4

    Topics: Adult; Aged; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Lymphocyte Count; Lymphocyte Depletion; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
[Subcutaneous panniculitis-like T-cell lymphoma following treatment with rituximab and cyclophosphamide].
    Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:3

    Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Transformation, Neoplastic; Cyclophosphamide; Diagnosis, Differential; Gene Rearrangement, T-Lymphocyte; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell, Cutaneous; Male; Mitomycin; Neoplasms, Second Primary; Panniculitis; Rituximab; Subcutaneous Tissue; T-Lymphocytes; Vidarabine

2013
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines.
    Leukemia research, 2013, Volume: 37, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinofuranosylcytosine Triphosphate; Bacterial Proteins; Biosensing Techniques; Cell Line, Tumor; Cytarabine; HL-60 Cells; Humans; K562 Cells; Leukemia; Luminescent Measurements; Luminescent Proteins; Treatment Outcome; Vidarabine

2013
Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
    Postepy higieny i medycyny doswiadczalnej (Online), 2013, Mar-01, Volume: 67

    Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Caspase 3; Caspase 9; Cladribine; Cyclophosphamide; Down-Regulation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proteasome Inhibitors; Rituximab; Sirolimus; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vidarabine

2013
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2013
Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine.
    Lipids in health and disease, 2013, Mar-16, Volume: 12

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Arachidonic Acid; Cell Line, Tumor; Docosahexaenoic Acids; Doxorubicin; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, B-Cell; Lipid Peroxidation; Malondialdehyde; Organ Specificity; Reactive Oxygen Species; Vidarabine; Vincristine; Vitamin E

2013
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-20, Volume: 31, Issue:12

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; International Agencies; Male; Neoplasm Grading; Neoplasm Staging; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine

2013
The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:12

    Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Female; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; Mitochondrial Membrane Transport Proteins; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2013
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6

    Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2013
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
    Bone marrow transplantation, 2013, Volume: 48, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Efficacy of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2013, Volume: 38, Issue:3

    Topics: Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine

2013
Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia.
    Pediatric transplantation, 2013, Volume: 17, Issue:4

    Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Blood Platelets; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Neutrophils; Retrospective Studies; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine

2013
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6

    Topics: Aged; Busulfan; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2013
Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation.
    Experimental and molecular pathology, 2013, Volume: 95, Issue:1

    Topics: Animals; Bone Marrow Transplantation; Central Nervous System; Cyclophosphamide; Gamma Rays; Green Fluorescent Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Monocytes; Myeloablative Agonists; Retina; Transplantation Conditioning; Treatment Outcome; Vidarabine

2013
Release of an ~55kDa fragment containing the actin-binding domain of β-spectrin by caspase-8 during FND-induced apoptosis depends on the presence of protein 4.1.
    Archives of biochemistry and biophysics, 2013, Jul-15, Volume: 535, Issue:2

    Topics: Actins; Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Brain; Caspase 8; Caspase Inhibitors; Cytoskeletal Proteins; Dexamethasone; Drug Interactions; Erythrocyte Membrane; Humans; Jurkat Cells; Membrane Proteins; Mitoxantrone; Molecular Sequence Data; Protein Structure, Tertiary; Proteolysis; Spectrin; Swine; Vidarabine

2013
Successful fludarabine-based hematopoietic stem cell transplantation in a pediatric patient with idiopathic CD4+ lymphocytopenia.
    Pediatric transplantation, 2013, Volume: 17, Issue:4

    Topics: CD4-Positive T-Lymphocytes; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphopenia; Myeloablative Agonists; Opportunistic Infections; Transplantation Conditioning; Treatment Outcome; Vidarabine

2013
Less could be better: the case for reducing the dose of cyclophosphamide for children undergoing allogeneic stem cell transplant for severe aplastic anemia.
    Pediatric transplantation, 2013, Volume: 17, Issue:4

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Transplantation Conditioning; Vidarabine

2013
Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:3

    Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance; Humans; Infant; Male; Red-Cell Aplasia, Pure; Sirolimus; Splenectomy; Treatment Outcome; Vidarabine

2014
Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
    International journal of cancer, 2013, Volume: 133, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bayes Theorem; Biomarkers, Tumor; Blotting, Western; Carboplatin; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Survival Rate; Tumor Cells, Cultured; Vidarabine

2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Rituximab; Treatment Outcome; Vidarabine; Vincristine

2013
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:7

    Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Transfusion; Male; Methotrexate; Middle Aged; Pilot Projects; Secondary Prevention; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2013
Effect of IFN-α on KC and LIX expression: role of STAT1 and its effect on neutrophil recruitment to the spleen after lipopolysaccharide stimulation.
    Molecular immunology, 2013, Volume: 56, Issue:1-2

    Topics: Animals; Blotting, Western; Chemokines; Chemokines, CXC; Gene Expression; Imidazoles; Immunohistochemistry; Interferon-alpha; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Spleen; STAT1 Transcription Factor; Vidarabine

2013
Drug repurposing for gastrointestinal stromal tumor.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:7

    Topics: Apoptosis; Auranofin; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Repositioning; Gastrointestinal Stromal Tumors; Humans; Vidarabine

2013
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte ant
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:8

    Topics: Adult; Age Factors; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2013
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
    European journal of haematology, 2013, Volume: 91, Issue:2

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Rituximab; Treatment Outcome; Vidarabine

2013
[Fatal zygomycosis caused by Mucor indicus after haplo-identical stem cell transplantation].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2013, Volume: 54, Issue:3

    Topics: Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Mucor; Treatment Outcome; Vidarabine; Zygomycosis

2013
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Cell death & disease, 2013, May-16, Volume: 4

    Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Bcl-2-Like Protein 11; Beclin-1; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lysosomal-Associated Membrane Protein 2; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Ubiquitin-Activating Enzymes; Vidarabine

2013
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
    Annals of hematology, 2013, Volume: 92, Issue:10

    Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine

2013
[Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2013
Cyclosporine-related posterior reversible encephalopathy syndrome after cord blood stem cell transplantation.
    Hematology/oncology and stem cell therapy, 2013, Volume: 6, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome; Radiography; Vidarabine; Whole-Body Irradiation

2013
Hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen in pediatric patients with Griscelli syndrome type 2.
    Pediatric transplantation, 2013, Volume: 17, Issue:5

    Topics: Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immune System; Immunologic Deficiency Syndromes; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Myeloablative Agonists; Piebaldism; Primary Immunodeficiency Diseases; Prospective Studies; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2013
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Annals of hematology, 2013, Volume: 92, Issue:10

    Topics: Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult

2013
Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: implications for survival.
    Molecular cancer, 2013, Jun-05, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Male; MicroRNAs; Prostatic Neoplasms; Vidarabine

2013
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
    International journal of oncology, 2013, Volume: 43, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-1 Antigen; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Synergism; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Vidarabine; Xenograft Model Antitumor Assays

2013
Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma.
    Pediatric transplantation, 2013, Volume: 17, Issue:6

    Topics: Antilymphocyte Serum; Blood Platelets; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Neutrophils; Remission Induction; Siblings; Transplantation Conditioning; Treatment Outcome; Vidarabine; Wiskott-Aldrich Syndrome

2013
Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, Jul-15, Volume: 931

    Topics: Antineoplastic Agents; Chromatography, Liquid; Cladribine; Drug Stability; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Vidarabine

2013
Fludarabine in Waldenstrom's macroglobulinemia.
    Expert review of hematology, 2013, Volume: 6, Issue:3

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Disease-Free Survival; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2013
Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia.
    Pediatrics international : official journal of the Japan Pediatric Society, 2013, Volume: 55, Issue:3

    Topics: Bone Marrow Purging; Bone Marrow Transplantation; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hypophosphatasia; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Retreatment; Vidarabine

2013
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
    Leukemia, 2013, Volume: 27, Issue:9

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Treatment Outcome; Vidarabine

2013
The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:8

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Breaks, Double-Stranded; Gene Expression Regulation, Leukemic; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proliferating Cell Nuclear Antigen; Signal Transduction; Transcriptional Activation; Tumor Suppressor Protein p53; Vidarabine

2013
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:5

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoprevention; Chronic Disease; Disease Progression; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Recurrence; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2014
Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma.
    Molecular imaging and biology, 2014, Volume: 16, Issue:1

    Topics: Automation; Chromatography, High Pressure Liquid; Fluorine Radioisotopes; Humans; Lymphoma; Positron-Emission Tomography; Quality Control; Vidarabine

2014
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
    American journal of hematology, 2013, Volume: 88, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine

2013
2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models.
    Molecular imaging and biology, 2014, Volume: 16, Issue:1

    Topics: Adult; Animals; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Lymphoma, Follicular; Mice; Mice, SCID; Positron-Emission Tomography; Radiometry; Tissue Distribution; Vidarabine

2014
Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:9

    Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation, Homologous; Vidarabine

2013
The quest for the optimal conditioning regimen: some answers, more questions.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:9

    Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2013
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
    Leukemia, 2013, Volume: 27, Issue:10

    Topics: Adenine; Antineoplastic Agents; Casein Kinase II; Drug Synergism; Hematologic Neoplasms; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthyridines; Phenazines; Piperidines; Prognosis; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Receptors, Antigen, B-Cell; Signal Transduction; Vidarabine

2013
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catalytic Domain; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA Helicases; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Histones; Humans; Indoles; Ku Autoantigen; Leukemia, Lymphoid; Middle Aged; Niacinamide; Oligonucleotides; Phosphorylation; Protein Binding; Telomerase; Vidarabine

2013
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
    Cancer, 2013, Nov-01, Volume: 119, Issue:21

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Female; Humans; Immune Tolerance; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Neoadjuvant Therapy; Pancytopenia; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Young Adult

2013
B-cell function after unrelated umbilical cord blood transplantation using a minimal-intensity conditioning regimen in patients with X-SCID.
    International journal of hematology, 2013, Volume: 98, Issue:3

    Topics: Antineoplastic Agents; B-Lymphocytes; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; HLA Antigens; Humans; Immunoglobulins; Infant; Male; Melphalan; Survival Rate; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; X-Linked Combined Immunodeficiency Diseases

2013
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2013, Nov-15, Volume: 20, Issue:14

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Line; Cell Proliferation; Cimicifuga; Deoxycytidine; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Humans; Male; Nucleosides; Phytotherapy; Plant Extracts; Prostate; Prostatic Neoplasms; RNA, Small Interfering; Saponins; Thymidine; Vidarabine

2013
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.
    Bone marrow transplantation, 2014, Volume: 49, Issue:1

    Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2014
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
    Cancer, 2013, Dec-01, Volume: 119, Issue:23

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Observational Studies as Topic; Prednisone; Prospective Studies; Rituximab; Treatment Outcome; United States; Vidarabine; Vincristine

2013
Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.
    Journal of pharmaceutical and biomedical analysis, 2013, Volume: 86

    Topics: Chromatography, Liquid; Humans; Intracellular Fluid; Leukocytes, Mononuclear; Mass Spectrometry; Tandem Mass Spectrometry; Vidarabine

2013
Fludarabine, low-dose cyclophosphamide and rabbit antithymocyte globulin allowed stable engraftment after allogeneic peripheral blood stem cell transplantation for poly-transfused dyskeratosis congenita patient: case report.
    Transplantation proceedings, 2013, Volume: 45, Issue:7

    Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Graft vs Host Disease; Humans; Male; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine

2013
Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report.
    Transplantation proceedings, 2013, Volume: 45, Issue:7

    Topics: Acute Disease; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Crohn Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Transplantation Conditioning; Vidarabine

2013
An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lung Diseases; Lymphocytes; Male; Middle Aged; Mucositis; Outcome Assessment, Health Care; Proportional Hazards Models; Quality of Life; Recovery of Function; Retrospective Studies; Surveys and Questionnaires; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2013
A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
    Cancer, 2011, Jun-01, Volume: 117, Issue:11

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine

2011
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Leukemia research, 2013, Volume: 37, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2013
Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Bone marrow transplantation, 2013, Volume: 48, Issue:12

    Topics: Age Factors; Aged; B-Lymphocytes; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine

2013
Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
    Bone marrow transplantation, 2014, Volume: 49, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Australia; Bone Marrow Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Myeloablative Agonists; New Zealand; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2014
Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
    Apoptosis : an international journal on programmed cell death, 2014, Volume: 19, Issue:1

    Topics: Adult; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Drug Synergism; Enzyme Activation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Tumor Cells, Cultured; Up-Regulation; Valproic Acid; Vidarabine

2014
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
    Journal of geriatric oncology, 2013, Volume: 4, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Comorbidity; Creatinine; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multivariate Analysis; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Rituximab; Vidarabine

2013
A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
    American journal of hematology, 2014, Volume: 89, Issue:1

    Topics: Adult; Age Factors; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Middle Aged; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2014
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
    British journal of haematology, 2014, Volume: 164, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Treatment Outcome; Vidarabine

2014
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:7

    Topics: Adenine Nucleotides; Antineoplastic Agents, Alkylating; Apoptosis; Arabinonucleosides; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Clofarabine; DNA Damage; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Mitochondria; Nuclear Proteins; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2014
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning.
    Bone marrow transplantation, 2014, Volume: 49, Issue:2

    Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Graft vs Host Disease; Humans; Male; Melphalan; Methotrexate; Middle Aged; Vidarabine; Young Adult

2014
[Ultra high risk chronic lymphocytic leukemia -  characteristics and treatment options].
    Vnitrni lekarstvi, 2013, Volume: 59, Issue:10

    Topics: Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2013
[A comparative study of fludarabine-based versus CHOP-like regimens in untreated primary indolent lymphoma].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Non-Hodgkin; Vidarabine

2013
In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
    European journal of pharmacology, 2013, Nov-15, Volume: 720, Issue:1-3

    Topics: Amino Acid Sequence; Binding Sites; Cells, Cultured; Computer Simulation; Cyclic S-Oxides; Endothelial Cells; Humans; Interferon-alpha; Interferon-gamma; Molecular Docking Simulation; Molecular Sequence Data; Phosphorylation; Protein Binding; Sequence Alignment; src Homology Domains; STAT1 Transcription Factor; STAT2 Transcription Factor; STAT3 Transcription Factor; Vidarabine

2013
Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cells, Cultured; Female; Gene Expression; Humans; Immunity, Cellular; Interleukin-17; Kaplan-Meier Estimate; Killer Cells, Natural; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; T-Lymphocytes, Regulatory; Th17 Cells; Treatment Outcome; Vidarabine

2013
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Public Health Surveillance; Registries; Salvage Therapy; Sweden; Treatment Outcome; Vidarabine

2014
Chronic lymphocytic leukemia in a child: a challenging diagnosis in pediatric oncology practice.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:5

    Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Receptor Nuclear Translocator; Cyclophosphamide; Female; Gene Deletion; Humans; Leukemia, Prolymphocytic, T-Cell; Rituximab; Treatment Outcome; Vidarabine

2014
Richter syndrome: chronic lymphocytic leukemia transformation into Hodgkin's disease.
    The Israel Medical Association journal : IMAJ, 2013, Volume: 15, Issue:10

    Topics: Antineoplastic Agents; Antiviral Agents; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Risk Factors; Vidarabine

2013
Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
    Future oncology (London, England), 2013, Volume: 9, Issue:12

    Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Neoplasm Recurrence, Local; Rituximab; Vidarabine

2013
Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
    Acta haematologica, 2014, Volume: 131, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Salvage Therapy; Vidarabine

2014
The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
    Acta haematologica, 2014, Volume: 131, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Secondary Prevention; Survival Analysis; Vidarabine

2014
Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome.
    Annals of hematology, 2014, Volume: 93, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Time Factors; Treatment Outcome; Vidarabine

2014
Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3

    Topics: Adenoviridae Infections; Adolescent; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Lung; Male; Myeloablative Agonists; Roseolovirus Infections; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2014
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3

    Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myeloablative Agonists; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2014
Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
    European journal of haematology, 2014, Volume: 92, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Myeloablative Agonists; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine

2014
STAT1 interaction with E3-14.7K in monocytes affects the efficacy of oncolytic adenovirus.
    Journal of virology, 2014, Volume: 88, Issue:4

    Topics: Active Transport, Cell Nucleus; Adenoviridae; Adenovirus E3 Proteins; Analysis of Variance; Animals; Blotting, Western; Cell Line; DNA, Complementary; Enzyme-Linked Immunosorbent Assay; Gene Deletion; Humans; Immunoprecipitation; Mice; Microscopy, Confocal; Monocytes; Oncolytic Viruses; Phosphorylation; Real-Time Polymerase Chain Reaction; STAT1 Transcription Factor; Vidarabine

2014
Cyclophosphamide for CLL: to be or not CYP2B activated?
    Blood, 2013, Dec-19, Volume: 122, Issue:26

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cyclophosphamide; Cytochrome P-450 CYP2B6; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine

2013
Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:3

    Topics: Adolescent; Adult; Aged; Busulfan; Cross Infection; Female; Graft vs Host Disease; Health Care Costs; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Patient Readmission; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
Second malignancies in chronic lymphocytic leukemia.
    Oncology nursing forum, 2014, Jan-01, Volume: 41, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chlorambucil; Combined Modality Therapy; Ear Neoplasms; Early Diagnosis; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Neoplasms, Second Primary; Risk; Rituximab; Skin; Skin Neoplasms; Vidarabine

2014
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2014
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Annals of transplantation, 2014, Jan-08, Volume: 19

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Middle Aged; Myeloablative Agonists; Prognosis; Retrospective Studies; Risk Factors; Transplantation Conditioning; Vidarabine; Young Adult

2014
Allogeneic transplantation after reduced-intensity conditioning with fludarabine-CY for both indolent and aggressive lymphoid malignancies.
    Bone marrow transplantation, 2014, Volume: 49, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2014
Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
    Transplant infectious disease : an official journal of the Transplantation Society, 2014, Volume: 16, Issue:2

    Topics: Adolescent; Antineoplastic Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Hematopoietic Stem Cell Transplantation; Herpesvirus 3, Human; Humans; Immunity, Cellular; Immunosuppression Therapy; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; T-Lymphocytes; Vidarabine; Virus Activation; Young Adult

2014
HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:4

    Topics: Adolescent; Antigens, CD34; Child; Fanconi Anemia; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Lymphocyte Depletion; Male; Myeloablative Agonists; Prospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2014
Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2014, Feb-15, Volume: 949-950

    Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Male; Purines; Quinazolinones; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thalidomide; Vidarabine

2014
Fludarabine metabolite level on day zero does not affect outcomes of hematopoietic cell transplantation in patients with normal renal function.
    Bone marrow transplantation, 2014, Volume: 49, Issue:4

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Kidney; Multivariate Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine

2014
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
    British journal of haematology, 2014, Volume: 165, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boron Compounds; Caspase 3; Caspase 9; Cell Death; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Gossypol; Humans; Intracellular Membranes; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mitochondria; Neoplasm Staging; Permeability; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine

2014
Multifocal central nervous system demyelination and Lhermitte's phenomenon secondary to combination chemotherapy for chronic lymphocytic leukaemia.
    Journal of the neurological sciences, 2014, Mar-15, Volume: 338, Issue:1-2

    Topics: Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Hamartoma Syndrome, Multiple; Hereditary Central Nervous System Demyelinating Diseases; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Vidarabine

2014
A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia.
    International journal of hematology, 2014, Volume: 99, Issue:3

    Topics: Adolescent; Adult; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Preoperative Care; Retrospective Studies; Treatment Outcome; Vidarabine; Young Adult

2014
A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.
    Oncotarget, 2014, Jan-30, Volume: 5, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Case-Control Studies; Cyclin-Dependent Kinase 9; Drug Synergism; HEK293 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Transcription, Genetic; Vidarabine

2014
[The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies].
    Zhonghua nei ke za zhi, 2013, Volume: 52, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult

2013
Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.
    Bone marrow transplantation, 2014, Volume: 49, Issue:5

    Topics: Administration, Intravenous; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Lung Diseases; Lymphocyte Depletion; Male; Middle Aged; Myeloablative Agonists; Respiratory Function Tests; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2014
Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.
    The American Journal of dermatopathology, 2014, Volume: 36, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Merkel Cell; Cyclophosphamide; Diagnosis, Differential; Fatal Outcome; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Merkel cell polyomavirus; Neoplasms, Multiple Primary; Polyomavirus Infections; Rituximab; Skin Neoplasms; Tumor Virus Infections; Vidarabine

2014
Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.
    Blood, 2014, Feb-27, Volume: 123, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cyclophosphamide; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine

2014
Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning.
    Bone marrow transplantation, 2014, Volume: 49, Issue:6

    Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2014
Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.
    International journal of hematology, 2014, Volume: 99, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Female; Humans; Immunohistochemistry; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Pleural Effusion; Treatment Outcome; Tumor Lysis Syndrome; Vidarabine

2014
Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology.
    Expert review of hematology, 2014, Volume: 7, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2014
Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
    Leukemia, 2014, Volume: 28, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Bendamustine Hydrochloride; Bone Marrow Cells; CD40 Antigens; Cell Cycle; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Female; Gene Deletion; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Naphthoquinones; Nitrogen Mustard Compounds; Stromal Cells; Survivin; Toll-Like Receptor 9; Vidarabine

2014
Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2014, Volume: 16, Issue:2

    Topics: Adult; Aged; Bacteremia; C-Reactive Protein; Citrulline; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mucositis; Myeloablative Agonists; Neutropenia; Prospective Studies; Transplantation Conditioning; Vidarabine

2014
Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia.
    British journal of haematology, 2014, Volume: 166, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Vidarabine

2014
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Comorbidity; Cyclophosphamide; Databases, Factual; Disease Management; Doxorubicin; Ethnicity; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medicare; Practice Patterns, Physicians'; Prednisone; Rituximab; SEER Program; Socioeconomic Factors; Treatment Outcome; United States; Vidarabine; Vincristine

2014
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multivariate Analysis; Oral Hygiene; Prednisone; Sirolimus; Stomatitis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2014
Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Leukemia research, 2014, Volume: 38, Issue:5

    Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2014
A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
    International journal of hematology, 2014, Volume: 99, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Cord Blood Stem Cell Transplantation; Drug Interactions; Female; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycoses; Premedication; Prospective Studies; Risk Factors; Transplantation Conditioning; Vidarabine; Voriconazole; Young Adult

2014
[Fludarabine-based increased-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2014
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
    Hematological oncology, 2015, Volume: 33, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Germany; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Office Visits; Prednisone; Prospective Studies; Registries; Rituximab; Vidarabine

2015
Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.
    Blood, 2014, Jun-12, Volume: 123, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Bone Marrow Cells; Cells, Cultured; Drug Administration Schedule; Drug Evaluation, Preclinical; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nitrogen Mustard Compounds; Primary Cell Culture; Stromal Cells; Time Factors; Vidarabine

2014
The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
    Leukemia, 2015, Volume: 29, Issue:1

    Topics: Aged; Amyloid Precursor Protein Secretases; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Receptor, Notch1; Tetrahydronaphthalenes; Tumor Cells, Cultured; Valine; Vidarabine

2015
Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2014, Jun-01, Volume: 960

    Topics: Adenine Nucleotides; Arabinonucleosides; Chromatography, Liquid; Clofarabine; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine

2014
The effects of fludarabine on rat cerebral ischemia.
    Journal of molecular neuroscience : MN, 2015, Volume: 55, Issue:2

    Topics: Animals; Apoptosis; Brain; Infarction, Middle Cerebral Artery; Male; Phosphorylation; Rats; Rats, Sprague-Dawley; STAT1 Transcription Factor; STAT3 Transcription Factor; Vidarabine

2015
Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.
    Leukemia research, 2014, Volume: 38, Issue:7

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2014
Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:9

    Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Male; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2014
Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
    European journal of haematology, 2014, Volume: 93, Issue:6

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2014
Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; B7-H1 Antigen; Down-Regulation; Histocompatibility Antigens Class I; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Phosphorylation; Proteasome Endopeptidase Complex; Protein Stability; RNA Interference; RNA, Messenger; RNA, Small Interfering; STAT1 Transcription Factor; T-Lymphocytes; Tumor Cells, Cultured; Vidarabine

2014
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
    Annals of hematology, 2014, Volume: 93, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Female; Genes, Immunoglobulin; Genes, p53; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Prospective Studies; Receptor, Notch1; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2014
Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:10

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Intracellular Signaling Peptides and Proteins; Lymphoproliferative Disorders; Male; Melphalan; Mutation; Myeloablative Agonists; Prognosis; Retrospective Studies; Signaling Lymphocytic Activation Molecule Associated Protein; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2014
Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Logistic Models; Male; Middle Aged; Multivariate Analysis; Peptide Hydrolases; Pilot Projects; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases; Vidarabine

2015
Small lymphocytic lymphoma presenting as bulky renal incidentaloma.
    International journal of hematology, 2014, Volume: 100, Issue:2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Humans; Kidney; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Middle Aged; Rituximab; Tomography, X-Ray Computed; Vidarabine

2014
Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
    Leukemia research, 2014, Volume: 38, Issue:8

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2014
Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells.
    Nucleosides, nucleotides & nucleic acids, 2014, Volume: 33, Issue:4-6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Lymphoma; Tumor Suppressor Proteins; Unfolded Protein Response; Vidarabine

2014
Diverse intracellular pathogens activate type III interferon expression from peroxisomes.
    Nature immunology, 2014, Volume: 15, Issue:8

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Differentiation; Cell Line; Cyclohexanes; DEAD Box Protein 58; DEAD-box RNA Helicases; Enzyme Inhibitors; Humans; Immunity, Innate; Interferons; Intestinal Mucosa; Janus Kinase 2; Mice; p38 Mitogen-Activated Protein Kinases; Peroxisomes; Pyridones; Receptors, Immunologic; Reoviridae; Reoviridae Infections; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Tyrphostins; Vidarabine

2014
Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Membrane; Down-Regulation; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Transcription, Genetic; Up-Regulation; Vidarabine

2014
Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Outcome Assessment, Health Care; Prednisone; Rituximab; SEER Program; Survival Analysis; United States; Vidarabine; Vincristine

2015
Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:10

    Topics: Adolescent; Carcinoma, Squamous Cell; Child; Child, Preschool; Cyclophosphamide; Cystitis; Fanconi Anemia; Female; Gamma Rays; Hematopoietic Stem Cell Transplantation; Hemorrhage; Histocompatibility Testing; Humans; Infant; Male; Myeloablative Agonists; Oropharyngeal Neoplasms; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2014
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Molecular cancer, 2014, Jun-27, Volume: 13

    Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cladribine; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mass Spectrometry; Mice; Proteomics; Rituximab; Vidarabine; Xenograft Model Antitumor Assays

2014
Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymphopro
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:5

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Calcineurin; Child; Combined Modality Therapy; Drug Resistance, Neoplasm; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Male; Mycophenolic Acid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2014
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning.
    Bone marrow transplantation, 2014, Volume: 49, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2014
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Hematological oncology, 2015, Volume: 33, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Therapy; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2015
Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:6

    Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Vidarabine

2015
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult

2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
    American journal of hematology, 2014, Volume: 89, Issue:10

    Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Vidarabine

2014
Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.
    International journal of hematology, 2014, Volume: 100, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine

2014
Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11

    Topics: Acute Disease; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Prognosis; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine

2014
Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5

    Topics: Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease Progression; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Living Donors; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins c-ets; Repressor Proteins; Ring Chromosomes; Rituximab; Transplantation Chimera; Vidarabine

2014
A myeloablative conditioning regimen with fludarabine demonstrates good results in UCBT for 30 pediatric patients with hematologic malignancies, especially acute lymphoblastic leukemia.
    Neoplasma, 2014, Volume: 61, Issue:5

    Topics: Adolescent; Child; Cord Blood Stem Cell Transplantation; Female; Graft vs Host Disease; Humans; Male; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Transplantation Conditioning; Vidarabine

2014
Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2014
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.
    Cancer, 2014, Nov-15, Volume: 120, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Rituximab; Vidarabine

2014
Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
    Molecular cancer research : MCR, 2014, Volume: 12, Issue:9

    Topics: B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Oxidative Phosphorylation; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Vidarabine

2014
Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Risk Factors; Survival Rate; Thalassemia; Transplantation Conditioning; Vidarabine

2014
Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.
    Bone marrow transplantation, 2014, Volume: 49, Issue:11

    Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Female; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine

2014
Successful hematopoietic reconstitution by unrelated donor cord blood transplantation in children with Fanconi anemia: report of 3 cases.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:8

    Topics: Animals; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoiesis; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Rabbits; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2014
The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.
    Bone marrow transplantation, 2014, Volume: 49, Issue:12

    Topics: Adolescent; Adult; Aged; BK Virus; Busulfan; Cystitis; Cytomegalovirus Infections; Female; Graft vs Host Disease; HLA Antigens; Humans; Male; Middle Aged; Multivariate Analysis; Polyomavirus Infections; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Viremia; Young Adult

2014
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine

2014
Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Time Factors; Vidarabine; Virus Activation

2015
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
    Pediatric hematology and oncology, 2014, Volume: 31, Issue:8

    Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
[Detection of p53 gene deletion in Xinjiang patients with chronic lymphocytic leukemia by fluorescence in situ hybridization and its clinical significance].
    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2014, Volume: 31, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2014
Successful transplantation of kidney allografts in sensitized rats after syngeneic hematopoietic stem cell transplantation and fludarabine.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014, Volume: 14, Issue:10

    Topics: Animals; Base Sequence; DNA Primers; Female; Hematopoietic Stem Cell Transplantation; Kidney Transplantation; Polymerase Chain Reaction; Rats; Rats, Inbred Lew; Vidarabine

2014
[The outcome of thirteen patients with nonmalignant hematologic diseases treated with HLA haploidentical stem cell transplantation].
    Zhonghua nei ke za zhi, 2014, Volume: 53, Issue:6

    Topics: Anemia, Aplastic; Busulfan; Graft vs Host Disease; Hematologic Diseases; Histocompatibility; HLA Antigens; Humans; Incidence; Methotrexate; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014
Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antilymphocyte Serum; Busulfan; Child, Preschool; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Transplantation Conditioning; Vidarabine

2015
Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2015
Silica network improve the effect of fludarabine and paclitaxel on HCT8 cell line.
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2014, Volume: 55, Issue:2 Suppl

    Topics: Biocompatible Materials; Cell Shape; Endothelial Cells; Humans; Microscopy, Electron, Scanning; Paclitaxel; Silicon Dioxide; Spectrophotometry, Infrared; Tumor Cells, Cultured; Vidarabine; X-Ray Diffraction

2014
[Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:8

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Rituximab; Vidarabine

2014
Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.
    Bone marrow transplantation, 2014, Volume: 49, Issue:12

    Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2014
Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1

    Topics: Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Injections, Intravenous; Male; Myeloablative Agonists; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult

2015
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).
    Blood, 2014, Nov-13, Volume: 124, Issue:20

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine

2014
Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:2

    Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Thiotepa; Vidarabine

2015
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2014, Volume: 45, Issue:4

    Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2014
A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Female; Graft Survival; Graft vs Host Disease; Haplotypes; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2015
Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms.
    International journal of hematology, 2014, Volume: 100, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2014
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Vidarabine

2015
[Retrospective analysis of therapeutic efficacy of haploidentical allogeneic hematopoietic stem cell transplantation for severe aplastic anemia].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:5

    Topics: Adolescent; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclosporine; Graft vs Host Disease; Haploidy; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Siblings; Survival Rate; Tissue Donors; Transplantation Conditioning; Vidarabine

2014
[Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Allografts; Cytarabine; Disease-Free Survival; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult

2014
Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
    American journal of hematology, 2015, Volume: 90, Issue:2

    Topics: Adult; Analysis of Variance; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
The impact of SF3B1 mutations in CLL on the DNA-damage response.
    Leukemia, 2015, Volume: 29, Issue:5

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cohort Studies; DNA Damage; DNA Mutational Analysis; Doxorubicin; Flow Cytometry; Gene Deletion; Gene Expression Regulation, Leukemic; Genome, Human; Histones; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phosphoproteins; Piperazines; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Tumor Suppressor Protein p53; Vidarabine

2015
Successful T-cell-depleted haploidentical hematopoietic stem cell transplantation in a child with dyskeratosis congenita after a fludarabine-based conditioning regimen.
    Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:4

    Topics: Child; Dyskeratosis Congenita; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; T-Lymphocytes; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2015
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
    Leukemia, 2015, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; B-Lymphocytes; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; CD40 Ligand; Cell Hypoxia; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrogen Mustard Compounds; Nitrophenols; Oxygen; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Vidarabine

2015
Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Cancer, 2015, Apr-01, Volume: 121, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Young Adult

2015
Prolonged remission of marginal zone lymphoma in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor agents.
    The Journal of rheumatology, 2014, Volume: 41, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Receptors, Tumor Necrosis Factor; Remission Induction; Rituximab; Treatment Outcome; Tumor Necrosis Factor-alpha; Vidarabine

2014
Extensive acute toxic leukoencephalopathy induced by fludarabine: two months follow-up on brain MRI.
    Journal of neuroradiology = Journal de neuroradiologie, 2015, Volume: 42, Issue:2

    Topics: Antineoplastic Agents; Brain; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Follow-Up Studies; Humans; Leukemia; Leukoencephalopathies; Male; Middle Aged; Treatment Outcome; Vidarabine

2015
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:2

    Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2015
Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:2

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Chimerism; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Male; Melphalan; Mucopolysaccharidoses; Myeloablative Agonists; Retrospective Studies; Severe Combined Immunodeficiency; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2015
Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.
    Hematological oncology, 2016, Volume: 34, Issue:3

    Topics: Aged; Allografts; Busulfan; Disease-Free Survival; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine

2016
Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
    Bone marrow transplantation, 2015, Volume: 50, Issue:3

    Topics: Antilymphocyte Serum; Busulfan; Child, Preschool; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2015
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
    Leukemia, 2015, Volume: 29, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Gene Expression Regulation, Leukemic; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Multivariate Analysis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Vidarabine

2015
Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
    Medicine, 2014, Volume: 93, Issue:27

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Vidarabine; Young Adult

2014
B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:11

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lymphoma, B-Cell; Prednisone; Recurrence; Remission Induction; Risk; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Virus Activation

2014
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
    International journal of hematology, 2015, Volume: 101, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Leukemia, Myelomonocytic, Juvenile; Male; Melphalan; Retreatment; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2015
Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Feb-01, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Outcome Assessment, Health Care; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Survival Analysis; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult

2015
Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Japan; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2015
Treatment-refractory hypereosinophilic syndrome responding to fludarabine in a 12-year-old boy.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:9

    Topics: Bone Marrow; Child; Combined Modality Therapy; Humans; Hypereosinophilic Syndrome; Male; Treatment Outcome; Vidarabine

2015
Cytomegalovirus retinitis complicating combination therapy with rituximab and fludarabine.
    Annals of hematology, 2015, Volume: 94, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Cytomegalovirus Retinitis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Rituximab; Vidarabine

2015
[Efficacies of hematopoietic stem cell transplantation for severe aplastic anemia: a report of 43 patients].
    Zhonghua yi xue za zhi, 2014, Nov-04, Volume: 94, Issue:40

    Topics: Adolescent; Adult; Anemia, Aplastic; Child; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Siblings; Transplantation Conditioning; Vidarabine; Young Adult

2014
HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine.
    Blood, 2015, Jan-08, Volume: 125, Issue:2

    Topics: Adolescent; Child; Cyclophosphamide; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Transplantation Conditioning; Vidarabine; Young Adult

2015
A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT.
    Bone marrow transplantation, 2015, Volume: 50, Issue:4

    Topics: Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Comorbidity; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Vidarabine

2015
I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.
    Bone marrow transplantation, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Hematologic Diseases; Humans; Male; Melphalan; Middle Aged; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2015
Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
    Bone marrow transplantation, 2015, Volume: 50, Issue:4

    Topics: Adolescent; Allografts; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Databases, Factual; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Quality of Health Care; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine

2015
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
    Transplant infectious disease : an official journal of the Transplantation Society, 2015, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult

2015
The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor.
    Biochemical pharmacology, 2015, Mar-15, Volume: 94, Issue:2

    Topics: 5'-Nucleotidase; Cytosol; Electrophoresis, Capillary; Enzyme Inhibitors; HL-60 Cells; Humans; Molecular Docking Simulation; Mutagenesis, Site-Directed; Vidarabine

2015
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6

    Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Haematologica, 2015, Volume: 100, Issue:5

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult

2015
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.
    Annals of hematology, 2015, Volume: 94, Issue:7

    Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Chimerism; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult

2015
Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
    American journal of hematology, 2015, Volume: 90, Issue:5

    Topics: Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2015
[Elderly chronic lymphocytic leukemia combined with invasive aspergillosis infection in one case].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Rituximab; Vidarabine

2015
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
    European journal of haematology, 2015, Volume: 95, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Survival Analysis; Treatment Outcome; Vidarabine

2015
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
    Experimental hematology, 2015, Volume: 43, Issue:6

    Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine

2015
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6

    Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Mucopolysaccharidoses; Myeloablative Agonists; Neurodegenerative Diseases; Practice Guidelines as Topic; Prognosis; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2015
Pathological fractures in a patient with chronic lymphatic leucaemia without disease progression.
    BMJ case reports, 2015, Feb-25, Volume: 2015

    Topics: Accidental Falls; Allopurinol; Antineoplastic Agents; Bone Marrow; Female; Femur; Fractures, Bone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Osteolysis; Pelvis; Positron-Emission Tomography; Radiography; Rituximab; Sacrum; Sodium Bicarbonate; Treatment Outcome; Vidarabine

2015
[Successful treatment of Bing-Neel syndrome using combination therapy with fludarabine and rituximab].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:12

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Bone Marrow; Drug Combinations; Humans; Magnetic Resonance Imaging; Male; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia

2014
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
    Haematologica, 2015, Volume: 100, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine

2015
Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
    Hematological oncology, 2017, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission.
    Annals of hematology, 2015, Volume: 94, Issue:6

    Topics: Adult; Aged; Busulfan; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2015
Permanent chemotherapy-induced nonscarring alopecia and premature ovarian failure.
    Clinical and experimental dermatology, 2015, Volume: 40, Issue:5

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Primary Ovarian Insufficiency; Thiotepa; Vidarabine

2015
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:12

    Topics: Acrylonitrile; Aniline Compounds; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Coculture Techniques; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Stromal Cells; Tumor Microenvironment; Vidarabine

2015
[Chronic lymphatic leukemia].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:7

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Remission Induction; Rituximab; Vidarabine

2015
[Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2015
Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside-Nucleoside Analogue Radiosensitization.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:6

    Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cytarabine; DNA Breaks, Double-Stranded; DNA Repair; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Green Fluorescent Proteins; Homologous Recombination; Humans; Microscopy, Confocal; Rad51 Recombinase; Radiation-Sensitizing Agents; RNA Interference; Vidarabine; X-Rays

2015
Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease.
    Pediatric transplantation, 2015, Volume: 19, Issue:4

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Child; Child, Preschool; Chimerism; Graft Survival; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2015
[Establishment of a graft-versus-host disease mouse model for haplo-identical bone marrow transplantation with busulfan and fludarabine conditioning regimen].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:3

    Topics: Animals; Bone Marrow Transplantation; Busulfan; Disease Models, Animal; Drug Combinations; Graft vs Host Disease; Mice; Transplantation Conditioning; Vidarabine

2015
IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.
    Biochimica et biophysica acta, 2015, Volume: 1850, Issue:7

    Topics: 5'-Nucleotidase; Antineoplastic Agents; Cell Survival; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance; Gemcitabine; Green Fluorescent Proteins; Guanosine Monophosphate; HEK293 Cells; Humans; Immunoblotting; Inosine Monophosphate; Nucleotides; Phosphorylation; Prodrugs; Substrate Specificity; Vidarabine

2015
Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:8

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chimerism; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2015
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.
    Bone marrow transplantation, 2015, Volume: 50, Issue:7

    Topics: Adult; Aged; Benzylamines; Busulfan; Cell Movement; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
    Biochemical and biophysical research communications, 2015, May-29, Volume: 461, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Inhibitors; Female; Growth Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MAP Kinase Signaling System; Middle Aged; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Vidarabine

2015
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
    Pancreas, 2015, Volume: 44, Issue:6

    Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Cell Death; Cell Line, Tumor; Cytosine Deaminase; Docetaxel; Dose-Response Relationship, Drug; Enzymes; Flucytosine; Fluorouracil; Humans; Methanol; Molecular Targeted Therapy; Organoselenium Compounds; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Recombinant Fusion Proteins; Selenomethionine; Taxoids; Tubulin Modulators; Vidarabine

2015
Diagnosis: Melanoderma after Hematopoietic Stem Cell Transplantation.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:4

    Topics: Antilymphocyte Serum; Busulfan; Deferoxamine; Diagnosis, Differential; Ecchymosis; Humans; Infant; Iron Overload; Male; Melanosis; Peripheral Blood Stem Cell Transplantation; Severe Combined Immunodeficiency; Transfusion Reaction; Transplantation Conditioning; Vidarabine

2015
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
    Leukemia, 2015, Volume: 29, Issue:11

    Topics: Antineoplastic Agents; Bone Marrow; Cladribine; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Genetic Therapy; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Vidarabine

2015
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
    Blood, 2015, Jun-18, Volume: 125, Issue:25

    Topics: Animals; Antigens, CD19; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cyclophosphamide; Disease Models, Animal; Down-Regulation; Flow Cytometry; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Lymphoma; Mice; Mice, SCID; Real-Time Polymerase Chain Reaction; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; T-Lymphocytes; Vidarabine; Xenograft Model Antitumor Assays

2015
Effective treatment of Bing-Neel Syndrome with oral fludarabine: a case series of four consecutive patients.
    British journal of haematology, 2016, Volume: 172, Issue:3

    Topics: Administration, Oral; Adult; Aged; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2016
Phospholipid derivatives of cladribine and fludarabine: synthesis and biological properties.
    Bioorganic & medicinal chemistry, 2015, Jul-01, Volume: 23, Issue:13

    Topics: Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransformation; Cell Line, Tumor; Cell Survival; Cladribine; Diglycerides; Humans; Male; Mice; Mice, Inbred ICR; Molecular Structure; Organophosphonates; Phospholipids; Prodrugs; Rats; Rats, Wistar; Vidarabine

2015
Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult

2015
How I treat Waldenström macroglobulinemia.
    Blood, 2015, Aug-06, Volume: 126, Issue:6

    Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia

2015
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Leukemia research, 2015, Volume: 39, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center.
    Transplantation proceedings, 2015, Volume: 47, Issue:4

    Topics: Adult; Antilymphocyte Serum; Busulfan; Cohort Studies; Cross-Sectional Studies; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Jul-15, Volume: 195, Issue:2

    Topics: Adoptive Transfer; Animals; Cisplatin; Cyclophosphamide; Cytotoxins; Deoxycytidine; Drug Resistance; Etoposide; Female; Fibrosarcoma; Gemcitabine; Lymph Nodes; Lymphocyte Depletion; Lymphopenia; Methylcholanthrene; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Vidarabine; Whole-Body Irradiation

2015
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy.
    Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Remission Induction; Rituximab; Vidarabine

2015
Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2015, Volume: 13, Issue:5

    Topics: Adult; Antigens, CD34; Antilymphocyte Serum; B-Lymphocyte Subsets; Blood Component Removal; Busulfan; Cross-Sectional Studies; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Leukemia, Myeloid, Acute; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Factors; T-Lymphocyte Subsets; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Turkey; Vidarabine

2015
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:6

    Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.
    Oncology reports, 2015, Volume: 34, Issue:3

    Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Count; Cell Lineage; Cyclophosphamide; Female; Flow Cytometry; GPI-Linked Proteins; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Neoplastic Cells, Circulating; Receptors, Cell Surface; Receptors, IgG; Rituximab; Vidarabine

2015
The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia.
    European journal of clinical pharmacology, 2015, Volume: 71, Issue:9

    Topics: Antigens, CD19; Antineoplastic Agents; Apoptosis; Blood Cells; Bone Marrow Cells; Caspase 3; CD5 Antigens; Cell Line, Tumor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine

2015
Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.
    The Journal of pediatrics, 2015, Volume: 167, Issue:3

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Collagen Type VII; Epidermolysis Bullosa Dystrophica; Epithelial Cells; Fibroblasts; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Mutation; Myeloablative Agonists; RNA, Messenger; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation.
    Blood, 2015, Aug-20, Volume: 126, Issue:8

    Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Lymphoproliferative Disorders; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2015
ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
    Oncology reports, 2015, Volume: 34, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Cells, Cultured; Drug Synergism; Female; Flow Cytometry; Heterocyclic Compounds, 1-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Potential, Mitochondrial; Middle Aged; Reactive Oxygen Species; Vidarabine

2015
Successful Treatment With Total Skin Electron Beam Therapy in a Child With Isolated Cutaneous Relapsed AML.
    Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Electrons; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Skin Diseases; Vidarabine

2015
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11

    Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2015
[Transplant-Related Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Busulfan-Based Reduced-Intensity Conditioning - A Retrospective Analysis in a Single Institution].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:6

    Topics: Adult; Aged; Allografts; Busulfan; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine

2015
Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
    American journal of hematology, 2015, Volume: 90, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Administration Schedule; Female; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Phosphoproteins; Receptor, Notch1; Recurrence; Remission Induction; Retrospective Studies; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine

2015
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
    Bone marrow transplantation, 2015, Volume: 50, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease Progression; Female; Graft Survival; Humans; Janus Kinase 2; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Polycythemia Vera; Primary Myelofibrosis; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2015
Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies.
    Medical science monitor : international medical journal of experimental and clinical research, 2015, Aug-04, Volume: 21

    Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Quality of Life; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2015
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
    American journal of hematology, 2015, Volume: 90, Issue:11

    Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Female; Gene Expression; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Myeloablative Agonists; Pilot Projects; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine

2015
Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
    Cell death & disease, 2015, Aug-06, Volume: 6

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Biological Assay; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gamma Rays; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multiplex Polymerase Chain Reaction; Mutation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Sensitivity and Specificity; Tumor Suppressor Protein p53; Vidarabine

2015
An atypical case of bilateral posterior scleritis in a patient with chronic lymphocytic leukemia.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2015, Volume: 50, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Eye Neoplasms; Fluorescein Angiography; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Magnetic Resonance Imaging; Male; Rituximab; Scleritis; Vidarabine

2015
Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; Humans; Isotope Labeling; Lymphoma, Mantle-Cell; Male; Proteomics; Tandem Mass Spectrometry; Tumor Cells, Cultured; Vidarabine

2015
Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies.
    Journal of clinical neuromuscular disease, 2015, Volume: 17, Issue:1

    Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Female; Humans; Immunoglobulin M; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Myelin-Associated Glycoprotein; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Retrospective Studies; Severity of Illness Index; Vidarabine

2015
[Efficacy of Nonmyeloablative Allogeneic Hematopoietic Stem Cells for 14 Case of Severe Acquired Aplastic Anemia].
    Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:4

    Topics: Allografts; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Mycophenolic Acid; Neutrophils; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine

2015
Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Jan-01, Volume: 22, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 9; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunoglobulin Heavy Chains; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutation; Tumor Suppressor Protein p53; Vidarabine; X-Linked Inhibitor of Apoptosis Protein

2016
Leukaemia cutis after starting bendamustine: cause or coincidence?
    BMJ case reports, 2015, Sep-21, Volume: 2015

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Erythema Nodosum; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Rituximab; Skin; Vidarabine

2015
Successful Allogeneic Hematopoietic Stem Cell Transplantation in XIAP Deficiency Using Reduced-Intensity Conditioning.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Child, Preschool; Genetic Diseases, X-Linked; Hematopoietic Stem Cell Transplantation; Humans; Lymphoproliferative Disorders; Male; Melphalan; Myeloablative Agonists; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2016
European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:1

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Europe; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Multivariate Analysis; Retrospective Studies; Societies, Medical; Transplantation Conditioning; Treatment Outcome; Vidarabine

2016
Reduced-intensity conditioning with fludarabine and busulfan for allogeneic hematopoietic cell transplantation in elderly or infirm patients with advanced myeloid malignancies.
    Annals of hematology, 2016, Volume: 95, Issue:1

    Topics: Adult; Aged; Bone Marrow Diseases; Busulfan; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2016
Local bacteria affect the efficacy of chemotherapeutic drugs.
    Scientific reports, 2015, Sep-29, Volume: 5

    Topics: Animals; Antineoplastic Agents; Aziridines; Biotransformation; Cladribine; Colonic Neoplasms; Deoxycytidine; Escherichia coli; Female; Gemcitabine; Injections, Intralesional; Injections, Subcutaneous; Listeria; Mice; Neoplasm Transplantation; Skin; Treatment Outcome; Vidarabine

2015
[STAT signaling pathway mediates high glucose induced cardiac fibroblasts proliferation and collagen deposition in vitro].
    Zhonghua xin xue guan bing za zhi, 2015, Volume: 43, Issue:5

    Topics: Aminosalicylic Acids; Animals; Benzenesulfonates; Cell Proliferation; Cells, Cultured; Collagen Type I; Collagen Type III; Fibroblasts; Glucose; Myocardium; Phosphorylation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Up-Regulation; Vidarabine

2015
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:1

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2016
Development and Validation of a High Pressure Liquid Chromatography-UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies.
    Journal of chromatographic science, 2016, Volume: 54, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Biphenyl Compounds; Busulfan; Child; Child, Preschool; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Ditiocarb; Epoxy Compounds; Female; Humans; Infant; Male; Methanol; Prodrugs; Reference Standards; Solvents; Vidarabine; Water

2016
Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies.
    Bone marrow transplantation, 2016, Volume: 51, Issue:1

    Topics: Aged; Aged, 80 and over; Allografts; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine

2016
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Rituximab; Treatment Outcome; Vidarabine

2016
Efficient Fludarabine-Activating PNP From Archaea as a Guidance for Redesign the Active Site of E. Coli PNP.
    Journal of cellular biochemistry, 2016, Volume: 117, Issue:5

    Topics: Adenosine; Arabinonucleosides; Archaeal Proteins; Binding, Competitive; Biocatalysis; Catalytic Domain; Crystallography, X-Ray; Escherichia coli Proteins; Isoenzymes; Kinetics; Models, Molecular; Molecular Structure; Protein Binding; Protein Domains; Purine-Nucleoside Phosphorylase; Substrate Specificity; Sulfolobus solfataricus; Vidarabine

2016
Improved Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Infantile Malignant Osteopetrosis Using Fludarabine-Based Conditioning.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:3

    Topics: Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Hypercalcemia; Infant; Infant, Newborn; Male; Osteopetrosis; Postoperative Complications; Tissue Donors; Tissue Survival; Transplantation Conditioning; Treatment Outcome; Vidarabine

2016
Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:2

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Salvage Therapy; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2016
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
    Blood, 2016, Jan-21, Volume: 127, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Second Primary; Prognosis; Recurrence; Remission Induction; Retreatment; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Young Adult

2016
Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway.
    Molecular medicine reports, 2015, Volume: 12, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Bevacizumab; Cell Adhesion; Cell Line, Tumor; Cell Movement; Disease Progression; Drug Synergism; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; Neoplasm Invasiveness; Ovarian Neoplasms; Signal Transduction; Vidarabine

2015
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.
    Oncotarget, 2015, Dec-08, Volume: 6, Issue:39

    Topics: Adenine; Aged; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cyclophosphamide; Cytokines; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Vidarabine

2015
Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:21

    Topics: Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2015
Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:3

    Topics: Administration, Intravenous; Adult; Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Transplantation Conditioning; Unrelated Donors; Vidarabine

2016
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
    Leukemia research, 2015, Volume: 39, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease Susceptibility; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; IgG Deficiency; Immunocompromised Host; Immunotherapy; Incidence; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia; Prednisone; Proportional Hazards Models; Retrospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine; Young Adult

2015
The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
    Oncotarget, 2015, Dec-01, Volume: 6, Issue:38

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; BRCA1 Protein; Cell Line, Tumor; Chromatography, Liquid; Cyclin D1; DNA Damage; DNA Repair; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; NF-kappa B p52 Subunit; Nucleolin; Phosphoproteins; Protein Interaction Maps; Proteomics; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Signal Transduction; Tandem Mass Spectrometry; Tumor Suppressor Protein p53; Vidarabine

2015
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.
    Haematologica, 2016, Volume: 101, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prednisolone; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Rituximab; Survival Rate; Vidarabine

2016
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cyclophosphamide; Female; Follow-Up Studies; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Statistical; Quality-Adjusted Life Years; Rituximab; Treatment Outcome; Vidarabine

2016
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
    Cancer, 2016, Feb-15, Volume: 122, Issue:4

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2016
Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
    Blood, 2016, Jan-28, Volume: 127, Issue:4

    Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocytes; Melphalan; Prospective Studies; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Young Adult

2016
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
    Blood, 2016, Feb-25, Volume: 127, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Separation; Cyclophosphamide; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exome; Humans; Immunoprecipitation; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation, Missense; Neoplasm Recurrence, Local; Ribosomal Proteins; Rituximab; Transfection; Tumor Suppressor Protein p53; Vidarabine

2016
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
    The Lancet. Haematology, 2015, Volume: 2, Issue:10

    Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2015
Synthesis, characterization and bioevaluation of drug-collagen hybrid materials for biomedical applications.
    International journal of pharmaceutics, 2016, Aug-30, Volume: 510, Issue:2

    Topics: Collagen Type I; Drug Delivery Systems; Epirubicin; Humans; Materials Testing; Pharmaceutical Preparations; Vidarabine

2016
Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Male; Middle Aged; Myeloablative Agonists; Neoplasm Metastasis; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2016
Role of Tumor Necrosis Factor-Producing Mesenchymal Stem Cells on Apoptosis of Chronic B-lymphocytic Tumor Cells Resistant to Fludarabine-based Chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:18

    Topics: Adipose Tissue; Adult; Antineoplastic Agents; Apoptosis; Cells, Cultured; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mesenchymal Stem Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Vidarabine

2015
[Molecular diagnosis and hematopoietic stem cell transplantation in 17 children with inherited bone marrow failure syndrome].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2015, Volume: 53, Issue:11

    Topics: Anemia, Aplastic; Anemia, Diamond-Blackfan; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Dyskeratosis Congenita; Fanconi Anemia; Fetal Blood; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Retrospective Studies; Siblings; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine

2015
Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; CD40 Antigens; Heterografts; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2016
[Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:12

    Topics: Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Methotrexate; Mycophenolic Acid; Retrospective Studies; Siblings; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine

2015
Clinical and laboratory outcomes after umbilical cord blood transplantation in a patient with mucolipidosis II alpha/beta.
    American journal of medical genetics. Part A, 2016, Volume: 170A, Issue:5

    Topics: Abnormalities, Multiple; Animals; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Immunoglobulins; Mucolipidoses; Psychomotor Disorders; Rabbits; Transferases (Other Substituted Phosphate Groups); Transplantation, Homologous; Vidarabine

2016
Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    International journal of hematology, 2016, Volume: 103, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; C-Reactive Protein; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2016
Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.
    Bone marrow transplantation, 2016, Volume: 51, Issue:5

    Topics: Alemtuzumab; Bone Marrow; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Graft Survival; Hematopoietic Stem Cell Transplantation; Heterozygote; Humans; Immunosuppressive Agents; Male; Mutation; Transplantation Conditioning; Vidarabine; Whole Body Imaging

2016
[Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
    Zhonghua yi xue za zhi, 2015, Nov-24, Volume: 95, Issue:44

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Follicular; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine; Young Adult

2015
Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
    Medicine, 2016, Volume: 95, Issue:4

    Topics: Adolescent; Adult; Anthracyclines; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; China; Consolidation Chemotherapy; Cytarabine; Female; Humans; Incidence; Infant; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prospective Studies; Survival Rate; Vidarabine; Young Adult

2016
[Chronic alveolar condensations with erythematous cutaneous lesions].
    Revue des maladies respiratoires, 2016, Volume: 33, Issue:7

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Deoxycytidine; Diagnosis, Differential; Doxorubicin; Erythema; Female; Gemcitabine; Humans; Lung Neoplasms; Mycosis Fungoides; Pulmonary Alveoli; Skin Neoplasms; Vidarabine

2016
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:6

    Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2016
Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.
    Journal of hematology & oncology, 2016, Feb-13, Volume: 9

    Topics: Adult; Agammaglobulinemia; Antilymphocyte Serum; Cyclophosphamide; Genetic Diseases, X-Linked; Humans; Immunity, Humoral; Immunoglobulin A; Immunoglobulin M; Male; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2016
Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation.
    Bone marrow transplantation, 2016, Volume: 51, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Agents; Blood Platelets; Cord Blood Stem Cell Transplantation; Feasibility Studies; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neutrophils; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2016
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel
    Leukemia & lymphoma, 2016, Volume: 57, Issue:10

    Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comorbidity; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2016
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
    International journal of hematology, 2016, Volume: 103, Issue:5

    Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine

2016
Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.
    International journal of hematology, 2016, Volume: 103, Issue:4

    Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Siblings; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2016
An unusual manifestation in a patient with Neurofibromatosis type 1.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2016, Volume: 151, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cyclophosphamide; Diagnosis, Differential; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neurofibromatosis 1; Rituximab; Treatment Outcome; Vidarabine

2016
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
    Zhonghua nei ke za zhi, 2016, Volume: 55, Issue:3

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2016
Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24

    Topics: Antineoplastic Agents; DNA Transposable Elements; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutagenesis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins B-raf; Transcription Factors; Tumor Cells, Cultured; Vidarabine

2016
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7

    Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine

2016
Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
    Clinical therapeutics, 2016, Volume: 38, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bayes Theorem; Chlorambucil; Contraindications; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2016
[The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases].
    Terapevticheskii arkhiv, 2016, Volume: 88, Issue:1

    Topics: Adult; Age Factors; Antilymphocyte Serum; Arthritis, Rheumatoid; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Melphalan; Multiple Sclerosis; Patient Acuity; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vidarabine

2016
Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: Targeting the BCR-signaling pathway.
    International journal of biological macromolecules, 2016, Volume: 88

    Topics: Antineoplastic Agents; B-Lymphocytes; Base Sequence; Cell Line, Tumor; Chromosomes, Human, Pair 17; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Microarray Analysis; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Polypropylenes; Precision Medicine; Proto-Oncogene Proteins c-bcr; Sequence Deletion; Signal Transduction; Trisaccharides; Vidarabine

2016
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
    Cancer medicine, 2016, Volume: 5, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Positron-Emission Tomography; Remission Induction; Rituximab; Tomography, X-Ray Computed; Treatment Outcome; Vidarabine

2016
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    The Korean journal of internal medicine, 2016, Volume: 31, Issue:4

    Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Living Donors; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Recurrence; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2016
Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
    Annals of hematology, 2016, Volume: 95, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine

2016
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7

    Topics: Adult; Brentuximab Vedotin; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lung Diseases; Male; Melphalan; Middle Aged; Nausea; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2016
Comparative Analysis between [(18)F]Fludarabine-PET and [(18)F]FDG-PET in a Murine Model of Inflammation.
    Molecular pharmaceutics, 2016, 06-06, Volume: 13, Issue:6

    Topics: Animals; Fluorodeoxyglucose F18; Inflammation; Mice; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tissue Distribution; Vidarabine

2016
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
    American journal of hematology, 2016, Volume: 91, Issue:8

    Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Consolidation Chemotherapy; Cytarabine; Female; Gemtuzumab; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2016
Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.
    Translational research : the journal of laboratory and clinical medicine, 2016, Volume: 175

    Topics: Adult; Aged; Cohort Studies; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precision Medicine; Recurrence; Regression Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2016
Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Age Factors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cells, Cultured; Drug Synergism; Female; Humans; Immunoblotting; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Mice, Inbred NZB; Neoplasms, Experimental; NF-kappa B; Proto-Oncogene Proteins c-akt; Rotenone; Signal Transduction; Tumor Cells, Cultured; Vidarabine

2016
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
    Annals of hematology, 2016, Volume: 95, Issue:7

    Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Cells; Busulfan; Cyclophosphamide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2016
Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect?
    Bone marrow transplantation, 2016, Volume: 51, Issue:7

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2016
Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transpla
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult

2016
Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
    American journal of hematology, 2016, Volume: 91, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Humans; Male; Middle Aged; Pancytopenia; Retrospective Studies; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2016
[Clinical Summarization of Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: A Report of 100 Cases].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2

    Topics: Antilymphocyte Serum; Disease-Free Survival; Graft vs Host Disease; HLA Antigens; Humans; Incidence; Leukemia; Peripheral Blood Stem Cell Transplantation; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine

2016
[Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2

    Topics: Antilymphocyte Serum; Busulfan; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Leukemia; Mycophenolic Acid; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2016
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Middle Aged; Myeloablative Agonists; Pneumonia; Prospective Studies; Seizures; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2016
Cladribine and Fludarabine Nucleotides Induce Distinct Hexamers Defining a Common Mode of Reversible RNR Inhibition.
    ACS chemical biology, 2016, 07-15, Volume: 11, Issue:7

    Topics: Biopolymers; Chromatography, Gel; Cladribine; Fluorescence Polarization; Nucleotides; Ribonucleotide Reductases; Vidarabine

2016
Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.
    Bone marrow transplantation, 2016, Volume: 51, Issue:9

    Topics: Adolescent; Antilymphocyte Serum; Child; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Infant; Lymphocyte Depletion; Male; Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2016
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2016
Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8

    Topics: Adolescent; Adult; Alemtuzumab; Bone Marrow Transplantation; Child; Child, Preschool; Female; Follow-Up Studies; Graft Survival; Hemoglobinopathies; Humans; Male; Melphalan; Myeloablative Agonists; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2016
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
    Prescrire international, 2016, Volume: 25, Issue:170

    Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine

2016
Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.
    Oncotarget, 2016, Jun-21, Volume: 7, Issue:25

    Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Cladribine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2016
Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen.
    The Journal of allergy and clinical immunology, 2016, Volume: 138, Issue:4

    Topics: Cell Lineage; Chimerism; Disease-Free Survival; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunologic Deficiency Syndromes; Infant; Infant, Newborn; Melphalan; Stem Cell Transplantation; Stem Cells; Vidarabine

2016
Addition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:9

    Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Cytarabine; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloablative Agonists; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine

2016
High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD.
    Bone marrow transplantation, 2016, Volume: 51, Issue:11

    Topics: Adolescent; Adult; Cohort Studies; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Prevalence; Prospective Studies; Small Fiber Neuropathy; Vidarabine; Young Adult

2016
Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Combined Modality Therapy; Deoxycytidine Kinase; Drug Delivery Systems; Female; Humans; Ovarian Neoplasms; Phosphorylation; Receptor, ErbB-2; Tumor Cells, Cultured; Vidarabine

2016
Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
    Leukemia research, 2016, Volume: 47

    Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Chromatin Assembly and Disassembly; Clofarabine; Depsipeptides; DNA Damage; Drug Synergism; Histone Code; Humans; Metabolic Networks and Pathways; Tumor Cells, Cultured; Vidarabine

2016
Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning.
    Bone marrow transplantation, 2016, Volume: 51, Issue:11

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung Diseases; Male; Myeloablative Agonists; Respiratory Function Tests; Transplantation Conditioning; Vidarabine; Young Adult

2016
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2016, Volume: 19, Issue:4

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cost-Benefit Analysis; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Treatment Outcome; United Kingdom; Vidarabine

2016
A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10

    Topics: Adult; Aged; Busulfan; Female; Graft Survival; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2016
Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning.
    Bone marrow transplantation, 2016, Volume: 51, Issue:11

    Topics: Adolescent; Adult; Age Factors; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Male; Middle Aged; Myeloablative Agonists; Siblings; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2016
Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays.
    Anti-cancer agents in medicinal chemistry, 2017, Volume: 17, Issue:1

    Topics: Aged; Aged, 80 and over; Antimetabolites; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dendrimers; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polypropylenes; Trisaccharides; Vidarabine

2017
Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient.
    Hematology/oncology and stem cell therapy, 2018, Volume: 11, Issue:2

    Topics: Aged; Allografts; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Mycophenolic Acid; Tacrolimus; Transplantation Conditioning; Vidarabine

2018
Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.
    Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:13

    Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2016
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, B-Cell; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2016
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10

    Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2016
[SYNERGISTIC ACTIVITY OF DEGUELIN AND FLUDARABINE IN PRIMARY CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) AND IN A CLL MURINE MODEL].
    Anales de la Real Academia Nacional de Medicina, 2014, Volume: 131, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Primary Cell Culture; Rotenone; Tumor Cells, Cultured; Vidarabine

2014
US regulator stops leukemia treatment trial after three patients die.
    BMJ (Clinical research ed.), 2016, Jul-14, Volume: 354

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunotherapy; Leukemia; Treatment Failure; United States; United States Food and Drug Administration; Vidarabine

2016
Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies.
    Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:8

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid; Male; Melphalan; Myeloablative Agonists; Myeloproliferative Disorders; Remission Induction; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2016
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine

2016
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
    Zhonghua yi xue za zhi, 2016, Jul-26, Volume: 96, Issue:28

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2016
The FDA, Juno Therapeutics, and the ethical imperative of transparency.
    BMJ (Clinical research ed.), 2016, Aug-15, Volume: 354

    Topics: Brain Edema; Clinical Trials, Phase II as Topic; Disclosure; Drug Industry; Drugs, Investigational; Humans; Immunotherapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Safety-Based Drug Withdrawals; United States; United States Food and Drug Administration; Vidarabine

2016
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Annals of hematology, 2016, Volume: 95, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine

2016
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine

2016
Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia.
    International immunopharmacology, 2016, Volume: 40

    Topics: Aged; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Female; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Interleukin-10; Interleukin-17; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nuclear Receptor Subfamily 1, Group F, Member 3; Prognosis; Rituximab; T-Lymphocytes, Regulatory; Th17 Cells; Vidarabine

2016
Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL.
    Bone marrow transplantation, 2017, Volume: 52, Issue:1

    Topics: Adult; Aged; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Transplantation Conditioning; Vidarabine

2017
TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia.
    Leukemia research, 2016, Volume: 50

    Topics: Adult; Aged; Apoptosis; Apoptosis Regulatory Proteins; Cell Survival; Female; Glycolysis; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphoric Monoester Hydrolases; Prognosis; RNA, Messenger; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine; Young Adult

2016
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult

2016
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
    Cancer medicine, 2016, Volume: 5, Issue:11

    Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2016
The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
    Transplantation, 2017, Volume: 101, Issue:1

    Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Radiation Dosage; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
    Leukemia, 2017, Volume: 31, Issue:5

    Topics: Animals; Apoptosis; Cell Line, Tumor; Clinical Trials as Topic; Dioxoles; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; Tumor Cells, Cultured; Vidarabine

2017
Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia.
    Acta haematologica, 2017, Volume: 137, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine

2017
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:7

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Recurrence; Vidarabine

2017
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.
    Cellular signalling, 2017, Volume: 29

    Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyurea; Models, Biological; Mutation; Neoplasms; NF-kappa B; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine

2017
Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients.
    British journal of haematology, 2017, Volume: 176, Issue:1

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cohort Studies; Disease Management; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Neoplasm Invasiveness; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Vidarabine

2017
Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia.
    Haematologica, 2017, Volume: 102, Issue:3

    Topics: Anemia, Diamond-Blackfan; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine

2017
PPI-G4 Glycodendrimers Upregulate TRAIL-Induced Apoptosis in Chronic Lymphocytic Leukemia Cells.
    Macromolecular bioscience, 2017, Volume: 17, Issue:5

    Topics: Adult; Apoptosis; Cell Line, Tumor; Dendrimers; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Oligonucleotide Array Sequence Analysis; Polypropylenes; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine

2017
Spousal hematopoietic stem cell transplantation.
    International journal of hematology, 2017, Volume: 105, Issue:5

    Topics: Adult; Allografts; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fatal Outcome; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia; Male; Melphalan; Middle Aged; Radiotherapy Dosage; Recurrence; Spouses; Transplantation Conditioning; Treatment Outcome; Vidarabine

2017
[Clinical Efficacy of Haploidentical Allo-HSCT of Reduced Intensity Preconditioning Combined with Induced Immune Tolerance after Transplantation for Severe Aplastic Anemia].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:6

    Topics: Anemia, Aplastic; Busulfan; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Fathers; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Immune Tolerance; Male; Methotrexate; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine

2016
Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
    Cell death & disease, 2016, 12-29, Volume: 7, Issue:12

    Topics: Aminobenzoates; Apoptosis; Ataxia Telangiectasia Mutated Proteins; B-Lymphocytes; Cell Cycle Checkpoints; Cell Line, Transformed; Cell Survival; Cyclophosphamide; Herpesvirus 4, Human; Histones; Humans; Naphthalenes; S Phase; Signal Transduction; Telomerase; Telomere; Telomere Homeostasis; Vidarabine

2016
Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.
    Human molecular genetics, 2017, 01-15, Volume: 26, Issue:2

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D3; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Repressor Proteins; Vidarabine

2017
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia.
    American journal of hematology, 2017, Volume: 92, Issue:4

    Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Stem Cell Transplantation; Survival Rate; Vidarabine

2017
Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:4

    Topics: Adolescent; Alemtuzumab; Antineoplastic Agents, Immunological; Child; Child, Preschool; Graft vs Host Disease; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Count; Melphalan; Prospective Studies; Transplantation Conditioning; Vidarabine

2017
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:5

    Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2017
Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working
    Journal of hematology & oncology, 2017, 01-24, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Leukocyte Reduction Procedures; Lymphocyte Depletion; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2017
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
    Bioscience trends, 2017, Mar-22, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Stem Cell Transplantation; Treatment Outcome; Vidarabine; Young Adult

2017
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3

    Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Length of Stay; Male; Middle Aged; Myeloablative Agonists; Polyomavirus Infections; Recurrence; Risk Factors; Sex Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2017
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:5

    Topics: Adult; Aged; Alemtuzumab; Allografts; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult

2017
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.
    International journal of hematology, 2017, Volume: 105, Issue:6

    Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Vidarabine

2017
Successful Myeloablative Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in a Young Girl With GATA2 Deficiency and Emberger Syndrome.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:3

    Topics: Busulfan; Child, Preschool; Female; GATA2 Transcription Factor; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphedema; Myeloablative Agonists; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine

2017
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood.
    Bone marrow transplantation, 2017, Volume: 52, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Alopecia; Busulfan; Child; Child, Preschool; Cross-Sectional Studies; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Risk Factors; Transplantation Conditioning; Vidarabine

2017
Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.
    Transplantation, 2017, Volume: 101, Issue:11

    Topics: Animals; Bone Marrow Diseases; CD8-Positive T-Lymphocytes; Cyclophosphamide; Disease Models, Animal; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Major Histocompatibility Complex; Mice, Inbred BALB C; Myeloablative Agonists; Spleen; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2017
Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Applied health economics and health policy, 2017, Volume: 15, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Quality-Adjusted Life Years; Rituximab; Vidarabine

2017
Fludarabine resistance mediated by aminoglycoside-3'-phosphotransferase-IIa and the structurally related eukaryotic cAMP-dependent protein kinase.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:7

    Topics: Antineoplastic Agents; Binding Sites; Cell Line, Transformed; Cloning, Molecular; Cyclic AMP-Dependent Protein Kinases; Drug Resistance, Neoplasm; Fibroblasts; Gene Expression Regulation, Enzymologic; Humans; Kanamycin Kinase; Molecular Structure; Structure-Activity Relationship; Vidarabine

2017
Fludarabine is effective in treating refractory hemophagocytic lymphohistiocytosis with brucellosis.
    International journal of rheumatic diseases, 2017, Volume: 20, Issue:12

    Topics: Anti-Bacterial Agents; Brucellosis; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Treatment Outcome; Vidarabine

2017
Influences of FLU/BU and FLU/MEL on incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2017, Volume: 58, Issue:3

    Topics: Adult; Aged; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2017
Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice.
    International immunopharmacology, 2017, Volume: 47

    Topics: Animals; Antineoplastic Agents; Carcinogenesis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Growth Processes; Cell Line, Tumor; Female; Fluorouracil; Immune Tolerance; Lymphoma; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Vidarabine

2017
Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017, May-15, Volume: 1053

    Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cladribine; Clofarabine; Humans; Limit of Detection; Neoplasms; Polyphosphates; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine

2017
Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017, Jun-15, Volume: 1055-1056

    Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Chromatography, Liquid; Clofarabine; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Isotopes; Limit of Detection; Tandem Mass Spectrometry; Transplantation Conditioning; Vidarabine

2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    British journal of haematology, 2017, Volume: 178, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Databases, Factual; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Risk Factors; Rituximab; Vidarabine; Young Adult; Yttrium Radioisotopes

2017
[18F]Fludarabine-PET in a murine model of multiple myeloma.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Animals; Fluorine Radioisotopes; Heterografts; Mice; Mice, Nude; Multiple Myeloma; Myeloablative Agonists; Positron-Emission Tomography; Vidarabine

2017
Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.
    Bone marrow transplantation, 2017, Volume: 52, Issue:7

    Topics: 5' Untranslated Regions; 5'-Nucleotidase; Adolescent; Adult; Allografts; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; GPI-Linked Proteins; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Polymorphism, Genetic; Vidarabine

2017
Involvement of STAT1 in proliferation and invasiveness of trophoblastic cells.
    Reproductive biology, 2017, Volume: 17, Issue:3

    Topics: Cell Line; Cell Movement; Cell Proliferation; Gene Expression Regulation; Humans; Interleukins; Oncostatin M; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Trophoblasts; Vidarabine

2017
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
    Advances in therapy, 2017, Volume: 34, Issue:7

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bayes Theorem; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Vidarabine

2017
Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
    Annals of hematology, 2017, Volume: 96, Issue:9

    Topics: Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bridged Bicyclo Compounds, Heterocyclic; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Sulfonamides; Vidarabine

2017
Fludarabine inhibits STAT1-mediated up-regulation of caspase-3 expression in dexamethasone-induced osteoblasts apoptosis and slows the progression of steroid-induced avascular necrosis of the femoral head in rats.
    Apoptosis : an international journal on programmed cell death, 2017, Volume: 22, Issue:8

    Topics: Animals; Apoptosis; Caspase 3; Dexamethasone; Femur Head Necrosis; Gene Expression Regulation; Glucocorticoids; Humans; Osteoblasts; Phosphorylation; Rats; STAT1 Transcription Factor; Vidarabine

2017
Extensive ulcerated lesions in a patient with cutaneous myeloid sarcoma responded to twice-daily fludarabine and cytarabine regimen.
    Blood cells, molecules & diseases, 2018, Volume: 69

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cytarabine; Drug Administration Schedule; Fatal Outcome; Humans; Male; Positron Emission Tomography Computed Tomography; Sarcoma, Myeloid; Skin Neoplasms; Skin Ulcer; Treatment Outcome; Vidarabine

2018
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    American journal of hematology, 2017, Volume: 92, Issue:10

    Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult

2017
Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
    Blood, 2017, 06-22, Volume: 129, Issue:25

    Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Ear, External; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hearing Loss, Unilateral; Humans; Idarubicin; Leukemia, Monocytic, Acute; Leukemic Infiltration; Male; Orbit; Tumor Lysis Syndrome; Vidarabine

2017
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:12

    Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Melphalan; Middle Aged; Myelodysplastic Syndromes; Rabbits; Risk Assessment; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2017
Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:11

    Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Female; Humans; Male; Middle Aged; Thiotepa; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro-Preliminary Study.
    Macromolecular bioscience, 2017, Volume: 17, Issue:11

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Dendrimers; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nanoparticles; Tumor Stem Cell Assay; Vidarabine; Wnt Signaling Pathway

2017
Persistence of the losing cord blood unit following double cord blood transplantation: finding the unseen.
    Blood, 2017, 09-21, Volume: 130, Issue:12

    Topics: Adolescent; Adult; Blood Cells; Bone Marrow Cells; Busulfan; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Hematopoiesis; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult

2017
Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:4

    Topics: Adult; Age Factors; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Patient Selection; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2018
IFN-γ aggravates neointimal hyperplasia by inducing endoplasmic reticulum stress and apoptosis in macrophages by promoting ubiquitin-dependent liver X receptor-α degradation.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2017, Volume: 31, Issue:12

    Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Apolipoproteins E; Apoptosis; Endoplasmic Reticulum Stress; Hyperplasia; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Interferon-gamma; Liver X Receptors; Macrophages; Male; Mice; Mice, Knockout; Neointima; Protein Inhibitors of Activated STAT; Ubiquitin; Ubiquitination; Vidarabine

2017
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2017, 10-04, Volume: 25, Issue:10

    Topics: Adult; Antigens, CD19; B-Lymphocytes; Cyclophosphamide; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Receptors, Antigen, T-Cell; T-Lymphocytes; Vidarabine

2017
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.
    Leukemia, 2017, Volume: 31, Issue:12

    Topics: Antineoplastic Agents; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Risk; Vidarabine

2017
Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation.
    International journal of hematology, 2017, Volume: 106, Issue:4

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cystitis; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infant; Male; Middle Aged; Transplantation Conditioning; Vascular Diseases; Vidarabine

2017
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:12

    Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2017
Downregulated SOCS1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type.
    Molecular medicine reports, 2017, Volume: 16, Issue:5

    Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Drugs, Chinese Herbal; Enzyme Inhibitors; Gene Expression Regulation; Interferon-gamma; Interleukin-10; Interleukin-4; Janus Kinase 1; Macrophages, Peritoneal; Mice; Phosphorylation; Primary Cell Culture; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Suppressor of Cytokine Signaling 1 Protein; Tumor Necrosis Factor-alpha; Vidarabine

2017
Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cel
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Sep-01, Volume: 28, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult

2017
HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:1

    Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Cohort Studies; Dexamethasone; Graft Survival; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Transplantation, Haploidentical; Transplantation, Homologous; Vidarabine; Young Adult

2018
IL-27 Modulates Chemokine Production in TNF-α -Stimulated Human Oral Epithelial Cells.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 43, Issue:3

    Topics: Cell Line; Chemokine CCL20; Chemokines; Humans; Interleukin-27; Interleukin-8; Mouth Mucosa; Phosphorylation; Pyridines; Receptors, Interleukin; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha; Tyrphostins; Vidarabine

2017
Toward Individualizing Conditioning Regimens in Reduced-Intensity Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:12

    Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Precision Medicine; Survival Analysis; Transplantation Conditioning; Vidarabine

2017
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclophosphamide; Databases, Factual; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2018
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
    Cancer, 2017, 12-15, Volume: 123, Issue:24

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine

2017
Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
    American journal of hematology, 2018, Volume: 93, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Retrospective Studies; Vidarabine

2018
Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:2

    Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Mycophenolic Acid; Premedication; Tacrolimus; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2018
Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies.
    Bone marrow transplantation, 2018, Volume: 53, Issue:2

    Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2018
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 03-01, Volume: 36, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Rituximab; Vidarabine; Vincristine

2018
Reply to S. Opat et al.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 12-20, Volume: 35, Issue:36

    Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2017
Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 12-20, Volume: 35, Issue:36

    Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2017
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
    Bone marrow transplantation, 2018, Volume: 53, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Comorbidity; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Staging; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2018
Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen.
    Current pharmaceutical design, 2018, Volume: 24, Issue:11

    Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured; Vidarabine

2018
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    British journal of haematology, 2018, Volume: 180, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proportional Hazards Models; Rituximab; Treatment Outcome; Vidarabine; Young Adult

2018
Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation.
    Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:6

    Topics: Allografts; Antilymphocyte Serum; Child; Cyclophosphamide; Female; GATA2 Deficiency; GATA2 Transcription Factor; Graft vs Host Disease; Humans; Mutation; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Skin Diseases; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2018
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    British journal of haematology, 2018, Volume: 180, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Vidarabine

2018
Intravenous immunoglobulin as salvage therapy for refractory thrombotic thrombocytopenic purpura.
    American journal of hematology, 2018, Volume: 93, Issue:3

    Topics: Adult; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Recurrence; Registries; Retrospective Studies; Salvage Therapy; Splenectomy; Treatment Outcome; Vidarabine; Vincristine; Young Adult

2018
The struggle to do no harm in clinical trials.
    Nature, 2017, 12-21, Volume: 552, Issue:7685

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine

2017
Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation.
    Transplantation, 2018, Volume: 102, Issue:4

    Topics: Animals; Complement C4b; Composite Tissue Allografts; Desensitization, Immunologic; Graft Rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Hindlimb; Immunosuppressive Agents; Isoantibodies; Male; Models, Animal; Myeloablative Agonists; Peptide Fragments; Rats, Inbred Lew; Skin Transplantation; Tacrolimus; Time Factors; Transplantation, Isogeneic; Vascularized Composite Allotransplantation; Vidarabine

2018
The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
    Cell death & disease, 2018, 01-09, Volume: 9, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Carrier Proteins; Caspase 7; CRADD Signaling Adaptor Protein; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; NF-kappa B; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Up-Regulation; Vidarabine

2018
[Outcomes of alternative donor allogeneic hematopoietic stem cell transplantation for Fanconi anemia: a five cases report].
    Zhonghua nei ke za zhi, 2018, Jan-01, Volume: 57, Issue:1

    Topics: Antilymphocyte Serum; Bone Marrow; Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine

2018
Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
    Bioorganic & medicinal chemistry letters, 2018, 02-01, Volume: 28, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Molecular Structure; Purine Nucleosides; Vidarabine

2018
Efficacy of Rituximab for Patients with Chronic Lymphocytic Leukemia.
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2017, Dec-20, Volume: 39, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine

2017
Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide.
    Bone marrow transplantation, 2018, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult

2018
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
    British journal of haematology, 2019, Volume: 184, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Vidarabine

2019
Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemia: A case report.
    Medicine, 2017, Volume: 96, Issue:51

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 2; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Translocation, Genetic; Vidarabine

2017
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:6

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Infant; Italy; Lymphohistiocytosis, Hemophagocytic; Male; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2018
Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.
    Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:4

    Topics: Adolescent; Adult; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Humans; Male; Severity of Illness Index; Survival Rate; Tissue Donors; Vidarabine

2018
FDG PET and MRI Findings in a Case of Bing-Neel Syndrome.
    Clinical nuclear medicine, 2018, Volume: 43, Issue:4

    Topics: Brain; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron Emission Tomography Computed Tomography; Vidarabine

2018
Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:6

    Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Melphalan; Myeloablative Agonists; Osteopetrosis; Prognosis; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2018
Single centre results of targeted busulphan, fludarabine and serotherapy conditioning in haematopoietic stem cell transplantation for haemophagocytic lymphohistiocytosis.
    Bone marrow transplantation, 2018, Volume: 53, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunization, Passive; Lymphohistiocytosis, Hemophagocytic; Male; Transplantation Conditioning; Vidarabine

2018
Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
    International journal of hematology, 2018, Volume: 108, Issue:3

    Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Tumor Burden; Vidarabine

2018
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
    Haematologica, 2018, Volume: 103, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine

2018
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8

    Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2018
Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; France; Humans; Immunosuppression Therapy; Incidence; Lymphoma, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Rituximab; Survival Rate; Vidarabine

2018
DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
    Haematologica, 2018, Volume: 103, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Progression; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutation; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Vidarabine

2018
A comparison of intrauterine hemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassemia in a HbbTh3/+ murine model.
    Experimental hematology, 2018, Volume: 62

    Topics: Animals; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Cell Survival; Cellular Microenvironment; Disease Models, Animal; Female; Fetal Therapies; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Hepatocytes; Lentivirus; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Transplantation Chimera; Transplantation Conditioning; Vidarabine

2018
Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis.
    Journal of pediatric hematology/oncology, 2018, Volume: 40, Issue:6

    Topics: Allografts; Antilymphocyte Serum; Busulfan; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Infant; Male; Mucopolysaccharidoses; Survival Rate; Transplantation Conditioning; Vidarabine

2018
Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
    Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Down Syndrome; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Vidarabine; Vorinostat

2019
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 06-20, Volume: 36, Issue:18

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine

2018
An ultrasonic nanobubble-mediated PNP/fludarabine suicide gene system: A new approach for the treatment of hepatocellular carcinoma.
    PloS one, 2018, Volume: 13, Issue:5

    Topics: Carcinoma, Hepatocellular; Gene Transfer Techniques; Genes, Transgenic, Suicide; Green Fluorescent Proteins; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Nanostructures; Purine-Nucleoside Phosphorylase; Ultrasonics; Vidarabine

2018
Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis.
    Bone marrow transplantation, 2018, Volume: 53, Issue:6

    Topics: Adrenoleukodystrophy; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mucopolysaccharidoses; Transplantation Conditioning; Transplantation, Haploidentical; Transplantation, Homologous; Vidarabine

2018
Apoptosis of CD19+ chimeric antigen receptor T cells after treatment with chemotherapeutic agents.
    Molecular medicine reports, 2018, Volume: 18, Issue:1

    Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cyclophosphamide; Humans; Membrane Potentials; Receptors, Antigen, T-Cell; Recombinant Fusion Proteins; Vidarabine

2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies.
    Leukemia, 2018, Volume: 32, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prospective Studies; Rituximab; Vidarabine

2018
Fludarabine and neurotoxicity in engineered T-cell therapy.
    Gene therapy, 2018, Volume: 25, Issue:3

    Topics: Antigens, CD19; Humans; Immunotherapy, Adoptive; Neurotoxicity Syndromes; Receptors, Antigen, T-Cell; T-Lymphocytes; Vidarabine

2018
Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018, Volume: 16, Issue:6

    Topics: Adolescent; Adult; Busulfan; China; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult

2018
Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation.
    Bone marrow transplantation, 2018, Volume: 53, Issue:10

    Topics: Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Busulfan; Cyclosporine; Gastroparesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Male; Methotrexate; Nausea; Unrelated Donors; Vidarabine; Vomiting

2018
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
    Bone marrow transplantation, 2019, Volume: 54, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2019
Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice.
    Scientific reports, 2018, 06-14, Volume: 8, Issue:1

    Topics: Animals; Cell Line, Tumor; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Transplantation Conditioning; Vidarabine

2018
TBI: To Be (Irradiated) or Not To Be? That Remains the Question.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8

    Topics: Busulfan; Cyclophosphamide; Vidarabine; Whole-Body Irradiation

2018
Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients.
    Bone marrow transplantation, 2019, Volume: 54, Issue:2

    Topics: Adolescent; Area Under Curve; Body Surface Area; Child; Child, Preschool; Female; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Nonlinear Dynamics; Pediatrics; Republic of Korea; Transplantation Conditioning; Treatment Outcome; Vidarabine

2019
Point: Does Chemoimmunotherapy Still Have a Role in CLL? Chemoimmunotherapy With FCR Is Still an Important Option in CLL.
    Oncology (Williston Park, N.Y.), 2018, Volume: 32, Issue:6

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2018
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
    Annals of hematology, 2018, Volume: 97, Issue:10

    Topics: Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Ontario; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2018
Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
    European journal of haematology, 2018, Volume: 101, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retreatment; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Young Adult

2018
Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpla
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:11

    Topics: Busulfan; Europe; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Vidarabine

2018
(1-3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
    Annals of hematology, 2019, Volume: 98, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta-Glucans; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Pulmonary Aspergillosis; Retrospective Studies; Risk Factors; Triazoles; Vidarabine

2019
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    American journal of hematology, 2018, Volume: 93, Issue:10

    Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Drug Evaluation; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Retrospective Studies; Siblings; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2018
Successful hematopoietic cell transplantation in Fanconi anemia patients with renal impairment using ultra-reduced doses of cyclophosphamide and fludarabine.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:12

    Topics: Cyclophosphamide; Fanconi Anemia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Transplantation Conditioning; Vidarabine

2018
Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:11

    Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Myeloablative Agonists; Retrospective Studies; Thalassemia; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2018
Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes.
    Bone marrow transplantation, 2019, Volume: 54, Issue:3

    Topics: Adolescent; Adult; Busulfan; China; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Vidarabine; Young Adult

2019
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
    Bone marrow transplantation, 2019, Volume: 54, Issue:4

    Topics: Aged; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Vidarabine

2019
MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
    Leukemia, 2019, Volume: 33, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; DNA Damage; Female; Follow-Up Studies; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Prognosis; Receptors, Antigen, B-Cell; Repressor Proteins; Rituximab; Signal Transduction; Survival Rate; Vidarabine

2019
Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
    Bone marrow transplantation, 2018, Volume: 53, Issue:12

    Topics: Adult; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Transplantation Conditioning; Vidarabine

2018
Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose.
    American journal of hematology, 2018, Volume: 93, Issue:11

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult

2018
CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
    Leukemia research, 2018, Volume: 74

    Topics: Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; THP-1 Cells; Vidarabine

2018
Affecting NF-κB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles.
    Toxicology and applied pharmacology, 2018, 10-15, Volume: 357

    Topics: Cell Line, Tumor; Dendrimers; Gene Expression Regulation; Humans; Leukemia, Lymphoid; Nanoparticles; NF-kappa B; Protein Array Analysis; Signal Transduction; Transcriptome; Vidarabine

2018
A 56-year-old woman with blindness and mental status changes.
    Brain pathology (Zurich, Switzerland), 2018, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Blindness; Female; Humans; Leukoencephalopathies; Mental Disorders; Middle Aged; Vidarabine

2018
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult

2019
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
    Journal of hematology & oncology, 2018, 08-30, Volume: 11, Issue:1

    Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Young Adult

2018
Chemotherapy based combinations in AML: Time to take a step back?
    Leukemia research, 2018, Volume: 73

    Topics: Anthracyclines; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Vidarabine

2018
[
    Theranostics, 2018, Volume: 8, Issue:16

    Topics: Animals; Central Nervous System Neoplasms; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioblastoma; Heterografts; Histocytochemistry; Humans; Image Processing, Computer-Assisted; Lymphoma; Magnetic Resonance Imaging; Neoplasm Transplantation; Positron-Emission Tomography; Radiopharmaceuticals; Rats, Nude; Sensitivity and Specificity; Vidarabine

2018
Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.
    Clinical pharmacokinetics, 2019, Volume: 58, Issue:5

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Middle Aged; Models, Biological; Myeloablative Agonists; Transplantation Conditioning; Vidarabine; Young Adult

2019
TLR4/NF-κB axis induces fludarabine resistance by suppressing TXNIP expression in acute myeloid leukemia cells.
    Biochemical and biophysical research communications, 2018, 11-17, Volume: 506, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Lipopolysaccharide Receptors; Lipopolysaccharides; NF-kappa B; Signal Transduction; THP-1 Cells; Toll-Like Receptor 4; Vidarabine

2018
Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
    Cancer biomarkers : section A of Disease markers, 2018, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Purines; Remission Induction; RNA, Long Noncoding; Vidarabine

2018
Waldenström macroglobulinaemia terminating in acute lymphoblastic leukaemia after treatment with fludarabine.
    British journal of haematology, 2019, Volume: 184, Issue:3

    Topics: Aged; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine; Waldenstrom Macroglobulinemia

2019
Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Disease Susceptibility; Female; Flow Cytometry; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Sirolimus; Treatment Outcome; Vidarabine

2019
Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 50, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Line, Tumor; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Spleen; Survival Rate; Transcription Factor Brn-3A; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Ubiquitination; Vidarabine

2018
Long-Term Follow-Up of
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2018
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
    Blood advances, 2018, 11-27, Volume: 2, Issue:22

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia

2018
Downregulating STAT1/caspase-3 signaling with fludarabine to alleviate progression in a rat model of steroid-induced avascular necrosis of the femoral head.
    Journal of biochemical and molecular toxicology, 2019, Volume: 33, Issue:4

    Topics: Animals; Caspase 3; Dexamethasone; Disease Models, Animal; Disease Progression; Down-Regulation; Femur Head; Femur Head Necrosis; Male; Rats, Sprague-Dawley; Signal Transduction; STAT1 Transcription Factor; Vidarabine

2019
Impact of low-dose irradiation and in vivo T-cell depletion on hematopoietic stem cell transplantation for non-malignant diseases using fludarabine-based reduced-intensity conditioning.
    Bone marrow transplantation, 2019, Volume: 54, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Lymphocyte Depletion; Male; Middle Aged; Transplantation Conditioning; Vidarabine; Young Adult

2019
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
    Bone marrow transplantation, 2019, Volume: 54, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2019
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
    Blood, 2019, 02-28, Volume: 133, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine

2019
Immunosuppressive Total Nodal Irradiation-Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    International journal of radiation oncology, biology, physics, 2019, 05-01, Volume: 104, Issue:1

    Topics: Adolescent; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Follow-Up Studies; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppression Therapy; Kaplan-Meier Estimate; Lymphatic Irradiation; Muromonab-CD3; Myeloablative Agonists; Radiotherapy Dosage; Retreatment; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2019
Visual loss secondary to fludarabine toxicity: optical coherence tomography findings in two patients.
    Eye (London, England), 2019, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Follow-Up Studies; Hematologic Neoplasms; Humans; Prognosis; Retina; Tomography, Optical Coherence; Vidarabine; Vision, Low; Visual Acuity; Visual Field Tests; Visual Fields

2019
Telomere length predicts for outcome to FCR chemotherapy in CLL.
    Leukemia, 2019, Volume: 33, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Rituximab; Telomere; Vidarabine

2019
Fludarabine-Specific Molecular Interactions with Maltose-Modified Poly(propyleneimine) Dendrimer Enable Effective Cell Entry of the Active Drug Form: Comparison with Clofarabine.
    Biomacromolecules, 2019, 03-11, Volume: 20, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clofarabine; Dendrimers; Humans; Maltose; Polypropylenes; Surface Plasmon Resonance; U937 Cells; Vidarabine

2019
Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; DNA Damage; Female; Gene Expression Regulation, Leukemic; Humans; Influenza, Human; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minichromosome Maintenance Complex Component 7; RNA, Messenger; Up-Regulation; Vidarabine; Virus Replication

2019
Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.
    International journal of hematology, 2019, Volume: 109, Issue:4

    Topics: Adult; Allografts; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Vidarabine

2019
Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients.
    Pathology oncology research : POR, 2020, Volume: 26, Issue:2

    Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytochrome P-450 CYP2B6; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Transport Proteins; Middle Aged; Pharmacogenomic Testing; Pharmacogenomic Variants; Vidarabine

2020
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
    Haematologica, 2019, Volume: 104, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Prognosis; Remission Induction; Rituximab; Treatment Outcome; Vidarabine

2019
Distinct cellular responses to replication stress leading to apoptosis or senescence.
    FEBS open bio, 2019, Volume: 9, Issue:5

    Topics: Apoptosis; Cell Line, Tumor; Cellular Senescence; DNA Replication; Humans; Lamin Type A; MCF-7 Cells; Mutation; Tumor Suppressor Protein p53; Vidarabine

2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
    Journal of hematology & oncology, 2019, 04-25, Volume: 12, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2019
First Report of a Patient With Natural Killer-Lymphoblastic Leukemia/Lymphoma in Korea.
    Annals of laboratory medicine, 2019, Volume: 39, Issue:5

    Topics: Antineoplastic Agents; Bone Marrow Cells; Clopidogrel; Drug Therapy, Combination; Female; Humans; Killer Cells, Natural; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Republic of Korea; Tomography, X-Ray Computed; Vidarabine

2019
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Leukemia research, 2019, Volume: 81

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 11; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Rituximab; Survival Rate; Vidarabine

2019
Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation.
    Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:8

    Topics: Abatacept; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-2 Antigen; CD28 Antigens; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation

2019
FLAI induction regimen in elderly patients with acute myeloid leukemia.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:13

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Sex Factors; Time Factors; Transplantation, Homologous; Vidarabine

2019
Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Patient Selection; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Sulfonamides; Treatment Outcome; Vidarabine

2019
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs.
    The Lancet. Haematology, 2019, Volume: 6, Issue:8

    Topics: Adenine; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine

2019
Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Life sciences, 2019, Sep-01, Volume: 232

    Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Heme Oxygenase-1; Histone Deacetylase 1; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Nude; Middle Aged; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyridines; Random Allocation; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine; Xenograft Model Antitumor Assays

2019
High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Fas Ligand Protein; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prognosis; Treatment Outcome; Vidarabine

2019
High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:14

    Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Case-Control Studies; Cladribine; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Vidarabine

2019
Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Leukemia, 2019, Volume: 33, Issue:11

    Topics: Aged; Antigens, CD19; B-Lymphocytes; Cell Separation; Cyclophosphamide; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Kinetics; Leukemia, B-Cell; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell; Remission Induction; T-Lymphocytes; Vidarabine

2019
Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Clinical lymphoma, myeloma & leukemia, 2019, Volume: 19, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Mutation; Predictive Value of Tests; Prognosis; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine

2019
Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin.
    Annals of transplantation, 2019, Aug-09, Volume: 24

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Female; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2019
Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia.
    BMC cancer, 2019, Aug-14, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunoglobulin Variable Region; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mutation; Neoplasm, Residual; Prognosis; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine

2019
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
    Bone marrow transplantation, 2020, Volume: 55, Issue:1

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
    Stem cells and development, 2019, 10-15, Volume: 28, Issue:20

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2019
Structural Basis for Inhibition of Human Primase by Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine.
    ACS chemical biology, 2019, 09-20, Volume: 14, Issue:9

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Antiviral Agents; Catalytic Domain; Crystallography, X-Ray; DNA Primase; Enzyme Assays; Humans; Protein Binding; Vidarabine

2019
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
    American journal of hematology, 2019, Volume: 94, Issue:12

    Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2019
Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia.
    The Lancet. Oncology, 2019, Volume: 20, Issue:11

    Topics: Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Retrospective Studies; Rituximab; Vidarabine

2019
Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens.
    Bone marrow transplantation, 2020, Volume: 55, Issue:8

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine

2020
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.
    American journal of hematology, 2019, Volume: 94, Issue:12

    Topics: Adult; Aged; Bone Marrow; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Proportional Hazards Models; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult

2019
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.
    The Lancet. Haematology, 2020, Volume: 7, Issue:1

    Topics: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation, Homologous; Vidarabine

2020
[Effect of miR-214 on Fludarabine Resistance in Chronic Lymphocytic Leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2019, Volume: 27, Issue:5

    Topics: Apoptosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Phosphatidylinositol 3-Kinases; Vidarabine

2019
Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma.
    International journal of hematology, 2019, Volume: 110, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2019
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.
    Bone marrow transplantation, 2020, Volume: 55, Issue:4

    Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine

2020
Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation.
    Journal of the American Academy of Dermatology, 2020, Volume: 83, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Busulfan; Case-Control Studies; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Karnofsky Performance Status; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Staging; Risk Factors; Skin; Skin Neoplasms; Tissue Donors; Transplantation Conditioning; Ultraviolet Rays; Vidarabine; Whole-Body Irradiation; Young Adult

2020
Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia.
    Acta haematologica, 2020, Volume: 143, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemorrhage; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Vidarabine

2020
FLAG With Bortezomib in Childhood Relapsed/Refractory Leukemia: Remission Induction With Limited Toxicity in the Era of Multidrug-resistant Bacteria.
    Journal of pediatric hematology/oncology, 2021, 03-01, Volume: 43, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Child, Preschool; Cytarabine; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Vidarabine

2021
Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.
    Anti-cancer agents in medicinal chemistry, 2020, Volume: 20, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Line, Tumor; Dendrimers; Drug Development; Heterografts; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Neoplasms, Experimental; Polypropylenes; Tissue Distribution; Trisaccharides; Vidarabine

2020
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
    Annals of hematology, 2019, Volume: 98, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Databases, Factual; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Vidarabine

2019
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy.
    Clinical epigenetics, 2019, 12-02, Volume: 11, Issue:1

    Topics: Adult; Aged; Cyclophosphamide; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Rituximab; Treatment Outcome; Vidarabine

2019
Elucidation of binding interactions and mechanism of Fludarabine with dsDNA via multispectroscopic and molecular docking studies.
    Journal of pharmaceutical and biomedical analysis, 2020, Feb-05, Volume: 179

    Topics: Binding Sites; DNA; Hydrogen Bonding; Molecular Docking Simulation; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Vidarabine; Viscosity

2020
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
    Blood, 2020, 02-06, Volume: 135, Issue:6

    Topics: Age Factors; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2020
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation.
    Pediatric transplantation, 2020, Volume: 24, Issue:1

    Topics: Busulfan; Child; Child, Preschool; Drug Eruptions; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t
    Annals of hematology, 2020, Volume: 99, Issue:1

    Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplasms; HLA Antigens; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:4

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia.
    International journal of hematology, 2020, Volume: 111, Issue:3

    Topics: Adolescent; Adult; Anemia, Aplastic; Antilymphocyte Serum; Blood Transfusion; Child; Child, Preschool; Drug Therapy, Combination; Female; Fetal Blood; Hematopoiesis; Humans; Immunosuppressive Agents; Male; Middle Aged; Recovery of Function; Severity of Illness Index; Survival Rate; Treatment Outcome; Vidarabine; Young Adult

2020
The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors.
    Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:3

    Topics: Animals; Cell Line, Tumor; Escherichia coli; Genetic Therapy; Genetic Vectors; Glioma; Humans; Lentivirus; Mice; Mice, Nude; Purine-Nucleoside Phosphorylase; Squamous Cell Carcinoma of Head and Neck; Trichomonas vaginalis; Vidarabine

2020
Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation.
    CPT: pharmacometrics & systems pharmacology, 2020, Volume: 9, Issue:5

    Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Computer Simulation; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Randomized Controlled Trials as Topic; Research Design; Vidarabine

2020
Mendelian susceptibility to mycobacterial disease-Challenges in hematopoietic stem cell transplantation.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:5

    Topics: Allografts; Child, Preschool; Dexamethasone; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Mutation; Mycobacterium; Mycobacterium Infections; Receptors, Interleukin-12; Transplantation Conditioning; Vidarabine

2020
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:5

    Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Transplantation Conditioning; Vidarabine

2020
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report.
    Transplantation proceedings, 2020, Volume: 52, Issue:2

    Topics: Antilymphocyte Serum; Busulfan; Ectodermal Dysplasia; Hematopoietic Stem Cell Transplantation; Humans; I-kappa B Kinase; Immunologic Deficiency Syndromes; Infant; Male; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2020
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
    Annals of hematology, 2020, Volume: 99, Issue:4

    Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms, Second Primary; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2020
Systemic Large-Vessel Vasculitis and Retroperitoneal Fibrosis in the Setting of T-Cell Chronic Lymphocytic Leukemia: A Case Report.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:2

    Topics: Aged; Antineoplastic Agents; Aorta, Thoracic; Chest Pain; Computed Tomography Angiography; Coronary Vessels; Cyclophosphamide; Humans; Leukemia, Prolymphocytic, T-Cell; Lymphadenopathy; Male; Prednisone; Retroperitoneal Fibrosis; Systemic Vasculitis; Treatment Outcome; Vidarabine

2020
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:6

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2020
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine

2020
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Leukemia research, 2020, Volume: 91

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease Management; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine

2020
Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome.
    Journal of pediatric hematology/oncology, 2021, 04-01, Volume: 43, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Child; Cytarabine; Female; Fetal Blood; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Shwachman-Diamond Syndrome; Transplantation Conditioning; Vidarabine

2021
The interaction mechanism between fludarabine and human serum albumin researched by comprehensive spectroscopic methods and molecular docking technique.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2020, Jun-05, Volume: 233

    Topics: Humans; Molecular Docking Simulation; Serum Albumin, Human; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Vidarabine

2020
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:6

    Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2020
Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
    Bone marrow transplantation, 2020, Volume: 55, Issue:10

    Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Vidarabine

2020
Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors.
    Experimental oncology, 2020, Volume: 42, Issue:1

    Topics: Antigens, CD; Antineoplastic Agents; B-Lymphocytes; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Receptors, Cell Surface; Vidarabine

2020
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
    Molecular carcinogenesis, 2020, Volume: 59, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cyclophosphamide; Female; Follow-Up Studies; Humans; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Prognosis; Progression-Free Survival; Skin Neoplasms; Vidarabine

2020
Retrospective institutional analysis of fludarabine/8 Gy TBI reduced intensity conditioning in high risk ALL.
    Bone marrow transplantation, 2020, Volume: 55, Issue:11

    Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2020
Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner.
    Cancer discovery, 2020, Volume: 10, Issue:8

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Coculture Techniques; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Immunotherapy; Interleukin-1beta; Male; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Derived Suppressor Cells; Sex Characteristics; T-Lymphocytes; Vidarabine

2020
DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy.
    Scientific data, 2020, 05-01, Volume: 7, Issue:1

    Topics: Bendamustine Hydrochloride; DNA Methylation; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Suppressor Protein p53; Vidarabine

2020
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine.
    Open biology, 2020, Volume: 10, Issue:5

    Topics: Adult; Aged; Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Neoplasm Transplantation; Polyethylene Glycols; Treatment Outcome; Tumor Microenvironment; Vidarabine

2020
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:8

    Topics: Aged; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Sirolimus; Tacrolimus; Transplantation Conditioning; Vidarabine

2020
UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
    British journal of cancer, 2020, Volume: 123, Issue:2

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Pharmacological; Female; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mass Spectrometry; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Piperidines; Purines; Quinazolinones; Vidarabine

2020
Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide.
    Bone marrow transplantation, 2020, Volume: 55, Issue:7

    Topics: Anemia, Aplastic; Bone Marrow Transplantation; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation Conditioning; Vidarabine

2020
Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia.
    Annals of hematology, 2020, Volume: 99, Issue:10

    Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Multiple, Fungal; Drug Substitution; Fatal Outcome; Febrile Neutropenia; Female; Filgrastim; Fluconazole; Humans; Immunocompromised Host; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperacillin, Tazobactam Drug Combination; Purines; Quinazolinones; Recurrence; Rituximab; Scedosporium; Triazoles; Valacyclovir; Vidarabine

2020
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
    Transplantation, 2021, 04-01, Volume: 105, Issue:4

    Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Retrospective Studies; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2021
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
    Yonsei medical journal, 2020, Volume: 61, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2020
Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?
    Leukemia & lymphoma, 2020, Volume: 61, Issue:7

    Topics: Busulfan; Humans; Leukemia, Myeloid, Acute; Melphalan; Transplantation Conditioning; Vidarabine

2020
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
    JAMA oncology, 2020, 07-01, Volume: 6, Issue:7

    Topics: Allografts; Busulfan; Cohort Studies; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Melphalan; Myeloablative Agonists; Recurrence; Registries; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2020
Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
    Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:6

    Topics: Busulfan; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine

2020
Donor's graft ex vivo T-cell depletion with fludarabine reduces graft-versus-host disease signs and improves survival after intestinal transplantation - an experimental study.
    Transplant international : official journal of the European Society for Organ Transplantation, 2020, Volume: 33, Issue:10

    Topics: Animals; Graft vs Host Disease; Rats; Rats, Inbred Lew; T-Lymphocytes; Transplantation, Homologous; Vidarabine

2020
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Clinical transplantation, 2020, Volume: 34, Issue:9

    Topics: Aged; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myeloablative Agonists; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2020
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
    Bone marrow transplantation, 2021, Volume: 56, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2021
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 09-15, Volume: 26, Issue:18

    Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clonal Evolution; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunological Synapses; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Piperidines; Purines; Quinazolinones; Rituximab; T-Lymphocytes; Vidarabine

2020
Fludarabine, Campath, and Low-Dose Cyclophosphamide (FCC
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:10

    Topics: Alemtuzumab; Anemia, Aplastic; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2020
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:8

    Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Sirolimus; Tacrolimus; Thiotepa; Transplantation Conditioning; Vidarabine

2020
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
    International journal of hematology, 2020, Volume: 112, Issue:4

    Topics: Age Factors; Aged; Busulfan; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Radiation Dosage; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2020
Interim Phase 2 ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL.
    Oncology (Williston Park, N.Y.), 2020, Jul-15, Volume: 34, Issue:7

    Topics: Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Salvage Therapy; Vidarabine

2020
Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL.
    Toxicology and applied pharmacology, 2020, 09-15, Volume: 403

    Topics: Animals; Cell Line, Tumor; Dendrimers; Drug Delivery Systems; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred NOD; Neoplasms, Experimental; Pilot Projects; Polypropylenes; Trisaccharides; Vidarabine

2020
Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2020
Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in pediatric patient with IL10 receptor deficiency.
    Pediatric transplantation, 2021, Volume: 25, Issue:2

    Topics: Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Genetic Markers; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Myeloablative Agonists; Primary Immunodeficiency Diseases; Receptors, Interleukin-10; Transplantation Conditioning; Vidarabine

2021
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
    International journal of hematology, 2021, Volume: 113, Issue:1

    Topics: Adult; Age Factors; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2021
Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acut
    Bone marrow transplantation, 2021, Volume: 56, Issue:2

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2021
HuR Affects Proliferation and Apoptosis of Chronic Lymphocytic Leukemia Cells via NF-
    BioMed research international, 2020, Volume: 2020

    Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Chlorambucil; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Humans; I-kappa B Kinase; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; TNF Receptor-Associated Factor 1; Tumor Necrosis Factor-alpha; Up-Regulation; Vidarabine

2020
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
    Leukemia, 2021, Volume: 35, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Follow-Up Studies; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Vidarabine

2021
IFN‑γ induces apoptosis in human melanocytes by activating the JAK1/STAT1 signaling pathway.
    Molecular medicine reports, 2020, Volume: 22, Issue:4

    Topics: Cell Line; Cell Survival; Gene Expression Regulation; Humans; Interferon-gamma; Janus Kinase 1; MAP Kinase Signaling System; Melanocytes; Phosphorylation; STAT1 Transcription Factor; Vidarabine

2020
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
    International journal of molecular sciences, 2020, Sep-16, Volume: 21, Issue:18

    Topics: Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Calreticulin; Cell Line, Tumor; Cytarabine; Daunorubicin; Dendritic Cells; Etoposide; Extracellular Space; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Immunogenic Cell Death; Leukemia, Myeloid, Acute; Lymphocyte Activation; Neoplasm Proteins; Organelles; Protein Transport; T-Lymphocyte Subsets; Vidarabine

2020
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).
    International journal of biological macromolecules, 2020, Nov-15, Volume: 163

    Topics: Adenosine Monophosphate; Amino Acid Sequence; Betacoronavirus; Binding Sites; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Enzyme Inhibitors; Folic Acid; Genome, Viral; Glucosides; Humans; Methyltransferases; Molecular Docking Simulation; Mutation; Pandemics; Pneumonia, Viral; RNA Helicases; SARS-CoV-2; Stilbenes; Vidarabine; Viral Nonstructural Proteins

2020
The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:1

    Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Homologous; Vidarabine

2021
Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies.
    Scientific reports, 2020, 10-01, Volume: 10, Issue:1

    Topics: Adult; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Pemphigus; Prednisone; Prognosis; Retrospective Studies; Rituximab; Vidarabine

2020
Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult

2020
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:2

    Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Thiotepa; Transplantation Conditioning; Vidarabine

2021
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
    Bone marrow transplantation, 2021, Volume: 56, Issue:3

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine

2021
Improving survival rates for patients with acute myeloid leukemia: Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT.
    Current research in translational medicine, 2020, Volume: 68, Issue:4

    Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Humans; Leukemia, Myeloid, Acute; Survival Rate; Transplantation Conditioning; Vidarabine

2020
Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen.
    Hematological oncology, 2021, Volume: 39, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Edema; Cyclophosphamide; Demyelinating Diseases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Steroids; Vidarabine

2021
Haploidentical Stem Cell Transplant With Post-transplant Cyclophosphamide for Chediak-Higashi Syndrome: A Very Rare Case Report.
    Journal of pediatric hematology/oncology, 2021, Oct-01, Volume: 43, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chediak-Higashi Syndrome; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Prognosis; Transplantation Conditioning; Vidarabine

2021
Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
    Medicine, 2020, Oct-23, Volume: 99, Issue:43

    Topics: Adult; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytokine Release Syndrome; Humans; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Remission Induction; T-Lymphocytes; Vidarabine

2020
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).
    Haematologica, 2020, 11-01, Volume: 105, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine

2020
Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:4

    Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2021
Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning.
    Journal of pediatric hematology/oncology, 2021, 05-01, Volume: 43, Issue:4

    Topics: Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine

2021
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy.
    Hematology. American Society of Hematology. Education Program, 2020, 12-04, Volume: 2020, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Rituximab; Vidarabine

2020
Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
    Investigational new drugs, 2021, Volume: 39, Issue:3

    Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Mesothelioma; Pleural Neoplasms; Risedronic Acid; STAT1 Transcription Factor; Vidarabine

2021
Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 144

    Topics: Aged; Antineoplastic Agents; Fatal Outcome; Humans; Immunotherapy, Adoptive; Leukoencephalopathies; Lymphoma, Large B-Cell, Diffuse; Male; Neurotoxicity Syndromes; Retroperitoneal Neoplasms; Vidarabine

2021
Fludarabine modulates expression of type VII collagen during haematopoietic stem cell transplantation for recessive dystrophic epidermolysis bullosa.
    The British journal of dermatology, 2021, Volume: 185, Issue:2

    Topics: Collagen Type VII; Epidermolysis Bullosa Dystrophica; Hematopoietic Stem Cell Transplantation; Humans; Phosphatidylinositol 3-Kinases; Vidarabine

2021
Systemic capillary leak syndrome: a rare but potentially life-threatening cause of protein loss and oedema in B cell prolymphocytic leukaemia.
    BMJ case reports, 2020, Dec-22, Volume: 13, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Cyclophosphamide; Edema; Humans; Hypoalbuminemia; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Rituximab; Serum Albumin, Human; Treatment Outcome; Vidarabine

2020
Periodontitis aggravates kidney injury by upregulating STAT1 expression in a mouse model of hypertension.
    FEBS open bio, 2021, Volume: 11, Issue:3

    Topics: Animals; Disease Models, Animal; Gene Knockdown Techniques; Humans; Hypertension; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Periodontitis; Porphyromonas gingivalis; Renal Insufficiency, Chronic; STAT1 Transcription Factor; Up-Regulation; Vidarabine

2021
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
    Bone marrow transplantation, 2021, Volume: 56, Issue:7

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2021
Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
    Journal of clinical immunology, 2021, Volume: 41, Issue:5

    Topics: Busulfan; Child, Preschool; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Leukocyte Count; Male; Melphalan; Primary Immunodeficiency Diseases; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine

2021
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
    American journal of hematology, 2021, 04-01, Volume: 96, Issue:4

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Female; Ferritins; Humans; Immunotherapy, Adoptive; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Retrospective Studies; Thrombocytopenia; Vidarabine; Young Adult

2021
Design, Synthesis and In Vitro Cytotoxic Activity of New 6,9-Disubstituted Purine Analogues.
    Acta chimica Slovenica, 2020, Volume: 67, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Molecular Structure; Purines; Vidarabine

2020
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    British journal of haematology, 2021, Volume: 193, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Cohort Studies; Denmark; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Risk Assessment; Survival Analysis; Vidarabine

2021
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
    Annals of hematology, 2021, Volume: 100, Issue:4

    Topics: Aged; Allografts; Antilymphocyte Serum; Busulfan; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Progression-Free Survival; Retrospective Studies; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation

2021
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
    Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult

2021
Syngeneic leukemia models using lentiviral transgenics.
    Cell death & disease, 2021, 02-18, Volume: 12, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Viral; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Immunocompetence; Lentivirus; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Oncogenes; Transplantation, Isogeneic; Vidarabine

2021
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
    American journal of hematology, 2021, 06-01, Volume: 96, Issue:6

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia

2021
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Journal of medical case reports, 2021, Feb-19, Volume: 15, Issue:1

    Topics: Antibodies, Viral; B-Cell Maturation Antigen; Cough; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Cyclophosphamide; Disease Progression; Fever; Hospitalization; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Middle Aged; Multiple Myeloma; Receptors, Chimeric Antigen; SARS-CoV-2; Vidarabine

2021
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
    Journal of pediatric hematology/oncology, 2021, Oct-01, Volume: 43, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2021
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
    Bone marrow transplantation, 2021, Volume: 56, Issue:7

    Topics: Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Propensity Score; Transplantation Conditioning; Vidarabine

2021
Bone marrow transplant using fludarabine-based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia.
    Pediatric transplantation, 2021, Volume: 25, Issue:4

    Topics: Bone Marrow Transplantation; Child; Drug Therapy, Combination; Fanconi Anemia; Humans; Lymphocyte Depletion; Myeloablative Agonists; Siblings; T-Lymphocytes; Transplantation Conditioning; Vidarabine

2021
Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:7

    Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Thiotepa; Transplantation Conditioning; Vidarabine

2021
Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71.
    Viruses, 2021, 04-27, Volume: 13, Issue:5

    Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Cells, Cultured; Enterovirus A, Human; Humans; Phlebovirus; RNA Viruses; Vidarabine; Virus Replication; Zika Virus

2021
An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:5

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Cyclophosphamide; Humans; Retrospective Studies; Vidarabine; Young Adult

2021
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
    Journal for immunotherapy of cancer, 2021, Volume: 9, Issue:5

    Topics: Adult; Clinical Trials, Phase II as Topic; Cyclophosphamide; Cytokines; Female; Humans; Immunotherapy, Adoptive; Length of Stay; Lymphocyte Depletion; Male; Melanoma; Middle Aged; Myeloablative Agonists; Receptors, Chimeric Antigen; Recovery of Function; Skin Neoplasms; T-Lymphocytes; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2021
Conditioning with 10 Gy Total Body Irradiation, Cyclophosphamide, and Fludarabine without ATG Is Associated with Improved Outcome of Cord Blood Transplantation in Children with Acute Leukemia.
    Journal of Korean medical science, 2021, May-17, Volume: 36, Issue:19

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Infant; Leukemia, Myeloid, Acute; Male; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2021
Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:8

    Topics: Antilymphocyte Serum; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2021
Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults.
    European journal of haematology, 2021, Volume: 107, Issue:3

    Topics: Adult; Blood Platelets; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Myeloablative Agonists; Neutrophils; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine

2021
Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation.
    Asian Pacific journal of cancer prevention : APJCP, 2021, May-01, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Iran; Male; Middle Aged; Prognosis; Quality of Life; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult

2021
Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2.
    Cellular & molecular immunology, 2021, Volume: 18, Issue:7

    Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Antiviral Agents; Binding Sites; COVID-19; COVID-19 Drug Treatment; Enzyme Induction; HEK293 Cells; HeLa Cells; Humans; Interferon Type I; Phosphorylation; Promoter Regions, Genetic; Receptors, Virus; STAT1 Transcription Factor; Vidarabine

2021
Full Dose Cyclophosphamide with the Addition of Fludarabine for Matched Sibling Transplants in Severe Aplastic Anemia.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:10

    Topics: Adult; Anemia, Aplastic; Cyclophosphamide; Humans; Prospective Studies; Retrospective Studies; Siblings; Vidarabine

2021
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
    Cancer medicine, 2021, Volume: 10, Issue:13

    Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2021
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
    Leukemia, 2022, Volume: 36, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, Local; Prognosis; Rituximab; Survival Rate; Telomere Homeostasis; Tumor Suppressor Protein p53; Vidarabine

2022
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
    Bone marrow transplantation, 2021, Volume: 56, Issue:9

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine

2021
[Cutaneous complications following hematopoietic stem cell transplantation].
    Bulletin du cancer, 2021, Volume: 108, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Disease; Dermatomycoses; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Genitalis; Humans; Induction Chemotherapy; Malassezia; Male; Melphalan; Middle Aged; Morocco; Prospective Studies; Skin Diseases; Skin Diseases, Infectious; Vidarabine; Young Adult

2021
Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies.
    Pathology oncology research : POR, 2021, Volume: 27

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Retrospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Vidarabine

2021
Successful allogeneic stem cell transplantation with fludarabine-based reduced intensity conditioning in bone marrow failure syndrome 4.
    Pediatric transplantation, 2021, Volume: 25, Issue:7

    Topics: Antineoplastic Agents; Bone Marrow Failure Disorders; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2021
MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Jul-01, Volume: 22, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine

2021
Does fludarabine have a beneficial effect in recessive dystrophic epidermolysis bullosa?
    The British journal of dermatology, 2021, Volume: 185, Issue:2

    Topics: Collagen Type VII; Epidermolysis Bullosa Dystrophica; Humans; Skin; Vidarabine

2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:11

    Topics: Aged; Busulfan; Graft vs Host Disease; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Vidarabine

2021
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
    CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:9

    Topics: Administration, Intravenous; Adolescent; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Glutathione Transferase; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Models, Biological; Polymorphism, Genetic; Precision Medicine; Transplantation Conditioning; Vidarabine; Young Adult

2021
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
    Bone marrow transplantation, 2021, Volume: 56, Issue:12

    Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Propensity Score; Retrospective Studies; Transplantation Conditioning; Vidarabine

2021
Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
    Cellular oncology (Dordrecht), 2021, Volume: 44, Issue:6

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Immunologic Surveillance; Immunosuppression Therapy; Inflammation; Liver Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Male; Mice, Inbred C57BL; Oncolytic Viruses; Recombinant Fusion Proteins; Treatment Outcome; Vidarabine; Virus Replication

2021
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    British journal of haematology, 2021, Volume: 195, Issue:3

    Topics: Adrenal Cortex Hormones; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modality Therapy; Cyclophosphamide; Cytokine Release Syndrome; Female; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Leukapheresis; Lymphocyte Depletion; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Pancytopenia; Progression-Free Survival; Receptors, Antigen, T-Cell; Retrospective Studies; Salvage Therapy; Vidarabine

2021
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
    PloS one, 2021, Volume: 16, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; DNA Mutational Analysis; Female; Gene Expression Regulation, Leukemic; Genomics; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Rituximab; RNA Splicing; Vidarabine

2021
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    British journal of haematology, 2021, Volume: 195, Issue:3

    Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult

2021
Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
    Leukemia research, 2021, Volume: 110

    Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Artemisinins; Biomarkers; Cell Proliferation; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1; Vidarabine

2021
Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.
    International journal of hematology, 2022, Volume: 115, Issue:1

    Topics: Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; DNA-Binding Proteins; Etoposide; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; Liver Neoplasms; Lymphoma, T-Cell; PAX5 Transcription Factor; Prognosis; Proto-Oncogene Proteins c-ets; Remission Induction; Repressor Proteins; Splenic Neoplasms; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2022
Non-myeloablative umbilical cord blood transplantation for atypical dyskeratosis congenita.
    Pediatric transplantation, 2022, Volume: 26, Issue:2

    Topics: Alemtuzumab; Antineoplastic Agents; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Female; Germ-Line Mutation; Humans; Mismatch Repair Endonuclease PMS2; Vidarabine; Whole-Body Irradiation

2022
Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
    International journal of hematology, 2022, Volume: 115, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2022
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:10

    Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
    Bone marrow transplantation, 2022, Volume: 57, Issue:2

    Topics: Antilymphocyte Serum; Busulfan; Chimerism; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine

2022
Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning.
    Pediatric transplantation, 2022, Volume: 26, Issue:2

    Topics: Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen.
    Blood advances, 2022, 03-22, Volume: 6, Issue:6

    Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine

2022
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
    Blood advances, 2022, 04-12, Volume: 6, Issue:7

    Topics: Adolescent; Adult; Child; Child, Preschool; Humans; Immunotherapy, Adoptive; Infant; Prospective Studies; Recurrence; Retrospective Studies; Vidarabine; Young Adult

2022
Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:1

    Topics: Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.
    Nucleosides, nucleotides & nucleic acids, 2022, Volume: 41, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cyclophosphamide; Humans; Neoplasms; Nucleosides; Tumor Suppressor Protein p53; Vidarabine

2022
Fludarabine-based Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Bone Marrow Failure Syndrome Type 3.
    Journal of pediatric hematology/oncology, 2022, 11-01, Volume: 44, Issue:8

    Topics: Bone Marrow Failure Disorders; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Transplantation Conditioning; Vidarabine

2022
Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
    Annals of hematology, 2022, Volume: 101, Issue:3

    Topics: Adolescent; Antineoplastic Agents; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
    Bone marrow transplantation, 2022, Volume: 57, Issue:3

    Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2022
5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
    Antiviral research, 2022, Volume: 198

    Topics: Antiviral Agents; Cell Line; COVID-19 Drug Treatment; Deoxyguanosine; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Microbial Sensitivity Tests; Nucleic Acid Synthesis Inhibitors; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Thionucleosides; Tubercidin; Vidarabine; Vidarabine Phosphate

2022
Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors.
    American journal of hematology, 2022, Volume: 97, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Rituximab; Treatment Outcome; Vidarabine

2022
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
    Blood advances, 2022, 04-12, Volume: 6, Issue:7

    Topics: Antigens, CD19; Child; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Retrospective Studies; Vidarabine; Young Adult

2022
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
    Oncotarget, 2022, Volume: 13

    Topics: Alkylating Agents; AMP-Activated Protein Kinases; Antineoplastic Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Caspase 3; Drug Combinations; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Nucleosides; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; STAT5 Transcription Factor; Sulfonamides; Transplantation Conditioning; Vidarabine

2022
Proteomic Analysis Reveals a Novel Therapeutic Strategy Using Fludarabine for Steroid-Resistant Asthma Exacerbation.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Animals; Asthma; Cytokines; Mice; Mice, Inbred BALB C; Ovalbumin; Proteomics; Steroids; Vidarabine

2022
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:6

    Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies; Vidarabine

2022
Combined Effects of Fludarabine and Interferon Alpha on Autophagy Regulation Define the Phase of Cell Survival and Promotes Responses in LLC-MK2 and K562 Cells.
    Medical sciences (Basel, Switzerland), 2022, 03-17, Volume: 10, Issue:1

    Topics: Antiviral Agents; Autophagy; Cell Survival; Humans; Interferon-alpha; K562 Cells; TOR Serine-Threonine Kinases; Vidarabine

2022
Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Annals of hematology, 2022, Volume: 101, Issue:6

    Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
    Bone marrow transplantation, 2022, Volume: 57, Issue:6

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice.
    Nature biotechnology, 2022, Volume: 40, Issue:8

    Topics: Animals; CRISPR-Cas Systems; Dependovirus; Endonucleases; Gene Editing; Genetic Vectors; Homologous Recombination; Humans; Mice; Vidarabine

2022
Single-dose (4.5 mg/m
    British journal of haematology, 2022, Volume: 198, Issue:2

    Topics: Adult; Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Vidarabine

2022
First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18 F-Fludarabine and l -[methyl- 11 C]Methionine.
    Clinical nuclear medicine, 2022, Aug-01, Volume: 47, Issue:8

    Topics: Adrenal Cortex Hormones; Brain Neoplasms; Diagnosis, Differential; Fluorodeoxyglucose F18; Glioblastoma; Humans; Lymphoma; Methionine; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Vidarabine

2022
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
    International journal of hematology, 2022, Volume: 116, Issue:3

    Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2022
Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning.
    Blood advances, 2022, 07-12, Volume: 6, Issue:13

    Topics: Creatinine; Graft vs Host Disease; Humans; Iothalamic Acid; Melphalan; Retrospective Studies; Vidarabine

2022
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
    Bone marrow transplantation, 2022, Volume: 57, Issue:7

    Topics: Aged; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2022
Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:7

    Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Thiotepa; Vidarabine; Young Adult

2022
Successful desensitization protocol for a patient with fludarabine anaphylaxis during hematopoietic transplantation.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2022, Volume: 33, Issue:6

    Topics: Anaphylaxis; Desensitization, Immunologic; Drug Hypersensitivity; Hematopoietic Stem Cell Transplantation; Humans; Vidarabine

2022
Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:9

    Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2022
Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:11

    Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning; Vidarabine

2022
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities.
    Bone marrow transplantation, 2022, Volume: 57, Issue:11

    Topics: Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning; Vidarabine

2022
Beyond fludarabine: pentostatin plus cyclophosphamide are a well-tolerated alternative in reduced intensity conditioning.
    Bone marrow transplantation, 2022, Volume: 57, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Pentostatin; Transplantation Conditioning; Vidarabine

2022
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
    Bone marrow transplantation, 2023, Volume: 58, Issue:1

    Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult

2023
Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment.
    Computational and mathematical methods in medicine, 2022, Volume: 2022

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2022
Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results fro
    Bone marrow transplantation, 2023, Volume: 58, Issue:1

    Topics: Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine

2023
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2023
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
    Acta haematologica, 2023, Volume: 146, Issue:1

    Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine

2023
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.
    International journal of hematology, 2023, Volume: 117, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine

2023
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par
    Bone marrow transplantation, 2023, Volume: 58, Issue:3

    Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2023
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
    American journal of hematology, 2023, Volume: 98, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Vidarabine

2023
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
    Annals of hematology, 2023, Volume: 102, Issue:3

    Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Transplantation Conditioning; Vidarabine

2023
Haploidentical Transplant Achieves Long-Term Remission in Relapsed Refractory Leukemia With Fludarabine-Induced Neurotoxicity Complication.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2023, Volume: 21, Issue:3

    Topics: Child; Hematopoietic Stem Cell Transplantation; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Transplants; Vidarabine

2023
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
    Bone marrow transplantation, 2023, Volume: 58, Issue:6

    Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation

2023
Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine and Discussion of Treatment.
    Journal of drugs in dermatology : JDD, 2023, 05-01, Volume: 22, Issue:5

    Topics: Carcinoma, Squamous Cell; Humans; Skin Neoplasms; Vidarabine

2023
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
    Bone marrow transplantation, 2023, Volume: 58, Issue:9

    Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine

2023
Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
    Blood advances, 2023, 06-27, Volume: 7, Issue:12

    Topics: Immunotherapy, Adoptive; Receptors, Antigen, T-Cell; Vidarabine

2023
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.
    Blood cancer journal, 2023, 08-09, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; East Asian People; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prospective Studies; Rituximab; Tumor Suppressor Protein p53; Vidarabine

2023
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
    Blood, 2023, Nov-23, Volume: 142, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Outcome; Vidarabine

2023
del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
    Leukemia, 2023, Volume: 37, Issue:11

    Topics: Chromosome Aberrations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Prognosis; Receptors, TNF-Related Apoptosis-Inducing Ligand; Vidarabine

2023
Quantification of Clofarabine and Fludarabine in Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
    Methods in molecular biology (Clifton, N.J.), 2024, Volume: 2737

    Topics: Chromatography, High Pressure Liquid; Clofarabine; Humans; Tandem Mass Spectrometry; Vidarabine

2024